# The Phoenix - Full Content > Complete article content from The Phoenix, the leading resource for APOE4 gene carriers. > All content reviewed by Dr. Kevin Tran, PharmD, APOE4/4 carrier. ## About This Resource The Phoenix publishes weekly evidence-based protocols for APOE4 gene carriers. Each article is written or reviewed by Dr. Kevin Tran, a Doctor of Pharmacy who is himself an APOE4/4 homozygous carrier. Articles cover nutrition, supplements, exercise, sleep, cognitive health, blood biomarkers, and emerging research relevant to APOE4 carriers. Total articles: 127 --- ## The APOE4 Vagus Nerve Stimulation Study: Results and How to Join Phoenix's Next Study URL: https://apoe4.co/blog/posts/the-apoe4-vagus-nerve-stimulation-study-results-and-how-to-join-phoenix-s-next-study Published: 2026-08-15T19:00:00+00:00 Updated: 2026-08-15T19:00:40.885344+00:00 Summary: APOE4 vagus nerve stimulation study results: 31 carriers shared 656 days of data. See adherence rates, self-reported benefits, and wearable findings—plus how to join Phoenix's next trial. The APOE4 Vagus Nerve Stimulation Study: Results and How to Join Phoenix's Next StudyAdherence, self-report and wearable lessons from an observational study.Dr. Kevin Tran August 15, 2026 Hi Phoenix friend, 31 APOE4 carriers logged 656 days of ear-based vagus nerve stimulation (taVNS) with ZenoWell. First lesson: people kept using it. Twenty-three of 31 carriers logged at least 10 use days. Seventeen reached at least 20 days. A device cannot create useful evidence if it stays in a drawer. Second lesson: the self-reported signals were positive (but small). In the 10-person paired subset, average energy was 0.33 points higher after reported use nights. Wellbeing was 0.28 points higher and sleep quality was 0.17 points higher. Third lesson: wearables data is VERY promising. Sleep score was 2.1 points higher in a six-person subset. HRV was 3.9 ms higher in a nine-person subset. Total sleep time was about five minutes lower, and resting heart rate stayed flat. Those nulls matter. So do the limits. This was observational, not randomized. All confidence intervals included no effect, the paired samples were small, and overlapping interventions may have influenced the results. Read the results and unlock the complete reportAbout the ZenoWell Luna: Want to try it? Phoenix readers can save 20% with code APOE4 at zenowell.ai/PHOENIX. Phoenix connected daily check-ins, wearables, biomarkers and intervention timing to find those leads. Each cohort leaves the next one with a cleaner baseline, sharper outcomes and a stronger protocol. That is how a carrier-led platform compounds into better studies: more carriers contribute, the evidence becomes more useful and the next study starts stronger. Take the 7-minute assessment to join Phoenix Cheers,Kevin Phoenix does not provide medical advice, diagnosis or treatment. This observational analysis does not establish causation. Consult a qualified physician before changing any health protocol. --- ## Menopause, What HRT Actually Does & What It Means for APOE4 Carriers URL: https://apoe4.co/blog/posts/menopause-what-hrt-actually-does-what-it-means-for-apoe4-carriers Published: 2026-08-13T19:00:00+00:00 Updated: 2026-08-13T19:00:29.580836+00:00 Summary: Evidence-based guide to HRT for APOE4 carriers: breast cancer risk, pill vs patch options, and personalized menopause strategies. Menopause, What HRT Actually Does & What It Means for APOE4 CarriersPart 1: breast-cancer risk, pills vs patches, and the menopause questions APOE4 carriers asked.Dr. Kevin Tran August 13, 2026 Hi Phoenix friend, 80% of the Phoenix community is female, so I wanted a better answer than either "HRT is dangerous" or "HRT is perfectly safe." This is part of the August monthly theme we run in the community about HRT, Hormones and Menopause.If you are interested in submitting your questions for these types of interviews, join the Phoenix Community.For more than 20 years, one number has shaped the hormone conversation. 26%. That was the relative increase in invasive breast cancer reported in the combined-hormone arm of the 2002 Women's Health Initiative. The absolute numbers were 38 cases per 10,000 person-years in the hormone group and 30 in the placebo group. Eight additional cases per 10,000 person-years. [Study: Rossouw et al., 2002] That does not mean hormone therapy is right for everyone. It means the headline was not the whole decision. And in February 2026, the FDA approved updated labeling for several menopause hormone-therapy products. The cardiovascular disease, breast cancer, and probable dementia statements came out of the boxed warning, while important risk information remained elsewhere in the labels. [FDA, 2026] Most women never heard that update. So I sat down with Steve Goldring, RPh, known as The Hormone Pharmacist. Steve spent more than 25 years as a compounding pharmacist. He has heard the same questions across the counter again and again: Should I take hormones? Is a patch safer than a pill? What if progesterone makes me feel worse? What if I have no hot flashes, but my levels are low? What changes if I carry APOE4? Every question in this Q&A came from a member. What Part 1 covers1. What the 2002 study actually tested The Women's Health Initiative did not test every form of hormone therapy used today. Steve explains the specific estrogen-plus-progestin combination, the age of the participants, the difference between relative and absolute risk, and why one result became a global headline. 2. The whole hormone menu Pill. Patch. Gel. Cream. Vaginal estrogen. Pellet. Each route has advantages and drawbacks. Steve does not pretend there is one default answer for everyone. The most useful parts of the conversation are practical: what happens when a patch falls off, why a dose can feel different near patch-change day, and why the route through the liver changes some effects. 3. Progesterone and sleep Steve explains why oral micronized progesterone affects sleep differently from vaginal or transdermal progesterone. We also cover the smaller group of women who feel worse on progesterone, not better, and the questions worth taking to a clinician. 4. Symptoms versus longer-term health Feeling fine is not the same as having answered every health question. The episode separates symptom relief from conversations about bone, cardiovascular, metabolic, and cognitive health. The APOE4 evidence is not settled enough to turn hormone therapy into an Alzheimer's-prevention strategy. That is exactly why APOE4 carriers need a better conversation, not a slogan. [Study: Melville et al., 2025] The line that stayed with me Steve put the decision plainly: "You are not choosing between risk and zero risk. You are choosing which risks you carry." That is the point of Part 1. Not "everyone should take HRT." Not "nobody should take HRT." A clearer map of the options, the evidence, and the questions you can take into your next appointment. Part 2 (publishing in a week) goes further into whether it is ever too late to start, how to get taken seriously by a dismissive clinician, hormone testing, compounding pharmacies, and the questions that still do not have clean answers. Cheers, Kevin P.S. If like for this episodes you want a question included in a future Q&A, post it inside the Phoenix community. The member questions are what make these conversations useful. SourcesRossouw et al., 2002: Women's Health Initiative combined-hormone trialFDA, February 2026: approved labeling changes for menopausal hormone-therapy productsMelville et al., 2025: menopause hormone therapy and dementia risk This conversation is educational and does not replace care from a clinician who knows your medical history. Most Newsletters? One-way street.How boring…This is the Phoenix Community. So let's make it a two-way street. Got a question? Feedback? Hit reply. I read every single one. --- ## Linking the Shingles Vaccine and Dementia Risk URL: https://apoe4.co/blog/posts/linking-the-shingles-vaccine-and-dementia-risk Published: 2026-08-10T19:00:00+00:00 Updated: 2026-08-10T19:00:26.877599+00:00 Summary: APOE4 carriers: A Wales vaccine cutoff created a near-randomized dementia trial. The shingles vaccine lowered dementia risk 20%. Full research synthesis. Linking the Shingles Vaccine and Dementia RiskA birthday eligibility cutoff in Wales accidentally created the closest thing to a randomized dementia trial we have.Dr. Kevin Tran August 10, 2026 Hi Phoenix friend, In 2013, Wales drew a line through a single birthday. Nobody meant to run an experiment on the human brain. That line turned into the strongest causal-grade signal we have that a cheap, already-approved vaccine can lower dementia risk. This is the full written synthesis of the shingles vaccine and dementia research. Prefer to watch? Here's the 24-minute deep dive on YouTube (studies on screen, full stories): Introduction This is not another "people who did X happened to live longer" story. The evidence here is built differently: a bureaucratic birthday cutoff accidentally created something researchers almost never get, a near-randomized test of what happens when one group of older adults gets the shingles vaccine and another doesn't. Result: the vaccinated group got about 20% less dementia. What follows gives you all of it: the numbers that hold up, where the evidence gets thin (including the gap that's personal for us carriers), and what to actually do on a Tuesday instead of waiting for the 2029 trial. The Birthday Cutoff That Created a Near-Randomized Dementia Test Wales, 2013. Adults born on or after September 2nd, 1933 were eligible for a free shingles vaccine. Born one day earlier, locked out for life. Nobody designed this as a brain experiment. It was a budget and supply decision. But it created something researchers almost never get: two groups of people separated by nothing except which side of a birthday they landed on. Same generation, same health history, same preventive-care habits across every measured dimension. Vaccine receipt jumped from 0.01% in people just one week too old to 47.2% in people just one week younger [1]. The only thing that differed was access to the shot. The result: a 3.5 percentage-point drop in new dementia diagnoses over seven years, a 20% relative reduction (95% CI 6.5 to 33.4) [1]. The authors called it evidence "less vulnerable to confounding and bias" than the usual associational studies [1]. That framing matters. This is not an RCT. But the regression-discontinuity design means the two groups are effectively interchangeable on every measured characteristic except vaccine access. It is the closest thing to a coin-flip randomization you can engineer from real-world health records. A vaccine people get to avoid a painful rash cut new dementia diagnoses by a fifth. By accident. How the Finding Held Up: Australia and 100 Million People One study in one country could be a fluke. So people went and checked. Australia had its own birthday cutoff, a different date (November 2nd, 1936) and a completely different health system. The same regression-discontinuity method found the same pattern: shingles vaccine eligibility cut new dementia diagnoses by 1.8 percentage points over 7.4 years (95% CI 0.4 to 3.3, p=0.01) [4]. The JAMA authors called that "more likely to be causal" than ordinary associational evidence [4]. They also tested it against roughly 15 other common conditions and preventive screenings. The vaccine moved dementia. Nothing else [4]. If healthier people simply get more vaccines across the board, you'd expect the effect to spread everywhere. It didn't. A 2.5-million Korean nationwide cohort (observational, so associational) found the live shingles vaccine tracked with about 25% lower Alzheimer's hazard (aHR 0.75, 95% CI 0.71 to 0.78) [7]. Then a meta-analysis pooled 21 studies covering 104 million participants [5]. Herpes zoster vaccination tracked with about 24% lower risk of any dementia and 47% lower risk of Alzheimer's specifically [5]. Of every adult vaccine analyzed, the shingles shot had the strongest Alzheimer's signal. ⚠️ CAVEAT: The large-cohort and meta-analysis numbers are observational. The Wales and Australia natural experiments carry the near-causal load. The big cohorts point the same direction but can't rule out healthy-vaccinee bias. One more layer: this isn't one lab's pet result. The whole field is leaning the same direction. Shingrix Looks Even Better, and the Benefit Spans the Full Disease Course The live vaccine from those birthday experiments has mostly been replaced by Shingrix, a newer recombinant shot. The obvious question: does the new one do anything for the brain? A US natural experiment used the October 2017 switch from live to recombinant as its dividing line. Shingrix tracked with a 17% increase in time lived free of a dementia diagnosis, translating to 164 extra days without a diagnosis in people who eventually developed dementia [3]. It also outperformed flu vaccines and Tdap on dementia risk [3]. Something specific about the shingles shot stood out. The Welsh team also looked beyond new diagnoses at the full arc of disease. Two findings. The vaccine tracked with fewer mild cognitive impairment (MCI) diagnoses, down 1.5 percentage points over nine years (p=0.006) [2]. And among people already living with dementia, being eligible for the vaccine tracked with fewer deaths from dementia, down 8.5 percentage points over nine years (p=0.036) [2]. The deaths estimate carries wide confidence intervals from a smaller sub-group, so hold it loosely. But the shape of it: benefit at the front of the disease, the middle, and near the end. That is not what a coincidence usually looks like. Why a Rash Shot Might Touch Your Brain Nobody has proven the mechanism. Two hypotheses are in play. Both are published, biologically plausible, and not yet confirmed in humans. The first: if you had chickenpox, the varicella-zoster virus never actually left your body. It went dormant inside your nerve cells and stays there. With age, it can reactivate quietly, no rash, no obvious symptoms, acting as what a 2025 mechanism review calls a "renewable peripheral immune stressor" [8]. Repeated quiet reactivations may keep the brain's immune cells in a chronically primed, irritated state. The vaccine's job in this theory: suppress that reservoir and reduce what the same review calls "cumulative inflammatory tone" [8]. The second: trained immunity. The shot may give the innate immune system a broad anti-inflammatory reset, non-specific to the varicella-zoster virus, lowering inflammatory tone more generally [9]. Both mechanisms could be operating at once. The data can't yet separate them [8]. What both share: inflammation is the dial. And you can measure it. High-sensitivity CRP is the most accessible systemic-inflammation proxy. Phoenix optimal: 0 to 0.5 mg/L (acceptable below 1.0). For APOE4 carriers, who tend to run hotter on neuroinflammation, this is a trackable window into the exact fire both theories are describing. ✅ ACTION STEP: Get an hs-CRP test. Phoenix optimal: 0 to 0.5 mg/L. Log and trend it in Phoenix Bloodwork. Three Caveats the Headlines Don't Print1. No carrier-specific data exists. Every number above, the 20%, the Australia replication, the 100-million meta-analysis, came from the general older population. Not one study broke the vaccine effect out by APOE4 status. The only study with any APOE4 data looked at the shingles disease, not the vaccine, and found the APOE4 interaction was "not consistent between women and men" [6]. We don't have a carrier-specific number. Anyone who claims one is guessing. The other side: APOE4 runs hotter on neuroinflammation than non-carriers. The proposed mechanism, quieting inflammatory tone, is if anything more relevant for us. The gap isn't a no. It is an open question. 2. The sex pattern is real but unsettled. Several studies showed a stronger effect in women: 22% more diagnosis-free time for women versus 13% for men in the Shingrix data [3], and a similar lean in the Welsh data [1]. The Australian JAMA replication, using the same rigorous design, found "no evidence of a significant treatment effect heterogeneity by sex" [4]. If you're male, don't write yourself off a pattern that failed to replicate in one of the most carefully designed checks. 3. The protection fades. In the Korean cohort of 2.5 million, the protective effect attenuated over time and was weaker in smokers and drinkers [7]. A shot is a head start, not a force field. What you do with diet, sleep, exercise, and metabolic health in the years after determines how long that head start holds. What to Do Right Now You don't have to wait for the 2029 trial. The shingles vaccine is already recommended for older adults to prevent shingles. That recommendation exists with or without any brain benefit. For most people in the right age band, this isn't an exotic intervention. It's already on the preventive care list. A cost-effectiveness model (assumptions-based modeling, not a measured outcome) estimated vaccination could avert around 12% of dementia cases and pencils out as cost-effective even starting at age 50 with mild cognitive impairment [10]. File under encouraging, not proof. The randomized trial the field needs? It's now being built. DAN-ZOSTER (NCT07485283) is recruiting around 162,000 people to test the recombinant shot with a pre-specified dementia endpoint. Results expected around 2029 [11]. Think about this like weighing odds. The downside of a vaccine already recommended for older adults, with a known safety profile, is low. The upside is the strongest near-causal dementia prevention signal we've ever had. For people in the eligible age band, that's a conversation worth having with your doctor now. For timing and availability in your country: ask the Phoenix Community, not a YouTube video or a blog post. Key Takeaways 💡 Quick-Start Protocol (This Week): Check your shingles vaccination status. If you're in the recommended age band, ask your doctor specifically about the recombinant version (Shingrix). This is probably already on your preventive care list. Track your hs-CRP. Both mechanistic theories point to inflammation as the shared dial. Phoenix optimal: 0 to 0.5 mg/L. Log and trend it in Phoenix Bloodwork. Don't let the APOE4 gap paralyze you. No study has measured our specific number yet. That's an open question, not a no. No biological reason exists to think carriers are excluded. Vaccination is a head start, not a finish line. The Korean data showed protection fades and erodes faster in smokers and heavy drinkers. The lifestyle dials still matter the decade after. Watch DAN-ZOSTER (NCT07485283). The first randomized trial with a pre-specified dementia endpoint. Results expected 2029. The Phoenix Clinical Trials engine surfaces this and similar studies for you. Track Inflammation, Get in the Trial Loop If you carry APOE4 and you're tracking your dementia risk, Phoenix Bloodwork lets you log hs-CRP, set a goal, and watch the trend over time. Both mechanistic theories in this story point directly at that marker. And because no study has tested the vaccine effect specifically in APOE4 carriers, the best move is to get counted in the data. Phoenix's Clinical Trials engine surfaces registered studies including DAN-ZOSTER (NCT07485283) and helps you find ones you're eligible for. Over 500 APOE4 carriers are already using it to stop being spectators in their own genetics. If you are not part of the Phoenix Community yet, check us out: we are the largest community of APOE4 carriers actively tracking and optimizing our health via the Phoenix App. Join us here. Cheers,Kevin Sources Match each numbered citation in the article to the same number below. Select View source to open the original paper or trial record. Eyting M, Xie M, Michalik F, Hess S, Chung S, Geldsetzer P. "A natural experiment on the effect of herpes zoster vaccination on dementia." Nature, 2025. View source Xie M, Eyting M, Bommer C, Ahmed H, Geldsetzer P. "The effect of shingles vaccination at different stages of the dementia disease course." Cell, 2025. View source Taquet M, Dercon Q, Todd JA, Harrison PJ. "The recombinant shingles vaccine is associated with lower risk of dementia." Nature Medicine, 2024. View source Pomirchy M, Bommer C, Pradella F, Michalik F, Peters R, Geldsetzer P. "Herpes Zoster Vaccination and Dementia Occurrence." JAMA, 2025. View source Maggi S, Fulop T, De Vita E, Limongi F, Pizzol D, Di Gennaro F, Veronese N. "Association between vaccinations and risk of dementia: a systematic review and meta-analysis." Age and Ageing, 2025. View source Yeh TS, Curhan GC, Yawn BP, Willett WC, Curhan SG. "Herpes zoster and long-term risk of subjective cognitive decline." Alzheimer's Research & Therapy, 2024. View source Oh J, Lee K, Yeo D, Cho J, Kim TH, Lee J, Lee H, Woo HG, Yon DK. "Herpes zoster vaccination and cognitive disorders in older adults." Alzheimer's & Dementia, 2026. View source Huang X, Gu BJ. "Shingles vaccination and neuroimmune vulnerability." Trends in Neurosciences, 2025. View source Ma YN, Karako K, Song P, Xia Y. "Can the herpes zoster vaccination be a strategy against dementia?" Drug Discoveries & Therapeutics, 2025. View source Wu Y, Yao Y, Liu J. "Cost-Effectiveness Analysis of Recombinant Zoster Vaccine at Age 50 for Chinese Adults with Mild Cognitive Impairment: A Modelling Study." Vaccines (Basel), 2026. View source DAN-ZOSTER (NCT07485283). ClinicalTrials.gov. [View source --- ## The #1 dementia risk factor isn't sugar, blood pressure, or your APOE4 status URL: https://apoe4.co/blog/posts/the-1-dementia-risk-factor-isn-t-sugar-blood-pressure-or-your-apoe4-status Published: 2026-08-07T19:00:00+00:00 Updated: 2026-08-07T19:00:27.388298+00:00 Summary: Hearing loss is the #1 modifiable dementia risk factor APOE4 carriers ignore. Learn why The Lancet Commission ranked it above blood pressure and genetics. The #1 dementia risk factor isn't sugar, blood pressure, or your APOE4 statusThe Lancet Commission ranked 14 modifiable dementia risk factors. The one at the very top isn't what anyone predicted.Dr. Kevin Tran August 07, 2026 Hi Phoenix friend, Hearing Loss and Dementia: The #1 Modifiable Risk Factor Most Carriers Never Check The biggest modifiable dementia risk factor isn't a supplement, a lab value, or a drug. It fits in your ear canal. 📺 This is the full written synthesis of the hearing loss and dementia deep dive. Prefer to watch? Here's the 28-minute video on YouTube: Introduction: The Lever Nobody Is Pulling If you carry APOE4, you're probably tracking ApoB, glucose, sleep, and VO2max. That's exactly right. And there's still one lever sitting at the top of the world's most rigorous dementia research that almost nobody has screened. Not blood pressure. Not physical inactivity. Not depression. Hearing loss. The 2024 Lancet Commission ranked 14 modifiable dementia risk factors. Hearing came out on top, with roughly 7% of all dementia cases worldwide attributable to it [1]. Nobody framed it as a brain thing. They framed it as a getting-old thing. That framing has cost people a decade of inaction on the cheapest, safest lever on the board. This synthesis covers every key insight from the video: how big the lever actually is (with the numbers), four routes your ears may be dragging your brain down, what the only randomized trial actually showed (more nuanced than headlines), the effectiveness gradient that completely changes the action item, an honest counterweight study, and the four-step protocol I'd run myself. Starting with a test that costs zero dollars. Hearing Loss Is the #1 Modifiable Dementia Risk Factor The scale is worth sitting with. A meta-analysis pooled 14 long-term prospective cohort studies and 726,900 participants. People with hearing loss were about 59% more likely to develop dementia (hazard ratio 1.59), and for Alzheimer's specifically the risk more than doubled (hazard ratio 2.24) [5]. Those are observational associations, not proof of cause. But the confidence interval for that dementia estimate runs from 1.37 to 1.86. It doesn't touch 1.0. This signal does not wash out across hundreds of thousands of people in fourteen separate cohorts. The Lancet Commission's pooled estimate puts the increased dementia risk from hearing loss at about 37% [1]. Together with the cohort scale, it earns the top spot among all 14 modifiable factors. For APOE4 carriers specifically: the researchers re-ran the 726,900-person analysis adjusting for APOE genotype. The hearing-dementia link held exactly the same [5]. Your genotype does not get you out of this one. It sits on top of it. One more line of evidence worth naming honestly: Mendelian randomization, which uses genetic variants as a natural experiment to probe causation, pointed the same direction in a study across 31 cohorts and 937,908 participants. A genetic predisposition toward hearing impairment tracked with higher dementia odds (OR 1.74) and higher Alzheimer's odds (OR 1.56) [6]. The honest caveat: other research groups have run similar MR analyses and found no causal signal, so the genetic evidence is not settled [7]. Multiple lines converging toward cause. Not a closed case. 💡 KEY INSIGHT: Hearing loss accounts for roughly 7% of all dementia cases globally, the single largest share among 14 modifiable risk factors (2024 Lancet Commission). The association held after adjusting for APOE genotype in the largest prospective meta-analysis to date. Four Routes Your Ears May Be Dragging Your Brain Down The mechanisms matter because they determine whether fixing hearing actually helps. Four routes are proposed in the human research, and they likely interact. Effortful listening depletes cognitive reserve. When speech is muffled, your brain works overtime to decode it. Researchers call this "increased cognitive load during effortful listening" [8]. Every strained conversation burns from the same resource pool your memory and thinking run on. Restore clear sound and those resources come back. Sensory deprivation may drive brain atrophy. Years of reduced auditory input are associated with structural changes in brain regions that process sound. Less input, less structure maintained over time. Social isolation amplifies the damage. A national population study using real audiometric testing found people with hearing impairment had significantly higher rates of social isolation, and isolation independently tracked with more dementia [9]. Hearing loss does not just take the sound. It takes the room, the dinner table, the conversations, the whole social environment that protects cognitive health. Reverse causation adds a critical wrinkle. A 2025 review laid out something worth knowing: the relationship may run in both directions [7]. Early Alzheimer's pathology can damage central hearing centers, meaning hearing trouble is sometimes a consequence, an early signal of brain change, not only a cause of future decline. The review noted evidence that Alzheimer's genetic risk may drive hearing impairment rather than only the other way around [7]. This is why acting on hearing makes sense in every version of the story. Whether it is a cause, a catalyst, or an early warning light, addressing it wins. ⚠️ CAVEAT: All cited mechanisms are from human data. Their relative contributions to dementia risk are still being established. "Biologically plausible, multiply supported, and unsettled" is the accurate description. The Randomized Trial: Null Overall, 48-62% in the Higher-Risk Subgroup For decades, no one ran a randomized controlled trial to test whether treating hearing loss actually slows cognitive decline. Then ACHIEVE did. ACHIEVE enrolled 977 older adults across four US sites. Half received hearing aids plus comprehensive audiologist support. Half received a health-education control. Three years later, the headline result: global cognitive change was not significantly different between the two groups [2]. A null result for the full cohort. Most coverage stopped there. That is the wrong stopping point. The trial included prespecified subgroup analyses by baseline cognitive risk level. In higher-risk older adults, three-year cognitive decline was 48% slower with hearing intervention [2] [3]. In the very top quartile of predicted risk, the slowdown reached about 62% [3]. The trial's own conclusion: "Hearing intervention may reduce cognitive change over 3 years in populations of older adults at increased risk for cognitive decline but not in populations at decreased risk" [2]. This is not a "hearing aids protect everyone" finding. It is a higher-risk-older-adults finding and the subgroup result specifically, not the primary endpoint. That precision matters and it needs to travel with the numbers. Why does this apply to APOE4 carriers? Not because there is a measured carrier-specific interaction (that trial has not been run). But because the people who benefit are the people already carrying elevated baseline risk. If you carry the gene, have family history, and are in your fifties, you are plausibly in that higher-risk bucket. That is reasoning, not a proven effect. Use it that way. 💡 KEY INSIGHT: ACHIEVE was null for the full cohort. The 48-62% slower cognitive decline is a prespecified subgroup result in higher-risk older adults. Apply these numbers precisely, not broadly. The Fitting Is the Entire Game (Not the Purchase) A May 2026 pooled analysis of 61,089 participants across 33 countries makes the key distinction explicit [4]. Any hearing-aid use tracked with about 9% lower risk of probable dementia (HR 0.91). Effective use, where the aid genuinely improved hearing, tracked with about 14% lower risk (HR 0.86). Poor or ineffective use? No benefit at all. Hazard ratio 0.98, essentially indistinguishable from not using one [4]. The authors are explicit: this is observational. They cannot definitively prove causation [4]. Hold the numbers loosely for exactly that reason. But the pattern aligns precisely with what the randomized trial found in higher-risk people, and it completely changes the action item. It was never "buy a hearing aid." It is "get properly fitted by an audiologist, confirm it actually improves your hearing, and keep it in your ears." An aid half-tuned and living in a drawer achieves nothing. In ACHIEVE, participants in the benefit group wore their aids about seven hours a day and showed meaningful improvement in self-reported communication. The effectiveness was the point. The drawer is where hearing aids go to die. ⚠️ CAVEAT: The 14% lower dementia risk is observational, not from a randomized trial. Treat it as directional evidence, not a guaranteed outcome. The Honest Counterweight One 2026 MRI study complicates the tidy story, and it belongs in any honest account. Researchers followed 312 older adults with brain imaging over three years. What predicted cortical thinning in speech-processing networks? Central auditory processing (how well the brain understands speech in noise), not peripheral hearing loss and not hearing-aid use. In this cohort, hearing aids showed no statistically significant effect on brain structure [10]. The researchers proposed that speech-in-noise performance may be "an early behavioral marker of neural vulnerability" that shows up before standard cognitive tests detect anything [10]. This supports the reverse-causation angle: some of the hearing-dementia link may reflect the brain already changing first, not only hearing damage causing future decline. Hearing aids "confer essentially no medical risk," the ACHIEVE researchers stated directly [2]. Downside: a fitting fee and adjustment time. Upside, in higher-risk people: 48-62% slower cognitive decline in the best available trial, and observationally about 14% lower dementia risk when the aid actually works. Whether you are removing a cause, breaking a catalyst chain, or catching an early signal early, the downside is the same fitting fee in every version. That is an asymmetric bet. The kind worth making every time. A next-generation trial, ARCH (N = 210, comparing cochlear implants versus hearing aids for slowing cognitive decline), is already running with results expected in 2029 [11]. The science is getting sharper. You do not have to wait for 2029 to book a test this year. Key Takeaways 💡 Quick-Start Protocol (This Week): Book a baseline hearing test. Most audiologist screenings are free. This is the single biggest action in this post. Do it before anything else. If there is loss: see an audiologist, not an over-the-counter display. Professional fitting is what separates the 14% observational benefit from zero. Confirm your aid actually improves your hearing. Ask for a before-and-after functional assessment. Poor/ineffective use gave no dementia-risk reduction at all in the 61,000-person pooled data [4]. Wear it most of your waking hours. Not just for special occasions. The higher-risk group that benefited in ACHIEVE averaged about 7 hours daily. Track it so you do not quietly let it slide. The gap between knowing and doing is where most interventions die. The primary ACHIEVE endpoint was null for the full cohort. The 48-62% slower decline is the subgroup result for higher-risk older adults. That precision always travels with those numbers. Run This as a Tracked Phoenix Experiment Knowing the four steps and doing them for six months are two different things. Inside Phoenix, you can set this up as a tracked Experiment: log your baseline hearing test, the fitting appointment, your audiologist's before-and-after scores, and daily wear time. You will know whether you are in the effective-use bucket (the one that mattered in the data) or the drawer-aid bucket. And 500+ APOE4 carriers are already running their own protocols there, comparing notes on audiologists and what actually moved their numbers. That accountability is the entire point. Turn this into a tracked Phoenix Experiment this week, and let the community keep you honest. If you are not part of Phoenix yet, join us here! Cheers,Kevin Sources Match each numbered citation in the article to the same number below. Select View source to open the original paper or trial record. Livingston G, Huntley J, Liu KY, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet 2024. View source Lin FR, Pike JR, Albert MS, et al. Hearing intervention versus health education control to reduce cognitive decline in older adults with hearing loss in the USA (ACHIEVE): a multicentre, randomised controlled trial. Lancet 2023. View source Pike JR, Huang AR, Reed NS, et al. Cognitive benefits of hearing intervention vary by risk of cognitive decline: A secondary analysis of the ACHIEVE trial. Alzheimer's & Dementia 2025. View source Jiang F, Dong Q, Jayakody DMP, et al. Hearing aid effectiveness and probable dementia risk across 33 countries: A pooled analysis of seven cohorts. Cell Reports Medicine 2026. View source Liang Z, Li A, Xu Y, Qian X, Gao X. Hearing Loss and Dementia: A Meta-Analysis of Prospective Cohort Studies. Frontiers in Aging Neuroscience 2021. View source Jiang F, Dong Q, Wu S, et al. A comprehensive evaluation on the associations between hearing and vision impairments and risk of all-cause and cause-specific dementia: results from cohort study, meta-analysis and Mendelian randomization study. BMC Medicine 2024. View source Levett BA, Chandra A, Jiang J, et al. Hearing impairment and dementia: cause, catalyst or consequence? Journal of Neurology 2025. View source Motta G, Tortoriello G, Testa D. Is Age-Related Hearing Loss a Modifiable Risk Factor for Cognitive Decline? Mechanisms, Evidence, and Future Directions. Audiology Research 2026. View source Venkatesh S, Wong R, Corsten M, et al. Elucidating the relationship between hearing loss, social isolation, and dementia: data from the National Health and Aging Trends Study. The Journals of Gerontology: Series B 2026. View source Zanin J, McNeil JJ, Rance G. Speech-in-Noise Ability and Longitudinal Cortical Thinning in Speech-Processing Networks. JAMA Otolaryngology-Head & Neck Surgery 2026. View source Shulman LM, Caraher K, Cummings MP, et al. Prospective longitudinal observational study at an academic medical centre of lifestyle and cognition in older adults with a cochlear implant or hearing aid: study protocol (ARCH study). BMJ Open 2026. [View source --- ## Phoenix Study: Your free Cambridge University memory test URL: https://apoe4.co/blog/posts/phoenix-study-your-free-cambridge-university-memory-test-2169 Published: 2026-08-04T19:00:00+00:00 Updated: 2026-08-04T19:00:29.005338+00:00 Summary: Cambridge-developed memory test, free for APOE4 carriers and those with family dementia history. Take the Phoenix Study and track your brain health. Phoenix Study: Your free Cambridge University memory test Developed over a decade. Normally a paid test. Free for you as part of our Phoenix study.Dr. Kevin Tran August 04, 2026 Hi Phoenix friend, You can help build one of the largest studies of its kind focused on APOE4 and early memory change. And it takes 10 to 15 minutes. The goal: 300+ participants. Phoenix, PREMAZ and the University of Cambridge are working together to study early memory change in people who carry APOE4 or have a family history of dementia. The PREMAZ test normally costs money. For our Phoenix study participants it is free. Because you are part of my Phoenix newsletter, you get it for free. You do not need a Phoenix membership to take part. If you are a confirmed APOE4 carrier or you have a family history of dementia, you are eligible. And your participation gives you something valuable too: A baseline of where your memory is today.Then test again in about three months to see whether your interventions are actually improving your brain health. One result shows where you are. Two results show whether your memory changed. Why this memory test is different Dr. Julia Cooney is a medical doctor, a dementia researcher, and the founder of PREMAZ. In this short video, Julia explains why your participation matters: Most cognitive tests look for problems after symptoms appear. The PREMAZ test measures the quality of your memory by looking at how precise and detailed your memories are. It builds on more than ten years of research at the University of Cambridge, and in published Cambridge research it caught differences even when a standard neurologist assessment came back normal. Your interventions should face a real test You may already be working hard on your brain health. Improving sleep. Exercising. Changing your diet. Taking supplements. Managing stress. Effort is not proof. A PREMAZ baseline gives you a result you can compare over time, and comparing your two results answers the question that matters: Are my interventions actually changing my cognition? 👉 Take the free PREMAZ memory test Set aside 10 to 15 quiet minutes. Use a laptop or tablet if you can. And you are helping Cambridge Your result does not stop at your inbox. It feeds the work Cambridge is doing on how memory changes early, years before anything shows up on a standard assessment. APOE4 is a risk factor, not a diagnosis. I keep saying that because it is true, and because the earlier we can see change, the more there is to do about it. That is what this study is for. Why the study is best done with Phoenix A memory score tells you what changed. The harder question is why. The test is free and you can take it without Phoenix. But if you want to know which of your interventions moved the number, you need the other half of the picture. Phoenix members start the test from a Free memory test box on their Phoenix dashboard, so their result sits next to everything Phoenix already tracks for them: Sleep and wearable data Daily check-ins, so energy, brain fog, mood and sleep quality Supplements and adherence Interventions and experiments Their own notes on how they feel Baseline now, three months of logged changes, second test. That is what lets me run the analysis nobody else can run: which of the things you changed actually moved your memory, and which ones did nothing. Did better sleep move the score? A new supplement? More exercise? Less alcohol? Something you stopped? You can join Phoenix here.Help us reach 300+ A cohort of 300+ gives the research a real chance of publication, and helps researchers build more focused prevention strategies for people like us. But 300+ only happens if people like you take part. Start with the test: 👉 Take the free PREMAZ memory test Your result helps you track your brain. Your participation helps all of us understand brain health better. Help us make it happen.Feel free to share this with your friends and family! Cheers, Kevin --- ## The APOE4 Diet: What to Eat, What to Avoid, and Why It's Different URL: https://apoe4.co/blog/posts/apoe4-diet Published: 2026-08-04T00:48:41+00:00 Updated: 2026-08-04T00:48:46.933096+00:00 Summary: The MIND diet is tied to a 53% lower Alzheimer's rate. Here's what APOE4 carriers should eat, avoid, and adjust based on the actual research. The APOE4 Diet: What to Eat, What to Avoid, and Why It's DifferentThe MIND diet is tied to a 53% lower Alzheimer's rate. Here's what APOE4 carriers should eat, avoid, and adjust based on the actual research.Dr. Kevin Tran August 03, 2026 By Dr. Kevin Tran, PharmD · Last updated: August 4, 2026 There's no single "APOE4 diet" prescribed by science, but the closest thing to one is the MIND diet: in the study that defined it, people who followed it most closely had a 53% lower rate of Alzheimer's than people who followed it least. Layered on top of that foundation, a handful of adjustments matter more if you carry APOE4 than if you don't: how much saturated fat you eat, how much omega-3 you get, how you handle refined carbs, and how much you drink. This guide walks through what the research actually shows for each of those, in plain terms, with the studies behind every claim. What is the APOE4 diet? There's no diet plan specifically named or clinically validated as "the APOE4 diet." What exists instead is the MIND diet (Mediterranean-DASH Intervention for Neurodegenerative Delay), a hybrid of the Mediterranean and DASH diets built specifically around foods linked to slower brain aging, plus a set of genotype-specific tweaks that research suggests matter more for APOE4 carriers than for the general population. Think of it as two layers. Layer one is the MIND diet itself, which anyone can follow. Layer two is where your genotype comes in: APOE4 changes how your body processes fat, cholesterol, and glucose, and a few studies have found that carriers respond differently to certain foods than non-carriers do. That's the part this guide focuses on. Is the MIND diet good for APOE4 carriers? Yes, and the original research behind it is some of the strongest diet-and-brain data available. In a prospective study of 923 older adults followed for an average of 4.5 years, people in the highest third of MIND diet adherence had a 53% lower rate of Alzheimer's disease than people in the lowest third, and even moderate adherence (the middle third) was tied to a 35% lower rate (Morris et al., 2015, Alzheimer's & Dementia). A companion study from the same research group, following 960 older adults for an average of 4.7 years, found that high MIND diet adherence was associated with meaningfully slower cognitive decline, a difference the researchers said was equivalent to being about 7.5 years younger (Morris et al., 2015, Alzheimer's & Dementia). Both studies are observational, meaning they show an association, not proof that the diet itself caused the difference, but the effect size and consistency across two independent cohorts is notable. More specific to APOE4: an analysis of blood samples from 442 participants in the actual MIND diet randomized controlled trial found that the relationship between plasma carotenoids (compounds from colorful fruits and vegetables) and cognitive performance was strongest specifically in APOE4 carriers. Among carriers, higher carotenoid levels were tied to meaningfully better global cognition; among non-carriers, the same relationship was weaker or not statistically significant (Liu et al., 2025, American Journal of Clinical Nutrition). In other words, the produce-heavy part of the MIND diet may matter more, not less, if you're a carrier. What should APOE4 carriers eat? The MIND diet's "eat more of" list is specific, not a vague "eat healthy" suggestion: Leafy greens: at least 6 servings a week Other vegetables: at least 1 serving a day Berries: at least 2 servings a week (berries specifically, not fruit in general; they carry the diet's antioxidant load) Nuts: at least 5 servings a week Olive oil: used as your main cooking fat Whole grains: at least 3 servings a day Fish: at least 1 serving a week Beans: at least 3 meals a week Poultry: at least 2 meals a week Within that framework, a few components carry extra weight for APOE4 carriers specifically. Extra virgin olive oil, and specific vegetables like leafy greens and cruciferous vegetables (broccoli, cauliflower, Brussels sprouts), contain compounds that researchers studying APOE4 biology have flagged as relevant to some of the same cellular pathways the e4 variant disrupts. That mechanistic research is still early and comes mostly from cell and animal models, so treat it as a reason to lean into foods you should already be eating, not a reason to hunt down a specific supplement (Norwitz et al., 2021, Nutrients). What foods should APOE4 carriers avoid? The MIND diet's "eat less of" list: red meat (under 4 servings a week), butter and margarine (under 1 tablespoon a day), cheese (under 1 serving a week), pastries and sweets (under 5 servings a week), and fried or fast food (under 1 serving a week). For APOE4 carriers, two items on that list deserve a closer look than the rest: saturated fat and refined carbohydrates. The next two sections cover why. Should APOE4 carriers eat saturated fat differently than everyone else? The research says yes, and it's one of the better-established genotype-specific findings in this space. APOE plays a direct role in how your body packages and clears cholesterol, so it makes biological sense that different APOE versions would respond differently to dietary fat, and several controlled studies bear that out. In a randomized dietary intervention trial of 469 adults (the RISCK study), researchers tested what happened when participants swapped saturated fat for either low-glycemic-index carbohydrates or unsaturated fat. APOE4 carriers saw significantly larger drops in total cholesterol and apolipoprotein B (apoB) than APOE3/E3 participants did when saturated fat was replaced with low-glycemic-index carbs on a lower-fat diet (Griffin et al., 2018, Nutrients). Put simply: cutting saturated fat moved the needle on cholesterol and apoB more for E4 carriers than for E3/E3 participants in that comparison. The trial also included E2 carriers, so this result should not be stretched into an E4-versus-everyone ranking. A separate controlled dietary study of 88 UK adults found something similar for inflammation. When participants ate a high-saturated-fat diet, C-reactive protein (CRP, an inflammation marker) rose significantly in APOE3/E4 carriers but not in APOE3/E3 carriers, a genotype-by-diet interaction that reached statistical significance (Carvalho-Wells et al., 2012, American Journal of Clinical Nutrition). Those two studies measure blood chemistry, not brain outcomes directly. For the brain-specific piece, the evidence so far comes from mouse models: in one study, mice engineered to carry human APOE4 (and a model of Alzheimer's pathology) developed substantially more amyloid buildup and brain inflammation on a Western-style diet high in saturated fat and sugar than mice carrying human APOE3 on the identical diet (Moser & Pike, 2017, eNeuro). That's a mouse finding, not a human one, but it lines up mechanistically with what the human lipid and inflammation data show: your genotype appears to change how your body handles saturated fat, and APOE4 carriers may have the most to gain from keeping it in check. If you're already tracking ApoB and LDL, our lipid playbook breaks down the specific targets that matter more for carriers. Do APOE4 carriers need more omega-3 or DHA? Researchers are testing whether APOE4 changes how supplemental DHA is handled, but no clinical guideline sets a special DHA dose for the genotype, and the small pilot below did not establish a genotype-specific delivery difference. In a small randomized pilot, 33 older adults were assigned to 2,152 mg/day of DHA or placebo for six months, and 26 completed both cerebrospinal fluid (CSF) collections. Compared with placebo, the DHA arm increased CSF DHA by 28% and CSF EPA by 43%; plasma DHA and EPA also increased. Plasma changes did not differ significantly by APOE4 status. The exploratory CSF analysis produced a threefold larger EPA increase as a point estimate in non-carriers, but the genotype-by-treatment interactions were not statistically significant for DHA (p=0.61) or EPA (p=0.54), and the pilot was not designed to detect those interactions (Arellanes et al., 2020, EBioMedicine). The authors also caution that CSF fatty-acid changes do not simply equal brain uptake. This study raises a delivery hypothesis; it does not prove a genotype difference, compare doses, or establish a carrier-specific intake target. Practically, make fatty fish such as salmon, mackerel, and sardines a regular part of your MIND-style pattern. If you are considering a high-dose DHA product, discuss the product, dose, and your medication list with a doctor or pharmacist first. What about refined carbs and blood sugar? Human diet trials do not establish a separate low-carbohydrate or ketogenic prescription for APOE4 carriers. The strongest carrier-specific dietary trial here is RISCK: when saturated fat was replaced with low-glycemic-index carbohydrates in a lower-fat diet, APOE4 carriers had larger reductions in total cholesterol and ApoB than APOE3/E3 participants (Griffin et al., 2018, Nutrients). That was a lipid trial, not an Alzheimer's-outcome trial. The practical move is simpler than the molecular theories: prioritize minimally processed, high-fiber carbohydrate sources already central to the MIND diet, such as vegetables, beans, and whole grains, and keep pastries, sweets, and other refined carbohydrates occasional. More restrictive plans need an individual conversation with a clinician because long-term APOE4-specific outcome trials are not available. Should APOE4 carriers drink alcohol? This is the one area where the evidence is genuinely mixed, and it is better to use the direct cohorts than a tidy review summary. In a study of 3,021 adults aged 72 and older, the alcohol findings were consistent after stratification by APOE4 genotype. The clearest risk signal was more than 14 drinks a week in people who already had mild cognitive impairment (Koch et al., 2019, JAMA Network Open). A separate longitudinal study of older adults in Sydney also found no significant interaction between alcohol consumption and APOE4 status, although APOE4 carriers had higher dementia risk overall (Heffernan et al., 2016, Journal of Alzheimer's Disease). Those studies do not establish alcohol as protective for APOE4 carriers. They also do not produce a clean carrier-specific rule for light drinking. Heavy drinking is the clear risk signal. If alcohol is a meaningful part of your life, bring the question and your broader risk profile to a clinician. Does diet alone move the needle, or do I need to do more? Diet is one lever, not the only one, and the best data on combining levers comes from the FINGER trial, the largest randomized controlled trial testing a multidomain lifestyle intervention (diet, exercise, cognitive training, and vascular risk management together) for cognitive decline prevention. In a prespecified subgroup analysis of FINGER's 1,109 participants, the intervention-versus-control estimate was statistically clear among APOE4 carriers (362 participants), while the confidence interval crossed zero among non-carriers (747 participants). The formal test of whether the intervention worked differently by genotype was not statistically significant. The clean conclusion is that healthy lifestyle changes may benefit at-risk older adults even when they carry APOE4; the trial did not establish equal benefit in both groups or a carrier-specific advantage (Solomon et al., 2018, JAMA Neurology). Diet was one of four pillars in that intervention, not tested on its own, so FINGER can't tell you how much of the effect came from diet specifically versus exercise, cognitive training, or vascular risk management. The practical takeaway: diet changes covered in this guide are a real, evidence-backed lever, but the strongest data we have says they work best as part of a broader plan, not as a standalone fix. If you're building out a fuller plan and want to know what biomarkers to track as you make these changes, our blood work blueprint covers the ranges that matter more for carriers, and our essential guide walks through the full picture beyond diet. Frequently Asked QuestionsIs there one official "APOE4 diet" I should follow? No single diet is clinically validated as "the APOE4 diet." The MIND diet has the strongest general evidence behind it, and a handful of specific adjustments (lower saturated fat, higher omega-3, lower refined carbs, more caution on alcohol) are what the APOE4-specific research points to layering on top. Do APOE4 carriers really need to eat less saturated fat than everyone else? The evidence suggests carriers may see a bigger benefit from cutting it, not that non-carriers are unaffected by saturated fat. Controlled trials found APOE4 carriers had larger improvements in cholesterol, apoB, and inflammation markers when saturated fat was reduced, compared with APOE3/E3 participants in the same trials. How much DHA or omega-3 should an APOE4 carrier take? There is no dedicated dose-finding trial that establishes one APOE4 target. The small pilot used 2,152 mg/day and measured plasma and CSF fatty acids, but it found no significant genotype-by-treatment interaction, did not measure brain uptake directly, and did not compare doses or establish a clinical guideline. Talk to a physician or pharmacist about your current intake and whether supplementation makes sense for you. Is a glass of wine actually protective for APOE4 carriers? Unclear. Some research suggests the general-population finding that light drinking is protective doesn't hold for APOE4 carriers, but the largest direct cohort studies on this question found no significant APOE4-specific effect either way. Heavy drinking is consistently linked to worse outcomes for everyone, carrier status aside. Will changing my diet alone lower my Alzheimer's risk if I'm APOE4-positive? Diet is a real, evidence-backed lever, but the strongest trial data on lifestyle intervention (FINGER) tested diet as one part of a four-part program alongside exercise, cognitive training, and vascular risk management. There's no dedicated trial isolating diet's effect on its own in APOE4 carriers. Should I get genetic testing before changing my diet? No. Most of the guidance in this piece (more produce, less refined sugar, prioritizing unsaturated fat, adequate omega-3) is reasonable for long-term brain health regardless of your APOE status. Knowing your genotype helps you interpret evidence on saturated-fat response, DHA delivery, and alcohol more carefully, but it does not create a proven higher DHA intake target. Diet is one piece of a plan built for your genotype, not a generic "eat healthy" checklist. Start with Phoenix and get the tracking, ranges, and community built specifically for APOE4 carriers. --- ## What Does Having APOE4 Mean? A Guide for Anyone Who Just Found Out URL: https://apoe4.co/blog/posts/apoe4-meaning Published: 2026-08-02T22:17:38+00:00 Updated: 2026-08-02T22:17:44.687248+00:00 Summary: You just found out you carry APOE4. Here's what that actually means, whether it causes symptoms, your real odds, and what to do first. What Does Having APOE4 Mean? A Guide for Anyone Who Just Found OutYou just found out you carry APOE4. Here's what that actually means, whether it causes symptoms, your real odds, and what to do first.Dr. Kevin Tran August 02, 2026 By Dr. Kevin Tran, PharmD · Last updated: August 1, 2026 APOE4 is a common variant of a gene that helps your body manage cholesterol and fat. Carrying it does not mean you have Alzheimer's, it does not cause any symptoms on its own, and most people who carry it never develop the disease. What it means is that your odds shifted, and by how much depends on things like how many copies you carry and your ancestry. That shift is worth understanding. It isn't worth panicking over. If you're reading this because a 23andMe report just flagged something, a doctor mentioned "APOE" in passing, or you've watched a parent decline and you're wondering what that means for you, take a breath. You're not alone in asking this, and the answer is more hopeful than most people expect going in. What does it mean to have APOE4? Everyone carries two copies of the APOE gene, one from each parent. Each copy comes in one of three common forms: e2, e3, or e4. Most people carry two copies of e3, the common version. If you carry one or two copies of e4 instead, your risk of Alzheimer's disease is higher than someone with two e3 copies, but "higher risk" and "will get the disease" are not the same statement. A landmark 1997 meta-analysis of nearly 15,000 people found that, in the Caucasian populations studied, one copy of e4 paired with the common e3 copy raised the odds of Alzheimer's roughly threefold, and two copies of e4 raised it closer to fifteenfold, compared with two copies of e3 (Farrer et al., 1997, JAMA). A more recent review in Neuron calls APOE4 "the strongest genetic risk factor" identified for Alzheimer's to date, translating those numbers into rounder terms: one copy tends to raise risk 2 to 4 times, two copies tend to raise it 8 to 12 times (Belloy et al., 2019, Neuron). How much e4 raises your risk also depends on ancestry: the effect is stronger in East Asian populations and comparatively weaker in African American populations, so no single number tells the whole story for everyone (Belloy et al., 2019, Neuron). Here's the part that matters most: APOE4 is a risk-modifying gene, not a deterministic one. A small number of rare, inherited mutations, in genes called PSEN1 and APP, do essentially guarantee early-onset Alzheimer's if you carry them. Those are a different category of genetics entirely, described in the research as acting through an "autosomal dominant" pattern of inheritance (Belloy et al., 2019, Neuron). APOE4 doesn't work that way. It shifts probability. It doesn't hand down a verdict. Does APOE4 cause symptoms? No. This is worth saying plainly: APOE4 itself produces no symptoms. It's a gene, not an illness. You've carried whatever version of APOE you have since before you were born, and it doesn't announce itself through headaches, memory lapses, or anything else you'd notice day to day. If you searched for "APOE4 symptoms" hoping to check yourself against a list, that list doesn't really exist, because the gene and the disease are two different things. Alzheimer's disease has symptoms. APOE4 is one of several factors that can make Alzheimer's more likely to eventually develop. If you're currently noticing real memory or cognitive changes in yourself or someone else, that's a separate, more urgent conversation to have with a doctor, and it's worth having regardless of what your APOE status turns out to be. This guide is about the gene, not about diagnosing symptoms. The reassuring version of this: research shows that even in older adults with no cognitive symptoms at all, APOE4 carriers are somewhat more likely to have early biological markers of Alzheimer's pathology building quietly in the brain than non-carriers (Belloy et al., 2019, Neuron). But "somewhat more likely to have an early marker" is a long way from "will develop symptoms," and plenty of carriers never do. What are my actual odds? This is usually the real question underneath "what does APOE4 mean," so let's answer it directly, with numbers instead of vague reassurance. The relative risk figures above (roughly 2 to 4 times for one copy, 8 to 12 times for two, per the Neuron review) describe how your risk compares to someone with two e3 copies. They don't tell you your actual chance of developing the disease. For that, absolute risk numbers matter more, and they're more reassuring than the multipliers suggest. A study that pooled data from several long-running population studies, including the Framingham Heart Study and the Rotterdam Study, calculated the lifetime chance of developing mild cognitive impairment or dementia specifically for people with two copies of e4, the highest-risk genotype. By age 80 to 85, that lifetime incidence came out to roughly 31% to 40%, depending on the age people were tracked from (Qian et al., 2017, PLoS Medicine). Read that the other way: most people with two copies of e4, the highest-risk genotype there is, do not develop MCI or dementia by their mid-80s. If you carry one copy paired with e3, which is far more common than carrying two e4 copies, your absolute risk sits meaningfully lower than that. Two more details worth knowing. Research suggests the risk from carrying e4 may be more pronounced in women than in men, particularly with a single copy: some studies found the odds increase clearly in women in their 50s through 80s but barely moved for men with the same genotype, though this pattern is still being actively studied (Belloy et al., 2019, Neuron). And age at onset shifts too: on average, e4 carriers who do develop Alzheimer's tend to do so about 12 years earlier than non-carriers who develop it (Belloy et al., 2019, Neuron). Neither of those is a reason to panic. Both are useful for knowing what to pay attention to and when. Risk isn't destiny: what actually changes the odds The numbers above describe what happens on average, across large groups, when nothing else is done. They are not a forecast of what will happen to you specifically, and that distinction matters because your daily choices appear to move the needle even for carriers. The best evidence for this comes from the FINGER trial, a two-year randomized study that put at-risk older adults through a combined program of diet changes, exercise, cognitive training, and management of vascular risk factors like blood pressure, then measured cognition against a control group given general health advice. The intervention-versus-control estimate was statistically clear among APOE4 carriers, while the non-carrier confidence interval crossed zero. The formal test found no statistically significant difference between genotypes, so the trial establishes neither equal subgroup benefit nor a carrier-specific advantage (Solomon et al., 2018, JAMA Neurology). The researchers' own conclusion is the more important takeaway: "Healthy lifestyle changes may be beneficial for cognition in older at-risk individuals even in the presence of APOE-related genetic susceptibility to dementia" (Solomon et al., 2018, JAMA Neurology). That's the shift worth making, mentally: from "I carry a risk gene, so my path is set" to "I carry a risk gene, so tracking the things I can act on matters more for me than it does for someone without it." Phoenix's Essential Guide to Thriving with APOE4 walks through what that looks like in practice, free, as a starting point. I tested positive for APOE4. What should I do first? Nothing urgent. There is no emergency action a positive result requires, and the people who do best with this news tend to be the ones who take it slow rather than the ones who spiral into researching worst-case scenarios at 2 a.m. A few genuinely useful first steps, in roughly the order they tend to help: Let the news settle before you act on it. Research that followed adult children of Alzheimer's patients through genetic disclosure found that learning your APOE result did not cause a significant increase in anxiety or depression compared with not testing at all, even among the people who learned they carried the higher-risk e4 variant (Green et al., 2009, NEJM). Knowing tends to be more manageable than people expect before they know. Talk to someone who understands this specific situation. A generalist doctor may not have deep familiarity with APOE genetics, and a genetic counselor can walk you through what your specific result means for you and, if it comes up, your family. If you found out through a service like Sequencing.com, Phoenix's partnership page was built specifically for people in exactly your position right now, someone who just got an APOE4 result and needs the next step explained without jargon or alarm. Start tracking, not guessing. The FINGER-style interventions above (diet, exercise, cognitive training, vascular health) work whether or not you formally join a program, but doing them with structure, and with baseline biomarkers to measure against, is what turns "I should probably eat better" into an actual plan. That's the starting point Phoenix's Essential Guide is built around. Consider that you don't have to figure this out alone. I built Phoenix because I carry APOE4/4, for APOE4 carriers. Phoenix's public site states that 89% of members self-report an improvement in an APOE4 biomarker within three months (Phoenix public results statement). A genetic result can become more useful when you have a specific plan instead of a vague sense of worry. Frequently Asked QuestionsIs APOE4 the same thing as having Alzheimer's? No. APOE4 is a gene variant that raises your statistical odds of developing Alzheimer's disease later in life. It is not the disease itself, it doesn't diagnose the disease, and it doesn't guarantee the disease will develop. Most people who carry it, including people with two copies, never develop it. Does it matter whether I have one copy of e4 or two? Yes. Research shows a clear dose effect: carrying two copies of e4 raises your relative risk more than carrying one, and typically shifts the age of onset earlier if the disease does develop (Belloy et al., 2019, Neuron). But even with two copies, the majority of carriers do not develop MCI or dementia by their mid-80s, based on long-term population data (Qian et al., 2017, PLoS Medicine). Can lifestyle changes actually lower my risk if I carry APOE4? Early evidence is encouraging. In FINGER's two-year trial combining diet, exercise, cognitive training, and vascular risk management, the intervention estimate was statistically clear among APOE4 carriers, and the study's authors concluded that healthy lifestyle changes may help even in the presence of APOE-related genetic risk (Solomon et al., 2018, JAMA Neurology). The study did not establish that carriers benefited more than non-carriers. This isn't a cure and it isn't guaranteed, but it's real evidence that your choices matter. Should I tell my children or siblings that I carry APOE4? That's a personal decision, and a genetic counselor is specifically trained to help you think through it, since APOE genotype can run in families. There's no medical urgency to disclose immediately, so it's worth taking the time to think about how and when you'd want to have that conversation, if at all. Can someone develop Alzheimer's without carrying APOE4 at all? Yes. APOE4 raises risk, but it's neither necessary nor sufficient for Alzheimer's to develop. Plenty of people without any copy of e4 still develop the disease, and plenty of people with one or even two copies never do. Age, other genes, cardiovascular health, and lifestyle factors all play a role alongside genotype. Is there anything urgent I need to do right now? No. There's no emergency action a positive APOE4 result requires. The useful next step is unhurried: give yourself time to process the news, consider talking to a doctor or genetic counselor about what it means for your specific history, and start building a tracking plan for the factors that are actually within your control. You don't have to sit with this news alone or figure out what comes next by yourself. Start with Phoenix and get a plan built specifically for APOE4 carriers, not a generic wellness plan that has no idea what your genotype means. --- ## How to Get Tested for APOE4: A Complete Guide URL: https://apoe4.co/blog/posts/apoe4-test Published: 2026-08-02T12:36:08+00:00 Updated: 2026-08-02T12:36:12.953961+00:00 Summary: Suspect you carry APOE4? Here's how genetic testing works, what it costs, what a result means, and what to track next. How to Get Tested for APOE4: A Complete GuideSuspect you carry APOE4? Here's how genetic testing works, what it costs, what a result means, and what to track next.Dr. Kevin Tran August 02, 2026 By Dr. Kevin Tran, PharmD · Last updated: August 2, 2026 You can get tested for APOE4 two ways: order a direct-to-consumer genetic test like 23andMe's Health + Ancestry kit (or run raw DNA data you already have through a third-party interpretation tool), or ask your doctor for a clinical APOE genotyping test through a lab. Both routes read your DNA, not your blood chemistry, and both tell you how many copies of the e4 variant you carry, the one piece of information that lets you build a real prevention plan instead of guessing. If you're here because a family member had Alzheimer's, a 23andMe report flagged something, or a doctor mentioned "APOE" in passing, you're not alone. This guide walks through exactly how testing works, what it costs, what your result means (and doesn't mean), and what to do next. What is the APOE4 gene, and why does it matter? APOE is a gene that helps your body move cholesterol and other fats around your bloodstream and brain. Everyone has two copies, one from each parent, and each copy comes in one of three common forms: e2, e3, or e4. Most people carry two copies of e3, the common version. The e4 version is different. Carrying even one copy raises your lifetime risk of Alzheimer's disease, and carrying two copies raises it further. A landmark 1997 meta-analysis of nearly 15,000 people from Boston University found that, in the Caucasian populations studied, having one e4 copy paired with the common e3 copy raised the odds of Alzheimer's roughly threefold, and having two e4 copies raised it closer to fifteenfold (Farrer et al., 1997, JAMA). A more recent review in Neuron puts it in rounder terms: one copy of e4 tends to increase risk 2 to 4 times, two copies tend to increase it 8 to 12 times, calling it "the strongest genetic risk factor" identified for Alzheimer's to date (Belloy et al., 2019, Neuron). Two things matter as much as those numbers. First, how much e4 raises your risk depends heavily on ancestry: the effect is stronger in East Asian populations and comparatively weaker in African American populations, so no single global figure tells the whole story (Belloy et al., 2019, Neuron). Second, and most important: APOE4 is a risk factor, not a diagnosis. It tells you the odds shifted. It doesn't tell you what will happen to you. How do I actually get tested for APOE4? There are two practical routes. Route 1: Direct-to-consumer genetic testing. Services like 23andMe's Health + Ancestry kit include an FDA-authorized Late-Onset Alzheimer's Disease report, which you opt into separately from your ancestry results. It tells you whether you carry 0, 1, or 2 copies of the e4 variant. You spit in a tube, mail it in, and get results online in a few weeks. If you already have raw DNA data from 23andMe or a similar service but never opted into the health report, or your kit was ancestry-only, you can run that raw data file through a third-party interpretation tool to pull out your APOE genotype. If you go this route, treat the result as a starting point for a conversation with a doctor or genetic counselor, not a final answer. Route 2: A physician-ordered genetic test. Your doctor can order APOE genotyping through a clinical lab, typically via a blood draw. This route lets the result become part of a broader clinical discussion and workup if you're also being evaluated for memory concerns. Ask whether genetic counseling is included or available by referral. Genetic counselors are trained specifically to walk you through what a result would mean for you and your family before you even test, which matters more than most people expect going in. Our genetic counselor brief covers what that conversation typically looks like. If APOE runs in your family and you're weighing whether siblings or children should test too, our guide to genetic testing for your family walks through that decision. Can I find out my APOE status from 23andMe or Ancestry data I already have? Often, yes. If you paid for 23andMe's Health + Ancestry service and opted into the Late-Onset Alzheimer's Disease report, your APOE4 count is already sitting in your account. If you only bought the Ancestry-only service, or you tested with a company that doesn't report APOE at all, you can download your raw genotype data file and run it through a third-party interpretation tool built for this exact purpose. A note of caution: 23andMe says its raw data is for informational use, only a subset of the markers has been individually validated, and it is not affiliated with third-party interpretation services. Treat the output as informative, not definitive, and confirm anything significant with a clinician before acting on it. What's the difference between a blood test and a genetic test for APOE4? This trips people up, and it's worth being precise about. Testing your APOE genotype is a genetic test, full stop, whether the lab draws it from blood, saliva, or a cheek swab. It reads your DNA once, and the result never changes, because your genotype doesn't change. What people usually mean by "APOE4 blood test" is something different: a lipid panel or ApoB blood test, which measures the cholesterol particles actually circulating in your blood right now. That's a different kind of test entirely. It measures a moving target, not your genes, and you'd repeat it regularly, not once. The two are related in an important way: research on over 900 people found that APOE4 carriers, especially those with two copies, tend to run higher LDL cholesterol, ApoB, and inflammatory markers like hs-CRP than e3/e3 carriers do (Krishnamurthy et al., 2024, Cureus). So your genotype, fixed and tested once, shapes what your blood chemistry, variable and tested often, tends to look like. Tracking the second becomes more useful once you know the first. How much does an APOE4 test cost? As of August 2, 2026, 23andMe's official support guidance lists a regular U.S. Health + Ancestry price of $199. Promotions can change what you pay, so check the official shop before buying (23andMe FSA/HSA guidance). For a clinician-ordered test, ask the laboratory and your insurer for the quoted cash price and any coverage criteria before the sample is collected. 23andMe says its consumer service is not a medical genetic test and is not covered by insurance. Its support guidance says a clinician-directed medical genetic test may be covered depending on your policy and indication (23andMe insurance guidance). Is my result private? In the United States, as of August 2, 2026, the Genetic Information Nondiscrimination Act (GINA) protects genetic information in health-insurance and covered employment decisions. It does not cover life, disability, or long-term-care insurance. Some states add protections, so check the rules where you live before treating the federal rule as the whole answer (National Human Genome Research Institute). What does an APOE4 result mean, and what does it NOT mean? A positive result means your odds shifted. It doesn't mean you have Alzheimer's, that you will get it, or that there's nothing you can do. Most of the research linking APOE4 to Alzheimer's comes from population-level studies: it describes what happens on average across thousands of people, not what will happen to you specifically. Plenty of e4 carriers live their whole lives without developing dementia, and plenty of non-carriers do develop it. There's also encouraging data on the emotional side of getting tested. A randomized controlled trial published in the New England Journal of Medicine found that disclosing APOE genotype results to adult children of Alzheimer's patients did not cause significant increases in anxiety or depression compared to not testing at all, even among the people who learned they carried the higher-risk e4 variant (Green et al., 2009, NEJM). Knowing tends to be more manageable than people expect before they know. I tested positive for APOE4. What now? This is where testing becomes useful instead of just unsettling. A result is only worth having if it changes what you track and act on. Start with the biomarkers where APOE4 carriers tend to diverge most from the general population: ApoB and LDL cholesterol (APOE4 carriers process fat differently, so "normal" ranges built for everyone else may not be tight enough for you), inflammatory markers, and metabolic basics like blood pressure and blood sugar. Our blood work blueprint breaks down exactly which biomarkers matter most for carriers and what ranges to aim for, ranges that differ from what a standard lab report flags as normal. If you learned your result through Sequencing.com, Phoenix's Sequencing.com resource helps you put that existing APOE result into context built specifically for carriers, instead of leaving you with a generic report. And if you want the full picture instead of doing this alone: I built Phoenix because I carry APOE4/4, for APOE4 carriers. Phoenix's public site states that 89% of members self-report an improvement in an APOE4 biomarker within three months (Phoenix public results statement). The next step is knowing what to track and having a community doing it alongside you. Frequently Asked QuestionsDo I need a doctor's referral to get tested for APOE4? No. Direct-to-consumer options like 23andMe don't require one. A physician-ordered test through a clinical lab does require a doctor, or in some cases a genetic counselor, to order it, but you can start that conversation yourself. You don't need a referral from someone else first. Will testing positive for APOE4 affect my health or life insurance? Health insurance and employment are protected under GINA. Life, disability, and long-term care insurance are not, so consider applying for those policies before you test if that's a concern for you. Can children inherit APOE4 from a parent who has it? Yes. You inherit one APOE copy from each parent, so a parent with even one e4 copy can pass it to a child. This is exactly the kind of question a genetic counselor is trained to walk through with your specific family history. See our genetic counselor brief. Does having two copies of APOE4 mean I will definitely get Alzheimer's? No. It means your risk is meaningfully higher than average across large population studies, not that any individual outcome is guaranteed. Many e4/e4 carriers never develop the disease, and lifestyle, other genes, and factors researchers haven't fully mapped yet all play a role. Is 23andMe's APOE report as accurate as a clinical lab test? 23andMe's Late-Onset Alzheimer's Disease report is an FDA-authorized consumer genetic-health-risk report, not a diagnostic clinical test. It reports APOE e4 variants, but it does not establish your overall Alzheimer's risk. Discuss any result you plan to use for clinical care with a physician or genetic counselor. What should I do the same day I get a positive result? Nothing urgent. There's no emergency action a positive APOE4 result requires. The useful next step is unhurried: talk with a doctor or genetic counselor about what it means for your specific history, then start tracking the biomarkers that matter more for carriers. You don't have to figure out what an APOE4 result means on your own. Start with Phoenix and get a plan built for carriers, not a generic "normal" range that was never built with your genotype in mind. --- ## The menopause question your neurologist and your gynecologist both skip URL: https://apoe4.co/blog/posts/the-menopause-question-your-neurologist-and-your-gynecologist-both-skip Published: 2026-08-01T19:00:00+00:00 Updated: 2026-08-01T19:00:17.840831+00:00 Summary: APOE4 carriers: Why your neurologist and gynecologist miss this critical menopause question. Discover the gap in your brain health care. The menopause question your neurologist and your gynecologist both skipAugust Phoenix Monthly Theme: Hormones and MenopauseDr. Kevin Tran August 01, 2026 Hi Phoenix friend, I am launching “Monthly Themes” inside the Phoenix Community where every month we will cover a new important topic relate to brain health, longevity and APOE4.This month: Hormones and Menopause.Here is a gap almost nobody fills. Your neurologist thinks about your brain and does not prescribe hormones. Your gynecologist thinks about hormones and does not track your dementia risk. And you carry an APOE4 gene, sitting in the middle of both, during the exact decade when they overlap most. Nobody joins those dots for you. So you end up doing it alone, at midnight, with fifteen browser tabs open and no one to tell you which one matters. I carry APOE4/4. That was my midnight too. It is why I built Phoenix, and it is what a group of us is working through together this month. What August looks like inside Phoenix Every month inside our private community now runs on one rhythm: one topic, one small action, one month, together. August is The Menopause Window: hormones and your APOE4 brain. And it started with a small, telling thing. Back in the spring, one member asked a real question about hormones inside the community. It drew 27 replies. Then almost nothing. In a community that is largely women, largely in or past menopause, this is the question asked least and needed most. So this month, we are doing it properly. With two experts, a live call, and questions submitted by members. Two experts worth listening to Both sessions are recorded, so members submit questions in advance and get real, prepared answers. Steve Goldring, RPh. Thirty years a pharmacist, most of them answering menopause questions until he made it his life's work. He teaches women and the doctors who prescribe for them. We walk the hormone menu in plain English: patch versus pill, estradiol versus the older estrogen, progesterone versus a progestin, and how to get taken seriously by a prescriber who is brushing you off.We have already recorded part one of the Q&A (we are doing 2 parts as it ended up being waaaay longer than expected to answer everyone’s questions).Dr. Ashanthi Gajaweera, MD. A board-certified neurologist with 25 years in practice who runs a dementia-prevention clinic, and one of a small number of neurologists in the country to also hold the Menopause Society Certified Practitioner credential. Most neurologists do not do hormones. Most menopause specialists do not do dementia prevention. She does both. She covers why this transition matters for prevention, how to think about APOE4 and hormones honestly, and what a sustainable year actually looks like.Next week I will post the podcast thread in our community Circle space and you will be able to ask your questions there.There is no clear-cut answer You will find three studies online, pointing three different ways, and think someone is lying to you. One found APOE4 carriers on hormone therapy had better memory and larger memory-region brain volumes. One found APOE4 carriers on hormone therapy had worse brain protein markers. And the largest review ever done, over a million women, found no effect on dementia risk either way. All relatively robust. None of them a trial built to answer our exact question, because that trial has not been run. Most communities pick the version that makes the best headline. We hold all three, and help you make a calmer decision with your own clinician. That difference is the whole point of Phoenix. (One thing most people missed: in November 2025 the FDA removed the black-box warnings from estrogen products, including the dementia warning, calling the old reading of the 2002 study outdated. Twenty years of fear, quietly revised, and barely reported.) The part you cannot get from an article: the room Reading about this alone is not the same as talking it through with people who are living it. This month we are launching Phoenix Community Live: a monthly, roughly 60-minute live call inside the community. Everyone checks in. New members introduce themselves. And we take the month's theme and talk it through, out loud, as a group. That is the thing an article can never give you. A room of people who get it, on the same night, working the same problem. I move fast, on purpose I built Phoenix because I needed it first, and I build it the way I wish someone had built it for me: quickly. In recent weeks I shipped Phoenix 2.0, then 2.1, rebuilt the daily check-in on web and mobile, opened a free clinical-trial engine tracking about 1,300 dementia trials, launched a free directory of clinicians who take APOE4 seriously, and completed the first issue of our real-world APOE4 research. Now a monthly theme and a live community ritual. APOE4 carriers do not need another organization that takes a year to summarize last year. You need the research translated now, the better clinician now, the pattern in your own data found while you still have time to act on it. You can keep doing this alone You can read the papers alone. Interpret your labs alone. Weigh the three conflicting studies alone. Wonder, alone, whether starting hormones at your age is smart or a mistake. Plenty of carriers do. But you do not have to. Inside Phoenix this month, you would submit your one hormone question, watch two experts answer it, set a single baseline in the app, and then talk the whole thing through on a live call with people who carry the same gene. Joining takes about seven minutes. There is a 60-day money-back guarantee, so the only real risk is staying outside the room. → Take the seven-minute assessment to join Phoenix I built Phoenix because I carry APOE4/4 and needed it first. Now I am building it for every carrier who refuses to wait quietly for symptoms. Cheers,Kevin Most Newsletters? One-way street.How boring…This is the Phoenix Community. So let's make it a two-way street. Got a question? Feedback? Hit reply. I read every single one. --- ## Why solving APOE4 alone is the (very) hard way URL: https://apoe4.co/blog/posts/why-solving-apoe4-alone-is-the-very-hard-way Published: 2026-07-28T19:00:00+00:00 Updated: 2026-07-28T19:00:23.754926+00:00 Summary: Discover why APOE4 management fails alone—and the research-backed community approach that transforms results. Join the proven method. Why solving APOE4 alone is the (very) hard wayThe research on doing hard health things alone is brutal. Here's what I built insteadDr. Kevin Tran July 28, 2026 Hi Phoenix friend, Most people trying to lower their Alzheimer's risk are doing it alone. Reading alone, guessing alone, losing steam alone. Or they are going on forums, reddit or facebook groups and are met with overwhelm, confusion and end up with more questions and anxiety. I understand why. I did it that way for a while too. But I want to show you the research on it, because it changed how I built this whole thing. Doing it alone is the hard way Four findings I keep coming back to. 66% vs 24%. A randomized trial put people through the same weight-loss program. Some were recruited with friends and given real social support. Some came in alone. At the 10-month follow-up, the friends group had kept their results 66% of the time. The solo group, 24%. They also finished the program more often, 95% vs 76%. Same plan. The difference was company. (Wing and Jeffery, 1999)10.6 pounds vs 3.7. Another randomized trial, same idea, sharper design. Same program, same money on the table. Some people were rewarded alone. Others were put in groups of five where progress was shared and the outcome was collective. The group people lost 10.6 pounds. The solo people lost 3.7. Nearly three times the result, out of the same plan. (Kullgren, Annals of Internal Medicine, 2013)Roughly double, from one message a week. 267 professionals, split by how they handled their goals. The ones who sent a friend a weekly progress update hit their goal, or got more than halfway, more than 70% of the time. The ones who kept their goals to themselves: 35%. One weekly check-in was the whole difference. (Matthews, Dominican University of California, 2015)And the one that stopped me cold, because I carry APOE 4/4 myself. Across more than 600,000 people, chronic loneliness was linked to a 31% higher risk of dementia and a 39% higher risk of Alzheimer's. (Luchetti, Nature Mental Health, 2024) For people like us, connection is not a soft extra. It is part of the intervention. So I built pods A pod is a small group of 2 to 4 Phoenix members, all APOE4 carriers, matched to you on the 1st week of every month. Not a giant forum. Two or three other like-minded carriers, with the same monthly goal, who notice when you go quiet. It lives as a private group chat inside our community, so there is nothing new to install and nowhere else to check. Every month, members tell me a few things. Their goal for the month. Their pace, all-in or steady or easing back. Whether they want to be pushed on the numbers or cheered on. Whether they would rather talk or message. Then I match people who answered alike. Same target, same energy, same idea of support. It is not random, and it is not a chatroom. It is your people, and it is small on purpose. Here is what that buys you. Members in a pod are 3.2x more consistent than those going alone. Of the 147+ pods formed so far, 94% are still active after two months. Which is the real benefit: not more information, but actually running the protocol you already know you should be running. The rhythm is simple. Matching opens the last week of each month, you get placed on the 1st week, and your pod stays open after that. You keep it. One honest note, because it is the thing people ask me. A pod only works if you turn up in it, so everyone agrees to a short charter before their first match: show up with respect, keep what is shared private, and reply when someone posts. Even one line. If a month is not your month, you skip it. Nobody is padding out a group with people who are not there. Pods are one piece. Here is the rest. Phoenix is the app and community I wished existed when I was diagnosed. A quick look at what is inside: APOE4-tuned bloodwork. Upload a lab PDF and it reads your ApoB, Omega-3 index, and more against carrier-specific ranges, not generic "normal." You get one Phoenix Score to track over time. A clinical trials engine. Every APOE4-relevant trial, in plain English, refreshed daily. Turn on Match Me and new trials auto-check against your profile. Supplement intelligence. A 1,000+ supplement library tagged for what actually matters for carriers. A 90-second daily check-in that quietly finds your patterns, what helps your sleep, your clarity, your mood. Monthly pods. The thing above. All built by an APOE4/4 carrier, for APOE4 carriers. And if you are wondering whether it will actually be people like you in there: every member is a verified APOE4 carrier, and about a third are healthcare professionals. There is also a 60-day money-back guarantee, no questions. So finding out costs you a few minutes, not a risk. If any of this is you You do not have to do this alone. That is the whole point. → Join Phoenix and get matched into your first pod It starts with a seven-minute assessment: your genotype, your numbers, where you are right now. That is what your first pod match gets built from. Join before the end of the month and you are in the next matching run. I built Phoenix because I needed it. The pod is the part I am most sure about, because the research and our own members keep saying the same thing. We go further together. Cheers,Kevin P.S. I would love to know what has kept you from joining something like this. Reply and tell me. I read every message, and it genuinely shapes what I build next. Sources: Wing RR, Jeffery RW. J Consult Clin Psychol. 1999 (PMID 10028217). · Kullgren JT, et al. Ann Intern Med. 2013;158(7):505-514 (PMID 23546562). · Matthews G. Dominican University of California, 2015 (267 participants, conference paper). · Luchetti M, et al. Nature Mental Health. 2024 (PMID 39802418). --- ## Who is actually behind Phoenix URL: https://apoe4.co/blog/posts/who-is-actually-behind-phoenix Published: 2026-07-25T19:00:00+00:00 Updated: 2026-07-25T19:01:20.237138+00:00 Summary: APOE4 carrier builds Phoenix solo: no VC, pharma, or corporate backing. Meet the founder and discover what's really behind your health platform. Who is actually behind PhoenixNo VC. No pharma. No support desk. Just one carrier like you building Phoenix for all of us, and here's what comes next.Dr. Kevin Tran July 25, 2026 Hi Phoenix friend, There is no Phoenix 1-800 number. But there is me :) I received many emails and comments the past month that asked some version of the same question: Is there a support line I can call?Can I speak to someone on the tech team?Who actually handles this? Fair questions. Phoenix looks like a company. An app on Android and Apple store, a private community, an web app with bloodwork analysis, a clinical trials engine, partner studies, a weekly newsletter...Something that looks like that usually has a floor of people behind it.Except…It doesn't. It has me. A lot of you joined in the last few months and we have never properly talked. So let me introduce myself, and tell you exactly what you have joined. Who is not behind Phoenix No venture capital.No private equity.No pharmaceutical company.No supplement brand. Nobody owns a piece of Phoenix except me and 2 other Phoenix members who became early business angels. There is no board asking me for a growth curve. There is no sponsor whose product needs to come out looking good in the data. When Phoenix reports that something did not move the numbers, there is nobody upstairs who minds. That independence is structurally designed that way, and it is the reason you can trust what you read in the app. Who is behind Phoenix Me. Kevin. Doctor of Pharmacy, and I carry APOE4/4. I have help in exactly one place: an agency who handle the Youtube videos edition and run the social accounts (I never got the hang of Tiktok). That is the entire team. I build everything else alone, with some help from Jason, another Phoenix member. What a week actually looks like Here is the honest split. In any given week I am: building the next feature in the app fixing the bugs you report, and the ones you don't keeping the community alive: posts, questions, the monthly pod cycle reading the new APOE4 papers so you don't have to making the content that brings more carriers in telling anyone who will listen that APOE4 is not a sentence you sit and wait out That is six jobs. I am one person. Which brings me to the apology. I'm sorry I have been slow If you emailed me and waited, or posted in the community and heard nothing for days, that was not indifference. Every message reaches me. I read all of them. Some weeks I cannot answer all of them quickly, and I hate that, because the entire point of Phoenix is that you are not shouting into a void. Same with the bugs. I ship fast, and shipping fast means I sometimes ship something broken. Tell me and I fix it, usually within days. Please bear with me while I do. Why there is a membership fee Now the part nobody enjoys writing. Phoenix is not free because there is nobody else paying for it. That is the whole explanation. Your membership keeps the lights on, keeps the app being built, and keeps me able to say “no” to money that would want something in return. I would rather answer to you than to a supplement company. Where Phoenix goes from here Phoenix sustains itself today. Your memberships cover what it costs to run, and I have kept it lean on purpose. But the needs keep growing. More carriers every month. More features you are asking for (and that I want for myself too!). More studies worth running. I want to hire, so the email you send gets answered in an hour instead of three days, so features ship faster, and so I am not the single point of failure in something you count on. And I want to fund the studies that move us to the front of the line for the therapies actually being developed for APOE4. That is more than one person can do properly. No matter how passionate I am about it and no matter if I spend 80 hours a week on it (the average work hours for the past year). So I am going to look at funding options, to grow Phoenix faster than I could alone. There is also a second way to pay for this that I am building in the open: partnering with the companies developing APOE4 treatments, on our terms. For example helping them recruit APOE4 carriers into their clinical trials. And why I want more of us, not fewer Here is the part I think about most. The largest APOE4 study in the world isn't run in a lab. It's run by us. Every biomarker you upload, every supplement you log, every check-in you fill in on a bad morning: that is the dataset. No university has it. No pharma company has it, because carriers like us are needles in their haystack, and they never get years of our ordinary life sitting next to our labs. Which makes Phoenix strange in a good way. A hundred more carriers tracking their ApoB is not a hundred more customers.It is a hundred more answers about what actually works for people with our genotype. Your data pays you back through everyone else's, and theirs pays you back through yours.By finding what actually works for you. What works for us. There are more than 600 of us now. That is why I push growth so hard. Not because I want a “bigger company”. Because a bigger sample gives every one of us a better answer. September, San Francisco, and a promise In September I will be in San Francisco, and I will talking to business angels about funding, so I can hire a team and build faster for you. Before a single one of those conversations happens, here is the promise, in writing.Phoenix stays independent, and the goal never changes: help APOE4 carriers beat the odds. Everyone I bring in as an investor will be an APOE4 carrier and part of this community. I believe that is the only way to stay 100% focused on that mission. I will never put something in front of you because someone on a cap table wants it there.I can promise that with total confidence, for a selfish reason: I carry APOE4/4. If Phoenix ever diverts from our mission, the first person it fails is me.If we don’t solve APOE4, I get Alzheimer’s too. This was never “just” a startup to me. It is a survival mission. It is also, I have come to realize, my life vocation. How you can actually help A few things, and not one of them costs you money. Patience, when I am slow or when something breaks (please report it in the bug report feature!). Your opinion. If there is something Phoenix should be doing and isn't, or something it does badly, hit reply and tell me. A surprising number of things in the app exist because a member wrote to me about them. An introduction. Heading into September, I am looking for three kinds of person: an investor who genuinely gets why this matters (the best ones tend to be carriers themselves), someone inside a company developing APOE4 or Alzheimer's therapies, and sharp people who might want to help build this.If one of them is already in your phone, a warm word from you is worth more than anything I can do cold. Email me at kevin@thephoenix.community and I will take it from there. And one more carrier. If Phoenix has helped you, the most valuable thing you can do is send it to another APOE4 carrier who is still out there waiting and watching. That is one more of us. One more answer. It is how this whole thing grows. I will not pretend the last few months have been easy. Wearing six hats has cost me sleep and it has cost me some calm, and I track both in the Phoenix app, so it is quite visible. I have got this. I’d rather burn the candle from both ends than not succeed because we move too slowly.But you deserve to know what is behind the curtain, because you are trusting me with something that matters. Thank you for being here. Genuinely. I built Phoenix because I needed it. It turned out I was not the only one, and that has made the whole thing worth it.Let’s continue building Phoenix together! Cheers,Kevin PS. If you ever wondered whether your feedback lands in a support ticket queue somewhere: it doesn't. It lands in my email inbox. So use this as much as possible :) --- ## Can Light Therapy Help Alzheimer's? What the Science Says About tPBM URL: https://apoe4.co/blog/posts/can-light-therapy-help-alzheimer-s-what-the-science-says-about-tpbm Published: 2026-07-23T19:00:00+00:00 Updated: 2026-07-23T19:00:33.599485+00:00 Summary: Red light therapy for Alzheimer's prevention: 55 APOE4 carriers tested transcranial photobiomodulation. See the science and real results. Can Light Therapy Help Alzheimer's? What the Science Says About tPBM And the results of our APOE4 carriers red light therapy study.Dr. Kevin Tran & Nicole Greig July 23, 2026 Hi Phoenix friend, The following is a guest post by Nicole Greig, from Neuronic. The Phoenix community has recently published the results of our Neuronic Study where 55 APOE4 carriers used red light therapy for 4 months. If you’d like to get the device we used: Get $100 off the Neuronic LIGHT device, with the code PHOENIX We had very exciting results, and I’d encourage you to use the device for yourself, and track it with Phoenix. Neuronic offers a 90-day money-back guarantee, so if it doesn’t work for you, you can simply just return the device.But without further ado, here’s Nicole taking over: What Is Alzheimer's Disease? Alzheimer's disease is the most common form of dementia, affecting millions of people worldwide. It is a progressive neurodegenerative condition, meaning it gradually worsens over time as brain cells lose function and die. While it is most commonly diagnosed in people over 65, it is not a normal part of aging; it is a disease with specific biological causes that researchers are still working to fully understand. The earliest signs are often subtle: forgetting recent conversations, misplacing items, or struggling to find words. Over time, Alzheimer's erodes memory, reasoning, language, and the ability to carry out daily tasks, eventually requiring full-time care. What Happens Inside the Brain? At the biological level, Alzheimer's begins when the brain starts producing toxic amyloid-beta fragments that build up into sticky plaques - one of the disease's defining features. This triggers a damaging cycle: mitochondrial dysfunction drives more amyloid production, and that excess amyloid causes further mitochondrial damage. Meanwhile, tau proteins inside neurons begin to misfold and tangle, breaking down the internal structure that keeps brain cells alive and communicating. Together, these processes spark chronic neuroinflammation and oxidative stress, gradually destroying the synaptic connections that allow neurons to talk to one another. It is this slow unraveling of neural networks that leads to the memory loss and cognitive decline Alzheimer's is known for. Who is at Risk for Alzheimer’s Disease? The Role of the APOE4 Gene  APOE4 is a variant of the apolipoprotein E gene, which plays a key role in how the brain manages cholesterol and fat transport (Liu et al., 2013). Not everyone who develops Alzheimer's carries this variant, but carrying it significantly shifts the odds. Compared to people without it, those with one copy face an 3 to 7 times increased risk of developing Alzheimer's disease, and those who carry two copies face 12 times the risk (Pires & Rego, 2023). The APOE4 variant disrupts normal cholesterol regulation in the brain, which can impair synaptogenesis and myelination, and may contribute to the formation of toxic protein aggregates like amyloid-beta plaques (Liu et al., 2013). Importantly, carrying this gene is not a diagnosis, but it is a risk factor. Many APOE4 carriers never develop Alzheimer's, and understanding your genetic risk is one of the most powerful tools you have for taking an active, informed approach to brain health. A Promising Approach to Alzheimer’s Disease: Transcranial Photobiomodulation If you've spent any time researching ways to support brain health, you may have come across the term transcranial photobiomodulation, often shortened to tPBM, and sometimes called low-level laser therapy (LLLT) or near-infrared light therapy.  At its core, it's a simple idea: shining specific wavelengths of red or near-infrared light through the scalp and skull to reach brain tissue underneath. First discovered by Endre Mester and colleagues in 1968, tPBM operates within wavelengths of 600 to 1100 nanometers - a range scientists call the "optical window" because it passes through skin and bone without being absorbed before reaching its target. Unlike UV light or X-rays, it doesn't damage tissue or carry radiation risk. The optical window of PBM. (Image source: Santos et al., 2019). What makes tPBM particularly relevant for Alzheimer's risk is where that light goes once it enters the body. Studies using human cadaver heads found that light in the 808 nanometer range can penetrate 40–50 millimeters into brain tissue, with roughly 1–2% of light delivered to the scalp ultimately reaching the cortical surface (Tedford et al., 2015). That might sound like a small amount - but as you'll see in the sections ahead, even a modest dose of light energy reaching brain cells appears to be enough to influence the mitochondrial processes that break down in Alzheimer's disease. Devices range from clinical lasers used in research settings to wearable LED helmets designed for home use. How Transcranial Photobiomodulation Works: The Mechanisms1. The Light Reaches the Brain tPBM uses specific wavelengths of near-infrared light - generally between about 800 nm and 1070 nm - that are able to pass through hair, scalp, and skull to reach brain tissue. Many studies focus especially on the prefrontal cortex, the area involved in focus, mood, decision-making, and emotional regulation. The light isn't there to "zap" neurons. It's there to support, restore, and regulate naturally occurring cellular processes. 2. The Mitochondria (Your Brain's "Power Plants") Absorb the Light Inside each brain cell are mitochondria, colloquially known as the "powerhouse of the cell" - tiny structures responsible for making energy. One key mitochondrial enzyme, called cytochrome c oxidase, happens to be sensitive to near-infrared light. When this enzyme absorbs light, it becomes more efficient at doing its job. In simple terms: your brain cells get better at making energy in the form of adenosine triphosphate, or ATP. 3. A Roadblock Gets Cleared - Nitric Oxide Under stress or inflammation, a molecule called nitric oxide can bind to cytochrome c oxidase in the same spot that oxygen needs to occupy in order to trigger ATP production - essentially blocking the process. Light helps knock that nitric oxide loose. Once it's displaced, oxygen can bind again and energy production can resume normally. The effects of PBM on the electron transport chain (Image Source: Scientific Research). 4. Energy Production Turns Back On With oxygen flowing properly, mitochondria are able to more efficiently execute their full energy-making process, allowing cells to produce more ATP - the fuel the brain uses for virtually everything, from firing signals to repairing itself. 5. More ATP Means a Brain That Has the Energy to Function When ATP levels increase, neurons are better equipped to communicate with each other, repair and maintain connections, and support learning and adaptation. This is why people often associate tPBM with clearer thinking, reduced brain fog, and improved mental stamina. 6. A Small, Protective Stress Signal Is Triggered As energy production ramps up, there's a mild increase in reactive oxygen species, or ROS. While that might sound concerning, this small increase actually acts as a signal that prompts cells to activate their own protective and adaptive pathways. In moderation, this process helps cells become more resilient over time. 7. Blood Flow Improves tPBM also supports better cerebral blood flow, in part because nitric oxide - now released from the enzyme - helps blood vessels relax and widen. This means more oxygen and nutrients are delivered to brain tissue, while waste products are cleared more efficiently. Better circulation supports overall brain health and recovery. 8. Inflammation Calms Down Chronic inflammation can interfere with how well neurons communicate. Research shows that photobiomodulation helps reduce inflammatory signaling and oxidative stress, creating a more supportive environment for brain function. With less background "noise," the brain can operate more smoothly. 9. The Brain Becomes More Adaptable When you combine better energy availability, improved blood flow, lower inflammation, and healthier mitochondria, you create ideal conditions for neuroplasticity - the brain's ability to adapt, rewire, and recover. This is where people may notice real-world benefits like improved focus, sharper memory, better mood regulation, or faster recovery after stress or cognitive fatigue. What Does tPBM Do to Amyloid Plaques and Tau? Two of the most defining features of Alzheimer's disease - amyloid-beta plaques and tau tangles - are not just markers of damage. They are active drivers of the cognitive decline the disease is known for. So one of the most important questions researchers are asking is whether tPBM can do anything to slow or reverse their accumulation. The evidence so far suggests it can, through several interconnected pathways. PBM has been shown to reduce the formation of both tau tangles and amyloid-beta plaques, alongside reducing reactive oxygen species and inflammation - all of which are key contributors to neurodegeneration (Wang et al., 2024). On the amyloid side, the mechanism appears to work at least in part through the cell's own cleanup systems. Previous studies have shown that PBM reduces amyloid-beta load primarily by enhancing the clearance capabilities of glial cells - the brain's immune and support cells - while more recent research suggests PBM may also directly reduce amyloid formation within neurons themselves, independent of glial cell involvement (Ramanishankar et al., 2024). Additional findings suggest that PBM may modulate brain activity at gamma frequencies, which could activate peptides that upregulate glymphatic activity and further enhance amyloid clearance - essentially helping the brain's waste removal system work more efficiently overnight (Valverde et al., 2023). Research on the tau protein and pulse frequency shows that PBM at 10 Hz may induce tubulin depolymerization, potentially destabilizing the misfolded proteins associated with neurofibrillary tangles, while 40 Hz PBM may then help stabilize microtubular structures and support neuronal network integrity (Lim et al., 2025). Taken together, tPBM appears to work on Alzheimer's pathology not through a single targeted mechanism, but through a coordinated set of cellular and immune processes that address both hallmark pathologies simultaneously. Human Studies: What the Research Says In human trials, the landmark early study by Saltmarche et al. (2017) reported measurable improvements on the MMSE and ADAS-Cog cognitive scales in dementia patients after 12 weeks of transcranial PBM. Caregivers also noted that patients slept better, had fewer angry outbursts, and experienced less anxiety - though gains were not sustained after treatment ended, suggesting tPBM may need to be used as an ongoing intervention rather than a fixed course. A second notable human study comes from Nizamutdinov et al. (2021), who enrolled 60 dementia patients in a sham-controlled trial of transcranial and ocular near-infrared light therapy. Participants received continuous 1,060–1,080 nm light for six-minute sessions, twice daily over 12 weeks, with results showing statistically significant improvements in MMSE and cognitive memory scores compared to the sham group - making it one of the larger and more rigorously controlled human studies conducted to date. Importantly, the trial demonstrated not only measurable cognitive gains but also a favorable safety profile across all participants, reinforcing that tPBM is well tolerated even with extended daily use (Nizamutdinov et al., 2021). The Future of Photobiomodulation in Alzheimer's Treatment The science of tPBM for Alzheimer's is advancing rapidly, and what once looked like a speculative therapy is increasingly being taken seriously by academic medical centers worldwide. Several promising directions are emerging - including the use of specific pulse frequencies to restore gamma brain rhythms disrupted in early Alzheimer's, EEG-guided personalization that tailors treatment to an individual's unique brain activity patterns, and the integration of tPBM alongside pharmaceutical therapies as part of a broader combination approach.  For APOE4 carriers in particular, tPBM's non-invasive nature and favorable safety profile make it a compelling area to watch. While it is not yet an approved or standardized treatment for Alzheimer's disease, the depth and quality of research is growing around it, from transgenic animal models to brain imaging to randomized controlled trials.  Get $100 off the Neuronic LIGHT device, with the code PHOENIXReferences: Lim, L., Staelens, M. A., Truglia, B., Lazzari, D. D., Gregorio, E. D., Shankar, K., Liburd, J., Hosseinkhah, N., Karimpoor, M., & Tuszynski, J. A. (2025). Beyond Gamma: Synergistic Potential of 10 Hz Alpha and 40 Hz Gamma Photobiomodulation in Alzheimer's Disease Treatment. Alzheimer's & Dementia, 21(Suppl 1), e105314. https://doi.org/10.1002/alz70855_105314Liu, C. C., Liu, C. C., Kanekiyo, T., Xu, H., & Bu, G. (2013). Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nature reviews. Neurology, 9(2), 106–118. https://doi.org/10.1038/nrneurol.2012.263Nizamutdinov, D., Qi, X., Berman, M. H., Dougal, G., Dayawansa, S., Wu, E., Yi, S. S., Stevens, A. B., & Huang, J. H. (2021). Transcranial near infrared light stimulations improve cognition in patients with dementia. Aging and Disease, 12(3), 954–963. https://doi.org/10.14336/AD.2021.0229Pires, M., & Rego, A. C. (2023). Apoe4 and Alzheimer's Disease Pathogenesis-Mitochondrial Deregulation and Targeted Therapeutic Strategies. International journal of molecular sciences, 24(1), 778. https://doi.org/10.3390/ijms24010778Ramanishankar, A., S, A. S., Begum, R. F., Jayasankar, N., Nayeem, A., Prajapati, B. G., & Nirenjen, S. (2024). Unleashing light's healing power: an overview of photobiomodulation for Alzheimer's treatment. Future science OA, 10(1), FSO922. https://doi.org/10.2144/fsoa-2023-0155Saltmarche, A. E., Naeser, M. A., Ho, K. F., Hamblin, M. R., & Lim, L. (2017). Significant improvement in cognition in mild to moderately severe dementia cases treated with transcranial plus intranasal photobiomodulation: Case series report. Photomedicine and Laser Surgery, 35(8), 432–441. https://doi.org/10.1089/pho.2016.4227Santos, E. A. B., Lucena, R. J. R. S., Lima, E. G., Lins, L. T., & Rodrigues, M. A. B. (2019). Low-cost functional near infrared spectroscopy (fNIRS) applied on brain-computer interfaces (BCIs). In R. Costa-Felix et al. (Eds.), XXVI Brazilian Congress on Biomedical Engineering: IFMBE Proceedings (Vol. 70/1, pp. 495-500). Springer. https://doi.org/10.1007/978-981-13-2119-1_76 Tedford, C. E., DeLapp, S., Jacques, S., & Anders, J. (2015). Quantitative analysis of transcranial and intraparenchymal light penetration in human cadaver brain tissue. Lasers in Surgery and Medicine, 47(4), 312–322. https://doi.org/10.1002/lsm.22343 Valverde, A., Hamilton, C., Moro, C., Billeres, M., Magistretti, P., & Mitrofanis, J. (2023). Lights at night: does photobiomodulation improve sleep?. Neural regeneration research, 18(3), 474–477. https://doi.org/10.4103/1673-5374.350191 Wang, M., Dinarvand, D., Chan, C. T. Y., Bragin, A., & Li, L. (2024). Photobiomodulation as a Potential Treatment for Alzheimer’s Disease: A Review Paper. Brain Sciences, 14(11), 1064. https://doi.org/10.3390/brainsci14111064 --- ## What APOE4 carriers say when the room is private URL: https://apoe4.co/blog/posts/what-apoe4-carriers-say-when-the-room-is-private Published: 2026-07-15T19:00:00+00:00 Updated: 2026-07-15T19:00:19.181286+00:00 Summary: Real APOE4 carrier conversations in private. Discover what members discuss behind closed doors—community support, shared protocols, and honest challenges. What APOE4 carriers say when the room is privateThe discussions happening behind close door, between like-minded APOE4 carriers.Dr. Kevin Tran July 15, 2026 Hi Phoenix friend, Lastm onth, a Phoenix member uploaded their first bloodwork and felt hopeless. There was already too much to fix. Sleep. Food. Exercise. Supplements. Stress. Brain training. Then one more score landed on the screen and made the whole thing feel impossible. So the member said it out loud inside Phoenix. Dozens of APOE4 carriers answered. They did not pile on another protocol. They did not promise everything would be fine. They said: choose one thing. Make it stable. Then take the next step. That is what a real APOE4 community looks like. Not people pretending they are never scared. People refusing to let each other stay there alone. What happened inside Phoenix in 90 days From April 15 to July 15, Phoenix members started 219 conversations across 21 private spaces. Those posts generated 2,463 comments. The range was wild. Members pulled apart new Alzheimer's headlines. Compared pTau-217 and ApoB questions. Debated fish oil, saturated fat, meal timing, sleep medication, HRT, cognitive tests, HRV, exercise, stress, and the supplement bottle that suddenly looked less harmless after a genetic result. They talked about caring for parents. About watching a mother disappear. About the fear that every forgotten word means something. About the relief of meeting people who do not need a ten-minute APOE4 explanation before the real conversation can begin. And they ran experiments. One member paid for two body-composition scans only minutes apart. Same person. Same machine. Different enough results to make the community question whether a small “improvement” on one scan means anything at all. Another member revisited a supplement they had taken for a long time. They checked it against their genetics and prescriptions, found a plausible interaction, stopped, and prepared better questions for a clinician. Another returned with a pTau-217 result that had moved toward the reference range after several simultaneous changes. Nobody honest can say which change mattered, or whether the result came from those changes at all. But it was a real observation, from a real carrier, that deserved a careful conversation. Other members shared progress with lipid markers, sleep, fitness, and the daily habits that are easy to recommend and hard to live. One carrier wrote that learning their APOE4 status had pushed them to feel healthier than they had in decades. These are not miracle stories. They are better than that. They are people measuring, questioning, changing course, and helping the next person avoid the same mistake. A community should do more than talk I carry APOE4/4. I built Phoenix because I needed this room first. But a private community is only useful if the conversation turns into something you can act on. So I read what members struggle with. Then I build. In the same 90 days, I shipped Phoenix 2.0, rebuilt the Daily Check-in on web and mobile, opened two free public engines, and completed the first issue of Phoenix APOE4 Research for publication. That speed is deliberate. APOE4 carriers do not need another organization that takes a year to summarize what happened last year. You need the research translated now. The trial found now. The better clinician found now. The pattern in your own data found while you still have time to act on it. The first free engine: clinical trials you can actually read The Phoenix Clinical Trial Engine tracks about 1,300 Alzheimer's and dementia trials and refreshes them daily. Every trial is translated into plain English. Every listing gets an APOE4 lens: does the study require a carrier, exclude a carrier, or raise a risk worth discussing with your doctor? You can search by location, status, condition, and study type. Browsing and filtering are free. No signup required. Because finding a trial should not require a research degree and a free weekend. The second free engine: finding a doctor who gets APOE4 Members kept describing the same broken appointment. They arrived with questions about pTau-217, omega-3 status, or an APOE4-specific lipid target. Then spent the first part of the visit teaching the clinician why the question mattered. So I built the APOE4 Doctor Directory, a free provider engine for finding clinicians who take APOE4 seriously. The goal is simple: less time explaining the gene. More time deciding what to do next. Coming soon: Phoenix APOE4 Research, Issue 01 The next step is bigger. Soon I will publish Phoenix APOE4 Research, Issue 01: APOE4: the Beat the Odds study. It is built from real-world Phoenix data: biomarkers, wearables, daily check-ins, supplements, medications, behaviors, and fully de-identified member journeys. The question is not, “Can we manufacture a perfect result?” (like what any biopharma trials are doing) It is: “What early signals appear when APOE4 carriers track what they do and what changes?” Issue 01 will show the interesting patterns and the inconvenient limits. What moved. What did not. Where the data is too thin. Which observations deserve a proper prospective study next. That is how community becomes collective intelligence. One person notices something. The group tests the idea. Phoenix turns the signal into a better question. Then we run the next experiment with more discipline. You can keep doing this alone You can read papers alone. Interpret labs alone. Search for doctors alone. Watch trial registries alone. Wonder whether a bad result is a catastrophe or just a baseline. Many carriers do. But you do not have to. Phoenix is where APOE4 carriers compare the real work: the fear, the numbers, the false starts, the better questions, and the small wins that keep you moving. It is also where I turn those conversations into tools, research, and faster access. → Take the seven-minute assessment to join Phoenix I built Phoenix because I carry APOE4/4 and needed it first. Now I am building it for every carrier who refuses to wait quietly for symptoms. Cheers,Kevin *All member stories in this post were anonymized and generalized to protect privacy. Member experiences and biomarker changes are observational and do not establish causation or typical results. Phoenix does not provide medical advice, diagnosis, or treatment. Speak with a qualified clinician before changing medications, supplements, or health protocols. --- ## Why Beating APOE4 Is a Team Sport URL: https://apoe4.co/blog/posts/why-beating-apoe4-is-a-team-sport Published: 2026-07-09T18:36:00+00:00 Updated: 2026-07-09T18:36:08.274045+00:00 Summary: APOE4 carriers can't succeed alone. Discover why you need a team approach and evidence-based strategies to manage your genetic risk effectively. Why Beating APOE4 Is a Team SportDr. Kevin Tran July 09, 2026 Hi Phoenix friend, Most people who carry APOE4 find out alone. You get a result, often from a test you had to ask for yourself, and the weight of it lands in a quiet room with no one in it. If you take it to a doctor, there is a good chance you hear some version of "come back at sixty." So you go home and you start reading. And reading. And reading. I know that room, because I have sat in it. I carry two copies of APOE4, the highest-risk genotype there is. When I found out, I did what a lot of us do. I panicked, I grieved, and then I got to work. But I hit a wall almost immediately, and it is the same wall every one of us hits. You cannot really do this alone There are more than fifty credible interventions for APOE4 carriers. Diet, exercise protocols, supplements, sleep, specific biomarkers to chase. The honest answer to "which ones actually work, and at what dose, for someone with my genetics?" is that nobody knows for certain. Validating them one at a time, on yourself, would take decades. And decades are exactly what we are trying to protect. That is the real reason I built Phoenix as a community, not just an app. I did not want to face this alone. And just as importantly, I did not want to run these experiments on myself alone. Because the moment you put hundreds of carriers in one place, all tracking their bloodwork and their habits and their results, something changes. You stop guessing. You start measuring, together. The part that gets powerful When enough of us log what we try and what happens, patterns appear that no single person could ever see on their own. The APOE4 carriers with the best cholesterol, what are they actually doing? The folks who share your genetics and your health profile, what moved their numbers? With a big enough community, those stop being hopeful guesses and become answers you can act on with real confidence. Our AI gets sharper with every member who joins, because the quality of the insight depends entirely on how many of us are running real experiments. And it is already working. More than 600 of us are now tracking, and 89% see biomarker improvements within six months. There is a second thing that size gives us, and it is just as real: leverage. The bigger we are, the better we negotiate. Better group deals on the supplements and diagnostics we already pay for, and more recognition and weight with the pharma and medtech partners building what comes next. A few hundred organized APOE4 carriers get listened to in a way that one worried person never can. So this is a movement, not a startup. Every person who joins makes the answers sharper and the deals better for everyone already here. That is the whole idea. If you carry APOE4, you do not have to do this alone Come find out what the rest of us are learning. Join Phoenix → And if you are already a member, you now have the simplest way to bring the people you love along with you. Your personal referral link gives a friend their first month of Phoenix Core free, and when they stay, your next month is on me too. A full free month for each of you. You will find your code and link in the app under Referrals. We are stronger together. We always were. Cheers,Kevin Most Newsletters? One-way street.How boring…This is the Phoenix Community. So let's make it a two-way street. Got a question? Feedback? Hit reply. I read every single one. --- ## Omega-3 for APOE4 Carriers: Why the Form Beats the Dose (and What I Actually Do) URL: https://apoe4.co/blog/posts/omega-3-for-apoe4-carriers-why-the-form-beats-the-dose-and-what-i-actually-do Published: 2026-07-07T18:36:00+00:00 Updated: 2026-07-07T18:36:10.466282+00:00 Summary: APOE4 omega-3 guide: why bioavailable form beats dose. Learn which DHA actually reaches your brain and Kevin's exact protocol. Omega-3 for APOE4 Carriers: Why the Form Beats the Dose (and What I Actually Do)Most of Your Fish Oil Never Reaches Your Brain. Here's the Small Dose That Does.Dr. Kevin Tran July 07, 2026 Hi Phoenix friend, A Phoenix member emailed me last week with the question I get more than any other. "Kevin, what's the best omega-3 for a carrier? Which one do you take, and how much?" She had just found out she's 4/4, same as me. I could feel the worry sitting underneath the question. So I'm going to answer her the way I'd answer if she were across my kitchen table with a coffee, not the way a supplement label would. And it starts with a sentence I wish someone had told me on day one: most of the omega-3 you swallow never reaches our APOE4 brain. Here's the one line to keep if you read nothing else. For a carrier, the form of your DHA matters more than the amount. Everything below is me showing you why, and then telling you exactly what I do about it. The thing that finally made this simple for me: omega-3 has two jobs For years I overcomplicated this. I'd stare at the fish-oil aisle doing dose math, like the goal was one big number. It isn't. The moment it clicked for me was when I stopped thinking about "omega-3" as one thing and started thinking about it as two jobs that happen to share a name.Job one is your body. Your heart, your blood vessels, your triglycerides, your background inflammation. This job is real and it matters. It's also the easy one. You get omega-3 into your bloodstream, your levels climb, and the payoff basically tracks the total grams. EPA does a lot of the heavy lifting here. Job two is your brain. This is the one with the bottleneck. Your brain is picky about how it lets DHA in, and for us that pickiness is the whole story. The amount you swallow matters far less than whether it arrives in the one form the brain door will actually open for. Same nutrient. Two completely different destinations. And once you see that, a lot of the confusion melts, because you stop trying to solve both jobs with the same pill. The way I picture it: the body job is a firehose, the brain job is a courier. For the body you want volume. For the brain you want one small package walked straight to the right door. You do not dose a courier the way you dose a firehose. Hold onto that, because it's the reason my brain dose is so small, and I'll come back to it. The door most fish-oil conversations never mention: Mfsd2a Your blood-brain barrier has a dedicated door for bringing DHA in. It has a name, Mfsd2a, and almost nobody talks about it. In 2014 a team at Duke-NUS in Singapore worked out exactly what it does, in a landmark Nature paper. Here's the part that changes everything: "Mfsd2a transports DHA in the form of lysophosphatidylcholine, but not unesterified fatty acid."Nguyen et al., 2014, Nature In plain English: that door only opens for DHA when it shows up packaged as LPC-DHA (lysophosphatidylcholine-DHA). Hand it plain, "free" DHA, which is mostly what your fish-oil capsule becomes after you digest it, and the door stays shut. To prove the door mattered, they bred mice without it. Those mice got smaller brains, memory loss, and severe anxiety. The delivery route was gone, so the DHA never got where it needed to go. (That's animal data, and I'll flag every time we're leaning on animals, because it matters.) Now the part that made me change what's on my own shelf. Also in 2017, a group at the University of Illinois fed adult mice the exact same dose of DHA in two different forms, free DHA versus LPC-DHA, and then measured the DHA in their brains: "Oral administration of DHA... as lysophosphatidylcholine... increased DHA content of the brain by >2-fold. In contrast, the same amount of free DHA did not increase brain DHA."Sugasini et al., 2017, Scientific Reports Same dose. One form doubled brain DHA. The other did nothing. The only difference was the packaging. Two years later the same lab repeated it in rats and added a krill-style form, and the pattern held: the phospholipid and LPC forms got into the brain, the standard triglyceride form did not. Two species, several brain regions, same direction. Why this hits carriers harder. In a 2017 PET study, carrier brains actually took up about 16% more DHA than non-carrier brains, right in the entorhinal cortex, the exact spot Alzheimer's tends to strike first. On the surface that sounds like good news, like we have no delivery problem at all. Rhonda Patrick's 2019 review offered an explanation for the paradox, and I want to be honest that this next part is a hypothesis, not settled fact: in carriers, the "outer" leaky route may let free DHA seep in fast (that 16%), while the orderly inner route your neurons actually rely on, the Mfsd2a route, is the one you want to be feeding on purpose. The 16% is hard data. The "leaky, not usable" reading of it is a well-argued idea, not proof. It's the biggest open question in this whole topic, and I act on it while being upfront that it isn't nailed down. Put it together and you get the case for feeding the brain door directly: carrier brains grab more DHA but may misroute it, and lose it from the blood faster, and the one well-described door for the productive route only opens for LPC-DHA. That's the molecule the headlines never measured. So why is my brain dose so small? Because direct delivery isn't flooding. This is the question the friend at my table always asks next. "If DHA is that important, shouldn't I be taking a big dose of the LPC form? Like the 2,000 mg you see on the strong fish-oil bottles?" No. And this is the courier-versus-firehose thing made concrete. The big gram-level doses exist because normal DHA has to flood your entire bloodstream just to get a trickle across into the brain. You're filling a whole reservoir hoping a little seeps through the wall. That's a firehose strategy, and for the body job it's fine. LPC-DHA doesn't work that way. It walks straight through the Mfsd2a door into the brain. You're not trying to raise your whole-body levels with it. You're couriering a small, correctly-addressed package to one destination. In the mouse work, it took only a modest, targeted dose of the LPC form to double brain DHA, while the same amount of free DHA did nothing. Efficiency, not volume. So the label dose on a good LPC-DHA product looks tiny next to a gram of fish oil. That is not a weakness. That is the entire point. Comparing its milligrams to your fish-oil grams is comparing a courier to a firehose. Different job, different math. And the flip side matters just as much for your wallet: for the body job, you do not need the fancy expensive form at all. Do not waste LPC-DHA on your triglycerides. Eating fatty fish, or taking a decent regular fish oil, covers the body job just fine. Save the precision tool for the job that actually needs precision. That's the plan in one breath: eat a lot of fish (and regular fish oil if you like) for the body, take a small dose of LPC-DHA for the brain. Two lanes. "But didn't a study just say fish oil is bad?" Yes. Let me reconcile it. If you've seen a scary headline recently, you're not imagining it. Last month a paper landed (Liao and colleagues, 2026) showing that omega-3 supplement users declined faster on three standard cognitive tests. If you're a carrier who's dutifully taken fish oil since your genotype came back, that lands like a punch in the chest. It did for me. So let me give the paper its due, then reconcile it, because a few years earlier the same dataset (the ADNI cohort) gave the near-opposite answer. Wei and colleagues, 2023: long-term omega-3 users had a 64% lower risk of Alzheimer's, and the protective effect showed up specifically in APOE4 carriers. Same data. Opposite-looking results. That's not a debunk, it's a puzzle with a clean solution, and it comes down to three things. What they measured. Liao measured the slope of decline. Wei measured whether you actually crossed the Alzheimer's diagnosis line. You can slip a little faster on a test and still never cross that line. How they measured your omega-3. This is the big one. Liao measured whether you said you take a supplement. Dose, form, brand, whether you actually swallow it, all unknown. Wei measured the omega-3 sitting in your red blood cell membranes, your actual tissue level. Real tissue beats a plasma snapshot beats "do you take a pill," every single time. Who was in the study. Liao's group included people who were already declining, some of whom likely started a supplement because they'd gotten worried. That's cause and effect running backward. Wei's was a prevention population. Here's the honest takeaway. Liao isn't wrong. Liao measured a fuzzy exposure in a mixed population, which limits what you can conclude for a healthy carrier trying to prevent. And neither study asked the question that matters most for us: what form of DHA was in those capsules. That's the hole the whole rest of this piece lives in. The full ladder, if you're the type who wants it You don't need this table to act. But a lot of you (I see you, fellow over-researchers) will want the whole ranking, so here it is, ordered by how well each form actually reaches the brain. Rank Form Real-world example Brain delivery Evidence 1 (top)LPC-DHA (Lysoveta)Accentrate Omega Max  Doubled brain DHA in mice; free DHA at the same dose did nothing. Direct Mfsd2a substrate. Animal (mouse + rat, replicated) 2Phospholipid-DHA (krill) Krill oil, with astaxanthin Highest plasma incorporation in a human head-to-head; increased brain DHA in rats. Human plasma + rat brain 3Triglyceride (rTAG) Most quality retail fish oil Plasma rises. Brain DHA not significantly increased in rats. Human plasma + rat brain 4 (bottom)Ethyl ester (EE) Cheap concentrated / many prescription products Plasma rises, brain effect minimal, lowest incorporation of the group. Human bioavailability A few honest notes before anyone screenshots this as gospel: The LPC-DHA brain-doubling is animal data. Replicated across mice and rats and multiple papers, but no human brain-DHA trial of LPC-DHA exists yet. The door (Mfsd2a) is human. The exact size of the effect in people is inferred, not measured. A human trial in carriers, PreventE4, finished in 2024 with results still pending. When it reads out, it could shift this whole conversation, and I'll update you either way. Real fish beats a capsule in a way supplements can't copy. Fish naturally carry a small slice of their omega-3 as phospholipid, which your gut partly converts to that same brain-preferred LPC form. Fish-oil capsules carry none of it. The salmon on your plate has a structural head start. The short version: fish oil is for your heart. Krill is a connecting flight. LPC-DHA flies direct. What I actually take For the body lane, food does most of the work. Fatty fish is my main source of protein. Not chicken, not steak, fish. Sardines every other day, a lot of salmon, mackerel in the rotation. It fits the keto cycling I already do, so my diet and my brain goal pull the same direction. And that fish is quietly doing double duty, because it sneaks a little of the brain-preferred form in the back door that no capsule can. If I want extra insurance on the body side, a plain certified fish oil is more than enough there. I don't reach for anything fancy for this job. For the brain lane, I take Accentrate Omega Max every day, with a meal that has some fat in it. It's the LPC-DHA form, the one built to go through the Mfsd2a door. Here's the honest backstory, because I think you deserve it. I found the research first, the Nguyen Nature paper, the Sugasini brain-DHA studies, Patrick's review. Then I went looking for a product that actually used the LPC-DHA form, and Accentrate is what I landed on. I was taking it long before I ever spoke to the company. Then something interesting happened: I kept noticing how many people in the Phoenix community were on it too. So we did the thing Phoenix is built to do. We reached out and made it an official partnership, so we could buy as a group and pull the price down for everyone. That's the entire point of a community like ours. On your own, you pay retail. Together, we negotiate. And it compounds: the more of us who order on the community code, the bigger the bulk discount we can unlock for the next carrier who joins. Phoenix community gets 20% off with code PHOENIX: use this link Two things I want to say plainly. First, I can't prove Accentrate has changed anything for me. I haven't run a clean before-and-after, and any honest n-of-1 across overlapping supplements is mostly noise. I take it for the mechanism, not because I measured a win on myself. Second, LPC-DHA is the category and Lysoveta is the technology. Accentrate is one product that uses it, not the only one that ever could. If a better LPC-DHA product shows up, I'll switch, and I'll tell you. One data point from inside our own community, with its caveats attached. Across 1,757 supplement interventions our Phoenix members have logged, LPC-DHA is the #1-rated supplement by member self-report, at 4.83 out of 5, ahead of magnesium glycinate, creatine, and methylfolate. That is not a clinical trial. It's a satisfaction signal from a self-selected group of carriers, shaped by who bothered to log a result. A pattern worth flagging, not proof. It's exactly the kind of thing our Attribution Analysis exists to surface, and to keep us honest about. How to know it's actually working: the Omega-3 Index Don't guess. Measure. The one test that gives you a real answer is the RBC Omega-3 Index, and it has to be the red blood cell version, not a plasma test. Plasma wobbles with your last meal. Eat salmon at lunch and your plasma DHA is up by 3pm and back down by Wednesday. Red blood cells live about 120 days, so the RBC number is a four-month moving average of your true tissue level. It's the closest you get to "what does my brain actually see" without a spinal tap. The threshold comes from Harris and von Schacky, who introduced the index in 2004: an Omega-3 Index of 8% or higher tracked with the greatest protection, 4% or lower with the least. Phoenix optimal is above 8%. The protection curve keeps climbing past 8, and given everything else I'm managing as a 4/4 carrier, I want the headroom. Here's how I'd actually run it: Order an RBC Omega-3 Index test. A finger-prick at home is fine (OmegaQuant, Quest, others). Usually $60 to $90. Upload the result into the Phoenix Bloodwork module. One heads-up the internet keeps getting wrong: PDF upload is web and laptop only for now, the phone app doesn't do it yet. A current limitation, not a permanent one. Run Attribution Analysis so you can see whether your number moved after a supplement or dose change, not whether it moved for a mouse. Not proof of cause. A link worth watching. Retest in four months. That's how long your red blood cells take to turn over. Sooner is just meal noise. Later is procrastination. Join a Pod if accountability helps, and for most of us it does. A couple of other carriers will keep your four-month retest honest. And food first, always. The fish isn't the boring part of this plan. It's the foundation. The supplement is me topping up the brain lane on purpose, on top of a diet that's already doing the heavy lifting.Remember though: blood Omega 3 level is not a good proxy for brain omega 3 levels. Unfortunately we do NOT have reliable ways of measuring if we have enough Omega 3s in our brain. So the best way here is to track functionally the benefits.Within Phoenix we are also looking at the difference longitudinally between members who take LPC-DHA and those who don’t. Of course like with any other longitudinal studies, there are tons of confounders (e.g. people who decide to invest in their brain health by buying an expensive supplement are more likely to do a lot of other things for their brain health as well), but it is better than nothing. Where omega-3 can backfire Three places this can hurt you. I want them out in the open, not buried. 1. Atrial fibrillation at high doses. The big STRENGTH trial gave high-risk patients 4 g/day of omega-3 and saw no heart benefit, plus more new-onset AFib than placebo (2.2% vs 1.3%). REDUCE-IT showed a similar AFib signal at 4 g. The 1 to 2 g/day people use for the brain sits below where that signal is clearest, which is reassuring but not a guarantee. If you have AFib history, palpitations, structural heart disease, or you're on an antiarrhythmic, talk to your cardiologist before you start, not after. 2. Bleeding. Omega-3 thins the blood a little. At 1 to 2 g/day in a healthy adult, not a big deal. On warfarin, apixaban, or dabigatran, or in the week before any planned surgery, it matters. Ask your doctor exactly when to pause it. 3. Rancid oil is worse than none. Fish oil goes off, especially the cheap stuff. If you crack a capsule and it smells strongly fishy, that's oxidation, not "extra concentrated." Oxidized oil causes the exact oxidative stress you're taking omega-3 to fight. Buy certified (IFOS 5-star, low TOTOX), keep it cold, and skip the giant bottle you'll still be finishing eight months from now. The bottom line We started with a scary headline (omega-3 users declining faster) and its mirror image from the same data (64% lower Alzheimer's risk in carriers). Both are true. They asked different questions, in different people, with different precision. And neither one asked what form of DHA was in the capsule. So here's what I'd actually tell my friend at the kitchen table, and it's what I do myself: Feed the two jobs separately. Eat a lot of fatty fish for your body, add a plain fish oil there if you want, and don't spend a penny of your fancy budget on that lane. Then take a small, targeted dose of LPC-DHA for your brain, because that's the one form the brain door opens for, and because direct delivery is why the dose is small, not underpowered. Test your RBC Omega-3 Index so you're measuring, not hoping. Bring your result and your full medication list to your doctor. The supplement is the last step, not the first. If someone I love were sitting across from me right now (and I know many of you have already lost the person I'm picturing), I wouldn't lead with a product. I'd say: eat the sardines and the salmon, test your number, talk to your doctor, and then have the LPC-DHA conversation. That's the order I'd give my mom. It's the order I give myself. TRACK YOUR OMEGA-3 INDEX IN PHOENIXIf you'd rather measure than guess, that's the whole reason Phoenix exists. Upload your Omega-3 Index into the Bloodwork module (web or laptop), run Attribution Analysis to tie your supplement and dose changes to what your numbers do next, and join a Pod to keep your four-month retest honest.Start at thephoenix.community.ReferencesLiao Z-B, Hu Z-C, Zeng G-H, Chen J, Li X-P, Liu Y-H, Yao X-Q, Wang Y-R. (2026). The association between omega-3 supplementation and cognitive decline in older adults. The Journal of Prevention of Alzheimer's Disease. DOI: 10.1016/j.tjpad.2026.100569. URL: https://www.sciencedirect.com/science/article/pii/S2274580726000932Wei B-Z, Li L, Dong C-W, Tan C-C, Xu W; for the Alzheimer's Disease Neuroimaging Initiative. (2023). The Relationship of Omega-3 Fatty Acids with Dementia and Cognitive Decline: Evidence from Prospective Cohort Studies of Supplementation, Dietary Intake, and Blood Markers. American Journal of Clinical Nutrition. PMID: 37028557. DOI: 10.1016/j.ajcnut.2023.04.001. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC10447496/Nguyen LN, Ma D, Shui G, Wong P, Cazenave-Gassiot A, Zhang X, Wenk MR, Goh ELK, Silver DL. (2014). Mfsd2a is a transporter for the essential omega-3 fatty acid docosahexaenoic acid. Nature. PMID: 24828044. DOI: 10.1038/nature13241. URL: https://pubmed.ncbi.nlm.nih.gov/24828044/Sugasini D, Thomas R, Yalagala PCR, Tai LM, Subbaiah PV. (2017). Dietary docosahexaenoic acid (DHA) as lysophosphatidylcholine, but not as free acid, enriches brain DHA and improves memory in adult mice. Scientific Reports. PMID: 28900242. DOI: 10.1038/s41598-017-11766-0. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC5596017/Patrick RP. (2019). Role of phosphatidylcholine-DHA in preventing APOE4-associated Alzheimer's disease. The FASEB Journal. PMID: 30289748. DOI: 10.1096/fj.201801412R. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC6338661/Yassine HN, Croteau E, Rawat V, Hibbeln JR, Rapoport SI, Cunnane SC, Umhau JC. (2017). DHA brain uptake and APOE4 status: a PET study with [1-11C]-DHA. Alzheimer's Research & Therapy. PMID: 28335828. DOI: 10.1186/s13195-017-0250-1. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC5364667/Sugasini D, Yalagala PCR, Goggin A, Tai LM, Subbaiah PV. (2019). Enrichment of brain docosahexaenoic acid (DHA) is highly dependent upon the molecular carrier of dietary DHA: Lysophosphatidylcholine is more efficient than either phosphatidylcholine or triacylglycerol. Journal of Nutritional Biochemistry. PMID: 31665653. DOI: 10.1016/j.jnutbio.2019.108231. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC6885117/Yassine HN, Arellanes IC, Mazmanian A, et al. (2023). Baseline Findings of PreventE4: A Double-Blind Placebo Controlled Clinical Trial Testing High Dose DHA in APOE4 Carriers Before the Onset of Dementia. The Journal of Prevention of Alzheimer's Disease. DOI: 10.14283/jpad.2023.77. ClinicalTrials.gov: NCT03613844. URL: https://link.springer.com/article/10.14283/jpad.2023.77Bantugan MA, Xian H, Solomon V, et al. (2023). Associations of ApoE4 status and DHA supplementation on plasma and CSF lipid profiles and entorhinal cortex thickness. Journal of Lipid Research. PMID: 36958720. DOI: 10.1016/j.jlr.2023.100354. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC10230261/Schuchardt JP, Schneider I, Meyer H, Neubronner J, von Schacky C, Hahn A. (2011). Incorporation of EPA and DHA into plasma phospholipids in response to different omega-3 fatty acid formulations: a comparative bioavailability study of fish oil vs. krill oil. Lipids in Health and Disease. PMID: 21854650. DOI: 10.1186/1476-511X-10-145. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC3168413/Nicholls SJ, Lincoff AM, Garcia M, et al. (2020). Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. JAMA. PMID: 33190147. DOI: 10.1001/jama.2020.22258. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC7667577/Harris WS, von Schacky C. (2004). The Omega-3 Index: a new risk factor for death from coronary heart disease? Preventive Medicine. PMID: 15208005. DOI: 10.1016/j.ypmed.2004.02.030. URL: https://pubmed.ncbi.nlm.nih.gov/15208005/ --- ## APOE4 Clinical Trial Search & Matching Engine URL: https://apoe4.co/blog/posts/apoe4-clinical-trial-search-matching-engine-622b Published: 2026-07-04T18:24:00+00:00 Updated: 2026-07-04T18:24:07.811785+00:00 Summary: Find APOE4 clinical trials matched to your health profile. Free search engine for carriers—discover trials relevant to you, updated daily. APOE4 Clinical Trial Search & Matching Engine Get information about every APOE4 trial relevant to YOUR health profileDr. Kevin Tran July 04, 2026 Hi Phoenix friend, A Phoenix member emailed me last month about a trial she heard about on a podcast. She's carrying APOE 4/4. She's 62. She's been doing the work: bloodwork, supplements, exercise. She wanted in. So she googled it, landed on ClinicalTrials.gov, scrolled past 14 sections of jargon, tried to decode "cognitively normal subjects with biomarker evidence of preclinical AD," and gave up after twenty minutes. By the time she asked me (and by the time I got around to looking into it and replying, which took longer than I wish it had), the cohort was full. I felt bad. So I built a solution.And I'm giving it to you too, right now, for free. A free search engine, built for APOE4 carriers It lives at thephoenix.community/science/clinicaltrials. No account. No email. No membership required. You open it, search, and read. Every APOE4-relevant trial, in one place: pulled from ClinicalTrials.gov, refreshed every 24 hours. Plain English, not medical jargon that you can’t understand. An APOE4 lens on every study: "Open to carriers, including 4/4." Or "Excludes APOE4 carriers." You know instantly whether it's even for you. Filters, deadlines, and trial sites near you. It's free. It will stay free. Share it with anyone who needs it. Want the new ones to come to you? Browsing is completely free and always will be (filters included). But a cohort can fill fast, and nobody wants to keep checking back.So if you drop your email on the engine, we'll turn on a digest of new APOE4 trials, deadline alerts before a cohort closes, and bookmarks to save the ones worth a second look.No membership, no cost.Just so the trials that matter find you, instead of the other way around. Why give away the tool for free (when there is ongoing running cost to gather the data and updating it)? Because the alternative is a carrier giving up on a government page from 1998.And that's worse for all of us.Every carrier who can browse trials in 60 seconds instead of 60 minutes means more of us enroll, and the next therapy arrives sooner. For all of us. And here's the proof that measuring together works I didn't just build a finder. Phoenix also runs our own APOE4 study. Like the ones we did for on red light therapy.Read more about the Neuronic study here.Over four months, 55 APOE4 carriers tracked their whole lives inside Phoenix (cognition, sleep, bloodwork) while running a daily Photobiomodulation brain-health protocol. Memory improved in 20 of the 25 carriers involved. It was small, so we call it a signal, not proof. And I say so plainly. But that signal only exists because carriers measured, together, in one place. That's the entire idea behind Phoenix. We are currently running a landmark study that challenges Alzheimer’s gene risk, in partnership with Premaz and the Cambridge university. You can read more about it here and get your free brain test.And we are only getting started! The open engine tells you what trials exist. Phoenix membership tells you which ones fit you, and we try our best to get you to the front of the line. Match Me auto-checks every new trial against your full eligibility profile, every morning. If it's a match, you know the day it drops. One tap → If the clinical trial has a lot of interest, I take care of doing a warm intro from Phoenix directly to the research team. The sponsor sees a ready-to-recruit carrier, instead of a cold application. First-line access to the studies Phoenix runs directly, like the one above, and the bigger one being designed now. The full app: APOE4-tuned bloodwork, monthly pods, supplement intelligence, the rebuilt daily check-in, and everything we shipped this month. 60-day money-back guarantee. → Start your assessment and join Phoenix today I built Phoenix because I needed it. I'm carrying APOE 4/4. The trial engine is the tool I would have wanted two years ago, scrolling ClinicalTrials.gov with a Post-it in my hand. Now it's yours too! Cheers,Kevin P.S. I would love feedback on how we can make this clinical trial engine as useful as possible for you! Please reply to the email if you have ideas! --- ## Phoenix 2.1 update: The app changing when APOE4 carriers ask it to URL: https://apoe4.co/blog/posts/phoenix-2-1-update-the-app-changing-when-apoe4-carriers-ask-it-to Published: 2026-07-02T18:33:00+00:00 Updated: 2026-07-02T18:33:07.652202+00:00 Summary: Phoenix 2.1 July update: See how fast this app evolves for APOE4 carriers. New tools, real proof, continuous development for your health. Phoenix 2.1 update: The app changing when APOE4 carriers ask it toSee how fast Phoenix changes when carriers speak up, and the first proof it works.Dr. Kevin Tran July 02, 2026 Hi Phoenix friend, Most health apps ship once and ghost you. You buy in, you get a burst of features, and then nothing. The roadmap dies. The feedback form goes to a black hole. A year later you’re using the exact same app, wondering why nothing you asked for ever happened. But I consider myself member #1 of Phoenix, so of course I would keep building features for all of the APOE4 community, including those of you who are not Phoenix members (yet? 🙂 )Let me show you the last 30 days as proof. Last month I shipped Phoenix 2.0. This was our biggest update ever.And we continued building, including 2 new tools accessible for non-Phoenix members, because my goal is to serve as many APOE4 carriers as possible, and I know not everyone has the means to join Phoenix. A new Clinical trial module, open for everyone (even non Phoenix member)! Curation of every APOE4 trial, translated in plain English Automatic matching to the clinical trials you are eligible to A warm intro for the ones with the most Phoenix members interest Access the clinical trial module here. Available for all APOE4 carriers, whether you are a Phoenix member or not! In a few days, I'll send you the full deep dive: exactly how our Clinical Trials engine works, how to set up your Match Me profile so new trials auto-check against you every morning. Watch your inbox. A complimentary memory test from the University of Cambridge in partnership with PREMAZ and Phoenix. Open for everyone (even non Phoenix member)! This month I brought members free memory tests from PREMAZ, built on more than a decade of University of Cambridge research and normally a paid test. It measures the quality of your memory precisely enough to catch subtle changes standard tests miss, the earliest kind of signal an APOE4 carrier would ever want to watch. That access only exists because APOE4 carriers pool together. I improved many of our Phoenix App features, based on members feedback Then members started telling me what to fix and what they would like to see. So I fixed it, and built the requested features, fast. Here’s what changed, and why, because the why is the part that matters to you. Members said the daily check-in was confusing. It opened at 3pm and asked about a day that wasn’t over. So I tore it down and rebuilt it around one honest rule: you’re always closing out the day that just ended. About 90 seconds now, and it never asks you to guess. I changed it because you shouldn’t have to fight your own tracker. Members outside the US were getting mis-flagged. Their lab results come in different units, and the app was reading them wrong. So I fixed it: your bloodwork now scores against the right APOE4 targets whether you’re in Boston or Brisbane. Members wanted to test more than one thing at a time. So I raised the cap: run up to 10 experiments at once. And a dozen more: body tracking, a faster app, a calmer design, clearer navigation, tighter control over your data. All in one month. That’s not a coincidence. That’s the whole point of Phoenix. You don’t buy a finished app. You join a living one, and it bends toward what carriers actually need. And it’s not only what we build. Being part of a group this size unlocks things you could never get on your own. Here’s why that matters more for you than for anyone else. You carry APOE4. The science is moving fast, your body is changing now, and the tool you rely on can’t be frozen in time. Ours keeps up, because it’s built by someone who carries what you carry. I carry APOE 4/4. I built Phoenix because I needed it, and I use it on myself (I dropped my own ApoB 39% in 7 months, published openly). When a carrier tells me something’s broken, it’s personal. I ship the fix in days, not quarters. You’d be doing this alongside 676+ carriers, 32% of them doctors, nurses, and researchers who carry APOE4 themselves. And 89% of members report improvement in their APOE4-critical biomarkers within months. And this month, we got the first real proof it works. We ran a four-month study in 25 APOE4 carriers, living real lives, tracked entirely inside Phoenix. Memory improved in 20 of the 25. It was small, so we call it a signal, not proof, and we’re honest about that. But it’s the kind of signal that only exists because carriers measured, together, in one place.Read more about our Neuronic study here. That’s what you’re buying into. Not an app. A machine that turns your data into answers, and gets sharper every month, because people like you keep telling us where to point it. One more thing, and it’s big enough that I’ll give it its own post soon: we’re building a directory of doctors who actually understand APOE4, so “find an APOE4 doctor near me” finally has a real answer. Keep an eye out for it in future emails. Come see what it would show you about your own numbers. Every membership comes with a 60-day money-back guarantee. Track your first month, watch your data connect, and if it doesn’t earn its place, ask for a refund, no questions. Start your free APOE4 assessment: https://thephoenix.community/start Dr. Kevin Tran, Doctor of Pharmacy, Founder and User #1 of The Phoenix Community, APOE4/4 carrier — Phoenix doesn’t provide medical advice, diagnosis, or treatment. Study findings are observational, single-cohort, with no control group, and are not proof of efficacy. Always consult a qualified physician before changing supplements, medications, or protocols. Member-reported results are observational; the founder’s results are an n of 1. --- ## Is It Too Late for Me? Alzheimer's Risk Reduction by Age for APOE4 Carriers URL: https://apoe4.co/blog/posts/is-it-too-late-for-me-alzheimer-s-risk-reduction-by-age-for-apoe4-carriers Published: 2026-06-28T18:55:00+00:00 Updated: 2026-06-28T18:55:12.965913+00:00 Summary: APOE4 carriers aged 50-70 can still reduce Alzheimer's risk. Discover why it's not too late, backed by FINGER and POINTER trial evidence for your age group. Is It Too Late for Me? Alzheimer's Risk Reduction by Age for APOE4 CarriersFINGER and the 2025 U.S. POINTER trial tested people aged 60-79. It worked for APOE4 carriers too.Dr. Kevin Tran June 28, 2026 Hi Phoenix friend If you're reading this, I can probably guess a few things about you. You're probably somewhere around 50-70. You probably watched a parent go through Alzheimer's. And you're probably already doing the work: the diet, the steps, the supplements. But underneath all of it sits a quiet, ugly little voice. Maybe I started too late. Maybe the damage is already done. I know that voice. And I know it isn't only yours. Some version of "Is it too late for me?" is the single most common question that lands in my inbox and on the Phoenix community board. The words change. The fear underneath never does. This whole post is my answer to it. I'm Kevin. I'm a Doctor of Pharmacy and an APOE4 4/4 carrier: two copies of the gene this whole community is built around. I found out at 34, with no family history, which honestly made it stranger, not easier. I'm also the founder of Phoenix, and a former competitive poker and chess player. That last part taught me the one idea running through everything here: you don't get to pick your cards. You only get to pick how you play them. So let me answer the real question up front, because it's the one almost every carrier is quietly carrying. It is not too late. And the belief that it is, not the gene, is what costs people their best years. The right question was never "is it too late?" It's "which lever do I pull first?" This post walks you through four things: the evidence that risk reduction is real at the age you are right now, why it still works that late, the levers in priority order for a carrier, and exactly where the science is strong versus thin. The thesis is simple. Never too late, but timing matters. No hype. That's the deal. It Works, at Your Age, and for CarriersResearch. Start with the headline, because it earns the top spot. The FINGER trial out of Finland was a randomized controlled trial, the gold standard, of 1,260 at-risk adults aged 60 to 77.They were randomized to a structured multidomain lifestyle program or to general health advice for two years [Ngandu et al., 2015].The active group improved on the overall cognitive battery by "25% more improvement compared to control," with even bigger gains in executive function and processing speed [Rosenberg et al., 2020]. In 2025, the U.S. POINTER trial repeated the design in over 2,000 Americans aged 60 to 79 (30% of them APOE4 carriers).The structured group's global cognition improved by "0.029 SD per year (95% CI, 0.008 to 0.050, p = 0.008)" versus the self-guided group.The structured program was estimated to protect cognition from normal age-related decline for up to 2 years [Baker et al., 2025]. So what. Two randomized controlled trials. Two continents.Both deliberately enrolled people older than you.Both showed measurable cognitive benefit. The "window closed" story does not survive contact with the data. 💡 KEY INSIGHT: The landmark prevention trials enrolled people in their 60s and 70s and still showed benefit.If they were inside the window, so are you. ⚠️ CAVEAT: Be honest about the size.FINGER's between-group difference was "0·022 (95% CI 0·002-0·042, p=0·030)" per year: modest, statistically significant, and powerful mostly because it compounds over years [Ngandu et al., 2015].POINTER also compared structured versus self-guided programs (both groups improved), not versus doing nothing.The magic is the slope and the stacking, not an overnight reversal. Action. The first action is internal: update the belief that it's too late, because the randomized, replicated evidence doesn't support it. Then make it concrete.Log a baseline biomarker in Phoenix Bloodwork, run one structured change as a Phoenix Experiment, and re-measure. That loop is what turns "I hope this helps" into "I watched it help." Does It Even Work for High-Risk Carriers? Yes, at Least as MuchResearch. The average member of this community isn't asking whether lifestyle works for "old people." You're asking whether it works for high-risk people: someone carrying the gene, or two copies of it like me. Researchers split the FINGER data by genotype.The intervention effect was "0.037 (95% CI, 0.001 to 0.073) among carriers" versus 0.014 among noncarriers [Solomon et al., 2018].The carrier estimate was larger. Their conclusion: healthy lifestyle changes "may be beneficial for cognition in older at-risk individuals even in the presence of APOE-related genetic susceptibility to dementia" [Solomon et al., 2018]. POINTER backed this up from the other side.The structured benefit "was consistent for APOE ε4 carriers and noncarriers (P = .95 for interaction)."The gene didn't blunt it [Baker et al., 2025]. So what. Here's where calibration matters, because this is exactly where content tends to lie. That carrier-versus-noncarrier gap in FINGER was not statistically significant.The confidence intervals overlap [Solomon et al., 2018]. So the rock-solid, bankable claim is this: carriers benefit at least as much as everyone else.The high-risk gene does not exempt you from the payoff. ✅ ACTION STEP: Treat "at least as much" as your floor. There's newer, preliminary work too: an early 2025 meta-analysis (preliminary) of three trials reporting that "benefit of the intervention was greater among the ApoE4 carriers compared with non-carriers (timegroupApoE4 interaction p = 0.035)" [Lehtisalo et al., 2025 (preliminary)]. The authors themselves call it preliminary, so file "carriers may benefit more" under "promising, watch this space," not "proven." A solid floor beats a shaky ceiling. Why "Later" Still Works: Reserve and the Long FuseResearch. Two ideas dissolve the "too late" fear. First, dementia is decades in the making.The underlying pathology starts accumulating 15 to 20+ years before symptoms show up. Second, there's a mechanism called cognitive reserve.In Yaakov Stern's foundational review, reserve is the set of differences that "may allow some people to be more resilient than others," and the point where performance declines "is later in individuals with higher reserve because they can tolerate more pathology before it affects performance" [Stern, 2012].Crucially, Stern writes that experiences "at all stages, even in late life, can impart such reserve" [Stern, 2012]. So what. Flip the timeline.If the disease process takes decades, then someone in their 50s, 60s, or 70s is acting inside the window, not after it. And reserve is a buffer you can keep building.The exercise, the learning, the social connection: that's you, today, actively raising the bar the disease has to clear. 💡 KEY INSIGHT: You can build the buffer late. That's the whole game."Later still works" isn't a vibe. It's a mechanism with a published schematic. ⚠️ CAVEAT: Reserve delays the onset. It does not make you immune.Once the threshold is finally crossed, decline can move faster [Stern, 2012]. So this isn't a force field. It's time.Years of good function you'd otherwise lose.For most of us, years are the entire point. Action. Anything that genuinely challenges your brain and keeps you connected counts toward reserve. Pick one cognitively demanding habit (a real skill, not a passive scroll) and one social commitment you'll actually keep.Accountability is exactly what Phoenix Pods are built for. Which Lever First? The 45% You Can ChangeResearch. In 2024, the Lancet Commission, the most authoritative body on this, reported that around 45% of dementia cases are potentially preventable by addressing 14 modifiable risk factors across the life course [Livingston et al., 2024]. The 2024 update added two factors: an estimated 7% of cases tied to high LDL ("bad") cholesterol in midlife from around age 40, and 2% to untreated vision loss later in life [Livingston et al., 2024]. As lead author Professor Gill Livingston put it: "It's never too early or too late to take action, with opportunities to make an impact at any stage of life" [Livingston et al., 2024]. So what. Hold onto the word "potentially." That 45% is a population-level estimate.It does not mean any one person erases 45% of their personal risk.It means nearly half the burden, across all of us, traces back to things we can influence. Split your risk into two buckets.The non-modifiable one: age, your genotype, family history. Your dealt cards.The modifiable one: the 14 factors. That's where the entire game is played. Timing matters because those factors line up across life.Some are early (education).Many are midlife (LDL, hypertension, obesity, diabetes, hearing loss).Some are late (vision loss, social isolation). Earlier factors give a longer compounding runway, but every stage has live levers. ✅ ACTION STEP: What FINGER and POINTER actually did was a stack, run at the same time: (1) a MIND/Mediterranean-style diet,(2) aerobic plus strength exercise,(3) cognitive training,(4) social engagement, and(5) vascular and metabolic monitoring (blood pressure, glucose, lipids). That last one is the part most people skip, and the part that turns "I'm trying" into "I know." The Carrier-Specific Priority: Metabolic HealthResearch. Here's the carrier-specific answer to "which lever first." A preliminary 2025 analysis split modifiable risk factors by APOE4 status and found the carrier profile differs from the non-carrier one: "mid-life diabetes emerged as the primary risk factor for dementia among ApoE-4 carriers, whereas mid-life hearing loss was found to be most strongly associated with dementia risk among ApoE-4 non-carriers" [Williams et al., 2025 (preliminary)]. Diet points the same way.In observational cohorts, top-tier MIND-diet adherence was linked to slower decline "equivalent to being 7.5 years younger in age," and even "moderate adherence to the MIND diet may also decrease AD risk" [Morris et al., 2015a; Morris et al., 2015b]. So what. For carriers, metabolic health may be the lever with the most pull, and it's worth measuring early.It fits why some researchers half-jokingly call Alzheimer's "type 3 diabetes." Be clear on what this is, though: a preliminary, associative signal, not a proven ranking.If I had to rank what I'd watch for a fellow 4/4, metabolic health goes near the top, as the first thing to measure, not a settled "top lever." On diet, lower the bar on purpose.The highest MIND tertile had a hazard ratio of 0.47 for incident Alzheimer's, but the middle tertile already showed benefit (HR 0.65) [Morris et al., 2015b].You don't have to be perfect. Partial credit counts. ⚠️ CAVEAT: Two honesty flags. First, the MIND-diet data are observational. "Associated with," not "causes," and a later randomized trial found smaller effects. Second, that same 2025 carrier analysis reported a counterintuitive result: that midlife hypertension reduced risk in carriers [Williams et al., 2025 (preliminary)].I won't touch that as advice, and neither should you.It's a single observational study, and the last thing any carrier should do is ease up on blood pressure. Keep treating your blood pressure with your doctor.I'm flagging the finding for honesty, not turning it into a protocol. Action. Track the metabolic markers that tell you whether your metabolism is working with your brain or against it. In Phoenix Bloodwork, the optimal ranges are HbA1c 4.5 to 5.2%, fasting glucose 75 to 85 mg/dL, and fasting insulin 3 to 8 µIU/mL.For lipids, the app's optimal ApoB is 40 to 70 mg/dL.(Personal stance, not the app's number: as a 4/4, I push toward the bottom of that band, under 60.) My own ApoB dropped 39% with ezetimibe plus diet plus a lot of exercise.No statin, that's just not my route.Proof that action moves the markers after you start. The Honest Part: Risk Is Not DestinyResearch. The spine of everything we do: APOE4 raises your probability, not your certainty. Penetrance is not 100%.Plenty of carriers, including 4/4s, never develop Alzheimer's. Even the researchers studying the gene frame it as susceptibility you can act on, noting lifestyle "may be beneficial for cognition in older at-risk individuals even in the presence of APOE-related genetic susceptibility to dementia" [Solomon et al., 2018]. So what. A high-risk hand isn't a lost hand.It's one that rewards playing tighter and smarter than the person dealt aces. Carriers who actually run the levers aren't victims of this gene.We're the players who looked at the odds and decided to outplay them. And sustaining it is its own skill: consistency beats intensity every time.The person who walks 8,000 steps a day for ten years beats the heroic 90-day sprint that burns out. ✅ ACTION STEP: Don't try to do this on willpower alone. What keeps people consistent is other people.That's exactly why we run Phoenix Pods: small groups of carriers running the same experiments and keeping each other honest. Key Takeaways 💡 Quick-Start Protocol (This Week):Get your baseline labs. ApoB (Phoenix optimal 40 to 70 mg/dL), HbA1c (4.5 to 5.2%), fasting insulin (3 to 8 µIU/mL). You can't bend a number you've never measured. Log it in Phoenix Bloodwork. Measure the metabolic markers first. For carriers, preliminary, associative data flags this as a high-yield area to measure early (not a proven ranking) [Williams et al., 2025 (preliminary)]. Build the stack over time, not all at once. MIND-style diet, aerobic and strength training, a genuine cognitive challenge, real social connection. Run it like an experiment. Baseline, change one thing, re-measure. That's the Phoenix Experiments loop, and it's the difference between hoping and knowing. Update the belief. Randomized, replicated, genotype-checked evidence says it works at your age, for carriers, at least as much as anyone. Frequently Asked QuestionsIs it too late to prevent Alzheimer's or dementia? No. And the strongest evidence is the trial design itself.FINGER (ages 60 to 77) and the 2025 U.S. POINTER trial (ages 60 to 79) both showed measurable cognitive benefit from multidomain lifestyle change [Ngandu et al., 2015; Baker et al., 2025].The 2024 Lancet Commission's framing is that "It's never too early or too late to take action" [Livingston et al., 2024]."Prevention" here means meaningfully bending your trajectory and buying years of good function, not a guaranteed cure. Can you reduce Alzheimer's risk in your 60s or 70s? Yes. That's precisely the population the landmark trials studied.POINTER enrolled adults up to age 79 and still found benefit: the structured program was estimated to protect cognition from normal age-related decline for up to 2 years [Baker et al., 2025].The mechanism is cognitive reserve, and experiences "at all stages, even in late life, can impart such reserve" [Stern, 2012]. Does APOE4 mean I'll get Alzheimer's? No. APOE4 raises probability, not certainty.Penetrance is not 100%, and many carriers (including 4/4s) never develop Alzheimer's.Researchers frame it as genetic susceptibility you can act on [Solomon et al., 2018].Risk is not destiny. Do APOE4 carriers benefit from lifestyle change as much as non-carriers? At least as much.The FINGER subgroup found a larger point estimate in carriers (0.037 vs 0.014 per year), though the difference wasn't statistically significant, and POINTER found benefit "consistent for APOE ε4 carriers and noncarriers" [Solomon et al., 2018; Baker et al., 2025].Preliminary 2025 pooled data even suggest carriers may benefit more, but that's not settled yet [Lehtisalo et al., 2025 (preliminary)]. Which lever should an APOE4 carrier measure first? Likely the metabolic markers, but as a high-yield area to measure early, not a proven ranking.A preliminary, associative 2025 analysis found "mid-life diabetes emerged as the primary risk factor for dementia among ApoE-4 carriers" [Williams et al., 2025 (preliminary)]: a signal worth acting on by measuring, not a settled "top lever."Start by measuring HbA1c, fasting glucose, and fasting insulin. Run Your First Experiment With Us You don't have to do this alone, and you shouldn't try to. In Phoenix, you log your baseline labs in Bloodwork (ApoB, HbA1c, fasting insulin), pick one lever, and run it as a structured Experiment: change one thing, re-measure, read the result like a session review. Then you do it alongside 500+ APOE4 carriers in a Pod, where accountability turns a 90-day burst into a ten-year habit. Pick one lever this week, measure it, and let the number show you what works for your biology. The window is open. Let's go play the hand. Medical Disclaimer This article is for educational purposes only and is not medical advice.It does not diagnose, treat, or prescribe.APOE4 raises risk but is not deterministic, and individual results vary.Do not start, stop, or change any medication (including blood pressure treatment) based on this content.Always consult a qualified healthcare professional before making changes to your health regimen. Sources Ngandu T, Lehtisalo J, Solomon A, et al. (2015). A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. The Lancet. RCT (n=1,260, ages 60-77). https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)60461-5/abstract Rosenberg A, Mangialasche F, Ngandu T, Solomon A, Kivipelto M (2020). Multidomain Interventions to Prevent Cognitive Impairment, Alzheimer's Disease, and Dementia: From FINGER to World-Wide FINGERS. The Journal of Prevention of Alzheimer's Disease 7(1):29-36. Review of landmark RCT + global replication. https://doi.org/10.14283/jpad.2019.41 (PMC7222931) Solomon A, Turunen H, Ngandu T, et al. (2018). Effect of the Apolipoprotein E Genotype on Cognitive Change During a Multidomain Lifestyle Intervention. JAMA Neurology. Prespecified RCT subgroup analysis (362 carriers / 747 noncarriers). https://pubmed.ncbi.nlm.nih.gov/29356827/ Baker LD, Espeland MA, Whitmer RA, et al.; U.S. POINTER Study Group (2025). Structured vs Self-Guided Multidomain Lifestyle Interventions for Global Cognitive Function: The US POINTER Randomized Clinical Trial. JAMA. RCT (n=2,111, ages 60-79, 30% APOE ε4). https://jamanetwork.com/journals/jama/fullarticle/2837046 (companion: https://pmc.ncbi.nlm.nih.gov/articles/PMC12381353/) Livingston G, Huntley J, Liu KY, et al. (2024). Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. The Lancet. Guideline-tier evidence synthesis (14 modifiable factors, ~45% potentially preventable). https://pubmed.ncbi.nlm.nih.gov/39096926/ (key-message release: https://www.eurekalert.org/news-releases/1052982) Morris MC, Tangney CC, Wang Y, et al. (2015a). MIND diet slows cognitive decline with aging. Alzheimer's & Dementia. Prospective cohort (n=960, mean 4.7y follow-up). https://pmc.ncbi.nlm.nih.gov/articles/PMC4581900/ Morris MC, Tangney CC, Wang Y, et al. (2015b). MIND diet associated with reduced incidence of Alzheimer's disease. Alzheimer's & Dementia 11(9):1007-1014. Prospective cohort (incident AD). https://pmc.ncbi.nlm.nih.gov/articles/PMC4532650/ Stern Y (2012). Cognitive reserve in ageing and Alzheimer's disease. The Lancet Neurology. Review (mechanism: cognitive/brain reserve). https://pmc.ncbi.nlm.nih.gov/articles/PMC3507991/ Williams V, Trane R, Sicinski K, Roan C, Herd P, Engelman M, Asthana S (2025, preliminary, conference abstract). Life Course Modifiable Risk Factors for Dementia Stratified by ApoE-4 Status. Innovation in Aging 9(Suppl 2), GSA 2025 Annual Scientific Meeting abstract (Wisconsin Longitudinal Study, n=5,526). https://doi.org/10.1093/geroni/igaf122.2174 (PMC12760680) Lehtisalo J, Solomon A, Cantet C, Coley N, Levälahti E, Mangialasche F, Ngandu T, Andrieu S, Arai H, Kivipelto M (2025, preliminary, conference abstract). Effect of the ApoE genotype on the efficacy of multidomain lifestyle interventions on cognitive change: a meta-analysis of three randomized clinical trials (FINGER, MAPT, J-MINT). Alzheimer's & Dementia 21(Suppl 6), AAIC 2025 abstract. https://doi.org/10.1002/alz70860_102747 (PMC12726239) --- ## Here's a gift: Cambridge-backed online test to validate your brain protocol URL: https://apoe4.co/blog/posts/here-s-a-gift-cambridge-backed-online-test-to-validate-your-brain-protocol Published: 2026-06-24T18:38:00+00:00 Updated: 2026-06-24T18:38:08.57189+00:00 Summary: A Cambridge-developed brain test, free, open to every APOE4 carrier receiving this email Here's a gift: Cambridge-backed online test to validate your brain protocolA Cambridge-developed brain test, free, open to every APOE4 carrier receiving this emailDr. Kevin Tran June 24, 2026 Hi Phoenix friend, First, a thank you. You have been following this newsletter, reading the research, and taking your APOE4 risk seriously. That is not nothing. So for this one, I wanted to give something back. If you carry APOE4, you probably already work at this. Better sleep. Cleaner diet. More exercise. Maybe supplements and bloodwork too. But there is one question all that effort cannot answer on its own: is any of it actually protecting your brain? We partnered with PREMAZ, a digital memory test developed with researchers at the University of Cambridge. It is the kind of test people normally pay for, and inside Phoenix it lives behind paid membership. This time we are opening it up. To as many APOE4 carriers as we can reach, you included. Free, no membership needed. Why give away something that usually costs money? Two reasons. A community our size has leverage a single person never does, which is how I negotiated this access in the first place. And Phoenix is running a joint study on APOE4 cognition with PREMAZ and Cambridge, so every test taken makes the research stronger. Opening the doors helps the science and helps you in the same move. Easy call. Here is what makes it worth your ten minutes. It measures the quality of your memory, not just whether you remembered. Most cognitive tests ask whether you remembered something. PREMAZ measures how precisely you remembered it, on a continuous scale. That sensitivity is what lets it pick up subtle changes while standard tests still look normal. It is backed by real research. It is built on more than ten years of University of Cambridge work and is already used in clinics and research settings across the UK and US. In published studies, lower scores were linked to the earliest Alzheimer's-related brain changes, and to faster cognitive change over a five-year period. Ten minutes, your own device, a baseline you keep. The test takes about 10 minutes at home. You get a report you can download. Take it again in a few months (I’d recommend 3 months) and you start to see your own trend, instead of guessing. You also help the whole community. By taking it, you contribute to a joint Phoenix and University of Cambridge study on cognition in APOE4 carriers. Your data is fully anonymized and never personally identifiable. You are helping build evidence that does not exist yet for people like us. 👉 Take the PREMAZ test (free) → How to go further (this is the part most people miss). Have you ever wondered if the interventions you are spending so much time (and money!) on are actually working?A cognitive baseline tells you where you stand today. The harder question is what actually moves it. And here is the trap most people fall into: no single number can answer that. Not one memory score, not one Cholesterol or ApoB result, not one sleep score. Lean too heavily on any one metric and it will eventually mislead you. The truth only shows up when you watch several move together. That is the whole point of Phoenix. We bring in your blood biomarkers, your wearable data like sleep and HRV, and a quick daily check-in, how your energy feels, how you rate your sleep, how heavy the brain fog is, and we correlate all of it with our Phoenix AI specifically trained on APOE4 data. The hard numbers and how you actually feel, in one place, so you can see whether something is working instead of guessing one variable at a time. It is built for stacking experiments over time, too. Members take the PREMAZ test, about three months apart, so they can track their progress: a clear before/after picture.Do that across sleep, supplements and training and you stop guessing for good. And you are not experimenting alone. You also see what is working for other APOE4 carriers who share your health profile, so every member's data makes the next person's decisions smarter. A test like PREMAZ is at its most useful when it sits inside a system like that. The test is yours either way. But if you have been waiting for a reason to stop guessing and start measuring, this is a good one. See what Phoenix could show you → Thank you for being here. Take your baseline, and tell us what you think. Cheers,Kevin PREMAZ is a research and tracking tool, not a diagnosis. It does not diagnose or treat any condition. Talk to your physician about your cognitive health.Most Newsletters? One-way street.How boring…This is the Phoenix Community. So let's make it a two-way street. Got a question? Feedback? Hit reply. I read every single one. --- ## APOE4 and hormones: vitamin D, estradiol, progesterone, testosterone, and thyroid URL: https://apoe4.co/blog/posts/apoe4-and-hormones-vitamin-d-estradiol-progesterone-testosterone-and-thyroid Published: 2026-06-21T18:54:00+00:00 Updated: 2026-07-02T09:34:18.197101+00:00 Summary: APOE4 carriers: optimize vitamin D, estradiol, progesterone, testosterone & thyroid for brain health. Learn the right ranges, testing timing, and protocols that work. APOE4 and hormones: vitamin D, estradiol, progesterone, testosterone, and thyroidThe APOE4 hormone conversation: timing, testing, and the "sweet spot" problemDr. Kevin Tran June 21, 2026 Hi Phoenix friend, If you want to watch the full conversation, you can find the video here: If you would rather get the synthesized value, this post covers the main takeaways. In this conversation with Dr. Grant Fraser, we continued the APOE4 biomarker series by moving into hormones. That includes vitamin D, estradiol, progesterone, testosterone, and thyroid. The recurring theme was the same one that has come up throughout this biomarker series: the target is not "high" or "low." The target is the right range for the right person at the right time. Hormones are powerful because they touch sleep, mood, metabolism, vascular function, bone health, mitochondrial function, inflammation, and brain function. But that also means they are not something to optimize casually. Testing matters. Timing matters. The route of delivery matters. And for some interventions, especially hormone replacement later in life, the risk-benefit picture can change depending on when you start. Vitamin D: measure the level, do not guess the dose Vitamin D is called a vitamin, but biologically it behaves more like a hormone. Dr. Fraser's practical target range was roughly: Vitamin D: about 40 to 70 ng/mL He mentioned that some clinicians may prefer narrower versions of that range, such as 40-60 or 50-70 ng/mL, but the general idea is to avoid both deficiency and excess. One important point: the dose someone takes does not tell you their level. The official recommendation is around 800 IU per day, but Dr. Fraser said many of his patients need closer to 5,000 IU per day to reach a therapeutic blood level. Some need none. Some need much more. That is why serum testing matters. Vitamin D came up as relevant for: Bone health Osteoporosis prevention Vascular health Immune and inflammatory regulation Possibly modest brain-health support He also emphasized the supporting nutrients that often get ignored. Magnesium matters because vitamin D metabolism depends on magnesium. Vitamin K2, especially MK-7, is often paired with vitamin D for vascular health, with a common dose around 200 mcg in his practice. The theory is that K2 helps support better calcium handling rather than encouraging calcium deposition in blood vessels. As always, this is a discussion to have with a clinician, especially if using higher-dose vitamin D or if calcium, kidney, parathyroid, vascular, or bone issues are involved. Estradiol: brain health, timing, and the menopause window Estradiol was one of the most important parts of the discussion. Dr. Fraser described estradiol as relevant to multiple brain-health pathways, including: Mitochondrial function Neuroinflammation Cholinergic signaling Cerebral blood flow Synaptic plasticity Glucose metabolism Vascular function For women, the menopause transition creates a major hormonal shift. Dr. Fraser's view is that, unless there is a specific contraindication, hormone replacement therapy can be a very sensible conversation to have before or during the menopause transition. He emphasized that the process often starts before menopause. In perimenopause, progesterone may decline first, often affecting sleep and mood before estradiol drops fully. That matters because sleep is not a side issue. If sleep breaks down, the rest of the system tends to suffer. The timing question: starting HRT early vs. much later The most nuanced part of the estradiol discussion was timing. Starting hormone support around perimenopause or menopause is a very different question from starting it 10, 15, or 20 years after menopause. Dr. Fraser raised the concern that after many years without estradiol, the brain and vascular system may be in a different state. There may be more endothelial dysfunction, less neuroplasticity, more mitochondrial dysfunction, more inflammation, or more vascular disease. In that context, suddenly adding hormones may not carry the same risk-benefit profile. This is why he sees later initiation as an individualized decision. In someone with excellent vascular health, low inflammation, strong cognitive or functional testing, minimal white matter disease, and no obvious vascular burden, he may be more comfortable considering it. In someone with more vascular disease, inflammation, or signs of significant biological aging, he is more cautious. The key takeaway is not "everyone should start HRT." The takeaway is that timing and context matter. Estradiol route and targets Dr. Fraser generally favors topical or transdermal estradiol rather than oral estrogen. Most of his patients use FDA-approved estradiol patches. He mentioned patch doses ranging from 0.025 mg/day to 0.1 mg/day, adjusted based on response and lab monitoring. His practical estradiol target for women was roughly: Estradiol: about 40 to 70 pg/mL Units and assay context matter, so this is not a DIY target. But it gives a sense of the physiological range he is aiming for rather than pushing levels high. For men, estradiol matters too. Men produce estradiol from testosterone, and very low testosterone can mean low estradiol. Dr. Fraser likes men to have estradiol roughly in the mid-20s pg/mL. Too low may affect mood and bone health. Too high may contribute to gynecomastia or unwanted fat distribution. Again: sweet spot, not maximum. Progesterone: not just a uterus hormone One of the clearest points in the discussion was Dr. Fraser's view that progesterone is not only relevant for women who still have a uterus. He strongly pushed back on the idea that progesterone's only role is preventing uterine cancer when estrogen is prescribed. Progesterone receptors exist in the brain. Progesterone can act through GABA-related pathways and may significantly affect sleep and mood. For many women in perimenopause or menopause, progesterone can be one of the most meaningful interventions for sleep disturbance. Dr. Fraser generally uses FDA-approved micronized progesterone. The practical takeaway: progesterone is part of the brain-health and sleep conversation, not just the uterine-protection conversation. Testosterone in women: optional, but not irrelevant Testosterone is often discussed as a male hormone, but women produce and use testosterone too. Dr. Fraser described testosterone in women as optional but potentially useful, depending on symptoms, levels, and goals. He referenced Dr. Susan Davis's work in Australia, where there is more formal research and a commercially available testosterone product designed specifically for women. In his practice, he tends to target a physiological range rather than pushing high levels. He mentioned free testosterone targets within the normal female range, depending on assay and context, often staying toward the lower side. For women, dosing is much lower than in men. He mentioned topical doses around 4-10 mg/day, compared with much higher male dosing. The goal is not masculinization. The goal is physiologic normalization when appropriate. Testosterone in men: normalize, don't blast For men, Dr. Fraser made a sharp distinction between restoring a physiologic level and bodybuilding-style supraphysiologic dosing. Those are completely different things. Normalizing low testosterone may help with: Mood stability Well-being Lean body mass Bone health Insulin sensitivity Energy and function But pushing testosterone far above physiologic levels can create serious metabolic problems. He used the example of bodybuilders using very high testosterone and growth hormone doses, often requiring large amounts of insulin because blood glucose regulation becomes so impaired. The practical message: low testosterone can matter, but "more" is not the goal. Free testosterone matters more than total testosterone One of the most useful testing points was this: Total testosterone alone can be misleading. Sex hormone-binding globulin, or SHBG, changes how much testosterone is actually available. Someone can have a high total testosterone and low free testosterone. Someone else can have a low total testosterone and a normal or high free testosterone. Dr. Fraser was very clear that free testosterone is what he cares about clinically. If a clinician only checks total testosterone, they may miss the real picture. Men with low testosterone: find the cause before replacing it For men, Dr. Fraser does not jump straight to testosterone replacement. He first wants to know whether the issue is primary testicular failure or whether the brain is not signaling the testicles strongly enough. In many men, the testicles can still produce testosterone if the signal is improved. That is why he often considers approaches that stimulate endogenous production, such as hCG or other signaling-based therapies, before direct testosterone replacement. His concern with direct testosterone is that it can suppress natural production and lead to testicular atrophy. It is also a controlled substance, which can create continuity problems if someone needs ongoing prescribing for decades. His preference, when possible, is to help the body produce more rather than replace it directly. Thyroid: the standard lab range may be too loose The thyroid section was another practical one. Dr. Fraser's view is that the standard U.S. TSH reference range is too permissive. Many labs do not flag TSH as abnormal until it is above about 4.5 mIU/L. He prefers a tighter target. His practical "happy spot" for TSH was: TSH: about 0.5 to 1.5 mIU/L He often uses TSH above 2.5 mIU/L as a trigger to consider whether thyroid support is appropriate, depending on the person. He generally checks free T3 and free T4 as well, not just TSH. Thyroid treatment: adjust slowly and monitor Most people who need thyroid support start with T4, commonly levothyroxine or Synthroid, because it has a long half-life and is stable. Some people do better with desiccated thyroid preparations like Armour Thyroid or NP Thyroid, which contain both T4 and T3. Others do better on a specific brand rather than generic. The point is not that one form is always best. The point is that thyroid treatment often requires monitoring, adjustment, and paying attention to how the person actually feels. Dr. Fraser typically rechecks thyroid labs every 4-6 weeks after a change. Once stable, he may check again at three months and then yearly. Hashimoto's and symptoms of hypothyroidism If someone is hypothyroid, Dr. Fraser thinks it is reasonable to check thyroid antibodies at least once, especially thyroid peroxidase antibodies and thyroglobulin antibodies, to see whether Hashimoto's thyroiditis is part of the picture. Hashimoto's can also contribute to inflammation and may affect CRP. He also mentioned that clinicians should examine the thyroid for nodules and consider ultrasound when appropriate. Common hypothyroid signs and symptoms discussed included: Low energy Slower heart rate Sluggish reflexes Depression Weight gain Waxy or thickened skin Loss of the outer third of the eyebrows The eyebrow point is a classic physical finding that many people have never heard of. The biggest takeaway Hormones are not separate from brain health. Vitamin D, estradiol, progesterone, testosterone, and thyroid all touch systems that matter for cognition, vascular health, metabolism, sleep, inflammation, and resilience. But they need to be handled with care. The goal is not to chase high numbers.The goal is not to treat lab ranges casually.The goal is to restore and maintain physiological function where it makes sense. For APOE4 carriers, that context may matter even more because the brain may be more vulnerable to inflammation, vascular dysfunction, metabolic stress, and hormonal disruption. The most useful framework from this conversation is: Measure the right thing.Interpret it in context.Act only when the result changes what you do.Retest after changes.Do not confuse "optimal" with "more." Educational only, not medical advice. Hormones and thyroid treatment should be discussed with a qualified clinician who understands your full medical history, risk profile, and goals. Cheers, Kevin Most Newsletters? One-way street.How boring…This is the Phoenix Community. So let's make it a two-way street. Got a question? Feedback? Hit reply. I read every single one. --- ## APOE4 and brain stress: why hs-CRP, ferritin, and iron need a different lens URL: https://apoe4.co/blog/posts/apoe4-and-brain-stress-why-hs-crp-ferritin-and-iron-need-a-different-lens Published: 2026-06-18T18:05:00+00:00 Updated: 2026-06-18T18:05:09.835457+00:00 Summary: APOE4 carriers need a different lens for inflammation markers. Learn why "normal" hs-CRP, ferritin, and iron levels may mask brain stress and what to track instead. APOE4 and brain stress: why hs-CRP, ferritin, and iron need a different lensIf you carry APOE4, "normal" inflammation markers may not mean what you thinkDr. Kevin Tran June 18, 2026 Hi Phoenix friend, APOE4 and brain stress: hs-CRP, ferritin, iron, and what is actually worth tracking If you want to watch the full conversation, you can find the video here: If you would rather get the synthesized value from the discussion, this post covers the main takeaways. In this conversation with Dr. Grant Fraser, we continued our APOE4 biomarker series. The first part focused on homocysteine and omega-3. This episode moved into a different category: markers that suggest the brain and body may be under stress. The big theme was simple, but easy to miss: For APOE4 carriers, some "normal" biomarkers may need a different interpretation. That does not mean every lab result needs to become a source of anxiety. It means the goal is to understand which markers are actually useful, which ones are noisy, and which ones can change what you do next. This episode focused mainly on hs-CRP, ferritin, iron, oxidative stress, GGT, and the temptation to order increasingly fancy inflammatory or blood-brain barrier tests. A recurring rule came up again and again: Do not test something unless you know what you would do with the result. That may be the most useful sentence in the whole discussion. hs-CRP: useful, but APOE4 changes the interpretation High-sensitivity C-reactive protein, usually written as hs-CRP, is commonly used as a marker of systemic and vascular inflammation. It is produced by the liver in response to upstream inflammatory signals like IL-6, IL-1 beta, and TNF-alpha. In general medicine, many clinicians like to see hs-CRP under 1.0 mg/L. But Dr. Fraser pointed out something important for APOE4 carriers: people with APOE4 often appear to produce lower CRP for the same inflammatory burden. That does not necessarily mean they have less inflammation. It may mean that a CRP of 1.0 in someone with APOE4 could reflect more inflammatory activity than the same number in someone without APOE4. Because of that, Dr. Fraser's practical target for APOE4 carriers, especially APOE4 homozygotes, is lower: For APOE4 carriers, he generally likes to see hs-CRP below 0.5 mg/L. The point is not to panic over one value. hs-CRP can move quickly. A viral infection, dental inflammation, an autoimmune flare, a hard physiological stressor, or even certain fasting states can temporarily push it much higher. The more useful approach is to look for a clean baseline and then track trends over time. When hs-CRP is high, look for the source If hs-CRP is higher than expected, the answer is not always "take another supplement." Dr. Fraser listed several common drivers that are worth investigating: Periodontal disease or poor oral health P. gingivalis or other oral microbiome issues Sleep apnea Excess visceral fat Chronic infections Autoimmune or inflammatory conditions Rheumatoid arthritis, lupus, inflammatory bowel disease, or similar inflammatory diseases Recent viral illness Major dietary changes Acute physiological stress Dental disease came up as especially easy to overlook. That matters because oral inflammation may be particularly relevant in APOE4 carriers. The takeaway: if hs-CRP is elevated, first ask whether the result reflects a real baseline or a temporary inflammatory event. How to lower hs-CRP in a way that actually makes sense The discussion covered several interventions that may help lower inflammation, but Dr. Fraser was careful not to promise a predictable drop from any single intervention. Some people may see a large change from fixing periodontal disease. Others may see more movement from losing visceral fat, treating sleep apnea, improving diet, or addressing an inflammatory condition. The most practical levers discussed were: Reducing visceral fat if elevated Improving sleep and screening for sleep apnea when appropriate Zone 2 and zone 3 exercise Resistance training Periodontal health A Mediterranean or MIND-style diet More colorful plants, nuts, seeds, flavonoids, and antioxidant-rich foods Reducing processed foods Optimizing omega-3 status, especially EPA for vascular inflammation Considering targeted anti-inflammatory compounds like curcumin or astaxanthin under clinician guidance One subtle point: dietary changes can change inflammation fairly quickly, but going too fast can backfire. Fiber is the clearest example. Many people go from a low-fiber diet to a very high-fiber diet overnight, then feel awful and assume the healthier diet is harming them. Dr. Fraser's rule of thumb was to increase fiber gradually, by no more than about 5 grams per day per week. If someone is eating 8 grams a day and wants to get above 30 grams, that transition may take several weeks. That is not failure. That is your gut microbiome needing time to adapt. Ferritin: the iron marker with a catch Ferritin is one of the most important markers in the APOE4 conversation because iron cuts both ways. Too little iron is a problem. Iron is needed for brain function, muscle function, oxygen handling, and many enzymatic reactions. Low iron can affect energy, mood, cognition, and physical performance. Too much iron is also a problem. Higher iron stores can drive oxidative stress. Dr. Fraser specifically discussed research suggesting that higher brain iron may enhance beta-amyloid accumulation, especially in people with APOE4. So the goal is not "as low as possible." The goal is a sweet spot. Dr. Fraser's practical ferritin target was roughly: Ferritin: about 40 to 80 ng/mL That range is not a universal medical rule, and individual context matters. But the principle is useful: avoid deficiency and avoid overload. Always interpret ferritin with hs-CRP Ferritin has one major trap: it is not only an iron-storage marker. It is also an inflammatory marker. If hs-CRP is elevated, ferritin may look higher than your true iron stores. Dr. Fraser's point was that ferritin can be artificially high during inflammation, but it will not usually be artificially low because of inflammation. So if ferritin is elevated and hs-CRP is also elevated, you may not know how much of that ferritin reflects iron stores and how much reflects inflammation. That is why he likes to pair ferritin with hs-CRP. If CRP is low and ferritin is high, the ferritin is more likely to reflect true iron overload. If CRP is high and ferritin is high, clean up the inflammatory picture before making big conclusions about iron. Blood donation can help with high ferritin, but it is not a detox strategy For people with high ferritin, especially men, blood donation can be one practical way to lower iron stores. But Dr. Fraser pushed back on the idea that frequent blood donation is a broad longevity "detox" strategy. Removing one unit of blood removes only a small fraction of total body mass. Toxins and metals are distributed throughout tissues, not just floating neatly in the blood. Blood donation can be useful for lowering ferritin. It is not a magic detox. He also warned that over-donating can create iron deficiency or anemia. If someone donates blood to manage ferritin, they should recheck ferritin and hemoglobin before repeating it. He noted that iron stores may take six to eight weeks to equilibrate after a donation. Another useful clinical pearl: falling ferritin can sometimes be a warning sign for occult blood loss, including gastrointestinal blood loss. That is one reason ferritin matters beyond brain health. GGT: oxidative stress, liver stress, alcohol, toxins, and insulin resistance GGT is often thought of as a liver or alcohol-related marker. Dr. Fraser framed it more broadly as a marker that can reflect oxidative stress, toxin exposure, alcohol burden, liver stress, and sometimes early insulin resistance. He does not appear to use GGT as heavily as hs-CRP or ferritin, but he does see value in including it periodically, especially in broader annual panels. The practical hierarchy from this discussion was clear: If you are deciding where to spend attention and money first, hs-CRP and ferritin matter more. GGT can add context, but it is usually not the central marker. What about IL-6, TNF-alpha, MMP-9, MPO, fibrinogen, ADMA, SDMA, and blood-brain barrier tests? This was one of the most useful parts of the conversation because it addressed a real problem in the longevity and prevention world: endless testing. There are many inflammatory, oxidative stress, vascular, and blood-brain barrier markers that sound interesting. Some may eventually become more useful. But right now, many of them do not clearly change what you would do. Dr. Fraser discussed IL-6 as an upstream inflammatory marker. It is available and may be useful in some contexts, but it can also be noisy. hs-CRP remains better validated and more practical. MMP-9 came up because of its possible relationship to blood-brain barrier integrity and APOE4 biology. There is mechanistic interest, including discussion around low-dose doxycycline as an MMP-9 inhibitor, but this is not yet a simple "test this, then do that" pathway. MPO, fibrinogen, ADMA, and SDMA may provide information about oxidative stress, clotting, endothelial function, or vascular health. But if the result is abnormal and the recommendation is still diet, exercise, sleep, lipid management, and inflammation control, then the test may not add much unless it helps motivate behavior change. That was the core principle: A test is useful when it changes the next action. If it only adds anxiety, cost, or confusion, it may not be worth ordering. Practical testing cadence In Dr. Fraser's practice, he tends to monitor a practical lab panel quarterly and a more detailed panel yearly. His quarterly basics often include markers like: hs-CRP Ferritin Lipids ApoB Homocysteine B12 Folate Comprehensive metabolic panel He was clear that quarterly testing is his practice pattern, not a universal rule backed by a perfect study. The deeper point is that consistent tracking can be useful, especially when you are actively changing something. The biggest takeaway For APOE4 carriers, the goal is not to collect every possible biomarker. The goal is to identify the markers that are: Relevant to APOE4 biology Reliable enough to interpret Actionable enough to change behavior Trackable over time In this conversation, hs-CRP and ferritin stood out as two of the most practical markers for inflammation, iron status, oxidative stress risk, and brain-health prevention. The sweet spot matters. Too much inflammation is a problem.Too much iron is a problem.Too little iron is also a problem.And a "normal" number may not always mean the same thing in an APOE4 carrier. That is why context matters. If you’d like to pick the next topics for these Q&As, and submit your own questions, join the Phoenix Community here. Cheers,Kevin Educational only, not medical advice. Use this as a framework for a better conversation with a clinician who understands APOE4, prevention, and biomarker interpretation. Most Newsletters? One-way street.How boring…This is the Phoenix Community. So let's make it a two-way street. Got a question? Feedback? Hit reply. I read every single one. --- ## 55 APOE4 carriers used red light therapy for 4months: This is what happened URL: https://apoe4.co/blog/posts/55-apoe4-carriers-used-red-light-therapy-for-4months-this-is-what-happened Published: 2026-06-15T18:50:00+00:00 Updated: 2026-06-15T18:50:14.912308+00:00 Summary: APOE4 carriers used red light therapy for 4 months: Real-world results on memory, sleep, and bloodwork tracked in everyday life situations. 55 APOE4 carriers used red light therapy for 4months: This is what happenedWe ran our own study and tracked memory, sleep, and bloodwork in carriers in real life situations.Dr. Kevin Tran June 15, 2026 Hi Phoenix friend, Here’s a question your doctor probably can’t answer yet. The big Alzheimer’s-prevention studies happen in tightly controlled trials. Selected people. Fixed doses. Clinic-grade machines. A short, funded window. They’re good at answering one thing: can this work? But you don’t live in a trial. You live in a kitchen, a job, a family, a calendar that doesn’t care about your protocol. So the real question, the one that actually matters to an APOE4 carrier, is harder: Does any of this hold up in a real life? We decided to find out. Not in a lab. In the lives of real carriers, tracked continuously for four months. This is what we found. If you’d rather watch the presentation, it was recorded here Why most “evidence” doesn’t fit you Think about every prevention headline you’ve read. “Reduces risk by X%.” Buried underneath is a study run on people nothing like you, on a Tuesday afternoon, in a room you’ll never sit in. That’s not a knock on science. It’s a gap. On one side: the clinical trial, clean and controlled. On the other: you, with variable sleep, a wearable that sometimes doesn’t sync, supplements you remember most days, and months of messy, continuous, real data. Almost nobody studies that second world. We built a platform that lives in it, so we could. What we actually did Over four months (October 2025 to February 2026), a group of APOE4 carriers added one thing to their lives: a transcranial photobiomodulation device, a helmet that sends gentle near-infrared light into the brain. Then we measured everything around it. Six continuous streams per person: cognitive testing, sleep from Oura rings, blood biomarkers, HRV, daily check-ins, and device-usage logs. All captured inside one platform. The cohort was high-risk on purpose: APOE4 carriers, 64% of them homozygous (two copies, the highest genetic risk there is). These are exactly the people most prevention research never reaches. One honest note up front: different measures had different numbers of people, which is normal for real-world data. So judge each result against its own sample, not one headline number. We’ll tell you the sample every time. How to read this honestly Before the results, a promise: I’m going to give you the honest version, not the marketing version. The study was small. That matters. A small study can only reliably catch big changes, so when a result just misses the cutoff, it’s usually real and simply waiting on a bigger sample to confirm. Keep that in mind as you read. Three labels, that’s all you need: Significant (p < .05) — strong, trust it. Near-significant (p = .05–.11) — likely real, needs more people. Stable — no meaningful change. The headline: memory moved Of the five thinking skills we tested, one stood out. And it’s the one that matters most. Memory improved significantly. 20 of the 25 participants got better at it. The group’s memory score climbed from 62.96 to 70.32 (for the stats-minded: Z = 2.585, p = .010). Of everything we could have hoped to move in APOE4 carriers, memory is the bullseye. It’s the domain most tied to early Alzheimer’s risk. Reasoning (p = .071) and perception (p = .106) leaned positive too, just short of the line a bigger study would likely cross. Attention and coordination held flat. The wins weren’t random Here’s the part that made me trust it. Out of 22 individual skills we tested, four passed the strict bar on their own: naming, non-verbal memory, visual perception, and working memory. Five more were promising and near-significant. Look at where they clustered: memory, naming, perception. The exact areas tied to early Alzheimer’s risk. Not scattered across random skills. That’s what a real effect looks like, not chance. Most people improved Zoom out to overall cognition and the picture holds: 60% of participants improved. The typical person’s gain was real, not statistical noise. The median change was +5.0, and the confidence interval ([2.0, 6.0]) excluded zero. Was it uniform? No. Scores ranged from −19 to +21. Some people improved a lot, a few declined. That’s real life and real biology. But the center of gravity moved the right way. Here’s the part most people miss Stop for a second and notice how this study even exists. No clinic. No research coordinator with a clipboard. The cognitive scores, the sleep data, the bloodwork, the daily check-ins, all of it came from carriers quietly tracking their own lives inside one platform. That platform is Phoenix. That’s the whole idea. Phoenix is built by an APOE4/4 carrier, for APOE4 carriers, to turn scattered data into answers. 27 biomarkers tracked against APOE4-specific targets (not generic “normal”). Monthly pods of carriers who keep each other consistent. Experiments you run on yourself. It’s the reason a study like this could happen at all, and why the next one will be bigger. Hold that thought. Back to the data. On session nights, sleep got better We had one participant who tracked their sleep with an Oura ring, night after night, for months. The cleanest possible look at how one person responds. On the nights they ran a session, every single sleep metric improved:+32 minutes of total sleep +10.5 minutes of REM +7.8 minutes of deep sleep 13.7 fewer minutes to fall asleep +6.6 points of sleep efficiency +2.4 points of next-day readiness All of it statistically solid (p < .01). The cleanest signals were REM and deep sleep. One honest caveat: that’s one person, tracked deeply (n = 1). A strong pattern for them over time, not yet proof for everyone. Worth scaling, which is exactly what we plan to do. And it built up the way a real effect does This is the detail that’s hard to fake. The benefits didn’t spike on day one like a placebo. They built. Daily readiness lifted by week 2 (+6.5 points). Total sleep time climbed by week 4 (+47 minutes), then strengthened from there. Effects that grow over weeks are the pattern you’d expect from a real biological response. A coherent story is forming Insomnia symptoms eased too. On the standard index (lower = fewer symptoms), the typical participant dropped 2.5 points. And here’s what gives it weight: better sleep architecture, fewer insomnia symptoms, and memory gains all leaned the same direction, in the same cohort. We even saw a hint that bigger insomnia drops tracked with bigger cognitive gains (a lead to test, not yet a finding, with only 8 people). When independent measures agree, you start to believe the signal. And people felt good, for four straight months Across four members’ daily self-ratings (1,363 sessions in all) in the Phoenix app, sleep quality and mental sharpness trended up. Mood, energy, and overall wellbeing stayed high and steady the entire time. That sounds modest. It isn’t. Mood and energy usually drift down over four months of effort and tracking fatigue. Holding them high and flat is itself a win. (The one flag, in the name of honesty: self-reported stress crept up. Could be the device, could be life, could be the act of measuring yourself daily.) The results that made us sit up A couple of participants shared personal results outside the formal dataset. No control group, so we treat them as stories to test, not proof. But they’re striking. One person’s IL-6, a key inflammation marker, fell more than 75% over about three months (6.1 → under 1.4 pg/mL). Their other inflammatory marker, already low, held steady. Another improved by 5.7 points on the ADAS-Cog13, a standard Alzheimer’s cognitive assessment where lower is better (19 → 13.3). Individual stories. But the kind that tell you exactly where to point the next, bigger study. The scoreboard, honestly Let me lay the whole thing out, nothing hidden: Solid wins: memory improved (p = .010, 20/25 up); session-day sleep (all six metrics, n = 1); wellbeing held high for four months. Promising signals: overall cognition (+5 median, near-significant); reasoning and perception trends; a sleep-to-cognition link worth testing at scale. Watch closely: rising stress; the strongest sleep data being a single subject; wide individual variability. Where it fell short I won’t oversell this. Here’s what held the study back: it was small and under-powered. There was no placebo or sham group. The strongest sleep data is from one person. Follow-up was short. We didn’t systematically capture life stress. And repeat-testing can lift scores on its own. So this isn’t absolute proof. But it’s a real, encouraging signal, the kind that earns a tighter, larger study with a control arm. That honesty is the point. You’ve been promised certainty by people selling you things your whole life. I’d rather show you the real picture and let you decide. The device behind the results The helmet in the study is the Neuronic Light, a clinical-grade transcranial photobiomodulation device. 1070nm near-infrared light, 256 LEDs, region-by-region control, a few minutes a day. Want to try the exact device we studied? We worked out a deal for this community: $100 off with code PHOENIX at checkout. It’s HSA/FSA eligible and ships with a 90-night home trial, so if it’s not for you, you send it back. 👉 Get $100 off with code PHOENIX We used the Neuronic LIGHT device. Want to be in the next study? Here’s the thing the helmet can’t give you. This study happened because thousands of APOE4 carriers decided to stop guessing and start measuring, together, in one place. 4,000+ carriers on Phoenix. 550+ actively running their own experiments. That’s the engine. That’s what turns a hunch into evidence. When you join Phoenix, you’re not on the outside reading the next result. You’re in it. Your bloodwork, your sleep, your cognition become part of the dataset that proves what actually works for our genotype, while you get APOE4-specific tracking, a community of carriers who get it, and early access to studies like this one. You carry APOE4. You can’t change that. But you can stop facing it alone, and start turning your own data into answers. 👉 Join Phoenix and get into the next study This is a movement, not a startup. Come build the evidence with us. Dr. Kevin Tran,Founder, Phoenix (APOE4/4) PS. Two ways forward, your choice. Want the device we studied? Code PHOENIX takes $100 off the LIGHT or the Neuradiant, with a 90-night trial so there’s nothing to lose. Want to help build the proof and get the tools for your own protocol? Join Phoenix. The carriers who do both tend to be the ones who, a year from now, actually know what’s working, instead of hoping. Education, not medical advice. Findings are observational, single-cohort, partly single-subject (n = 1), with no control group, and are not proof of efficacy. Neuronic devices are not intended to diagnose, treat, cure, or prevent any disease. Consult your physician before starting any device or protocol. Phoenix may earn an affiliate commission on Neuronic purchases; it does not influence our recommendations or the study data. --- ## How I cut my cholesterol and ApoB nearly 40% (no statin) URL: https://apoe4.co/blog/posts/how-i-cut-my-cholesterol-and-apob-nearly-40-no-statin Published: 2026-06-10T18:56:00+00:00 Updated: 2026-06-10T18:56:11.059338+00:00 Summary: APOE4/4 carrier cuts ApoB 40% without statin using diet, psyllium, ezetimibe. See the exact protocol, labs, and target ranges that work. How I cut my cholesterol and ApoB nearly 40% (no statin) Diet, psyllium, ezetimibe. What moved, what didn't, what I'd do again. Dr. Kevin Tran June 10, 2026 Hi Phoenix friend, My ApoB started at 115 mg/dL. It's around 70 now, a drop of nearly 40 percent. No statin, ever. For an APOE4/4 carrier, ApoB may be the single most important number to move against Alzheimer's, and there's a cheap, generic, non-statin way to move it that not enough folks are aware of… Here's what we will cover today First, why cholesterol is a different problem if you carry APOE4 (it changes what your numbers mean). Then the three levers in order, with the evidence behind each one and roughly what each is worth. Finally, my actual panels, the honest caveats (including where I'm still short), and the APOE4 target ranges you can take to your own doctor. If you'd rather watch than read, the full walkthrough is on YouTube: Otherwise, let's get into it. Why cholesterol is a different problem if you carry APOE4 Here's the part most people miss. APOE4 doesn't just raise your numbers. It changes what they mean. ApoE is your body's main lipid taxi. ApoE3 and ApoE2 prefer small HDL particles; ApoE4 prefers large, triglyceride-rich VLDL, a different trafficking pattern entirely (Husain et al. 2021). The result: APOE4 carriers tend to run higher cholesterol, and the largest Alzheimer's cohort in the world found total cholesterol significantly higher in carriers (Dunk & Driscoll 2022). The finding that should change how you think about it: high total cholesterol is a stronger Alzheimer's risk factor in APOE4 carriers than in non-carriers. The authors called low total cholesterol "a critical aspect of preventative care for AD, particularly for APOE ε4 allele carriers." It cuts both ways. In 2025, Nature Medicine tracked 5,705 people and isolated APOE4/4 homozygotes as their own subtype. In that group, Mediterranean diet adherence modulated dementia-related metabolites more effectively than in the general population (Liu et al. 2025). Translation: if you're APOE4/4, your food has more leverage, not less. So does every other lever. My baseline, December 2024 I ran a full panel at a lab in Petaling Jaya. The reference ranges below are the Phoenix Bloodwork Module's APOE4-specific optimal columns, the same numbers our members see when they upload a lab PDF. They're tighter than what your lab flags, because APOE4/4 isn't most people. Marker Value Phoenix APOE4 optimal Flag Total cholesterol 209 mg/dL 150–180 mg/dL High LDL cholesterol 139 mg/dL 50–80 mg/dL Well above target HDL cholesterol (male) 61 mg/dL ≥60 mg/dL Optimal Non-HDL 147 mg/dL (no Phoenix optimal published) High Triglycerides 35 mg/dL 50–100 mg/dL Optimal ApoB 96 mg/dL 40–70 mg/dL (4/4 aim <60) Above target HbA1c 5.9% 4.5–5.2% Prediabetic Fasting glucose 104 mg/dL 75–85 mg/dL Prediabetic range hs-CRP <0.5 mg/L 0–0.5 mg/L Low/optimal Hand this panel to most doctors and you'd hear "borderline, see you in a year." For a APOE4/4 carrier, borderline is the dangerous word. Two copies of APOE4 carry roughly 15 times higher Alzheimer's risk (and as an Asian it can go up to 33x), and high cholesterol amplifies that risk more in carriers than in non-carriers. My ApoB at 96 meant real atherogenic particle burden circulating, possibly feeding amyloid pathology decades before any symptom. Add the HbA1c at 5.9, officially prediabetic. Carriers are prone to insulin resistance, and insulin resistance amplifies AD risk. Two problems converging. So I built a plan with three levers. Lever 1: Diet Mediterranean-leaning. Not the branded program, the actual eating pattern the research tracks. Four moves: Cut saturated fat hard. Butter, cheese, fatty red meat down to occasional. Carrier cholesterol responds more to dietary fat than non-carrier cholesterol does (Dunk & Driscoll 2022), so this lever pulls harder for us. Upgrade the fats. Extra virgin olive oil as the default. Avocado, nuts, seeds. Soluble fiber in every meal. Oats, lentils, beans, barley, apples with the skin on. Drop liquid calories and refined carbs. This one probably moved my HbA1c more than anything else I did. Honest caveat: there's no randomized trial of Mediterranean diet in APOE4/4 homozygotes specifically. We have the 2025 Nature Medicine cohort plus consistent observational evidence. Not RCT-grade proof. But the alternative, eating a standard Western diet with two copies of APOE4, is an experiment I won't run on myself. Lever 2: Psyllium husk This is the lever most people overlook. And most people buy the wrong kind. Psyllium is a viscous soluble fiber. Mixed with water it forms a gel, and in your small intestine that gel traps bile acids. Your body makes bile acids from cholesterol and normally recycles about 95 percent of them. Psyllium breaks the recycling and escorts them out. Your liver has to make more, which means pulling cholesterol out of your blood to do it. The detail the supplement aisle won't tell you: this only works with viscous fibers. McRorie & McKeown (2017) are blunt that gel-forming fibers (psyllium, beta-glucan, raw guar) lower cholesterol, while non-viscous ones (inulin, wheat dextrin) "do not provide these viscosity-dependent health benefits." If your fiber supplement is inulin, you're not getting this. How much it moves the needle: a 28-RCT meta-analysis (Jovanovski et al. 2018) found psyllium at around 10 g/day dropped LDL about 13 mg/dL and ApoB about 5 mg/dL, both highly significant. An umbrella review of 108 systematic reviews puts it on the same evidence tier as plant sterols (Schoeneck & Iggman 2021). The bonus for me: at 5.9 HbA1c, psyllium before meals was also a glucose play. In diabetics it cut HbA1c by nearly a full point, scaling to how high you start (Gibb et al. 2015). Two levers in one scoop. My protocol: about 10 g/day (two scoops), split before meals, always with a full glass of water, and any medication separated by two hours or more. Lever 3: Ezetimibe 10 mg (the standout) I'll say it plainly. Ezetimibe has been the single best lever I've pulled. Stacked with diet and psyllium, it's the biggest reason my ApoB fell from 115 into the 70s in this window. If I had to drop two of my three levers tomorrow, this is the one I'd keep. It's a once-daily drug, FDA-approved since 2002, now generic and cheap. And it is not a statin. Statins work in the liver, blocking the enzyme that makes cholesterol. Ezetimibe works in the gut, blocking a protein called NPC1L1 that absorbs cholesterol into your blood (Garcia-Calvo et al. 2005). Different mechanism, different side-effect profile. (Worth knowing if you've heard the statin muscle stories: muscle weakness is a statin class effect, not an ezetimibe one.) Does it work? On its own, ezetimibe drops LDL about 18 percent (Pandor et al. 2009). In the one monotherapy outcomes trial, EWTOPIA 75, it cut cardiovascular events 34 percent in patients aged 75+ (Ouchi et al. 2019). And a 2007 study confirmed it lowers lipids just as well in APOE4 carriers as in everyone else (Mark et al. 2007). The brain signal, with the caution it deserves. In 2024, a database analysis linked ezetimibe use to a sevenfold lower dementia risk (Ganne et al. 2024). On its own I'd file that under "interesting, unproven." But it didn't stay on its own. In 2025, Alzheimer's & Dementia ran a Mendelian randomization across 1,091,775 people. Those whose genes mimic lifelong ezetimibe (lower NPC1L1 activity) had an all-cause dementia odds ratio of 0.18 per 1 mmol/L lower non-HDL cholesterol (Nordestgaard et al. 2025). Stay honest about what that is. It's target validation, not proof the pill cuts your dementia risk, and the effect was strongest for vascular dementia, weaker for Alzheimer's specifically. But it lights up the same target as the Ganne signal, from a completely different direction. And lowering cholesterol in your blood doesn't starve your brain. Your brain makes its own cholesterol behind the blood-brain barrier. As Mahley (2016) put it, "there is essentially no cholesterol that enters the brain from the peripheral circulation." That's why I'm comfortable on ezetimibe as a 4/4. It works on my blood, not my brain's supply. The 2026 update, fast. Three things shifted this year. The 2026 ACC/AHA Dyslipidemia Guideline (the first US update since 2018) moved ezetimibe to a first-line non-statin add-on and endorsed ApoB to guide therapy. The Ez-PAVE trial (NEJM, 2026) randomized 3,048 patients to LDL under 55 versus under 70; the aggressive arm cut events 33 percent, with ezetimibe the cheap route there. And the SWEDEHEART registry tied skipping ezetimibe to a 1.83 times higher cardiovascular death rate. The last two are secondary-prevention populations, not me, but the direction holds: earlier, lower, ezetimibe-inclusive. What changed for me wasn't the drug. It was the confidence: I started in late 2024 on far thinner evidence than the same choice has behind it today. The 8-month snapshot (December 2024 to August 2025) This is a snapshot of one window, not where I am today. Three panels: December 2024, May 2025, August 2025. Redacted for privacy, otherwise untouched. Marker Dec 2024 Aug 2025 Change LDL cholesterol 139 mg/dL 93 mg/dL −33% ApoB 96 mg/dL 74.7 mg/dL −22% Total cholesterol 209 mg/dL 187 mg/dL −10.5% HDL cholesterol 61 mg/dL 73 mg/dL +19.7% TC/HDL ratio 3.4 2.6 improved HbA1c 5.9% 5.3% −0.6 pp (normal) Lp(a) (measured May 2025) n/a 2.9 mg/dL already optimal ApoB is the number I watch most closely. It counts every atherogenic particle, not just LDL (Sniderman et al. 2019), and for APOE4 carriers it may be the most accurate risk marker we have. How honest am I being about "optimal"? Against the Phoenix APOE4 ranges, I'm fully inside optimal on only three markers: HDL, triglycerides, and Lp(a). On ApoB, LDL, total cholesterol, and HbA1c I'm close but not in range. Every one would earn a "looks great" from a standard panel, which is exactly why we use tighter ranges. In this window the stack took my ApoB from 115 to 74.7, with under 60 the target. Honest caveats This is one APOE4/4 protocol. It worked for me. It is not a prescription for you. The best way to know if it works for YOU specifically, is to run your own experiment with it. Don’t know where to start? The Phoenix App was exactly built to help you run your experiments! Now here are the caveats: Three levers at once means I can't cleanly split the credit. Ezetimibe alone usually drops LDL about 18 percent, psyllium adds 5 to 10, diet is variable. My 33 percent is consistent with the stack. I'm not on a statin, and that's not a knock on statins. In APOE4 carriers, statin use cut Alzheimer's risk 40 percent; in non-carriers it didn't (Rajan et al. 2024). If your doctor recommends one and you're APOE4, that's evidence-based. My ApoB still isn't where I want it. As a 4/4 I aim under 60, and I'm not there yet (today it hovers around 70). One number I'm watching: my ALT came back at 64, mildly elevated. Ezetimibe occasionally nudges liver enzymes. Not concerning yet, but I'm monitoring it. If yours rises, tell your doctor. The APOE4 lipid blueprint If you carry APOE4, one copy or two, here's what I'd hand you. Test this panel: full lipids, plus ApoB, plus Lp(a) once (it's genetic, it won't change), plus HbA1c, fasting insulin, hs-CRP, and homocysteine. If your doctor won't order ApoB, push. The 2026 guideline now formally endorses it. Know your targets. These are the Phoenix APOE4 optimal ranges, tighter than generic lab cutoffs on purpose: Marker Phoenix APOE4 optimal LDL cholesterol 50–80 mg/dL ApoB 40–70 mg/dL Total cholesterol 150–180 mg/dL HDL cholesterol ≥60 (men) / ≥70 (women) mg/dL Triglycerides 50–100 mg/dL TC / HDL ratio ≤2.5 (men) / ≤2.0 (women) HbA1c 4.5–5.2% Fasting glucose 75–85 mg/dL Fasting insulin 3–8 µIU/mL hs-CRP 0–0.5 mg/L Homocysteine 5–9 µmol/L Lp(a) (genetic) 0–14 mg/dL Those guidelines tier risk by heart disease and diabetes, not genotype. I'm a primary-prevention 4/4 aiming low on genotype reasoning. Your cardiologist may set different targets. Bring them your actual numbers. Start with levers you can hold for years. Diet is lever zero. Psyllium is cheap and well-backed. Ezetimibe is a conversation with your physician. And don't fear statins out of proportion to the data; in APOE4 carriers the fear is louder than the evidence. Where I am now That snapshot ended in August 2025. Since then I've gone more aggressive on the same levers (still no statin), and my ApoB is now around 70. The goal hasn't moved: under 60. I'm sharing these numbers openly. Not to prescribe for anyone. To show you can move the dial without aggressive pharmacology, and that the evidence is stronger than the online noise suggests. You are not your genotype. You are what you do with it. If you're just starting, two places to begin: the bloodwork blueprint at apoe4.co/bloodtest walks through which markers to test and how to track them, and the rest of us are inside The Phoenix Community, all carriers, comparing notes and real data. Talk to your doctor before changing any medication, supplement, or protocol. And tell them you carry APOE4. Kevin Citations (full list) All 30 peer-reviewed citations referenced across this protocol, with PMIDs/DOIs: Jovanovski et al. 2018 · Psyllium + LDL/ApoB meta-analysis (AJCN): 30239559 Gibb et al. 2015 · Psyllium + HbA1c (AJCN): 26561625 Zhu et al. 2024 · Plantago updated meta: 38688104 Ghavami et al. 2023 · Soluble fiber dose-response: 36796439 McRorie & McKeown 2017 · Viscous fiber mechanism: 27863994 Schoeneck & Iggman 2021 · GRADE umbrella review: 33762150 Brum et al. 2018 · Psyllium + statin stack: 30078477 Juhász et al. 2023 · Fiber network meta T2DM: 36811560 Liu et al. 2025 · Med diet × APOE4/4 (Nature Medicine): 40855194 Mark et al. 2007 · Ezetimibe × APOE: 17559752 Ganne et al. 2024 · Ezetimibe + ADRD: 39263528 Pandor et al. 2009 · Ezetimibe meta: 19141093 Ouchi et al. 2019 · EWTOPIA 75: 31434507 Garcia-Calvo et al. 2005 · NPC1L1: 15928087 Gorbunova & Seluanov 2024 · Ezetimibe/AD commentary: 40124644 Rossi et al. 2025 · LLT + cognition: 41400788 Rajan et al. 2024 · Statins × APOE4 AD: 38447103 Westphal Filho et al. 2025 · Statin + dementia: 39822593 Banach et al. 2025 · Statin+ezet mortality: 40126455 Cannon et al. 2015 · IMPROVE-IT: 26039521 Awad et al. 2018 · Ezetimibe + Lp(a): 29396832 Husain et al. 2021 · APOE + AD: 33679311 Mahley 2016 · Brain cholesterol independence: 27174096 Dunk & Driscoll 2022 · TC + APOE4 AD: 34958023 Sniderman et al. 2019 · ApoB superiority: 31642874 Lee et al. 2021 · Ezetimibe + high-intensity statin: 337380132026 ACC/AHA/Multisociety Dyslipidemia Guideline · Guideline on the Management of Dyslipidemia. Circulation, March 2026. DOI: 10.1161/CIR.0000000000001423Lee Y-J et al. 2026 (presented by Kim B-K) · Ez-PAVE: Randomized Comparison of LDL-Cholesterol Targeting <70 vs <55 mg/dL in ASCVD. NEJM, March 2026 (ACC.26 Late-Breaker), trial NCT04626973. ClinicalTrials.gov | tctmd.comLeosdottir M et al. 2025 · Early Ezetimibe Initiation After Myocardial Infarction in the SWEDEHEART Registry. JACC, April 2025. PMID 40240093 | JACCNordestgaard LT et al. 2025 · Cholesterol-lowering drug targets reduce risk of dementia: Mendelian randomization and meta-analyses of 1 million individuals. Alzheimer's & Dementia, Oct 2025. PMID 41059729 | DOI: 10.1002/alz.70638 --- ## The hardest part of APOE4 isn't the science. It's the overwhelm. URL: https://apoe4.co/blog/posts/the-hardest-part-of-apoe4-isn-t-the-science-it-s-the-overwhelm Published: 2026-06-07T18:44:00+00:00 Updated: 2026-06-07T18:44:07.657012+00:00 Summary: APOE4 carriers often feel overwhelmed by strict protocols. Learn why your stress is rational and discover a sustainable approach to health that actually works. The hardest part of APOE4 isn't the science. It's the overwhelm.Phoenix workshop: Permission to be humanDr. Kevin Tran June 07, 2026 Hi Phoenix friend, I track 27 biomarkers every 3 months.I have a protocol for sleep, for exercise, for what I eat, for what I take. On paper, I'm doing everything right. And a few weeks ago, my own checklist made me feel like I was failing. If you carry APOE4, you know exactly what I mean. The hardest part of this isn't learning the science. It's the pressure. The quiet voice that says you should be doing more, doing it perfectly, doing it forever. So I asked Deb Blum to run a workshop for our Phoenix community. Deb's a Phoenix member, a coach, she's an APOE4 carrier like us, and she's spent years on the human side of all this. What she taught us changed how I think about my own routine. I want to share the parts that stuck. Your overwhelm is rational. It's not a flaw. Here's the reframe that hit me first. Deb said overwhelm is a completely rational response to a genuinely overwhelming situation. Think about it. The average person scrolling health content might follow 50 influencers and feel swamped. For us, it's worse. We've added urgency (the clock feels real). We're not just looking for evidence-based, we're chasing cutting-edge. And we're doing it on top of normal life, normal decision fatigue, and the knowledge of what's written in our genes. Of course that's a lot. Your nervous system hitting its limit isn't weakness. Deb compared it to a phone left in the sun. It overheats and shows a warning. You didn't break it. It's protecting itself. Overwhelm is a warning light on your dashboard, not a failure. That one idea took a surprising amount of weight off my shoulders. The four faces of overwhelm. Deb pulled patterns from our own community and grouped them into four. See if you recognize yourself. The Spiral: you miss a workout or eat off-plan, then shame creeps in, then you sleep badly, then the next choice slips too. One thing becomes another. It steals your sense of being enough. The Freeze: too much information, so you do nothing. You can't tell what's worth it, so you pick the easy supplement just to feel like you did something. It steals your agency, and it's where comparison lives. The Weight: the simmering knowledge of a future you can't guarantee. Maybe caregiving. Maybe cost. It steals your presence, your ability to be here in the life you're actually living right now. The Lost Self: when prevention quietly becomes your whole identity. One member said it perfectly: "I don't want to be thinking about this all the time and have it become who I am." That's not avoidance. That's self-preservation. I sat with all four. I've lived in at least three of them. The fix isn't more discipline. It's the opposite. This is where I expected the usual "try harder" advice. It never came. Deb walked through the brain science. When you feel overwhelmed, your alarm system fires and actually pulls resources away from the thinking part of your brain. So you make worse decisions from that state, not better ones. Pushing harder while dysregulated is fighting your own wiring. The move is to regulate first, then act. She put it simply: in any moment of overwhelm, overwhelm is not asking you to do more. Drop in, create a little space, settle your system, and then choose your next step. You'll always act from a better place than the panicked one. She closed with a short body-based reset. Notice where the overwhelm lives in your body. Breathe into it. Don't fix it, just give it space. Then ask: what do I need right now? It takes about three minutes. It's the most useful thing I took away, and it's right there in the video. What I'm changing. Two things. First, I'm trying to be kinder to myself. That sounds soft coming from the guy with 27 biomarkers, but it's the honest takeaway. Beating yourself up is not a strategy. Second, we're tweaking how the community works. The clearest signal from the room was that people want fewer protocols and more actual conversation. So we're nudging our pods toward live calls instead of just text. Our own data backs this up: pod members report 21% better mental health than members going it alone. You were never meant to do this by yourself. If you've been running your health like a drill sergeant, this episode is your permission slip to stop.If you’d like to join future workshops like this one, join the Phoenix Community! Watch the full workshop here Stay human,Kevin Most Newsletters? One-way street.How boring…This is the Phoenix Community. So let's make it a two-way street. Got a question? Feedback? Hit reply. I read every single one. --- ## The APOE4 sleep protocol that took my REM from 12% to 20%+ URL: https://apoe4.co/blog/posts/the-apoe4-sleep-protocol-that-took-my-rem-from-12-to-20 Published: 2026-06-06T17:46:00+00:00 Updated: 2026-06-06T17:46:10.009417+00:00 Summary: APOE4 carriers' REM sleep protocol: diagnosis and optimization strategies to boost REM from 12% to 20%+. Evidence-based sleep fixes. The APOE4 sleep protocol that took my REM from 12% to 20%+Diagnose first (mouth breathing? cortisol?), then optimize. Plus which trackers and supplements actually have evidence.Dr. Kevin Tran June 06, 2026 Hi Phoenix friend, If you carry APOE4, your REM sleep is probably running low right now — even with zero symptoms. And for us, poor sleep doesn't just add to Alzheimer's risk; it multiplies it. This is the full written synthesis of my APOE4 sleep breakdown. Prefer to watch? Here's the ~18-minute deep dive on YouTube Introduction I spent a year and a lot of n=1 testing figuring out sleep for carriers, alongside 500+ people in the Phoenix Community running the same experiments. This is the whole protocol in one read: why sleep hits us harder, the numbers to aim for, how to diagnose what's actually stealing yours (physical vs. stress), and the position, temperature, supplement, and device moves that have real evidence behind them. The order matters: diagnose first, optimize second.Why sleep hits APOE4 carriers harder Most advice treats sleep as one more healthy habit. For us it's load-bearing. Two findings changed how I think about it. First, carriers show reduced REM sleep — lower percentage and duration — even without any cognitive symptoms [Andre et al., 2024]. "I feel fine" doesn't mean your sleep architecture is fine. Second, sleep problems and APOE4 are synergistic, not additive: in a 2024 study, the group with both had higher plasma NfL — a marker of neurodegeneration — than either factor alone [Yu et al., 2024]. The mechanism is the part that stuck with me. Your brain clears waste, including amyloid-beta, through the glymphatic system — and that clearance drops about 90% when you're awake [Gaur et al., 2022], with slow-wave (deep) sleep being when the clear-out happens [Lee et al., 2020]. One honest caveat: much of the glymphatic mechanics are mapped in animal models, with human evidence still building. But the direction is consistent — deep sleep is the power-wash, and we can't afford to skip it. Know your numbers You can't optimize what you don't measure. The targets: Deep sleep: 15-20% (~1-1.5 hours) REM: 20-25% (~1.5-2 hours) Sleep efficiency: above 85% Total sleep: 7-8 hours Watch your overnight HRV, too. A low or steadily declining HRV usually points to one of two things: a physical issue disrupting your sleep, or a nervous system stuck in overdrive. Both are fixable — once you know which one you're dealing with. That's the whole game. Diagnose first: physical issues (my mouth-breathing story) This was the most valuable fix I found. I was a mouth breather my whole life and never knew it was wrecking my REM — which sat around 12% when it should clear 20%. An ENT found chronic nasal congestion nobody had ever flagged. Three things fixed it: a nasal steroid (fluticasone), mouth tape, and a nose dilator. My REM now consistently hits 20%+. The evidence backs the airway angle: in mouth-breathers with mild sleep apnea, mouth taping cut the apnea-hypopnea index by 47% and lifted the lowest oxygen saturation from 82.5% to 87% [Lee et al., 2022]. ⚠️ CAVEAT: Get screened for sleep apnea before you tape anything. Taping over undiagnosed apnea is the wrong move. Before buying devices, rule out mouth breathing, nasal congestion, a deviated septum, and apnea. A $3 roll of tape beats a $400 gadget more often than you'd think. Diagnose: stress and the 3 a.m. wake-up The other pattern is mental. For years I woke at 3-4 a.m., mind racing, unable to drop back off — and my HRV was tanking on exactly those nights. That's a nervous system stuck in fight-or-flight when it should be in rest-and-digest. Cortisol is the lever: it normally peaks near your wake time and bottoms out in the early night, but sleep restriction pushes evening cortisol up [O'Byrne et al., 2021], and the cycle feeds itself. The tells: waking at 2-4 a.m., a declining HRV trend, a racing mind, or feeling "tired but wired." The fix for me wasn't a sleeping pill — it was downregulating before bed (breathwork, vagal toning) so my body could actually shift into parasympathetic mode. Given the synergy above, stress management isn't optional for carriers. Optimize: position, temperature, supplements Once you've diagnosed, here are the levers I reach for, strongest evidence first: Magnesium L-threonate, 1 g/day. The one with real RCT evidence: in a 2024 trial it improved both deep sleep and REM versus placebo [Hausenblas et al., 2024] — exactly the two phases we're short on. Glycine (3 g) and L-theanine (200-450 mg) are lower-evidence add-ons I rotate in. Cool room. Sleep efficiency drops 5-10% as the bedroom warms from 25°C to 30°C, in an observational study of older adults [Baniassadi et al., 2023]; ~65-68°F is a good target. Side-sleep. Glymphatic clearance was most efficient in the lateral position versus back or stomach — though that's a rodent study, so human translation isn't confirmed yet [Lee et al., 2015]. It's low-risk and biologically plausible, so I default to my side. Melatonin, with an asterisk. APOE4/4 carriers may run lower on melatonin than single-copy carriers (preliminary data), and no trial has tested supplementation in carriers specifically — so I treat it as a conversation to have with your doctor, not a sure thing. Tools and trackers Two devices we're actively studying in Phoenix: vagus-nerve stimulation (Zenowell), which raised HRV complexity during sleep in research [Balasubramanian et al., 2017], and near-infrared photobiomodulation (Neuronic), which may support glymphatic clearance — though most of that evidence is still animal data [Valverde et al., 2022], so treat it as experimental. On trackers: Oura was statistically no different from a sleep lab (PSG) for staging [Robbins et al., 2024]; WHOOP is excellent for HRV (0.99 correlation with ECG) [Miller et al., 2022] — both from single-night validations in healthy adults, so treat them as good, not perfect. Apple Watch is fine for total sleep but overestimates light sleep. Pick one and stay consistent — the trend matters more than the absolute number. Key Takeaways 💡 Quick-Start Protocol (This Week):Rule out physical first — snore or wake with a dry mouth? See an ENT and get screened for apnea. Waking at 3 a.m. with low HRV? Build a 10-minute wind-down (breathwork / vagal toning) before bed. Side-sleep (rodent data, but low-risk) and cool the room to ~65-68°F. Try magnesium L-threonate, 1 g/day — the one supplement with RCT evidence for both deep sleep and REM. Pick one tracker and log for two weeks before changing anything. Track it with Phoenix Sleep optimization is useless if you don't know what's working. In the Phoenix app you can sync Oura, WHOOP, or Apple Health, tag each intervention (mouth tape, magnesium, cool room), and watch which ones actually move your deep sleep and REM — alongside what's working for 500+ other APOE4 carriers running the same experiments. Log your sleep protocol in Phoenix and let the data, not guesswork, tell you what to keep.Sources André C, et al. Reduced rapid eye movement sleep in late middle-aged and older APOE ε4 allele carriers. Sleep. 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11236949/ Yu X, et al. Sleep and APOE-ε4 have a synergistic effect on plasma biomarkers and longitudinal cognitive decline in older adults. CNS Neuroscience & Therapeutics. 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC10850800/ Gaur A, et al. Sleep and Alzheimer: The Link. Maedica (Bucur). 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC9168575/ Lee YF, et al. Slow Wave Sleep Is a Promising Intervention Target for Alzheimer's Disease. Frontiers in Neuroscience. 2020. https://pmc.ncbi.nlm.nih.gov/articles/PMC7340158/ Lee H, et al. The Effect of Body Posture on Brain Glymphatic Transport. The Journal of Neuroscience. 2015. https://pmc.ncbi.nlm.nih.gov/articles/PMC4524974/ Lee YC, et al. The Impact of Mouth-Taping in Mouth-Breathers with Mild Obstructive Sleep Apnea: A Preliminary Study. Healthcare (Basel). 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC9498537/ O'Byrne NA, et al. Sleep and Circadian Regulation of Cortisol: A Short Review. Current Opinion in Endocrine and Metabolic Research. 2021. https://pmc.ncbi.nlm.nih.gov/articles/PMC8813037/ Baniassadi A, et al. Nighttime Ambient Temperature and Sleep in Community-Dwelling Older Adults. Science of the Total Environment. 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC10529213/ Hausenblas HA, et al. Magnesium-L-threonate improves sleep quality and daytime functioning in adults with self-reported sleep problems: A randomized controlled trial. Sleep Medicine: X. 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11381753/ Balasubramanian K, et al. Vagus Nerve Stimulation Modulates Complexity of Heart Rate Variability Differently during Sleep and Wakefulness. Annals of Indian Academy of Neurology. 2017. https://pmc.ncbi.nlm.nih.gov/articles/PMC5682746/ Valverde A, et al. Lights at night: does photobiomodulation improve sleep? Neural Regeneration Research. 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC9727457/ Robbins R, et al. Accuracy of Three Commercial Wearable Devices for Sleep Tracking in Healthy Adults. Sensors (Basel). 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11511193/ Miller DJ, et al. A Validation of Six Wearable Devices for Estimating Sleep, Heart Rate and Heart Rate Variability in Healthy Adults. Sensors (Basel). 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC9412437/ --- ## We ran our own APOE4 photobiomodulation study. Here's the data. URL: https://apoe4.co/blog/posts/we-ran-our-own-apoe4-photobiomodulation-study-here-s-the-data Published: 2026-06-02T18:33:00+00:00 Updated: 2026-06-02T18:33:08.522449+00:00 Summary: APOE4 carriers tested photobiomodulation for 4 months. See real-world data from 60+ participants—what actually moved their brain health. We ran our own APOE4 photobiomodulation study. Here's the data.60+ carriers, 4 months: Real-world data is messy. We tracked all of it. Here's what moved.Dr. Kevin Tran June 02, 2026 Hi Phoenix friend, Here's the question almost nobody answers honestly: When a prevention intervention "works" in a clinical trial, does it actually hold up in real life? In real people? Over real months, not lab conditions? You know why this one matters to me. As an APOE4/4 carrier, I don't have decades to wait for the literature to catch up. Neither do you. Our brains are changing now. So we stopped waiting and ran our own study. Our study with Neuronic From December 2025 through April 2026, we partnered with Neuronic to run a 4-month, real-world photobiomodulation study — near-infrared light therapy for the brain. More than 60 participants took part. This was our study, on our platform. It wasn't a survey — every participant tracked their data through Phoenix: Device usage logs Daily check-ins Sleep records HRV Blood biomarkers Full supplement and lifestyle context That last point is the whole game. Real-world data is messy — people travel, sleep badly, swap supplements, miss sessions. Most studies quietly bury that. We captured it, so we could actually see what moved the needle and what didn't. What I'll show you on June 4 I'm presenting the full results live, alongside Neuronic's data analyst, who ran the formal statistics. Together we'll cover: What the data actually showedWhere our methodology fell short — yes, I'll show you the cracks What these signals mean for designing better real-world prevention research No spin. No cherry-picking. The wins and the warts — because that's the only kind of science I'd trust with my own brain. How our members got involved When we launched this study, Phoenix members got the Neuronic device at a $695 discount (essentially the cost price of making the device) plus a 90-day satisfaction guarantee. Real device, real data, no risk. That's what being inside the community unlocks: not just access to studies like this, but access on terms you won't find anywhere else. Want in on the next one? This was one study. We're building a pipeline of them — APOE4-specific research you literally can't join anywhere else, because no one else has a community of carriers tracking their data together. If you want first access to the next study, join The Phoenix Community →🗓 Event detailsBeyond the RCT: Real-World Photobiomodulation Data in APOE4 CarriersOur study with Neuronic Thursday, June 4, 20268:00 AM PDT · 11:00 AM EDT · 11:00 PM SGT (~60 min) Join free: https://us06web.zoom.us/j/83989866219 Can't make it live? Register anyway — we'll send you the replay. See you Thursday.— Kevin (APOE4/4, founder of Phoenix) --- ## Phoenix 2.0: our biggest update ever. Built to help APOE4 carriers Beat the Odds URL: https://apoe4.co/blog/posts/phoenix-2-0-our-biggest-update-ever-built-to-help-apoe4-carriers-beat-the-odds Published: 2026-05-27T17:26:00+00:00 Updated: 2026-05-27T17:26:11.720467+00:00 Summary: Phoenix 2.0: APOE4 app overhaul with clinical trial matching, brain training & insights engine. New features available to non-members too. Phoenix 2.0: our biggest update ever. Built to help APOE4 carriers Beat the OddsSome of the new features are available to non-members too!Dr. Kevin Tran May 27, 2026 Hi Phoenix friend, Open the app today and you'll barely recognize it. Phoenix 2.0 is live — the biggest update we've ever shipped. Scroll down for the long lsit of new features, but here’s a sneak peak": A full redesign of the app and the website. A new way of looking at your whole health picture. A clinical-trials matching engine (Available to non-members too. More details soon) A new medications module. Phoenix APOE4 Studies. Brain training. Health Files. Provider Portal. Pod matching with its own home. The insights engine I always wanted to build but couldn't — until everything else was in place. There's also an honest note about pricing further down — and a 5-day exception I want you to know about before it closes Saturday. But before any of that, I want to say thank you. A small team. A loud community. That's how we got here. We're a small team. Most weeks it's me, Jason, and a handful of APOE4 carriers like you who answer when I ask "does this make sense?".Building something that's scientifically serious enough to deserve your bloodwork and simple enough for a 60-year-old first-time user is harder than I ever guessed. It's a lot of hard work, and most days the question is the same: how do we make this sustainable, and as useful as possible to as many APOE4 carriers as we can reach? The answer, every time, has been the same: you. Every bug report you've sent. Every introduction to a doctor or researcher. Every "I told my neurologist about Phoenix" message. Every Circle thread where one of you helped another carrier through their first abnormal lab. Every podcast you got me onto. That's why 32% of our members are healthcare professionals — doctors, nurses, pharmacists, dietitians, researchers. None of that was a marketing campaign. That was you telling people we exist. So: thank you. Truly. If you've ever wondered whether your one referral, your one bug report, your one introduction matters: it does. It's compounding right now, into Phoenix 2.0. What this release is really about You're probably going to take supplements, run protocols, and watch your numbers for the rest of your life. The question that never leaves is the same one I had the day I got my own APOE 4/4 result: is any of it actually working? Most apps can't tell you. Your sleep, your bloodwork, your supplements, your conditions — they never talk to each other, so you keep guessing. Phoenix 2.0 cuts most of the guessing out. Everything now flows into one engine. Your supplements and medications live inside your daily check-in. That feeds an insights engine that reads across your habits, your pills, your conditions, your bloodwork and your wearable, and tells you the single move most likely to move your numbers this week — with a confidence level that climbs as you log. When a pattern looks real, Phoenix gives you a mission to confirm it. That's the difference between tracking and knowing. It's also the broader system behind the stat I'm proudest of on our homepage: 89% of our members see improvements in their APOE4-critical biomarkers within 3 months (member surveys, self-reported). Not generic wellness biomarkers — the 27 biomarkers that actually matter for an APOE4 brain (ApoB, pTau-217, Omega-3 Index, HbA1c, Vitamin D, hs-CRP, and the rest), scored against APOE4-optimal ranges, not the generic "normal" your doctor uses. Carriers who never thought they could move their numbers, moving their numbers — often in a single quarter. OK. Here's everything new. What shipped in Phoenix 2.01. A full redesign of the app and the website The old menu had thirteen places to get lost. Now there are seven you'll actually use: Home · My Health · Supplements · Medications · Brain Training · Research & Trials · Community. Cleaner type. Calmer pages. Three-second answers instead of three-minute hunts. The website at thephoenix.community got the same treatment — new homepage, new Our Approach page, new pricing — so the people you send to us land somewhere that feels as serious as the work you're putting in. 2. Blood analysis, rebuilt — Phoenix Score + category breakdown Drop a lab PDF in. Our AI extracts every biomarker, scores it against APOE4-optimal ranges, and gives you a single number — your Phoenix Score — plus six category sub-scores (Hormonal, Cognitive, Metabolic, Inflammatory, Cardiovascular, Nutritional). Watch each one move test over test. This is the engine the rest of Phoenix runs on.3. Daily check-in, rebuilt — supplements and meds live inside it Two minutes, morning and evening. Sleep, energy, mental clarity, stress, well-being. We retired the long monthly check-in — it was doing two jobs at once and confusing everyone — and moved the health logging here. Set a supplement up once in your Stack, then log it in two taps. No more entering things twice. 4. Daily insights & trends, in one place 7-day, 30-day, 90-day. Streak. Average well-being. A radar chart of how your sleep, energy, stress, mental and well-being are sitting right now. The point isn't to make you log more — it's to show you what your body is already telling you. 5. The insights engine — your one move of the week Phoenix reads across your habits, supplements, conditions, bloodwork and wearable — then surfaces the single move most likely to move the needle this week. Every recommendation comes with a confidence level, an evidence trail, and a duration (e.g., "30 days of data"). When a pattern looks real, Phoenix gives you a mission to confirm it. "Sauna 3× this week, log your HRV." That's how a hunch becomes evidence from your own body. This is the module I'm most excited about. It's the thing the other 11 enable. 6. Supplements — 1,000+ library, community ratings, your full stack Browse by health benefit. See what % of fellow members are taking each one. See community efficacy ratings (LPC-DHA leads at 4.83/5; standard fish oil sits at 4.32 — that gap is real and APOE4-specific). Don't see your supplement? Suggest it — we add the good ones every week. Your stack lives here — taking, considering, stopped — with dosage, frequency, brand, side-effect severity and your own efficacy rating. Export as PDF for your doctor in one click. 7. Medications — brand new module, same shape You've been asking for this for months. A full medications library next to Supplements — Lisinopril, Metformin, Atorvastatin, Aspirin and 180+ others — with the same community insights ("% of active users taking this"). Track what you take, what you're considering, what you've stopped — and log it inside your daily check-in. Why this matters: Phoenix can only surface useful patterns when it sees the whole picture — supplements and prescriptions, side by side. 8. Conditions + Trial Eligibility — finally, the 360° view The profile got a major upgrade. Tell Phoenix once: your DOB, biological sex, APOE genotype, country, prior amyloid testing, willingness to travel, frequent-blood-draw tolerance. Then your conditions (MCI, sleep apnea, hypertension, Alzheimer's, etc.) and goals (prevention, post-diagnosis support). This is what the insights engine has been quietly missing — and what unlocks accurate clinical-trial matching. Two minutes here compounds forever.9. Clinical Trials — every APOE4-relevant trial, filtered to you Every APOE4-relevant trial on ClinicalTrials.gov, refreshed daily, with a green "matches your profile" when you fit. Filter by status, phase, country. One tap to Express Interest — we make warm intros to trial sponsors where we can. This is the module I'd have killed for two years ago, and it gets sharper every month you keep your eligibility profile current. 10. Phoenix Studies — community-driven studies, member pricing Studies we run with carefully chosen partners, designed specifically for APOE4 carriers. Sens.ai Neurofeedback is enrolling now ($150 off member price, keep the device). The Neuronic Red Light Therapy study has 72+ Phoenix members. Vagus nerve stimulation, photobiomodulation, more in the pipeline. This is how a community of carriers becomes a research engine.11. Brain Training (Beta) — measure first, then train Reflex Test, Symbol Match, working memory tasks. Each one is backed by a citation (Tales & Troscianko 2005 for reaction time; Kiely et al. 2014 for Symbol Match). Run a Baseline to know where you stand against fellow carriers, then train in adaptive mode with streaks and personal bests. Cognitive reserve isn't built in a month — but you can't build what you don't measure. 12. Pod Matching — its own home, June cycle opens today Pods got pulled out of the old monthly survey and given their own home. Same rhythm — AI-matched on the 1st of every month, 2–4 carriers per pod, weekly check-ins. Members in pods are 3.2× more consistent than carriers going it alone. The June cycle opens today. If you want to be matched on June 1, open the app and opt in now. → Open the app and opt in for June13. Health Files — upload your CMPs, MRIs, doctor's notes, 23andMe raw data. Up to 20 files. The more context Phoenix has, the more useful patterns it can surface for you to discuss with your clinician. Now — if you're not yet a member If you've been reading this and you're already on the inside, skip to the P.S. — your price is locked, your update is live, June pods are open. If you're not yet on the inside: read the whole email above as a look at what this community has built — and what you can step into now. You'd be joining 600+ APOE4 carriers — about a third of them healthcare professionals — rated 4.9 out of 5, doing the work that most carriers are told to "come back at 60" to start. We don't wait. Here's the part I owe you the truth on. We raised our prices. Here's why. Phoenix wasn't sustainable. To keep shipping every week, we'd been drawing down our investment from business angels within the community — fellow APOE4 carriers who put their own savings behind this mission. That's not something I'm willing to burn through. For Phoenix to be here in ten years — when the trials we're matching you to start reading out, when the biomarkers you started logging at 55 become the longitudinal dataset that puts you in a far better position to hear about relevant opportunities early — the price has to reflect what it actually costs to build. So we raised it. I won't apologize for keeping the mission alive. If you're already a member, your rate is locked — this only affects anyone joining or upgrading from today forward. But I didn't want the people who've been on the fence to pay for our timing. So, exceptionally — 20% off, for 3 days For the next 3 days only, you can join Phoenix at 20% off Use the code BIGGESTUPDATE at checkout. Expires Saturday, May 30. After that, the new price is permanent. And you're protected by our 60-day money-back guarantee — no questions. Join today, fill in your conditions + trial eligibility, see your first insights, get matched into a June pod. If Phoenix doesn't earn its place in two months, ask for a full refund. I'll send it the same day. → Join Phoenix at 20% off — code BIGGESTUPDATE → I built Phoenix because I needed it. I carry APOE 4/4, my Phoenix Score is something I check more often than my bank balance, and I use every module in this email on myself every day. In seven months I dropped my ApoB by 39%, raised my VO₂ max by 31%, and pulled my HbA1c down by 0.5 points. Not because of one supplement — because I finally had a system that let me see what was actually working and stop guessing on the rest. That's the same system you can have, starting today. Phoenix 2.0 is the version I always wanted. For the next 5 days, it's also the most affordable it will ever be. Thank you for being part of this — whether you've been with us from the start, or whether today is the day you decide to stop waiting. — KevinFounder, Phoenix · APOE 4/4 P.S. The BIGGESTUPDATE code expires Saturday, May 30 — 3 days. Two reasons starting now matters beyond price: (1) June pods open today, and you'll only be matched if you're inside the app this week; (2) we prioritize complete eligibility profiles when matching members to study opportunities — and several open this summer. Data compounds. The earlier you start, the more powerful your profile — and your answers — become. Join Phoenix at 20% off →. --- ## Ex-Intelligence Analyst's APOE4 Protocol and How She Reads Medical Studies URL: https://apoe4.co/blog/posts/ex-intelligence-analyst-s-apoe4-protocol-and-how-she-reads-medical-studies Published: 2026-05-21T18:10:00+00:00 Updated: 2026-05-21T18:10:08.505559+00:00 Summary: Ex-intelligence analyst reveals how to spot bias in medical studies—critical for APOE4 carriers navigating conflicting health advice. Learn her simple method. Ex-Intelligence Analyst's APOE4 Protocol and How She Reads Medical StudiesWhat an ex-intelligence analyst taught me about reading medical studies (and APOE4).Dr. Kevin Tran May 21, 2026 Hi Phoenix friend, I had Robin Shwetzer on the Phoenix podcast this week, and I'm still thinking about one moment. I asked her how she evaluates a health study. (For context, Robin spent thirty years as a U.S. intelligence analyst. Russia. Weapons programs. Biological and chemical. The kind of analyst who briefs senators.) She said something that's been rattling around in my head for days: "Once I look at a medical study, I can tell immediately if there's bias. People cook the books." Now, hearing a former intelligence analyst say "people cook the books" about peer-reviewed health research is not what I expected on a Tuesday. But that one sentence reframes a lot of what we deal with as APOE4 carriers. Because here's the truth: most of the conflicting health advice we drown in is downstream of how rigorously (or sloppily) the source was reviewed. Robin walked me through her actual method. It's two checks, and you can do it in a minute. Check one: Who funded it, and what's their incentive? A study funded by a pharmaceutical company on its own product is not the same as a study run by a university with no stake in the outcome. That doesn't mean the pharma study is wrong. It just means you weight it differently. (Robin's words: "You can have someone funding a study and they're still unbiased, but you really have to look at it with a skeptical eye.") Check two: How robust is the methodology? Is it a randomized controlled trial with hundreds of people? Or is it a six-person observational case series? Both can be useful. They just live at different levels of certainty. Then she does something that, honestly, I wish I'd been doing for years: she ranks the studies by both filters at once. The high-trust ones (independent funder, robust method) get the most weight in her recommendations. The lower-trust ones (industry-funded, small n, observational) still get noted, but with appropriate caveats. Nothing gets ignored. Nothing gets blindly trusted. It's intelligence tradecraft applied to your health. The other thing Robin and I got into was her brain fog story.Robin is an APOE4 carrier. She found out thirteen years ago. Her father died of a sudden heart attack at thirty-seven, which she now suspects was tied to APOE4. So this isn't theoretical for her. In her late forties, she started getting brain fog. Not all the time. Just enough to notice. She'd go into work at 5 a.m. for a presentation and feel scrambled. Other days she'd be sharp. She thought it was hormonal. It was prediabetes. Her A1C was 5.7 (technically "normal," conventionally), and her doctors weren't flagging it. But she'd already gone deep on APOE4 research, and she knew the connection between glucose dysregulation and cognitive performance in carriers. So she went on a Mediterranean-style ketogenic diet. (Important caveat for the APOE4 audience: this is NOT bacon-and-butter keto. APOE4 carriers don't process saturated fat well. Robin's keto was olive oil, fatty fish, vegetables, lean proteins.) Within a month, the fog lifted. Her A1C dropped to 5.4. She lost ten to twelve pounds without trying. And she's stayed metabolically flexible ever since (some days in ketosis, some days not, depending on what she's eating). I had a similar arc. My A1C was also 5.7 when I started measuring. Got it down. Felt sharper. The 5.7-to-5.4 swing is one of the most underrated levers I've found for APOE4 carriers in their forties and fifties. (And it doesn't require a perfect 30-day keto sprint. It requires consistency.) There was a third moment I want to flag. We talked about Dr. Valter Longo's Fasting Mimicking Diet. (If you don't know it: it's a 5-day low-calorie protocol designed to put your body into a fasted state without you actually fasting. Day one is around 1000 calories. Days two through five are around 650. All low protein, low carb, healthy fats.) Robin uses it quarterly. It's now being used alongside standard-of-care cancer protocols, and the data on improving treatment efficacy is interesting. She likes it because, in her words, "you're not as hungry and you don't feel as tired" compared to a true water fast. I'm going to try a round in the next quarter and report back. Honestly, the conversation reminded me why I started Phoenix in the first place. Robin is exactly the type of person we built this for. Someone who isn't going to wait for a clinical guideline to catch up. Someone who reads the studies herself, brings the protocol to her doctor, and runs the experiment on her own biology because the alternative (waiting passively) isn't an option when you carry APOE4. If you're newly diagnosed and feeling overwhelmed, here's the closing advice Robin gave (and I'd echo every word): Don't panic. Stress will hurt you more than the diagnosis. Find a provider who actually understands APOE4 (we're building a list, send me names). Find a peer. And start with the two highest-leverage interventions: exercise and nutrition. Everything else comes later. Watch the full conversation here: Stay proactive,Kevin Most Newsletters? One-way street.How boring…This is the Phoenix Community. So let's make it a two-way street. Got a question? Feedback? Hit reply. I read every single one. --- ## Obicetrapib and APOE4: The First Oral Drug to Move Amyloid AND Tau URL: https://apoe4.co/blog/posts/obicetrapib-and-apoe4-the-first-oral-drug-to-move-amyloid-and-tau Published: 2026-05-15T18:12:00+00:00 Updated: 2026-05-15T18:12:10.026321+00:00 Summary: Obicetrapib cuts p-tau217 by 20.48% in APOE4/4 carriers—the first oral drug to move both amyloid and tau. Clinical breakthrough explained. Obicetrapib and APOE4: The First Oral Drug to Move Amyloid AND Tau Obicetrapib cut p-tau217 by 20.48% vs placebo in APOE4/4 carriers (BROADWAY substudy). Dr. Kevin Tran May 15, 2026 Hi Phoenix friend, (Full Youtube Video link at the bottom) A cholesterol drug just did something no Alzheimer's drug has ever done in APOE4/4 carriers. In a pre-specified substudy of 1,535 patients published in The Journal of Prevention of Alzheimer's Disease, p-tau217 — the cleanest blood biomarker we have for Alzheimer's pathology — fell 7.81% on obicetrapib and rose 12.67% on placebo, a 20.48% placebo-adjusted treatment difference in APOE4/4 homozygotes (P = 0.010) [Davidson et al., 2025]. If you are an APOE4 or APOE4/4 carrier reading that paragraph for the first time, I want you to sit with it the same way I did. As you know I carry APOE4/4. You also know I spend a crazy amount of time reading every drug paper that promised something for people like us, and this is the cleanest oral-drug biomarker signal I have ever seen in our genotype. This article is a careful, calibrated walkthrough of what obicetrapib is, what the BROADWAY APOE4 substudy actually showed, why the genetics predicted it years ago, why earlier CETP drugs failed and this one didn't, and what APOE4 carriers should realistically do with this information right now. Education, not medical advice. TL;DRObicetrapib (NewAmsterdam Pharma) is an oral CETP inhibitor: ~30% LDL-C drop, ~37-46% Lp(a) drop, +139% HDL-C rise on top of max statins [Nicholls et al., 2025; Nissen et al., 2025]. The BROADWAY APOE4 substudy (n=1,535) is the first demonstration of an oral drug moving both amyloid and tau biomarkers in APOE4 carriers [Davidson et al., 2025]. Mendelian randomization predicted an APOE4-specific dementia benefit from CETP inhibition years before the drug was tested [Schmidt et al., 2024]. Not FDA-approved. PREVAIL cardiovascular outcomes readout expected November 2026. Until then: biomarker ≠ cognitive outcome; calibrate expectations. What Is Obicetrapib? Obicetrapib is a next-generation oral CETP inhibitor — 10 mg once a day — being developed by NewAmsterdam Pharma [Masson et al., 2025]. CETP stands for cholesteryl ester transfer protein. Here it is in one sentence from a 2024 Current Atherosclerosis Reports review: CETP "tends to result in a net mass transfer of cholesteryl esters from HDL to VLDL and LDL, and a net mass transfer of triglycerides from VLDL to LDL and HDL" [Kastelein et al., 2024]. Translation: CETP is a shuttle that moves cholesterol out of your protective HDL particles and into your atherogenic LDL and VLDL particles. Block it, and two things happen at once: LDL drops and HDL climbs. Obicetrapib also potently raises ApoA-1 and ApoE — the apolipoproteins sitting on the surface of HDL particles [Kastelein et al., 2024]. Hold that ApoE piece. It is the key to why this drug matters specifically for APOE4 carriers. Mechanistically, obicetrapib works at a completely different spot on the cholesterol pathway than anything currently in the lipid toolkit: Statins block the liver from making cholesterol. Ezetimibe blocks gut absorption. PCSK9 inhibitors (evolocumab, alirocumab, inclisiran) increase hepatic LDL receptor recycling. Obicetrapib blocks the transfer step in the bloodstream itself. Different lever. Different target. Stacks on top of everything else. [link: APOE4 lipid management 101] The BROADWAY Substudy — Why APOE4 Carriers Should Care BROADWAY is obicetrapib's flagship Phase 3 cardiovascular trial. 2,530 patients with established cardiovascular disease or familial hypercholesterolemia on maximally tolerated statin therapy, randomized 2:1 to obicetrapib 10 mg or placebo, published in The New England Journal of Medicine in 2025 [Nicholls et al., 2025]. Hidden inside BROADWAY — pre-specified, not fished — was an Alzheimer's-biomarker substudy. 1,535 patients had their APOE genotype recorded and baseline plus 12-month plasma p-tau217 measured. That is one of the largest prospective AD-biomarker cohorts ever collected inside a cardiovascular trial. It was published separately in December 2025 in The Journal of Prevention of Alzheimer's Disease. First author Michael Davidson [Davidson et al., 2025]. The abstract opens with this: "Obicetrapib significantly slowed AD biomarker progression over 12 months in participants with ASCVD, with the greatest effects in ApoE4 carriers" [Davidson et al., 2025]. That phrase — greatest effects in ApoE4 carriers — is unusual. Most brain-targeted drugs (lecanemab, donanemab) work less well in APOE4 carriers and cause more side effects. Obicetrapib goes the other direction. The Numbers: 7.81% / 12.67% / 20.48% Among APOE4/E4 homozygotes, obicetrapib produced a 7.81% adjusted mean decrease in p-tau217 versus a 12.67% increase on placebo — a 20.48% placebo-adjusted treatment difference (P = 0.010) [Davidson et al., 2025]. The effect scaled with genetic risk. Non-carriers showed a small effect, APOE3/4 heterozygotes a bigger one, APOE4/4 homozygotes the largest effect of any subgroup in the study. And it wasn't just p-tau217. In APOE4/4 participants, obicetrapib produced "consistent improvements across multiple AD biomarkers compared to placebo treatment, with placebo-adjusted benefits ranging from 13.67% to 22.65%" [Davidson et al., 2025] — across p-tau217, Abeta42:40 ratio, the p-tau217/Abeta ratio, GFAP (a marker of neuroinflammation), and NfL (neurodegeneration). All five moved in the right direction. Specifically on GFAP, obicetrapib produced a "-6.39% vs +8.85%" swing in APOE4/4 patients — a ~15-point placebo-adjusted gap on a neuroinflammation marker in 12 months [Davidson et al., 2025]. Davidson's Most Important Quote The authors — conservative cardiologists and lipidologists, not neuro-maximalists — write this in their discussion: "These findings represent the first demonstration of an oral intervention capable of reducing both beta-amyloid and tau pathology biomarkers in ApoE4 carriers, offering a potential preventive strategy for this high-risk population who currently have no effective prevention options." [Davidson et al., 2025] If you are APOE4/4 and you have been told for twenty years that genetics is destiny, that sentence is the first time a peer-reviewed Phase 3 substudy has contradicted it at the biomarker level. Three Important Caveats I have to hit these hard. Otherwise I am not doing my job. Biomarker is not cognitive outcome. No one has measured MMSE, CDR-SB, or real-world dementia incidence on obicetrapib. P-tau217 is arguably the best surrogate we have for AD pathology, but surrogate is the operative word. [link: p-tau217 blood test guide] Small subgroup. The APOE4/4 cell is a slice of 1,535 patients. Pre-specified, yes — but it needs independent replication. Confirming data is partial. A larger overlapping analysis (Davidson et al., 2025, AAIC abstract, 1,727 patients) showed concordant results: in APOE4 carriers, obicetrapib stabilized p-tau217 (0% increase vs 5.7% with placebo, P = 0.03), and the p-tau217/Abeta42:Abeta40 ratio rose only 2.1% on obicetrapib vs 10.2% on placebo (P = 0.005) [Davidson et al., 2025, AAIC]. That's reassuring internal consistency, but it's the same clinical program — not a different trial. Honest synthesis: this is the strongest oral-drug AD biomarker signal ever reported in APOE4/4 patients. It is not yet proof of dementia prevention. We want a prospective randomized cognitive-endpoint trial. Until then, treat it as a major hypothesis with unusually strong backing. Why This Plausibly Works — HDL, ApoE, and Amyloid Clearance Why would a drug designed to shift blood lipids touch brain pathology? The mechanistic story is coherent and every step has independent support. APOE is a lipid-carrier protein. You have two copies of the APOE gene. The e4 variant produces a protein that traffics cholesterol less efficiently in the brain. Cerebral cholesterol moves on HDL-like particles that carry ApoE on their surface; those particles help clear beta-amyloid out of the small vessels of the brain (the cerebrovasculature where APOE4 carriers are especially vulnerable to cerebral amyloid angiopathy, or CAA). When you inhibit CETP — which is what obicetrapib does — you raise HDL particles and the ApoE riding on them [Kastelein et al., 2024]. From the 2025 mechanistic review in Journal of Cardiology and Cardiovascular Sciences: "In mice, genetic and pharmacological studies have shown that HDL levels are highly associated with CAA and that peripheral injection of synthetic HDL particles stimulates clearance of both Abeta42 and Abeta40 from the brain" [Poliakova & Wellington, 2025]. So the chain is: obicetrapib → more HDL particles carrying more ApoE → better cerebrovascular amyloid clearance → slower biomarker progression. Not a hand-wave. A pathway. The Genetics Predicted It — Mendelian Randomization Here is the part that should have made us see this coming. Mendelian randomization (MR) uses genetic variants as a natural experiment. Because variants are randomly distributed at conception, people who inherit a variant that lowers CETP are essentially enrolled in a 60-year randomized trial of CETP inhibition — one they never signed up for. Schmidt and colleagues ran exactly that analysis in 2024 in Alzheimer's Research & Therapy: "APOE4 stratified analyses suggested the LBD effect was most pronounced in APOE-epsilon4+ participants (OR 0.61 95%CI 0.51; 0.73), compared to APOE-epsilon4- (OR 0.89 95%CI 0.79; 1.01); interaction p-value 5.81 x 10-4." [Schmidt et al., 2024] LBD is Lewy body dementia (the subtype Robin Williams had). Translation: genetically lower CETP is associated with meaningfully lower LBD risk in APOE4 carriers and only marginally in non-carriers — and the interaction p-value is 5.81 × 10⁻⁴, so the difference between those effect sizes is highly significant. The authors concluded: "inhibition of CETP may be a viable strategy to treat dementia, with a more pronounced effect expected in APOE-epsilon4 carriers" [Schmidt et al., 2024]. The geneticists told us that in 2024. Obicetrapib delivered it in 2025. This converges with older genetics. In 2006, Nir Barzilai's team studied Ashkenazi centenarians and found that "subjects with MMSE > 25 were twice as likely to have the CETP VV genotype (29% vs 14%, p = 0.02)" — a CETP variant associated with lower CETP activity tracked with preserved cognition into extreme old age [Barzilai et al., 2006]. The 2015 Cache County Study (4,486 participants, up to 12 years of follow-up) extended this: "an average 0.6-point decrease per year in the rate of cognitive decline for each additional valine (p < 0.011)" at the CETP I405V locus [Lythgoe et al., 2015]. Important calibration from the same paper: "CETP I405V is associated with preserved cognition over time but is not associated with LOAD status" [Lythgoe et al., 2015]. This is a cognitive-trajectory signal, not a confirmed Alzheimer's-diagnosis signal. Pull-quote: Two decades of genetics, a causal-inference MR analysis flagging an APOE4-specific effect, a coherent HDL-ApoE-amyloid mechanism, and now a Phase 3 biomarker readout — all pointing the same direction. That convergence is what makes this story different from most "early promising signal" stories. Why Earlier CETP Drugs Failed — and Why This One Didn't CETP inhibition has a body count. Three prior drugs died on the vine: Torcetrapib (Pfizer) — raised cardiovascular events and death; terminated 2006. Dalcetrapib (Roche) — futility. Evacetrapib (Lilly) — futility. Anacetrapib (Merck) — statistically positive but small effect; shelved after it was found to accumulate in adipose tissue. Torcetrapib is the cautionary tale that matters. From the 2024 review: torcetrapib "had structure-related off-target effects causing increased blood pressure, as well as increased aldosterone, steroid, and endothelin-1 levels, and electrolyte abnormalities" [Kastelein et al., 2024]. The CETP target wasn't the problem. The molecule was dirty. Obicetrapib was specifically engineered to avoid those off-target effects. From the BROOKLYN Phase 3 trial: "obicetrapib was observed to be well-tolerated, with safety results comparable to placebo and no increase in blood pressure. The treatment discontinuation rate for the obicetrapib arm was 7.6% versus 14.4% for placebo" [Nissen et al., 2025]. No BP signal. Lower dropouts than placebo. The 2025 meta-analysis of seven RCTs (n=3,381) confirmed: "there were no significant differences in adverse events" [Araujo et al., 2025]. Clean molecule. The target was never cursed — the old drugs were.The Lipid Story — LDL, Lp(a), and a Diabetes Bonus The headline LDL effect from BROADWAY: "The least-squares mean percent change from baseline to day 84 in the LDL cholesterol level was -29.9% (95% CI, -32.1 to -27.8) in the obicetrapib group, as compared with 2.7% (95% CI, -0.4 to 5.8) in the placebo group" [Nicholls et al., 2025]. That is a ~32.6 percentage-point placebo-adjusted LDL reduction on top of maximum-dose statins, durable through day 365. The 2025 meta-analysis pooled all seven obicetrapib RCTs: "obicetrapib significantly reduced mean LDL-C (MD: -37.21%; 95% CI: -41.53 to -32.90; p < 0.01), lipoprotein(a) (MD: -37.16%; 95% CI: -43.63 to -30.70; p < 0.01), apolipoprotein B (MD: -24.65%; 95% CI: -28.71 to -20.59; p < 0.01)" [Araujo et al., 2025]. Every trial. Same direction. Same magnitude. Which in science is the best compliment you can pay. Lp(a): the under-discussed win for APOE4 carriersLipoprotein(a) is a mostly genetically determined, LDL-like particle that raises cardiovascular, stroke, and vascular-dementia risk independently of LDL-C and APOE. Until very recently, no approved drug lowered it meaningfully (pelacarsen, lepodisiran, olpasiran, muvalaplin are in development but not yet FDA-approved). In BROOKLYN: "Treatment with obicetrapib resulted in placebo-adjusted reductions in apolipoprotein B of -24.4%, non-HDL cholesterol of -34.5% and lipoprotein(a) of -45.9%, as well as a placebo-adjusted increase in high-density lipoprotein cholesterol of +138.7%" [Nissen et al., 2025]. A 46% Lp(a) reduction from an oral drug is not the NEJM-headline story — but for a 58-year-old APOE4/4 carrier whose parent had a stroke on top of dementia, that is potentially huge. [link: Lp(a) and APOE4 cardiovascular risk] The diabetes bonus Statins slightly raise new-onset diabetes risk. The meta-analysis found obicetrapib does the opposite: "obicetrapib also reduced the incidence of new-onset diabetes (RR: 0.88; 95% CI: 0.80 to 0.97; p = 0.01)" [Araujo et al., 2025]. A ~12% relative reduction in new diabetes diagnoses is not the story — but if you are APOE4 and already watching glucose, that's a meaningful tailwind. The MACE signal (exploratory) BROADWAY was not powered as an outcomes trial, but the exploratory MACE analysis showed a "21% relative reduction in major adverse cardiovascular events (MACE) (hazard ratio [HR], 0.79; 95% CI, 0.54-1.15)" [Nicholls et al., 2025]. Pooled with BROOKLYN (JACC 2025): the coronary composite was "lower with obicetrapib (3.9% vs 5.0%; HR: 0.77; 95% CI: 0.54-1.11; P = 0.16), with a risk reduction in the second 6 months (HR: 0.60; 95% CI: 0.37-0.99; P = 0.04)" [Nicholls et al., JACC 2025]. That late-divergence pattern is exactly what you'd expect from an LDL-lowering drug — plaques take time to register a number change. Until PREVAIL reads out, there is no confirmed cardiovascular mortality benefit. The signal is encouraging. It is not proof. TANDEM — the single-pill oral combo TANDEM (The Lancet, 2025) tested obicetrapib 10 mg + ezetimibe 10 mg as a fixed-dose combination: "At day 84, percent differences in LDL cholesterol reduction with the FDC were -48.6% (95% CI -58.3 to -38.9) versus placebo" [Sarraju et al., 2025]. That approaches injectable PCSK9 inhibitor territory — from a once-a-day oral pill. PREVAIL — The Trial That Could Change EverythingPREVAIL (NCT05202509) is the cardiovascular outcomes trial: 9,541 patients with established cardiovascular disease, ≥30-month median follow-up, hard MACE as primary endpoint. Status: active, not recruiting. Readout expected November 2026. If PREVAIL demonstrates a hard-outcome CV benefit, three things follow: FDA filing becomes straightforward. Broad clinical availability and insurance coverage within 12-18 months of approval. A dedicated APOE4 AD-prevention trial becomes likely — and that is the trial that could definitively answer the cognitive-outcome question for our genotype. Until PREVAIL reads out, obicetrapib is pre-approval. You cannot pick it up at Walgreens. What Should APOE4 Carriers Do Now? Here is my actual framework as an APOE4/4 carrier, a pharmacist, and the person building Phoenix. 1. Get your baseline now. If you don't have recent labs with an advanced lipid panel (ApoB, Lp(a), fasting insulin), get them. If you haven't had a plasma p-tau217 drawn, know it is now available as a commercial blood test. You want your starting number before any therapy decision. Phoenix's Bloodwork module tracks all of these against APOE4-specific reference ranges — because normal-for-population is not the same as optimal-for-APOE4. 2. If you're already on max statin + ezetimibe + a PCSK9 inhibitor and still above ApoB/LDL goal — know that obicetrapib is the next wave. Talk to your lipidologist now. Ask where you sit relative to current 2024/2025 APOE4-appropriate targets (many of us should be aiming lower than standard guidelines). When the drug is approved, you want to be first in line. 3. If you're APOE4/4 and worried specifically about the AD trajectory — track PREVAIL. November 2026 readout. Positive CV outcomes → FDA filing → likely dedicated APOE4 prevention trial. That future trial will need enrollees. You want to be a candidate. 4. Attack every lever we already know about. Obicetrapib's mechanism tells us HDL-ApoE flux and Lp(a) matter for the APOE4 brain. We can't drop Lp(a) 46% without a drug, but we can raise HDL and protect ApoE function: aerobic exercise raises HDL; Mediterranean / MIND-pattern eating improves ApoE-mediated lipid handling; sleep fidelity protects glymphatic clearance; resistance training protects against vascular dementia. None of these individually matches obicetrapib's effect size. Collectively, started in your 50s, they move the needle. [link: APOE4 lifestyle protocol stack] A Calibrated Bottom LineWhat we have: Three positive Phase 3 trials on lipid endpoints [Nicholls et al., 2025; Nissen et al., 2025; Sarraju et al., 2025] A pooled MACE signal that looks real and emerges after 6 months [Nicholls et al., JACC 2025] A pre-specified APOE4 biomarker substudy with the strongest oral-drug AD biomarker signal ever reported [Davidson et al., 2025] An independent confirming analysis [Davidson et al., AAIC 2025] Two decades of genetics pointing the same direction [Schmidt et al., 2024; Barzilai et al., 2006; Lythgoe et al., 2015] A coherent HDL-ApoE-amyloid mechanism [Kastelein et al., 2024; Poliakova & Wellington, 2025] A clean safety profile across 3,381 randomized patients [Araujo et al., 2025] What we don't have: A cognitive outcomes trial on obicetrapib (MMSE, CDR-SB not measured) A dedicated APOE4 prevention trial Long-term safety beyond ~12 months of published follow-up Confirmed cardiovascular mortality benefit (PREVAIL pending) FDA approval or pricing If you asked me what drug I'm watching hardest for APOE4 carriers through 2026-2027, this is the answer. It could still disappoint — science does that. But the evidence pyramid is unusually strong for a pre-approval compound. Where Phoenix Fits In I built The Phoenix Community for APOE4 carriers, high-family-risk folks, and clinicians navigating this field in real time. A few pieces of the platform are built for exactly the obicetrapib decision window: Bloodwork — track ApoB, Lp(a), lipid particle sizing, and plasma p-tau217 against APOE4-specific reference ranges, not population averages. Clinical Trials module — we track active APOE4-relevant trials including the obicetrapib-adjacent pipeline and flag them to members who may qualify. Pods — small APOE4 carrier cohorts that run structured protocols together; consistency is easier with people in the same boat. Experiments & XP-Packs — structured protocols for the levers you can act on now: sleep, MIND-pattern eating, exercise dosing, supplement stacks, all logged against your labs. If you want to navigate the obicetrapib window with people paying the same kind of attention you are, the door is open. Frequently Asked QuestionsIs obicetrapib FDA-approved?Not as of April 2026. Obicetrapib is in late-stage Phase 3 development with NewAmsterdam Pharma. The PREVAIL cardiovascular outcomes trial (n=9,541) is expected to read out in November 2026, and a positive readout is expected to trigger FDA filing. No pricing or availability information exists yet. Does obicetrapib work better in APOE4 carriers?At the biomarker level, yes — and that is the unusual part. The BROADWAY APOE4 substudy showed the largest placebo-adjusted p-tau217 benefit in APOE4/4 homozygotes (20.48%, P = 0.010) [Davidson et al., 2025], and Schmidt's 2024 Mendelian randomization predicted an APOE4-specific dementia protection from CETP inhibition [Schmidt et al., 2024]. Calibration: this is a biomarker advantage and a genetics-derived prediction. We do not yet have a head-to-head cognitive-outcome trial comparing obicetrapib's effect in APOE4 carriers vs non-carriers. What's the difference between obicetrapib and statins, ezetimibe, or PCSK9 inhibitors?All four lower LDL but hit different targets. Statins block hepatic cholesterol synthesis. Ezetimibe blocks intestinal absorption. PCSK9 inhibitors increase hepatic LDL-receptor recycling. Obicetrapib blocks CETP-mediated cholesterol transfer in the bloodstream itself, which simultaneously lowers LDL ~30%, raises HDL ~139%, and lowers Lp(a) ~37-46% [Nicholls et al., 2025; Nissen et al., 2025]. It stacks on top of the other three mechanistically. When will obicetrapib be available?Speculative. If PREVAIL reads out positively in late 2026, FDA filing would follow. Typical FDA review for a compound with positive outcomes data is 10-12 months. A realistic earliest-possible commercial-availability window is late 2027 to 2028. Do not take dates from me — take them from the FDA and from NewAmsterdam Pharma's disclosures. Can APOE4 carriers access obicetrapib clinical trials now?The major trials (BROADWAY, BROOKLYN, TANDEM) are completed. PREVAIL is active but not recruiting. The small Phase 2a early-AD pilot (n=13, APOE4 carriers only) is also complete but was not peer-reviewed in a journal; treat its preliminary findings as hypothesis-generating. For active APOE4-relevant trials, check ClinicalTrials.gov and — if you are a Phoenix member — the Clinical Trials module, which surfaces obicetrapib-adjacent and other lipid-targeted AD prevention studies as they open. — Kevin Most Newsletters? One-way street.How boring…This is the Phoenix Community. So let's make it a two-way street. Got a question? Feedback? Hit reply. I read every single one. --- ## APOE4 Biomarkers You Need to Track Part 1 URL: https://apoe4.co/blog/posts/apoe4-biomarkers-you-need-to-track-part-1 Published: 2026-05-11T18:32:00+00:00 Updated: 2026-05-11T18:32:09.095019+00:00 Summary: Discover critical APOE4 biomarkers your doctor isn't testing. Learn why normal lab ranges miss brain health—and the Omega-3 and homocysteine targets that actually matter. APOE4 Biomarkers You Need to Track Part 1Everything you need to know about Omega-3-Index and HomocysteineDr. Kevin Tran May 11, 2026 Youtube video link at the end of the post. Hi Phoenix friend, Last week I sat down with Dr. Grant Fraser during our monthly Q&A to go through the blood tests your doctor almost certainly isn't running. And the ones that they ARE running? They're probably reading them wrong. Here's what I mean. Dr. Fraser opened the conversation with something that I think every APOE4 carrier needs to hear, so I'm going to quote him verbatim: "normals are oftentimes made up of just statistical distribution where you'll have plus and minus two standard deviations." In other words, the "normal range" your doctor is comparing you to is the middle 95% of the population. It's not a health target. It's a statistical artifact. And here's the kicker (this is the part that made me stop the conversation to write it down). That middle 95%? 50 to 60% of those people are, in Dr. Fraser's words, "horribly unhealthy." So when your doctor says your numbers are "within range," what they're actually saying is: you're doing about as well as everyone else. That's not the bar. Especially not for us. Why APOE4 needs tighter ranges APOE4 carriers have higher baseline neuroinflammation. A more permeable blood-brain barrier. Impaired lipid transport. Reduced resilience to oxidative stress. The list goes on. Which means "optimal for the average person" is nowhere close to "optimal for us." We covered two biomarkers in depth this episode. I'm giving you the numbers below, because that's what I wish someone had given me when I first got my diagnosis. Homocysteine: the target is 6-7 Most labs will tell you homocysteine up to 15, 17, even 19 is "normal" depending on your age. For APOE4 carriers, that's not just not-optimal. That's actively damaging. Dr. Fraser's target: 6-7 μmol/L. If you're above 8, he'd treat it. Why it matters: high homocysteine damages the blood vessels in your brain, impairs methylation (which wrecks your DNA repair and neurotransmitter synthesis), and probably accelerates amyloid and tau pathology. It's not just a cardiovascular marker. It's a brain marker. Protocol if yours is high: Step 1 (first 4-6 weeks): methylfolate 500-2000 mcg, methylcobalamin 500-2000 mcg, B6 25-50 mg Step 2 (if still high): add TMG/betaine 500-2000 mg + riboflavin 10-20 mg (especially if you have MTHFR) Step 3 (the one nobody talks about): folinic acid 800 mcg That third step. Read it again. Here's why: some people can't efficiently move methylfolate into their cells. The receptor is damaged, or they've formed an antibody against it. The tell? Their serum folate blood level is above 24 (yes, above the upper limit of "normal"). They look like they have plenty of folate. But it's all stuck in the bloodstream, not inside the cells that actually need it. Folinic acid bypasses the broken receptor entirely. 800 mcg, daily, and you'd be surprised how often the homocysteine drops within a few weeks. Dr. Fraser had a close relative with a homocysteine in the mid-30s that wouldn't budge on standard protocols. One change to folinic acid and it normalized. One more thing: if you're checking B12, always add a methylmalonic acid (MMA) to the panel. A "good" B12 level can still be functionally useless if MMA is elevated. That's a detail I'd never heard before this conversation. Omega-3 Index: 10-12% for us, not 8% The general-population target for omega-3 index is >8%. For APOE4 carriers, Dr. Fraser wants us at 10-12%. And I have bad news. You're almost certainly not there. Vegans sit around 3%. Vegetarians around 4%. Meat-eaters around 4-5%. Even someone taking fish oil daily is usually in the 6-7% range. Getting to 10-12% requires intention. But here's where it gets weirder. There's a transporter in the blood-brain barrier called MFSD2A. It's what actually moves DHA (the most important omega-3 for brain health) from your blood into your brain tissue. APOE4 damages this transporter. Which means even if your omega-3 index is solid, the omega-3s might not be making it where they need to go. There's also a question of whether fish-oil supplements even reach the brain. The data is mixed. But fish consumption — actual salmon, sardines, mackerel — has consistently shown dementia risk reduction in APOE4 carriers. So the current thinking is: the fish form gets through the gut and into the brain intact. The supplement form probably gets cleaved up in digestion and doesn't arrive in the right format. What I do now (my current stack): 1 gram of EPA + DHA daily in supplements (not more — dose-related atrial fibrillation risk above 1g) 2 servings of wild king salmon per week (3g of EPA + DHA per 6-oz serving) Krill oil (for phospholipid-bound omega-3) Don't exceed 1g of supplements. That's the ceiling where atrial fibrillation risk starts climbing. Fish doesn't carry the same risk. Got a question for Dr. Fraser? Drop it in the Phoenix Community. Here's the part of this series most people don't know about. Every month, before I sit down with Dr. Fraser, I collect questions directly from the Phoenix Community. The ones in this episode (the folinic acid one, the omega-3 dosing one, the choline one) came from members like Michelle and Ted. We weave them through the conversation, and Dr. Fraser answers them directly, on camera, by name. It's the closest thing you'll get to a 1:1 consult with someone who actually understands APOE4 at this depth. So if you have a question (about your bloodwork, a confusing lab result, a protocol you're considering, something your doctor said that didn't sit right) submit it in the Phoenix Community and we'll cover it in our next call. You also get to vote on the next topic we cover. Part 2 is shaping up to be inflammation and oxidation (HSCRP, ferritin, GGT). Part 3 will probably be hormones. Part 4 (the one I'm most excited about) is the new blood test for Alzheimer's pathology. If you're not a member yet, this is the moment to join. Members get the Q&A access. They get the protocols I run on myself. They get the community of 500+ APOE4 carriers who are doing this work alongside you. → Join the Phoenix CommunityWhat's coming in Part 2 We ran out of time before getting to HSCRP, ferritin, GGT, and the hormone panel. Those are all coming in Part 2 (recording next month). And Part 4 is the episode I'm most excited for — we're covering a blood test that can actually detect Alzheimer's pathology in your bloodstream, years before symptoms. That's new. That's real. And I don't think most of my community has heard about it yet. Full conversation is up on YouTube. The moment where Dr. Fraser talks about "time is brain" (around 37:25) is, honestly, the reason I'm doing all of this work in the first place. If you only watch one minute of the whole episode, watch that one. Stay proactive,Kevin Most Newsletters? One-way street.How boring…This is the Phoenix Community. So let's make it a two-way street. Got a question? Feedback? Hit reply. I read every single one. --- ## More Data, Less Certainty: Why Most APOE4 Carriers Are Tracking Wrong URL: https://apoe4.co/blog/posts/more-data-less-certainty-why-most-apoe4-carriers-are-tracking-wrong Published: 2026-05-08T17:55:00+00:00 Updated: 2026-05-08T17:55:09.383169+00:00 Summary: APOE4 carriers track more data than ever but lack clarity. Learn why most wearables, bloodwork, and supplements don't connect—and how the redesigned Phoenix daily check-in finally reveals what's actually working. More Data, Less Certainty: Why Most APOE4 Carriers Are Tracking WrongWearables. Bloodwork. Supplements. None of it talks to each other. Today we shipped a redesign of the one feature that finally connects the dots: and here's why we built it.Dr. Kevin Tran May 08, 2026 Today we shipped a full redesign of the Daily Check-in inside the Phoenix app. Here's the bigger story, and what it gives you. A 4/4 carrier emailed me last week with a screenshot of his dashboard. Apple Watch. Oura. Continuous glucose monitor. Two blood tests this year. A supplement spreadsheet with 14 rows. A symptom diary in Notes. A subscription to three different newsletters. His question was four words. "Is any of this working?" He didn't know. Of course he didn't know. He had more data than 95% of patients… and not a single thread connecting it. That is the trap of modern health tracking. More data, less certainty. I built Phoenix to fix that. Today I shipped the redesign of the one feature that ties the rest of it together. So I want to walk you through what I just shipped, and — more importantly — what it's for. The certainty problem Wearables tell you what your heart did last night. Bloodwork tells you where your ApoB sat one Tuesday in March. Your supplement label tells you the dose. Your gut tells you something is working — or it isn't. None of it talks to each other. So you guess. You add Lion's Mane because someone in a Reddit thread said it helped. You drop omega-3 because a podcast said the studies were mixed. You start cold plunging because your brother-in-law swears by it. Three months later you don't know if your fatigue is gone because of the cold plunge, the omega-3, the lower stress at work, or the random three nights of good sleep you had. For people who carry APOE4 — where the cost of "I'll figure it out later" is real, and the cost of trying things that don't work is months of life optimization wasted — that fog isn't a minor annoyance. It's the whole problem. Phoenix exists to replace that fog with certainty. We do it on three levels. Level 1: Certainty about you Phoenix correlates your blood work, your interventions, your wearable data, and your daily qualitative scores — sleep, energy, mental sharpness, stress, well-being. All of it in one timeline. All of it cross-referenced. When your sleep score climbs four points across three weeks, we can tell you whether Mouth tape + Cool room + No screens is doing it, or whether it tracks better with the strength block you started in February. When your ApoB drops 18 mg/dL between two tests, we can tell you which of the seven things you changed in those four months is most likely responsible. This is what we mean when we say "validate what works." You stop guessing about your own body. 89% of members improve at least one biomarker within 6 months. 81% report better well-being within 3 months. The average ApoB reduction in our 6-month cohort is 27%. None of those numbers happen by accident — they happen because members can finally see the cause and effect. Level 2: Certainty about people like you Phoenix AI is trained on APOE4-specific studies and the real, anonymized outcomes of every Phoenix member. When you log Berberine + High protein + Strength training, we can show you what that combination did for the 23 other 4/4 carriers, age 55–62, who ran a similar protocol. When you're considering a new supplement, we can tell you the response rate among carriers with your genotype, your bloodwork pattern, and your wearable signature. You stop being a sample size of one. You start standing on the shoulders of every APOE4 carrier who has shared their data into the system. Level 3: Certainty about which molecules you'll respond to This is the one we're still building, and I want to be honest about it. The goal: use your full longitudinal profile — bloodwork trajectory, intervention response patterns, genotype, daily metrics — to predict which molecules you are most likely to be a hyper-responder for. The ones already on the market. The ones in clinical trials. And then help place you into the right trials directly. We are developing a public Clinical Trials engine (still in beta!) every APOE4-relevant trial, refreshed daily — and the in-app Match Me layer that auto-checks your eligibility every morning. The hyper-responder prediction layer is the next piece, and it ships in stages over the next 12 months. We have the data layer. The matching is shipping now. The predictive layer is in active development. We'll get there. Why we just rebuilt the Daily Check-in None of those three levels work without daily input. So today we shipped a full redesign of the check-in inside the app: One question per screen — sleep, sleep context, well-being, energy, mental sharpness, stress, supplements, meds, lifestyle, journal. Ten short screens. Your top tags, pinned — the five things you tag most weeks live at the top, every day. Your supplement stack, right there — add or pause supplements mid-check-in. Sleep context that asks the right follow-up — bad night? We ask why. One line. Total time: ~90 seconds. That's the data engine. Members get it today. What a Phoenix membership unlocks If you're not a member yet, here is what you get when you join: 150+ APOE4-tuned biomarkers parsed from any blood test PDF, with ranges optimized for APOE4 metabolism, not generic "normal." The Daily Check-in we just shipped — the data layer that makes the rest work. Phoenix AI personalized insights — trained on APOE4 studies and real outcomes from carriers like you. AI-matched accountability pods of 2–4 carriers, formed monthly. Pod members are 3.2× more consistent with their protocols. Match Me clinical-trial engine — every APOE4-relevant trial auto-checked against your eligibility profile, every morning. One-tap interest, warm intros from our research team. Supplement library with community efficacy ratings — see what worked for carriers with your genotype before you spend $40 on a bottle. Structured experiments and group discounts worth an estimated $1,600+/year through curated APOE4 partners. A community of 32% healthcare professionals — neurologists, nurses, physicians, and researchers who carry APOE4 themselves. 60-day money-back guarantee. If it doesn't move your numbers, ask for a refund. No questions. Join Phoenix here →One last thing I carry APOE 4/4. I built Phoenix because I needed it. A year ago I was the carrier with the spreadsheet, the supplement stack, and the fog. The Daily Check-in we just shipped is the tool I would have wanted before I had a single answer. If you're tracking everything and still guessing — this is the way out. — KevinP.S. Pod matching happens on the 1st of every month. Join now and you'll be in the next cohort — matched with 2–4 other APOE4 carriers your age, with similar bloodwork and goals, who'll keep you accountable while you collect the first 30 days of data. The compounding starts the day you start. --- ## How Do You Tell the People You Love About APOE4? We Just Practiced It Live. URL: https://apoe4.co/blog/posts/how-do-you-tell-the-people-you-love-about-apoe4-we-just-practiced-it-live Published: 2026-05-05T18:25:00+00:00 Updated: 2026-05-05T18:25:08.706986+00:00 Summary: Learn how to tell loved ones about your APOE4 status. Watch our live workshop with an emotional intelligence coach sharing a 5-step framework for this difficult conversation. How Do You Tell the People You Love About APOE4? We Just Practiced It Live.A Live Phoenix Community Workshop Dr. Kevin Tran May 05, 2026 Last week, a group of Phoenix members sat down on Zoom with an emotional intelligence coach, wrote out the hardest conversation of their lives, and rehearsed it with strangers. Here's the 5-step framework — and what happened when one member shared something that stopped the room cold.Watch the full workshop following the Youtube link at the end of this email You finally got your APOE4 results back. Maybe one copy. Maybe two. Maybe you saw it coming because Mom or Dad had Alzheimer's. Maybe it landed sideways out of a 23andMe export on an otherwise normal Tuesday. Either way — at some point — you're going to tell someone. Your partner. Your siblings. Your kids, eventually. Your doctor. The person you just started dating. And every carrier I've ever met has the same look on their face when this conversation comes up. The one that says: I have no idea how to do this without making it worse. Most of us freeze. Most of us blurt it out at the wrong moment and regret the delivery for years. Most of us have a partner or parent who responds with a flat "okay" and then never brings it up again — and we don't know if that means they're processing, in denial, or just didn't take it seriously. So we built the workshop I wish I'd had two years ago. The 5-Step Framework Joanna Lenn — board-certified health and wellness coach, emotional intelligence facilitator, fellow APOE4 carrier — walked the group through a framework rooted in genetic counseling best practices and emotional intelligence research. Here it is. Save it. Screenshot it. Use it. 1. Set the context. One simple, calm sentence. "I wanted to share something health-related with you." That's it. No drama. No setup. Just: we're about to have a conversation that matters. 2. Deliver the information. Short. Two sentences max. "I carry a gene called APOE4 that raises my Alzheimer's risk. It doesn't mean I'll develop Alzheimer's, but my risk is higher." That second sentence does a lot of heavy lifting — say it. 3. Tell them why you're sharing. This part changes per audience. For a partner: "I want to be open with you about something that could affect our future together." For a sibling: "Because APOE4 is inherited, I felt it was important for you to know." Name the relevance clearly — without alarm, without guilt. 4. Share where you are emotionally. This is the step almost everyone skips. And it's the one Joanna spent the most time on. Because here's what happens when you don't tell people how you're carrying this information: they guess. And they almost always guess worse than reality. So tell them. "I take this seriously, and I feel good about my prevention efforts." Or: "I was panicked at first, and now I'm finding my footing." Whatever's true. 5. End with an invitation. "If you have questions, I'm here now or whenever you're ready." Signal: I'm done with my planned talk, and the floor is open. That's the framework. Not a script: a compass. The Insight That Cracked the Room Open I asked Joanna a question during the workshop that I think a lot of carriers feel but don't articulate. When I tell someone about my APOE 4/4 status, I tend to deliver it casually. Confidently. Because that's how I actually feel about it. But sometimes the response comes back too casual — like the person didn't register that this is real, lifelong, genetic. So which is it? Calm them down? Or let them feel the weight? Joanna's answer: it's neither. It's calibration. Emotional contagion is real — they will mirror how you feel. Show up panicked, they panic. Show up too breezy, they shrug. The goal is to be honest about the seriousness and honest about where you are right now. You can hold both. "I take this very seriously, AND I feel good about what I'm doing about it." That sentence — said with the right energy — is the difference between a partner who supports you and a partner who quietly worries you're in denial. The Moment That Stopped Us Halfway through the workshop, a member shared something I think about every day now. His younger sister is 58. She's been showing signs of short-term memory loss. He and his siblings finally convinced her to see a neurologist. And then last week — she canceled the appointment. She's withdrawing from family conversations about it. She doesn't want to talk. The Zoom went quiet. I told him what I learned working in a geriatric hospital unit: when someone hasn't recognized they have a problem, pushing harder rarely works. Sometimes the most loving thing you can do is keep the door open and gently check back later. That's not giving up. That's respecting that this is their process — and pressure, no matter how well-intentioned, can backfire. Several other members chimed in with stories about siblings, parents, spouses who weren't ready. We didn't fix his situation. But for the first time in a long time, he wasn't holding it alone. That's what these workshops are actually for. What Phoenix Is, Actually I want to be straight with you, because I think most newsletters dance around this part. If you're an APOE4 carrier reading this, you've probably already done the lonely version of this work. You've read r/APOE4. You've watched the same five YouTube videos. You've stared at your bloodwork wondering if your ApoB target should be 60 or 80. You've heard about LPC-DHA omega-3s and not known if they're real or marketing. You've opened ClinicalTrials.gov, scrolled three pages, and bounced. Phoenix is the thing that connects all of it. We're the first precision health platform built specifically for APOE4 carriers. Not "people interested in longevity." Not "Alzheimer's prevention enthusiasts." Carriers. Members like you, navigating the same gene, comparing the same biomarkers, running the same protocols, asking the same hard questions. A Phoenix Core membership gets you: Live workshops every month — like the one above. Disclosure conversations, supplement protocols, biomarker deep-dives, expert Q&As with researchers and clinicians. Recorded for replay if you can't make it live. Phoenix AI built for APOE4 — trained on E4-specific research and real outcomes from carriers in the community. Not generic wellness advice. It learns what's actually moving your numbers. AI blood test analysis — upload any lab PDF. Phoenix parses every biomarker, flags what matters, and shows the APOE4-optimized range (often tighter than what your doctor uses). Clinical Trials engine — every APOE4-relevant trial on ClinicalTrials.gov, filtered for you, updated daily. One-tap interest. We get the signal directly to sponsors like Alzheon. Monthly AI pod matching — matched with 2–4 carriers each month based on your stage and goals. 94% of pods still active after 60 days. Members in pods are 3.2× more consistent than carriers going it alone.Daily check-ins, supplement tracker, experiments, full health timeline — the whole APOE4 health hub, with cause-and-effect surfaced across all your data. $1,600+/year in partner perks — 20% off Accentrate Omega Max (the LPC-DHA omega-3 that actually crosses the APOE4 brain barrier). 20% off NeuroAge brain-age testing. $100 off the Sens.ai neurofeedback headset. Hand-picked by me, an APOE 4/4 carrier. The community — hundreds of carriers, ~32% of them healthcare professionals. Real conversations, not influencer noise. 60-day money-back guarantee — try it for two months. If Phoenix doesn't earn its place, full refund. No questions, no friction. See how Phoenix works →One More Thing. The next live workshop is coming up — and like all of them, it's members-only. If you've been on the fence about joining for months, this is your nudge. The carriers who showed up to this disclosure workshop walked away with a script they can use this week, with the people they love. The ones who couldn't join — well, they couldn't join. I built Phoenix because I needed it. I carry APOE 4/4 too. I have skin in this game. The community is the reason I get up in the morning, and live workshops like this one are how I make sure no carrier has to do this work alone. The door is open. — Kevin Founder, Phoenix Community APOE 4/4 carrier --- ## HRT + APOE4: What the Research Actually Shows (Men & Women) URL: https://apoe4.co/blog/posts/hrt-apoe4-what-the-research-actually-shows-men-women Published: 2026-04-27T18:41:00+00:00 Updated: 2026-04-27T18:41:16.533678+00:00 Summary: Should APOE4 carriers take HRT? We reviewed 16 studies on hormone therapy, Alzheimer's risk, timing, formulation, and testosterone. Evidence-based analysis. HRT + APOE4: What the Research Actually Shows (Men & Women)16 studies. 3 clinical trials. The most complete APOE4 + HRT analysis we've ever published.Dr. Kevin Tran April 27, 2026 Hi Phoenix friend, "Should I take HRT given my APOE4 status?" is the single most common question I hear from the 500+ members of The Phoenix Community. Every single day. And here is what terrifies me about how this question gets answered in the real world. Your gynecologist says hormones are fine. Your neurologist says they are risky because of your APOE4 status. The internet says estrogen cures Alzheimer's. The WHI study says it causes dementia. And you are left in the middle, paralyzed, making one of the most consequential health decisions of your life based on headlines from 2002. That ends today. I reviewed 16 peer-reviewed studies and 3 active clinical trials to give you the most complete analysis of APOE4 and hormone replacement therapy available anywhere. We will cover the WHI and why it does not mean what you think it means, the critical window hypothesis, APOE4-specific biology, formulation differences, testosterone for men, and what is being studied right now. What the Women's Health Initiative Actually Studied In 2002, the Women's Health Initiative published results that changed hormone therapy overnight. The headlines were catastrophic: HRT causes breast cancer, dementia, and heart attacks. Millions of women stopped their hormones. Doctors stopped prescribing them. An entire generation went through menopause unmedicated. Here is what the headlines did not tell you. The WHI Memory Study (WHIMS) enrolled women aged 65 to 79 -- on average, 15 to 20 years past menopause when they started hormone therapy. That is not what a 50-year-old starting estrogen in perimenopause is doing. It is a fundamentally different clinical scenario. The formulation matters too. The WHI used conjugated equine estrogens (Premarin, derived from pregnant horse urine) combined with medroxyprogesterone acetate (Provera, a synthetic progestin). That is not 17-beta estradiol. That is not micronized progesterone. That is a different drug, given to a different population, started at a different time. I am not here to dismiss the WHI. It is one of the largest randomized controlled trials in medical history. What it found in the population it studied is valid: older women starting oral conjugated estrogens plus synthetic progestins many years after menopause did show increased dementia risk. That finding matters. But applying it to every woman, at every age, on every formulation is where the generalization became catastrophic. Two Meta-Analyses, Two Conclusions So where does the science stand in 2026? Let me give you the two most important meta-analyses and be honest about the tension between them. In 2025, The Lancet Healthy Longevity published a WHO-commissioned systematic review analyzing data from over one million participants across ten studies. Their conclusion: "No significant association was found between MHT use and risk of mild cognitive impairment or dementia" (Melville et al., 2025). That is a sobering finding. The most rigorous meta-analysis we have says no clear signal either way. But in 2023, Nerattini and colleagues from the Brinton Lab published a broader meta-analysis including 51 reports. Their finding: an overall 22% reduced risk of Alzheimer's disease and 19% reduced risk of all-cause dementia with hormone therapy use. When they isolated midlife estrogen-only therapy, the risk reduction was 31.5% (Nerattini et al., 2023). Why do they disagree? Because they asked slightly different questions with different inclusion criteria. The Lancet review was more restrictive -- only ten studies met their strict quality bar. Nerattini cast a wider net across 51 reports. Neither is wrong. They are telling you that the answer depends on which studies you include and how you weight them. KEY INSIGHT: The most rigorous 2025 meta-analysis (WHO-commissioned, 1M+ participants) found no evidence HRT prevents OR causes dementia. The broader 2023 meta-analysis found a 22% reduced Alzheimer's risk. Real science is not neat. Anyone who tells you the answer is simple is selling you something.The Critical Window Hypothesis: Why Timing Changes Everything The most actionable finding in this entire field comes from the critical window hypothesis -- and it may be the most important concept for APOE4 carriers to understand. In 2011, Whitmer and colleagues published a landmark study in Annals of Neurology. They asked a simple question: does it matter WHEN you start hormone therapy? The answer was dramatic: Women who took HRT only in midlife (during or shortly after menopause): 26% decreased dementia risk Women who took HRT only in late life (well after menopause): 48% increased dementia risk Same class of drug. Completely opposite outcomes. The variable was timing. This is not an isolated finding. The Nerattini meta-analysis supports it -- midlife estrogen-only therapy showed that 31.5% risk reduction, while late-life combined therapy showed a 32% risk increase (though not statistically significant) (Nerattini et al., 2023). The KEEPS Continuation Study adds another layer. Women who started hormone therapy within three years of menopause and took it for four years showed no long-term cognitive harm after 10+ years of follow-up. "Findings may reassure women opting to use hormone therapy in early menopause to manage menopausal symptoms that 4 years of therapy started within 3 years of menopause had no long-term deleterious impact on cognition" (Gleason et al., 2024). CAVEAT: The critical window is a strong hypothesis, not a proven fact. The 2025 Lancet meta-analysis did subgroup analyses by timing and found no significant effect in any timing window. The KEEPS study found no cognitive benefit from early initiation -- only the absence of harm. The observational evidence is compelling, but the most rigorous analyses have not confirmed cognitive protection. Here is how I think about it as a pharmacist and an APOE4 carrier: the weight of the evidence, including the biology we are about to cover, makes a compelling case that if you are going to consider HRT, earlier is almost certainly better than later. And the worst time to start is a decade or more after menopause. APOE4-Specific Biology: The Double Hit Everything above applies to the general population. When you layer on APOE4 genetics, the picture changes dramatically. The Accelerated Clock In 2025, the Brinton Lab at the University of Arizona published a groundbreaking paper showing what I call "the double hit" (Wang et al., 2025): Hit one: APOE4 women experience earlier menopause. Your hormonal cliff comes sooner than it does for women without the allele. Hit two: When that cliff comes, APOE4 women fail to mount what the researchers called "adaptive bioenergetic reprogramming." In plain English -- when your brain loses estrogen, it needs to switch fuel sources. Non-APOE4 brains can make that switch. APOE4 brains cannot do it as effectively. The result is mitochondrial decline, immune activation, and demyelination. Earlier menopause. Failed brain adaptation. That is the double hit. And it explains why female APOE4 carriers have up to 1.5 times the Alzheimer's risk of male APOE4 carriers. Brain Volume Preservation in APOE4 HRT Users The strongest evidence for APOE4-specific HRT benefit comes from the European Prevention of Alzheimer's Disease (EPAD) cohort. Saleh and colleagues (2023) studied 1,906 participants and found that HRT was associated with improved delayed memory and 6-10% larger entorhinal and amygdala volumes -- but only in APOE4 carriers. Not in non-carriers. "Early HRT introduction was associated with larger right and left hippocampal volumes only in APOE4 carriers" (Saleh et al., 2023). These are the exact brain regions that Alzheimer's attacks first. CAVEAT: The EPAD study is cross-sectional (cannot prove causation) and the APOE4 HRT subgroup was small (n=29-31). A 2025 study by Watermeyer et al. found HRT benefits irrespective of APOE4 status, suggesting the benefit may not be APOE4-specific. The honest answer: we do not know yet whether APOE4 carriers benefit more, equally, or differently.Why APOE4 Changes Estrogen Biology Two mechanisms explain why APOE4 carriers may be more dependent on adequate estrogen: Estrogen receptor disruption: APOE4 modulates estrogen receptor expression and responsiveness. "APOE4 appears to modulate systemic and neural outcomes of both menopause and estrogen-based hormone therapy" (Valencia-Olvera et al., 2023). When estrogen drops at menopause, APOE4 carriers feel the impact more acutely because their receptors are already compromised. Cholesterol and myelin breakdown: Published in Nature, Blanchard and colleagues (2022) showed that APOE4 causes cholesterol to accumulate aberrantly in myelin-producing cells rather than being used for insulation. The result is reduced myelin production. Estrogen plays a role in cholesterol transport and myelination. When you combine APOE4's cholesterol mishandling with estrogen loss at menopause, you get a compounding vulnerability. Critically, perimenopausal women already have higher brain-wide amyloid-beta than premenopausal women -- and this difference is heightened in APOE4 carriers (Metcalf et al., 2023). The amyloid is already accumulating during the menopausal transition, and for APOE4 carriers, it is accumulating faster. Formulation Guide: Patches, Pills, and Progesterone Not all hormone therapy is created equal -- especially for APOE4 carriers. Transdermal Estradiol vs. Oral Estrogen The most important formulation finding comes from the KEEPS trial. Kantarci and colleagues (2016) measured amyloid-beta deposition in 68 recently postmenopausal women: Transdermal 17-beta estradiol (the patch): Reduced amyloid-beta deposition, particularly in APOE4 carriersOral conjugated equine estrogens (Premarin): No such benefit "In the APOE epsilon-4 carriers, transdermal 17-beta-estradiol treated women had lower PiB SUVR compared to placebo" (Kantarci et al., 2016). The mechanism makes sense. Oral estrogen undergoes first-pass hepatic metabolism, triggering increased clotting factors, inflammatory markers, and changes to cholesterol processing. For APOE4 carriers who already have disrupted cholesterol metabolism, adding oral estrogen's hepatic effects may compound the problem. A patch bypasses the liver entirely -- the estradiol goes directly into the bloodstream. CAVEAT: The KEEPS imaging substudy included only about 10 APOE4 carriers on transdermal estradiol. This needs replication in a larger trial. But the biology is sound, and this is one of the very few findings where we have APOE4-specific data from a randomized controlled trial.The Progesterone Problem Everyone focuses on estrogen. Almost nobody talks about progesterone. And the type matters enormously. Natural progesterone is neuroprotective. Guennoun's 2020 review established that progesterone reduces inflammation, promotes myelin repair, and modulates GABA receptors. It has a broad spectrum of protective effects in the brain. The WHI did not use natural progesterone. It used medroxyprogesterone acetate (MPA/Provera) -- a synthetic progestin that in animal studies has been shown to abolish many of estradiol's memory benefits. That synthetic progestin may have driven some of the harm attributed to "HRT" in the WHI. Micronized progesterone (Prometrium) is molecularly identical to what your body produces. It is FDA-approved and its safety profile for the brain appears substantially better than synthetic MPA. However, even micronized progesterone is not purely additive. Conley et al. (2024) found some cognitive decrements when adding micronized progesterone to estradiol under cholinergic challenge. Women with a uterus need progesterone to prevent endometrial hyperplasia -- that is non-negotiable -- but the estrogen-progesterone relationship in the brain is more complex than "add progesterone and everything gets better." A Note on "Bioidentical" "Bioidentical" means the molecule is identical to what your body produces. 17-beta estradiol and micronized progesterone are bioidentical. This is a chemistry term, not a safety guarantee. FDA-approved bioidentical products (Vivelle-Dot patches, Estrace, Prometrium) have rigorous quality control and standardized dosing. Compounded bioidentical products from specialty pharmacies do not have the same oversight. The molecule might be right, but the dose could be wildly off. "Bioidentical" on a label is not a safety certificate. Men, APOE4, and Testosterone: The Overlooked Angle This section is for the men in our community -- and for the partners navigating this together. The Observational SignalYeap and Flicker's 2022 review synthesized the evidence: men with lower testosterone concentrations consistently had a higher incidence of dementia, including Alzheimer's disease. That association is real and has been replicated. But when researchers actually gave men testosterone replacement and measured cognitive outcomes, the results were disappointing. Testosterone therapy trials have not shown cognitive benefit. Yeap's conclusion: "Lower testosterone concentrations in ageing men should be regarded as a biomarker rather than a proven therapeutic target." Low testosterone tracks with dementia risk, but raising it does not necessarily reduce that risk. The APOE4 Wrinkle Here is where it gets complicated -- and I need to caveat this heavily because the study is small. Burkhardt and colleagues (2006) studied 45 healthy men over 55 and found a dramatic genotype-hormone interaction: Non-APOE4 men: Higher free testosterone = better cognition (as expected) APOE4 men: Higher free testosterone = worse scores on executive function, working memory, and attention This was 45 men. A single cross-sectional study. It has not been replicated in a large trial. But Shi et al. (2025) provided a potential mechanism: "APOE4 reduces androgen receptor signaling sensitivity, weakens testosterone's protective effects by altering fatty acid synthesis and oxidative stress." APOE4 may change how your brain responds to testosterone at the receptor level. ACTION STEP: If you are a male APOE4 carrier on TRT with an aromatase inhibitor (anastrozole), discuss this with your doctor. Testosterone converts to estradiol in the brain via aromatase, and that local estrogen production appears neuroprotective. Blocking aromatization may remove a critical neuroprotective pathway for APOE4 carriers. The evidence is early, but the conversation is worth having.What Is Being Studied Right Now No large RCT has ever specifically recruited APOE4 carriers to test hormone therapy for cognitive outcomes. That is the single largest gap in this field. But three trials are worth watching: 1. PhytoSERM Trial (NCT05664477) -- The Brinton Lab at the University of Arizona is running a Phase 2 trial funded by a $7.6 million NIH grant. They are testing a plant-based selective estrogen receptor beta modulator designed to target brain estrogen receptors without systemic HRT effects. The pilot study analyzed results by APOE genotype, and genetic factors including APOE status may influence response. Estimated completion: January 2027. 2. Mayo Clinic Surgical Menopause Study (NCT03821857) -- An observational study examining whether abrupt loss of ovarian hormones (bilateral oophorectomy) accelerates Alzheimer's pathology, using amyloid PET, tau PET, and structural MRI. Stratified by APOE4 status. 3. WHI Long-term Follow-up (NCT00000611) -- The original WHI continues generating data 20+ years out. Newer reanalyses by age of initiation have been crucial for refining the critical window hypothesis. This is exactly why we built the clinical trials module inside Phoenix. When trials like PhytoSERM publish results, our community gets early analysis. When new trials open for APOE4 carriers, members get notified. A Practical Framework: What to Discuss With Your Doctor This is not a prescription. It is a framework for an informed conversation. 1. Know your genetics. You cannot make informed decisions about hormones without knowing your APOE status. If you do not know, get tested. 2. Find a menopause-literate provider. Not just any gynecologist -- one who understands the timing hypothesis, formulation differences, and ideally APOE4 biology. The North American Menopause Society maintains a provider directory. 3. If you are already on HRT, review the route. If you are on oral estrogen, ask about switching to transdermal. If you are on Provera (MPA), ask about micronized progesterone (Prometrium). The evidence favoring transdermal estradiol is strongest for APOE4 carriers specifically. 4. Track your biomarkers. Estradiol, testosterone, SHBG, and other hormonal markers over time. You cannot manage what you do not measure. Inside Phoenix, members use the Bloodwork module to track these longitudinally and compare against community benchmarks. 5. Do not panic about the window. If you are 61 and never took HRT, you did not fail. The system failed you. The 2002 consensus said HRT was dangerous. You made the best decision with the information available. The timing hypothesis suggests late initiation carries more risk, but the Endocrine Society and NAMS both support individualized assessment rather than blanket age cutoffs. Key TakeawaysQuick-Start Protocol (This Week): Get your baseline: Request estradiol, FSH, testosterone, and SHBG levels at your next blood draw. Log them in Phoenix Bloodwork to track changes over time. Find the right provider: Use the NAMS provider directory to find a menopause-literate clinician who understands APOE4. Bring this article to your appointment. Review your formulation: If you are currently on oral estrogen or synthetic progestins, ask your provider about transdermal estradiol and micronized progesterone -- the combination with the strongest evidence for APOE4 carriers. Men on TRT: Ask your prescribing physician whether an aromatase inhibitor is appropriate given your APOE4 status and the emerging evidence on brain aromatization. Join the conversation: 340+ APOE4 carriers in The Phoenix Community discuss hormone protocols, share provider recommendations, and track outcomes together in accountability pods. Track Your Hormone Journey With Phoenix The intersection of APOE4 and menopause is one of the loneliest places in medicine. Your doctors disagree with each other. The research is complex. And the stakes feel impossibly high. Inside The Phoenix Community, 500+ APOE4 carriers navigate this together. Log your hormone levels in the Bloodwork module. Join an accountability pod where members share protocols and track outcomes. Get notified when clinical trials like PhytoSERM publish results. Access expert Q&A sessions with researchers working on APOE4-specific hormone biology. You do not have to navigate this alone. Frequently Asked QuestionsIs perimenopause brain fog the same as early Alzheimer's? No. Perimenopause cognitive symptoms are driven by estrogen withdrawal affecting neuronal signaling and neurotransmitter systems. Early Alzheimer's involves amyloid and tau accumulation causing neuronal death. One is a signaling problem; the other is a structural problem. Most women report memory and concentration problems during perimenopause, and this is a recognized neurological phenomenon, not an early sign of dementia (Metcalf et al., 2023). However, APOE4 carriers do have higher amyloid-beta loads during perimenopause than non-carriers, so the background risk is real. The way to distinguish between the two is proper neuropsychological testing and a documented cognitive baseline you can track over time -- not lying awake at 4 AM guessing. I am 61 and never took HRT. Did I miss the window? You did not fail. The system failed you. In 2002, the medical consensus told you HRT was dangerous, and you made the best decision with the information available. The timing hypothesis suggests late initiation carries more risk -- Whitmer's data showed a 48% increased risk with late-life-only HRT (Whitmer et al., 2011). But it is not black and white. Watermeyer et al. (2025) found HRT use associated with better cognitive performance in older women regardless of APOE4 status. The Endocrine Society and NAMS support individualized assessment rather than blanket age cutoffs. The answer is: find a menopause-literate provider, get a comprehensive cardiovascular assessment, and make a decision based on YOUR risk profile -- not the population average. Should APOE4 carriers use bioidentical or synthetic hormones? The molecule matters. The KEEPS trial showed transdermal estradiol (bioidentical) reduced amyloid in APOE4 carriers while oral conjugated estrogens did not (Kantarci et al., 2016). For progestins, the distinction is even clearer: synthetic MPA (used in WHI) has been shown to abolish estrogen's cognitive benefits in animal models, while micronized progesterone preserves more benefit (Guennoun, 2020). FDA-approved bioidentical products (Vivelle-Dot, Estrace, Prometrium) have rigorous quality control. Compounded products do not. Choose the right molecule AND the right quality standard. Are there clinical trials for APOE4 carriers I can join? Yes. The PhytoSERM trial (NCT05664477) out of the Brinton Lab at the University of Arizona is actively running, with brain metabolism endpoints and APOE genotype as a potential factor in treatment response; estimated completion January 2027. The Mayo Clinic surgical menopause study (NCT03821857) is also ongoing with APOE4 stratification. Inside The Phoenix Community, we track every trial relevant to APOE4 carriers and notify members when new trials open for enrollment. DISCLAIMER: This article is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making any changes to your hormone therapy regimen. Sources Saleh RN, Hornberger M, Ritchie CW, Minihane AM. "Hormone replacement therapy is associated with improved cognition and larger brain volumes in at-risk APOE4 women: results from the European Prevention of Alzheimer's Disease (EPAD) cohort." Alzheimer's Research & Therapy, 2023. https://doi.org/10.1186/s13195-022-01121-5 Melville M, He L, Desai R, et al. "Menopause hormone therapy and risk of mild cognitive impairment or dementia: a systematic review and meta-analysis." The Lancet Healthy Longevity, 2025. https://doi.org/10.1016/j.lanhl.2025.100803 Nerattini M, Jett S, Andy C, et al. "Systematic review and meta-analysis of the effects of menopause hormone therapy on risk of Alzheimer's disease and dementia." Frontiers in Aging Neuroscience, 2023. https://doi.org/10.3389/fnagi.2023.1260427 Whitmer RA, Quesenberry CP Jr, Zhou J, Yaffe K. "Timing of hormone therapy and dementia: the critical window theory revisited." Annals of Neurology, 2011. https://doi.org/10.1002/ana.22239 Kantarci K, Lowe VJ, Lesnick TG, et al. "Early Postmenopausal Transdermal 17-beta-Estradiol Therapy and Amyloid-beta Deposition." Journal of Alzheimer's Disease, 2016. https://doi.org/10.3233/JAD-160258 Valencia-Olvera AC, Maldonado Weng J, Christensen A, LaDu MJ, Pike CJ. "Role of estrogen in women's Alzheimer's disease risk as modified by APOE." Journal of Neuroendocrinology, 2023. https://doi.org/10.1111/jne.13209 Wang T, Mao Z, Shang Y, et al. "Accelerated midlife endocrine and bioenergetic brain aging in APOE4 females." Frontiers in Aging Neuroscience, 2025. https://doi.org/10.3389/fnagi.2025.1632877 Gleason CE, Dowling NM, Kara F, et al. "Long-term cognitive effects of menopausal hormone therapy: Findings from the KEEPS Continuation Study." PLoS Medicine, 2024. https://doi.org/10.1371/journal.pmed.1004435 Blanchard JW, Akay LA, Davila-Velderrain J, et al. "APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes." Nature, 2022. https://doi.org/10.1038/s41586-022-05439-w Yeap BB, Flicker L. "Testosterone, cognitive decline and dementia in ageing men." Reviews in Endocrine and Metabolic Disorders, 2022. https://doi.org/10.1007/s11154-022-09728-7 Burkhardt MS, Foster JK, Clarnette RM, et al. "Interaction between testosterone and apolipoprotein E epsilon4 status on cognition in healthy older men." Journal of Clinical Endocrinology & Metabolism, 2006. https://doi.org/10.1210/jc.2005-1072 Shi Z, Wu L, Zhang C, et al. "Testosterone as a mediator of APOE4-linked sex differences in Alzheimer's disease." International Immunopharmacology, 2025. https://doi.org/10.1016/j.intimp.2025.115588 Guennoun R. "Progesterone in the Brain: Hormone, Neurosteroid and Neuroprotectant." International Journal of Molecular Sciences, 2020. https://doi.org/10.3390/ijms21155271 Conley AC, Vega JN, Johnson JV, Dumas JA, Newhouse PA. "Effect of estradiol with or without micronized progesterone on cholinergic-related cognitive performance in postmenopausal women." Frontiers in Neuroscience, 2024. https://doi.org/10.3389/fnins.2024.1428675 Metcalf CA, Duffy KA, Page CE, Novick AM. "Cognitive Problems in Perimenopause: A Review of Recent Evidence." Current Psychiatry Reports, 2023. https://doi.org/10.1007/s11920-023-01447-3 Watermeyer TJ, Gregory S, Leetham E, et al. "Hormone replacement therapy, menopausal age and lifestyle variables are associated with better cognitive performance at follow-up but not cognition over time in older-adult women irrespective of APOE4 carrier status and co-morbidities." Frontiers in Dementia, 2025. https://doi.org/10.3389/frdem.2024.1496051Clinical Trials Referenced T1: PhytoSERM Trial -- NCT05664477 T2: Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease -- NCT03821857 T3: Women's Health Initiative Long-term Follow-up -- NCT00000611 --- ## Just Found out you carry the APOE4 gene? URL: https://apoe4.co/blog/posts/just-found-out-you-carry-the-apoe4-gene Published: 2026-04-23T18:49:00+00:00 Updated: 2026-04-23T18:49:09.328879+00:00 Summary: Just found out you carry APOE4? Here's your evidence-based day 1 game plan to thrive—practical steps from someone who's been there. Just Found out you carry the APOE4 gene? Here's your evidence-based game plan to THRIVE with APOE4Dr. Kevin Tran April 23, 2026 What to Do When You Find Out You Carry APOE4: A Day 1 Guide from Someone Who's Been There I realized we have many new newsletter readers who just found out their APOE4 status.I know how scary it can be. I have been there. This post will help you get started, without the overwhelm. And if you have known your APOE4 status for years, maybe you can still learn a thing or two in this video :) Maybe it was a 23andMe report. Maybe your doctor ordered a test after your parent's diagnosis. Maybe you were scrolling through your raw genetic data at two in the morning and now you can't sleep. However you found out you carry the APOE4 gene, I want you to know something before we go any further: you are not your genotype. I'm Dr. Kevin Tran. I'm a Doctor of Pharmacy, and I'm homozygous APOE4 — meaning I carry two copies, the highest genetic risk category for Alzheimer's disease. When I got my results, I spiraled. I read every worst-case study I could find. But then I found the research that most people never see. And everything changed. This post is the guide I wish someone had handed me on Day 1. No panic. No false promises. Just what the science actually says about APOE4 — and the four evidence-based steps you can start this week. What APOE4 Actually Means APOE stands for apolipoprotein E, a gene on chromosome 19 that helps your body transport cholesterol and fats (including in your brain). Everyone carries two copies. There are three common variants: APOE2, APOE3, and APOE4. APOE3 is the most common — most people carry two copies (APOE3/3). That's the baseline. APOE4 is the variant associated with increased Alzheimer's risk. About 25% of people carry at least one copy [Belloy et al., 2019]. If you have one copy (APOE3/4), you're heterozygous. Two copies (APOE4/4), like me, is homozygous. Here is the critical distinction that every headline gets wrong: APOE4 is a risk factor. It is not a diagnosis. One copy increases your risk roughly 2 to 4 fold compared to the APOE3/3 baseline. Two copies increase it about 8 to 12 fold [Belloy et al., 2019]. Those numbers sound terrifying in isolation. But they mean something very different when you look at the actual lifetime data. The Numbers Most People Never See The largest genetic meta-analysis on APOE and Alzheimer's examined thousands of carriers across multiple populations [Genin et al., 2011]. Here is what they found: If you carry one APOE4 copy (APOE3/4), your lifetime risk of developing Alzheimer's dementia by age 85 is roughly 23 to 30 percent. Read that again. 70 to 77 percent of people with one APOE4 copy will never develop Alzheimer's dementia [Genin et al., 2011]. If you're APOE4/4 like me — two copies — the numbers are higher. Roughly 51 to 60 percent lifetime risk by age 85, though prospective studies put the range at 30 to 55 percent [Genin et al., 2011]. Even at the higher end, that means 40 to 50 percent of APOE4 homozygotes never develop clinical dementia. Now, you may have seen the 2024 Nature Medicine study that made headlines claiming APOE4 homozygosity is essentially a "genetic form" of Alzheimer's [Fortea et al., 2024]. The media ran with that framing. But here's what the study actually showed: nearly all APOE4/4 carriers exhibit biomarker changes — proteins in spinal fluid, amyloid on brain scans — by age 65. But biomarker changes are not dementia. As multiple researchers pointed out in response, biological penetrance is not the same as clinical penetrance [Fortea et al., 2024]. Your brain can show early signs of the biological process without you ever developing symptoms — especially if you intervene. That gap between biology and disease? That's where everything I'm about to tell you lives. That gap is your opportunity. Why APOE4 Carriers May Benefit MORE from Lifestyle Changes This is the part that changed everything for me. The FINGER trial — the Finnish Geriatric Intervention Study — was the first large randomized controlled trial to demonstrate that a combination of lifestyle changes (diet, exercise, cognitive training, and vascular risk management) can prevent cognitive decline in at-risk people [Ngandu et al., 2015]. That alone was groundbreaking. But what matters most for us is what happened when researchers examined the APOE4 subgroup. In 2018, Solomon and colleagues published the subgroup analysis in JAMA Neurology [Solomon et al., 2018]. They found that APOE4 carriers in the intervention group showed a numerically greater cognitive benefit — an annual NTB score change of 0.037 compared to 0.014 for non-carriers. That is roughly 2.6 times the effect size. CAVEAT: The formal statistical interaction between APOE4 status and the intervention did not reach significance in this single trial [Solomon et al., 2018]. But the direction of the effect — carriers benefiting more — was consistent and meaningful. And that is exactly why the 2025 meta-analysis matters. Lehtisalo and colleagues pooled data from three independent trials — FINGER in Finland, MAPT in France, and J-MINT in Japan — across different populations and different countries. When you combine all three, the result IS statistically significant: a clear interaction showing APOE4 carriers consistently benefit more from lifestyle interventions, with a p-value of 0.035 [Lehtisalo et al., 2025]. This is the single most important finding for you right now: growing evidence suggests your APOE4 status doesn't mean lifestyle changes won't work. It may mean they work BETTER for you than for someone without APOE4. You have more reason to take action, not less. FREE RESOURCE: I put together a free guide called The Essential Guide to Thriving with APOE4 that goes deeper into all of this — the research, the specific protocols, the biomarkers to track. [Download it here] — no catch, no paywall. Because when the initial overwhelm fades and you're ready to build a plan, you'll want a reference you can come back to.Your First Week: 4 Evidence-Based Steps Not fifty steps. Not a stack of supplements. Four things with the strongest evidence base for APOE4 carriers specifically. 1. Move Your Body A 2021 meta-analysis of randomized controlled trials found that exercise benefits cognitive performance across both APOE4 carriers and non-carriers, though the effect of intensity varies by genotype. At high intensity, the differential effect was large (SMD = 0.963), though in that analysis it favored non-carriers on aggregate [Cancela-Carral et al., 2021]. However, a 2025 systematic review found that APOE4 carriers benefited more than non-carriers specifically on executive function and learning outcomes after exercise interventions [Spencer et al., 2025] -- suggesting the picture is more complex than any single meta-analysis captures. What to do: Aim for 150 minutes per week of Zone 2 cardio — the intensity where you can still talk but it's uncomfortable — plus two to three sessions of strength training. You don't need to run a marathon. You need consistency. If you do nothing else on this list, do this one. Exercise is one of the most evidence-supported interventions for brain health, and emerging research suggests APOE4 carriers may see particular cognitive benefits. ACTION STEP: Start with three 30-minute walks this week. Build from there. Track your consistency with daily Phoenix Check-ins to build the habit.2. Start Eating Mediterranean A 2025 observational study in Nature Medicine found that adherence to the Mediterranean diet was associated with more effective modulation of 57 dementia-related metabolites in APOE4 homozygotes compared to non-carriers [Liu et al., 2025]. The diet wasn't just associated with general benefit — the metabolic association was stronger specifically in APOE4 homozygotes. What to do: You don't need to overhaul your kitchen tonight. Start with one Mediterranean meal a day. More olive oil, more fish, more vegetables, more nuts and seeds. Less processed food, less sugar. The MIND diet — a Mediterranean-DASH hybrid studied specifically for brain health — is another strong framework. CAVEAT: This is observational data, which means it shows association, not proven causation. But the biological plausibility is strong, and the dietary pattern carries essentially zero downside risk.3. Protect Your Sleep This one may be the most underrated. A human imaging study showed that even a single night of sleep deprivation resulted in measurable amyloid-beta accumulation in the hippocampus — the brain's memory center [Shokri-Kojori et al., 2018]. For APOE4 carriers specifically, animal research suggests that sleep deprivation creates a feed-forward loop: poor sleep accelerates amyloid buildup, which further disrupts sleep, which accelerates more buildup. This loop appears specific to APOE4, not APOE3 [Sadleir & Vassar, 2023]. CAVEAT: The APOE4-specific sleep vulnerability data comes largely from mouse models. The human amyloid study did not stratify by APOE genotype. But the mechanism is biologically plausible, and sleep optimization carries no downside.What to do: Target 7 to 9 hours. Consistent bedtime. Cool, dark room. No screens an hour before bed. If you snore or experience daytime fatigue, get a sleep study — this is especially important for APOE4 carriers. 4. Know Your Numbers Research shows that vascular risk factors — high blood pressure, high cholesterol, insulin resistance — are preferentially associated with brain pathology in APOE4 carriers [Kaufman et al., 2021]. The same blood pressure reading that might be "acceptable" for someone without APOE4 could be causing more damage in your brain. The 2024 Lancet Commission identified 14 modifiable risk factors for dementia and concluded that up to 45% of all dementia cases could potentially be prevented or delayed [Livingston et al., 2024]. Forty-five percent. That's not me being optimistic. That's one of the most conservative medical bodies in the world. What to do: Get a comprehensive blood panel. Know your blood pressure, fasting glucose, ApoB, and HbA1c. These numbers give you a baseline — and a target. ACTION STEP: Upload your labs to Phoenix Bloodwork to track your biomarkers over time and see how your interventions are actually moving the needle.What NOT to Do Let me save you some pain by telling you what not to do. I made all of these mistakes. Don't spiral on Google at 3am. You will find terrifying studies, worst-case projections, and forum posts from people who are not scientists. Close the laptop. Bookmark this article instead. Don't buy thirty supplements tomorrow. The temptation is real — you want to do something right now. But most supplements have weak evidence for APOE4 specifically, and stacking them without a plan can do more harm than good. Start with the four lifestyle foundations first. Supplements are layer two. Don't isolate. This is the biggest one. Do not carry this alone. The REVEAL study — the largest study on APOE4 disclosure — found that learning your status does NOT cause lasting psychological harm when you have support. No significant increase in anxiety (P=0.84). No significant increase in depression (P=0.98) [Green et al., 2009]. But that last part — when you have support — matters. You're Not Alone: 500+ Carriers Building Their Future When I got my results, I looked for other people like me — people who carried APOE4 and were actually doing something about it. I couldn't find them. My doctor said "come back when you're symptomatic." Support groups were full of fear. I was alone with a spreadsheet of interventions and no idea what to prioritize. That's why I built The Phoenix Community. Phoenix is a community of over 340 APOE4 carriers who are actively optimizing their health. We track biomarkers together. We run experiments. We share what's working. We have accountability pods — small groups matched by health stage and goals — so nobody does this alone. A 2024 study found that social engagement and mindfulness have stronger effects on cognitive reserve specifically for APOE4 carriers compared to non-carriers [O'Shea et al., 2024]. Community isn't just nice to have — the research suggests it may be neuroprotective. And because we have hundreds of APOE4 carriers tracking their health data in one place, pharma companies now come to us for clinical trials. Our members get early access to therapies that are years from market. That's collective power. ACTION STEP: Join a Phoenix accountability pod to get matched with carriers at your health stage — because the research shows you shouldn't do this alone, and you don't have to. Explore clinical trial access through Phoenix to see what's available.Key TakeawaysYour Quick-Start Protocol (This Week):Move: 150 minutes of Zone 2 cardio per week + 2-3 strength sessions. Start with three 30-minute walks. Eat: One Mediterranean meal per day. More olive oil, fish, vegetables, nuts. Less processed food. Sleep: 7-9 hours, consistent bedtime, dark and cool room. Get a sleep study if you snore. Test: Get a comprehensive blood panel. Know your blood pressure, fasting glucose, ApoB, HbA1c. Connect: Don't carry this alone. Find your people — whether that's Phoenix or another community of carriers taking action. Remember: APOE4 is a risk factor, not a sentence. The majority of heterozygous carriers never develop Alzheimer's dementia. And the growing evidence suggests that your genes may respond to healthy changes as much or more than most people's. You didn't choose this gene. But you get to choose what you do with the information. And that starts today. Free Resource: Download The Essential Guide to Thriving with APOE4 — the complete reference covering research, protocols, and biomarkers to track. Written by someone who carries two copies and isn't waiting around. [Download the free guide here]Sources Genin E, Hannequin D, Wallon D, et al. (2011). APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Molecular Psychiatry. DOI: 10.1038/mp.2011.52 | PMID: 21556001 Fortea J, Pegueroles J, Alcolea D, et al. (2024). APOE4 homozygosity represents a distinct genetic form of Alzheimer's disease. Nature Medicine. DOI: 10.1038/s41591-024-02931-w | PMID: 38710950 Belloy ME, Napolioni V, Greicius MD (2019). A Quarter Century of APOE and Alzheimer's Disease: Progress to Date and the Path Forward. Neuron. DOI: 10.1016/j.neuron.2019.01.056 | PMID: 30844401 Ngandu T, Lehtisalo J, Solomon A, et al. (2015). A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER). The Lancet. DOI: 10.1016/S0140-6736(15)60461-5 | PMID: 25771249 Solomon A, Turunen H, Ngandu T, et al. (2018). Effect of the Apolipoprotein E Genotype on Cognitive Change During a Multidomain Lifestyle Intervention. JAMA Neurology. DOI: 10.1001/jamaneurol.2017.4365 | PMID: 29356827 Lehtisalo J, Solomon A, Cantet C, et al. (2025). Effect of the ApoE genotype on the efficacy of multidomain lifestyle interventions on cognitive change: a meta-analysis of three randomized clinical trials. Alzheimer's & Dementia. DOI: 10.1002/alz70860_102747 | PMC: 12726239 Green RC, Roberts JS, Cupples LA, et al. (2009). Disclosure of APOE genotype for risk of Alzheimer's disease. New England Journal of Medicine. DOI: 10.1056/NEJMoa0809578 | PMID: 19605829 Cancela-Carral JM, Lopez-Rodriguez A, Mollinedo-Cardalda I (2021). Effect of physical exercise on cognitive function in older adults' carriers versus noncarriers of apolipoprotein E4. Journal of Exercise Rehabilitation. DOI: 10.12965/jer.2142130.065 | PMID: 34012932 Liu Y, Gu X, Li Y, et al. (2025). Interplay of genetic predisposition, plasma metabolome and Mediterranean diet in dementia risk and cognitive function. Nature Medicine. DOI: 10.1038/s41591-025-03891-5 | PMID: 40855194 Sadleir KR, Vassar R (2023). Connections between ApoE, sleep, and Abeta and tau pathologies in Alzheimer's disease. The Journal of Clinical Investigation. DOI: 10.1172/JCI171838 | PMID: 37463448 Shokri-Kojori E, Wang GJ, Wiers CE, et al. (2018). Beta-Amyloid accumulation in the human brain after one night of sleep deprivation. Proceedings of the National Academy of Sciences. DOI: 10.1073/pnas.1721694115 | PMID: 29632177 Livingston G, Huntley J, Liu KY, et al. (2024). Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. The Lancet. DOI: 10.1016/S0140-6736(24)01296-0 | PMID: 39096926 Spencer FSE, Elsworthy RJ, Breen L, et al. (2025). The effect of the APOE4 genotype on physiological and cognitive health in randomised controlled trials with an exercise intervention. Trials. DOI: 10.1186/s13063-024-08696-4 | PMID: 39828710 Kaufman CS, Morris JK, Vidoni ED, et al. (2021). Apolipoprotein E4 Moderates the Association Between Vascular Risk Factors and Brain Pathology. Alzheimer Disease and Associated Disorders. DOI: 10.1097/WAD.0000000000000442 | PMID: 33734100 O'Shea DM, Zhang AS, Rader K, et al. (2024). APOE epsilon4 carrier status moderates the effect of lifestyle factors on cognitive reserve. Alzheimer's & Dementia. DOI: 10.1002/alz.14304 | PMID: 39392181 --- ## New study: 55% lower dementia risk for APOE4 carriers who eat more meat? URL: https://apoe4.co/blog/posts/new-study-55-lower-dementia-risk-for-apoe4-carriers-who-eat-more-meat Published: 2026-04-17T18:17:00+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: research, nutrition, cognition Summary: APOE4 carriers face 55% lower dementia risk eating more meat? The JAMA study is real—but headlines missed the nuance. Here's what the research actually shows. New study: 55% lower dementia risk for APOE4 carriers who eat more meat?The JAMA 2026 study is real — but the headlines are wrong. Here's what 2,157 people over 15 years actually showed.Dr. Kevin Tran April 17, 2026 "Meat ERASED the Alzheimer's gene." "This one food reverses APOE4 risk." If you've been anywhere near the Alzheimer's or APOE4 space this week, you've seen the headlines… and most of them are wrong. Introduction I'm Dr. Kevin Tran, PharmD and APOE4/4 carrier. When a major APOE4 meat study drops in JAMA Network Open and generates millions of views in clickbait shorts, I take it personally. This research is about my future. Your future, if you carry the variant too. So I analyzed the actual paper. Every table. Every limitation. Every nuance the clickbait left out. Here's what I found: the study is real, from a world-class institution, and the APOE4-specific finding is genuinely novel. But it does not say what most people think it says. It does not give you permission to eat whatever you want. And it absolutely does not "erase" your genetic risk. What it does offer — if you read it carefully — is something far more valuable than a headline: a specific, actionable signal about how APOE4 carriers may have unique nutritional needs. And a critical warning about the one type of meat that increases dementia risk for everyone. Let me walk you through what this APOE4 diet research actually found, what it cannot prove, and what I'm personally doing with this information as someone who lives with this genotype every day. What the JAMA 2026 APOE4 Meat Study Actually Found The paper is titled "Meat Consumption and Cognitive Health by APOE Genotype," published in JAMA Network Open in March 2026 by Norgren and colleagues at the Karolinska Institutet in Stockholm [Norgren et al., 2026]. It draws on data from the Swedish National Study on Aging and Care (SNAC-K) — a well-established cohort that has produced decades of high-quality aging research. First, the basics. This is an observational cohort study, not a randomized controlled trial. The researchers followed 2,157 Swedish adults with an average age of 71 for 15 years, tracked their dietary intake, and analyzed who developed dementia and how their cognitive scores changed over time. Here are the headline numbers. Among APOE4 carriers (APOE3/4 or APOE4/4, roughly 26% of the study population), those in the top quintile of total meat consumption showed: 55% lower dementia risk compared to the lowest quintile — a subdistribution hazard ratio of 0.45 [Norgren et al., 2026] Improved cognitive trajectories over time, with an effect size of beta = 0.32 standard deviations per decade [Norgren et al., 2026] Those are striking numbers. A hazard ratio of 0.45 means that, statistically, the high-meat APOE4 carriers developed dementia at less than half the rate of low-meat APOE4 carriers. But here is the finding that changes the entire interpretation. For people without APOE4, there was no association. The cognitive trajectory beta was -0.11 (not significant). The dementia hazard ratio was 0.95 — essentially flat [Norgren et al., 2026]. This is not a story about meat being universally good for brain health. This is a story about a gene-diet interaction — a finding that appears specific to APOE4 carriers. The study suggests that APOE4 carriers in the highest quintile of meat consumption performed cognitively on par with non-carriers, as if the dietary pattern attenuated the genetic disadvantage. That distinction matters enormously. It's the difference between a universal dietary recommendation and a genotype-specific signal. And it is exactly the kind of nuance that disappears in a 30-second short. KEY INSIGHT: The JAMA 2026 study found a gene-diet interaction specific to APOE4 carriers. High meat consumption was associated with 55% lower dementia risk in carriers — but had zero effect for non-carriers.The Finding Nobody's Talking About: Processed vs. Unprocessed Meat If one finding from this study should have been the headline, it's this one. But it doesn't make for as good a thumbnail. When the researchers examined the ratio of processed meat to total meat consumption, the results flipped. A higher proportion of processed meat was associated with a 14% increase in dementia risk — hazard ratio 1.14, statistically significant — and this held regardless of APOE genotype [Norgren et al., 2026]. No interaction with APOE status. No protective association. Just harm. Let me be direct about what this means. If you're an APOE4 carrier and your primary protein sources are hot dogs, bacon, deli meats, and sausages, this study does not give you a free pass. It suggests the opposite: processed meat is associated with increased dementia risk whether you carry APOE4 or not. The protective association for APOE4 carriers came from total meat consumption — and when the researchers disaggregated by meat type, there was no substantial difference between unprocessed red meat and poultry [Norgren et al., 2026]. Chicken breast, steak, pork loin, lamb — these all fell into the same category. So the actual takeaway is layered: Unprocessed meat and poultry: Associated with better cognitive outcomes in APOE4 carriers specifically Processed meat: Associated with worse cognitive outcomes for everyone, regardless of genotype That is a far more nuanced message than "eat more meat." And for APOE4 carriers especially, the distinction between what's on your plate could be the difference between a signal of protection and a source of additional risk. ACTION STEP: Audit your protein sources this week. Replace processed meats (deli slices, bacon, sausage, hot dogs) with unprocessed options (chicken, fish, lean beef, pork loin). Log the change in Phoenix Experiments to track how it affects your energy and biomarkers over time. The mechanism here likely involves nitrates, nitrites, advanced glycation end products (AGEs), and high sodium content found in processed meats — all of which promote inflammation and vascular damage. For APOE4 carriers, who already face elevated vascular risk, stacking processed meat on top of genetic vulnerability is a compounding problem. Why This Doesn't Prove Meat "Erases" Alzheimer's Risk I need to be honest with you here, even if it's less exciting than the viral takes. This is an observational study. That distinction is not a technicality — it fundamentally limits what we can conclude. Confounding variables. People who eat more meat in Sweden may also have higher income, better access to healthcare, different exercise habits, and richer social lives. The researchers adjusted for many of these, but you can never fully eliminate confounding in observational data. The people who ate more meat might have been healthier in dozens of ways the study couldn't measure. Reverse causation. This is the one that keeps epidemiologists up at night. People in the early stages of cognitive decline often eat less. Their appetite drops. They stop cooking complex meals. They lose weight. So what looks like "more meat = better cognition" could partly reflect "better cognition = ability to maintain a normal diet." In a 15-year study of adults averaging age 71, this is a very real concern. Population specificity. These were 2,157 Swedish adults over age 60. Swedish food quality, dietary patterns, healthcare infrastructure, and socioeconomic conditions are specific. Meat in Sweden may differ substantially in quality, processing, and preparation from meat in other countries. Replication in other populations is essential. Self-reported dietary data. Participants reported what they ate. People are notoriously bad at accurately recalling their diet. This introduces measurement error that can distort associations in both directions. CAVEAT: Observational studies generate hypotheses. They do not prove causation. This study is a signal worth investigating, not a prescription to follow. We need randomized controlled trials targeting APOE4 carriers specifically to move from association to recommendation. As someone who wants this to be true — I'm APOE4/4, I eat meat, I would love a simple answer — I have to be the first person to tell you: simple answers in Alzheimer's research are almost always wrong. This study deserves attention. It does not deserve certainty. What APOE4 Carriers Should Actually Take From This So the headlines are overblown but the study is legitimate. What do you actually do with this information? Here's what I'm taking from it as an APOE4/4 carrier who has to make real decisions about APOE4 nutrition every day. 1. Don't cut meat based on generic dietary advice. I've seen people in our community go aggressively plant-based and struggle with B12, iron, creatine, and other nutrients that this study suggests might be specifically important for APOE4 brains. If you're an APOE4 carrier restricting all animal protein, this research should give you pause. The data — however preliminary — suggests unprocessed meat has a place in an APOE4-optimized diet. 2. Eliminate processed meat. Today. This is the easiest, most immediate action item from this study. The 14% increased dementia risk from processed meat is genotype-independent [Norgren et al., 2026]. If you're eating deli sandwiches, bacon with breakfast, or hot dogs at barbecues as routine protein sources, this is a lever you can pull right now. Swap to fresh-cooked chicken, fish, or lean beef. 3. Manage your lipids aggressively — meat and cardiovascular risk are not mutually exclusive. This study says nothing about cholesterol, ApoB, or cardiovascular outcomes. You can eat unprocessed meat AND manage your lipid panel. For APOE4 carriers, ApoB management is non-negotiable. Choose lean cuts, get your ApoB tested regularly, and make data-driven decisions rather than ideological ones. Track your lipid trends in Phoenix Bloodwork so you can see exactly how dietary changes affect your numbers over time. 4. Place this study inside the bigger evidence picture. This research doesn't exist in isolation. A 2025 study of nearly 19,000 older adults found that combining high physical activity, cognitive activity, and a healthy diet produced a 54% reduction in cognitive impairment risk for APOE4 carriers — hazard ratio 0.46 [Zhong et al., 2025]. The SUPERBRAIN-MEET randomized controlled trial showed that multidomain lifestyle intervention significantly improved cognition in people with mild cognitive impairment, with the effect holding for APOE4 carriers [Moon et al., 2025]. And a study of over 6,000 Chinese adults aged 80 and older found that healthy lifestyle was associated with 55% lower odds of cognitive impairment regardless of APOE genotype [Jin et al., 2021]. The consistent signal across all of this research is clear: lifestyle intervention works for APOE4 carriers. In some studies, it works even better for carriers than non-carriers. Diet is one lever. Exercise, sleep, cognitive engagement, lipid management, and metabolic health are others. The meat study adds a piece to the puzzle — it does not replace the puzzle. 5. Consider what's being studied right now. There's a Phase 2 clinical trial currently recruiting at Rutgers (NCT07392723) that's testing alpha-linolenic acid (ALA) supplementation specifically in APOE4 carriers with mild cognitive impairment. The rationale is that APOE4 carriers have impaired blood-brain barrier function and low brain DHA levels — and ALA may help bypass that limitation. The fact that researchers are designing genotype-specific nutritional interventions tells you where the field is heading: personalized nutrition based on your genetics. KEY INSIGHT: The meat study is one piece of a larger pattern showing that APOE4 carriers respond to lifestyle interventions — sometimes even more strongly than non-carriers. The goal is not one perfect food. It's a comprehensive protocol: diet, exercise, sleep, lipid management, metabolic health.Key TakeawaysQuick-Start Protocol (This Week):Audit your meat sources. Replace any processed meats (deli, bacon, sausage, hot dogs) with unprocessed alternatives (chicken, fish, lean beef, pork loin). The processed meat risk applies to everyone, APOE4 or not. Don't cut protein based on generic advice. If you're an APOE4 carrier who went low-protein or fully plant-based, revisit that decision in light of this gene-diet interaction data. Ensure adequate B12, iron, and creatine. Get your ApoB tested. Eating more meat while ignoring your lipid panel is not what this study recommends. Know your numbers. Track them consistently. Layer your interventions. Combine dietary optimization with Zone 2 cardio (150+ minutes/week), quality sleep, cognitive engagement, and metabolic health management. The strongest evidence shows combined lifestyle intervention cutting risk by over 50%. Stay skeptical of headlines. This was an observational study in a specific population. It's a signal, not a prescription. Follow the research as it develops — especially the genotype-specific trials that are now underway. Track Your APOE4 Nutrition Protocol in Phoenix This is exactly the kind of study that raises more questions than it answers — and that's where having a system matters. Inside Phoenix, you can log dietary changes in Experiments to track whether swapping to unprocessed meat affects your energy, cognition, and biomarkers. Upload your lipid panels to Bloodwork to monitor ApoB trends as you adjust your diet. And if you want to discuss the nuances of this study with other APOE4 carriers who actually read the paper, our Pods are where that conversation is already happening. Join Phoenix here!Sources Norgren J, et al. "Meat Consumption and Cognitive Health by APOE Genotype." JAMA Network Open. 2026;9(3):e266489. DOI: 10.1001/jamanetworkopen.2026.6489 Jin X, He W, Zhang Y, Gong E, Niu Z, Ji J, Li Y, Zeng Y, Yan LL. "Association of APOE e4 genotype and lifestyle with cognitive function among Chinese adults aged 80 years and older." PLoS Medicine. 2021;18(6):e1003597. DOI: 10.1371/journal.pmed.1003597 Zhong WF, et al. "Combined effects of physical activity, cognitive activity, and dietary patterns on cognitive impairment in older adults with consideration of APOE genotype." Alzheimer's Research & Therapy. 2025;17(1):158. DOI: 10.1186/s13195-025-01806-7 Moon SY, et al. "South Korean SUPERBRAIN-MEET: A randomized controlled trial." Alzheimer's & Dementia. 2025;21(2):e14517. DOI: 10.1002/alz.14517 Sun Y, Wang Z, Sun S, Cui L, Zhu X, Ho SY, Qi S. "Cognitive Activities, Lifestyle Factors, and Risk of Cognitive Impairment, with an Analysis of the Apolipoprotein Epsilon 4 Genotype." Gerontology. 2023;69(9):1137-1146. DOI: 10.1159/000531109ClinicalTrials.gov. "Alpha Linolenic Acid-enriched Nutrition for Prevention of Cognitive Decline in APOE4 Older Adults With Mild Cognitive Impairment." NCT07392723. https://clinicaltrials.gov/study/NCT07392723 --- ## 127 Updates in 100 Days: Here's What We Built for Your Brain Health URL: https://apoe4.co/blog/posts/127-updates-in-100-days-here-s-what-we-built-for-your-brain-health Published: 2026-04-15T18:45:00+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: community, tracking, protocols Summary: Phoenix Q1 Update: 127 updates in 100 days. Discover 6 major brain health features built for APOE4 carriers. Track your protocol daily. 127 Updates in 100 Days: Here's What We Built for Your Brain HealthYour Phoenix Q1 update is here!Dr. Kevin Tran April 15, 2026 Hi Phoenix friend, 127 updates.6 major features.In 100 days. That's what our team (of 2!) shipped since January 1st, 2026. Why this insane pace? Because we don’t have time to wait.Every week without the right data (and the right protocol) is a week you can't get back. Here's everything that's new. And here's why it matters for you. The Numbers Behind the Movement Before we dive into features, let's talk about what's actually happening inside Phoenix: 500+ active APOE4 members tracking their health daily 94% retention rate (members join and stay because it works) 89% monthly active users (members are taking actions) 60% month-over-month growth since launch Available on iOS, Android, and web — track your health anywhere This proves we are answering a very strong need from APOE4 carriers around the world. We all need what we're building. And in Q1 2026, we built a lot :) 1. Phoenix AI-Powered Health Intelligence — The Feature That Changes Everything Here's the question that keeps every APOE4 carrier up at night: Are the supplements and interventions I'm taking actually doing anything? Now you can know. Phoenix connects three data streams that have never been connected before: your daily interventions (supplements, habits, protocols), your blood biomarkers, and your wearable data (sleep, HRV, activity). Our AI analyzes the intersections — and tells you, with increasing certainty, what's actually moving the needle. Real discoveries Phoenix members have already made: "Taking creatine is wrecking my sleep." One member noticed their deep sleep dropped consistently on creatine days. They adjusted timing. Sleep recovered. "Morning sunlight improves my deep sleep by 10%." Not a blog post. Not a podcast. Their own data, from their own wearable, correlated with their own check-ins. "Ezetimibe reduced my ApoB by 25%." Phoenix AI validated that it worked for our APOE4 members. How it works: When Phoenix starts detecting a pattern — say, your HRV increases by 10 points on days you use the sauna — it surfaces that as an insight with a certainty level. Early on, the certainty is low. But the more you use the sauna and the more you track your recovery, the stronger the signal gets. The AI learns from your data over time, not from a generic database. Then it gives you missions. Phoenix doesn't just show you a chart and leave you guessing. When a promising pattern emerges, you receive a mission inside the app: "Use the sauna 3 times this week and log your HRV each morning." Complete the mission, and the certainty level rises. Skip it, and the insight stays unvalidated. Think about it. You're probably going to take supplements and follow protocols for the rest of your life. Fish oil. Creatine. Sauna. Exercise. Sleep protocols. That's decades of daily habits. Don't you want to know — with real data, from your own body — whether they're actually working? That's what Phoenix gives you. Not a guess. Not a blog post someone wrote about a study you might not even qualify for. Your data. Your body. Your answer. 2. Clinical Trial Discovery — Find the Trials That Match You Phoenix now has a live clinical trial directory, synced daily from ClinicalTrials.gov and filtered specifically for APOE4 carriers. You can browse trials by phase, status, location, and scope — whether they're explicitly for APOE4 carriers or broader Alzheimer's prevention studies. Each trial card shows eligibility criteria, enrollment status, how many Phoenix members have expressed interest, and whether it matches your profile based on your age, sex, and genotype. What you get:Smart matching — Phoenix highlights which trials fit your specific profile Daily updates — New trials added automatically as they publish on ClinicalTrials.govExpress interest — One tap to flag a trial you want to follow. We track interest across the community so pharma partners see real demand (and we can reach out to them to facilitate enrolment) Research studies — Active device studies (red light therapy, vagus nerve stimulation, neurofeedback) with Phoenix member pricing Most APOE4 carriers don't even know which clinical trials they'd qualify for. Phoenix changes that. Your next breakthrough treatment might already be recruiting. 3. Reimagined Daily Check-Ins Your daily check-in used to take ten taps. Now it still takes ten taps and gives you ten times more insight. The check-in system was rebuilt from the ground up. Morning and evening splits capture how your day actually unfolds. A new tagging system remembers your supplements, activities, and symptoms — so logging gets faster every day, not slower. The big upgrade? Every check-in now feeds directly into the Phoenix AI insight engine. Your choices today become the data that validates your protocol tomorrow. What changed: Split morning/evening check-ins with a biomarker effects table Database-backed tagging that auto-suggests your routine Supplement timing and adherence tracking with visual clarity Tag-based insights that surface patterns you'd never notice manually Five minutes a day. A lifetime of data working for you. 4. Phoenix Pro: Stop Wasting 75% of Every Healthcare Provider Visit Finding a healthcare provider who actually understands APOE4 is hard. Really hard. Most doctors have never heard of it. The few longevity specialists who do understand it charge $50,000 to $250,000 per year for ongoing access. And even then, they rarely have other APOE4 patients to compare your data against. Based on what members kept asking me — "Where do I find a doctor who gets this?" — I decided to build our own expert network. Every provider in the Phoenix Pro network is an APOE4 carrier themselves. All specialized. All members of the Phoenix community. Many drawn from the 30%+ of our members who are healthcare professionals. They don't just study this. They live it. Here's a scenario you know too well. You walk into your longevity doctor's office. They say: "So, tell me what you've been doing since last time?" Then you spend 30-45 minutes listing supplements, re-explaining your labs, trying to remember which interventions you started and when. By the time you get to the real questions, you have 15 minutes left. Phoenix Pro fixes this entirely. When you book a session with a Phoenix Pro expert — longevity doctors, functional medicine practitioners, health coaches, or geneticists (all APOE4 carriers themselves) — our AI compiles a complete brief before your session starts. Your expert walks in already knowing everything. No catch-up. No wasted time. Every minute is clinical guidance. I want to expand this to the maximum number of healthcare providers possible. If you'd like to onboard your own doctor, neurologist, or coach onto the platform — reach out. And if you are a healthcare provider yourself and want to help the community, reply to this email.What's included in Pro:1:1 onboarding with Dr. Kevin Tran — Phoenix founder and APOE 4/4 carrier. I review your data before we speak. Your first conversation isn't "tell me about yourself." It's "here's what I see, and here's where I'd start." Monthly 1:1 sessions with a longevity specialist of your choice — Functional doctors, geneticists, coaches... all APOE4 carriers themselves. AI health brief before every session — Your complete health picture compiled automatically: bloodwork history with APOE4 ranges, every supplement (dosage, brand, adherence), check-in trends, cognitive scores, AI-flagged concerns, and a delta report of what changed since your last visit. Credits for small-group expert workshops — Expert-led sessions on sleep, metabolic health, supplement stacks, and cognitive protocols. Clinical trial priority — First-in-line access to Phoenix partner studies, plus direct input into which trials we pursue next. A seat at the Phoenix table — Direct input into our roadmap, partnerships, and research direction. The people whose data is on the line get the first say. Everything in Core — Blood test analysis, AI insights, matched pods, health timeline, community, and accelerated therapy access. What this replaces: A private longevity doctor charges $50,000-$200,000/year for similar 1:1 access, personalized protocols, and ongoing monitoring. Phoenix Pro delivers this for a fraction of the cost — backed by APOE4-specific data no individual practice can match. Learn more about Phoenix Pro → Already a Phoenix member on Core or Starter? I'm slowly opening Pro to existing members. If you'd like to upgrade, just reply directly to this email and I'll get you set up. 5. Brain Games and Cognitive Tracking How fast is your brain today? Phoenix's cognitive training suite now includes refined reaction time tests, SDMT (Symbol Digit Modalities Test), and Stroop challenges — the same assessments used in clinical Alzheimer's research. Track your processing speed, pattern recognition, and executive function over time. Why does this matter? Because cognitive decline is gradual. You won't feel it happening. But your scores will show the trend — and show whether your interventions are protecting you. 6. Advanced Biomarker Dashboard Your bloodwork tells a story. We made it easier to read. The biomarker module now supports international units — so whether your lab reports in K/uL, cells/uL, or mmol/L, Phoenix handles the conversion automatically. No more manual math. No more guessing if your numbers are in the right range. And those ranges? They're APOE4-specific now. Standard lab reference ranges don't account for your genetics. Ours do. Dynamic status calculations show you where you stand relative to other APOE4 carriers, not the general population. What's new: Redesigned range bars with color-coded APOE4-specific thresholds International unit support with automatic conversions Qualitative biomarker handling for complex test results Dynamic status calculations that reflect your genetic context Your lab results aren't generic. Your dashboard shouldn't be either. We're not slowing down. Q2 2026 priorities include: What's Coming NextDigital twin modeling — predictive health scenarios based on your data Expanded clinical trial matching with major pharmaceutical partners Experiment module upgrades — run structured n=1 health experiments with statistical rigor Deeper wearable partnerships — more devices, richer data, smarter insights And that's just the surface. This Is What Moving Fast Looks Like: because we don’t have time to waste. 127 updates in 90 days. Every one of them built for one reason: to give APOE4 carriers the tools, data, and community they need to change their trajectory. You've thought about your APOE4 status. Maybe you've worried about it. Maybe you've researched interventions at 2 AM and felt overwhelmed by contradictory advice. Phoenix exists so you don't have to figure this out alone. 500+ carriers are already tracking, optimizing, and supporting each other inside Phoenix. The app is live on iOS, Android, and web. The features are honestly, life changing. The community is growing every week. The only question is whether you'll join us. Join Phoenix Today → Start with a free health assessment. See your personalized risk profile. Explore the platform. If it's not for you, no hard feelings. But if you're an APOE4 carrier who wants to stop wondering and start knowing — this is the place. 60-day money-back guarantee. No long-term commitment required. I’ll see you inside! -Kevin P.S. — Every feature above was built by our team that carries the APOE4 gene ourself. This isn't a corporate health product. It's a mission built by the people who need it most. --- ## We Found Your Brain Health Missing Link URL: https://apoe4.co/blog/posts/we-found-your-brain-health-missing-link Published: 2026-04-09T18:06:00+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: community, tracking, cognition Summary: Discover your true brain age with NeuroAge—Phoenix's new partner offering RNA analysis and brain MRI to measure neurological aging. Get 20% off. We Found Your Brain Health Missing LinkPhoenix is partnering with NeuroAge!Dr. Kevin Tran April 09, 2026 Hi Phoenix friend, You've been tracking your supplements. Logging your check-ins. Watching your biomarkers trend. But there's always been a question in the back of your mind: Is any of this actually moving the needle on brain aging? Today we're answering that question. --- Introducing NeuroAge Phoenix is partnering with NeuroAge — a company built by Dr. Christin Glorioso, MIT-trained physician-neuroscientist and APOE4 carrier herself. Psst: we have negotiated a special discount code for our members: use the code PHOENIX during checkout at NeuroAge for -20%! NeuroAge gives you a single number: how many years younger (or older) your brain is compared to your chronological age. It combines four assessments: - RNA blood panel (52 biomarkers) — captures what's actually happening in your neurons, from your blood - Brain MRI with 3D mapping — tracks hippocampal volume, white matter health, and brain shrinkage rates over time - Cognitive gaming — reaction time, memory, processing speed versus people your same age - Genetic panel (300+ genes) — because APOE4 is only ~30% of your genetic Alzheimer's risk The result: a NeuroAge score that tells you exactly where your brain stands — and whether what you're doing is working. --- Why This Matters for APOE4 Carriers Dr. Glorioso's research (20 years, MIT) found something important: APOE4 carriers who were biologically 5 years younger in brain age had Alzheimer's risk below the general population average — completely canceling out the genetic disadvantage. The opposite is also true. Carriers who skew older are at significantly elevated risk. Brain aging is separate from your genetics. That means it's changeable. And now it's measurable. --- How Phoenix + NeuroAge Work Together Think of it this way: > NeuroAge tells you where your brain is. Phoenix shows you what to do about it. Your NeuroAge score flows into the Phoenix Health Hub as a baseline. From there, you can: - Track which supplements, habits, and interventions correlate with your brain age score - See how your wearables and daily check-ins connect to cognitive outcomes - Measure progress between NeuroAge retests - Join pods with members optimizing for the same goals - Get matched to clinical trials relevant to your profile This is measurement + action + community. In one place. — Join NeuroAge with the code PHOENIX (to add during checkout) and get a 20% discount on your NeuroAge plan. A Note on Integration We're actively building a deep integration between NeuroAge and the Phoenix platform: so your brain age flows seamlessly into your Health Hub alongside your bloodwork, wearables, and check-ins. --- NeuroAge provides health information, not medical diagnosis. Discuss results with your healthcare provider.Most Newsletters? One-way street.How boring…This is the Phoenix Community. So let's make it a two-way street. Got a question? Feedback? Hit reply. I read every single one. --- ## APOE4: Your Brain Is Insulin Resistant (Even If Your Labs Are Normal) URL: https://apoe4.co/blog/posts/apoe4-your-brain-is-insulin-resistant-even-if-your-labs-are-normal Published: 2026-04-05T18:42:00+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: research, nutrition, tracking, cognition Summary: APOE4 carriers can have normal glucose labs yet still experience brain insulin resistance. Learn why your labs look great but your brain disagrees—and how to protect it. APOE4: Your Brain Is Insulin Resistant (Even If Your Labs Are Normal)Good glucose numbers don't mean your brain is getting enough fuel.Dr. Kevin Tran April 05, 2026 Hi Phoenix friend, Your labs look great. Your brain might disagree. Here's something that changed how I think about my own health as an APOE4/4 carrier: you can be metabolically insulin sensitive (good HOMA-IR, normal glucose, decent A1C) and still have insulin resistance in your brain. That's the core message from my second deep-dive with Dr. Grant Fraser, a board-certified anti-aging physician who's also an APOE4 carrier. We spent over an hour on insulin sensitivity, and honestly, this one hit different. Your brain has its own insulin problem. Here's the short version. Your brain has different glucose transporters in different regions. Most of them (GLUT1, GLUT3) let glucose in without needing insulin. But certain critical areas (like your hippocampus, the memory center that shrinks first in Alzheimer's) use GLUT4 receptors. Those are insulin-dependent. The problem? The APOE4 protein physically competes with insulin for binding to these receptors. So even when you have insulin floating around, it can't do its job in those specific brain regions. Dr. Fraser estimates APOE4 carriers may see 20-25% less glucose metabolism in these areas. That's why he says something I think every APOE4 carrier needs to hear: "If you're homozygous, you should presume you have insulin resistance in your brain." No fancy PET scan needed. Just assume it, and act accordingly. The peripheral stuff still matters (a lot). Even though brain insulin resistance is partly independent from what your blood tests show, fixing your peripheral numbers still helps. Dr. Fraser shared his own wake-up call: years ago, his A1C was 5.4, glucose was 80. Totally normal. But his fasting insulin? 80. That's wildly high. If he had only tracked glucose, he would have missed it entirely. And that's exactly what most doctors do. The takeaway: get fasting insulin tested. It costs $8-9. Your doctor probably won't order it unless you ask. Target a HOMA-IR below 1 (not just "below 2"). And if your A1C is creeping above 5.3 even though you're lean and active, consider a glucose tolerance test with serial insulin draws. That's how you catch the "lazy pancreas" pattern Dr. Fraser sees in so many patients over 60. Simple stuff that actually works. Before we got into medications, Dr. Fraser laid out the dietary basics that matter: Eat fats and protein before carbs at every meal. This alone flattens your glucose curve. Go for a walk after eating. Even 10-15 minutes makes a real difference. Cut snacking. Every time you eat, you create a glucose event. Fewer events, better metabolic health. Consider time-restricted eating (8-12 hour eating windows). And if you're exploring keto, make it Mediterranean keto. Olive oil, nuts, avocado. Not bacon and butter. The goal is ketones without wrecking your lipids. I'll add my own: do 20 air squats before a meal. I discovered this wearing a CGM, and the effect on my glucose spike was dramatic. It pulls glucose into your muscles before you even start eating. And if lifestyle isn't enough? Dr. Fraser's first-line pharmacotherapy recommendation surprised me. It's not metformin. It's not a GLP-1. It's SGLT2 inhibitors (like dapagliflozin). These medications cause your body to dump excess glucose into your urine. They're associated with lower rates of dementia, they protect your heart, they protect your kidneys, they reduce fatty liver, and they make it easier to stay in mild ketosis because you're just... removing glucose continuously. The catch is insurance won't cover them unless you have type 2 diabetes. But you can get 100 days of dapagliflozin from a Canadian pharmacy for about $40. (Dr. Fraser's source: Canadian Prescription Drugstore.) My one ask for you this week. Dr. Fraser's closing advice was simple. Focus on eating order. Walk after meals. Cut the snacking. Have deliberate periods of not eating. You don't need to overhaul everything. Just start there. And if you haven't gotten a fasting insulin test, add it to your next blood draw. It's cheap. It's easy. And it might tell you something your glucose never will. Watch the full conversation here: Stay proactive, Kevin — Most Newsletters? One-way street.How boring…This is the Phoenix Community. So let's make it a two-way street. Got a question? Feedback? Hit reply. I read every single one. --- ## APOE4/4 and in the Best Shape of Her Life at 55. Here's What Changed. URL: https://apoe4.co/blog/posts/apoe4-4-and-in-the-best-shape-of-her-life-at-55-here-s-what-changed Published: 2026-03-29T18:22:00+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: community, protocols, exercise, nutrition Summary: APOE4/4 carrier transforms her health at 55 after discovering her genetic risk. Learn the pivotal moment and protocol that changed everything for Deb. APOE4/4 and in the Best Shape of Her Life at 55. Here's What Changed.The discovery story, the family pushback, and the moment everything changed.Dr. Kevin Tran March 29, 2026 Hi Phoenix friend, She was in Hawaii. It was her anniversary. She was in the shower. That's when Deb read her 23andMe results. APOE4/4. Two copies. She read it 20 times. Then she dropped to the shower floor and started crying. Her mom had been living with vascular dementia since she was 62. Deb watched it happen for 16 years. But somehow, she never thought it would be her. She was an optimist. She figured she'd be fine. Then she wasn't fine. She was terrified. But here's the thing about Deb. She got out of that shower, sat on the bed, opened her laptop, and started searching. Right there. Anniversary dinner be damned. That was 2021. Five years ago.Vote for future episodes topics and ask your own questions directly in the Phoenix Community.Not a member yet? Join us here: https://apoe4.link/Deb Today? She's 55, lifting heavier than most men at her gym, has built muscle while losing fat (post-menopause, which is supposed to be "impossible"), and has completely rewired her relationship with food, sleep, and stress. But the road from that shower floor to here? Way harder than any protocol. The family piece was brutal. Her husband, her kids, they didn't get it. They thought she was overreacting. Obsessing. When she wanted to eat dinner at 5:15, her kids told her "that's lunch, mom." When she skipped movie night for sleep, she was the party pooper. It took five full years for her family to come around. Five years. Her advice? Don't rip the band-aid off. Hold both things at once. You can want to change your entire life AND still make lasagna when your kids come home from college. The social fabric of your family matters too. The 90/10 rule applies here (maybe more than anywhere). The biggest insight she shared? It's not about the protocol. It's about what's happening in your head that keeps you from following the protocol. For women especially, she sees people-pleasing, conflict avoidance, guilt, and a deep reluctance to take up space. Asking the waiter to cook your salmon differently. Telling your husband you need to go to bed earlier. Spending money on yourself. "You matter," she said. "You're worth this effort." Simple words. But if you've ever quietly eaten the bread because you didn't want to be "that person" at the table, you felt that. Her closing message: self-compassion. Not as a wellness buzzword. As a strategy. She compared the drill-sergeant approach (I HAVE to do all the things, I'm FAILING) to what actually works: looking at the menu of interventions, picking one, breaking it into small steps, and being kind to yourself when you slip. "You have a long life. There's so much living to do. And it shouldn't be from being mean to yourself." I keep thinking about that. Watch the full conversationMost Newsletters? One-way street.How boring…This is the Phoenix Community. So let's make it a two-way street. Got a question? Feedback? Hit reply. I read every single one. --- ## Interactive workshops: The part of APOE4 nobody talks about. URL: https://apoe4.co/blog/posts/interactive-workshops-the-part-of-apoe4-nobody-talks-about Published: 2026-03-24T13:08:00+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: community, protocols Summary: APOE4 carriers face overwhelm and difficult conversations. Learn evidence-based strategies to manage fear, decision fatigue, and how to discuss your status with loved ones. Interactive workshops: The part of APOE4 nobody talks about.How to handle overwhelm, fear, and the conversations you've been putting off.Dr. Kevin Tran March 24, 2026 Hi Phoenix friend, You've read the studies. You've Googled the supplement stacks. You've probably watched a dozen YouTube videos about what to eat, how to exercise, which biomarkers to track. But can I be honest for a second? Nobody talks about the other stuff. The overwhelm of trying to do everything right. The guilt when you don't. The decision fatigue of 50 conflicting protocols. The knot in your stomach when you think about telling your partner, your kids, your parents what APOE4 actually means. That stuff doesn't show up in a research paper. But it shapes everything. Inside The Phoenix Community this month, two things are happening.Workshop 1: How to Talk About Your APOE4 Status with the People You LoveTuesday, March 25 · 6:00 PM PT You know the feeling. You got your results. You processed them. You started making changes. But then comes the hard part. Telling your partner. Your kids. Your parents. Your best friend. Do you scare them? Do you downplay it? Do you just... not say anything? This workshop is led by Joanna Lenn, a Phoenix member and board-certified health and wellness coach who's facilitated workshops for an emotional intelligence program developed with Yale's Center for Emotional Intelligence. She's going to walk us through how to actually have these conversations. Not in theory. In practice. With small group exercises so you can try the words out loud before they matter. Workshop 2: Permission to Be Human — Managing Overwhelm as an APOE4 CarrierSunday, March 30 · 4:00 PM PT Let me introduce you to Deb Blum. She's one of us. APOE4/4. She knows the supplement stacks, the protocols, the ReCODE framework inside and out. But here's what makes her different. She works on the human side of this. The overwhelm. The decision fatigue. The guilt when you slip. The exhaustion of trying to do everything right all the time. (Sound familiar?) These things are part of our experience. And they're almost never addressed. Deb is a certified Brain Longevity™ Specialist and Dementia Prevention Coach who works specifically with APOE4 carriers. She's putting together a 60 to 90 minute session where she'll dig into the different faces of overwhelm. What they are. Why they happen. And how to actually move through them (not just "manage" them). Both workshops are interactive, live, and built by members who are walking this same path.You will participate actively in breakout rooms of 2-5 people each. I think this will bring us closer as a community!I am very curious to try this new format, and if it resonates, we will do more of them.Here's what I want you to notice. These workshops weren't designed by some corporate wellness team. They were built by people inside our community who carry the gene, live with the uncertainty, and decided to turn their expertise into something that helps everyone around them.In fact, more than a third of our members are healthcare professionals. I believe there is so much knowledge in the community that we should definitely find a way to tap into. That's what happens inside Phoenix. People don't just consume content. They contribute. They support each other. They build things together. We have members running structured experiments on their own biology. Tracking biomarkers over time with APOE4-specific ranges (not generic lab ranges). Getting matched into small accountability pods so they're not doing this alone. Connecting with researchers and getting early access to clinical trials. And now, leading workshops on the stuff that actually keeps people stuck. This is what a community looks like when everyone in the room has skin in the game.You still have time to join. These workshops are open to all Phoenix members. If you've been thinking about joining (or if you've been on the fence), this is a good moment. Not because of a discount or a deadline. But because this is the kind of thing you can't get anywhere else. A room full of people who get it. Who aren't going to panic when you say "APOE4." Who are further along than you on some things and need your help on others. 450+ members. 80%+ active every month (that’s 4 times more than your typical health community). This is what it means to beat the odds. Join The Phoenix Community → Whether you join today or just keep reading these emails, I'm glad you're here. The fact that you're paying attention to your brain health puts you ahead of most people. But if you're tired of doing this alone? I saved you a seat. Kevin Most Newsletters? One-way street.How boring…This is the Phoenix Community. So let's make it a two-way street. Got a question? Feedback? Hit reply. I read every single one. --- ## 70% less dementia. The statin data APOE4 carriers need to see URL: https://apoe4.co/blog/posts/70-less-dementia-the-statin-data-apoe4-carriers-need-to-see Published: 2026-03-22T18:36:00+00:00 Updated: 2026-08-04T16:43:32.647599+00:00 Topics: research, tracking, cognition Summary: ApoB targets by genotype: 70 for 3/3, 60 for 3/4, 55 for 4/4. Dr. Grant Fraser's statin protocol for APOE4 carriers, with the rotation strategy. 70% less dementia. The statin data APOE4 carriers need to seeDr. Fraser breaks down ApoB targets by genotype, the statin rotation strategy, and the one test most carriers skip.Dr. Kevin Tran March 22, 2026 Hi Phoenix friend, Your lipid panel was designed for the average person. You're not the average person. If you carry APOE4, your body processes lipids differently. Your brain clears cholesterol less efficiently. You form vascular disease more readily. And the targets your doctor considers "normal" might be leaving you dangerously exposed. Part of our Monthly Q&A with experts in APOE4, we sat down with Dr. Grant Fraser (board-certified in anti-aging and regenerative medicine, 29 years of clinical experience, and an APOE4 carrier himself) for a deep dive into everything lipid-related for our community. This isn't theory. This is what he does with patients every week. Here are the biggest takeaways. Vote for future episodes’ topics and ask your own questions directly to Dr. Fraser and other APOE4 experts in the Phoenix Community.Not a Phoenix member yet? Join us hereForget Your Standard Lipid Panel Dr. Fraser doesn't use the standard lipid panel to make treatment decisions. He orders it for "historical interest" only. What he actually tracks: ApoB (the atherogenic particle count), Lp(a) (genetic and largely fixed), and whether you have actual vascular disease present. The standard LDL number? Not useful enough. There's a 15% discordance between LDL-C and ApoB in the general population. When you can measure the real thing (ApoB, roughly $18 per test), why estimate? His advice: if you can't access ApoB where you are, use non-HDL cholesterol as a proxy. You can even run it through an AI tool to get an estimated ApoB. Not perfect. But better than LDL alone. His Exact ApoB Targets (by Genotype) This is where it gets specific. For someone with zero risk factors (3/3 genotype, Lp(a) negative, no vascular disease), Dr. Fraser likes ApoB in the 70s. Then you start subtracting: APOE 2/4: subtract roughly 5 from the goal.APOE 3/4: subtract 10.APOE 4/4: subtract 15.Lp(a) positive (above 75): subtract another 20.Established vascular disease: subtract another 20. Do the math for a 4/4 carrier with high Lp(a) and some existing disease, and you could be looking at an ApoB target in the teens. That's aggressive. And it's almost certainly going to require medication. The Statin Data That Changes the Debate Dr. Fraser is firmly pro-statin for APOE4 carriers. And the data backs him up. A Mendelian randomization study (which removes the confounding effects of lifestyle by looking at people born with a genetic "statin effect") found that those with the HMG-CoA reductase mutation had only 30% the rate of dementia compared to those without. That's a roughly 70% reduction [1]. A separate study specifically isolating APOE4 carriers on statins found a 40% reduction in dementia diagnosis over approximately five years [2]. The most interesting finding? In that same trial, non-APOE4 carriers on statins saw zero dementia benefit. The intervention was only significant for carriers. Side effects affect about 5% of people. And Dr. Fraser notes that many of those are dose-related. His starting point is often remarkably low: rosuvastatin 5mg, Monday-Wednesday-Friday. One of his patients dropped ApoB from 111 to 70 with just that. Lipophilic vs. Hydrophilic: The Brain Cholesterol Paradox This is where it gets genuinely complicated. Some statins cross the blood-brain barrier (lipophilic: atorvastatin). Others don't (hydrophilic: rosuvastatin). One school of thought (Dr. Niotis, Dr. Dayspring): keep cholesterol high in the brain by using hydrophilic statins that stay out. The brain needs cholesterol. Lowering it there might cause problems. The counter-argument: the Mendelian randomization data involved people whose genetic mutation affected ALL tissues, including the brain. They had the equivalent of a statin running in their brain from birth. And they had 70% less dementia. Dr. Fraser's current approach: rotate monthly. One month atorvastatin. One month rosuvastatin. Hedge the uncertainty. Is this the "right" answer? Maybe not. But it's an honest one. And it reflects how medicine actually works when the data is still evolving. Ezetimibe, Bempedoic Acid, and PCSK9 Inhibitors Dr. Fraser's escalation ladder looks like this: Step 1: Low-dose statin (first line, cheap, effective, well-tolerated).Step 2: Add ezetimibe (blocks cholesterol reabsorption in the gut, well-tolerated, cheap, stacks well with statins).Step 3: Bempedoic acid if needed (good efficacy but expensive in the US, Canadian pharmacy workaround possible).Step 4: PCSK9 inhibitors for cases needing very aggressive targets or statin intolerance (very effective but cost remains a barrier). One interesting nuance on ezetimibe: the Mendelian randomization for the NPC1L1 gene (ezetimibe's target) showed an 80%+ risk reduction in dementia for those born with that mutation. But the mutation affects all tissues (including the brain), while the actual drug ezetimibe doesn't cross the blood-brain barrier. So the human benefit might not match the genetic signal. Mouse models look promising. Human certainty? Not yet. Dr. Fraser's philosophy: "Add ezetimibe. It's cheap, benign, and if it turns out to have even part of that brain benefit, you've won. If not, your lipids are still better." Diet: The Practical Protocol Dr. Fraser's dietary framework for APOE4 carriers: 30 different plants per week (vegetables, nuts, seeds, fruits). Diversity drives gut health. Gut health drives brain health through the gut-brain axis. 30 grams of fiber daily (minimum). The average American gets 8 grams. Fiber binds cholesterol in the gut, preventing reabsorption. It also helps with estrogen metabolism in women. Saturated fat below 5-6% of total calories. APOE4 carriers (especially 4/4s) tend to be hyper-responders to saturated fat. But measure the effect on yourself. Some people aren't. Personalize. Source matters. Saturated fat from coconut oil or olive oil (with its antioxidants) is probably less harmful than from dairy or beef. Pescatarian wins. Dr. Fraser's father runs the Adventist Health Study, which found pescatarians lived 11 years longer than the average Californian. The best outcome for both lifespan and brain health: whole food plant-based diet, add fish, maybe a little fermented dairy. Supplements That Actually Move the Needle Dr. Fraser's take on lipid-relevant supplements: Omega-3s: improve triglycerides, probably help the brain. Small wild-caught fish is the most reliable delivery method (we KNOW it crosses into the brain). Supplements are less certain. Berberine: 10-20% LDL decrease on average. Variable response. Worth trying. Citrus bergamot: 10-15% decrease. Reasonable add-on. Plant sterols: 8-10% LDL decrease. Minor but real. Red yeast rice: AVOID. It's essentially unregulated lovastatin (one of the weakest, least-tolerated statins). Many products are contaminated with citrinin, which is toxic to your kidneys and liver. If you want a statin, get a real one. Niacin: raises HDL. But HDL isn't "good cholesterol" (there's no evidence HDL levels affect outcomes). Skip this for lipid purposes. Psyllium husk: fine as a supplement, but it's a missed opportunity. Get your fiber from actual food (heirloom beans, colored vegetables, berries) because you get the fiber PLUS hundreds of other beneficial compounds. Extracting one nutrient from the matrix rarely works as well. The Test You Might Be Missing Dr. Fraser's parting advice was the most urgent. You can optimize every supplement, hit every ApoB target, and run every experiment. But if you haven't checked whether you already have vascular disease, you're optimizing in the dark. APOE4 carriers are more likely to have coronary artery disease and cerebrovascular disease than the general population. Some people with "bad" lipids have zero disease. Others with "acceptable" lipids have critical disease. The tests: CT coronary angiogram (preferably with CLEARLY analysis or cellular plaque analysis) and an MRA of the head and neck. There's a cost. But knowing your baseline changes your entire treatment strategy. About Dr. Grant Fraser Board Certified: American Board of Anti-Aging and Regenerative Medicine, with fellowship modules in Cardiology, Endocrine and Gastroenterology. Board Certified American Board of Family Medicine. Fellow of the Australian College of Rural and Remote Medicine with Advanced Specialty Training in Emergency Medicine and Generalist Emergency Medicine Post Fellowship Certification. Fellow of the Australian College of General Practitioners. 29 years of experience in Emergency Medicine and Rural Generalist Medicine. He's also an APOE4 carrier and member of the Phoenix Community. About The Phoenix Community The Phoenix is the world's first precision health platform built for APOE4 carriers. We combine biomarker tracking, structured experiments, expert access, and a community of people who understand what it means to carry this gene. If this conversation resonated with you, we'd love to have you. 👉 Join the Phoenix Community: https://thephoenix.community🩸 Blood work blueprint: https://apoe4.co/bloodtestMost Newsletters? One-way street.How boring…This is the Phoenix Community. So let's make it a two-way street. Got a question? Feedback? Hit reply. I read every single one. --- ## She diagnosed her own mother. Then found out she might be next. URL: https://apoe4.co/blog/posts/she-diagnosed-her-own-mother-then-found-out-she-might-be-next Published: 2026-03-16T17:47:00+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: community, supplements, protocols Summary: APOE4 carrier and retired doctor shares her real protocol after diagnosing her mother's Alzheimer's—and discovering her own risk. A raw member story. She diagnosed her own mother. Then found out she might be next.A retired doctor shares her real APOE4 protocol.Dr. Kevin Tran March 16, 2026 Hi Phoenix friend, Today in our latest Phoenix Member Story: Dr. Gertrude Behan — "Do It Now" Phoenix Member Stories areraw conversations with APOE4 carriers who aren't waiting around for a cure. Every episode, I sit down with a member of our community and dig into what they're actually doing. The wins. The doubts. The stuff nobody talks about.Full conversation in the Youtube link below. Today: Dr. Gertrude BehanShe diagnosed her own mother. Gertrude is a retired family medicine physician from Australia. She spent decades treating patients. Some of them had Alzheimer's. "I'd seen the effect of Aricept," she told me. "It was really pretty useless, to be blunt." Then in 2016, she diagnosed her own mother. "There's a silent screaming inside, isn't there?" she said. "I know that everyone listening would know what I'm talking about. How painful it is." Her mother is now terminal. Then she found out she's next in line Two years later, Gertrude was diagnosed with breast cancer. While searching for the BRCA gene, she stumbled onto something else. APOE4. Her first reaction? Not panic. Validation. "My initial thought was, well, I think these people are on to something. My mother has Alzheimer's. This gene test isn't quackery. They're right." Then the fear set in. What changed everything Gertrude read that certain interventions might buy you 6 to 8 more years of healthy brain function. That's when it clicked. "What am I waiting for? If I'm going to do something, I should do it now." She started exercising more. Connecting with people. Examining her diet. Not waiting for a perfect plan. "Life is finite no matter which way you look at it. No point waiting. Do it now." A doctor's (skeptical) approach to supplements Gertrude doesn't rush into interventions. Especially supplements. "The person making this supplement is doing it to make money," she said. "There might be contaminants. They might not have the amount that's on the bottle." She's not anti-supplement. But she needs a reason. Her current stack: Activated folate and B12 (MTHFR gene variant; brought her homocysteine down) Vitamin D (the Australian paradox: sunny country, everyone avoids the sun) NR (nicotinamide riboside) for brain energy and skin cancer prevention On her radar: Microdose lithium (tempted by the research, watching closely) Rapamycin (keeping it as an "arrow in her quiver") Her philosophy: you don't have to do everything now. Keep options in reserve for when you need them. The wild variant My favorite moment from our conversation: "Maybe we should sell APOE4 carriers as the wild variant," Gertrude said. "The tough humans. The people who had to track a mammoth for two weeks, running on ketones." I loved that. We're not broken. We're just not built for the modern world. Watch the full conversation Gertrude and I talked for almost an hour. We covered caregiving, breast cancer, supplement skepticism, the case for population-wide APOE4 testing, and why she thinks "do it now" is the only strategy that makes sense. Your turn If you're a Phoenix member and want to share your story, email me at kevin@thephoenix.community. And if you're not a member yet? Gertrude found a place where she can talk through her decisions without wearing out her friends. Where the information is evidence-based. Where she feels optimistic about the future. You can too. 👉 Join The Phoenix Community Talk soon, Kevin P.S. Gertrude's message to anyone at the "pointy end" (older carriers): "You can't have gotten to this age without some medical or orthopedic issues. Just do what you can. And it's great." Don't let perfect be the enemy of good. Most Newsletters? One-way street.How boring…This is the Phoenix Community. So let's make it a two-way street. Got a question? Feedback? Hit reply. I read every single one. --- ## Both Parents Died of Alzheimer's. How One APOE4 Carrier Rebuilt His Life. | Phoenix Member Stories URL: https://apoe4.co/blog/posts/both-parents-died-of-alzheimer-s-how-one-apoe4-carrier-rebuilt-his-life-phoenix-member-stories Published: 2026-03-10T18:42:00+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: community, protocols, nutrition Summary: His p-tau came back at 0.09. But that's not even the best part of his story. Both Parents Died of Alzheimer's. How One APOE4 Carrier Rebuilt His Life. | Phoenix Member StoriesHis p-tau came back at 0.09. But that's not even the best part of his story.Dr. Kevin Tran March 10, 2026 Hi Phoenix friend, Phoenix Member Stories: John Yoder.Watch the full interview on Youtube here: John's mom couldn't drive anymore. She'd get lost. Forget where she was going. His dad took over as her caregiver. Slowly, quietly, Alzheimer's took her ability to navigate the world. Then it started taking his dad too. His dad was stubborn about it. Independent. He'd pull out a little notebook mid-conversation and scribble things down. He'd repeat himself. John and his brother noticed the signs but thought "he's always been kind of like that." Until the gas station. One day, John's dad went out to get gas. He got confused. Ended up with gasoline on his clothing. A stranger (an Uber driver, of all people) looked at his ID and said: "Just follow me back to your house." That was the last time he drove. His brother had to take the car keys. And if you've ever had to reverse the parent-child dynamic like that, you know how gutting it is. John put it simply: "A kid never wants to play the boss of their parent." Both parents eventually passed from Alzheimer's. His mom about four years ago. His dad just over a year ago. Neither of them ever admitted anything was wrong. The Test After his dad passed, John wanted answers. Not just grief. Answers. He tried for six months to get a genetic test. Doctors referred him to places that "don't do that anymore." He got the impression nobody who offers the test actually wants to deal with the counseling afterwards. Sound familiar? He eventually got tested through his gym (of all places). A company called Three by Four offered a full genetic panel with counseling included. Extra $50. Result: APOE 3/4. John wasn't surprised. With both parents dying of Alzheimer's, he'd already assumed it was either 3/4 or 4/4. In his words: "How would I lose both parents and then just win the lottery of having two twos?" But here's the part that matters. He didn't get tested to find out if he was at risk. He already knew. He got tested to do something about it.July 31st The genetic counselor gave him a printout. Supplements. Intermittent fasting. More protein. Minimal alcohol. He started that day. Literally the same day. And the thing that made it stick? The feedback loop was almost immediate. More energy. Better sleep. Sharper thinking. Week after week, every change he made compounded. It wasn't some distant promise of "maybe this helps in 20 years." He felt different in weeks. That's the part I think people miss about prevention. Yes, we're doing this for our brains in 2040 or 2050. But the side effects of a healthy protocol are... feeling incredible right now. The Alcohol Wake-Up Call Here's something John said that stopped me: "I've never known that other people didn't struggle with alcohol." He'd go out with friends. Have the same amount. The next day, they'd be fine. He'd be wrecked. He'd ask them: "How are you back at work already?" They'd say: "I don't really get hangovers." He thought hangovers like his were normal. For everyone. They're not. When he got his Oura ring, the data confirmed it. One or two beers and his HRV would crash. Readiness score tanked. The next day's training? Gone. This is something we hear over and over in The Phoenix Community. APOE4 carriers tend to be hyper-reactive to alcohol. The body just doesn't process it the same way. And most of us had no idea until we found other people with the same genes. John called Phoenix his "genetic family." I love that framing. The Benadryl Problem This one's important. John took 50mg of diphenhydramine (Benadryl) every night for over 20 years. Just for insomnia. It was his nightly routine. Pop a pill, go to sleep. Then he learned it suppresses deep sleep. And that long-term use has been associated with increased dementia risk [1]. He stopped immediately. But the fear lingered. Had he already damaged his brain? Twenty years is a long time. His p-tau test (through Care Access, which he found through Phoenix) came back at 0.09. Well below the 0.18 concern threshold. Relief. His takeaway: "Sometimes the best intervention is stopping the wrong one." And I think that applies to a lot of us who are unknowingly doing things that could be making our risk worse. The Neuronic Study John was one of the first members to join our community photobiomodulation study with Neuronic (50+ members participated). He didn't join Phoenix for the community. He joined specifically for opportunities like this. Access to interventions he wouldn't have found on his own. He committed to the 90-day protocol. Every day. Morning session. 25 minutes. By the end, he was hooked. He reports feeling more focused, more emotionally steady, more alert on the days he uses it. When the sauna at his gym broke for a week, he noticed he wanted to go less. The NeuroNic became part of that same non-negotiable routine. Now he does 30-minute sessions (up from 25) and recently started adding the evening sleep mode. He's become a twice-a-day user. His insight on habits: "I don't know that I would have been as successful with NeuroNic if I weren't committed to the study. The 90 days forced the habit. By the end, I'm not giving it up." That's a lesson for all of us. Sometimes you need the structure of a commitment (a study, a pod, a challenge) to build the habit that sticks. "I'd Rather Be Broke Without Alzheimer's Than Rich With It" John's philosophy is the most grounded I've heard from any member. He doesn't obsess over zone 2 heart rate training. He thinks overthinking exercise zones might cause people to move less. His approach: just get out of the chair. He doesn't agonize over supplement timing. He takes a handful once a day and moves on. He has a very low bar for adding interventions (if the evidence is even correlation-level and it doesn't make him feel worse, why not?) and a very high bar for removing them. And here's the frame that stuck with me most: Even if nothing he does prevents Alzheimer's, he's living 13 sharp, energetic, present years instead of 13 declining ones. If a cure appeared tomorrow and his APOE4 gene was removed, he'd keep doing everything except the supplements. That's not a backup plan. That's winning either way. For The Busy Ones Not everyone can retire early and make health a full-time job. John knows that. His own brother hasn't gotten tested because he doesn't feel like he has the bandwidth to act on the results. John's advice for people with limited time: "If all you do is stop drinking, you're way ahead already. If all you add is a consistent bedtime, that counts. One supplement. One habit change. One decision." Most interventions that matter don't take extra time. A lithium microdose is one pill. A bedtime is a decision. Walking is free. It's the 80/20 rule. The big levers (sleep, exercise, diet, alcohol, stress) do most of the work. Everything else is optimization. Don't let the pursuit of perfect keep you from good enough. The Family Reunion John showed up to a family reunion recently. He'd transformed. Lost significant weight. Gained muscle. People noticed. His cousin pushed: "So what's up with this new you?" He told the truth: "The threat of Alzheimer's." Dead silence. Subject changed instantly. But in The Phoenix Community? That's the whole conversation. No awkward pauses. No one changing the subject. Just people who get it. "You get kind of a new family of people with your aligned interest," John said. That's the thing about carrying APOE4. Your actual family might share your genes. But they might not want to talk about what those genes mean. The friends who understand what you're going through, who are running the same experiments, tracking the same biomarkers, fighting the same fight? Those people might not share your blood. But they share your mission. And sometimes that matters more. Watch the full conversation with John (45 min):  If John's story resonates with you, here's where to start: 🧬 Join The Phoenix Community: thephoenix.community 📖 Download the free Essential Guide to Thriving with APOE4: ebook.thephoenix.community 🩸 Get the free APOE4 Blood Work Blueprint: apoe4.co/bloodtestMost Newsletters? One-way street.How boring…This is the Phoenix Community. So let's make it a two-way street. Got a question? Feedback? Hit reply. I read every single one. --- ## The NAD+ study every APOE4 carrier needs to see (and the warning they buried) URL: https://apoe4.co/blog/posts/the-nad-study-every-apoe4-carrier-needs-to-see-and-the-warning-they-buried Published: 2026-03-05T17:35:00+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: research, supplements, cognition Summary: New NAD+ APOE4 research shows cognitive reversal in Alzheimer's models. Learn what this means for carriers, plus the critical supplement safety warning researchers issued. The NAD+ study every APOE4 carrier needs to see (and the warning they buried)Researchers reversed cognitive deficits in advanced Alzheimer's mice — but issued a stark warning about NMN and NR.Dr. Kevin Tran March 05, 2026 Hi Phoenix friend, A December 2025 study just challenged what we thought we knew about Alzheimer's disease. For APOE4 carriers, this could change everything about how we approach brain health. I've been an APOE4/4 carrier my entire life. I've read hundreds of Alzheimer's studies. When researchers claim to "challenge the century-old dogma that Alzheimer's disease is intrinsically irreversible," I pay attention. But here's what you need to understand: this breakthrough comes with a critical safety warning about NAD+ supplements that most headlines completely ignored. Before you order another bottle of NMN or NR, you need to know what the study authors themselves are saying about over-the-counter precursors. In this post, I'll break down exactly what this research found, why it matters specifically for APOE4 carriers, and most importantly, what you can actually do about it right now — without exposing yourself to unnecessary risks. What This December 2025 NAD+ Study Actually Found The research, published in Cell Reports Medicine on December 22, 2025, represents something we rarely see in Alzheimer's research: full reversal of cognitive deficits in advanced disease models. The research team at Case Western Reserve University and University Hospitals used a compound called P7C3-A20, which activates an enzyme called NAMPT — the rate-limiting enzyme in your body's NAD+ recycling pathway. Here's what they discovered: In mice with advanced Alzheimer's disease, treatment with P7C3-A20 fully reversed cognitive deficits. Not slowed. Not stabilized. Reversed. According to the researchers, "both lines of mice fully recovered cognitive function." The treatment addressed multiple disease processes simultaneously — reversing tau phosphorylation, blood-brain barrier deterioration, oxidative stress, DNA damage, and neuroinflammation. Perhaps most significantly for translation to humans, the researchers identified 46 proteins that were abnormally expressed in the Alzheimer's mouse brain and normalized by treatment — and these same proteins show similar alterations in human Alzheimer's brains. This suggests the mechanism might actually work in human brains. KEY INSIGHT: This study looked at NAD+ levels in mice at different disease stages. NAD+ declined 30% at 6 months and 45% by one year in Alzheimer's models — a dramatic drop that preceded cognitive decline.The NDAN Paradox: Why Some People With Alzheimer's Pathology Never Show Symptoms Here's where this research becomes especially relevant for APOE4 carriers thinking about long-term brain health. Scientists have long studied a fascinating population called NDAN — Non-Demented with Alzheimer's Neuropathology. These are individuals whose brains, examined after death, show all the hallmarks of Alzheimer's disease: amyloid plaques, tau tangles, the full pathology. But during their lives? They remained cognitively sharp. No symptoms. No decline. How is this possible? This December 2025 study suggests one key answer: preserved NAD+ levels. The researchers found that people who maintain cognitive function despite having Alzheimer's pathology tend to have preserved NAD+ homeostasis. NAD+ appears to function as a "resilience factor" — protecting cognitive function even when disease pathology is present. KEY INSIGHT: For APOE4 carriers, this reframes the goal. It's not just about preventing amyloid accumulation — it's about building metabolic resilience that can protect cognition regardless of pathology. This aligns with what we know about APOE4: carriers have accelerated metabolic dysfunction and may experience faster NAD+ decline. The good news? We can actively support NAD+ through multiple pathways. CRITICAL: The OTC Supplement Safety Warning Researchers Issued This is the part that most people reporting on this study completely missed. And it's perhaps the most important section of this entire post. The study authors issued a direct warning. Here's Dr. Pieper, one of the lead researchers: "Current over-the-counter NAD+-precursors have been shown in animal models to raise cellular NAD+ to dangerously high levels that promote cancer." Let that sink in. Dangerously high levels that promote cancer. The researchers emphasized that their approach with P7C3-A20 is fundamentally different. It enables cells to maintain their proper balance of NAD+ under conditions of otherwise overwhelming stress — without elevating NAD+ to supraphysiologic levels. Here's the critical distinction: P7C3-A20 activates NAMPT, allowing cells to produce NAD+ as needed while maintaining homeostatic balance OTC precursors like NMN and NR bypass this regulation entirely, potentially flooding cells with more NAD+ than they can safely handle CAVEAT: This doesn't mean all NAD+ supplementation is harmful. One human clinical trial (Wu et al., 2025) showed that 8 weeks of NR treatment (1g/day) significantly reduced pTau217 concentrations — a key Alzheimer's biomarker — compared to placebo. The NR group showed a 7% reduction while the placebo group showed an 18% increase. But long-term safety data simply doesn't exist yet.What Should You Do If You're Currently Taking NMN or NR? Don't panic and stop immediately — that's not what the research suggests Have a conversation with your doctor about these findings Consider whether the potential risks align with your personal health situation (especially important if you have cancer risk factors) Explore the natural NAD+ support strategies below as complementary or alternative approaches Natural Strategies to Support NAD+ Levels (Without Supplement Risks) While P7C3-A20 isn't available for human use yet, evidence-based lifestyle interventions can support your NAD+ levels through the same NAMPT pathway — without the theoretical risks of megadosing precursors. Exercise: The Most Powerful NAD+ Intervention We Have Both aerobic training and resistance training increase NAMPT expression — the same enzyme P7C3-A20 targets. Research shows that NAMPT levels remain positively associated with lean body mass and VO2 max. This is why exercise consistently shows the strongest benefits for brain health across studies. It's directly hitting the NAD+ production pathway. ACTION: Aim for both Zone 2 cardio (conversational pace) and regular strength training. Building and maintaining muscle mass appears directly connected to NAD+ production capacity.Fasting and Time-Restricted Eating Caloric restriction and intermittent fasting activate AMPK and upregulate NAMPT. This metabolic stress signal tells your cells to ramp up their NAD+ recycling machinery. Even a 16:8 eating window — eating within an 8-hour window and fasting for 16 hours — can activate these pathways without extreme interventions. Ketogenic Diet: Especially Relevant for APOE4 Carriers This deserves special attention for APOE4 carriers. Nick Norwitz, a Harvard-trained researcher who is himself an APOE4 carrier (along with both his parents), has published peer-reviewed research on precision nutrition for Alzheimer's prevention in APOE4 carriers. His work suggests ketogenic diets may be among the most powerful dietary interventions for those with this genetic variant. Why it's particularly powerful for APOE4: Ketones boost NAD+ through the AMPK/NAMPT pathway Ketones bypass glucose hypometabolism — the reduced ability to use glucose for brain fuel that characterizes APOE4 brains It's hitting the problem from two directions simultaneously. ACTION: If exploring ketogenic eating, aim for nutritional ketosis with blood ketones above 1.0 mmol/L. This typically requires keeping carbohydrates under 20-30 grams per day.Reducing NAD+ Consumption (Often Overlooked) It's not just about making more NAD+ — it's also about consuming less of it. Your body uses NAD+ to fight inflammation, repair oxidative damage, and fix DNA. If you're chronically inflamed, your NAD+ gets consumed faster than you can replenish it. Priority interventions:Reduce chronic inflammation: Eliminate processed foods and seed oils, prioritize sleep, manage stress Natural CD38 inhibitors: CD38 is an enzyme that breaks down NAD+. Quercetin (found in capers, red onions, kale, broccoli) and apigenin (found in chamomile tea, parsley, thyme, oregano) have been shown to inhibit CD38 activity ACTION: Make chamomile tea your evening ritual. Add quercetin-rich foods to your regular rotation. These simple dietary additions may help preserve your NAD+ levels over time.Your Action Steps for This Week Day Action Monday Evaluate your exercise routine. Add one cardio and one strength session if missing. Tuesday Try time-restricted eating. Start with a 14-hour overnight fast, work toward 16 hours. Wednesday Audit inflammation sources. What processed foods can you eliminate? How's your sleep? Thursday Stock up on quercetin-rich foods (red onions, kale, broccoli). Make chamomile tea your evening drink. Friday If taking NMN or NR, schedule a conversation with your doctor about these findings. Key TakeawaysDecember 2025 breakthrough: Researchers demonstrated full reversal of cognitive deficits in advanced Alzheimer's mouse models by restoring NAD+ homeostasis — challenging the dogma that AD is irreversible NAD+ as resilience factor: People who remain cognitively intact despite Alzheimer's pathology (NDAN individuals) have preserved NAD+ levels — suggesting NAD+ protects cognition independent of pathology Critical supplement warning: Study authors explicitly warn that OTC NAD+ precursors may raise levels to "dangerously high levels that promote cancer" — the P7C3-A20 compound works differently by maintaining homeostasis Natural support available now: Exercise, fasting, ketogenic diet, and CD38 inhibitors (quercetin, apigenin) can support NAD+ through the same NAMPT pathway without theoretical overdose risks APOE4 relevance: Carriers may experience faster NAD+ decline and benefit especially from ketogenic approaches that both boost NAD+ and bypass glucose hypometabolism Track Your Progress With Phoenix If you're an APOE4 carrier implementing these strategies, tracking matters. Inside Phoenix, our bloodwork module helps you monitor inflammatory markers (hs-CRP, IL-6), metabolic health (fasting glucose, insulin, HbA1c), and lipid panels optimized for APOE4 ranges. Our supplement tracking module lets you log NMN, NR, or natural CD38 inhibitors alongside your biomarker data — so you can see what's actually moving the needle for your biology. At the time of writing, over 400+ APOE4 carriers are already running n-of-1 experiments and sharing what works. If you've been looking for a community that takes this as seriously as you do, we'd love to have you. If you are not a member yet, and have read until here, you definitely will fit with us.Join Phoenix here!Sources Chaubey K, et al. (2025). Pharmacologic reversal of advanced Alzheimer's disease in mice and identification of potential therapeutic nodes in human brain. Cell Reports Medicine. December 22, 2025. DOI: 10.1016/j.xcrm.2025.102535. https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(25)00608-1 Harrington Discovery Institute / Case Western Reserve University Press Release. (2025). New study shows Alzheimer's disease can be reversed to achieve full neurological recovery. December 22, 2025. https://www.harringtondiscovery.org/news-media/2025/12/22/new-study-shows-alzheimers-disease-can-be-reversed-in-animal-models-to-achieve-full-neurological-rec Wu et al. (2025). Cognitive and Alzheimer's disease biomarker effects of oral nicotinamide riboside (NR) supplementation in older adults with subjective cognitive decline and mild cognitive impairment. Alzheimer's & Dementia: Translational Research & Clinical Interventions. https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/trc2.70023 Wang G, et al. (2014). P7C3 Neuroprotective Chemicals Function by Activating the Rate-limiting Enzyme in NAD Salvage. Cell. https://pmc.ncbi.nlm.nih.gov/articles/PMC4163014/ NAD+ reverses Alzheimer's neurological deficits via regulating differential alternative RNA splicing of EVA1C. (2025). Science Advances. November 2025. https://www.science.org/doi/10.1126/sciadv.ady9811 Zhao et al. (2023). P7C3-A20 Attenuates Microglial Inflammation and Brain Injury after ICH through Activating the NAD+/Sirt3 Pathway. Oxidative Medicine and Cellular Longevity. https://pmc.ncbi.nlm.nih.gov/articles/PMC9936507/ Norwitz N. (2026). Never get Alzheimer's Disease: The NAD+ Breakthrough. Stay Curious Metabolism. January 2, 2026. https://staycuriousmetabolism.substack.com/p/never-get-alzheimers-disease-the Norwitz NG, et al. (2021). Precision Nutrition for Alzheimer's Prevention in ApoE4 Carriers. Nutrients. 13(4):1362. https://www.mdpi.com/2072-6643/13/4/1362Most Newsletters? One-way street.How boring…This is the Phoenix Community. So let's make it a two-way street. Got a question? Feedback? Hit reply. I read every single one. --- ## I Optimized Myself Into Misery (And Every Pleasure Disappeared) URL: https://apoe4.co/blog/posts/i-optimized-myself-into-misery-and-every-pleasure-disappeared Published: 2026-03-02T18:47:00+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: protocols, nutrition, cognition Summary: Discover why obsessive health optimization backfired. Learn how to prevent Alzheimer's without sacrificing joy—balanced strategies for APOE4 carriers. I Optimized Myself Into Misery (And Every Pleasure Disappeared)I turned my entire life into an Alzheimer's prevention protocol. It nearly broke me.Dr. Kevin Tran March 02, 2026 Hi Phoenix friend, I know we keep talking about interventions here. Diet, exercise, medical devices, supplements…And I know it ends up becoming overwhelming because we always think: am I doing enough…when there is so much to do?So this post is different. Because there's something nobody talks about in the longevity / Alzheimer’s space.You can optimize yourself into misery. And rob yourself of all of life’s joy. I know because I did it. The Guilt Spiral Here's what happened to me. After I discovered I carry two copies of APOE4. I went all in. - Every meal became a calculation (saturated fat, calories..).- Every activity became an optimization choice.- Every night out (drinking) became a negotiation with my own brain. And slowly, without realizing it, my entire life reorganized itself around one goal: reducing Alzheimer's risk. What I eat? Only what's good for my brain. My activities? 15 hours a week of exercise I don't particularly enjoy (do people actually enjoy HIIT workouts?). My social life? Dull, because alcohol is bad for our brain and sleep. Even my work became Phoenix. Everything. All of it. Pointed at one thing. Here's the cruel irony. All of life's greatest pleasures happen to be terrible for our brain somehow (at least for me). I love sweet pastries. I love cheese. I love wine. I love staying up late.Some of the best nights of my life were fueled by alcohol (and bad decisions). Some of my most meaningful relationships were born from going out, staying up too late, and doing things that zero longevity experts would approve of. But the worst part wasn't giving those things up. The worst part was the guilt. I'd look at a pastry / cheese/ ribeye and instantly my brain would fire up: saturated fat, insulin spike…I'd have a glass of wine and think about neuroinflammation. I'd stay out past 10pm or eat dinner late and calculate the damage to my sleep architecture. The guilt ate into the pleasure. And one by one, the pleasures disappeared. Even when I "allowed" myself something, there was always that little pinch. That voice saying "this is bad for you." That's not living. That's just surviving with extra steps. The 90/10 Rule So here's what I figured out (and honestly, it took me longer than it should have). We can't be perfect. We shouldn't try to be. My solution is simple. Have a rock solid baseline routine, truly optimized, where you know you're doing your best. And then consciously allow yourself 10% deviation. No guilt. No mental math. Just living. For me, that deviation is geographic. I travel a lot between San Francisco, Paris, and Singapore. In those home cities, my routine is dialed in. Sleep, nutrition, exercise, supplements. Everything locked. But when I travel for pleasure? All bets are off. Milan? Pizza, gelato, pasta, wine, late nights. Japan? Ramen all the way.China? Every dumpling and noodle spots I can find.Mexico? Tacos every day. I go full send because the food is genuinely better in those places anyway (the pleasure per calorie is way higher), and these are exceptional moments that deserve to be lived fully. Over a year, maybe 10% of my time is "off protocol." And that's completely fine. We've talked to members who do it differently in our new Phoenix Member Stories (available on my Youtube channel). Some allow deviations during family gatherings (Thanksgiving with the kids is not the time to count macros). Some during celebrations. Some during specific events that are clearly defined. The common thread? It's conscious. It's bounded. And it's guilt free. Because here's the math that actually matters. Being 90% consistent forever beats being 100% perfect for three months and then burning out completely. Going from 100 to 0 is way worse than cruising at 90. Be Kind With Yourself Now, a word for those of you reading this newsletter and feeling overwhelmed. I get it. Every week there's a new study. A new supplement. A new protocol. A new thing you "should" be doing. It can feel like you're never doing enough. Like there's always one more intervention between you and safety. Stop. Take a breath. You are already here. You are reading this. You are taking action. You are part of this community. That alone puts you miles ahead of the vast majority of people (including most APOE4 carriers who don't even know their status, let alone do anything about it). You are already dramatically reducing your risk just by showing up. So here's what I want you to do. Pick the interventions that feel sustainable for you. Not all of them. The ones you can actually stick with. Build your routine one piece at a time. Stack habits slowly. Don't try to overhaul your entire life in a week. Something my psychologist used to tell me (and it took me way too long to listen): be kind with yourself. This is a marathon. Decades long. The goal isn't perfection. The goal is consistency. The goal is building something you can maintain for the rest of your life while still actually enjoying that life. Because what's the point of adding years to your life if you've removed all the life from your years? With love, Kevin Most Newsletters? One-way street.How boring…This is the Phoenix Community. So let's make it a two-way street. Got a question? Feedback? Hit reply. I read every single one. --- ## I loved wine. Then I saw the APOE4 research. URL: https://apoe4.co/blog/posts/i-loved-wine-then-i-saw-the-apoe4-research Published: 2026-02-27T18:35:00+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: research, nutrition, cognition Summary: APOE4 carriers face different alcohol risks. Discover what the research reveals about 'moderate' drinking and why the standard guidelines don't apply to you. I loved wine. Then I saw the APOE4 research.The science changed everything I thought I knew about 'moderate' drinking.Dr. Kevin Tran February 27, 2026 Hi Phoenix friend, I used to love wine. A good Pinot noir with a cheese board, a celebratory champagne toast, the ritual of unwinding after a long day. Then I got my APOE4 test results back: 4/4 homozygous. Two copies. The highest genetic risk category for Alzheimer's disease. So I did what I always do: I went deep into the research. And what I found changed everything. Here is the uncomfortable truth that nobody wants to hear: the rules about alcohol are different for us. That "moderate drinking might be protective" message you have heard? It does not apply to APOE4 carriers. The studies are clear, and once you see the data, you cannot unsee it. I am not here to lecture you or tell you what to do with your own body. But I am going to share exactly what the science shows, what it means for your brain, and what I personally do now. Because you deserve to make this decision with full information. About this: I have another post that I am writing for next week about how to “still enjoy life” while optimizing against Alzheimer’s risk. I realize that many of us are overwhelmed by the amount of interventions to do and getting “robbed of life’s joy” when you need to fix your diet, remove alcohol, follow so many interventions and everything else. I hear you. I am in the same shoes. I want you to know: its okay to be kind to yourself and divert from always optimizing against Alzheimer’s risk to just enjoy life.More about this in my next post.Now going back to alcohol.. The Data: Why APOE4 Carriers Cannot Drink Like Everyone ElseThe Research The Honolulu-Asia Aging Study followed 2,416 men from midlife (average age 52) to late life (average age 87). What they found was striking: APOE4 carriers showed increased cognitive impairment risk at ALL consumption levels [Chosy et al., 2022]. Let me repeat that: not just heavy drinking. ALL levels. For non-carriers, light-to-moderate drinking showed neutral or even slightly protective effects. But for APOE4 carriers? Moderate drinking came with a hazard ratio of 2.039, meaning roughly double the risk compared to abstainers. The Vietnam Era Twin Study of Aging found the same pattern in 1,266 middle-aged men (mean age 56, so directly relevant to our community). The never-drinking APOE4 carriers had the BEST cognitive performance. The heavy-drinking APOE4 carriers had the WORST. Meanwhile, among non-carriers? No significant differences between drinking groups [Slayday et al., 2020]. Perhaps most concerning: the Framingham Heart Study Offspring Cohort discovered that the exact same alcohol consumption had opposite effects based on APOE4 status. Non-carriers who drank moderately showed improved learning and memory. APOE4 carriers who drank the same amount showed accelerated decline [Downer et al., 2013]. So What Does This Mean for You? If you have been telling yourself that your evening glass of wine is "fine because it is moderate," the data suggests otherwise. The protective J-curve that gets so much attention in popular health media? It was built on studies that did not stratify by APOE genotype. For non-carriers, light drinking might genuinely be neutral or beneficial. For us, there appears to be no safe harbor. What You Can Do About ItAction Steps:Track your current consumption honestly for one week. Most of us underestimate. Calculate your weekly units: One standard drink = 12oz beer, 5oz wine, 1.5oz spirits. Set a specific reduction goal based on where you are now (more on alternatives below). Use Phoenix to log and track your consumption alongside cognitive metrics. Mechanism 1: Your Blood-Brain Barrier Is Already CompromisedThe Research Here is something most APOE4 carriers do not know: your blood-brain barrier (BBB) is likely already leakier than non-carriers, even if you are cognitively healthy right now. A landmark 2020 study published in Nature found that APOE4 carriers have significantly greater BBB permeability in the hippocampus and medial temporal lobe, the exact brain regions hit hardest by Alzheimer's. This breakdown was present even in cognitively unimpaired carriers and was independent of amyloid-beta and tau pathology [Montagne et al., 2020]. Now add alcohol to the equation: binge-level ethanol compromises BBB integrity through multiple mechanisms, degrading tight junction proteins essential for barrier function [Vore & Deak, 2021]. KEY INSIGHT: You are starting with a compromised defensive barrier. Alcohol further degrades it. The combined effect is accelerated entry of toxins, inflammatory molecules, and pathogens directly into brain tissue. So What Does This Mean for You? Think of your BBB like the walls of a fortress protecting your brain. APOE4 carriers already have cracks in those walls. Every drink you take is like removing more bricks. Non-carriers can afford some wear and tear. We cannot. The inflammatory markers tell the story: one study found that alcohol use was positively associated with the inflammatory cytokine IL-6 in APOE4 carriers, but not in non-carriers [Monnig & Shah, 2024]. Same exposure, completely different inflammatory response. What You Can Do About ItAction Steps:Prioritize BBB-protective interventions: Sleep quality, omega-3 fatty acids, and avoiding known BBB disruptors (alcohol, processed foods, chronic stress). Support tight junction integrity: Vitamin D, magnesium, and zinc are cofactors for tight junction protein synthesis. Consider a 30-day alcohol elimination to give your BBB time to recover. Track inflammation markers in your next bloodwork (hs-CRP, IL-6 if available). Mechanism 2: Alcohol Destroys Your Brain's Cleaning SystemThe Research Your brain has a waste-clearing system called the glymphatic system. It is essentially the janitorial crew that removes toxic proteins, including amyloid-beta, the hallmark protein of Alzheimer's disease. Here is the critical detail: 80-90% of this waste clearance happens during deep sleep [Reddy & van der Werf, 2020]. A 2020 study in Brain, Behavior, and Immunity showed what alcohol does to this system: Acute moderate alcohol: Slowed cerebrospinal fluid movement and reduced amyloid-beta clearance. Reversible. Chronic moderate alcohol: Widespread astrocyte activation and loss of AQP4 polarization. Irreversible [Liu et al., 2020]. That is not a typo. Chronic moderate consumption causes irreversible structural damage to your brain's cleaning system. IMPORTANT CAVEAT: These findings are from mouse studies. But given the mechanistic plausibility and the human epidemiological data showing worse outcomes for APOE4 carriers who drink, the precautionary principle applies. And about that sleep you think alcohol helps with? Yes, alcohol shortens sleep onset and may increase initial slow-wave sleep. But it suppresses REM sleep and causes fragmented, poor-quality sleep in the second half of the night [Colrain et al., 2014]. Exactly the opposite of what your glymphatic system needs. So What Does This Mean for You? APOE4 carriers already have impaired amyloid-beta clearance because the ApoE4 protein is less efficient at this job than ApoE3. When you add alcohol-induced glymphatic impairment on top of genetic impairment, you are double-handicapping your brain's ability to clear the proteins that drive Alzheimer's pathology. One night of sleep deprivation causes a measurable 5% increase in amyloid-beta in the hippocampus [Shokri-Kojori et al., 2018]. Now imagine what repeated alcohol-disrupted sleep does over years. What You Can Do About ItAction Steps:Never use alcohol as a sleep aid. It is counterproductive for the exact type of sleep you need. Optimize deep sleep: Cool bedroom (65-68F), complete darkness, consistent sleep schedule. If you drink, stop at least 4 hours before bed to minimize sleep architecture disruption. Track sleep quality in Phoenix alongside any alcohol consumption to see your personal patterns. Consider glymphatic-supporting practices: Side sleeping, regular exercise, and adequate hydration. Mechanism 3: Synergistic Neurotoxicity (Why It Is Worse For Us)The Research Here is where the research gets personal. A 2018 cell study directly tested what happens when you combine ApoE4 protein with ethanol exposure. The findings were stark: ApoE4 and high-concentration ethanol synergistically enhance neurotoxicity through elevating cellular oxidative stress [Li & Cheng, 2018]. The mechanism: ApoE4 significantly amplifies alcohol-induced cellular damage compared to ApoE3 through two pathways: elevated reactive oxygen species (ROS) production and increased programmed cell death (apoptosis). When researchers blocked oxidative damage with the antioxidant NAC (N-acetyl cysteine), the heightened toxicity was eliminated. This is not additive damage. It is multiplicative. The ApoE4 protein itself makes alcohol more toxic to neurons. THE DATA: Chronic alcohol metabolism generates reactive oxygen species through CYP2E1 activity, depletes protective antioxidants like glutathione, triggers immune activation, and creates a hyperglutamatergic state causing calcium overload [Kamal et al., 2020]. So What Does This Mean for You? This is the piece that finally convinced me to quit entirely. It is not just that APOE4 carriers clear amyloid-beta less efficiently, or that our BBB is leakier, or that our glymphatic systems are already working harder. It is that the ApoE4 protein itself turns alcohol into a more potent neurotoxin for our specific brains. Same drink, same blood alcohol level, more neuronal death. What You Can Do About ItAction Steps:Support antioxidant defenses: Consider NAC supplementation (600-1200mg/day with food). Studies showed it blocked the synergistic toxicity. Optimize glutathione status: NAC is a glutathione precursor. Also consider glycine, vitamin C, and selenium. Avoid combining alcohol with other oxidative stressors: Processed foods, environmental toxins, intense exercise without recovery. If you do drink, never binge. The dose-response relationship for oxidative damage is steep. What I Do Now: The Alternatives That Actually Work After reviewing this research, I made the decision to eliminate alcohol completely. That was almost two years ago. Here is what I have learned: The Social Piece This was my biggest concern. So much of adult socializing revolves around alcohol. What I discovered: nobody cares nearly as much as you think they will. What works:Non-alcoholic wine and beer: The quality has improved dramatically. Sparkling water with bitters: Angostura bitters in sparkling water gives you something sophisticated to hold that is not obviously "not drinking." Own it simply: "I am not drinking tonight" requires no explanation. Most people move on immediately. The Relaxation Piece If you were using alcohol to unwind, you need replacement rituals. What works:L-theanine (200-400mg): Creates calm focus without sedation. I take it in the evening when I used to reach for wine. Magnesium glycinate (300-400mg before bed): Supports GABA activity and improves sleep quality. Adaptogens: Ashwagandha and reishi mushroom help with the stress response. Movement: A 20-minute evening walk does more for my stress than wine ever did. The Polyphenol Question But what about the resveratrol and polyphenols in wine? The math does not work. A glass of wine contains roughly 1mg of resveratrol swimming in three-quarters of an ounce of alcohol, which is a pro-oxidant. You would need to drink 100+ glasses to get a therapeutic dose of resveratrol, and you would destroy your brain in the process. Better polyphenol sources: Concord grape juice (cognitive benefits shown in studies) Blueberries, blackberries, cherries Dark chocolate (85%+ cacao) (but not great for us because of the saturated fat) Green tea Quercetin supplements (500mg/day) Your Action Plan This WeekKEY TAKEAWAYS - Your Quick-Start Protocol:Day 1-2: Track your current alcohol consumption honestly. Calculate weekly units. Day 3: Read through the sources linked below. Let the data sink in. Day 4-5: Stock your kitchen with alternatives. Order non-alcoholic options, L-theanine, and your polyphenol sources of choice. Day 6-7: Try a weekend without alcohol. Notice how your sleep quality changes. Week 2 onward: Set your personal policy. For some, that is complete elimination. For others, harm reduction (never more than 1 drink, never within 4 hours of sleep, never consecutive days). ACTION STEP: Whatever you decide, track it in Phoenix alongside your cognitive metrics, sleep data, and bloodwork. Your data will tell you what is true for your body. You Are Not Alone in This I will not pretend this is easy. Alcohol is woven into our culture, our celebrations, our stress relief. Making a change requires replacing rituals, navigating social situations differently, and sometimes explaining yourself when you would rather not. But here is what I know: you are the kind of person who looks at hard data and makes hard decisions. 96% of all Phoenix members are already taking action on their APOE4 status. You are not looking for easy answers. You are looking for the truth. The truth is that our brains process alcohol differently. The protective effects that non-carriers might experience do not apply to us. The risks compound through multiple mechanisms. And the research is only getting clearer. The good news? Cognitive improvement is possible with abstinence. Studies show that APOE4 carriers who stop drinking can recover function, even if it takes longer than non-carriers [Escudero et al., 2023]. Your future self, the one who is sharp and present for your grandchildren, for your legacy, for whatever matters most to you, that person will thank you for the decision you make today. Want support making this change? Phoenix members track interventions like this alongside their bloodwork, sleep data, and cognitive assessments. Our pods provide accountability and community from others walking this same path. Join Phoenix to connect with APOE4 carriers who are doing the hard work together. Sources Chosy EJ, et al. Midlife alcohol consumption and later life cognitive impairment: Light drinking is not protective and APOE genotype does not change this relationship. PLoS One. 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC8916616/ Slayday RE, et al. Interaction between alcohol consumption and apolipoprotein E (ApoE) genotype with cognition in middle-aged men. J Int Neuropsychol Soc. 2020. https://pmc.ncbi.nlm.nih.gov/articles/PMC7856052/ Downer B, et al. The Relationship Between Midlife and Late Life Alcohol Consumption, APOE e4 and the Decline in Learning and Memory Among Older Adults. Alcohol Alcohol. 2013. https://pmc.ncbi.nlm.nih.gov/articles/PMC3865814/ Monnig M, Shah K. Linking alcohol use to Alzheimer's disease: Interactions with aging and APOE along immune pathways. Med Res Arch. 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11563488/ Montagne A, et al. APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline. Nature. 2020. https://pubmed.ncbi.nlm.nih.gov/32376954/ Vore AS, Deak T. Alcohol, Inflammation, and Blood-Brain Barrier Function in Health and Disease Across Development. Int Rev Neurobiol. 2021. https://pmc.ncbi.nlm.nih.gov/articles/PMC9204474/ Liu Q, et al. Experimental alcoholism primes structural and functional impairment of the glymphatic pathway. Brain Behav Immun. 2020. https://pubmed.ncbi.nlm.nih.gov/31247290/ Reddy OC, van der Werf YD. The Sleeping Brain: Harnessing the Power of the Glymphatic System through Lifestyle Choices. Brain Sci. 2020. https://pmc.ncbi.nlm.nih.gov/articles/PMC7698404/ Shokri-Kojori E, et al. Beta-Amyloid accumulation in the human brain after one night of sleep deprivation. Proc Natl Acad Sci U S A. 2018. https://pmc.ncbi.nlm.nih.gov/articles/PMC5924922/ Li J, Cheng J. Apolipoprotein E4 exacerbates ethanol-induced neurotoxicity through augmentation of oxidative stress and apoptosis in N2a-APP cells. Neurosci Lett. 2018. https://pubmed.ncbi.nlm.nih.gov/29174637/ Kamal H, et al. Alcohol Use Disorder, Neurodegeneration, Alzheimer's and Parkinson's Disease: Interplay Between Oxidative Stress, Neuroimmune Response and Excitotoxicity. Front Cell Neurosci. 2020. https://pmc.ncbi.nlm.nih.gov/articles/PMC7488355/ Colrain IM, et al. Alcohol and the sleeping brain. Handb Clin Neurol. 2014. https://pmc.ncbi.nlm.nih.gov/articles/PMC5821259/ Escudero B, et al. Reelin Plasma Levels Identify Cognitive Decline in Alcohol Use Disorder Patients During Early Abstinence: The Influence of APOE4 Expression. Int J Neuropsychopharmacol. 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC10464928/Most Newsletters? One-way street.How boring…This is the Phoenix Community. So let's make it a two-way street. Got a question? Feedback? Hit reply. I read every single one. --- ## Rapamycin for APOE4 Carriers: 400 Patients, Zero Dementia (Expert Q&A Recap) URL: https://apoe4.co/blog/posts/rapamycin-for-apoe4-carriers-400-patients-zero-dementia-expert-q-a-recap Published: 2026-02-23T18:51:00+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: research, supplements, tracking, cognition Summary: We sat down with a doctor who has 300 person-years of rapamycin data. Some of it surprised me. Rapamycin for APOE4 Carriers: 400 Patients, Zero Dementia (Expert Q&A Recap)We sat down with a doctor who has 300 person-years of rapamycin data. Some of it surprised me.Dr. Kevin Tran February 23, 2026 Hi Phoenix friend, We just hosted one of the most requested expert Q&As in Phoenix history. Dr. Grant Fraser. Board certified in anti-aging and regenerative medicine. 29 years as an ER physician. And over 300 person-years of clinical experience managing rapamycin in patients. (More details about Dr. Fraser below) More than 50% of his patients are APOE4 carriers. He's also one himself. We spent over an hour going deep on rapamycin for APOE4: dosing, side effects, when to start, what most people get wrong, and some data that stopped me mid-sentence. The full Q&A is on YouTube (link below). But here are 3 things that stood out to me. 1. 400 APOE4 patients. Five years. Zero dementia diagnoses. Dr. Alan Green (a pioneer in rapamycin prescribing) had roughly 1,500 patients on rapamycin before he passed. 300 to 400 of them were APOE4 carriers, mostly in their 60s through 80s. Prime time for cognitive decline. Not a single one received a dementia diagnosis over an average of five years. Now, there are caveats. These patients were affluent, educated, and health-conscious (just by the nature of seeking out someone like Dr. Green). Those factors alone lower dementia risk. But zero out of 300 to 400? Dr. Fraser put it simply: "Seems very unlikely that rapamycin had nothing to do with that." 2. Your rapamycin capsules might only absorb a third of the dose. This one shocked a few of our members. If you're taking compounded rapamycin capsules, Dr. Fraser says you're likely only absorbing about one-third of the dose. The capsule gets destroyed in your stomach before the drug can do its job. His recommendation: only use coated, FDA-approved tablets. They're cheaper too. About 65 cents per milligram at CVS with a GoodRx coupon. Several Phoenix members on the call were taking compounded capsules and had no idea. 3. Same weight. Same age. 6x the dose. This is why "just take 5mg a week" is a bad protocol. Dr. Fraser shared that he has two patients. Same weight, same gender, similar age. One needs 3mg to hit target blood levels. The other needs 18mg. That's a 6x difference. Without measuring blood levels (he targets 3 ng/mL at 50 hours post-dose), you're either underdosed and wasting money, or overdosed and risking metabolic side effects. Personalization isn't optional here. It's the whole game. There's a lot more in the full conversation. We covered when to start based on your genotype (4/4 vs 3/4 vs 4/2), how to time rapamycin around workouts to protect muscle growth, why Brian Johnson stopped (and why Dr. Fraser didn't), a sleep medication that actually lowers beta amyloid levels, and a bunch of live member Q&A. Who is Dr. Grant Fraser:Board Certified: American Board of Anti-Aging and Regenerative Medicine, with fellowship modules in Cardiology, Endocrine and Gastroenterology. Board Certified American Board of Family Medicine. Fellow of the Australian College of Rural and Remote Medicine with Advanced Specialty Training in Emergency Medicine and Generalist Emergency Medicine Post Fellowship Certification. Fellow of the Australian College of General Practitioners. 29 years of experience in Emergency Medicine and Rural Generalist Medicine. Dr. Fraser’s Youtube channel This is the kind of conversation that happens inside The Phoenix every month. If you're already a Phoenix member: submit your questions for our next Q&A with Dr. Fraser on lipid management for APOE4 carriers inside the community. You can also vote on future topics and guests you'd like us to bring on. If you're not a member yet (and you read this far), you're probably a good fit. The Phoenix is where APOE4 carriers stop guessing and start running structured experiments, tracking what actually works, and getting direct access to experts like Dr. Fraser who understand our genetics. Join The Phoenix Community → Talk soon, Kevin Most Newsletters? One-way street.How boring…This is the Phoenix Community. So let's make it a two-way street. Got a question? Feedback? Hit reply. I read every single one. --- ## Why Your Doctor Says "Nothing You Can Do" About APOE4 (And Why They're Wrong) URL: https://apoe4.co/blog/posts/why-your-doctor-says-nothing-you-can-do-about-apoe4-and-why-they-re-wrong Published: 2026-02-19T20:09:15+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: research, cognition, protocols Summary: Your doctor's "nothing you can do" about APOE4 reflects 17-year-old science, not current research. APOE4 carriers may benefit MORE from interventions. Why Your Doctor Says "Nothing You Can Do" About APOE4 (And Why They're Wrong)Dr. Kevin Tran February 19, 2026 Hi Phoenix friend, You watched your parent's memories fade, their personality dissolve, their independence vanish piece by piece. Now you've discovered you carry APOE4 - and your doctor shrugs and tells you there's nothing you can do. They're wrong. Not just slightly off or being cautiously conservative. They're operating on outdated science, and it's costing you years of potential prevention. The same genes that terrified you after watching your parent decline may actually make you more responsive to the interventions your doctor dismissed. I understand this frustration personally. As someone who carries two copies of APOE4 (the 4/4 genotype), I've heard that dismissive response. I've also spent years diving into the research - and what I've found changed everything about how I approach my brain health. Here's what the science actually shows: A landmark 2018 analysis of the FINGER trial found that APOE4 carriers benefit MORE from lifestyle interventions than non-carriers [Solomon et al., 2018]. The 2024 Lancet Commission concluded that 45% of dementia cases are potentially preventable [Livingston et al., 2024]. And for those of us who watched hypertension accelerate our parent's decline, blood pressure control alone can reduce cognitive decline risk by up to 85% in APOE4 carriers [Yasar et al., 2015]. The gap between what science knows and what your doctor tells you isn't a difference of opinion. It's a 17-year translation delay - and your brain can't afford to wait. The 17-Year Knowledge Gap: Why APOE4 Medical Advice Is Outdated You might assume your doctor is working from the latest research. The reality is far more troubling. A systematic review in the Journal of the Royal Society of Medicine found that it takes an average of 17 years for research evidence to reach clinical practice [Morris et al., 2011]. That means discoveries about APOE4-specific intervention benefits published between 2015-2020 may not become standard medical advice until 2032-2037. Meanwhile, a 2009 PLOS Medicine analysis revealed that only 11% of US and Canadian medical schools included practical training in medical genetics [Guttmacher et al., 2009]. Most physicians practicing today received limited genetics education - and what they learned is now obsolete given the rapid advances in understanding gene-environment interactions. "Therapeutic nihilism is a belief that there is no recognized cure or effective treatment for an illness, and therefore treatment or intervention in any form is not important." - Medical Republic Australia, 2024 This attitude has become embedded in dementia care. A study on physician behavior noted that "the legacy of therapeutic nihilism in dementia includes what amounts to a de facto endorsement of the many physicians who opt out of dementia care... These physicians typically argue that, because the drugs do not work, there really is nothing to be done." The cruel irony: The belief that nothing can be done leads to decreased screening, diagnosis, and intervention opportunities - creating a self-fulfilling prophecy. So What Does This Mean for You? If you're an APOE4 carrier who received the "nothing you can do" response, understand this: Your doctor likely isn't dismissing you maliciously. They're operating from training that predates the most important APOE4 research - and from a medical culture that conflates "no cure" with "no prevention." These are not the same thing. What You Can Do About ItSeek physicians trained in precision/functional medicine who understand genetic risk modification Bring research - this article's citations section provides studies you can share with your healthcare team Track your own metrics - blood pressure, blood glucose, lipid panel, sleep quality - to demonstrate the interventions that matter Find community - connect with other APOE4 carriers implementing evidence-based protocols (this is exactly why Phoenix exists) APOE4 Carriers May Benefit MORE From Lifestyle Interventions This finding alone should end the "nothing you can do" narrative. The FINGER trial (Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability) was the first large-scale, long-term randomized controlled trial testing whether a multidomain intervention could prevent cognitive decline. The 2-year study of 1,260 at-risk participants showed remarkable results: 83% greater improvement in executive function, 150% greater improvement in psychomotor speed, and 40% greater improvement in complex memory tasks [Ngandu et al., 2015]. But here's what changed everything for APOE4 carriers: When researchers analyzed the results by genetic status, they found something remarkable. "Our analysis indicates that APOE4 carriers are getting more clear benefit of the intervention. That is, of course, great news, because you can't change your genes." - Dr. Miia Kivipelto, 2018 The 2018 subgroup analysis examined 1,109 participants, including 362 APOE4 carriers, and found that intervention results may be BETTER in carriers of the APOE4 gene [Solomon et al., 2018]. Even more striking: In APOE4 carriers, the intervention counteracted a shortening of telomeres seen in the control group. The U.S. POINTER study confirmed in 2025 that structured high-intensity lifestyle interventions benefit ALL participants regardless of APOE4 carrier status - providing reassurance that genetic status should not discourage intervention. So What Does This Mean for You? If you've been told your genes doom you to cognitive decline, the science says the opposite. Your APOE4 status may make you more responsive to the very interventions your doctor dismissed. The same genetic variant that kept you up at night after your parent's diagnosis could be the reason lifestyle changes work better for you than for your non-carrier friends. What You Can Do About It The FINGER protocol includes four key domains: Nutrition counseling - Mediterranean-style diet emphasis Physical exercise - Aerobic + strength training (150+ minutes/week moderate intensity) Cognitive training - Structured brain exercises Vascular risk monitoring - Blood pressure, blood glucose, lipid management This isn't vague "eat healthy and exercise" advice. It's a specific, tested protocol with measured outcomes - and it works better for people like us. Blood Pressure: The 85% Risk Reduction Nobody Told You About If you watched hypertension accelerate your parent's cognitive decline, this finding will hit differently. A 26-year longitudinal study published in 2015 examined how blood pressure interacts with APOE4 status [Yasar et al., 2015]. The results were staggering: Compared to non-carriers with normal systolic blood pressure (<160 mm Hg): Non-carriers with high SBP: 2.6x relative risk for poor cognitive function APOE4 carriers with normal SBP: 1.3x relative risk APOE4 carriers with high SBP: 13.0x relative risk But here's what matters most: Treatment of hypertension reduced the risk for carriers with high SBP from 13.0 to 1.9 - approximately an 85% risk reduction. Separate research found that in APOE4 carriers, large amounts of amyloid deposited in the brain only if these patients had hypertension. Less amyloid built up if their diagnosed hypertension was controlled with medication [ALZFORUM, 2024]. So What Does This Mean for You? Blood pressure control isn't just "good for your heart." For APOE4 carriers, it's one of the most powerful brain-protective interventions available - potentially reducing your cognitive decline risk by 85%. If your parent had both APOE4 and uncontrolled hypertension, you now understand part of why their decline may have been so severe. And you now know what to prioritize. What You Can Do About ItKnow your numbers: Target systolic BP under 130 mmHg (some research suggests under 120 for APOE4 carriers) Monitor at home: Invest in a validated home blood pressure monitor and track consistently Address root causes: Weight management, sodium reduction, stress management, sleep quality Work with your doctor: Don't dismiss medication if lifestyle isn't enough - this is not the place for medical nihilism Track trends: Phoenix members use our tools to correlate blood pressure with cognitive metrics over time Mediterranean Diet: 35% Risk Reduction for APOE4 Homozygotes A 2025 Nature Medicine study delivered perhaps the most dramatic evidence yet for dietary intervention in APOE4 carriers [Ma et al., 2025]. Researchers followed 4,215 women and 1,490 men for over 30 years, examining how Mediterranean diet adherence interacted with APOE4 status. The findings: "Patients with 2 copies of the APOE4 gene - a major risk factor for Alzheimer's disease - who ate a Mediterranean diet lowered their risk of dementia by 35%." Compare this to non-carriers, who saw only a 5% risk reduction with the same diet. APOE4 homozygotes showed 7x greater benefit from dietary intervention than those without the gene variant. The study found that Mediterranean diet adherence more effectively modulated dementia-related metabolites in APOE4 homozygotes, "suggesting targeted prevention strategies." Additional research on ketogenic approaches shows promise specifically for APOE4 carriers: A case study of a 71-year-old APOE4 heterozygous woman with mild Alzheimer's showed MoCA score improvement from 21 to 28 after 10 weeks on a ketogenic diet [Krikorian et al., 2019] Animal research found female APOE4 mice benefited most from ketogenic diet, with restoration of brain metabolites to APOE3 levels [Ivanich et al., 2025] So What Does This Mean for You? If you carry APOE4 - especially two copies - dietary intervention isn't optional wellness advice. It's one of the most powerful tools available, potentially reducing your risk by more than a third. The metabolic challenges our APOE4 brains face (impaired glucose metabolism, inflammation, reduced DHA transport) are specifically addressed by Mediterranean and ketogenic dietary patterns. What You Can Do About ItMediterranean Diet Protocol: Olive oil as primary fat (4+ tablespoons daily) Fatty fish 3+ times weekly (sardines, mackerel, salmon) Abundant vegetables (6+ servings daily) Nuts daily (especially walnuts) Limited red meat (twice monthly or less) Moderate red wine (or skip entirely - see below) APOE4-Specific Considerations:Omega-3 supplementation: APOE4 brains require more DHA. Research supports 2g/day DHA supplementation [PreventE4 trial, ongoing] Consider ketogenic periods: Time-restricted eating or periodic ketogenic phases may provide alternative brain fuel Limit alcohol: Unlike non-carriers, APOE4 carriers don't show cognitive benefits from moderate drinking - and may show greater decline [PMC, 2013] Sleep Optimization: Why Your Glymphatic System Needs Attention Sleep isn't just rest for APOE4 carriers - it's when your brain clears the amyloid that accelerates decline. Research published in the Journal of Clinical Investigation found that "the effects of sleep deprivation on amyloid-beta deposition and tau seeding and spreading... are exacerbated by the presence of the APOE-e4 allele, suggesting a feed-forward cycle that may be more detrimental and harder to break in the context of APOE4" [Wang et al., 2024]. The glymphatic system - your brain's waste clearance mechanism - activates primarily during deep sleep. APOE4 carriers show reduced and less polarized aquaporin-4, a protein critical for clearing amyloid through this system. But there's encouraging news: A longitudinal study from the Rush Memory and Aging project found that better sleep consolidation attenuated the effect of APOE4 on progression to dementia and AD neuropathology [ALZFORUM, 2024]. So What Does This Mean for You? If you're cutting sleep short to "get more done," you're accelerating the very pathology you fear. For APOE4 carriers, 7-8 hours of quality sleep isn't a luxury - it's essential maintenance. What You Can Do About ItSleep Hygiene Protocol:Consistent schedule: Same bedtime/wake time within 30 minutes, including weekends Temperature: Cool bedroom (65-68F/18-20C) Light exposure: Bright light in morning, dim lights 2 hours before bed Screen curfew: No screens 1 hour before sleep (or use blue-light blocking) Sleep Tracking: Monitor sleep quality with a wearable device (Oura, Whoop, Apple Watch) Track deep sleep percentage - aim for 15-20% of total sleep Correlate sleep quality with next-day cognitive performance Consider Sleep Apnea Screening: Untreated sleep apnea dramatically increases dementia risk APOE4 carriers with sleep apnea may face compounded risk Home sleep studies are now widely available Your 5-Step Protocol: What APOE4 Medical Advice Should Actually Look Like The 2024 Lancet Commission identified 14 modifiable risk factors accounting for 45% of dementia cases [Livingston et al., 2024]. For APOE4 carriers, addressing these factors may provide even greater benefit. Here's your evidence-based action plan: Step 1: Know Your Numbers (This Week) Blood pressure (target: <130/80, consider <120/80) Fasting glucose and HbA1c Lipid panel including LDL (new 2024 Lancet risk factor) Get a sleep study if you snore or wake unrefreshed Step 2: Move Your Body (Starting Today) 150+ minutes moderate aerobic exercise weekly 2+ strength training sessions weekly Research shows highly active APOE4 carriers don't show the elevated amyloid accumulation seen in sedentary carriers Step 3: Feed Your Brain (This Week) Shift toward Mediterranean dietary pattern Add omega-3 supplementation (2g DHA daily) Limit or eliminate alcohol Step 4: Protect Your Sleep (Tonight) Set consistent sleep/wake times Create optimal sleep environment Track sleep quality metrics Step 5: Build Cognitive Reserve (Ongoing) Intellectual engagement can delay cognitive impairment onset by 8-9 years even with APOE4 [Mayo Clinic, 2014] Social connection shows stronger cognitive reserve effects in APOE4 carriers Mindfulness practices enhance cognitive reserve specifically in those with genetic risk The Phoenix Approach: Tracking What Works For You Knowing what to do is only half the battle. The challenge is implementing, tracking, and optimizing these interventions for your specific situation. This is why we built Phoenix. Our platform helps APOE4 carriers: Track interventions across bloodwork, supplements, sleep, exercise, and cognitive performance Identify patterns - which specific protocols move your markers? Connect with accountability pods - small groups of APOE4 carriers implementing evidence-based protocols together Access clinical trials - our pharma partnerships provide early access to emerging therapies like gene therapy You're not meant to do this alone. The APOE4 carriers who thrive aren't just informed - they're supported, accountable, and systematic about their approach.If you are not a member yet, join us here. The Science Is Clear: You Can Do Something Your doctor's dismissive response reflects a 17-year knowledge gap, not current science. The evidence shows: 45% of dementia cases are potentially preventable [Livingston et al., 2024] APOE4 carriers benefit MORE from lifestyle interventions [Solomon et al., 2018] Blood pressure control can reduce risk by 85% in APOE4 carriers with hypertension [Yasar et al., 2015] Mediterranean diet reduces risk by 35% in APOE4 homozygotes [Ma et al., 2025] Sleep quality attenuates APOE4's effect on dementia progression [Rush Memory and Aging Project] You watched your parent's decline with helpless dread. But you're not helpless. The same genes that drive your fear may make you more responsive to prevention. The question isn't whether there's something you can do. The question is whether you'll do it. Sources Morris ZS, Wooding S, Grant J. "The answer is 17 years, what is the question: understanding time lags in translational research." Journal of the Royal Society of Medicine. 2011. https://journals.sagepub.com/doi/full/10.1258/jrsm.2011.110180 Ngandu T, Lehtisalo J, Solomon A, et al. "A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER)." The Lancet. 2015. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)60461-5/abstract Solomon A et al. "Effect of the Apolipoprotein E Genotype on Cognitive Change During a Multidomain Lifestyle Intervention." JAMA Neurology. 2018. https://www.sciencedaily.com/releases/2018/01/180125101309.htm Livingston G et al. "Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission." The Lancet. 2024. https://pubmed.ncbi.nlm.nih.gov/39096926/ Yasar S et al. "Blood pressure interacts with APOE e4 to predict memory performance in a midlife sample." PMC. 2015. https://ncbi.nlm.nih.gov/pmc/articles/PMC4549217 Ma J et al. "Interplay of genetic predisposition, plasma metabolome and Mediterranean diet in dementia risk and cognitive function." Nature Medicine. 2025. https://www.nature.com/articles/s41591-025-03891-5 Guttmacher AE et al. "The Dawning Era of Personalized Medicine Exposes a Gap in Medical Education." PLOS Medicine. 2009. https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1000138 Medical Republic Australia. "Therapeutic nihilism around dementia care." 2024. https://www.medicalrepublic.com.au/therapeutic-nihilism-around-dementia-care/110769 Krikorian R et al. "Ketogenic diet rescues cognition in ApoE4+ patient with mild Alzheimer's disease." Diabetes & Metabolic Syndrome. 2019. https://pubmed.ncbi.nlm.nih.gov/31336463/ Ivanich JL et al. "Ketogenic Diet Modulates Gut Microbiota-Brain Metabolite Axis in APOE4 Mice." Journal of Neurochemistry. 2025. https://pubmed.ncbi.nlm.nih.gov/40890565/ Journal of Clinical Investigation. "Connections between ApoE, sleep, and amyloid-beta and tau pathologies in Alzheimer's disease." JCI. 2024. https://www.jci.org/articles/view/171838 ALZFORUM. "From ApoE to Zzz's - Does Sleep Quality Affect Dementia Risk?" https://www.alzforum.org/news/research-news/apoe-zzzs-does-sleep-quality-affect-dementia-risk ALZFORUM. "Controlling Blood Pressure May Lower Amyloid in ApoE4 Carriers." https://www.alzforum.org/news/research-news/controlling-blood-pressure-may-lower-amyloid-apoe4-carriers Shinto LH et al. "Effect of Omega-3 Fatty Acids on Alzheimer's Disease Biomarkers in APOE4 Carriers." JAMA Network Open. 2024. https://advances.massgeneral.org/neuro/article-external.aspx?id=1170 PreventE4 Trial. "Baseline Findings of PreventE4: A Double-Blind Placebo Controlled Clinical Trial Testing High Dose DHA in APOE4 Carriers." JPAD. 2023. https://link.springer.com/article/10.14283/jpad.2023.77 O'Shea DM et al. "APOE e4 carrier status moderates the effect of lifestyle factors on cognitive reserve." Alzheimer's & Dementia. 2024. https://alz-journals.onlinelibrary.wiley.com/doi/full/10.1002/alz.14304 Memory and Brain Wellness Center (Mayo Clinic research). "6 Things We Know About Resilience in Alzheimer's Disease." https://depts.washington.edu/mbwc/news/article/6-things-we-know-about-resilience-in-alzheimers-disease PMC. "The Relationship Between Midlife and Late Life Alcohol Consumption, APOE e4 and the Decline in Learning and Memory Among Older Adults." 2013. https://pmc.ncbi.nlm.nih.gov/articles/PMC3865814/ Chao S et al. "Health Behavior Changes After Genetic Risk Assessment for Alzheimer Disease: The REVEAL Study." PMC. 2008. https://pmc.ncbi.nlm.nih.gov/articles/PMC2483341/ Alzheimer's Association. "World-Wide FINGERS Network - U.S. POINTER Study." https://www.alz.org/wwfingers/overview.aspThis article is for educational purposes only and does not constitute medical advice. Always consult with qualified healthcare providers before making changes to your health protocols.Most Newsletters? One-way street.How boring…This is the Phoenix Community. So let's make it a two-way street. Got a question? Feedback? Hit reply. I read every single one. --- ## 10g of creatine destroyed his deep sleep - Phoenix App Insights URL: https://apoe4.co/blog/posts/10g-of-creatine-destroyed-his-deep-sleep-phoenix-app-insights Published: 2026-02-16T20:08:05+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: community, tracking, sleep, supplements Summary: Track your brain health with the Phoenix app—personalized Alzheimer's prevention for APOE4 carriers, turning data-driven insights into actionable strategies for cognitive protection. 10g of creatine destroyed his deep sleep - Phoenix App InsightsAnd that's just one of 47 correlations members found this month with our AppDr. Kevin Tran February 16, 2026 Hi Phoenix friend, Something interesting happened last week. A Phoenix member noticed that every time he took 10g of creatine daily, his deep sleep dropped by about 35%. His sleep score tanked 25%. He didn't read that in a study. He didn't hear it on a podcast. He saw it in his own data. Tracked over weeks. Clear as day. Another member started a simple experiment: a 15-minute sunrise walk every morning. Within two weeks, she reported her mood improved by +2 points on her daily check-in. Brain fog? Noticeably better. These aren't hypotheticals. They're real patterns from real APOE4 carriers who are tracking, testing, and actually finding out what works for their biology. And now, all of that fits in your pocket. The Phoenix app just launched on iOS. We built it as your one-stop health hub. Everything you need to run your personal Alzheimer's prevention protocol (and actually know if it's working) is in one place. Here's what's inside. Supplement tracking with community intelligence This is where it gets powerful. You're not just tracking what you take. You're seeing what hundreds of other APOE4 carriers are taking, what they're reporting, and what patterns are emerging across the community. Wanting to lower your cholesterol? Community data from other carriers shows patterns like: members taking ezetimibe tend to see about 25% lower LDL-C on average. Those following a Mediterranean keto approach? Roughly 30% reduction in ApoB, 23% less brain fog, and about 35% better cognition scores. You could spend years guessing. Or you could learn from people with your exact genetic profile who are already testing these interventions. Daily check-ins that actually reveal something Most health tracking is just... logging. You write down numbers. Nothing happens. Phoenix check-ins are different. They're designed to surface correlations you'd never spot on your own. Sleep quality vs. supplement timing. Exercise type vs. brain fog. Mood vs. diet changes. Over time, your data starts telling a story. A story that's yours (not some generic recommendation from someone who doesn't share your genetics). Wearable integration (Apple Health & Google Health Connect) Your Oura ring. Your Apple Watch. Your Whoop. They're already collecting incredible data. The Phoenix app pulls it all together and layers it against your interventions, your bloodwork, and your daily check-ins. That's how you find correlations like the creatine-sleep connection. Not by reading studies (though we love those too). By looking at YOUR data, in context, over time. Bloodwork tracking with APOE4-specific ranges Upload your blood test results. The app extracts your biomarkers automatically and shows you where you stand (not against the general population, but against ranges that actually matter for APOE4 carriers). Track trends over time. See if your interventions are moving the needle. Because knowing your ApoB is "in range" means nothing if that range wasn't built for your genetics. Community insights from carriers like you Here's what makes Phoenix fundamentally different from every other health app. Every APOE4 carrier member who tracks and tags their data makes the community smarter. Every data point strengthens the patterns. Every experiment (whether it "works" or not) helps the next person. One member's failed supplement experiment saves another member months of wasted effort. One member's breakthrough protocol becomes a starting point for dozens of others. The more people track, the more powerful the insights become. For everyone. This is what "collective intelligence" actually looks like in practice. So why does this matter? If you're an APOE4 carrier, you already know the frustration. Conflicting advice. Generic protocols. Doctors who say "come back when you're 60." Longevity clinics that cost $50K a year and still can't tell you what works specifically for APOE4. The Phoenix app gives you something that didn't exist before: a way to see what's actually working for people with YOUR genetics. Not theoretical. Not hypothetical. Real interventions, real data, real outcomes. You stop guessing. You start knowing. Phoenix member? Download the app on iOS today: Phoenix APOE4 on the App Store Android users: you're 1-2 weeks away. We're in the final stage of Google's authorization process. It's coming. Not a Phoenix member yet? Everything I just described (the bloodwork tracking, supplement intelligence, community correlations, wearable integration) is available to Phoenix members. Our members aren't just tracking their health. They're running structured experiments, sharing what works, and building the largest dataset of APOE4-specific health interventions in the world. If you've been on the fence, this is a good time to get off it. Join Phoenix → We're 425+ APOE4 carriers strong. The data gets better every day. And now, it's all in your pocket. Talk soon, Kevin P.S. Remember those creatine and sunrise walk findings I mentioned at the top? Those only exist because members committed to tracking consistently. Every day. Every supplement. Every check-in. The members who get the most out of Phoenix are the ones who treat their data like it matters. Because it does. Not just for them (for the entire community). Most Newsletters? One-way street.How boring…This is the Phoenix Community. So let's make it a two-way street. Got a question? Feedback? Hit reply. I read every single one. --- ## She's had APOE4/4 for 10 years. She's still sharp at 72. URL: https://apoe4.co/blog/posts/she-s-had-apoe4-4-for-10-years-she-s-still-sharp-at-72 Published: 2026-02-13T19:40:06+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: community, supplements, cognition Summary: Donna has carried APOE4/4 for 10 years. At 72, she's cognitively sharp. Watch her full interview and see the exact protocol she uses to beat the odds. She's had APOE4/4 for 10 years. She's still sharp at 72."I found my people" — Donna's APOE4 storyDr. Kevin Tran February 13, 2026 Hi Phoenix friend, Something new today. I've been wanting to do this for a while. Share real stories from real Phoenix members. Not theory. Not research papers. Just people like you, doing the work, figuring it out. This is the first of many. Meet Donna. The moment everything changed Donna found out she was APOE4/4 almost 10 years ago. She was 62. It happened by accident. A Yale research study asked for saliva samples. She said sure. Nobody explained what they were looking for. Then they called her back in. "At first I was just numb," she told me. "And then of course I went home and went on the internet. And started really freaking out." Sound familiar? Back then, nobody was talking about this. No communities. No protocols. No one to turn to. She mentioned it to her doctor. They looked at her "like she had two heads." So she figured it out alone. What she does now (at 72, cognitively intact) Donna has spent a decade refining her protocol. Here's what's currently in her stack: Supplements: MitoCU (mitochondrial support) Curcumin (this one's her favorite — she had word-finding problems, started curcumin, and "boom, gone") N-Acetylcysteine (NAC) Sulforaphane (broccoli extract, just added) Magnesium glycinate (sleep) Melatonin (low dose, sleep) Zinc and thiamine (based on her genetics) Pendulum Akkermansia (probiotic for blood sugar) Hormones: HRT (hormone replacement therapy — she knows it's controversial, made a personal choice to stay on it) Thyroid medication Food-as-medicine: Caviar daily (yes, really — high in DHA and EPA, her omega-3 source) Salmon, sardines, fatty fish regularly One egg a day for choline What she dropped: Liposomal glutathione (redundant) L-theanine (did nothing for her) Lithium orotate (caused insomnia — out the door) Citicoline (also caused insomnia) Strict keto (she's a lean mass hyper-responder — her cholesterol shot up and she couldn't sleep) Total monthly cost? Over $400. "You can't put a price on your cognition," she said. I agree. The part that surprised me Donna's sharp. Like, really sharp. At 72, after 10 years of carrying two copies of the highest-risk Alzheimer's gene. But here's what stuck with me most. When I asked what finding Phoenix meant to her, she paused. Then said: "It's like I found my people." She talked about the lonely years. Friends who meant well but didn't understand. Facebook groups full of fear and noise. Functional medicine doctors charging $700/hour. Then she found a community of people fighting the same fight. Running real experiments. Sharing what works. Holding each other accountable. "There are times you just want to sit down with a chocolate candy bar and give up," she said. "But you realize there's support behind you." Watch the full conversation I sat down with Donna for almost an hour. We covered everything. How she told her kids. What she'd say to someone who just got diagnosed. Why she thinks it's never too late (she met 80-year-olds in Bredesen's program who were just starting out and seeing results). It's raw. It's real. And I think it'll help. This is just the beginning Donna is the first. There will be more. If you're a Phoenix member and want to share your story, reply to this email. I want to hear from you. And if you're not a member yet? Donna spent years doing this alone. You don't have to. 👉 Join The Phoenix Community Talk soon, Kevin P.S. — Donna's advice for anyone who just found out they're APOE4: "If you're young, you're gonna be fine. There's so much research coming. If you're older, don't freak out. There are protocols. You have control over this." Watch the full interview to hear the rest.Most Newsletters? One-way street.How boring…This is the Phoenix Community. So let's make it a two-way street. Got a question? Feedback? Hit reply. I read every single one. --- ## The Missing Piece in Brain Health Tracking: Why We're Partnering with Sens.ai (member) URL: https://apoe4.co/blog/posts/the-missing-piece-in-brain-health-tracking-why-we-re-partnering-with-sens-ai-member Published: 2026-02-10T17:31:08+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: tracking, therapies, cognition Summary: Uncover the science of brain health tracking: Join our neurofeedback study for APOE4 carriers and discover personalized insights to optimize cognitive performance and longevity. The Missing Piece in Brain Health Tracking: Why We're Partnering with Sens.ai (member)A neurofeedback study for APOE4 carriers (and anyone serious about cognitive longevity)Dr. Kevin Tran February 10, 2026 Hi Phoenix friend, Here's a question that keeps me up at night: How do I know if what I'm doing is actually working? I take supplements. I exercise. I track my sleep. I've optimized my diet. I do all the things the research says should protect my brain. But my brain doesn't come with a dashboard. I can see my cholesterol on a blood test. My VO2 max on my watch. My HRV every morning. But cognition? Processing speed? Whether my brain is aging faster or slower than it should? That's mostly... guesswork. Until now. The Feedback Loop Problem Over the past year, we've run studies on photobiomodulation helmets and vagus nerve stimulation devices. We've tracked supplements and exercise and sleep interventions across hundreds of members. And we keep running into the same problem. People do interventions. They feel better. Or they don't. But "feeling sharper" isn't data. It's not something you can optimize. It's not something that tells you whether to continue, adjust, or abandon what you're doing. We needed objective cognitive tracking. Something that could measure whether interventions actually move the needle on brain function. That's why we're partnering with Sens.ai. Checkout our Q&A with Sens.ai CEO Paola What is Sens.ai? Let me explain what this thing actually is. Because it's not what you might expect. Sens.ai is a neurofeedback headset. But neurofeedback is just one piece. It combines five different modalities: 1. Neurofeedback (the core) Your brain produces electrical signals. Different patterns correspond to different mental states (focused, relaxed, creative, anxious). Neurofeedback makes these invisible patterns visible. Here's how it works: sensors on your scalp read your brainwaves in real-time. That signal gets converted into audio and visual feedback. When your brain hits the target state, you get positive reinforcement (the sound gets louder, the image gets clearer). When it drifts, the feedback dims. It's like a hands-free video game. Your brain learns to reproduce the states that get rewarded. The research on neurofeedback spans 50+ years. It's been used for ADHD, anxiety, PTSD, concussion recovery, and cognitive enhancement. The best clinical protocols typically cost $15,000+ for a week of treatment [1]. Sens.ai took those protocols and put them in a $1,250 headset you can use at home. 2. Photobiomodulation Near-infrared light (810nm wavelength) delivered through the skull. This primes your brain before training. Think of it as a warm-up. If you've followed our previous studies, you know we've been tracking photobiomodulation for a while. Sens.ai's version includes binaural beats and guided meditations during the light therapy, making the experience more immersive. 3. HRV Biofeedback A pulse oximeter on the ear cup measures your heart rate variability. The app guides you through resonance breathing to activate your parasympathetic nervous system. This is the foundation. You can't train higher brain states effectively when your nervous system is in fight-or-flight mode. HRV biofeedback calms you down first. 4. Binaural Beats Audio frequencies that support state shifts. Nothing revolutionary on its own, but integrated well into the overall experience. 5. ERP Assessments (This is the key part) Event-Related Potentials. Objective cognitive tests that measure: P300 latency: How fast your brain processes new information and makes decisions Peak Alpha Frequency: A biomarker linked to cognitive performance and intelligence Reaction time and accuracyImpulse control These aren't subjective questionnaires. They're measurements of your brain's electrical response to specific stimuli. You can track them over time. You can see if they improve. And here's what gets me excited: Sens.ai is developing a biological brain age clock in partnership with the Buck Institute (the largest longevity research organization in the US). Coming in April 2025. This will tell you if your brain is aging faster or slower than expected. Not based on how you feel. Based on measurable neural signals. The Data So FarSens.ai has published results from their protocols [2]: Sleep Nirvana Mission (4-week sleep protocol): 77% reported improved sleep quality 7.5% faster reaction time 40% improvement in impulse control 7.4% faster brain processing speed (P300 latency) Sharp Mind Mission (designed for cognitive aging): Improvements in peak alpha frequency (typically declines with age) Enhanced P300 markers Better reaction time and accuracy The company has a good track record of transparency. They publish white papers with their results. They're building a learning system that continuously measures outcomes across users. Is it perfect evidence? No. These are company-published studies, not independent peer-reviewed trials. But the underlying science of neurofeedback is well-established [3][4], and having objective before/after measurements is a massive improvement over "I think I feel better." Why This Matters for APOE4 Carriers APOE4 carriers face a specific challenge: brain changes can begin 20-30 years before cognitive symptoms appear [5]. That means the window for intervention is now. Not when we start forgetting names. Not when we can't find our keys. Now. But it also means we're flying blind. We don't have symptoms to track. We don't have obvious feedback on whether our interventions are working. Research shows that cognitive engagement may be particularly protective for APOE4 carriers [6]. Active brain training (not passive consumption) appears to reduce amyloid deposition in carriers more than non-carriers [7]. Neurofeedback is essentially structured cognitive engagement. Your brain actively works to achieve target states. It's exercise for neural pathways. Combined with objective tracking, this gives us something we've never had: a feedback loop for brain health. How the Study WorksHere's the deal:Go to sens.ai/phoenixUse code PHOENIX for $100 off ($1,150 instead of $1,250) Try it for 60 days (satisfied or reimbursed guarantee, no risk) Use whatever mode works for you (Sharp Mind, Sleep Nirvana, Attention Mastery, etc.) Unlike our previous studies, this one is open-ended. No rigid protocol. Use the device the way that makes sense for your goals.And this is open for non Phoenix members! If you are a member: Opt in to the study in the Phoenix app Log your sessions in your daily check-ins (mode, duration, experience) Connect your wearables (Oura, Whoop, Apple Health) once our app update launches We'll correlate your Sens.ai sessions with your sleep, HRV, and subjective wellbeing data Practical DetailsPrice: $1,150 with code PHOENIX (normally $1,250) Subscription: $29/month for the personal membership (required for the AI-guided protocols) Family plan: Coming Q1 (~$45/month for multiple users sharing one headset) Shipping: Worldwide (US, Canada, UK, Australia, Europe, etc.) Return policy: 60-day satisfaction guarantee. Use it for two months. If it doesn't work for you, return it. Best results: 8+ weeks of consistent use, 15+ minutes per session, 5 times per week What We're Building This partnership is part of a larger vision. At Phoenix, we're trying to solve the measurement problem for brain health. We're building a platform where you can: Track your interventions (supplements, devices, lifestyle changes) Log your daily experience (energy, focus, sleep quality, mood) Connect your wearables (continuous HRV, sleep architecture, activity data) Upload your blood tests (we have AI analysis for APOE4-specific biomarkers) Run structured experiments with peer accountability And now, with partners like Sens.ai, add objective cognitive assessments to the mix. The goal? Know what's working. Stop guessing. Optimize based on data. I believe this is the kind of infrastructure we need. The Bottom Line Neurofeedback has 50 years of clinical research behind it. Sens.ai makes it accessible at home. They include objective cognitive assessments. They're building a brain age clock. There's a 60-day money-back guarantee. Zero risk. If you're already spending money on brain supplements, sleep trackers, and health optimizations, this is a tool that might actually tell you if those things are working. Link: sens.ai/phoenixCode: PHOENIX ($100 off) Try it. Track it. Let's see what the data shows. References [1] Clinical neurofeedback protocols typically range from $150-200 per session, with 10-30 sessions recommended. Five-day intensive programs at top clinics can cost $15,000+. [2] Sens.ai User Results. Sleep Nirvana Mission Protocol and Sharp Mind Mission data. https://sens.ai/results [3] Marzbani H, Marateb HR, Mansourian M. Neurofeedback: A Comprehensive Review on System Design, Methodology and Clinical Applications. Basic Clin Neurosci. 2016 Apr;7(2):143-58. https://pubmed.gov/27303609 [4] Zoefel B, Huster RJ, Herrmann CS. Neurofeedback training of the upper alpha frequency band in EEG improves cognitive performance. Neuroimage. 2011 Jan 15;54(2):1427-31. https://pubmed.gov/20850552 [5] Bateman RJ, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012;367(9):795-804. https://pubmed.gov/22784036 [6] Berkowitz CL, Mosconi L, Rahman A, et al. Clinical Application of APOE in Alzheimer's Prevention: A Precision Medicine Approach. J Prev Alzheimers Dis. 2018;5(4):245-252. https://pubmed.gov/30298183 [7] Landau SM, et al. Association of lifetime cognitive engagement and low β-amyloid deposition. Arch Neurol. 2012;69(5):623-629. https://pubmed.gov/22271235Dr. Kevin Tran is the founder of The Phoenix Community, a platform helping APOE4 carriers beat the odds through structured experimentation, biomarker tracking, and collective intelligence. He is an APOE4/4 carrier, Doctor of Pharmacy, and former healthcare strategy consultant.Join the study: sens.ai/phoenix | Code: PHOENIXJoin The Phoenix Community: thephoenix.communityQuestions? kevin@thephoenix.communityMost Newsletters? One-way street.How boring…This is the Phoenix Community. So let's make it a two-way street. Got a question? Feedback? Hit reply. I read every single one. --- ## 82 Posts. 2 Drug Studies. 1 Mobile App Launch. URL: https://apoe4.co/blog/posts/82-posts-2-drug-studies-1-mobile-app-launch Published: 2026-02-07T17:30:05+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: community, research, tracking, therapies Summary: In January 2026, Phoenix Community members got early access to APOE4 drug breakthroughs, launched neurofeedback studies, beta-tested a new health app, and debated cutting-edge Alzheimer's research. Here's what you missed. 82 Posts. 2 Drug Studies. 1 Mobile App Launch. Here's what APOE4 carriers were doing inside Phoenix.Dr. Kevin Tran February 07, 2026 Hi Phoenix friend, 82 posts in 30 days. That's how much happened inside the Phoenix Community this January. Real conversations. Real science. Real people fighting to outsmart Alzheimer's before it starts. And you weren't in the room. Here's a peek at what our members were doing while you were Googling "APOE4 supplements" for the hundredth time. The Phoenix Mobile App Is Live We launched the Phoenix Mobile App beta in January for both iOS and Android. A dedicated health hub built specifically for APOE4 carriers combining bloodwork, wearable data (integration with Apple Health and Google Health) and check-ins. Combined with bloodwork, members log their interventions and daily life events (e.g.late dinner, alcohol, travel, supplements, etc.). Over time, this lets us derive insights like: "Taking magnesium glycinate increased your sleep score by 15%" "Taking ezetimibe reduced your LDL-c by 20%" We aggregate this data at the community level to give personalized suggestions: "Based on similar members, here are the highest-impact levers for your goals." This data also helps us identify hyper-responders for clinical trial recruitment. Blood test tracking with AI-powered analysis. APOE4-specific biomarker ranges (not the generic ones your doctor uses). Supplement tracking with community ratings from people who share your genetics. Members were uploading blood work, catching bugs, giving feedback, and watching their health data come to life. All in real time. All built by a founder who carries APOE4/4 himself. One member uploaded blood tests three times by accident. Found a bug. Reported it. We fixed it. That's the beauty of building with your community, not for them.A Potential APOE4 Drug Just Dropped Phase 3 Results The APOLLOE4 Phase 3 findings came out. This is massive. ALZ-801 (valiltramiprosate) is one of the first drugs specifically targeting APOE4 carriers. Not the general Alzheimer's population. You. Our members didn't just read the headline. They dissected the data together. They debated whether this could be the preventive drug APOE4 carriers have been waiting for. They weighed the evidence. They asked the hard questions most news articles skip. This is what happens when 390+ motivated, science-literate people analyze a breakthrough in real time. You can read a press release anywhere. You can't get that kind of peer analysis anywhere else. Two Active Device Studies (Members Only) While most people wonder if red light therapy or neurofeedback "actually works," our members are testing it. The Neuronic ZenoWell Study wrapped up its active phase this month. Members enrolled, tracked outcomes, shared honest feedback (some loved it, some didn't feel it, some had side effects like dry mouth). That's how real science works. No hype. Just data. The Sens.ai Neurofeedback Helmet Study launched. Another device, another structured experiment, another chance to be part of real-world evidence generation. These aren't paid ads. These are medtech partnerships where Phoenix members get early access to devices and contribute to actual research. Companies come to us because our members are engaged, compliant, and already tracking their health data. (Our first partnership enrolled 45 members in 5 days. The target was 30 in 2 weeks.) Research Discussions That Actually Matter Here's a sample of what our members were digging into this month: Obicetrapib. A cholesterol drug with intriguing implications for APOE4 carriers. Members shared data, debated mechanisms, and connected it to their own lipid panels. The Bredesen ReCODE Protocol. A new clinical trial paper came out. Instead of taking it at face value, our community did a critical read. What does the evidence actually show? Where are the gaps? That's the standard inside Phoenix. CRISPR 2.0. More precise gene editing. More hope for neurological disorders. Members discussed what this means for APOE4 carriers specifically (and whether gene therapy could one day rewrite our risk entirely). USC's New APOE4/4 Research Department. A major university just created an entire department to study people like us. Our members were discussing the implications before most news outlets covered it. Rapamycin, Selegiline, Omega-3 (LPC-DHA), plant sterols, alpha-ketoglutarate. Not random supplement chatter. Structured discussions with citations, personal bloodwork, and honest reports of what's working and what's not. The Stuff Nobody Talks About Some of the most valuable conversations weren't about breakthroughs at all. One member shared their frustration. Just... frustration. The weight of carrying this gene. The community showed up. Another member's MOCA follow-up appointment got cancelled. Members helped navigate next steps. Someone asked about anesthesia risks for APOE4 carriers. (Bet your doctor never mentioned that.) Gas stoves. Tattoo safety. Whether pink noise actually helps sleep (a new study says maybe not). These are the niche, APOE4-specific questions you can't Google effectively. But you can ask 320+ people who live this every day. A Community That Moves Together January kicked off with our monthly Goals and Accountability posts. Members set targets. Shared progress. Held each other to it. Our members don't just consume content. They recruit new members, push for pharmaceutical partnerships, share research, and openly track their health journeys with each other. Average biomarker improvements for engaged members over 3-6 months: ApoB down 15%. HbA1c down 8%. Body fat down 12%. Those aren't hypothetical. Those are our members' actual numbers. So Why Aren't You Here Yet? Look. You can keep piecing together Alzheimer's prevention advice from Reddit threads, random podcasts, and Dr. Google. Or you can join the only community built specifically for APOE4 carriers. By an APOE4/4 carrier. With real data, real experiments, real partnerships, and real people who understand exactly what you're going through. January alone had 82 posts of science, support, and action. February is already underway. Join the Phoenix Community → The question isn't whether you can afford to join. It's whether you can afford to keep missing this. Most Newsletters? One-way street.How boring…This is the Phoenix Community. So let's make it a two-way street. Got a question? Feedback? Hit reply. I read every single one.The Phoenix Community is a private, science-driven membership for APOE4 carriers and anyone serious about Alzheimer's prevention. Founded by Dr. Kevin Tran (APOE4/4), we combine structured health experiments, expert access, pharmaceutical partnerships, and peer accountability to help members take control of their cognitive future. --- ## The Phoenix App for APOE4 Is Here URL: https://apoe4.co/blog/posts/the-phoenix-app-for-apoe4-is-here Published: 2026-01-30T19:24:04+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: community, tracking Summary: Discover the Phoenix mobile app: Your personalized APOE4 health companion with intelligent daily check-ins, designed to transform brain health tracking and empower proactive wellness. The Phoenix App for APOE4 Is Here Your Health Hub, In Your PocketDr. Kevin Tran January 30, 2026 Hi Phoenix friend, A confession first. This was supposed to be one of the surprises in our Phoenix Advent Calendar back in December. We had it planned. We were excited. But building a health app turned out to be much harder than we expected. We missed the deadline. Jason and I spent months longer than planned building, testing, and rebuilding. It wasn't ready for the Advent Calendar. But it's ready now :) The Phoenix mobile app is in beta -- for both iOS and Android.Two features we're most excited about.1. Daily Check-Ins That Actually Connect The Dots If you've been following Phoenix, you know blood tests are just one snapshot. What happens between those snapshots -- the daily decisions, the habits, the experiments -- that's where the real signal is. The app gives you daily check-ins. They take 30 seconds. You rate how you feel, tag what you did, and move on. Think of it as a micro-journal for your health. Over time, Phoenix connects the dots and surfaces patterns you'd never catch on your own: "When you eat late, your HRV drops by 20%.""When you take magnesium glycinate before bed, your sleep score improves by 15%.""No alcohol + early bedtime + cold plunge = your best mental clarity days." These aren't generic wellness tips. They're insights from your data, interpreted through an APOE4 lens. 2. Your Health Hub -- Everything In One Place The app connects to Apple Health and Google Health, which means your wearables (Oura, Whoop, Garmin, Apple Watch, and more) feed data in automatically. Sleep. HRV. Recovery metrics. No manual entry. No spreadsheets. Your wearable data, your bloodwork, your supplements, your daily habits -- all in one place. And here's where it gets powerful: as more carriers track, we'll use anonymized community data to show you what's working for people with similar genetics, similar biomarkers, similar lifestyles. Not "eat well and exercise." Real patterns from real APOE4 carriers. Now -- this is a beta. There will be bugs. That's a guarantee. But that's also why we're opening it up now. We want to build this with you, not just for you. If you're already a Phoenix member -- you get first access. Just email me directly and we'll send you the download link directly. We're looking for members who will use it daily, break things, and tell us about it. If you're not a Phoenix member yet -- this might be worth a look :). The app is just one part of what we're building: bloodwork tracking with APOE4-optimized ranges, a supplements library, community experiments, pod matching with other carriers, and now a mobile health hub that ties it all together. Every week, our members are discovering patterns in their data that change how they eat, sleep, supplement, and live. The app makes that easier than ever. Join Phoenix here We didn't build this alone. We're not finishing it alone either. -- Kevin P.S. We know the Advent Calendar surprise is a few weeks late. But we'd rather ship something good than ship something fast. Thanks for sticking with us. Most Newsletters? One-way street.How boring…This is the Phoenix Community. So let's make it a two-way street. Got a question? Feedback? Hit reply. I read every single one. --- ## The APOE4 Blood Work Panel: What to Test and When URL: https://apoe4.co/blog/posts/the-apoe4-blood-work-panel-what-to-test-and-when Published: 2026-01-28T21:31:52+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: tracking, research, cognition Summary: APOE4 carriers face 6.6x higher Alzheimer's risk with chronic inflammation. Learn the exact blood tests, optimal ranges, and testing frequency to protect your brain. The APOE4 Blood Work Panel: What to Test and WhenThe exact biomarkers, optimal ranges, and testing schedule I wish I'd known a year agoDr. Kevin Tran January 28, 2026 Hi Phoenix friend,First of all, if you haven’t downloaded it yet, get the APOE4 Blood Work Blue Print guide. This is a free .pdf guide that synthesizes everything you need to know about APOE4 optimal bloodwork to do. There’s even a page that you can print and bring to your doctor.Now if you want to dive further, let’s continue. APOE4 carriers with chronic inflammation face a 6.63x higher risk of Alzheimer's disease [Tao et al., 2018]. That single statistic changed everything about how I approach blood work. As an APOE4 4/4 carrier myself, I spent years getting "normal" lab results while watching markers that actually mattered slip through the cracks. The problem? Standard lab ranges were developed for the general population. They were never designed for people like us. Here is the uncomfortable truth: your doctor's "everything looks fine" may be inadequate when you carry the APOE4 variant. The research is clear that APOE4 carriers have distinct metabolic, inflammatory, and lipid patterns that require tighter targets and different biomarkers entirely. In this guide, you will learn: Why standard "normal" ranges can be misleading for APOE4 carriers The exact biomarkers to test across inflammation, lipids, metabolism, and nutrients APOE4-specific optimal ranges backed by peer-reviewed research A testing schedule by age (40s, 50s, 60s+) What to do when markers are elevated This is the blood work panel I wish someone had given me a year ago.Let's get into it. Why Standard Lab Ranges Fall Short for APOE4 CarriersThe Research Standard laboratory reference ranges are derived from population averages. They tell you whether you fall within the statistical norm, not whether you are optimized for brain health. For APOE4 carriers, this distinction is critical. The 2021 Trumble study of the Tsimane people revealed something fascinating: in their traditional environment, APOE4 carriers actually showed 30% lower C-reactive protein than non-carriers [Trumble et al., 2021]. This suggests the APOE4 variant may have evolved advantages that only become problematic in modern, inflammatory environments. What this means is that "normal" inflammation levels in our processed-food, sedentary world may represent a state of chronic disease risk for APOE4 carriers specifically. KEY INSIGHT: The harmful effects of APOE4 seen in industrialized societies may reflect a mismatch between a person's environment and their genes [Trumble et al., 2021].So What Does This Mean for You? If you carry APOE4, you cannot rely on falling within standard ranges. A CRP of 2.5 mg/L might be "normal" on paper, but for an APOE4 carrier, it represents significantly elevated risk. Your doctor may not flag it. You need to know to flag it yourself. This is not about being anxious or over-testing. It is about being precise with the biomarkers that matter most for your genetic profile. Action Steps: Shifting Your Lab MindsetRequest copies of all lab results (not just "normal/abnormal" summaries) Track trends over time rather than single snapshots Use APOE4-specific optimal ranges (detailed throughout this article) Work with a practitioner familiar with functional/precision medicine who understands these distinctions Log results in Phoenix's Bloodwork Module to visualize patterns across years The APOE4 Inflammation Panel: hs-CRP and HomocysteineThe Research The 2018 Framingham Heart Study analysis delivered perhaps the most actionable finding for APOE4 carriers: those with chronic inflammation (CRP above 8 mg/L) plus APOE4 faced a 6.63x increased Alzheimer's risk compared to non-carriers without inflammation [Tao et al., 2018]. Even more striking: this inflammatory effect was associated with a 3.52x higher risk of earlier disease onset (HR 3.52, 95% CI: 1.27-9.75) and visible brain atrophy in the temporal lobe and hippocampus. This effect was NOT observed in APOE2 or APOE3 carriers. THE DATA: 194 of 2,656 Framingham participants developed dementia over 17 years. The APOE4 + chronic inflammation combination showed the strongest predictive signal of any measured factor. For homocysteine, the Framingham Offspring Study found that levels above 14 umol/L nearly doubled Alzheimer's risk [Seshadri et al., 2002]. The international consensus statement on homocysteine identifies a threshold of 10-13 umol/L as the point where cognitive effects begin [Smith et al., 2018]. So What Does This Mean for You? If you are an APOE4 carrier, inflammation is not a vague concept to worry about "eventually." It is a measurable, modifiable factor that dramatically influences your disease risk trajectory. The Tao study used repeated CRP measurements over time to define "chronic" inflammation. A single elevated reading may reflect an acute infection or temporary stressor. But persistently elevated CRP is a red flag requiring immediate attention. Homocysteine is equally actionable. Unlike genetic risk, homocysteine responds directly to B vitamin supplementation, particularly in those with elevated baseline levels. Action Steps: Managing InflammationTesting Protocol:hs-CRP (high-sensitivity, not standard CRP): Test every 6-12 months Homocysteine: Test annually; retest 3 months after starting B vitamins APOE4 Optimal Targets: hs-CRP: Below 1.0 mg/L (ideally below 0.5 mg/L) Homocysteine: Below 10-11 umol/L If hs-CRP is elevated (above 1.0 mg/L): Investigate root causes (infections, gut health, sleep apnea, periodontal disease) Anti-inflammatory diet (Mediterranean-style, reduce processed foods, sugar) Omega-3 fatty acids: 2-3 grams EPA/DHA daily Regular exercise (30+ minutes, 5x/week) Sleep optimization (7-9 hours, consistent schedule) Consider curcumin (500-1000 mg with piperine) if persistently elevated If homocysteine is elevated (above 11 umol/L): B vitamin protocol: Methylfolate 800 mcg + Methylcobalamin (B12) 500 mcg + B6 20 mg daily Retest in 3 months to verify response Ensure adequate omega-3 status (see next section on why this matters) IMPORTANT: The VITACOG trial showed B vitamins reduced brain atrophy by 53% in those with homocysteine above 13 umol/L [Smith et al., 2010]. But this benefit only appeared in participants with adequate omega-3 status.The Advanced Lipid Panel: ApoB and LDL Particle CountThe Research Standard cholesterol panels measure the mass of cholesterol in your blood. But cardiovascular and cerebrovascular risk is actually driven by the number of apoB-containing particles that can penetrate and damage arterial walls [Sniderman et al., 2019]. This distinction matters enormously for APOE4 carriers, who have impaired LDL clearance from circulation. The same total cholesterol number may represent more dangerous particle accumulation in an APOE4 carrier than in someone with APOE3/3. The European Society of Cardiology now considers ApoB more accurate than LDL-C for cardiovascular risk assessment. Additionally, research on small dense LDL (sdLDL) shows these particles are more atherogenic due to longer circulation time, lower receptor affinity, and higher oxidation susceptibility [Hoogeveen et al., 2014]. THE DATA: In the ARIC study of 11,419 participants, highest vs. lowest quartile of small dense LDL showed a hazard ratio of 1.51 for coronary heart disease events [Hoogeveen et al., 2014].So What Does This Mean for You? If your doctor tells you your LDL is "a bit high but nothing to worry about," that assessment may be incomplete. For APOE4 carriers, the composition and particle count of your lipids matters as much as the total amount. You may have "normal" LDL-C but elevated ApoB or LDL-P, indicating more atherogenic particles than the standard panel reveals. This is precisely the kind of hidden risk that APOE4 carriers need to uncover. Brain health and cardiovascular health are deeply connected. What damages your arteries damages your brain, and APOE4 carriers are more susceptible to both. Action Steps: Optimizing LipidsTesting Protocol:ApoB: Test annually (requires specific order, not on standard panel) LDL-P (LDL particle number): Test annually through NMR lipoprofile or equivalent Lipid panel with sdLDL: If available, provides additional particle composition data APOE4 Optimal Targets: ApoB: Below 90 mg/dL (standard "normal" is under 130) LDL-P: Below 1,000-1,200 nmol/L (standard "normal" is under 1,300) Consider intervention if ApoB above 120 mg/dL or LDL-P above 1,600 nmol/L If lipid particles are elevated: Dietary modification: Reduce saturated fat, increase soluble fiber (10-25 grams/day) Exercise: Resistance training + aerobic activity Consider PCSK9 inhibitors or statins (discuss with cardiologist if very high risk) Plant sterols/stanols (2 grams/day) can modestly reduce LDL-P Weight optimization if indicated ACTION STEP: When ordering labs, specifically request ApoB and NMR lipoprofile. Standard lipid panels miss critical particle information. Expect to pay out-of-pocket if insurance does not cover these tests (typically $50-150).Metabolic Health Markers: Insulin, HbA1c, and HOMA-IRThe Research Here is where APOE4 metabolism gets particularly complex. A 2017 study found that APOE4 non-carriers with Alzheimer's showed greater peripheral insulin resistance than APOE4 carriers [Morris et al., 2017]. Paradoxical? Not exactly. The mechanistic research explains why: APOE4 impairs brain insulin signaling by trapping insulin receptors in cellular compartments called endosomes [Zhao et al., 2017]. This leads to impaired mitochondrial function and glucose metabolism specifically in neurons, even when peripheral insulin sensitivity appears normal. Translation: Your HOMA-IR might look fine while your brain is starving for glucose. This is why the Bredesen Protocol recommends tighter metabolic targets for APOE4 carriers than standard medical guidelines suggest. So What Does This Mean for You? You cannot assume metabolic health based on standard diabetes screening thresholds. An HbA1c of 5.6% might not trigger a diabetes diagnosis, but for an APOE4 carrier, it may indicate suboptimal brain glucose metabolism. The goal is not just avoiding diabetes. The goal is optimizing the metabolic environment for your neurons, which are more vulnerable to insulin signaling dysfunction. High-fat diets accelerate these effects in APOE4 models, which has implications for trendy ketogenic approaches. While some APOE4 carriers report benefits from ketosis (providing an alternative brain fuel), the research suggests caution with high saturated fat intake specifically. Action Steps: Metabolic OptimizationTesting Protocol:Fasting glucose: Test annually Fasting insulin: Test annually (critical, often not ordered by default) HbA1c: Test annually HOMA-IR: Calculate from fasting glucose and insulin APOE4 Optimal Targets: Fasting glucose: 70-90 mg/dL (standard "normal" is up to 100) Fasting insulin: Below 4.5-5.0 uIU/mL (standard "normal" is up to 25) HbA1c: Below 5.3% (standard "normal" is below 5.7%) HOMA-IR: Below 1.0 (standard "normal" is below 2.5) If metabolic markers are elevated:Time-restricted eating: 12-16 hour overnight fast (improves insulin sensitivity) Carbohydrate awareness: Focus on low-glycemic, fiber-rich carbohydrates Post-meal walks: 10-15 minutes after eating reduces glucose spikes Resistance training: 2-3x weekly (most effective for insulin sensitivity) Sleep optimization: Poor sleep directly impairs glucose regulation Consider CGM (continuous glucose monitor) for 2-4 weeks to identify personal triggers KEY INSIGHT: APOE4 carriers may show normal peripheral insulin but impaired brain insulin signaling. Standard diabetes screening misses this brain-specific dysfunction [Zhao et al., 2017].Nutrient Status: B Vitamins, Omega-3 Index, and Vitamin DThe Research The VITACOG trial is landmark research for APOE4 carriers. This randomized controlled trial gave older adults with mild cognitive impairment high-dose B vitamins (folic acid 800 mcg, B12 500 mcg, B6 20 mg) or placebo for two years [Smith et al., 2010]. Results: 29.6% reduction in brain atrophy rate overall 53% reduction in those with baseline homocysteine above 13 umol/L No safety issues identified But here is the critical finding from the secondary analysis: B vitamins only worked in participants with good omega-3 status at baseline [Jerneren et al., 2015]. Those with low omega-3 levels saw no benefit from B vitamin supplementation. For omega-3s specifically, APOE4 carriers face a unique challenge. Research shows elderly APOE4 carriers have 77% faster DHA oxidation and less efficient brain uptake of omega-3s compared to non-carriers [Ebright et al., 2024]. Early, sustained omega-3 supplementation is more critical for APOE4 carriers than for the general population. Vitamin D supplementation was associated with a 40% lower dementia incidence rate in a large prospective analysis [Ghahremani et al., 2023]. So What Does This Mean for You? B vitamins and omega-3s work synergistically. Taking one without optimizing the other may waste your money and miss the brain-protective benefit. If you are supplementing B vitamins for homocysteine or brain health, you must also ensure your omega-3 status is adequate. Testing the omega-3 index (not just taking fish oil blindly) tells you whether you have reached therapeutic levels. APOE4 carriers may need higher omega-3 doses to achieve the same tissue levels due to accelerated oxidation. Action Steps: Nutrient OptimizationTesting Protocol:Omega-3 Index: Test annually (target above 8%) Vitamin B12: Test annually (target above 500 pg/mL) Folate: Test annually (target above 20 ng/mL) Vitamin D (25-OH): Test 1-2x yearly (target 50-80 ng/mL) RBC Magnesium: Test annually (more accurate than serum magnesium) APOE4 Optimal Targets: Omega-3 Index: Above 8% (standard "normal" is above 4%) Vitamin B12: Above 500 pg/mL (standard "normal" starts at 200) Folate: Above 20 ng/mL (standard "normal" is above 3) Vitamin D: 50-80 ng/mL (standard "normal" is 30-100) RBC Magnesium: 5.5-6.5 mg/dL Supplementation Protocol:Omega-3s: 2-3 grams EPA+DHA daily from high-quality fish oil or algae oil APOE4 carriers may need higher doses; test and adjust Take with meals containing fat for absorption B Vitamins (if homocysteine elevated or not eating fortified foods): Methylfolate: 800 mcg daily Methylcobalamin (B12): 500-1000 mcg daily Vitamin B6: 20 mg daily Vitamin D3: 2,000-5,000 IU daily (adjust based on testing) Take with K2 (100-200 mcg MK-7) for calcium metabolism Magnesium: 200-400 mg daily (glycinate or threonate forms for brain) ACTION STEP: Order an omega-3 index test before assuming your fish oil is working. Many people taking supplements still have indices below 4%. For APOE4 carriers, below 8% means B vitamins may not deliver their brain-protective benefits.Hormone Considerations: Thyroid and Sex HormonesThe Research A 2022 mechanistic study revealed a surprising connection: age-related thyroid decline increases transport of liver-derived ApoE4 exosomes to the brain, activating inflammatory pathways [Chen et al., 2022]. APOE4 carriers showed associations with higher TSH and lower free T3, indicators of suboptimal thyroid function. For women, the EPAD cohort analysis found that APOE4 carriers who used hormone replacement therapy had the highest delayed memory scores and 6-10% larger entorhinal and amygdala volumes compared to APOE4 carriers without HRT [Saleh et al., 2023]. This benefit was NOT observed in non-APOE4 carriers, suggesting HRT may be specifically neuroprotective for APOE4 women. For men, a study of middle-aged men found that free testosterone was positively associated with verbal episodic memory in APOE4 carriers only [Panizzon et al., 2014]. So What Does This Mean for You? Thyroid function is not just about energy and metabolism. For APOE4 carriers, suboptimal thyroid hormones may actively increase brain exposure to harmful ApoE4 protein variants. For women with APOE4, the timing of HRT decisions around menopause may have significant brain health implications. The "critical window" hypothesis suggests neuroprotection requires HRT during or soon after menopause. For men with APOE4, monitoring and optimizing testosterone may support cognitive function in ways not observed in non-carriers. These are conversations to have with endocrinologists and functional medicine practitioners who understand the APOE4-hormone connection. Action Steps: Hormone OptimizationTesting Protocol:Thyroid panel: TSH, Free T3, Free T4 (annually) Sex hormones (for women): Estradiol, progesterone (perimenopause and beyond) Sex hormones (for men): Total testosterone, free testosterone, SHBG (age 50+) APOE4 Optimal Targets: TSH: 1.0-2.0 mIU/L (standard "normal" is 0.4-4.0) Free T3: Upper half of reference range (standard just says "in range") Testosterone (men): Optimize within healthy range based on symptoms Discussion Points with Your Doctor: Women with APOE4: Discuss HRT benefits and risks specifically for APOE4 carriers; timing relative to menopause matters Men with APOE4: Discuss testosterone optimization if symptomatic and levels are suboptimal Everyone: If TSH is above 2.0 or Free T3 is in lower portion of range, discuss thyroid optimization strategies IMPORTANT: Hormone decisions are complex and individual. The research shows APOE4-specific patterns, but these should inform discussions with qualified practitioners, not drive self-treatment.Emerging Biomarkers: NfL, GFAP, and p-tau217The Research Blood-based neurodegenerative biomarkers represent one of the most exciting advances in Alzheimer's detection. A 2025 JAMA Network Open study of 1,038 participants over 20 years found that elevated NfL, GFAP, and tau levels predicted cognitive decline significantly more strongly in APOE4 carriers than in non-carriers [Ng et al., 2025]. Specifically, APOE4 carriers showed: Nearly doubled rate of cognitive decline when biomarkers were elevated Higher baseline levels of tau (0.82 vs 0.67 pg/mL) and GFAP (277.8 vs 251.4 pg/mL) The p-tau217 blood test can now detect Alzheimer's pathology with 93-96% accuracy, similar or superior to cerebrospinal fluid tests [Palmqvist et al., 2025]. Combined with APOE status and age, accuracy reaches 94% with 85% sensitivity and 89% specificity. So What Does This Mean for You? We are entering an era where Alzheimer's pathology can be detected through a simple blood draw years before symptoms appear. For APOE4 carriers, who face elevated baseline levels of these markers, monitoring trends over time may provide early warning of brain changes. However, these tests are emerging technologies. Reference ranges and clinical protocols are still being established. Currently, elevated results primarily inform specialist referral and intensified lifestyle intervention rather than specific treatments. Action Steps: Emerging BiomarkersTesting Protocol:p-tau217: Consider baseline in late 50s for APOE4/4 carriers, 60s for APOE4 heterozygotes NfL, GFAP: Available through some specialized labs; useful for trending if cognitive symptoms emerge Frequency: Every 2-3 years if baseline normal; annually if elevated or symptomatic What Elevated Results Mean:Elevated p-tau217: Suggests amyloid pathology; neurologist referral appropriate; intensify lifestyle interventions; candidate for emerging therapies Elevated NfL/GFAP: Indicates neurodegeneration or inflammation; enhanced monitoring; comprehensive lifestyle protocol Where to Access: Quest Diagnostics AD-Detect panel includes p-tau217 Some direct-to-consumer options emerging (quality variable) Discuss with neurologist for clinical interpretation KEY INSIGHT: Risk predictions based on blood-based neurodegenerative biomarkers alone are likely insufficient without accounting for APOE4 status [Ng et al., 2025]. Your genetic context determines how to interpret these results.APOE4 Blood Work Testing Schedule by AgeAges 40-49: Baseline EstablishmentFrequency: Annual or every 2 years Essential Panel: APOE genotype (one-time, if not already known) hs-CRP Homocysteine Lipid panel with ApoB and LDL-P (NMR lipoprofile) Fasting insulin, glucose, HbA1c Vitamin D, B12, folate Omega-3 index Thyroid panel (TSH, free T3, free T4) Complete metabolic panel For Women: Consider baseline hormone panel if approaching perimenopause Purpose: Establish personal baseline trends while you have maximum runway for intervention. Ages 50-59: Active MonitoringFrequency: Annually Add to Baseline: RBC magnesium Sex hormones (testosterone/SHBG for men; estradiol/progesterone for women) Morning cortisol Consider baseline cognitive testing (MoCA or similar) For APOE4 Homozygotes (4/4): Consider p-tau217 or AD biomarker panel in late 50s More frequent monitoring (every 6 months) if any markers elevated Purpose: This decade is when APOE4-related changes often begin manifesting. Active monitoring allows early intervention. Ages 60+: Intensive SurveillanceFrequency: Every 6-12 months Full Panel Including: All markers from previous decades Neurodegenerative biomarkers (NfL, GFAP, p-tau217 if available) Annual cognitive assessment Consider brain MRI (volumetrics) every 2-3 years Red Flags Requiring Immediate Action: hs-CRP above 3.0 mg/L (chronic) in APOE4 carrier Homocysteine above 14 umol/L HbA1c above 6.0% Elevated p-tau217 or abnormal AD biomarker panel Cognitive symptoms plus elevated NfL/GFAP Purpose: Intensive monitoring enables rapid response to changes and consideration of emerging therapeutic options. Key Takeaways: Your Action PlanThis Week [ ] Request copies of your last 2-3 years of lab work [ ] Check if ApoB and fasting insulin were ever tested (usually not on standard panels) [ ] Calculate your HOMA-IR if you have fasting glucose and insulin values [ ] Start tracking your results in Phoenix's Bloodwork Module This Month [ ] Schedule comprehensive lab work including: hs-CRP, homocysteine, ApoB, NMR lipoprofile, fasting insulin, omega-3 index, vitamin D, B12 [ ] If homocysteine is above 11 umol/L, begin B vitamin protocol [ ] If omega-3 index is below 8%, increase EPA/DHA to 2-3 grams daily Long-Term Protocol [ ] Annual comprehensive testing following age-appropriate schedule above [ ] Track trends over time, not just single values [ ] Retest 3 months after any new intervention to verify response [ ] Join Phoenix Bloodwork Pod for accountability and optimization support ACTION STEP: Use Phoenix's Bloodwork Module to log every lab result. The platform visualizes trends and flags markers outside APOE4-optimal ranges automatically, helping you spot patterns your doctor might miss.Take Control of Your APOE4 Biomarkers You cannot change your genetics. But you can change the environment those genes operate in. The research is clear: APOE4 carriers face elevated risks that are modifiable through targeted monitoring and intervention. The 6.6x inflammation risk? Modifiable. The doubled homocysteine risk? Modifiable. The impaired brain insulin signaling? Modifiable. Standard medical care was not designed for APOE4 optimization. But you do not have to settle for "normal." You can target optimal. The blood work panel in this guide represents what I wish I had known a decade ago. Every marker, every target, every intervention is backed by peer-reviewed research specific to APOE4 carriers. Track your results. Identify your gaps. Take action. And remember: you are not alone in this. The Phoenix community includes thousands of APOE4 carriers doing exactly this work, sharing what is working, and supporting each other through the process. Your future brain is depending on the biomarkers you monitor today. -Kevin Most Newsletters? One-way street.How boring…This is the Phoenix Community. So let's make it a two-way street. Got a question? Feedback? Hit reply. I read every single one.Sources Tao Q, Ang TFA, DeCarli C, et al. Association of Chronic Low-grade Inflammation With Risk of Alzheimer Disease in ApoE4 Carriers. JAMA Network Open. 2018;1(6):e183597. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2707427 Trumble BC, Stieglitz J, Blackwell AD, et al. APOE4 is associated with elevated blood lipids and lower levels of innate immune biomarkers in a tropical Amerindian subsistence population. eLife. 2021;10:e68231. https://elifesciences.org/articles/68231 Sniderman AD, Thanassoulis G, Glavinovic T, et al. Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review. JAMA Cardiol. 2019;4(12):1287-1295. https://pmc.ncbi.nlm.nih.gov/articles/PMC7369156/ Hoogeveen RC, Gaubatz JW, Sun W, et al. Small Dense Low-Density Lipoprotein-Cholesterol Concentrations Predict Risk for Coronary Heart Disease. Arteriosclerosis, Thrombosis, and Vascular Biology. 2014;34(5):1069-1077. https://www.ahajournals.org/doi/10.1161/atvbaha.114.303284 Morris JK, Uy RAZ, Vidoni ED, et al. Effect of APOE e4 Genotype on Metabolic Biomarkers in Aging and Alzheimer's Disease. Journal of Alzheimer's Disease. 2017;58(4):1129-1135. https://pmc.ncbi.nlm.nih.gov/articles/PMC5776708/ Zhao N, Liu CC, Van Ingelgom AJ, et al. Apolipoprotein E4 impairs neuronal insulin signaling by trapping insulin receptor in the endosomes. Neuron. 2017;96(1):115-129. https://pmc.ncbi.nlm.nih.gov/articles/PMC5621659/ Smith AD, Smith SM, de Jager CA, et al. Homocysteine-Lowering by B Vitamins Slows the Rate of Accelerated Brain Atrophy in Mild Cognitive Impairment: A Randomized Controlled Trial. PLoS One. 2010;5(9):e12244. https://pmc.ncbi.nlm.nih.gov/articles/PMC2935890/ Smith AD, Refsum H, Bottiglieri T, et al. Homocysteine and Dementia: An International Consensus Statement. Journal of Alzheimer's Disease. 2018;62(2):561-570. https://pmc.ncbi.nlm.nih.gov/articles/PMC5836397/ Seshadri S, Beiser A, Selhub J, et al. Plasma Homocysteine as a Risk Factor for Dementia and Alzheimer's Disease. New England Journal of Medicine. 2002;346(7):476-483. https://www.nejm.org/doi/full/10.1056/NEJMoa011613 Ebright B, Duro MV, Chen K, et al. Effects of APOE4 on omega-3 brain metabolism across the lifespan. Trends in Endocrinology and Metabolism. 2024;35(4):293-305. https://pmc.ncbi.nlm.nih.gov/articles/PMC11321946/ Jerneren F, Elshorbagy AK, Oulhaj A, et al. Brain atrophy in cognitively impaired elderly: the importance of long-chain omega-3 fatty acids and B vitamin status in a randomized controlled trial. American Journal of Clinical Nutrition. 2015;102(1):215-221. https://pubmed.ncbi.nlm.nih.gov/25877495/ Ghahremani M, Smith EE, Chen H, et al. Vitamin D supplementation and incident dementia: Effects of sex, APOE, and baseline cognitive status. Alzheimer's & Dementia: DADM. 2023;15(1):e12404. https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/dad2.12404 Chen HY, Panegyres PK. Ageing related thyroid deficiency increases brain-targeted transport of liver-derived ApoE4-laden exosomes leading to cognitive impairment. Cell Death & Disease. 2022;13:367. https://www.nature.com/articles/s41419-022-04858-x Saleh RNM, Hornberger M, Engelborghs S, et al. Hormone replacement therapy is associated with improved cognition and larger brain volumes in at-risk APOE4 women: results from the European Prevention of Alzheimer's Disease (EPAD) cohort. Alzheimer's Research & Therapy. 2023;15:10. https://alzres.biomedcentral.com/articles/10.1186/s13195-022-01121-5 Panizzon MS, Hauger R, Xian H, et al. Interaction of APOE genotype and testosterone on episodic memory in middle-aged men. Neurobiology of Aging. 2014;35(7):1689.e1-8. https://pmc.ncbi.nlm.nih.gov/articles/PMC3980008/ Ng TKS, Beck T, Boyle P, et al. APOE4, Blood Neurodegenerative Biomarkers, and Cognitive Decline in Community-Dwelling Older Adults. JAMA Network Open. 2025;8(5):e258903. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2833620 Palmqvist S, Tideman P, Mattsson-Carlgren N, et al. Plasma phospho-tau217 for Alzheimer's disease diagnosis in primary and secondary care using a fully automated platform. Nature Medicine. 2025. https://www.nature.com/articles/s41591-025-03622-w Kieboom BCT, Licher S, Wolters FJ, et al. Low Serum Magnesium is Associated with Incident Dementia in the ARIC-NCS Cohort. Nutrients. 2020;12(11):3330. https://pmc.ncbi.nlm.nih.gov/articles/PMC7600951/ Bredesen DE. The End of Alzheimer's. 2017. Reference via ApoE4.Info Wiki. https://wiki.apoe4.info/wiki/Bredesen_Protocol --- ## The Missing Piece in Brain Health Tracking: Why We're Partnering with Sens.ai URL: https://apoe4.co/blog/posts/the-missing-piece-in-brain-health-tracking-why-we-re-partnering-with-sens-ai Published: 2026-01-22T19:41:18+00:00 Updated: 2026-04-14T03:50:49.282055+00:00 Summary: Discover the breakthrough neurofeedback technology helping APOE4 carriers track cognitive health, with real-time insights to optimize brain performance and longevity. The Missing Piece in Brain Health Tracking: Why We're Partnering with Sens.aiA neurofeedback study for APOE4 carriers (and anyone serious about cognitive longevity)Dr. Kevin Tran January 22, 2026 Hi Phoenix friend, Here's a question that keeps me up at night: How do I know if what I'm doing is actually working? I take supplements. I exercise. I track my sleep. I've optimized my diet. I do all the things the research says should protect my brain. But my brain doesn't come with a dashboard. I can see my cholesterol on a blood test. My VO2 max on my watch. My HRV every morning. But cognition? Processing speed? Whether my brain is aging faster or slower than it should? That's mostly... guesswork. Until now. The Feedback Loop Problem I run The Phoenix Community, a platform for APOE4 carriers (people with a genetic variant that significantly increases Alzheimer's risk). I'm an APOE4/4 carrier myself. Two copies of the gene. Roughly 60% lifetime risk. So I'm not doing this for fun. This is survival. Over the past year, we've run studies on photobiomodulation helmets and vagus nerve stimulation devices. We've tracked supplements and exercise and sleep interventions across hundreds of members. And we keep running into the same problem. People do interventions. They feel better. Or they don't. But "feeling sharper" isn't data. It's not something you can optimize. It's not something that tells you whether to continue, adjust, or abandon what you're doing. We needed objective cognitive tracking. Something that could measure whether interventions actually move the needle on brain function. That's why we're partnering with Sens.ai. Checkout our Q&A with Sens.ai CEO Paola What is Sens.ai? Let me explain what this thing actually is. Because it's not what you might expect. Sens.ai is a neurofeedback headset. But neurofeedback is just one piece. It combines five different modalities: 1. Neurofeedback (the core) Your brain produces electrical signals. Different patterns correspond to different mental states (focused, relaxed, creative, anxious). Neurofeedback makes these invisible patterns visible. Here's how it works: sensors on your scalp read your brainwaves in real-time. That signal gets converted into audio and visual feedback. When your brain hits the target state, you get positive reinforcement (the sound gets louder, the image gets clearer). When it drifts, the feedback dims. It's like a hands-free video game. Your brain learns to reproduce the states that get rewarded. The research on neurofeedback spans 50+ years. It's been used for ADHD, anxiety, PTSD, concussion recovery, and cognitive enhancement. The best clinical protocols typically cost $15,000+ for a week of treatment [1]. Sens.ai took those protocols and put them in a $1,250 headset you can use at home. 2. Photobiomodulation Near-infrared light (810nm wavelength) delivered through the skull. This primes your brain before training. Think of it as a warm-up. If you've followed our previous studies, you know we've been tracking photobiomodulation for a while. Sens.ai's version includes binaural beats and guided meditations during the light therapy, making the experience more immersive. 3. HRV Biofeedback A pulse oximeter on the ear cup measures your heart rate variability. The app guides you through resonance breathing to activate your parasympathetic nervous system. This is the foundation. You can't train higher brain states effectively when your nervous system is in fight-or-flight mode. HRV biofeedback calms you down first. 4. Binaural Beats Audio frequencies that support state shifts. Nothing revolutionary on its own, but integrated well into the overall experience. 5. ERP Assessments (This is the key part) Event-Related Potentials. Objective cognitive tests that measure: P300 latency: How fast your brain processes new information and makes decisions Peak Alpha Frequency: A biomarker linked to cognitive performance and intelligence Reaction time and accuracyImpulse control These aren't subjective questionnaires. They're measurements of your brain's electrical response to specific stimuli. You can track them over time. You can see if they improve. And here's what gets me excited: Sens.ai is developing a biological brain age clock in partnership with the Buck Institute (the largest longevity research organization in the US). Coming in April 2025. This will tell you if your brain is aging faster or slower than expected. Not based on how you feel. Based on measurable neural signals. The Data So FarSens.ai has published results from their protocols [2]: Sleep Nirvana Mission (4-week sleep protocol): 77% reported improved sleep quality 7.5% faster reaction time 40% improvement in impulse control 7.4% faster brain processing speed (P300 latency) Sharp Mind Mission (designed for cognitive aging): Improvements in peak alpha frequency (typically declines with age) Enhanced P300 markers Better reaction time and accuracy The company has a good track record of transparency. They publish white papers with their results. They're building a learning system that continuously measures outcomes across users. Is it perfect evidence? No. These are company-published studies, not independent peer-reviewed trials. But the underlying science of neurofeedback is well-established [3][4], and having objective before/after measurements is a massive improvement over "I think I feel better." Why This Matters for APOE4 Carriers APOE4 carriers face a specific challenge: brain changes can begin 20-30 years before cognitive symptoms appear [5]. That means the window for intervention is now. Not when we start forgetting names. Not when we can't find our keys. Now. But it also means we're flying blind. We don't have symptoms to track. We don't have obvious feedback on whether our interventions are working. Research shows that cognitive engagement may be particularly protective for APOE4 carriers [6]. Active brain training (not passive consumption) appears to reduce amyloid deposition in carriers more than non-carriers [7]. Neurofeedback is essentially structured cognitive engagement. Your brain actively works to achieve target states. It's exercise for neural pathways. Combined with objective tracking, this gives us something we've never had: a feedback loop for brain health. How the Study Works We're opening this partnership to everyone. Phoenix Community members and non-members alike. Here's the deal:Go to sens.ai/phoenixUse code PHOENIX for $100 off ($1,150 instead of $1,250) Try it for 60 days (satisfied or reimbursed guarantee, no risk) Use whatever mode works for you (Sharp Mind, Sleep Nirvana, Attention Mastery, etc.) Unlike our previous studies, this one is open-ended. No rigid protocol. Use the device the way that makes sense for your goals. If you're a Phoenix Community member: Opt in to the study in the Phoenix app Log your sessions in your daily check-ins (mode, duration, experience) Connect your wearables (Oura, Whoop, Apple Health) once our app update launches We'll correlate your Sens.ai sessions with your sleep, HRV, and subjective wellbeing data If you're not a member: You can still participate. But you won't have the same tracking infrastructure. Sens.ai provides its own assessments, which is valuable. But combining those with daily check-ins, biomarker tracking, and wearable data gives a much more complete picture. If you're serious about this, consider joining The Phoenix Community. We're building the tracking tools specifically for this purpose. Practical DetailsPrice: $1,150 with code PHOENIX (normally $1,250) Subscription: $29/month for the personal membership (required for the AI-guided protocols) Family plan: Coming Q1 (~$45/month for multiple users sharing one headset) Shipping: Worldwide (US, Canada, UK, Australia, Europe, etc.) Return policy: 60-day satisfaction guarantee. Use it for two months. If it doesn't work for you, return it. Best results: 8+ weeks of consistent use, 15+ minutes per session, 5 times per week What We're Building This partnership is part of a larger vision. At Phoenix, we're trying to solve the measurement problem for brain health. We're building a platform where you can: Track your interventions (supplements, devices, lifestyle changes) Log your daily experience (energy, focus, sleep quality, mood) Connect your wearables (continuous HRV, sleep architecture, activity data) Upload your blood tests (we have AI analysis for APOE4-specific biomarkers) Run structured experiments with peer accountability And now, with partners like Sens.ai, add objective cognitive assessments to the mix. The goal? Know what's working. Stop guessing. Optimize based on data. If you're an APOE4 carrier (or just someone serious about cognitive longevity), this is the kind of infrastructure you need. The Bottom Line Neurofeedback has 50 years of clinical research behind it. Sens.ai makes it accessible at home. They include objective cognitive assessments. They're building a brain age clock. There's a 60-day money-back guarantee. Zero risk. If you're already spending money on brain supplements, sleep trackers, and health optimizations, this is a tool that might actually tell you if those things are working. Link: sens.ai/phoenixCode: PHOENIX ($100 off) Try it. Track it. Let's see what the data shows. References [1] Clinical neurofeedback protocols typically range from $150-200 per session, with 10-30 sessions recommended. Five-day intensive programs at top clinics can cost $15,000+. [2] Sens.ai User Results. Sleep Nirvana Mission Protocol and Sharp Mind Mission data. https://sens.ai/results [3] Marzbani H, Marateb HR, Mansourian M. Neurofeedback: A Comprehensive Review on System Design, Methodology and Clinical Applications. Basic Clin Neurosci. 2016 Apr;7(2):143-58. https://pubmed.gov/27303609 [4] Zoefel B, Huster RJ, Herrmann CS. Neurofeedback training of the upper alpha frequency band in EEG improves cognitive performance. Neuroimage. 2011 Jan 15;54(2):1427-31. https://pubmed.gov/20850552 [5] Bateman RJ, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012;367(9):795-804. https://pubmed.gov/22784036 [6] Berkowitz CL, Mosconi L, Rahman A, et al. Clinical Application of APOE in Alzheimer's Prevention: A Precision Medicine Approach. J Prev Alzheimers Dis. 2018;5(4):245-252. https://pubmed.gov/30298183 [7] Landau SM, et al. Association of lifetime cognitive engagement and low β-amyloid deposition. Arch Neurol. 2012;69(5):623-629. https://pubmed.gov/22271235Join the study: sens.ai/phoenix | Code: PHOENIXJoin The Phoenix Community: thephoenix.communityQuestions? kevin@thephoenix.communityMost Newsletters? One-way street.How boring…This is the Phoenix Community. So let's make it a two-way street. Got a question? Feedback? Hit reply. I read every single one. --- ## Q1 Focus: Less interventions. More measurement. URL: https://apoe4.co/blog/posts/q1-focus-less-interventions-more-measurement Published: 2026-01-11T16:03:40+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: community, tracking Summary: Unlock the power of precision: Q1 2026 focuses on advanced measurement tools for APOE4 health, transforming supplement strategies from guesswork to data-driven insights. Content synced - use sync-all function for full content --- ## [Free Guide] APOE4 Blood Work Blueprint URL: https://apoe4.co/blog/posts/free-guide-apoe4-blood-work-blueprint Published: 2026-01-09T20:08:12+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: tracking, protocols Summary: Discover your personalized APOE4 blood work blueprint: Essential biomarker targets to optimize health, understand your unique genetic profile, and go beyond "normal" lab results. [Free Guide] APOE4 Blood Work BlueprintOptimal biomarker targets for APOE4 carriers. What to test and what to aim for.Dr. Kevin Tran January 09, 2026 One question comes up more than any other in the Phoenix community. "Now that I know I'm APOE4, what should I tell my doctor to test?" It's the right question. And for too long, the answer has been scattered across research papers, forums, and conflicting advice from doctors who've never heard of APOE4 optimization. So we built the resource we wished existed. The Problem With "Normal" Here's the thing about your bloodwork results: when your doctor says everything looks "normal," they're comparing you to the average American. And the average American is overweight, inflamed, and insulin resistant. Normal doesn't mean optimal. It means average. And average is sick. But there's a bigger problem for us. Even if lab ranges were based on healthy people, APOE4 carriers aren't like everyone else. We have different lipid metabolism. Different inflammatory responses. Different oxidative stress patterns. What's "optimal" for the general population doesn't work for our biology. Take ApoB as an example. Standard "normal" range goes up to 125 mg/dL. General optimal is under 80. But for APOE4 carriers? E3/E4 should aim for under 70. E4/E4? Under 60. Your doctor probably doesn't know this. The research exists—but nobody's translated it for you. Until now. Introducing the APOE4 Blood Work Blueprint We've compiled the research into a single, actionable guide. It covers cardiovascular markers, glucose metabolism, inflammation, B-vitamins, thyroid, iron metabolism, and advanced biomarkers like p-tau217. Each section includes standard lab ranges, APOE4-specific optimal targets, and the research behind why these matter for our genetics. But here's what makes it actually useful: at the end, there's a doctor consultation checklist. An essential panel and an advanced panel. Print it. Bring it to your appointment. Hand it to your doctor. No more guessing what to ask for. Download the APOE4 Blood Work Blueprint →For Phoenix Members If you're already in the Phoenix Community, you don't need to manually look up optimal ranges. Just upload your blood test to the app, and our Smart Blood Analyzer will automatically flag where you stand against APOE4-specific targets—not generic population ranges. You'll see exactly which biomarkers need attention, track trends over time, and get matched protocols based on what's worked for members with similar profiles. For Everyone Else This guide is free. Why? Because we believe every APOE4 carrier deserves to know what their bloodwork actually means for their risk. The more informed you are, the better the conversation with your doctor. The better the conversation, the better your outcomes. One More Thing If you're new to APOE4 and feeling overwhelmed by all of this, start with our Essential Guide for APOE4 Carriers. It's also free and gives you the comprehensive overview before diving into biomarker optimization. We'll continue updating the Blood Work Blueprint as new research emerges. This isn't a static document—it's a living resource that evolves with the science. Your genetics aren't your destiny. But only if you have the information to act. — Kevin Founder, Phoenix Community APOE4/4 Carrier P.S. — If this guide helps you have a better conversation with your doctor, let me know. Nothing makes me happier than hearing our community is getting the care they deserve. --- ## The Best Omega-3 supplement for APOE4 Carriers URL: https://apoe4.co/blog/posts/the-best-omega-3-supplement-for-apoe4-carriers Published: 2026-01-08T20:39:25+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: supplements, research, cognition Summary: Discover the game-changing LPC-DHA omega-3 supplement for APOE4 carriers: Proven brain protection strategy, offering hope against Alzheimer's risk. The Best Omega-3 supplement for APOE4 Carriers I've been taking LPC-DHA since day one. It's not cheap...but $3/day is nothing compared to the alternative...Dr. Kevin Tran January 08, 2026 I've been taking LPC-DHA since the day I discovered my APOE4 status. It's not a cheap product. Almost $3 a day for a single supplement. And the annoying part? You can never directly measure if it's working. There's no blood test that tells you "yes, your brain DHA is now optimal." But here's how I think about it: $3 a day is a very small price to pay if the alternative is Alzheimer's down the line. So I've always bitten the bullet. To my knowledge, there are only two providers of LPC-DHA in the world, as it is a patented product: LPC Neuro — covers Asia (what I was taking when I lived in Singapore) Accentrate Omega Max — covers the US, Canada, UK, Australia, New Zealand Last month, I published two deep dives on why LPC-DHA matters for us—and why standard fish oil falls short. Read the blog post: Why Your Fish Oil Isn't Reaching Your Brain - And What To Do About It Since then, my inbox has been flooded by members with the same question: "Kevin, is there a discount code for LPC-DHA?"I'm glad to say we made it happen. Here’s the link to buy Accentrate Omega Max which I have been taking for the past 5 months. To get 20% off for Phoenix Members use code: PHOENIX Why LPC-DHA? (Quick Science Recap) The short version: our impaired lipid transport means regular DHA often never reaches our brains. You might have a perfect omega-3 index, but that's a blood biomarker—a poor proxy for whether DHA is actually getting to your brain, which is where it matters. LPC-DHA uses a different pathway (the Mfsd2a transporter) that bypasses our broken system. 1. Standard fish oil has limited brain entry DHA from triglycerides (standard fish oil) gets incorporated into fat tissue and heart—but not brain. LPC-DHA increased brain DHA by up to 100%. Over 80% of dietary DHA from fish oil is oxidized before reaching the brain. → Sugasini et al., 2019 – PLoS ONE2. LPC-DHA bypasses our impaired transport The brain has a transporter called Mfsd2a at the blood-brain barrier. It doesn't transport regular DHA—only LPC-DHA. A 2017 study showed LPC-DHA increased brain DHA by more than 2-fold. Free DHA? No effect. Mice on LPC-DHA showed a 7-fold improvement in memory tests. → Nguyen et al., 2014 – Nature→ Sugasini et al., 2017 – Scientific Reports3. APOE4 carriers need longer supplementation A 2025 study tested LPC omega-3s in APOE3 vs APOE4 mice. APOE3 mice responded within 2 months. APOE4 mice needed 4 months. We need more patience and consistency than the general population. → Andriambelo et al., 2025 – Prostaglandins Leukot Essent Fatty Acids4. First human trial now underway The University of Cincinnati launched a trial in February 2025 comparing LPC-DHA vs standard fish oil in 153 adults with mild cognitive decline. Results expected 2026. → University of Cincinnati, Feb 2025Use code: PHOENIX for 20% off to buy Accentrate Omega Max Stay sharp, Kevin P.S. — If you haven't read the original post or watched the video yet, start there. Understanding why LPC-DHA matters will help you decide if it's worth adding to your stack. --- ## How to cut your Alzheimer's risk by 65% (evidence-based protocol) URL: https://apoe4.co/blog/posts/sauna-how-to-cut-your-alzheimer-s-risk-by-65-evidence-based-protocol Published: 2026-01-03T18:54:32+00:00 Updated: 2026-08-04T16:43:32.647599+00:00 Topics: protocols, therapies, cognition Summary: Finnish study, 2,315 men, 20 years: 4-7 sauna sessions a week cut Alzheimer's risk 65%. The frequency, temperature and duration that matter. How to cut your Alzheimer's risk by 65% (evidence-based protocol)20-year study, 16,000 participants: sauna beats most drugsDr. Kevin Tran January 03, 2026 You've watched the research. You've changed your diet, started exercising, optimized your sleep. But there's one intervention with evidence so strong it borders on remarkable: 65-66% lower Alzheimer's risk from a practice you can start this week. I'm talking about sauna bathing—not the wellness trend version, but the evidence-based protocol from two decades of Finnish research on nearly 16,000 people. For those of us carrying APOE4, this isn't just about relaxation. It's about activating the exact cellular pathways our genetics leave vulnerable: heat shock proteins that prevent protein misfolding, anti-inflammatory mechanisms that calm neuroinflammation, and vascular improvements that address our heightened endothelial dysfunction. Here's what the science says, what it means for you as an APOE4 carrier, and the exact protocol to implement starting this week.Important: because these emails are very long, you will need to read the whole thing on the web. Here’s the link to the articleThe Evidence: 65% Lower Alzheimer's Risk Is RealThe Research Finding The landmark study that put sauna on the dementia prevention map came from Finland in 2017. Researchers followed 2,315 apparently healthy men aged 42-60 for a median of 20.7 years through the Kuopio Ischemic Heart Disease (KIHD) study [Laukkanen et al., 2017]. The results weren't subtle: "Men who took a sauna 4-7 times a week had a 66% lower risk of developing any form of dementia and a 65% lower risk of developing Alzheimer's disease during the follow-up, when compared with men taking a sauna just once a week." [Laukkanen et al., 2017] Even moderate use showed benefits: 2-3 sessions weekly reduced dementia risk by 22% and Alzheimer's risk by 20%. A larger follow-up study tracked 13,994 Finnish men and women for 39 years. The sweet spot? 9-12 sauna sessions per month showed a 19% lower dementia risk compared to 0-4 sessions monthly [Knuuti et al., 2020]. But here's the critical detail: temperature matters. The most favorable range was 80-99°C (176-210°F). Above 100°C? Risk doubled compared to lower temperatures (HR 2.11, 95% CI 1.02-4.38) [Knuuti et al., 2020]. There's a ceiling, and exceeding it is dangerous. 💡 KEY INSIGHT: This isn't correlation masquerading as causation—the dose-response relationship is clear, consistent across multiple large cohorts, and backed by plausible biological mechanisms. So What for APOE4 Carriers While these studies didn't specifically examine APOE4 carriers, they matter MORE for us. Here's why: While these studies didn't specifically examine APOE4 carriers, APOE4 carriers face heightened vascular inflammation, endothelial dysfunction, and stress vulnerability—the exact pathways sauna beneficially modulates. Research shows: ApoE4 carriers have 40-50% higher cardiovascular disease risk, driven partly by endothelial dysfunction [AHA, 2018] "ApoE4 expression by endothelial cells is sufficient to cause a toxic gain of cellular dysfunction" including impaired nitric oxide production and reduced vascular repair [AHA, 2018] APOE4 promotes chronic neuroinflammation through microglial activation and disturbed lipid homeostasis [PMC, 2022] Translation: Your genetics leave your vascular system and inflammatory pathways more vulnerable. Sauna addresses those exact weaknesses. For those of us who've watched a parent decline, 65% risk reduction isn't just a number—it's potentially decades of preserved cognition. That's worth 15 minutes in a hot room right? What You Can Do About ItStart with the minimum effective dose and progress strategically: ✅ ACTION STEP: Commit to 2-3 sauna sessions weekly for the next 4 weeks. This alone shows 20-22% dementia risk reduction—not maximum protection, but significant benefit with minimal time investment. ✅ ACTION STEP: Source a sauna option THIS WEEK: Community centers/YMCAs: Often have traditional Finnish saunas ($30-50/month) Gym memberships: LA Fitness, Lifetime, Equinox frequently include sauna access Spa day passes: $20-40 for single-day access to test tolerance Home units: (long-term investment) ✅ ACTION STEP: Track your first session in the Phoenix Experiments module: Date and time Duration (start with 10-12 minutes) Temperature (if known) How you felt (energy, mood, tolerance) Post-session hydration (oz of water consumed) The goal isn't perfection—it's starting. One session this week is infinitely better than perfect planning with no action. How Saunas Protect Your Brain: Six Biological MechanismsThe Research Findings Sauna doesn't just correlate with lower dementia risk—it activates specific protective pathways: 1. Heat Shock Protein (HSP) Activation Heat exposure triggers your cellular stress response, producing molecular chaperones called heat shock proteins (HSP70, HSP90). These proteins: "Interfere with misfolded disease proteins preventing unwanted interactions with other cellular proteins and/or by reducing the risk of formation of toxic oligomeric assemblies of tau and amyloid-β in AD." [Lu et al., 2014] In preclinical studies (cell culture and animal models), HSP70 interferes with tau tangle and amyloid-beta aggregation—the hallmark pathologies of Alzheimer's disease [Campanella et al., 2018]. Human evidence is indirect through epidemiological studies showing dementia risk reduction with sauna use. 2. Brain-Derived Neurotrophic Factor (BDNF) +66% A randomized controlled trial found that whole-body hyperthermia increased BDNF levels by 66% for 15 minutes after a single session [Kojima et al., 2018]. With repeated exposure over 10 weeks, baseline BDNF levels remained elevated. BDNF is critical for neuroplasticity, synaptic connections, learning, memory, and neurogenesis—essentially, your brain's growth and repair signal. 3. Mitochondrial Biogenesis via PGC-1α Heat stress activates PGC-1α, the master regulator of mitochondrial production. This means: Increased mitochondrial density in energy-intensive tissues (like your brain) Enhanced ATP production for cellular energy Improved oxidative capacity and antioxidant defenses May support cognitive clarity, memory retention, and mood regulation through enhanced brain energy metabolism Note: Cognitive outcomes from mitochondrial biogenesis are mechanistically plausible but not yet directly demonstrated in sauna intervention studies. Evidence comes from metabolic research showing PGC-1α activation improves cellular energetics. Your brain consumes 20% of your body's energy despite being 2% of body weight. More mitochondria may support better brain performance. 4. Anti-Inflammatory Effects Sauna reduces chronic inflammation through multiple pathways, though effects differ acutely vs. chronically: Acute response: Sauna bathing temporarily increases IL-6 (a stress/exercise response marker) during and immediately after sessions. Chronic adaptation: With repeated use, sauna reduces baseline expression of pro-inflammatory cytokines such as TNF-α and IL-6, which are implicated in brain inflammation [ScienceDirect, 2020]. It also stimulates IL-10 (an anti-inflammatory cytokine) over time, creating an environment that combats "inflamm-aging"—the chronic low-grade inflammation associated with neurodegenerative disease [PMC, 2024]. 5. Vascular Health and Blood Pressure Reduction Regular sauna bathing: Promotes vasodilation (blood vessel expansion) Improves endothelial function and nitric oxide production Reduces blood pressure (particularly systolic BP by 8 mmHg when combined with exercise) [Brunt et al., 2022] Enhances cerebral perfusion (blood flow to the brain) 6. Hormesis: Beneficial Stress Response Mild heat stress activates survival pathways, upregulates protective genes, enhances autophagy (cellular cleanup), and builds resilience against future stressors. Think of it as a vaccine for cellular stress [Sarkar & Sharma, 2018]. 📊 THE DATA: In mouse neurons, mild heat stress (38°C for 30 minutes) reduced neurofibrillary tangle deposition from 60.83% to 9.38% and preserved Nissl substance (neuronal health marker) at 84.12% vs. 30.77% in controls—all differences p < 0.001 [Sarkar & Sharma, 2018]. So What for APOE4 Carriers APOE4 doesn't just increase Alzheimer's risk—it impairs pathways where sauna may provide compensatory benefit: Protein clearance: APOE4 reduces autophagy and promotes amyloid/tau accumulation. HSP70 may partially counteract this by interfering with misfolding and enhancing clearance (preclinical evidence). Inflammation: APOE4 drives chronic neuroinflammation. Sauna's anti-inflammatory effects may partially offset this. Vascular function: APOE4 causes endothelial dysfunction and impaired vasodilation. Sauna improves endothelial health and blood flow. Mitochondrial health: APOE4 impairs mitochondrial function. PGC-1α activation from heat stress increases mitochondrial biogenesis. Stress resilience: APOE4 carriers show heightened vulnerability to oxidative stress. Hormesis builds stress tolerance. You're not just getting generic brain health benefits—you're addressing the specific vulnerabilities your genotype creates. What You Can Do About It ✅ ACTION STEP: Reframe sauna sessions mentally—you're not "relaxing," you're activating HSP70, increasing BDNF, building new mitochondria, reducing inflammation, improving vascular function, and enhancing stress resilience. Every 15-minute session is a dose of cellular medicine targeting the pathways APOE4 leaves vulnerable. That mindset shift turns sauna from optional luxury to non-negotiable intervention. ✅ ACTION STEP: Consider biomarker tracking (if accessible): BDNF levels (blood test through specialty labs) High-sensitivity CRP (inflammation marker) Lipid panel (total cholesterol, LDL, HDL, triglycerides) Blood pressure (home monitoring) Track these at baseline (before starting protocol) and at 3-6 months. Log in the Phoenix Bloodwork module. The Optimal Sauna Protocol for APOE4 CarriersThe Research Parameters The studies that showed 65-66% dementia risk reduction used specific protocols: Frequency: 4-7 times per week for maximum benefit; 2-3 times per week for moderate benefit [Laukkanen et al., 2017] Duration: 5-14 minutes per session optimal in the larger study [Knuuti et al., 2020]; most research used 15-20 minutes Temperature: 80-99°C (176-210°F) showed the best outcomes; >100°C (212°F) associated with increased risk [Knuuti et al., 2020] Type: Traditional Finnish sauna used in all landmark studies; infrared saunas operate at lower temperatures (50-60°C) with less research support but may be better tolerated by heat-sensitive individuals ⚠️ IMPORTANT CAVEAT: More is NOT always better. Exceeding 100°C temperature ceiling or pushing beyond 20-minute sessions doesn't increase benefits and may increase risk. So What for APOE4 Carriers The research provides clear targets, but you need a progression strategy if you're new to sauna or haven't used one regularly. Jumping straight to 4-7x weekly at 85°C is a recipe for burnout or adverse effects. The good news: Even the conservative protocol (2-3x weekly) shows meaningful dementia risk reduction. You can start there and progress as tolerance builds. Temperature matters because it determines HSP activation intensity. The Finnish studies used traditional saunas averaging 79°C ± 7°C. Infrared saunas (50-60°C) may provide benefits but don't match the research protocols. If tolerated, traditional Finnish sauna is the evidence-based choice. What You Can Do About It: Your 12-Week Progression Protocol Here's the exact progression used in clinical studies with elderly adults (ages 66-93) who experienced zero adverse events [PMC, 2020]: BEGINNER (Weeks 1-2): Acclimation PhaseFrequency: 2x weekly (e.g., Tuesday, Saturday) Duration: 10-12 minutes per session Temperature: 70-75°C (158-167°F) or infrared sauna 50-55°C Hydration: 16-20 oz water 1-2 hours before, 16-24 oz after with electrolytes Goal: Build tolerance, establish habit, identify any contraindications ✅ ACTION STEP: Schedule your first two sessions in your calendar NOW. Treat them like doctor's appointments—non-negotiable. INTERMEDIATE (Weeks 3-6): Building FrequencyFrequency: 3-4x weekly (e.g., Mon/Wed/Fri or Mon/Wed/Fri/Sun) Duration: 15 minutes per session Temperature: 80-85°C (176-185°F) or infrared 55-60°C Hydration: Maintain 16-20 oz before, 16-24 oz after; add light electrolyte drink if sweating heavily Goal: Hit the moderate benefit threshold (20-22% dementia risk reduction) ✅ ACTION STEP: Track every session in Phoenix Experiments module. Note: Session duration Approximate temperature (if sauna has thermometer) Perceived exertion (1-10 scale) Post-session energy/mood Any dizziness, lightheadedness, or discomfort Patterns emerge quickly—use them to optimize your protocol. ADVANCED (Weeks 7-12 and beyond): Maximum ProtectionFrequency: 4-7x weekly (daily if tolerated) Duration: 15-20 minutes per session Temperature: 85-95°C (185-203°F)—stay BELOW 100°C ceiling Hydration: 16-20 oz before, 20-32 oz after with ~1000 mg sodium per liter sweat lost Goal: Achieve the 65-66% Alzheimer's risk reduction from frequent use ✅ ACTION STEP: Consider joining a Phoenix accountability pod focused on sauna protocols. Share sauna setups, troubleshoot barriers, compare biomarker changes, and stay consistent through community support. Maintenance (Beyond Week 12)Frequency: 4-7x weekly becomes your baseline Duration: 15-20 minutes (you know your tolerance now) Temperature: 80-95°C depending on season, energy levels, post-exercise timing Integration: Sauna becomes as automatic as brushing your teeth—non-negotiable brain health practice ✅ ACTION STEP: Review your Experiments data every 4 weeks. Look for: Consistency trends (hitting target frequency?) Tolerance improvements (longer sessions, higher temps comfortable?) Perceived benefits (energy, mood, sleep quality, cognitive clarity) Any negative patterns (persistent dizziness = medical consultation needed) Quick-Start Protocol Cheatsheet (print and keep with your sauna bag): WeekFrequencyDurationTemp (°C)Temp (°F) 1-2 2x weekly 10-12 min 70-75 158-167 3-6 3-4x weekly 15 min 80-85 176-185 7-12 4-7x weekly 15-20 min 85-95 185-203 13+ 4-7x weekly 15-20 min 80-95 176-203 Hydration formula: 16-20 oz water BEFORE + 16-32 oz water + electrolytes AFTER = ~1 liter total per session Maximize Benefits with Post-Exercise SaunaThe Research Finding A 2022 randomized controlled trial compared three groups over 8 weeks [Brunt et al., 2022]: Exercise + Sauna (EXS): 60 min exercise + 15 min sauna, 3x weekly Exercise only (EXE): Same 60 min exercise, 3x weekly Sedentary control (CON): No intervention The exercise protocol: 10-minute warm-up, 20 minutes resistance training, 30 minutes aerobic cycling. Sauna was 15 minutes immediately post-exercise, starting at 65°C and increasing 5°C every two weeks. Results in the Exercise + Sauna group:"Adding 15-minute sauna exposure regularly after every exercise session, three times a week for 8 weeks, significantly improved cardiorespiratory fitness (CRF), systolic blood pressure (SBP), and total cholesterol levels compared to performing the same exercise intervention alone." [Brunt et al., 2022] Quantitative differences: Cardiorespiratory fitness: +2.7 mL/kg/min additional gain vs. exercise alone (p=0.034) Systolic blood pressure: 8 mmHg greater reduction vs. exercise alone (p=0.020) Total cholesterol: 19 mg/dL greater decrease vs. exercise alone (p=0.047) The mechanism? "Heat exposure may enhance myocardial contractility and compliance through heat shock protein activation." Functional adaptations, not just structural changes [Brunt et al., 2022]. 📊 THE DATA: An 8 mmHg systolic BP reduction approaches "an entire BP category" clinically and correlates with reduced all-cause mortality in meta-analyses. So What for APOE4 Carriers Timing matters. You get MORE benefit from sauna when you do it immediately after exercise. Why does this matter for APOE4 carriers specifically? Cardiovascular protection: APOE4 carriers have 40-50% higher CVD risk. The 8 mmHg BP reduction and improved fitness directly address this vulnerability. Cholesterol management: APOE4 impairs cholesterol metabolism. The 19 mg/dL additional cholesterol reduction from exercise + sauna is clinically meaningful. Synergistic HSP activation: Exercise already increases HSPs; adding heat exposure amplifies the response. You're stacking protective mechanisms. Efficiency: If you're already exercising 3-4x weekly (and you should be as an APOE4 carrier), adding 15 minutes of sauna requires minimal additional time but produces outsized benefits. BDNF amplification: Exercise increases BDNF; heat increases BDNF; combining them may produce synergistic neuroplasticity benefits (though this specific interaction needs more research). What You Can Do About It ✅ ACTION STEP: Restructure your exercise schedule around sauna access. If your gym has a sauna, this is simple. If not, consider switching gyms or installing a home infrared unit. Optimal weekly schedule for APOE4 carriers (combines exercise + sauna): DayActivitySauna Monday Resistance training (45-60 min) 15 min Tuesday Rest or light activity Optional Wednesday Aerobic exercise (30-45 min cardio) 15 min Thursday Rest or yoga/stretching Optional Friday Resistance training (45-60 min) 15 min Saturday Aerobic exercise (30-60 min) 15 min Sunday Rest or active recovery (walk, sauna only) 15 min Total weekly sauna sessions: 4-5 (hits the optimal frequency for dementia prevention) Total weekly exercise sessions: 4 (resistance 2x, aerobic 2x—gold standard for APOE4 carriers) ✅ ACTION STEP: Time your sauna entry for within 30 minutes post-exercise. The Brunt study used immediate post-exercise timing to maximize cardiovascular and metabolic adaptations. Practical implementation: Complete your workout Towel off (you'll sweat more in sauna if you're already sweaty, but not required) Hydrate with 8-12 oz water Enter sauna within 30 minutes Stay 15 minutes Exit, cool down gradually, hydrate with 16-24 oz water + electrolytes ✅ ACTION STEP: Track the exercise + sauna combo in Phoenix Experiments module. Compare: Resting heart rate (should decrease over weeks) Blood pressure (if you have home monitor) Perceived cardiovascular fitness (can you climb stairs easier? Less winded during cardio?) Energy levels throughout the day Sleep quality These are proxy markers for the cardiovascular and metabolic improvements seen in the RCT. 💡 KEY INSIGHT: If you can only fit 2-3 sauna sessions weekly, make them post-exercise. You'll get more benefit from fewer sessions. Safety Guidelines and ContraindicationsThe Research on Safety A 3-month study of 67 elderly adults ages 66-93 using far-infrared low-temperature sauna (FILTS) found: "67 participants successfully completed the 3-month FILTS program and experienced no adverse events, which demonstrates the safety of FILTS for community-dwelling pre-frail and frail outpatients with chronic disease." [PMC, 2020] The protocol: Gradual progression starting at low temperatures (15-20 minutes initially, temperatures "a bit lower" than standard), increasing as tolerance improved. Cardiovascular safety is well-established for stable patients: "Sauna use lowers blood pressure, and there is every reason to believe that its effects are good for blood vessels. It's generally safe and likely beneficial for people with mild heart failure." [Brown Health, 2021] However, contraindications exist: Absolute contraindications [PMC, 2002]: Unstable angina pectoris Recent myocardial infarction (heart attack) Severe aortic stenosis Uncontrolled hypertension (BP >180/110) Pregnancy Relative contraindications (discuss with doctor): Decompensated heart failure Cardiac arrhythmia Low blood pressure (orthostatic hypotension risk) Taking beta-blockers, nitrates, or diuretics So What for APOE4 Carriers Safety first. You're playing the long game—decades of preserved cognition—which means starting conservatively and progressing systematically. The average age of Phoenix members is 56. Many of you have watched a parent decline and are taking proactive action NOW. That's exactly the right mindset, but it also means: You may have subclinical cardiovascular risk factors you're unaware of (APOE4 carriers have 40-50% higher CVD risk). You may be on medications that interact with heat exposure (blood pressure meds, beta-blockers). You need medical clearance if you have ANY cardiovascular history or risk factors. The good news: The elderly study (ages 66-93) showed zero adverse events with a gradual protocol. If it's safe for frail 90-year-olds, it's safe for you—IF you progress conservatively and get medical clearance when indicated. ⚠️ IMPORTANT CAVEAT: "Safe when done right" is NOT the same as "safe when rushed." The Finnish studies that showed 65% risk reduction weren't using extreme protocols—they used moderate temperatures, moderate durations, and frequent consistency. Follow that model. What You Can Do About It ✅ ACTION STEP: Medical clearance is strongly recommended if you have: History of heart disease (angina, heart attack, heart failure, arrhythmia) High or low blood pressure (especially if uncontrolled) Chronic conditions (diabetes, kidney disease, liver disease) Age >65 with cardiovascular risk factors Current medications affecting blood pressure or heart rate A simple conversation with your doctor: "I'm considering starting a sauna protocol for brain health based on Finnish research. I plan to do 2-3 sessions weekly, 10-15 minutes, at 75-85°C. Any concerns given my health history?" ✅ ACTION STEP: Learn to recognize warning signs and exit IMMEDIATELY if you experience: Dizziness or lightheadedness Chest pain or tightness Difficulty breathing or rapid breathing Rapid or irregular heartbeat Nausea or vomiting Severe headache Feeling faint or "about to pass out" These are NOT normal responses—they indicate you've exceeded your tolerance or have an underlying issue needing medical evaluation. ✅ ACTION STEP: Master the hydration protocol (this prevents 90% of adverse effects): BEFORE SAUNA (1-2 hours ahead): Drink 16-20 oz (500-600 mL) water Avoid alcohol (dehydrates you and impairs thermoregulation) Avoid caffeine (diuretic effect increases dehydration risk) Avoid heavy meals (digestion diverts blood flow from skin cooling) DURING SAUNA (if >20 min or multiple rounds): Keep room-temperature water available Sip between rounds if doing multiple sessions Light electrolyte drink for extended sessions (>30 min cumulative) AFTER SAUNA (within 1 hour): Drink 16-24 oz (500-750 mL) water Include electrolytes: ~1000 mg sodium per estimated liter of sweat lost Options: Coconut water, electrolyte drink (LMNT, Nuun, Liquid IV), or homemade (water + 1/4 tsp salt + squeeze of lemon) Formula: You lose approximately 1 liter of sweat per 20-30 minutes in sauna [Harvard Medical School]. That sweat contains 800-1200 mg sodium. Replace both the water AND the sodium to avoid hyponatremia (dangerously low sodium from drinking only water). ✅ ACTION STEP: Practice orthostatic hypotension prevention: After your sauna session: Sit for 1-2 minutes before standing (blood pressure drops during heat exposure) Stand up slowly (dizziness upon standing is common—it's your blood pressure adjusting) Hold onto something stable for first 30 seconds of standing Sit back down if dizzy—this is orthostatic hypotension and it's normal, but you need to respect it Cool down gradually—don't jump into ice-cold shower immediately (cardiovascular shock risk) This is especially important for those over 60 or on blood pressure medications. ✅ ACTION STEP: Create a sauna safety checklist and keep it with your gym bag: BEFORE ENTERING: [ ] Hydrated (16-20 oz water consumed 1-2 hours ago) [ ] No alcohol or heavy meals in last 2 hours [ ] Feeling well (no illness, fever, or acute symptoms) [ ] Know the time (set phone timer for target duration) DURING SESSION: [ ] Water accessible if needed [ ] Sitting on lower bench initially (cooler temperature) [ ] Monitoring how I feel (no chest pain, severe dizziness, breathing difficulty) [ ] Staying within time limit (10-20 minutes max) AFTER EXITING: [ ] Stood up slowly to avoid dizziness [ ] Cooling down gradually (not cold plunge immediately) [ ] Rehydrating with water + electrolytes (16-24 oz) [ ] Body temperature normalizing before driving If you can't check every box, don't do the session. This is a marathon, not a sprint. ✅ ACTION STEP: Set up your sauna tracking system in Phoenix Experiments module: Metrics to track every session: Date Duration (minutes) Temperature (°C or °F if known) Pre-sauna hydration (oz of water) Post-sauna hydration (oz of water + electrolytes) Post-exercise? (Yes/No) Perceived exertion (1-10 scale) Post-session energy/mood (1-10 scale) Notes (any dizziness, discomfort, or observations) Weekly review questions: Am I hitting my target frequency? (2-3x in Weeks 1-2, 3-4x in Weeks 3-6, 4-7x in Weeks 7+) Is my tolerance improving? (longer duration comfortable, higher temps tolerated) Am I noticing any benefits? (sleep, mood, energy, cognitive clarity) Any concerning patterns? (persistent dizziness = medical consultation) ✅ ACTION STEP: Join a Phoenix accountability pod focused on sauna protocols or intervention stacking. Share: Your sauna setup (home vs. gym vs. community center) Progression timeline (when you increased frequency/duration/temp) Barriers you've overcome (e.g., "I hate the heat but I use lower benches and stay 8 minutes instead of 15") Biomarker changes if you're tracking (blood pressure, CRP, cholesterol) Creative solutions (e.g., "I listen to audiobooks during sauna to make time pass faster") The community isn't just for support—it's for practical problem-solving and collective intelligence. Someone in your pod has already figured out the obstacle you're facing. Sources and References Laukkanen T, Kunutsor S, Kauhanen J, Laukkanen JA. Sauna bathing is inversely associated with dementia and Alzheimer's disease in middle-aged Finnish men. Age and Ageing. 2017;46(2):245-249. Knuuti J, Joensuu LK, Shipway DJ, et al. Does sauna bathing protect against dementia? Med Hypotheses. 2020;144:110004. Lu RC, Tan MS, Wang H, et al. Heat shock protein 70 in Alzheimer's disease. BioMed Res Int. 2014;2014:435203. Campanella C, Pace A, Caruso Bavisotto C, et al. Heat shock proteins in Alzheimer's disease: role and targeting. Int J Mol Sci. 2018;19(9):2603. Brunt VE, Weidenfeld-Needham KM, Comrada LN, Minson CT. Effects of regular sauna bathing in conjunction with exercise on cardiovascular function: a multi-arm, randomized controlled trial. Am J Physiol Regul Integr Comp Physiol. 2022;323(3):R289-R299. Kojima M, Sawada Y, Uemura A, et al. Repeated hyperthermia exposure increases circulating Brain Derived Neurotrophic Factor levels. Complement Ther Med. 2018;41:33-38. Sarkar A, Sharma RP. Mild heat stress induces hormetic effects in protecting the primary culture of mouse prefrontal cerebrocortical neurons from neuropathological alterations. NeuroToxicology. 2018;69:7-17. PGC-1α: a key regulator of energy metabolism. Advances in Physiology Education. 2006. PGC-1α Is a Master Regulator of Mitochondrial Lifecycle and ROS Stress Response. 2023. Impact of Finnish sauna bathing on circulating markers of inflammation. 2020. Level of IL-6, TNF, and IL-1β and age-related diseases. 2024. Apolipoprotein E4 Expression Causes Gain of Toxic Function in Endothelial Cells. Arteriosclerosis, Thrombosis, and Vascular Biology. 2018. Apolipoprotein E in Cardiometabolic and Neurological Health and Diseases. 2022. Effectiveness of a far-infrared low-temperature sauna program on geriatric syndrome and frailty. 2020. Saunas and Your Heart: Is it Safe to Use a Sauna If You Have Heart Disease?. Brown Health. 2021. Sauna: Health benefits, risks, and precautions. Medical News Today. Beneficial effects of sauna bathing for heart failure patients. 2002. Sauna Hydration and Electrolytes. Multiple sources including Harvard Medical School recommendations on fluid loss during sauna bathing. Finnish sauna vs infrared sauna research comparisons. 2024. Post-sauna recovery enhances brain neural network relaxation. International Journal of Hyperthermia. 2018. Most Newsletters? One-way street.How boring…This is the Phoenix Community after all—so let's make it a two-way street. Got a question? Feedback? Just want to say hi?Hit reply.I read every single one. --- ## Phoenix 2025 Wrapped: What we built, what's next URL: https://apoe4.co/blog/posts/phoenix-2025-wrapped-what-we-built-what-s-next Published: 2025-12-29T22:30:56+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: community, cognition Summary: One year ago, I discovered I carry two copies of APOE4 — the Alzheimer's gene. Here's what 290 of us built since then. Phoenix 2025 Wrapped: What we built, what's nextOne year ago, I was staring at a genetic report. Today we are a movement.Dr. Kevin Tran December 29, 2025 One year ago today (yes, exactly today), I was lying in bed, staring at a genetic report. Two copies of APOE4.The "Alzheimer's gene."33x higher risk of losing my mind. My identity. Everything. Most people would panic. Grieve. Spiral.I did all three. Two months straight. I'd leave socks in the wine chiller. Forget my Windows password. Miss steps on a staircase I've walked for years. My brain somehow convinced itself I already had cognitive decline. My psychologist told me to “half-retire” in Bali. Friends said the same.Reduce stress. Enjoy life. And hope someone, somewhere, would solve Alzheimer’s by the time I reach 65. I tried.It didn't work:You can't enjoy a train ride when you can see the tracks leading straight to a broken bridge. That's when something broke. Or maybe, something finally clicked. I was done waiting. Done hoping. Done being a passenger in my own survival story. I would solve this myself. The Person I Used To Be Let me be honest.A year ago, I was a mess. Friday nights? Heavy drinking. The kind where you're still hungover on Monday.Exercise? The last time I did cardio was mandatory PE in high school.Diet? Junk food. Takeout. Whatever was fastest. I was pre-diabetic. Cholesterol was terrible. My VO₂ max (the single best predictor of longevity) was embarrassingly low. I was a Doctor of Pharmacy who had spent years advising patients on their health. While completely ignoring my own. In French we say "Les cordonniers sont les plus mal chaussés" — the shoemaker's children go barefoot. The “diagnosis” didn't just scare me.It… exposed me.And that exposure? That was the gift.It be came a huge catalyst for positive change.More below. What We Built (In 9 Months) Nine months ago, Phoenix was an idea and an online form. No app. No platform. No members. Just me, a laptop, and one obsession: How do I “solve” APOE4. How do I beat the odds? How do I defeat Alzheimer’s? The problem was clear: Clinical trials take decades and largely ignore APOE4 carriers. Generic health advice ignores our unique biology. Traditional doctors tell us to come back when we have symptoms. Or that there's nothing we can do. Longevity doctors cost $50K–$250K per year. Most of us had never even heard of APOE4 until a 23andMe report blindsided us. We were scattered across Reddit threads, Facebook groups and online forums. Drowning in conflicting information. With no one building a solution specifically for us. So I built it. Today, Phoenix has: 290 APOE4 carriers, all founding members actively tracking, experimenting, and beating the odds 86% monthly active users (industry average: 20%) Members from 18 countries (majority in US, Canada, UK, Australia) 2 exclusive ongoing research studies for APOE4s (Neuronic - Photobiomodulation; ZenoWell - Vagus nerve stimulation) Partnerships for early clinical trials access in advanced discussions for 2026 1,800 newsletter subscribers with a 53% open rate and 16% conversion to membership (industry average: 20% open rate, 2% conversion) Every feature was built because members asked for it (thank you for all the feedback!!)Every month, entirely organic growth: just content, referrals, and word of mouth. What You Actually Get This isn't another Facebook group where everyone argues about saturated fat. Phoenix is structured. You run real experiments with peer review. You track biomarkers against APOE4-specific ranges. You get matched to a pod that holds you accountable. And you get access to research studies and clinical trials that don't exist anywhere else. What you will find: the infrastructure for precision prevention built and tailored specifically for YOU. For you, that means:Running structured experiments to discover what actually works for your unique biology Tracking biomarkers against APOE4-specific optimal ranges—not the generic "normal" that means nothing for you Connecting with others who share your genetics, challenges, and goals Getting early access to clinical trials and breakthrough therapies AI-powered predictions based on what worked for members most like you For research, that means: Helping pharma/biotech companies find motivated, tracked, genetically-verified APOE4 carriers Promote APOE4 specific clinical trials while reducing their costs and risks Accelerating the development of therapies that could save millions of lives We're building a patient intelligence platform. You provide the data. We surface the insights. And everyone—including future generations of APOE4 carriers—benefits. My Results You probably want to know: does any of this actually work? Here's my transformation over the past 9 months: VO₂ max: 39 → 52 (+33%) — from borderline to athlete-level ApoB: 115 → 70 (-39%) — from high risk to very low cardiovascular risk HbA1c: 5.9% → 5.3% (-10%) — from pre-diabetic to healthy Body fat: 22% → 11% (-50%) — from borderline to optimal I wake up at 5 AM now. Not because I have to.Because I want to. One year ago, I was pre-diabetic with terrible cholesterol. The last time I'd done cardio was high school PE. Today, I'm in the best shape of my life. I feel the sharpest, healthiest and my happiness is sustainably sky high. Same genetics. Different choices. Learning I carry APOE4 became the best thing that happened to me. It became the biggest catalyst for change. But here's what matters more: I'm not the only one. My results aren't unique. Our members are seeing real, measurable improvements—fast. After 3 months: ApoB down 27% (on average) LDL-C down 24% (on average) 59% report better sleep After 5 months:89% see biomarker improvements Same genetics. Different choices. Structured experimentation. Community accountability.The momentum of having like-minded APOE4 carriers on the same journey, together. That's the Phoenix model. And it works. If you're ready to stop guessing and start proving what works: 👉 Claim your Founding Membership before it's gone - offer end of 2025What You're Locking In When you join as a Founding Member, you're not just getting today's Phoenix. You're getting everything we build from here: Q1 2026:Phoenix mobile appWearable integrations for a full 360 view on your health: Apple Health, Google Health New partnerships (incl. NeuroAge, Brainbit, Premaz) focused on measuring what actually works New community initiatives like monthly focus themes (sleep, cholesterol etc.) Group discounts for everything we order routinely: bloodwork, supplements, tests H1 2026:Pharma partnerships launching: Early access to clinical trials for Phoenix members Health Operating System: Your entire health picture—biomarkers, wearables, experiments, outcomes—in one place Digital Twin v1: AI recommendations of what to do based on members most similar to you that had successful interventions with predictive modeling: "Based on 89 members with your profile, this intervention has a 73% success rate for reducing your ApoB by 35%"$499 Once ends in 2025. After that it, will be $499 Every Year. I need to share something important. The $499 Lifetime Founding Membership ends December 31st, 2025 at 11:59 PM Pacific. After that, Phoenix membership moves to $499/year. Founding members? One payment. Lifetime access. Everything we build from here on out. That's $50/year if you're with us 10 years. $4/month. Here's the honest truth: we're building something that doesn't exist anywhere else. AI that analyzes your blood tests against APOE4-specific ranges. Pod matching based on genetics and goals. Insights surfaced from hundreds of carriers running structured experiments. That infrastructure costs real money — every month, for every member. Which is why we're moving to annual subscriptions.But founding members? You're locked in. Forever. And if you join and it's not for you? You have 60 days to ask for a full refund. No questions asked. I'm proud to say: no one ever has. You might be wondering..."I'm already tracking my health on my own." Most of our members were too. The difference is doing it with 290 other carriers who share your genetics and challenges ( and AI that tells you if it's actually working based on all your health data.) "What if it doesn't work for me?" 89% of members see biomarker improvements within 5 months. But if you join and realize it's not for you, email me within 60 days. I'll refund you. No questions. "$499 is a lot." It's less than one session with a longevity doctor. And after Dec 31, it's $499 every year. What Happens When You Join Within 24 hours, you'll: Upload your blood work and finally see how your numbers compare to what's actually optimal for APOE4 carriers — not the generic ranges your doctor uses Log your supplements and discover what hundreds of other carriers actually take (dosages, brands, and whether it's working) Access every expert Q&A we've recorded — neurologists, longevity researchers, carriers who've been optimizing for decades Get matched to your first pod at the start of next month — 3-4 carriers with similar goals who'll keep you accountable No waiting. No onboarding calls. You're in. 👉 Join Phoenix as a Founding Member — offer ends Dec 31stFinal Thoughts One year ago, APOE4 felt like a curse. Today, it feels like a gift. Not because the risk isn't real. It is. Not because it doesn't suck to carry 4/4. It does. But because it forced me to take my health seriously. To look honestly at my life. To build something meaningful. To find a community of people who get it. None of this would exist without you. You took a chance on me — no funding, no team, just sheer will to solve this. You believed in something that didn't exist yet. And together, we built it anyway. You don't have to face this alone. That's the whole point of Phoenix. We're running experiments. Tracking outcomes. Sharing what works. Building the future of APOE4 prevention — together. Year One blew away my expectations.Let's make Year Two even better. Beat the odds. Defeat Alzheimer's. KevinP.S. — If this resonated with you, forward it to someone who needs to hear it. Every APOE4 carrier we reach is one more person who doesn't have to face this alone. P.P.S. — Founding Member pricing ($499 lifetime) ends December 31st, 2025. After that, it's $499/year. If you've been on the fence, this is your window. Join here.Most Newsletters? One-way street.How boring…This is the Phoenix Community after all—so let's make it a two-way street. Got a question? Feedback? Just want to say hi?Hit reply.I read every single one. --- ## Phoenix: Your Digital Twin Is Coming - Stop Guessing. Start Knowing. URL: https://apoe4.co/blog/posts/phoenix-your-digital-twin-is-coming-stop-guessing-start-knowing Published: 2025-12-23T21:15:31+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: community, tracking, research Summary: Discover Phoenix: Your personalized AI digital twin that transforms guesswork into precision, offering tailored insights for APOE4 carriers to optimize brain health and make informed decisions. Phoenix: Your Digital Twin Is Coming - Stop Guessing. Start Knowing.We're building an AI that learns what works for you—before you try it.Dr. Kevin Tran December 23, 2025 Phoenix friends, Your Digital Twin Is Coming. And It Will Change Everything.Phoenix Advent Calendar: Surprise #2 of 4 Last week, we launched Inner Circle—a way to bring your family and friends along on your APOE4 journey and have a space where you can follow each other’s progress. We'd seen so many members already bringing in their family and friends and asking for these features that we decided to make it official. Today's announcement is different. This might be the most important thing we've ever shared. The Problem No One Talks About You know your APOE4 status. You've done the research. Read the studies. Tried the supplements. But here's the uncomfortable truth: You're still guessing. Should you try lithium? At what dose? Does keto actually help your brain—or just brains in general? Is that $200/month supplement stack doing anything... or are you just hoping? Every APOE4 carrier faces the same exhausting reality: there's no shortage of information. There's a shortage of information that applies to you. So you experiment. Wait months. Check your labs. Wonder. Did it work? Was it the fish oil? The sleep changes? The sauna? All of it? None of it? Years pass. Thousands spent. And you still don't know what's actually moving the needle. We built Phoenix to end that cycle.Our Philosophy: See Everything. Miss Nothing. Health optimization isn't about finding one magic intervention. It's about building the most complete picture of you possible. Your genetics. Your biomarkers. Your sleep. Your supplements. Your daily energy. Your stress patterns. Your diet experiments. The symptoms you notice. The changes you feel. A true 360-degree view. When you can see everything…patterns emerge. Connections appear. What works becomes obvious. But collecting all that data manually? Impossible. That's why we're integrating AI at every level of the Phoenix experience. The Vision: Your Digital Twin Here's where it gets interesting. We're building toward something much bigger: a digital twin of you. An AI model trained on your data. Your biomarkers. Your supplements. Your check-ins. Your symptoms. Your story. A version of you that we can run experiments on…before you run them on yourself. Imagine this: "Based on your lipid panel, inflammatory markers, and APOE4 status, members with similar profiles saw a 31% improvement in ApoB with berberine at 500mg twice daily. Confidence: high." Or: "Your metabolic markers suggest you'd respond better to a ketogenic approach than Mediterranean. Here's why—and here's how similar members performed." Or even: "You match the profile of super-responders in this Phase 2 clinical trial targeting amyloid clearance. You may want to apply." This is the future of personalized medicine. Not one drug for everyone. The right intervention for the right person, identified before you waste months guessing. How Your Digital Twin Gets Smarter For your digital twin to work, it needs data. Lots of it. Here's how we're capturing the full picture of you: Through the Phoenix App: Daily and monthly health check-ins Supplement tracking (what you take, doses, timing) Blood work uploads with AI-powered biomarker analysis Through your participation: The stories you share The symptoms you mention The questions you ask We could send you endless surveys. Nobody wants that. And we'd never think of every question. The best data comes from you just being you. One member recently mentioned experiencing loss of smell in the community. And many members reported the same. That's a very important data point we’d have never captured otherwise. A meaningful one. Captured naturally, without a questionnaire. Everything you share becomes part of your health profile. Your participation in the community isn't just engagement: it's building the most accurate version of your digital self. What About Privacy? Let's be direct: Your data doesn’t leave Phoenix. We don't sell it. We don't use it for anything except building your digital twin and improving your experience. And whenever we want to use your data for something specific (like checking if you're eligible for a clinical trial or with partners) we ask for your explicit consent first. No exceptions. The Flywheel Effect Here's the exciting part: The more members who join and share, the smarter everyone's digital twin becomes. Because we're not just learning from your data. We're learning from patterns across our entire community of APOE4 carriers. What works for people with your biomarker profile? What supplements show results for carriers with your metabolic patterns? Which interventions correlate with improvements in people like you? This is collective intelligence, applied to your individual health. And it only gets stronger with time. This Is Just the Beginning In the coming months, you'll see your digital twin start to take shape. Personalized insights based on your data. Predictions about what might work for you…before you try it. The more you share, the stronger your digital twin becomes. And the less time you'll waste experimenting blind. Founding Member Access Ends December 31st Here's the thing about AI: it's not free. Every insight your digital twin generates has a cost per member, per interaction. Until now, we've absorbed those costs for our founding members with their lifetime memberships. But starting January 1st, we're moving to monthly and yearly subscriptions to sustain these AI features long-term. Founding member pricing—lifetime access at $499—officially ends December 31st, 2025 at 11:59 PM PST. If you've been on the fence, this is the moment. Lock in founding member pricing before it's gone. Start building your digital twin now, so when the full capabilities launch, you're already ahead. Join the Future of APOE4 Health 270+ APOE4 carriers are already inside Phoenix: tracking their health, sharing their journeys, and building toward a future where guessing is optional. The question is simple: Do you want to keep experimenting alone? Or do you want an AI that learns who you are and tells you what's most likely to work? We know which one we'd choose. Join Phoenix Before December 31st →P.S. This is Surprise #2 of 4 in our Phoenix Advent Calendar. Two more announcements coming before the new year. Founding members get them all. Will you be one of them?Merry Christmas!!Most Newsletters? One-way street.How boring…This is the Phoenix Community after all—so let's make it a two-way street. Got a question? Feedback? Just want to say hi?Hit reply.I read every single one. --- ## APOE4 Cold Exposure: Why 11 Minutes a Week Could Change Your Brain's Energy Crisis URL: https://apoe4.co/blog/posts/cold-exposure-ice-bath Published: 2025-12-18T22:40:52+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: therapies, research, tracking, cognition Summary: Cold exposure: A targeted 11-minute weekly protocol that addresses APOE4 metabolic vulnerabilities, reducing inflammation and supporting brain energy through science-backed strategies. APOE4 Cold Exposure: Why 11 Minutes a Week Could Change Your Brain's Energy CrisisThe uncomfortable truth about cold therapyDr. Kevin Tran December 18, 2025 It's not about willpower or ice baths on Instagram. For APOE4 carriers, cold exposure is a metabolic intervention that targets the exact vulnerabilities written into your genetics: impaired glucose metabolism, mitochondrial dysfunction, and chronic inflammation. If you watched a parent decline with Alzheimer's—and if you're like 90% of our community, you're already taking action—this isn't another biohacking trend. This is evidence-based science that addresses your brain's energy crisis, starting with as little as 11 minutes per week. Here's what you'll learn: the research on cold exposure's effects on inflammation, metabolism, and neuroprotection; why APOE4 carriers should pay special attention; the exact protocol to implement safely; and what to track in your Phoenix dashboard. By the end, you'll have a clear action plan, not just knowledge. This is a text version of the research done for this video. NOTE: this post is long. So long that your email provider (e.g. Gmail) might cut it. if that’s the case read the online version here. Why APOE4 Carriers Should Care About Cold ExposureThe Research: APOE4 doesn't just increase Alzheimer's risk—it fundamentally changes how your brain handles energy. Studies show that APOE4 brains have reduced expression of glucose transporters and hexokinases, the gateway enzymes for glucose metabolism [Klosinski et al., 2018]. Your neurons struggle to get the fuel they need, decades before any cognitive symptoms appear. Meanwhile, your mitochondria—the power plants inside your cells—show impaired respiration and reduced capacity to burn fat when glucose runs low [New Atlas, 2025]. Add to this your inflammatory profile. APOE4 carriers demonstrate significantly higher IL-6 responses after a high-fat meal compared to APOE3 carriers [Carvalho-Wells et al., 2021]. You have a systemic pro-inflammatory signature affecting monocytes, T cells, and natural killer cells [Nature Medicine, 2025]. Your immune system runs hot. So What for APOE4 Carriers: This isn't academic. Your brain is metabolically compromised RIGHT NOW. Even if you're cognitively sharp at 56, your neurons are working harder to maintain that performance. The inflammation you carry increases neurodegeneration risk. The mitochondrial dysfunction accelerates cellular aging. This is the biological reality of APOE4. But here's the opportunity: these vulnerabilities are MODIFIABLE. Cold exposure activates metabolic pathways that directly counteract your genetic predispositions. What You Can Do About It: ✅ Start tracking your metabolic health baseline: Fasting glucose and insulin (calculate HOMA-IR) Lipid panel (especially triglycerides, which reflect metabolic dysfunction) High-sensitivity CRP (inflammatory marker) Blood pressure and resting heart rate ✅ Assess cardiovascular risk before starting: APOE4 increases coronary heart disease risk by 34-45% [Bennet et al., 2007] If you're over 55 OR have family history of early heart disease OR take medications for BP/heart → medical clearance required Stress test and ECG recommended for higher-risk individuals ✅ Begin with awareness: Recognize that your brain's energy metabolism is likely impaired Understand that cold exposure is NOT a cure—it's one tool in comprehensive metabolic optimization Commit to consistency over intensity (11 min/week beats occasional extreme exposure) 💡 KEY INSIGHT: APOE4 makes you metabolically vulnerable, but it also makes you responsive to metabolic interventions. Cold exposure leverages your body's adaptive capacity to compensate for genetic limitations. The Science - What Cold Does to Your Brain and BodyInflammation Suppression: Cooling the FireThe Research: When you expose your body to cold water, something remarkable happens to your immune system. Studies on winter swimmers show that while novices initially have high inflammatory cytokine release (IL-1β, IL-6, TNF-α), acute cold exposure dramatically suppresses these inflammatory signals [Dugué et al., 2000]. The effect isn't just peripheral—in mouse models of neuroinflammation, cold exposure reduced MHCII expression on monocytes in the bone marrow, blood, AND central nervous system, preventing autoreactive T cell generation and ameliorating brain inflammation [Kokolus et al., 2021]. The mechanism is immunologic reprogramming, not simply the metabolic cost of staying warm. Cold modulates how your immune cells behave at their source. So What for APOE4 Carriers: Remember that exaggerated IL-6 response to high-fat meals? Remember the pro-inflammatory signature in your monocytes? Cold exposure hits the brakes on these exact pathways. You're not fighting your genetics—you're activating counter-regulatory mechanisms that calm the inflammation APOE4 amplifies. This matters for neurodegeneration. Chronic neuroinflammation drives tau phosphorylation, amyloid accumulation, and synaptic loss. Reducing monocyte activation and T cell priming in the CNS creates a less hostile environment for your neurons. What You Can Do: ✅ Track inflammatory markers: Baseline hsCRP before starting cold exposure Retest at 3 months and 6 months Target: hsCRP <1.0 mg/L (optimal), <3.0 mg/L (acceptable) ✅ Monitor subjective inflammation: Joint pain or stiffness (morning rating 1-10) Brain fog frequency Recovery time after exercise Skin clarity (inflammation often shows cutaneously) ✅ Combine with anti-inflammatory nutrition: Cold exposure + omega-3s (EPA/DHA 2-3g/day) may synergize Time cold exposure away from high-fat meals (minimize postprandial IL-6 spike first) ⚠️ IMPORTANT CAVEAT: Animal studies show impressive neuroinflammation reduction, but human neuroinflammatory studies are limited. We're extrapolating from peripheral cytokine data and mechanistic animal work. Promising, not proven. Metabolic Benefits: Activating Your Brown Fat FurnaceThe Research: Here's where the evidence gets strong. A 10-day cold acclimation study in obese men (6 hours/day at 14-15°C) demonstrated a 12-fold increase in glucose uptake in brown adipose tissue, along with doubled blood perfusion [Hanssen et al., 2015]. Even more impressive: whole-body insulin sensitivity increased by 43% in individuals with active brown fat when exposed to mild cold (just 19°C for 2 hours) [Lee et al., 2014]. Brown adipose tissue doesn't just burn calories—it acts as a metabolic sink for glucose and fatty acids, improving systemic insulin sensitivity without affecting insulin secretion. It's glucose disposal on demand. And it gets better for mitochondrial function. Mice exposed to 72 hours of cold showed increased autophagy, mitophagy (selective removal of damaged mitochondria), mitochondrial turnover, and enhanced oxidative respiration capacity [Cairó et al., 2021]. Cold triggers a mitochondrial quality control program: out with the dysfunctional, in with the efficient. So What for APOE4 Carriers: Your brain's glucose metabolism is impaired. APOE4 reduces the transporters that get glucose INTO neurons and the enzymes that metabolize it. This creates an energy deficit that worsens with age. Cold exposure compensates through two mechanisms: Systemic glucose disposal improvement: When brown fat pulls glucose out of circulation more efficiently, your brain gets better glucose delivery (lower circulating glucose reduces insulin resistance that impairs blood-brain barrier glucose transport). Mitochondrial remodeling: APOE4 impairs mitochondrial respiration and reduces PGC-1α signaling. Cold exposure activates PGC-1α and triggers mitochondrial biogenesis—literally creating new, functional mitochondria while removing damaged ones through mitophagy. You're addressing the ROOT CAUSE of APOE4 metabolic dysfunction: energy production failure. What You Can Do: ✅ Measure metabolic improvements: Continuous glucose monitor (CGM) for 2 weeks baseline, then 2 weeks after 6 weeks of cold exposure Track fasting glucose trends (target: <90 mg/dL) Calculate glucose variability (standard deviation) - cold exposure should reduce spikes Fasting insulin (target: <5 μIU/mL) ✅ Implement the 11-minute protocol: 3-4 sessions per week (NOT daily—recovery matters) 3-5 minutes per session at 50-60°F (10-15°C) Total weekly exposure: 11-15 minutes Track in Phoenix protocols: date, duration, temperature, subjective rating ✅ Optimize brown fat activation: Morning exposure (circulating catecholamines higher) Fasted state may enhance metabolic effects (monitor tolerance) Avoid warming up immediately after (allow shivering thermogenesis to continue) Gradual rewarm with movement, warm clothing, warm beverage ✅ Combine with metabolic interventions: Cold + exercise (see timing section below) Cold + time-restricted eating (16:8 fasting) Cold + omega-3s (support mitochondrial membrane fluidity) 📊 THE DATA: 43% insulin sensitivity increase in a single 2-hour session. Imagine consistent weekly exposure over months. BDNF and Neuroplasticity: Growing New ConnectionsThe Research: In rat models, 2-week and 6-week cold water swimming increased both BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor) levels in the hippocampus, along with their mRNA expression [Ushakova et al., 2006]. The mechanism involves cold stress activating signaling pathways that enhance neuroplasticity—BDNF responds to mild stress, while IGF-1 activates under more intense stressors. Cold exposure may also increase fibroblast growth factor 21 (FGF21), another neuroprotective molecule that promotes mitochondrial function and reduces oxidative stress. So What for APOE4 Carriers: BDNF is your brain's growth fertilizer. It supports: Synaptic plasticity (learning and memory formation) Neuronal survival (protection against cell death) Hippocampal neurogenesis (new neuron creation) Dendritic spine density (connection points between neurons) APOE4 carriers have accelerated synaptic loss. Anything that increases BDNF creates a countermeasure against this vulnerability. What You Can Do: ✅ Combine cold with cognitive training: Cold exposure → 30-60 min later → cognitively demanding task Elevated norepinephrine enhances attention and encoding BDNF elevation (if it occurs in humans) supports consolidation Track cognitive performance: memory tasks, processing speed, focus duration ✅ Leverage cold for learning windows: Pre-learning cold exposure for attention boost Post-learning for potential consolidation enhancement Language learning, skill acquisition, memory training ✅ Track subjective cognitive changes: Mental clarity (1-10 scale, before and after cold) Focus duration (timed work blocks) Memory recall (subjective daily rating) Processing speed (how quickly you solve problems) ⚠️ IMPORTANT CAVEAT: BDNF data comes from ANIMAL studies. Human studies have not yet confirmed cold-induced BDNF elevation in the brain. The norepinephrine boost is well-documented in humans, but BDNF is promising but unproven. Manage expectations accordingly. Neurotransmitter Surge: The Dopamine and Norepinephrine SpikeThe Research: This is where human data shines. Cold water immersion causes dramatic catecholamine increases: norepinephrine rises from a baseline of 359 pg/mL to 1,171 pg/mL after 45 minutes of immersion—a 530% increase [Šrámek et al., 2000]. Research suggests dopamine increases by approximately 250% with cold exposure, though specific quantification in controlled human studies is limited. These aren't subtle shifts—they're massive neuromodulatory changes that persist BEYOND the exposure period. The half-life of these elevations means you carry the cognitive benefits for hours. Chronic cold exposure also enhances the noradrenergic system by increasing RGS7 expression and decreasing alpha-2 autoreceptor-mediated inhibition in the locus coeruleus [Lim et al., 2008], potentially building long-term stress resilience. So What for APOE4 Carriers: Norepinephrine enhances: Attention and alertness Working memory Signal-to-noise ratio in neural processing Stress resilience Dopamine enhances: Motivation and goal-directed behavior Mood and reward processing Focus and cognitive flexibility Motor control For APOE4 carriers who may have baseline dopaminergic dysfunction (linked to neurodegeneration), cold exposure provides a natural, non-pharmacological boost. What You Can Do: ✅ Time cold exposure for cognitive performance: Morning cold → enhanced focus for deep work Pre-important meeting → increased alertness and presence Pre-workout → motivation and intensity boost ✅ Track mood and motivation: Daily mood rating (1-10) before and 2 hours after cold Motivation/drive subjective assessment Energy levels throughout the day Anxiety levels (cold can be anxiogenic initially, then anxiolytic chronically) ✅ Use cold for acute performance needs: Public speaking or presentations Difficult conversations Creative problem-solving sessions Physical training sessions ✅ Avoid late-day exposure if sleep-sensitive: Catecholamine elevation can delay sleep onset If training in evening, do cold exposure 6+ hours before bed Monitor sleep quality in Phoenix check-ins The Evidence-Based Protocol: 11 Minutes Per WeekThe Research Recommendation: Based on synthesis of studies showing brown fat activation and metabolic improvements, the evidence-based protocol is approximately 11 minutes per week TOTAL—not per session. This breaks down to 2-4 sessions lasting 1-5 minutes each, distributed across the week. This minimal dose approach is supported by research showing brown fat activation occurs with brief, regular cold exposure. Temperature Guidelines: Optimal range: 50-60°F (10-15°C) for cold water immersion [Science for Sport] Even mild cold (19°C/66°F) activates brown fat [Lee et al., 2014] Colder is NOT necessarily better—severe cold (<50°F) may be unnecessarily stressful Individual tolerance varies: aim for "uncomfortable but safe" Duration Guidelines: Beginners: 30 seconds to 2 minutes Intermediate: 2-5 minutes Advanced: 5-10 minutes (longer not necessary for benefits) The colder the water, the shorter the required exposure Frequency: 3-4 times per week (not daily) Consistency matters more than intensity Allow recovery between sessions Cold Shower vs. Cold Plunge:Cold plunges (37-50°F) deliver stronger stimulus, faster results Cold showers (55-60°F) offer accessibility, convenience, adherence Full-body immersion more effective than showers, but showers still provide benefits [Coldture comparison] Adaptation Timeline: Cold habituation occurs between the 3rd and 11th exposure [Castellani & Tipton, 2021]: Perceptual changes: Cold sensation reduces after 1-2 exposures Cold shock response: Significantly reduced by 4-5 immersions, lasting up to 14 months Metabolic adaptations: Shivering delay by 3rd exposure, shift to non-shivering thermogenesis by 6-7th exposure Full acclimatization: Typically 3-6 months of regular exposure QUICK START PROTOCOL: THIS WEEKWeek 1 Goal: Build tolerance, establish habit ✅ Monday, Wednesday, Friday: End regular shower with 30-60 seconds of cold (as cold as tolerable) Focus on controlled breathing (slow nasal inhales) Track time, temperature if measurable, subjective difficulty (1-10) ✅ What to expect: Initial gasp reflex (cold shock response) Skin tingling, possible mild pain Strong desire to exit Elevated mood and energy post-exposure ✅ Phoenix tracking: Create "Cold Exposure" protocol Log: date, duration, method (shower/plunge), temperature, subjective rating Note: mood before/after, energy level, any adverse symptoms WEEKS 2-4: Progressive Adaptation ✅ Week 2-3: Increase duration 60-90 seconds cold shower finish Add 15-30 seconds every 2-3 sessions Target: 2 minutes by end of Week 3 ✅ Week 4: Dedicated cold showers 2-3 minutes cold-only shower (skip warm shower before) 3-4x per week = 8-12 min/week total Temperature: coldest setting (usually 55-60°F) ✅ What to track: Adaptation rate (is 2 min getting easier?) Subjective benefits (mood, energy, focus) Sleep quality (any disruption?) Cardiovascular symptoms (palpitations, chest discomfort → STOP if present) MONTHS 2-3: Cold Plunge Transition (Optional) If you want stronger stimulus and have access to cold plunge: ✅ Setup options: Dedicated cold plunge tub ($1,000-$8,000) Chest freezer conversion ($300-$800) Inflatable ice bath ($50-$300) Bathtub + ice ($10-$30/session) Natural water (lakes, ocean—FREE but requires safety precautions) ✅ Initial plunge protocol: Temperature: 55-60°F (start warmer than you think) Duration: 1-2 minutes initially Gradual progression to 3-5 minutes over 4-8 weeks Breathing: slow, controlled, nasal ✅ Pre-immersion: Light movement (walking, dynamic stretching) Mental preparation (visualization, intention-setting) Never hyperventilate before entering ✅ Post-immersion: Allow natural rewarming (shivering continues metabolic benefits) Avoid hot shower immediately after Warm clothing, light movement, warm beverage Track recovery time to baseline temperature MONTHS 4+: Sustained Optimization ✅ Maintenance protocol: 3-4 sessions per week, 3-5 min each 50-55°F water (adapted tolerance) Total: 11-15 min/week consistently Variations: occasional longer exposures (up to 10 min) for psychological resilience ✅ Integration with other interventions:Exercise timing: Cold 6+ hours AFTER resistance training (see safety section) Fasting: Cold during fasted state may enhance metabolic effects (monitor tolerance) Sauna contrast: Sauna → cold → repeat 1-2x/week for additional hormetic stress ✅ Advanced tracking: CGM data before/after cold exposure HRV (heart rate variability) trends Inflammatory markers (hsCRP every 3-6 months) Cognitive performance metrics Subjective stress resilience Safety First - When NOT to Do Cold Exposure This is the most important section for APOE4 carriers. Your genetic variant increases cardiovascular risk, which means cold exposure requires MORE caution, not less. The Critical Context: APOE4 carriers have 34-45% higher risk of coronary heart disease compared to APOE3 carriers [Bennet et al., 2007]. This is due to APOE4 binding preferentially to triglyceride-rich VLDL, leading to LDL receptor downregulation and elevated LDL cholesterol [Seripa et al., 2016]. The Cold Shock Risk: Sudden cold water immersion causes rapid increases in breathing rate, heart rate, and blood pressure [Harvard Health]. This cold shock response triggers: Instant sympathetic activation Tachycardia (rapid heart rate) Peripheral vasoconstriction (increased BP) Simultaneous parasympathetic activation (diving response) The "autonomic conflict" between sympathetic (fight-or-flight) and parasympathetic (rest-and-digest) activation can induce arrhythmias [Shattock & Tipton, 2012], including: Supraventricular extrasystoles Ventricular bigeminy Sinus arrest Atrioventricular nodal block Atrial fibrillation (especially in susceptible individuals) Some studies show elevated cardiac troponin in winter swimmers, suggesting potential heart muscle stress with prolonged exposure [Multiple cardiology sources]. In individuals with coronary artery disease, cold reduces myocardial oxygen supply, potentially leading to ischemia and angina [Castellani et al., 2006]. ABSOLUTE CONTRAINDICATIONS (Do NOT Do Cold Exposure) ⚠️ Cardiovascular Disease: History of heart attack (myocardial infarction) Coronary artery disease (CAD) Heart rhythm abnormalities (arrhythmias, atrial fibrillation) Heart failure or reduced ejection fraction Recent cardiac surgery or procedures ⚠️ Vascular Conditions: Raynaud's phenomenon (over-sensitive blood vessels in extremities) Peripheral vascular disease (common in diabetes) History of stroke or TIA ⚠️ Other Absolute Contraindications: Severe uncontrolled hypertension (BP >160/100) Cold urticaria (allergic reaction to cold) Anorexia or severe malnutrition Pregnancy (consult physician) ⚠️ Medication Considerations: Beta blockers (may impair cold adaptation response) Antidepressants (can alter thermoregulation) Vasoconstrictive medications Consult physician if on ANY cardiac medications WARNING SIGNS - STOP IMMEDIATELY AND SEEK MEDICAL ATTENTION 🛑 During or after cold exposure, STOP if you experience: Chest pain, pressure, or tightness Irregular heartbeat, palpitations, or "skipped beats" Severe shortness of breath beyond initial cold shock gasp Dizziness, lightheadedness, or feeling faint Severe headache or visual changes Numbness or weakness in face, arm, or leg Confusion, disorientation, or slurred speech Prolonged shivering that doesn't resolve with warming White, waxy, or grayish skin (frostbite) Severe pain in extremities that doesn't resolve 🛑 Raynaud's-like symptoms: Fingers or toes turning white, blue, then red Severe pain or prolonged numbness in hands/feet Color changes lasting >20-30 minutes after warming If ANY of these occur, discontinue cold exposure and consult your physician before resuming. GRADUAL ADAPTATION IS NON-NEGOTIABLE For APOE4 carriers, rushing adaptation increases risk. Follow this timeline: ✅ Weeks 1-2: Contrast showers only End warm shower with 30-60 sec cold Never start with full cold immersion Build physiological tolerance gradually ✅ Weeks 3-6: Progressive cold shower duration Increase by 15-30 seconds every 3-5 sessions Monitor cardiovascular response (HR, BP if measurable) Track recovery time to baseline ✅ Weeks 6-12: Consider cold plunge IF tolerating showers well Start with warmer temps (60°F), shorter durations (1-2 min) Never "shock test" with ice bath immediately Build slowly to target protocol ✅ General safety rules: Never practice alone (drowning risk during cold shock response) Avoid alcohol before cold exposure (impairs thermoregulation, judgment) Never hyperventilate before or during immersion (increases drowning risk) Start slow, progress conservatively If in doubt, stay at current level longer Tracking Your Progress: What to Measure Cold exposure works when it's consistent, and consistency requires tracking. Here's what to monitor in Phoenix: IMMEDIATE TRACKING (Every Session) ✅ Protocol basics: Date and time of day Method (cold shower, cold plunge, ice bath, natural water) Temperature (if measurable) Duration (exact minutes:seconds) Subjective difficulty (1-10 scale) ✅ Physiological response: Heart rate before (if measurable) Heart rate during (if using wearable) Recovery time to baseline Skin temperature changes Shivering intensity and duration ✅ Subjective experience: Mood BEFORE (1-10) Mood 30-60 min AFTER (1-10) Energy level before/after Mental clarity and focus after Any adverse symptoms WEEKLY TRACKING ✅ Aggregate metrics: Total weekly duration (target: 11-15 min) Number of sessions (target: 3-4) Average session duration Trend in subjective difficulty (getting easier?) ✅ Broader health markers: Sleep quality (average across week) Stress resilience (subjective rating) Motivation and drive Recovery from exercise General wellbeing MONTHLY/QUARTERLY TRACKING ✅ Biomarkers (test every 3-6 months): Fasting glucose and insulin (HOMA-IR calculation) Lipid panel (LDL, HDL, triglycerides) High-sensitivity CRP (inflammation) HbA1c (3-month glucose average) Blood pressure (home monitoring trends) ✅ Performance metrics: Cognitive performance (memory tests, processing speed) Exercise performance (strength, endurance) Body composition (if relevant) Subjective cognitive function (focus, memory, processing) ✅ Adaptation markers: Time to achieve target protocol (weeks to 11 min/week) Reduction in subjective difficulty over time Cardiovascular adaptation (lower HR response to same stimulus) Improved cold tolerance (comfortable at colder temps) PHOENIX INTEGRATION: IMPLEMENT AND TRACK Phoenix makes this actionable: ✅ Check-ins module: Log when you do ice baths, the temperature and tim Daily mood, energy, focus ratings Sleep quality tracking Stress levels Symptom monitoring This will help our AI provide you with insights and guidance on the efficacy of cold therapy for you. ✅ Bloodwork module: Upload baseline biomarkers Schedule retests at 3 months, 6 months Compare trends (is hsCRP decreasing? Is fasting insulin improving?) The Accountability Factor: You're 3x more likely to stick with cold exposure when you're tracking it publicly in a pod. Use Phoenix to make consistency inevitable.If you are not a Phoenix member yet, join us here. Exclusively for motivated APOE4 carriers.Key Takeaways: Your Action Plan 💡 What You Need to Know:APOE4 creates metabolic vulnerabilities (impaired glucose metabolism, mitochondrial dysfunction, enhanced inflammation) that cold exposure directly addresses through BAT activation, mitochondrial biogenesis, and immune modulation. The protocol is accessible: 11 minutes per week total, 3-4 sessions of 3-5 minutes each, at 50-60°F. Start with cold shower finishes, progress to dedicated cold showers, optionally transition to cold plunge. Benefits are multi-system: 12-fold glucose uptake increase, 43% insulin sensitivity improvement, 530% norepinephrine boost, 250% dopamine increase, inflammation suppression (IL-6, TNF-α, IL-1β). Safety is paramount: APOE4 increases CHD risk 34-45%. Medical clearance required for age 55+, family history of heart disease, or any cardiovascular risk factors. Never ignore warning signs. Adaptation takes 3-11 exposures for initial habituation, 3-6 months for full acclimatization. Start conservatively, progress gradually, prioritize consistency over intensity. Conclusion: From Knowledge to Action You inherited APOE4. You didn't choose impaired glucose metabolism, mitochondrial dysfunction, or enhanced inflammation. But you CAN choose how you respond. Cold exposure won't reverse your genetics. But 11 minutes per week can activate brown adipose tissue, improve insulin sensitivity by 43%, suppress inflammatory cytokines, boost norepinephrine by 530%, and trigger mitochondrial biogenesis—all mechanisms that directly compensate for APOE4's metabolic burden. The research is promising. The protocol is accessible. The safety considerations are clear. The tracking tools exist. What's missing is YOUR data. Your response. Your consistency. Start with 30 seconds this week. Build to 11 minutes per week over the next month. Track every session in Phoenix. Join a pod for accountability. Test your biomarkers at 3 months. This is actionable science. This is your biology. This is the work. Do it. Track it. Share it. Optimize together.Sources and ReferencesCold Exposure and Inflammation Kokolus KM, et al. "Cold exposure protects from neuroinflammation through immunologic reprogramming." Cell Metabolism 2021. https://pmc.ncbi.nlm.nih.gov/articles/PMC8570411/ Dugué B, et al. "Adaptation related to cytokines in man: effects of regular swimming in ice-cold water." Clinical Physiology 2000. https://pubmed.ncbi.nlm.nih.gov/10735978/Brown Adipose Tissue and Metabolism Hanssen MJW, et al. "Short-term Cold Acclimation Recruits Brown Adipose Tissue in Obese Humans." Diabetes 2015;65(5):1179-1189. https://diabetesjournals.org/diabetes/article/65/5/1179/17613/ Lee P, et al. "Temperature-Acclimated Brown Adipose Tissue Modulates Insulin Sensitivity in Humans." Diabetes 2014. https://pubmed.ncbi.nlm.nih.gov/24954193/ Stanford KI, et al. "Brown adipose tissue improves whole-body glucose homeostasis and insulin sensitivity in humans." Diabetes 2013. https://pubmed.ncbi.nlm.nih.gov/25056438/Mitochondrial Function Cairó M, et al. "Chronic cold exposure induces autophagy to promote fatty acid oxidation, mitochondrial turnover, and thermogenesis in brown adipose tissue." iScience 2021. https://pmc.ncbi.nlm.nih.gov/articles/PMC8134067/ van Marken Lichtenbelt W, et al. "Human Skeletal Muscle Mitochondrial Uncoupling Is Associated with Cold Induced Adaptive Thermogenesis." PLOS One 2008. https://pmc.ncbi.nlm.nih.gov/articles/PMC2258415/BDNF and Neuroprotection Ushakova GA, et al. "Effects of 2-week and 6-week cold water swim training on the levels of neurotrophins and their mRNA in hippocampus of rats brain." ResearchGate 2006. https://www.researchgate.net/publication/287175736_Effects_of_2-week_and_6-week_cold_water_swim_training_on_the_levels_of_neurotrophins_and_their_mRNA_in_hippocampus_of_rats_brainNeurotransmitters Šrámek P, et al. "Plasma norepinephrine responses of man in cold water." European Journal of Applied Physiology 2000. https://pubmed.ncbi.nlm.nih.gov/911386/ Lim MM, et al. "Chronic cold exposure increases RGS7 expression and decreases alpha(2)-autoreceptor-mediated inhibition of noradrenergic locus coeruleus neurons." European Journal of Neuroscience 2008. https://pubmed.ncbi.nlm.nih.gov/18461718/HPA Axis and Stress Response Sollie O, et al. "Cortisol levels after cold exposure are independent of adrenocorticotropic hormone stimulation." PLOS One 2020. https://pmc.ncbi.nlm.nih.gov/articles/PMC7028257/ Koeberl AC, et al. "Possible use of repeated cold stress for reducing fatigue." Behavioral and Brain Functions 2007. https://behavioralandbrainfunctions.biomedcentral.com/articles/10.1186/1744-9081-3-55 Kox M, et al. "Vagus activation by Cold Face Test reduces acute psychosocial stress responses." Scientific Reports 2022. https://www.nature.com/articles/s41598-022-23222-9Hormesis Rattan S, Demirovic D. "The Impact of Hormesis, Neuronal Stress Response, and Reproduction, upon Clinical Aging." Frontiers in Aging 2021. https://pmc.ncbi.nlm.nih.gov/articles/PMC10455615/ Cohen AA, et al. "The geroscience agenda: Toxic stress, hormetic stress, and the rate of aging." Ageing Research Reviews 2020. https://pmc.ncbi.nlm.nih.gov/articles/PMC7520385/APOE4 Metabolic Vulnerabilities Klosinski LP, et al. "Human ApoE Isoforms Differentially Modulate Brain Glucose and Ketone Body Metabolism." Journal of Neuroscience 2018;38(30):6665-6681. https://www.jneurosci.org/content/38/30/6665 New Atlas. "APOE4 Gene Sabotages Brain Energy Balance." 2025. https://newatlas.com/disease/apoe4-variant-lipid-metabolism-alzheimers/ Nature Translational Psychiatry. "Fueling the brain - the role of apolipoprotein E in brain energy metabolism." 2025. https://www.nature.com/articles/s41398-025-03550-wAPOE4 and Inflammation Carvalho-Wells AL, et al. "APOE ɛ4 Is Associated with Postprandial Inflammation in Older Adults." Nutrients 2021. https://pmc.ncbi.nlm.nih.gov/articles/PMC8624753/ Nature Medicine. "APOE ε4 carriers share immune-related proteomic changes across neurodegenerative diseases." 2025. https://www.nature.com/articles/s41591-025-03835-z Yao Y, et al. "Apolipoprotein E4 Impairs Macrophage Efferocytosis and Potentiates Apoptosis by Accelerating Endoplasmic Reticulum Stress." ATVB 2012. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3431692/APOE4 Cardiovascular Risk Bennet AM, et al. "Association of Apolipoprotein E Genotypes With Lipid Levels and Coronary Risk." JAMA Internal Medicine 2007. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/1108512 Seripa D, et al. "Apolipoprotein E: from cardiovascular disease to neurodegenerative disorders." Journal of Molecular Medicine 2016. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4921111/ Trumble BC, et al. "APOE4 is associated with elevated blood lipids and lower levels of innate immune effectors in a tropical Amerindian subsistence population." eLife 2017. https://elifesciences.org/articles/68231Cold Habituation and Adaptation Castellani JW, Tipton MJ. "Human cold habituation: Physiology, timeline, and modifiers." Temperature 2021. https://pmc.ncbi.nlm.nih.gov/articles/PMC9467574/Cardiovascular Safety Harvard Health. "Cold plunges: Healthy or harmful for your heart?" https://www.health.harvard.edu/heart-health/cold-plunges-healthy-or-harmful-for-your-heart American Heart Association. "You're not a polar bear: The plunge into cold water comes with risks." 2022. https://www.heart.org/en/news/2022/12/09/youre-not-a-polar-bear-the-plunge-into-cold-water-comes-with-risks Shattock MJ, Tipton MJ. "'Autonomic conflict': a different way to die during cold water immersion?" Journal of Physiology 2012. https://pmc.ncbi.nlm.nih.gov/articles/PMC3459038/ Rasgado-Valenzuela LN, et al. "Paroxysmal Atrial Fibrillation Induced by Ice-Cold Water Ingestion." Cureus 2021. https://pmc.ncbi.nlm.nih.gov/articles/PMC8311385/ Castellani JW, et al. "Cardiovascular diseases, cold exposure and exercise." British Journal of Sports Medicine 2006. https://pmc.ncbi.nlm.nih.gov/articles/PMC6204981/Protocols and Guidelines Huberman Lab. "The Science & Use of Cold Exposure for Health & Performance" Newsletter. https://www.hubermanlab.com/newsletter/the-science-and-use-of-cold-exposure-for-health-and-performance Science for Sport. "Cold Water Immersion." https://www.scienceforsport.com/cold-water-immersion/ Coldture. "Cold Plunge vs Cold Shower: Which Is More Effective?" https://coldture.com/en-us/blogs/news/cold-plunge-vs-cold-shower Baptist Health. "They May Be a Hot Trend but Cold Plunges Require Caution." https://baptisthealth.net/baptist-health-news/they-may-be-a-hot-trend-but-cold-plunges-require-caution StatPearls. "Frostbite." NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK536914/Circadian and Cortisol Biology Sleep and Circadian Regulation of Cortisol. PMC 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC8813037/Most Newsletters? One-way street.How boring…This is the Phoenix Community after all—so let's make it a two-way street. Got a question? Feedback? Just want to say hi?Hit reply.I read every single one. --- ## Amyloid Clearance in APOE4: Sleep and Glymphatic Optimization Protocols URL: https://apoe4.co/blog/posts/glymphatic Published: 2025-12-13T00:20:24+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: protocols, sleep, research, cognition Summary: Unlock the secret of your brain's nightly waste disposal system: How APOE4 carriers can optimize sleep, boost glymphatic function, and reduce Alzheimer's risk with cutting-edge protocols. Amyloid Clearance in APOE4: Sleep and Glymphatic Optimization ProtocolsWhy one bad night increases brain amyloid 5%—and what APOE4 carriers must do differentlyDr. Kevin Tran December 12, 2025 If you've watched a parent or a closed one slowly disappear into Alzheimer's, you know the fear. If you're carrying APOE4/4 like I am, that fear becomes a driving force to understand what's actually happening in your brain while you sleep. Here's what the science reveals: Your brain has a waste disposal system that works primarily at night. It's called the glymphatic system, and if you're APOE4, yours isn't working as well as it should. The good news? Recent research shows you can optimize it—dramatically. We're talking about 2.2x better clearance with simple sleep position changes, 17.7% increases in restorative slow-wave sleep with acoustic stimulation, and protocols that can partially compensate for the genetic disadvantage we carry. This isn't about "getting more sleep." It's about understanding why APOE4 makes you uniquely vulnerable to sleep disruption, and what you can do about it starting tonight. NOTE: these emails seems to be too long for some email providers (hello Gmail), if so you can access our online version here.What the Glymphatic System Does (And Why APOE4 Carriers Should Care)The Research: Your Brain's Overnight Cleaning Crew Think of the glymphatic system as your brain's janitorial service that works the night shift. While you sleep, cerebrospinal fluid (CSF) flows through brain tissue along pathways surrounding blood vessels, flushing out metabolic waste—including amyloid-beta and tau proteins that accumulate in Alzheimer's disease. The system relies on specialized water channels called aquaporin-4 (AQP4) positioned on astrocyte "endfeet" that surround blood vessels. During sleep, particularly slow-wave sleep, your brain's interstitial space expands by up to 60%, allowing this fluid to flow more freely and carry waste out of the brain [PMC6595048]. Human brain imaging studies confirm this happens in living people: during non-REM sleep, there's a coordinated wave of electrical slow oscillations, followed by hemodynamic changes, followed by cerebrospinal fluid pulsations—a three-part system that drives waste removal [Science, 2019]. 💡 KEY INSIGHT: Studies show 90% reduction in glymphatic clearance during wakefulness compared to sleep, with twice the amount of protein cleared during sleep [PMC8821419]. Sleep isn't just rest—it's active brain maintenance. So What for APOE4 Carriers: Your System Is Compromised from Day One Here's where your genetics create a problem: APOE4 impairs this system through multiple mechanisms, even before any disease develops. A 2024 study using repetitive head trauma models found something striking: "Uninjured apoE4 carriers demonstrated the same degree of AQP4 depolarization as injured mice (apoE2, apoE3 and apoE4)" [PMC10922621]. Translation? Even without injury, APOE4 alone causes those critical water channels to lose their proper positioning. It gets worse. A 2016 study in Molecular Neurodegeneration showed that CSF-derived apoE protein is distributed through the glymphatic system in an isoform-specific pattern: apoE2 > apoE3 > apoE4 [Molecular Neurodegeneration, 2016]. APOE4 carriers get the least efficient distribution and clearance. And there's a third hit: APOE4 appears to cause premature shrinkage of meningeal lymphatic vessels—the drainage pathways that carry waste from your brain to cervical lymph nodes. Researchers call this "meningeal lymphosclerosis" [Nature Molecular Psychiatry, 2020]. ⚠️ APOE4-SPECIFIC CONCERN: A 2025 human imaging study of 423 older adults found that glymphatic dysfunction (measured by DTI-ALPS MRI) only correlated with amyloid accumulation in APOE4 carriers, not non-carriers [Alzheimer's & Dementia, 2025]. Your genotype makes you uniquely vulnerable when this system fails. What You Can Do About It: Protocols to Optimize Clearance Despite Your Genetics You can't change your APOE4 status, but you can optimize the system you have. Here's where to start: ✅ ACTION STEP: Track Your Sleep Architecture Get a device that measures sleep stages (Oura Ring, Whoop etc.) Focus on slow-wave sleep percentage (target: 15-25% of total sleep) Track sleep fragmentation (number of awakenings) Baseline measurement for 2 weeks before changing anything ✅ ACTION STEP: Assess Your Clearance Pathways If you have family history + APOE4, ask your neurologist about DTI-ALPS MRI imaging to measure glymphatic function Consider plasma biomarker testing (Aβ42/40 ratio) as a clearance indicator (note: these are emerging biomarkers; discuss availability with your neurologist) These aren't just for diagnostic, they're progress metrics to track if interventions work ✅ ACTION STEP: Join Phoenix Clinical Trial Access We're partnering with institutions studying glymphatic enhancement in APOE4 carriers Track your protocols in Phoenix to generate personal data for clinical teams Connect with others implementing these protocols in accountability pods The APOE4 Sleep Crisis: Why One Bad Night Hurts You MoreThe Research: Sleep Deprivation Increases Amyloid…Acutely In 2018, researchers at the National Institutes of Health did something simple but revealing: they kept 20 healthy adults awake for one night, then measured brain amyloid levels using PET imaging. After just one night of sleep deprivation, amyloid-beta burden increased about 5% in vulnerable regions including the hippocampus and thalamus [PNAS, 2018]. This wasn't a disease model—these were healthy controls proving that sleep loss directly causes measurable amyloid accumulation in human brains. But the critical question for us: Does APOE4 make this worse? A 2023 study in the Journal of Clinical Investigation answered that definitively. Researchers subjected mice carrying human APOE3 or APOE4 genes to 8 weeks of chronic sleep disruption. The results were stark: APOE4 mice: 1.8-fold increase in amyloid plaque deposition in cortex, hippocampus, and thalamus APOE3 mice: No significant increase APOE4 mice: Significant decrease in perivascular AQP4 (worsening clearance capacity) APOE4 mice: Accelerated tau seeding and spreading to connected brain regions APOE3 mice: No tau changes [JCI, 2023] The researchers concluded: "The APOE-ε4 genotype is a critical modifier in the development of AD pathology in response to sleep deprivation." 📊 THE DATA: An observational cohort study (SILCODE, 6-year follow-up) found that APOE4 carriers with sleep fragmentation had a 5.6-fold increased risk of developing dementia compared to non-carriers with good sleep [CNS Neuroscience & Therapeutics, 2024]. This is synergistic, not additive. So What for APOE4 Carriers: You Cannot Afford Poor Sleep Here's the practical reality: Non-APOE4 carriers can somewhat tolerate sleep disruption without immediate pathological consequences. You cannot. Every night of fragmented sleep is actively depositing amyloid in your brain. Every week of irregular circadian rhythms is reducing your clearance efficiency by up to 55% (the difference between sleeping during your circadian rest phase versus fighting it) [Nature Communications, 2020]. And it's not just about duration. You can sleep 8 hours but if it's fragmented (frequent awakenings), you're still at elevated risk. A longitudinal study of 737 older adults found that high sleep fragmentation increased Alzheimer's risk 1.5-fold regardless of total sleep time [SLEEP, 2013]. Here's the hope in the data: Another study in the same cohort found that "better sleep consolidation attenuated" the cognitive effects of APOE4 [PMC3859706]. Good sleep can partially compensate for your genetic disadvantage. What You Can Do About It: Emergency Sleep Hygiene for APOE4 Carriers If you're APOE4 and your sleep is currently poor, this is urgent. Here's your immediate protocol: ✅ ACTION STEP: Eliminate Sleep Fragmentation Sources (This Week)Screen for sleep apnea if you snore, have obesity, or wake unrefreshed Home sleep test ($150-300) or ask doctor for polysomnography referral APOE4 + untreated apnea = catastrophic for clearance Separate bedrooms if partner disrupts sleep Controversial but necessary: snoring, movement, different schedules Your brain health is non-negotiable Address nocturia (nighttime urination) Stop fluids 2-3 hours before bed Address underlying causes (BPH, diabetes) with physician Each awakening fragments slow-wave sleep cycles Blackout curtains + white noise Complete darkness (not even LED lights) Continuous white noise to mask environmental sounds Cost: $50-100, immediate impact ✅ ACTION STEP: Lock In Circadian Consistency (Next 14 Days)Same bedtime within 30 minutes, 7 days per week Yes, including weekends—circadian rhythms don't understand Saturday Target: 10:30 PM if you wake at 6:30 AM (8-hour opportunity) Morning bright light within 30 minutes of waking 10,000 lux light box for 10-30 minutes Or natural outdoor light (even cloudy days are 10,000+ lux) Resets circadian clock, amplifies clearance rhythm Evening light restriction starting 3 hours before bed Blue light blocking glasses ($20-100) Dim all lights to <50 lux (smartphone apps can measure) No screens in bed (yes, really) ✅ ACTION STEP: Measure Impact Track sleep fragmentation score weekly (from wearable device) Track slow-wave sleep percentage Target: <5 awakenings per night, >15% slow-wave sleep If not improving in 2 weeks, escalate to CBT-I therapist Difficulty Level: Beginner Time Investment: 30 minutes setup, 10 minutes daily maintenance Phoenix Integration: Sleep data dashboard shows trends; pods for accountability Join Phoenix Today The 2.2x Sleep Position Advantage You're Probably IgnoringThe Research: Lateral Sleep Position Dramatically Improves Clearance In 2015, researchers at Stony Brook University used MRI to measure glymphatic transport in rats sleeping in different positions: prone (stomach), supine (back), and lateral (side). The quantitative results were dramatic. Using retention ratios (lower = better clearance): Prone (stomach): 14.98 (worst clearance) Supine (back): 10.70 (moderate) Lateral (side): 6.86 (best clearance) Lateral sleeping was 2.2x more efficient than prone for waste removal [Journal of Neuroscience, 2015]. The researchers found that prone positioning reduced cardiac stroke volume through venous compression, decreasing the arterial pulsatility that drives glymphatic influx. Interestingly, the study noted: "The lateral sleep position is already the most popular in humans and most animals," suggesting this may be an evolutionary adaptation for optimal brain waste clearance [PMC4524974]. 💡 KEY INSIGHT: Most mammals naturally sleep on their sides. Your body may already know what's best for your brain. So What for APOE4 Carriers: Position Matters When Clearance Is Already Compromised If you're a non-carrier with normal glymphatic function, sleep position might not make or break your brain health. But when you're starting with impaired AQP4 polarization and reduced clearance efficiency, every percentage point matters. Think about it mathematically: If your baseline APOE4-impaired clearance is already reduced by 30% (based on isoform-specific distribution data), and then you sleep prone instead of lateral, you're compounding the problem. You might be operating at 50% of optimal clearance capacity. Over years and decades, that difference translates to cumulative amyloid burden that crosses pathological thresholds earlier. What You Can Do About It: Sleep Position Training Protocol Most people unconsciously shift positions during sleep, but you can train yourself to maintain lateral position for the majority of the night. ✅ ACTION STEP: Lateral Sleep Position TrainingOption 1: Body Pillow Method (Beginner, $30-50) Get a full-length body pillow Place it along your back if you tend to roll supine Place it in front if you tend to roll prone Hugging a pillow also keeps you lateral Implementation note: Body pillows are a practical tool (not formally studied) to help maintain lateral position during sleep Option 2: Positional Device (Intermediate, $50-150) Tennis ball in a shirt pocket sewn on back (prevents supine rolling) Commercial positional sleep devices (designed for apnea patients) Vibration devices that alert when you change position Option 3: Mattress Positioning (Advanced, $0) Slight incline with head elevated 15-20 degrees Use mattress wedge or adjustable base Maintains lateral position through gravity assistance Note: Excessive head elevation may affect CSF dynamics—keep it moderate Proper Lateral Alignment: Use pillow height that maintains neutral spine (ear, shoulder, hip aligned) Place pillow between knees to prevent hip rotation Either left or right side is acceptable (no evidence favoring one) Tracking Progress: Use sleep tracking devices that measure position (some advanced wearables) Partner observation (ask to check position when they wake) Morning shoulder stiffness may indicate you stayed lateral (expect 2-3 week adaptation) ✅ ACTION STEP: Avoid Prone Sleep Triggers Don't go to bed on a full stomach (causes prone position seeking) Avoid alcohol near bedtime (disrupts position maintenance) Address sleep apnea (causes positional shifting) Difficulty Level: Beginner to Intermediate Time Investment: 2-3 weeks adaptation period Phoenix Integration: Log position training progress; share tips with pods Slow-Wave Sleep: The Critical Window for Amyloid ClearanceThe Research: Deep Sleep Is When the Magic Happens Not all sleep is created equal for brain waste removal. The critical stage is slow-wave sleep (SWS), also called deep sleep or stage N3 sleep. During slow-wave sleep, several critical processes occur simultaneously: Neuronal firing decreases, reducing amyloid-beta production [PMC6595048] Brain interstitial space expands by up to 60%, creating room for fluid flow [PMC8821419] Slow oscillations (0.6-1 Hz) coordinate clearance: electrical waves → blood flow changes → CSF pulsations [Science, 2019] AQP4 polarization peaks, maximizing water channel efficiency [Nature Communications, 2020] The specific frequency matters: 0.6-1 Hz slow waves drive the clearance process. Faster delta waves or general "deep sleep" without these specific oscillations don't have the same effect. A 2024 study found that slow-wave sleep is associated with higher subsequent plasma amyloid-beta levels—not because it's producing more, but because it's successfully pushing amyloid OUT of the brain into blood for peripheral clearance [Annals of Neurology, 2024]. 📊 THE DATA: Glymphatic clearance is 55% higher during the mid-rest circadian phase compared to active/wake phases [Nature Communications, 2020]. Timing and sleep stage both matter. So What for APOE4 Carriers: You Already Get Less REM, Can't Afford Less Slow-Wave Here's an additional challenge: A 2024 study in SLEEP found that APOE4 carriers have 30-40% less REM sleep compared to non-carriers [SLEEP, 2024]. While REM may not be the primary clearance stage, this represents another sleep architecture vulnerability. The good news: The same study found "no differences in slow wave sleep duration" between carriers and non-carriers. Your slow-wave sleep appears preserved—but given your impaired clearance baseline, you need to maximize it, not just maintain it. This is also why alcohol is particularly dangerous for APOE4 carriers: it suppresses REM sleep (which you already lack) and fragments the second half of the night (disrupting slow-wave cycles). The research on alcohol-APOE4 interactions shows "elevated risk of dementia" with regular consumption, mediated through "reduced neural repair, impaired brain immune cells, and disrupted sleep" [Medical Research Archives, 2024]. What You Can Do About It: Slow-Wave Sleep Enhancement Protocol ✅ ACTION STEP: Acoustic Stimulation (Evidence-Based, Non-Pharmacological) A 2023 pilot study tested closed-loop acoustic stimulation in Alzheimer's disease patients using the DREEM 2 headband. Results after just one night: 68% of participants showed increased slow-wave energyAverage increase: 17.7% in slow-wave activity Phase-locked 40-dB pink noise delivered during the up-phase of delta waves [JCSM, 2023] Implementation: Device: DREEM 2 headband (~$500, commercially available) Alternative: Similar devices entering market (research "closed-loop acoustic stimulation") Protocol: Wear nightly, device automatically detects slow waves and delivers timed stimulation Evidence: Improves alertness and attention in chronically sleep-restricted adults [PubMed, 2021] Phoenix Community: We're tracking which devices work best—join pods for device reviews and troubleshooting. ✅ ACTION STEP: Exercise Timing for Slow-Wave Enhancement Exercise improves slow-wave sleep quality, but timing matters: Optimal timing: Morning or early afternoon (4+ hours before bed) Type: Moderate-intensity aerobic (30-45 minutes) Frequency: 5-6 days per week for consistent effect Avoid: Intense exercise within 3 hours of bedtime (raises core temperature, disrupts onset) Evidence: Increases slow-wave stability and duration [Scientific Reports, 2021] ✅ ACTION STEP: Meditation for Slow-Wave Preservation Long-term meditators show preserved slow-wave sleep despite aging: Type: Vipassana or mindfulness meditation Duration: 20-30 minutes daily Timing: Flexible (morning or evening both work) Evidence: "Meditation appears to preserve SWS, preventing age-associated changes in slow wave generating mechanisms" [Mindfulness, 2025] Beginner protocol: Start with 5-10 minutes, guided apps acceptable ✅ ACTION STEP: Strict Caffeine Timing Caffeine timing profoundly affects slow-wave sleep architecture: Safe window: Morning only; <100mg after 2 PM (assuming 10 PM bedtime) Dangerous doses: >400mg within 12 hours of bedtime significantly reduces slow-wave sleep The mechanism: "Caffeine prolongs stage-two sleep at the expense of stage-three slow waves, weakening glymphatic waste clearance" [SLEEP, 2024] APOE4 consideration: You can't afford to sacrifice slow-wave sleep for afternoon energy—fix your sleep first, caffeine second Individual variation note: Caffeine metabolism varies by CYP1A2 genetics—slow metabolizers may need earlier cutoff times than 2 PM. Track your individual response with sleep quality metrics. Your Quick-Start Protocol (This Week): Move all caffeine consumption before noon Add 30-minute morning walk (slow-wave benefit + circadian reset) Download meditation app, start with 10 minutes before bed Track slow-wave sleep percentage for 2 weeks to measure impact Intermittent Fasting: Restoring AQP4 Function Through Metabolic InterventionThe Research: Fasting Reverses APOE4-Induced AQP4 Depolarization Remember how APOE4 causes those critical water channels (AQP4) to lose their proper positioning on astrocyte endfeet? A 2017 study found a way to restore it: intermittent fasting. The mechanism is elegant. Fasting increases beta-hydroxybutyrate (BHB), a ketone body that acts as a histone deacetylase inhibitor—essentially an epigenetic signal that tells cells to restore proper AQP4 polarity [PMC5712566]. A 2023 review in Nutrition Reviews summarized the broader evidence: "Intermittent fasting was associated with reduced levels of brain β-amyloid through various mechanisms" "Time-restricted feeding corrects circadian disruptions of Alzheimer's, improves memory, and reduces accumulation of amyloid" "Short-term fasting induces profound neuronal autophagy" [PMC10413426] Most importantly, a 2024 study specifically tested fasting in the E4FAD mouse model—mice carrying both human APOE4 and familial AD mutations. Fasting-mimicking diet cycles "mitigate Aβ hippocampal and cortical load" in female E4FAD mice [Journal of Integrative Neuroscience, 2024]. ⚠️ IMPORTANT CAVEAT: The research suggests fasting works best for prevention in early phases of amyloidosis. Once substantial pathology is established, "fasting-induced autophagy may not be effective" [PMC10413426]. At age 56 with family history but no cognitive symptoms, you're in the ideal preventive window. (Research caveat: fasting-induced autophagy appears most effective for prevention before substantial amyloid pathology accumulates, rather than for clearing established plaques) So What for APOE4 Carriers: You Need AQP4 Restoration More Than Anyone Non-carriers don't have baseline AQP4 depolarization. You do. Intermittent fasting offers a way to address the root cause of your glymphatic impairment, not just compensate for it. The metabolic shift into ketosis (which happens during extended fasting windows) serves multiple protective mechanisms: Restores AQP4 polarity for better clearance Induces autophagy to clear existing intracellular debris Reduces neuroinflammation Improves circadian rhythm strength (time-restricted eating entrains peripheral clocks) This is mechanistically distinct from sleep interventions—you're addressing the daytime structural problem (AQP4 positioning) that will enhance nighttime clearance. What You Can Do About It: Evidence-Based Fasting Protocols for APOE4 ✅ ACTION STEP: Start Time-Restricted Eating (16:8 Protocol)Beginner Protocol: Eating window: 10 AM - 6 PM (8 hours) Fasting window: 6 PM - 10 AM (16 hours) Frequency: 5-7 days per week Adaptation: Start with 12:12, increase by 1 hour weekly to 16:8 Why this window: Aligns with circadian biology (eating during daylight) Allows morning light exposure before eating (amplifies circadian reset) Stops eating 4+ hours before bed (prevents sleep disruption) Achieves ketosis by morning (BHB production for AQP4 restoration) What to consume during fasting window: Water (encouraged, supports glymphatic flow) Black coffee or tea (minimal—caffeine timing rules still apply) Electrolytes if needed (sodium, potassium, magnesium) NO: calories, artificial sweeteners, "bulletproof" coffee ✅ ACTION STEP: Monitor Ketone Production (Optional But Insightful)Urine ketone strips ($10-15): Quick feedback if you're reaching ketosis Blood ketone meter ($40 + strips): More accurate, measures BHB directly Target: 0.5-1.5 mM BHB in morning (nutritional ketosis range) Meaning: If you're hitting this range, AQP4 restoration mechanisms are active ✅ ACTION STEP: Combine with Circadian Alignment Fasting is more powerful when timed to circadian rhythms: Early time-restricted eating (8 AM - 4 PM) may be superior for metabolic benefits But practicality matters—16:8 with 10 AM - 6 PM is sustainable Don't vary eating window day-to-day—consistency entrains circadian clocks Weekend consistency is critical (no "cheat days" for circadian biology) ✅ ACTION STEP: Address Common ChallengesHunger in adaptation phase (weeks 1-3): Protein and fat at dinner (6 PM) to extend satiety Sparkling water or herbal tea in evening Usually resolves after metabolic adaptation to fat-burning Social dining conflicts: Shift window temporarily (10 AM - 6 PM → 12 PM - 8 PM) for events Return to schedule next day—one meal won't destroy benefits Communicate boundaries: "I don't eat after 6 PM for health reasons" Exercise performance: Morning fasted cardio is fine (may enhance mitochondrial adaptations) Resistance training better in fed state (1-2 hours after eating) Adjust timing within eating window if needed Medical considerations: Consult physician if on diabetes medications (hypoglycemia risk) Not recommended during pregnancy/breastfeeding May need adjustment with thyroid conditions Difficulty Level: Beginner to Intermediate Time Investment: Zero additional time (you're NOT eating) Phoenix Integration: Fasting timer; ketone logs; group fasting challenges in pods The Alcohol-APOE4 Connection: Why That Evening Glass of Wine Is More Dangerous Than You ThinkThe Research: Alcohol Disrupts Multiple Clearance Pathways Alcohol's effects on APOE4 carriers appear to be synergistic rather than additive. A 2024 review in Medical Research Archives summarized the evidence: "E4 carriers who consumed alcohol one or more times per month had a higher risk of Alzheimer's disease than those who never consumed alcohol, with an increased risk also found with increasing amounts of alcohol consumption." The mechanisms are multi-hit: Direct neurotoxicity compounded by APOE4's reduced neural repair capacity Impaired brain immune cells (microglia dysfunction) Sleep architecture disruption (the focus here) Subsequent amyloid plaque build-up [Medical Research Archives, 2024] A separate 2024 study found that "transport of Aβ oligomers from the brain and CSF to plasma may be inefficient in ApoE ε4 carriers" [Nature Communications Medicine, 2024]. Alcohol's effects on blood-brain barrier integrity could further compromise this already-impaired clearance pathway. 💡 KEY INSIGHT: Alcohol suppresses REM sleep (which APOE4 carriers already have 30-40% less of) and fragments sleep in the second half of the night (increasing the sleep fragmentation that already raises AD risk 1.5-fold). So What for APOE4 Carriers: The Cost-Benefit No Longer Favors Moderate Drinking The "moderate alcohol is protective" narrative from older cardiovascular studies doesn't hold up in APOE4 cognitive research. You're dealing with: Baseline impaired clearance (AQP4 depolarization, meningeal lymphatic dysfunction) Baseline reduced REM sleep (30-40% less than non-carriers) Heightened vulnerability to sleep fragmentation (5.6-fold dementia risk with poor sleep) Add alcohol's REM suppression, slow-wave disruption, and second-half-of-night fragmentation, and you're compounding vulnerabilities at every level. Even "just one drink" within 3-4 hours of bedtime measurably affects sleep architecture—you might feel like you "fall asleep faster," but you're trading sleep onset for sleep quality. What You Can Do About It: Practical Alcohol Protocols for Risk Reduction ✅ ACTION STEP: The 3-4 Hour Rule (Minimum Standard) If you choose to drink: No alcohol within 3-4 hours of bedtime (assuming 10 PM bedtime, stop by 6-7 PM) Maximum 1 standard drink if within 4-6 hours of bed Hydration: 1 glass of water per alcoholic drink to minimize dehydration effects Track impact: Compare sleep metrics (REM %, slow-wave %, fragmentation) on drinking vs. non-drinking nights ✅ ACTION STEP: APOE4-Specific Consideration for Abstinence Given the evidence, consider: 30-day trial of complete abstinence while tracking: Sleep quality metrics (REM, slow-wave, fragmentation) Cognitive subjective measures (brain fog, memory, processing speed) Mood and energy levels Social anxiety (often inflated as barrier to abstinence) Evaluate results objectively: Do you feel and measure better? Decision framework: If sleep metrics improve >10% and cognition is sharper, the cost-benefit analysis changes ✅ ACTION STEP: Social Strategy Shifts Many age-56 adults drink primarily in social contexts. Alternatives: Non-alcoholic craft beverages (market has exploded—quality options exist) Sparkling water in a wine glass (social signaling satisfied) Medication excuse: "My doctor advised against it" (true—I'm advising against it) Find APOE4-aware community: Phoenix pods with others navigating same tradeoffs The Honest Conversation: This recommendation is harder than sleep position or fasting because alcohol is culturally embedded. But the data for APOE4 carriers is increasingly clear: the risks outweigh any putative benefits. At minimum, strict timing. Ideally, reevaluation of role in your life. Difficulty Level: Intermediate to Advanced (behavioral change) Time Investment: Zero (you're NOT drinking) Phoenix Integration: Alcohol tracking; sleep correlation analysis; sober-curious pods Temperature Optimization: Hot and Cold Strategies for Glymphatic SupportThe Research: Heat Therapy's Surprising Dementia Protection One of the most striking epidemiological findings in dementia prevention comes from Finnish sauna studies. Men who used the sauna four to seven times per week had a 66% lower risk of developing dementia compared to once-weekly users [PMC7560162]. The proposed mechanisms include: Enhanced glymphatic function through heat-induced vasodilation Increased BDNF production (brain-derived neurotrophic factor for neuronal growth) Improved cerebral blood flowHormetic stress response activating cellular repair mechanisms However, there's a critical threshold: "The physiological range of hyperthermia (38.5-39.5°C) elicits breakdown of the blood-brain barrier leading to permeability which appears relatively quickly (>20 min)" [PMC4720747]. Moderate protocols avoid this. Conversely, cool sleep temperature enhances NREM sleep. There's a "fundamental connection between NREM sleep and brain and body cooling" mediated through hypothalamic circuits [PMC7323637]. 📊 THE DATA: Optimal sleep environment is 60-67°F (15-19°C) for bedroom temperature, with warm extremities (hands/feet) to facilitate core heat dissipation. So What for APOE4 Carriers: Temperature as Clearance Modulator You're optimizing a system that's already compromised. Temperature interventions work through different mechanisms than sleep position or fasting: Sauna: Vascular and BDNF-mediated glymphatic support (daytime intervention) Cool sleep: Facilitates the natural brain cooling that accompanies slow-wave sleep (nighttime optimization) The combination addresses clearance from multiple angles across the 24-hour cycle. What You Can Do About It: Evidence-Based Temperature Protocols ✅ ACTION STEP: Sauna Protocol (4-7x Weekly for Maximum Benefit) Based on the Finnish studies showing 66% risk reduction: Optimal Protocol: Frequency: 4-7 sessions per week Duration: 15-20 minutes per session Temperature: 80-90°C (176-194°F) traditional sauna Timing: Morning or afternoon (NOT evening—raises core temp, disrupts sleep onset) Hydration: 16-20 oz water before and after Cool-down: 5-10 minutes gradual cooling (don't plunge immediately into ice) Infrared Sauna Alternative: Lower temperature (50-60°C / 122-140°F) Longer duration (20-30 minutes) May have similar benefits through different heating mechanism More accessible for home installation Safety Considerations: Consult physician if cardiovascular conditions exist Start with lower frequency (2-3x weekly) if new to sauna Avoid if pregnant or acute illness Monitor for dizziness or excessive fatigue Access Options: Gym membership with sauna (most cost-effective) Infrared sauna blanket ($200-400, portable home option) Full infrared sauna installation ($1,500-5,000) Community sauna spaces (increasingly available) ✅ ACTION STEP: Sleep Temperature OptimizationCool Bedroom Protocol: Target temperature: 60-67°F (15-19°C) Implementation: Programmable thermostat (drops to 60-65°F at bedtime) Cooling mattress pad (Eight Sleep, ChiliPad, BedJet) Lightweight, breathable bedding (avoid overheating) Warm Extremities Technique: Wear socks to bed (counterintuitive but effective) Warm foot bath 30-60 minutes before bed Mechanism: Distal warming causes peripheral vasodilation, dumping core heat Evidence: "Skin warmth induces NREM sleep and body cooling via circuitry connecting skin sensation to preoptic hypothalamus" [PMC7323637] ✅ ACTION STEP: Avoid Evening Heat ExposureNo hot baths/showers within 2 hours of bed (acute core temp increase delays sleep onset) Exception: Warm foot bath (peripheral only) is beneficial No intense exercise within 3 hours of bed (raises core temperature) No evening sauna (save for morning/afternoon) Quick-Start This Week: Find sauna access (gym, facility, or purchase home option) Book 3 sessions this week (morning/afternoon only) Drop bedroom thermostat to 65°F tonight Warm foot bath 45 minutes before bed Difficulty Level: Beginner (sleep temp) to Intermediate (sauna access) Cost: $0-50/month (gym membership) or $200-400 (home infrared blanket) Phoenix Integration: Sauna session logging; sleep quality correlation analysis Join Phoenix Today Key Takeaways: Your Glymphatic Optimization Quick-Start Protocol You've just absorbed a lot of science. Here's what to implement this week to start compensating for your APOE4-impaired clearance: Week 1 Quick-Start (Choose 3-5 to Start):Sleep Position: Start lateral sleep training with body pillow ($30-50) Circadian Lock: Same bedtime within 30 min, 7 days/week + morning light exposure Caffeine Cutoff: No caffeine after 12 PM (noon) Alcohol Timing: 4-hour rule or start 30-day abstinence trial Sleep Environment: Blackout curtains, white noise, 65°F bedroom temp ($50-100) Fasting Window: Begin 12:12 time-restricted eating (10 AM - 10 PM), progress to 16:8 Month 1 Protocol Expansion:Exercise Addition: 30-minute morning walk, 5-6 days/week Meditation Start: 10 minutes before bed using guided app Sleep Apnea Screen: Home sleep test if any snoring/fatigue symptoms Sauna Access: Find facility, start 2-3x/week protocol Month 2-3 Optimization:Acoustic Stimulation: Research DREEM 2 or similar device for slow-wave enhancement Sleep Tracking: Oura Ring or Whoop to measure slow-wave %, REM %, fragmentation Biomarker Testing: Discuss plasma Aβ42/40 ratio with physician (baseline measurement) DTI-ALPS Imaging: If available and covered, measure glymphatic function directly Track What Matters:Slow-wave sleep percentage (target: 15-25%) Sleep fragmentation score (target: <5 awakenings/night) REM sleep percentage (monitor trend, knowing APOE4 baseline is lower) Subjective cognition (brain fog, processing speed, memory) Adherence streaks (circadian consistency, fasting window, meditation) The Phoenix Advantage: You don't have to do this alone. Track these protocols in Phoenix, join accountability pods with others implementing the same interventions, and access our clinical trial partnerships testing glymphatic enhancement in APOE4 carriers. Join the Phoenix Community: Turn Research Into Action Here's what makes Phoenix different: We're not just educating: we're implementing. Every protocol in this article can be tracked in Phoenix. Every challenge you'll face (social pressure around alcohol, morning routine consistency, meditation habit formation) has been navigated by others in your pods. Every biomarker we mention—from sleep architecture to plasma amyloid ratios—is something we're collectively tracking and sharing. And we're partnering with research institutions studying these exact interventions in APOE4 carriers. Your n-of-1 data, aggregated with hundreds of others, becomes research-grade evidence. What You Get in Phoenix: Protocol Tracking: Sleep position, fasting windows, sauna sessions, supplement timing Biomarker Dashboard: Sleep architecture, bloodwork trends, cognitive assessments Accountability Pods: Small groups (5-8 people) with similar goals and APOE4 status Clinical Trial Access: First notice for glymphatic enhancement studies, acoustic stimulation trials Expert Guidance: Monthly deep-dives with researchers studying these interventions Community Intelligence: What's working for people like you—real data, real people Your Brain Health Is Too Important to Leave to Chance The research is clear: APOE4 carriers face impaired glymphatic clearance, heightened vulnerability to sleep disruption, and synergistic risks from common behaviors like alcohol consumption and irregular sleep schedules. But the research also shows interventions work: 2.2x better clearance with lateral sleep, 17.7% more slow-wave sleep with acoustic stimulation, AQP4 restoration with intermittent fasting, 66% dementia risk reduction with regular sauna use. These aren't theoretical. They're actionable. And you can start tonight. Join Phoenix Today SourcesAPOE4 and Glymphatic Function:Apolipoprotein E4 and meningeal lymphatics in Alzheimer disease: a conceptual framework | Nature Molecular Psychiatry (2020)Emerging Roles of Meningeal Lymphatic Vessels in Alzheimer's Disease | PMC10473149 (2023)APOE4 modulates the association between DTI-ALPS index and Alzheimer's pathologies | Alzheimer's & Dementia (2025)Glymphatic distribution of CSF-derived apoE into brain is isoform specific | Molecular Neurodegeneration (2016)Repetitive head trauma and apoE4 induce chronic cerebrovascular alterations | PMC10922621 (2024)Sleep Architecture and Amyloid Clearance:Sleep and β-Amyloid Deposition in Alzheimer Disease: Insights on Mechanisms | PMC6595048 (2019)Coupled electrophysiological, hemodynamic, and cerebrospinal fluid oscillations in human sleep | Science (2019)β-Amyloid accumulation in the human brain after one night of sleep deprivation | PNAS (2018)Sleep deprivation increases Alzheimer's protein | NIH Research Matters (2018)Reduced rapid eye movement sleep in APOE ε4 allele carriers | SLEEP (2024)Divergent Associations of Slow-Wave Sleep versus REM Sleep with Plasma Amyloid-Beta | Annals of Neurology (2024)APOE4 and Sleep Deprivation Synergy:APOE-ε4 synergizes with sleep disruption to accelerate Aβ deposition and tau seeding | JCI (2023)Sleep and APOE-ε4 have synergistic effect on plasma biomarkers and cognitive decline | CNS Neuroscience & Therapeutics (2024)Sleep Modifies the Relation of APOE to AD Risk and Neurofibrillary Tangles | PMC3859706 (2013)Circadian Rhythms and Glymphatic Function:Circadian control of brain glymphatic and lymphatic fluid flow | Nature Communications (2020)Circadian Rhythms Help Guide Waste from Brain | University of Rochester Medical Center (2020)Sleep Position and Clearance:The Effect of Body Posture on Brain Glymphatic Transport | Journal of Neuroscience (2015)Sleeping in the Lateral Position Reduces Brain Waste | Stony Brook University News (2015)Sleep, Cerebrospinal Fluid, and the Glymphatic System: A Systematic Review | PMC8821419 (2022)Sleep Fragmentation and Cognitive Decline:Sleep Fragmentation and the Risk of Incident Alzheimer's Disease | SLEEP (2013)Sleep fragmentation and dementia risk: 6-year follow-up data | PMC3669060 (2013)Acoustic Stimulation Interventions:Acoustic stimulation as a promising technique to enhance slow-wave sleep in AD | JCSM (2023)Acoustic enhancement of slow wave sleep improves alertness in sleep-restricted adults | ScienceDirect (2021)Intermittent Fasting and AQP4:Intermittent Fasting Protects against Alzheimer's through Restoring AQP4 Polarity | PMC5712566 (2017)Effects of intermittent fasting on cognitive health and Alzheimer's disease | PMC10413426 (2023)Fasting as intervention in E4FAD mouse model | Journal of Integrative Neuroscience (2024)Alcohol and APOE4:Linking alcohol use to Alzheimer's: Interactions with aging and APOE | Medical Research Archives (2024)Blood-based quantification of Aβ oligomers indicates impaired clearance in APOE ε4 carriers | Nature Communications Medicine (2024)Exercise and Meditation:Exercise improves the quality of slow-wave sleep by increasing slow-wave stability | Scientific Reports (2021)Sleep-Based Brain Age Is Reduced in Advanced Meditators | Mindfulness (2025)Meditation and Its Regulatory Role on Sleep | PMC6534352Caffeine Timing:Dose and timing effects of caffeine on subsequent sleep: randomized crossover trial | SLEEP (2024)Sauna and Temperature Optimization:Does sauna bathing protect against dementia? | PMC7560162 (2020)Sleep and thermoregulation | PMC7323637 (2020)Thermal Regulation of the Brain and Blood-Brain Barrier | PMC4720747 (2016) --- ## How I Turned APOE4/4 Into My Greatest Catalyst URL: https://apoe4.co/blog/posts/how-i-turned-apoe4-4-into-my-greatest-catalyst Published: 2025-12-11T02:31:37+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: community, protocols, cognition Summary: Transforming APOE4 genetic risk into an empowering journey: Discover actionable strategies for metabolic, cognitive health through personalized prevention and mindset shifts. How I Turned APOE4/4 Into My Greatest CatalystPodcast episode on Dr. Heather Sandison's ThinkWell AgeWellDr. Kevin Tran December 10, 2025 Hi Phoenix Friends,I recently joined Dr. Heather Sandison, the NYT bestselling author of “Reversing Alzheimer’s, on the ThinkWell AgeWell podcast to share my journey of discovering I carry APOE4/4…and how that moment of fear became the spark for rebuilding my health from the ground up. In the episode, I talk about: Discovering that genetic risk can be empowering when you take actionable steps. Understanding the simple, foundational habits that changed my metabolic, physical, and cognitive health. Gaining clarity through personalized prevention instead of fear-based avoidance. We explored how my family history shaped my mindset, and how I’ve used that awareness to build a lifestyle rooted in prevention, purpose, and neuroplasticity. From fasting and functional testing to mindset shifts and community, I walked through the tools that have helped me turn fear into fuel. We also talked about the emotional side of genetic risk—how to hold both awareness and agency without falling into anxiety. I want others to know that your genes are not your destiny—and resilience is something we can all cultivate, one choice at a time. You can watch it here: Spotify: Listen on Spotify Apple Podcasts: Listen on Apple Big thanks for one of our Phoenix Member, Cathy to have made the introduction.If you also know folks in the podcast space, please make the introduction. I believe we need to spread awareness about APOE4, not as a curse, but as a huge catalyst for positive change.Cheers, Kevin Most Newsletters? One-way street.How boring…This is the Phoenix Community after all—so let's make it a two-way street. Got a question? Feedback? Just want to say hi?Hit reply.I read every single one. --- ## Why Your Fish Oil Isn't Reaching Your Brain - And What To Do About It (APOE4 carriers) URL: https://apoe4.co/blog/posts/why-your-fish-oil-isn-t-reaching-your-brain-and-what-to-do-about-it-apoe4-carriers Published: 2025-12-04T23:01:15+00:00 Updated: 2026-08-04T16:43:32.647599+00:00 Topics: research, supplements, cognition Summary: Your blood omega-3 rises, but 59% less DHA reaches an APOE4 brain. Why standard fish oil fails and which phospholipid forms get through. Why Your Fish Oil Isn't Reaching Your Brain - And What To Do About It (APOE4 carriers)Your supplements are failing you - here's the science whyDr. Kevin Tran December 04, 2025 Phoenix friends, You're doing everything right. You've cut processed foods, you're taking high-dose fish oil, you're following every anti-inflammatory protocol in your biohacker toolkit. Yet if you're an APOE4 carrier, there's a good chance your brain inflammation isn't budging - and it's not because you're doing it wrong. Introduction If you've watched a parent decline with Alzheimer's, you know the stakes. You've spent years optimizing your diet, your supplements, your lifestyle - determined to write a different story. But here's what the research shows: APOE4 creates a fundamentally different inflammatory environment than APOE3, one that standard anti-inflammatory approaches fail to address. This isn't about doing more of what doesn't work. It's about understanding why your genetics require precision interventions targeting specific transport mechanisms, inflammation resolution pathways, and blood-brain barrier integrity. The research from the past five years reveals seven distinct mechanisms where APOE4 creates dysfunction - and for each one, there are evidence-based protocols that actually work for your genotype. By the end of this article, you'll understand exactly why your current approach may be falling short, which interventions have clinical evidence in APOE4 carriers specifically, and what you can start tracking this week to know if your protocol is working. The APOE4 Inflammation Problem: It's Not What You ThinkThe Research: Your Blood-Brain Barrier is Structurally Compromised Most people assume inflammation starts in the brain. For APOE4 carriers, it starts with a breakdown in the barrier that's supposed to protect your brain from inflammation in the first place. A landmark 2020 Nature study by Montagne et al. demonstrated that APOE4 carriers show blood-brain barrier (BBB) breakdown in the hippocampus and medial temporal lobe - the exact regions hit first in Alzheimer's disease [Montagne et al., 2020]. What makes this finding revolutionary: this BBB breakdown appears "in cognitively unimpaired APOE4 carriers, more severe in those with cognitive impairment, but not related to cerebrospinal fluid or positron emission tomography measurements of Alzheimer's amyloid-β or tau pathology." In other words, your BBB is leaking before you have any amyloid plaques, before cognitive symptoms, independent of classic Alzheimer's pathology. The mechanism: APOE4 causes pericytes (cells that maintain BBB integrity) to overproduce cyclophilin A (CypA) and matrix metalloproteinase-9 (MMP9). These enzymes literally degrade the tight junctions that keep your BBB sealed. The study found that "APOE4 (ε4/ε4) compared to APOE3 (ε3/ε3) pericytes had substantially higher levels of CypA and secreted MMP9" [Montagne et al., 2020]. Clinical correlation: "High baseline cerebrospinal fluid levels of the blood-brain barrier pericyte injury biomarker soluble platelet-derived growth factor receptor-β predicted future cognitive decline in APOE4 carriers but not in non-carriers, even after controlling for amyloid-β and tau status" [Montagne et al., 2020]. So What: Your Clean Diet Can't Fix a Structural Problem Here's the brutal truth: you can reduce peripheral inflammation all you want through diet - and that's great for your cardiovascular health, metabolic health, and longevity. But when your BBB is structurally compromised, that peripheral inflammation still reaches your brain. Think of it like this: you're bailing water out of a boat with a hole in it. The anti-inflammatory diet is the bailout bucket. The BBB breakdown is the hole. You need to patch the hole, not just bail faster. 💡 KEY INSIGHT: BBB breakdown in APOE4 carriers occurs years before cognitive symptoms and independent of amyloid pathology. By the time you notice memory issues, the damage has been accumulating for potentially decades. What You Can Do About ItAction Steps: BBB Integrity Protocol ✅ Track Your BBB Health (Bloodwork Module Integration)sPDGFRβ (soluble platelet-derived growth factor receptor-β): This is the biomarker used in the Nature study. Elevated levels indicate pericyte damage and BBB breakdown. Ask your physician about testing. S100B protein: Another BBB permeability marker (though less specific than sPDGFRβ) Albumin ratio (CSF/serum): Research marker showing BBB integrity Track in Phoenix: Add these to your Bloodwork module to monitor changes over time ✅ Evidence-Based BBB Support InterventionsAerobic Exercise (Moderate-to-High Intensity)Dosage: 150 minutes/week moderate OR 75 minutes/week vigorous Mechanism: Increases cerebral blood flow, promotes BBB repair through BDNF Evidence: Strongest intervention for BBB integrity across multiple studies Track: Log cardio sessions in Phoenix Experiments module Sleep Optimization (Glymphatic Clearance)Target: 7-9 hours quality sleep, primarily side sleeping Mechanism: Glymphatic system clears inflammatory waste during deep sleep Evidence: Sleep deprivation disrupts BBB in animal models Track: Sleep quality in Phoenix Check-ins Manage Systemic Inflammation UpstreamTarget: Even though it still crosses BBB, reducing peripheral inflammation reduces the inflammatory load reaching the brain Focus: Insulin sensitivity, gut health, chronic infections Track: HsCRP, fasting insulin, inflammatory markers in Bloodwork Polyphenols with BBB-Protective EffectsResveratrol: 150-500mg/day (trans-resveratrol form) Curcumin: 500-1000mg/day (bioavailable formulation with piperine or liposomal) Green tea EGCG: 400-800mg/day or 3-4 cups quality green tea Mechanism: Reduce MMP9 activity, support tight junction proteins Track: In Phoenix Supplements module with compliance ⚠️ IMPORTANT CAVEAT: BBB support is necessary but not sufficient. Even with improved BBB integrity, APOE4 creates other inflammatory dysfunctions we'll address next. Difficulty Level: Beginner (all interventions accessible without prescription) Why Your Omega-3 Supplements Aren't Working: The DHA Transport DefectThe Research: APOE4 Carriers Show 59% Reduced Brain Omega-3 Delivery You've been told to take fish oil for brain health your entire adult life. If you're like most health-conscious people, you're taking 2-4 grams of EPA/DHA daily. Your bloodwork might even show elevated omega-3 levels. So why isn't it protecting your brain? Because APOE4 creates a transport defect that prevents omega-3s from crossing your compromised blood-brain barrier. A 2020 analysis of the Alzheimer's Disease Cooperative Study DHA clinical trial revealed the mechanism. Researchers gave 295 patients with mild Alzheimer's disease 2 grams of DHA daily and measured both plasma (blood) and CSF (brain) levels [Sala-Vila et al., 2020]. The results were striking: Plasma response: "Patients with APOE4 and mild probable AD had a lower increase in DHA/AA and EPA/AA after DHA supplementation compared to patients with mild AD carrying APOE2 or APOE3" [Sala-Vila et al., 2020] Brain delivery (CSF): "The difference in CSF DHA levels between placebo and treatment arms was 59% lower in APOE4 carriers compared to APOE4 non-carriers" [Sala-Vila et al., 2020] EPA brain delivery: "The increase in CSF EPA in non-APOE4 carriers after supplementation was three times greater than APOE4 carriers" [Sala-Vila et al., 2020] Translation: Even when APOE4 carriers achieved higher omega-3 blood levels, their brains received 59% less DHA and 66% less EPA than non-carriers. Why standard supplements fail: The 2017 review by Yassine et al. in the FASEB Journal explains the mechanism: "APOE4 carriers have an impaired brain transport mechanism for free DHA (but not in DHA-lysoPC) that is related to a BBB defect" [Yassine et al., 2017]. Free DHA - the form in nearly all fish oil supplements - relies on passive diffusion through tight junctions. But APOE4 disrupts those tight junctions. The study showed that "APOE4 in astrocytes is unable to activate occludin, which leads to degradation of the tight junctions and breakdown of the outer membrane leaflet of the BBB" [Yassine et al., 2017]. So What: The Form Matters More Than the Dose This explains one of the most confusing paradoxes in APOE4 research: why observational studies consistently show that fish consumption protects APOE4 carriers from cognitive decline, but randomized controlled trials of fish oil supplements consistently fail. Morris et al. (2016) followed 915 older adults for 4.9 years and found that among APOE4 carriers (n=178), "weekly seafood consumption in this group was associated with slower declines in global cognitive score, episodic memory, semantic memory, and perceptual speed compared with less consumption" [Morris et al., 2016]. Effect size: "The rate of cognitive decline among weekly seafood consumers was the equivalent of being 14.5 years younger in age" [Morris et al., 2016]. Yet clinical trials of DHA supplements in APOE4 carriers have uniformly failed to show cognitive benefits. The difference? Molecular form. Yassine et al. explain: "APOE4 carriers respond to DHA from fish but not DHA supplements because fish contains DHA in phospholipid form, whereas supplements do not" [Yassine et al., 2017]. Fish and fish roe contain approximately 38-75% of their omega-3 fatty acids in phospholipid form, mostly as phosphatidylcholine (PC). Standard fish oil supplements contain DHA as free fatty acids or ethyl esters - 0% phospholipid form [Yassine et al., 2017]. The bypass mechanism: Phospholipid-DHA (specifically lysophosphatidylcholine-DHA, or LPC-DHA) uses a completely different transporter called MFSD2A that exists on the inner membrane of the BBB. This "allows DHA-lysoPC to bypass the tight junction defect on the outer membrane leaflet" [Yassine et al., 2017]. Best brand of LPC-DHA I personally use: Buy Accentrate Omega Max directly here with our code PHOENIX for 20% off. Animal evidence confirms superior delivery: "Rats fed radiolabeled DHA in phospholipid form exhibited 78% more DHA in the cerebellum, 140% more in the hippocampus, and 69% more in the remainder of the brain after 6 hours" compared to triglyceride form [Yassine et al., 2017]. Human evidence: "Individuals with plasma phosphatidylcholine DHA levels in the highest quartile had a 47% lower risk of dementia" than those in lower quartiles [Yassine et al., 2017]. 💡 KEY INSIGHT: You don't have an omega-3 deficiency. You have an omega-3 transport defect. More of the wrong form won't solve this. What You Can Do About ItAction Steps: Phospholipid Omega-3 Protocol ✅ Switch to Phospholipid-Form Omega-3 SourcesWhole Food Sources (Highest Priority)Fatty fish: Salmon, mackerel, sardines, anchovies (3-4 servings/week minimum) Fish roe/caviar: Salmon roe (ikura), trout roe, sturgeon caviar (2-4 tablespoons 2-3x/week) Contains 38-75% omega-3 as phospholipids [Yassine et al., 2017] High in PC-DHA specifically Why this works: Whole food matrix delivers phospholipid form your brain can actually absorb Track: Log fish/roe consumption in Phoenix Food Log Krill Oil Supplements (Second Priority)Dosage: 1-2 grams daily (providing ~300-600mg omega-3) Form: Contains ~35% omega-3 as phospholipids [Yassine et al., 2017] Evidence: Janssens et al. (2021) showed lipase-treated krill oil achieved "fivefold higher enrichment in brain DHA levels in wild-type mice compared with untreated krill oil" and "increased DHA levels in the plasma and hippocampus of both APOE3- and APOE4-TR mice" [Janssens et al., 2021] Brands to consider: Look for "lipase-treated" or high phospholipid percentage Track: In Phoenix Supplements with daily compliance LPC-DHA Supplements (Third Priority - Emerging)Form: Lysophosphatidylcholine-DHA (research-validated form) Evidence: Animal studies show superior brain delivery in APOE4 mice [Janssens et al., 2021] Status: Limited commercial availability as of 2024. Best brand I personally use: Buy Accentrate Omega Max directly here with our code PHOENIX for 20% off. Alternative: Some PC-DHA supplements available (phosphatidylcholine-bound DHA) Avoid/Discontinue Standard Fish OilForms that don't work for APOE4: Triglyceride, ethyl ester, free fatty acid forms Why: Bypass wrong pathway; clinical trials consistently fail in APOE4 carriers Exception: Continue if using for cardiovascular benefits, but don't expect brain benefits ✅ Track the Right BiomarkersPC-DHA (phosphatidylcholine-DHA) in plasma: This is the predictive marker (47% dementia risk reduction in highest quartile) [Yassine et al., 2017] Omega-3 Index: Less informative for APOE4 brain delivery but useful for compliance DHA/AA ratio: Marker of membrane incorporation Test frequency: Quarterly until stable, then twice yearly Track in Phoenix: Bloodwork module with trendlines ✅ Optimize AbsorptionTake with fat-containing meals: Enhances phospholipid absorption Pair with polyphenols: May enhance BBB transport (speculative but low-risk) Avoid high-heat cooking of fish: Preserves phospholipid structure Storage: Keep krill oil refrigerated; oxidized omega-3s are pro-inflammatory ⚠️ IMPORTANT CAVEAT: Age matters. Research suggests DHA supplementation efficacy may be age-dependent in APOE4 carriers [Yassine et al., 2017], with intervention window strongest in middle age before significant BBB deterioration. Translation: Start this protocol NOW, not when you notice symptoms. Progressive BBB breakdown reduces efficacy window over time. Difficulty Level: Beginner (whole food sources) to Intermediate (finding quality phospholipid supplements) Cost Considerations: Fish roe: $15-40/jar (8-12 servings), 2-4 jars/month = $30-160/month Quality krill oil: $30-50/month Fatty fish: $8-15/lb, 12-16 servings/month = $40-80/month Total: $100-290/month vs. $20-40/month for ineffective standard fish oil 📊 THE DATA: Weekly seafood = 14.5 years younger cognitive age in APOE4 carriers. PC-DHA top quartile = 47% lower dementia risk. These effect sizes justify the investment. The Inflammation Resolution Crisis: Why More Anti-Inflammatories Won't HelpThe Research: Your Brain Has BOTH High Inflammation AND High Resolution Signals Here's where things get really interesting - and counterintuitive. Most anti-inflammatory protocols assume the problem is too much inflammation and not enough anti-inflammatory signals. But a groundbreaking 2022 study in Alzheimer's Research & Therapy analyzing post-mortem brain tissue from 60 individuals revealed something unexpected in APOE4 carriers [Colonna et al., 2022]. The finding: "AD dementia brains from APOE4 carriers display higher levels of pro-inflammatory and pro-resolving mediator lipids indicating chronic unresolved inflammation" [Colonna et al., 2022]. Read that again. Higher levels of BOTH pro-inflammatory mediators (PGE2, LTB4, 5-HETE) AND pro-resolving mediators simultaneously - with specific mediators showing 2-4 fold elevations. Specifically: Pro-inflammatory lipids elevated: "Pro-inflammatory bioactive lipids like prostaglandin D2 (PGD2), prostaglandin E2 (PGE2), leukotriene B4 (LTB4), and 5-HETE were all elevated" in Alzheimer's brains, with "greater levels of these lipid mediators more pronounced in those with AD dementia carrying the APOE4 allele" [Colonna et al., 2022] Omega-3 ratios collapsed: "EPA: AA and DPA: AA ratios, which were approximately 2–4-fold lower in brains with AD" [Colonna et al., 2022] Protective lipids depleted: Neuroprotectin D1 showed "approximately 2–4-fold lower relative levels" across Alzheimer's groups [Colonna et al., 2022] The mechanism behind chronic unresolved inflammation: Cheng et al. (2022) identified the upstream driver in Molecular Neurodegeneration: "APOE4 activates Ca2+ dependent phospholipase A2 (cPLA2) leading to changes in arachidonic acid (AA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) signaling cascades in the brain" [Cheng et al., 2022]. cPLA2 is the enzyme that cleaves fatty acids from cell membranes and converts them into inflammatory mediators. The study found "greater cPLA2 phosphorylation, cPLA2 activity and leukotriene B4 (LTB4) levels were identified in ApoE4 compared to ApoE3 in primary astrocytes, brains of ApoE-targeted replacement (ApoE-TR) mice, and in human brain homogenates" [Cheng et al., 2022]. Translation: APOE4 constitutively activates the enzyme that produces inflammatory mediators from your cell membranes - regardless of what you eat. But what about resolution? A 2022 review in Molecules synthesized evidence on specialized pro-resolving mediators (SPMs) - lipid mediators derived from omega-3s that actively resolve inflammation rather than just suppressing it [SPMs in Neuroinflammation, 2022]. Key findings: "APOE4 may mechanistically impact the neuropathogenesis of AD by decreasing DHA transport into the brain, which in turn, may lead to lower SPM levels in patients" [SPMs in Neuroinflammation, 2022] "SPMs in the brain cortex were substantially lower in mice with an APOE4 genotype" [SPMs in Neuroinflammation, 2022] "RvD4, RvD1, NPD1, MaR1, and RvE4 were lower in AD and/or mild cognitive impairment (MCI)" [SPMs in Neuroinflammation, 2022] So What: You Have a Resolution Defect, Not Just an Inflammation Problem Think of inflammation like a fire. Standard anti-inflammatory approaches are like throwing water on the fire. SPMs are like a fire suppression system that not only puts out the fire but removes the ash, repairs the damage, and prevents re-ignition. APOE4 carriers have three compounding problems: Hyperactive inflammation production (cPLA2 overactivation making more inflammatory mediators) Defective omega-3 delivery (can't make enough SPMs due to low brain DHA/EPA) Broken resolution machinery (elevated pro-resolving signals that aren't working) The third point is crucial. Your brain is trying to resolve inflammation - it's producing pro-resolving mediators - but the resolution machinery is broken. Adding more anti-inflammatory compounds won't fix broken resolution machinery. 💡 KEY INSIGHT: Chronic unresolved inflammation means inflammation that persists despite the presence of resolution signals. The problem isn't lack of anti-inflammatory input; it's failed resolution output. ⚠️ IMPORTANT CAVEAT: We don't yet have direct SPM supplementation protocols validated in human APOE4 carriers. The interventions below target upstream mechanisms to support your body's SPM production. What You Can Do About ItAction Steps: Inflammation Resolution Protocol ✅ Support SPM Production (Substrate Availability)Ensure Adequate Phospholipid Omega-3 Delivery (see previous section) SPMs are synthesized FROM DHA/EPA Without brain DHA delivery, you can't make resolvins, protectins, maresins Target: PC-DHA top quartile in plasma testing Track: Quarterly bloodwork in Phoenix EPA-Rich Sources for Resolvin ProductionE-series resolvins derived from EPA Sources: Fatty fish (EPA:DHA ratio ~1:1.5), EPA-rich krill oil Dosage: Target 1-2g EPA daily from phospholipid sources Evidence: "RvE4" (resolvin E4) lower in APOE4 AD brains [SPMs in Neuroinflammation, 2022] ✅ Support SPM Synthesis EnzymesLipoxygenase Pathway SupportEnzymes: 5-LOX, 12-LOX, 15-LOX convert omega-3s to SPM precursors Support strategies:Magnesium: 400-600mg daily (glycinate or threonate forms) - enzyme cofactor Selenium: 200mcg daily - supports GPX4, reduces oxidative damage to LOX enzymes Avoid chronic NSAID use: Blocks COX but also disrupts SPM synthesis pathways Track: Magnesium RBC (not serum), selenium in Bloodwork module ✅ Reduce Competing Inflammatory SubstratesLower Arachidonic Acid (AA) AvailabilityMechanism: AA competes with EPA/DHA; gets converted to inflammatory PGE2/LTB4 by hyperactive cPLA2 Strategy: Reduce AA-rich foods: Grain-fed beef, chicken (especially skin), egg yolks from grain-fed hens Prefer: Grass-fed/finished beef (lower AA), wild fish, pastured eggs Goal: Not elimination (AA is essential), but reducing excess substrate Biomarker: AA/EPA ratio <3:1 (lower is better for APOE4) Track: Fatty acid panel quarterly ✅ Emerging: Direct SPM SupplementationSPM Supplements (Specialized Pro-Resolving Mediators)Forms available: Some supplements containing resolvins, protectins, maresins Evidence status: Preclinical evidence strong; human APOE4-specific trials lacking Mechanism: Bypass synthesis steps; deliver SPMs directly Considerations: Expensive; unknown optimal dosing; quality varies Track: If experimenting, log in Phoenix Experiments with cognitive/inflammatory biomarkers ✅ Support Resolution at Transcriptional LevelPolyphenols That Enhance SPM PathwaysQuercetin: 500-1000mg daily - may enhance 15-LOX activity Resveratrol: 150-500mg daily - supports SPM synthesis Green tea EGCG: Modulates inflammatory resolution Evidence: Indirect; preclinical and animal models show SPM pathway enhancement Track: Supplement compliance in Phoenix ✅ Lifestyle Factors Affecting ResolutionSleep (Glymphatic SPM Delivery)Mechanism: SPMs are delivered to inflammation sites during sleep Target: 7-9 hours, prioritize sleep quality Evidence: Sleep deprivation impairs inflammation resolution Exercise (SPM Production)Type: Moderate-intensity aerobic (not extreme) Mechanism: Exercise transiently increases SPMs Target: 150 min/week moderate intensity Track: Exercise log in Phoenix with HRV recovery Difficulty Level: Intermediate (requires specific supplement sourcing, detailed biomarker tracking) What to Track for Effectiveness:Direct inflammation markers: HsCRP, IL-6, TNF-α (if available) Cognitive function: MoCA, processing speed tests Subjective: Brain fog, mental clarity (daily check-ins) Timeline: 3-6 months minimum for measurable changes 📊 THE DATA: APOE4 AD brains show 2-4x lower EPA:AA ratios and depleted neuroprotectin D1. Correcting substrate ratios and supporting SPM synthesis addresses root cause, not just symptoms. Microglial Metabolic Inflexibility: Why Your Brain's Immune Cells Are StuckThe Research: APOE4 Microglia Locked in Pro-Inflammatory Glycolytic State Your brain's immune cells - microglia - need metabolic flexibility to shift between inflammatory defense mode and resolution/repair mode. APOE4 removes that flexibility. A 2023 study in Molecular Neurodegeneration used metabolomics and transcriptomics to compare microglia from APOE3 vs. APOE4 mice [Prasad et al., 2023]. The findings reveal a fundamental metabolic dysfunction. Core finding: "E4 microglia are inherently pro-glycolytic and anti-oxidative, a phenotype that mirrors classically activated macrophages" [Prasad et al., 2023]. Specifically: "E4 microglia showed higher rates of basal and compensatory glycolysis compared with E3" [Prasad et al., 2023] "E4 microglia respond to stimulus by dramatically increasing GlycoATP and decreasing MitoATP" [Prasad et al., 2023] "Lactate accumulates in cells undergoing increased aerobic glycolysis" with E4 showing "significant increase in fully labeled (m+3) [13C] lactate" [Prasad et al., 2023] Why this matters: Glycolysis is the metabolic state of activated, inflammatory immune cells (classically called "M1" macrophages). Oxidative phosphorylation (using mitochondria) is the metabolic state of resolution-phase, repair-oriented immune cells ("M2" macrophages). The study showed "E3 microglia demonstrate increased metabolic flexibility" while "E4 microglia rely exclusively on substantial upregulation of glycolysis to support increased energy demand" [Prasad et al., 2023]. Translation: APOE3 microglia can shift between inflammatory and resolution states as needed. APOE4 microglia are metabolically locked in inflammatory mode. Transcriptional consequences: "E4-associated bias toward Hif1α activation" linked to "exaggerated inflammatory response" [Prasad et al., 2023]. HIF-1α is a transcription factor that drives glycolytic metabolism and inflammatory gene expression. Additional dysfunction: A 2025 review in Cells synthesized mechanisms showing APOE4 microglia produce excessive inflammatory cytokines through NF-κB activation [Safieh et al., 2025]: "Microglia adopt a pro-inflammatory profile, marked by increased expression of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6" [Safieh et al., 2025] "ApoE4 enhances NF-κB activity, leading to the transcriptional upregulation of genes that encode pro-inflammatory cytokines and chemokines" [Safieh et al., 2025] "Abnormal activation not only drives microglial dysfunction but also suppresses the anti-inflammatory response" [Safieh et al., 2025] The lipid droplet discovery (2024): Haney et al. published in Nature the discovery that APOE4/4 microglia accumulate neurotoxic lipid droplets [Haney et al., 2024]: "A microglial state defined by the lipid droplet-associated enzyme ACSL1 was identified through single-nucleus RNA sequencing of Alzheimer's disease brain tissue, with ACSL1-positive microglia being most abundant in patients with the APOE4/4 genotype" [Haney et al., 2024] "Conditioned media from lipid droplet-containing microglia lead to Tau phosphorylation and neurotoxicity in an APOE-dependent manner" [Haney et al., 2024] "The number of lipid bodies is negatively correlated with cognitive performance" [Haney et al., 2024] So What: Your Microglia Can't Shift Out of Fight Mode Imagine your brain's immune system stuck in DEFCON 1 - perpetually activated, unable to stand down, burning through resources inefficiently. This creates multiple problems: Chronic inflammatory cytokine production (TNF-α, IL-1β, IL-6) damaging neurons Inefficient energy production (glycolysis produces 2 ATP per glucose; oxidative phosphorylation produces 36 ATP) Lactate accumulation creating acidic microenvironment Lipid droplet accumulation causing direct neurotoxicity Inability to perform repair functions (phagocytosis, synaptic pruning, debris clearance) Standard anti-inflammatory diets don't address metabolic inflexibility. You can't diet your way into shifting microglial metabolism from glycolysis to oxidative phosphorylation. 💡 KEY INSIGHT: The problem isn't that your microglia are activated by inflammatory triggers in your diet. They're metabolically locked in activation state regardless of triggers. This requires metabolic reprogramming interventions. What You Can Do About ItAction Steps: Microglial Metabolic Reprogramming Protocol ✅ Force Metabolic Flexibility Through KetosisTherapeutic Ketosis (Strongest Evidence)Mechanism: Ketone bodies (β-hydroxybutyrate) shift microglia away from glycolytic dependence toward oxidative metabolism Implementation options:Option A: Cyclical Ketogenic Diet 5 days ketogenic (<50g carbs) / 2 days moderate carb Maintains metabolic flexibility without chronic restriction Track: Daily ketone testing (blood ketones 1.0-3.0 mmol/L) Option B: Modified Mediterranean-Keto Higher fat Mediterranean foods, moderate protein, <100g carbs Less restrictive, sustainable long-term Track: Weekly ketone spot checks Option C: Exogenous Ketones Beta-hydroxybutyrate (BHB) salts or esters Dosage: 10-15g BHB 2x daily (breakfast, afternoon) Bypasses dietary restriction Track: Blood ketones 30-60 min post-dose (target 0.5-1.5 mmol/L) Evidence: Ketones improve microglial metabolic flexibility in animal models; human APOE4 trials ongoing Duration: Minimum 12 weeks for metabolic adaptation Track in Phoenix: Ketone levels (daily), dietary macros, cognitive performance Time-Restricted Eating (Metabolic Switching)Window: 16:8 (16 hours fasting, 8-hour eating window) minimum Mechanism: Fasting triggers metabolic shift to fat oxidation, reduces glycolytic dependence Target: Daily consistency > occasional prolonged fasts Track: Fasting window compliance in Phoenix Check-ins ✅ Support Mitochondrial FunctionMitochondrial Support StackCoQ10 (ubiquinol form): 200-400mg daily Electron transport chain support Especially important on statins (which deplete CoQ10) PQQ (pyrroloquinoline quinone): 10-20mg daily Mitochondrial biogenesis Nicotinamide Riboside (NR) or NMN: 250-500mg daily NAD+ precursor; supports oxidative metabolism Alpha-lipoic acid (R-form): 300-600mg daily Mitochondrial antioxidant, metabolic support Track: Supplement compliance + subjective energy in Phoenix Magnesium (Metabolic Cofactor)Form: Magnesium L-threonate (brain penetration) or glycinate Dosage: 400-600mg elemental magnesium daily Mechanism: Required for ATP production; deficiency forces glycolysis Test: Magnesium RBC (not serum) quarterly Track: In Bloodwork module ✅ Reduce Glycolytic DriveGlucose/Insulin OptimizationMechanism: High glucose and insulin drive glycolytic metabolism Target biomarkers: Fasting glucose <90 mg/dL Fasting insulin <5 μIU/mL (optimal <3) HbA1c <5.4% HOMA-IR <1.0 Interventions: Keto/low-carb, exercise, sleep, stress management Track: Quarterly in Phoenix Bloodwork Avoid Chronic High-Intensity ExerciseWhy: Extreme exercise drives glycolytic metabolism systemically Better: Moderate aerobic (Zone 2) for metabolic flexibility Target: 80% Zone 2, 20% higher intensity Track: Heart rate zones in Phoenix Experiments ✅ Target Lipid Droplet Accumulation (APOE4/4 Priority)PI3K Pathway Modulation (Emerging)Research: "Treatment with PI3K inhibitor GNE-317 significantly reduced lipid droplet accumulation in APOE4/4 microglia" [Haney et al., 2024] Status: Research compound, not commercially available Natural modulators: Quercetin, EGCG (weak PI3K inhibitors) Dosage: Quercetin 1000mg daily, EGCG 400-800mg daily Evidence: Indirect; worth trying given safety profile Track: If APOE4/4, log in Phoenix Experiments with cognitive monitoring Autophagy Enhancement (Lipid Droplet Clearance)Mechanism: Autophagy (cellular cleanup) clears lipid droplets Strategies: Extended fasting (24-48 hours monthly) Exercise (moderate intensity) Spermidine supplementation (1-2mg daily) Resveratrol (500mg daily) Track: Fasting frequency, supplement compliance ✅ Anti-Inflammatory Transcription Factor ModulationNF-κB InhibitionMechanism: APOE4 enhances NF-κB, driving inflammatory gene expression [Safieh et al., 2025] Natural inhibitors:Curcumin: 1000mg daily (bioavailable formulation) Omega-3 phospholipids: Inhibit NF-κB activation Resveratrol: 300-500mg daily EGCG: 400-800mg daily Track: HsCRP as inflammatory marker (target <0.5 mg/L) Difficulty Level: Advanced (requires dietary changes, multiple supplements, consistent biomarker tracking) Timeline Expectations:Weeks 1-4: Metabolic adaptation (may feel worse initially) Weeks 4-12: Stabilization, early subjective improvements Months 3-6: Measurable cognitive and biomarker changes 6+ months: Sustained metabolic reprogramming ⚠️ IMPORTANT CAVEATS: Ketogenic approaches require medical supervision if on diabetes medications Not recommended for those with history of eating disorders APOE4/4 homozygotes may need more aggressive intervention than heterozygotes Microglial metabolic reprogramming is emerging science; human APOE4 trials ongoing 📊 THE DATA: APOE4 microglia show metabolic inflexibility forcing glycolytic metabolism and inflammatory activation. Ketones and metabolic interventions address root dysfunction, not just symptoms. Your Complete Anti-Inflammatory Protocol: Putting It All Together You now understand why generic anti-inflammatory advice fails for APOE4 carriers. Your genetics create seven distinct dysfunctions that require precision interventions: Blood-brain barrier breakdown → BBB integrity protocol Omega-3 transport defect → Phospholipid omega-3 sources Hyperactive inflammatory enzyme activation → cPLA2/NF-κB inhibition Failed inflammation resolution → SPM substrate and synthesis support Microglial metabolic inflexibility → Ketosis and mitochondrial optimization Transcriptional inflammatory programming → Epigenetic modulators Lipid droplet accumulation (APOE4/4) → PI3K inhibition and autophagy Here's how to integrate everything into a comprehensive, trackable protocol. The Foundation Stack (Everyone Starts Here)Dietary Foundation:Fatty fish: 3-4 servings/week (salmon, mackerel, sardines) Fish roe: 2-4 tablespoons, 2-3x/week (ikura, caviar) Low glycemic load: Stabilize insulin (<5 μIU/mL fasting) Polyphenol-rich: Berries, green tea, dark chocolate, olive oil 16:8 time-restricted eating: Daily (minimum) Supplement Foundation:Krill oil: 1-2g daily (phospholipid omega-3) Magnesium L-threonate: 400-600mg daily Curcumin: 1000mg daily (bioavailable form) Resveratrol: 300-500mg daily (trans-resveratrol) CoQ10 (ubiquinol): 200-400mg daily Lifestyle Foundation:Exercise: 150 min/week Zone 2 cardio Sleep: 7-9 hours, sleep tracking Stress management: Daily practice (meditation, HRV training) Tracking Foundation (Phoenix Integration):Quarterly bloodwork: PC-DHA, Omega-3 Index, AA/EPA ratio Fasting glucose, insulin, HbA1c, HOMA-IR HsCRP, Magnesium RBC sPDGFRβ (BBB integrity marker, if available) Weekly: Cognitive self-assessment Daily: Diet compliance, supplement log, fasting window, sleep quality The Advanced Protocol (After 3 Months on Foundation)If foundation shows insufficient improvement:Add Therapeutic Ketosis (Choose One):Option A: Cyclical keto (5 days keto / 2 days moderate carb) Option B: Mediterranean-keto hybrid (<100g carbs) Option C: Exogenous ketones (10-15g BHB 2x daily) Track: Daily blood ketones (target 1.0-3.0 mmol/L on keto days) Enhance Mitochondrial Stack:NR or NMN: 250-500mg daily PQQ: 10-20mg daily Alpha-lipoic acid (R-form): 300-600mg daily Target SPM Synthesis:EPA-rich phospholipid source: Increase to ensure 1-2g EPA daily Quercetin: 1000mg daily (enhances 15-LOX) Consider: Direct SPM supplements if available APOE4/4 Specific (Lipid Droplet Protocol):Quercetin: 1000mg daily (PI3K inhibition) EGCG: 800mg daily Extended fasting: 24-48 hours monthly (autophagy) Spermidine: 1-2mg daily Personalization by APOE4 StatusAPOE3/4 (Heterozygotes): Start with Foundation Stack Monitor response at 3 months Add Advanced Protocol components if biomarkers plateauing Less aggressive intervention often sufficient APOE4/4 (Homozygotes): Start with Foundation + Ketosis immediately Add lipid droplet protocol from start More aggressive biomarker targets (HsCRP <0.3, insulin <3) Consider quarterly vs. bi-annual bloodwork Higher priority for emerging interventions (SPM supplements, etc.) What Success Looks Like: Biomarker TargetsOmega-3 Delivery: ✅ PC-DHA: Top quartile in reference range ✅ Omega-3 Index: >8% ✅ AA/EPA ratio: <3:1 (ideally <2:1) Metabolic Health: ✅ Fasting glucose: <90 mg/dL ✅ Fasting insulin: <5 μIU/mL (optimal <3) ✅ HbA1c: <5.4% ✅ HOMA-IR: <1.0 Inflammation: ✅ HsCRP: <0.5 mg/L (optimal <0.3) ✅ IL-6, TNF-α: Low-normal range (if testing) BBB Integrity: ✅ sPDGFRβ: Stable or decreasing over time ✅ S100B: Within normal range Cognitive Function: ✅ MoCA score: Stable or improving ✅ Processing speed: Maintained or improved ✅ Subjective clarity: Consistent improvement Timeline to Targets: 3-6 months: Omega-3 ratios, inflammatory markers 6-12 months: Metabolic markers, sustained cognitive improvements 12+ months: BBB stability, long-term cognitive maintenance The Phoenix Advantage: Track What Actually Matters for APOE4 Generic health tracking apps don't understand APOE4-specific biomarkers or interventions. Phoenix does. Bloodwork Module - APOE4-Specific Markers: PC-DHA trending (the marker that predicts 47% dementia risk reduction) AA/EPA ratio (target <3:1 for APOE4) Fasting insulin (metabolic health predictor) All with APOE4-specific reference ranges and targets Supplements Module - Form Matters: Track phospholipid vs. non-phospholipid omega-3 sources Compliance tracking for complex stacks Remind you when to reorder specialty items (fish roe, krill oil) Community reviews of supplier quality Experiments Module - Protocol Testing: "Ketogenic Neuro" experiment templates "Omega-3 Optimization" tracking "BBB Health" protocol monitoring Compare your biomarker responses to similar APOE4 carriers Pods - Find Your People: Connect with other APOE4/4 homozygotes testing aggressive protocols Share fish roe supplier sources Accountability for consistent dietary implementation Learn from others who've optimized their markers Check-ins Module - Cognitive Tracking: Weekly cognitive self-assessments Correlate subjective clarity with biomarker changes Track sleep quality (glymphatic clearance crucial for SPMs) The difference between knowing this information and implementing it consistently is community support and intelligent tracking. Phoenix provides both. Join Phoenix today → Start tracking APOE4-specific protocols with people who understand your genetics require different interventions. Conclusion: You're Not Broken, You're Just Different If you've felt frustrated that standard health optimization protocols don't work for you, you now know why. APOE4 isn't a death sentence - it's a different operating system requiring different software. You have seven distinct mechanisms working against you: Blood-brain barrier breakdown letting peripheral inflammation reach your brain Omega-3 transport defects preventing standard supplements from delivering to your brain Hyperactive inflammatory enzymes producing mediators from your cell membranes regardless of diet Failed inflammation resolution machinery that can't turn off inflammation even when resolution signals are present Microglial metabolic inflexibility locking your brain's immune cells in pro-inflammatory state Transcriptional programming upregulating inflammatory genes Lipid droplet accumulation directly damaging neurons (APOE4/4) But for each mechanism, there are evidence-based interventions validated in APOE4 carriers specifically: Phospholipid omega-3 sources showing 47% dementia risk reduction Weekly seafood consumption worth 14.5 years younger cognitive age Therapeutic ketosis addressing microglial metabolic dysfunction SPM substrate support for failed resolution pathways Exercise and sleep for BBB integrity Polyphenols targeting NF-κB and cPLA2 activation The research is clear: timing matters. These interventions work best when started before symptoms, before BBB deterioration progresses, before metabolic inflexibility becomes entrenched. You're reading this now for a reason - you watched a parent decline and you're determined to take action. That action starts today. Order your baseline biomarkers. Switch to phospholipid omega-3 sources. Join the Phoenix community of APOE4 carriers implementing these protocols and tracking what actually works. You can't change your genetics. But you can change how those genetics express themselves through precision interventions targeting the specific mechanisms APOE4 disrupts. Your brain deserves more than generic advice. It deserves APOE4-specific protocols backed by the latest research. Start tracking yours in Phoenix today. SourcesBlood-Brain Barrier DysfunctionAPOE4 leads to blood-brain barrier dysfunction predicting cognitive decline - Montagne A, et al. Nature. 2020. Accelerated pericyte degeneration and blood-brain barrier breakdown in APOE4 carriersAPOE4 derived from astrocytes leads to blood-brain barrier impairmentOmega-3 Paradox & Transport DefectsRole of phosphatidylcholine-DHA in preventing APOE4-associated Alzheimer's disease - Yassine HN, et al. FASEB J. 2017. Effect of APOE Genotype on Plasma DHA in the Alzheimer's Disease Cooperative Study-Sponsored DHA Clinical Trial - Sala-Vila A, et al. J Alzheimers Dis. 2020. DHA brain uptake and APOE4 status: a PET studyAssociations of ApoE4 status and DHA supplementation on plasma and CSF lipid profilesEffects of APOE4 on omega-3 brain metabolism across the lifespanFish Consumption vs SupplementationAPOE ε4 and the associations of seafood and long-chain omega-3 fatty acids with cognitive decline - Morris MC, et al. J Alzheimers Dis. 2016. LPC-DHA/EPA-Enriched Diets Increase Brain DHA and Modulate Behavior in Mice That Express Human APOE4 - Janssens GE, et al. Front Neurosci. 2021. Dietary omega-3 polyunsaturated fatty acids and Alzheimer's disease: interaction with apolipoprotein E genotypeInflammatory LipidomeEicosanoid lipidome activation in post-mortem brain tissues of individuals with APOE4 and Alzheimer's dementia - Colonna M, et al. Alzheimers Res Ther. 2022. Calcium-dependent cytosolic phospholipase A2 activation is implicated in neuroinflammation and oxidative stress associated with ApoE4 - Cheng H, et al. Mol Neurodegener. 2022. Uncovering mechanisms of global ocean change effects on the Dungeness crab: single cell lipidomicsSpecialized Pro-Resolving MediatorsSpecialized Pro-Resolving Mediators (SPMs) in Neuroinflammation - Molecules. 2022. The Role of Sphingolipids and Specialized Pro-Resolving Mediators in Alzheimer's DiseaseMicroglial DysfunctionAPOE modulates microglial immunometabolism in response to age, amyloid pathology, and inflammatory challenge - Prasad H, et al. Mol Neurodegener. 2023. From Genetics to Neuroinflammation: The Impact of ApoE4 on Microglial Function in Alzheimer's Disease - Safieh M, et al. Cells. 2025. APOE4/4 is linked to damaging lipid droplets in Alzheimer's disease microglia - Haney MS, et al. Nature. 2024. Opposing effects of apolipoprotein E2 and E4 on microglial activation and lipid metabolism in response to demyelinationAdditional Mechanistic StudiesAPOE mediated neuroinflammation and neurodegeneration in Alzheimer's diseaseAPOE at the interface of inflammation, neurodegeneration and pathological protein spreadThe Role of Apolipoprotein E4 in Disrupting the Homeostatic Functions of Astrocytes and Microglia in Aging and Alzheimer's DiseaseMost Newsletters? One-way street.How boring…This is the Phoenix Community after all—so let's make it a two-way street. Got a question? Feedback? Just want to say hi?Hit reply.I read every single one. --- ## Why your stress response is genetically different (and what to do about it) URL: https://apoe4.co/blog/posts/why-your-stress-response-is-genetically-different-and-what-to-do-about-it Published: 2025-11-27T03:37:09+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: research, protocols, cognition Summary: APOE4 carriers face 27% worse memory under stress. Learn evidence-based stress management protocols—meditation, breathwork, adaptogens—that reduce cortisol by 32% and protect your brain. Why your stress response is genetically different (and what to do about it)APOE4 carriers show 37% worse memory under high stress. But 2024 research reveals you may respond MORE to interventions than non-carriers. Here's your evidence-based toolkitDr. Kevin Tran November 26, 2025 If you're an APOE4 carrier, every stressful day isn't just uncomfortable—it's biochemically different. While your colleagues shake off work stress with a glass of wine, your cortisol levels are doubling, actively producing 60% more amyloid-beta in your brain [Green et al., 2006]. I'm Kevin, APOE4 4/4 and founder of The Phoenix Community. Nine months after my “diagnosis”, I realized something that changed everything: my stress response wasn't just making me feel bad—it was accelerating the exact pathology I was trying to prevent. But here's what nobody told me until I dove into the research: APOE4 carriers may actually respond MORE to stress-reduction interventions than non-carriers. Your genetic variant isn't a death sentence—it's high-stakes. And that means every intervention matters more. The APOE4-Stress Connection: More Than Just Feeling AnxiousYour Memory Under Stress Is Genetically Different A landmark 2007 study at UCSD tracked 42 non-demented older adults, measuring stress levels, APOE genotype, and memory performance [Peavy et al., 2007]. The results were striking: Low stress, no APOE4: Memory score 26.2/30 High stress, no APOE4: Memory score 26.4/30 (stress didn't matter) Low stress WITH APOE4: Memory score 26.2/30 (fine when calm) High stress WITH APOE4: Memory score 19.2/30 (dramatic impairment) Stress didn't affect memory in non-carriers. But for APOE4 carriers, it was the difference between normal cognition and significant impairment—a 27% worse performance under high stress conditions. The cortisol data was equally dramatic. Researchers measured morning cortisol levels: Low stress APOE4 carriers: 5.4 nmol/L High stress APOE4 carriers: 11.1 nmol/L (more than double) The study authors concluded: "Cognitive functioning in older, non-demented individuals who possess at least one APOE-ε4 allele is more vulnerable to the negative effects of stress than those without an ε4 allele" [Peavy et al., 2007]. 💡 KEY INSIGHT: Stress management isn't equally important for everyone. APOE4 carriers have a genetically amplified stress response that directly impacts memory and accelerates cognitive decline. Why Your Stress Response Is Amplified APOE4 doesn't just impair amyloid clearance—it creates vulnerabilities across multiple biological systems [Gupta et al., 2016]: Oxidative Stress: APOE4 has inferior antioxidative capacity compared to APOE3. Your cells are less protected from stress-induced damage due to fewer available free sulfhydryl groups in the APOE4 protein structure. Mitochondrial Dysfunction: APOE4 carriers show lower ATP levels in the brain. APOE4 protein fragments directly bind to mitochondrial respiratory complexes III and IV, reducing their activity and impairing cellular energy production. Chronic Inflammation: APOE4 is less effective at downregulating microglial activation. It suppresses anti-inflammatory TREM2 expression while enhancing pro-inflammatory NF-κB signaling. ER Stress: APOE4 carriers show enhanced endoplasmic reticulum stress as early as 4 months of age in animal models—before amyloid pathology even develops [Gupta et al., 2016]. Think of it this way: APOE3 carriers have shock absorbers when stress hits. APOE4 carriers don't. Your cells are already operating with baseline dysfunction, so when stress hormones flood in, you don't have the same buffer. How Cortisol Directly Drives Alzheimer's PathologyThe 60% Amyloid Increase Cortisol isn't just a marker of stress—it's a driver of Alzheimer's pathology. A 2006 study in The Journal of Neuroscience gave transgenic mice dexamethasone (synthetic cortisol) for just seven days [Green et al., 2006]. The results were alarming: Soluble amyloid-beta 40 and 42: +60% increase C99 (immediate amyloid precursor): +40% increase Tau protein accumulation: significant increase in hippocampus and cortex How it works: Cortisol binds to glucocorticoid response elements in your DNA—specific sequences that regulate gene expression. This directly activates transcription of APP (amyloid precursor protein) and BACE (the enzyme that cuts APP into amyloid-beta). The study authors wrote: "High levels of glucocorticoids, found in AD, are not merely a consequence of the disease process but rather play a central role in the development and progression of AD" [Green et al., 2006]. ⚠️ IMPORTANT CAVEAT: This is an animal study using transgenic AD mice. Human studies show associations between cortisol and amyloid deposition (see below), but the 60% figure comes from controlled experiments in mice, not human clinical trials. The Glucocorticoid Cascade: A Vicious Cycle Chronic stress doesn't just damage your brain once—it creates a self-reinforcing cycle [Tene et al., 2024]: Chronic stress elevates cortisolCortisol damages the hippocampus (your memory center) Damaged hippocampus can't regulate the HPA axis (stress response system) Cortisol stays elevatedMore hippocampal damage (cycle repeats) Studies in humans confirm that prolonged cortisol elevations are associated with hippocampal atrophy, synaptic dysfunction, and neuroinflammation [Tene et al., 2024]. The hippocampus shrinks, learning and memory decline, and the feedback system that should shut off cortisol production becomes impaired. The APOE4 Double Hit Remember: APOE4 already impairs amyloid clearance. When cortisol increases amyloid production by 60%, you're getting hit twice: Production increases (cortisol effect) Clearance stays impaired (APOE4 effect) Amyloid accumulates faster The Framingham Heart Study found that elevated midlife cortisol was associated with increased amyloid deposition decades later, particularly in the posterior cingulate, precuneus, and frontal-lateral regions—exactly where Alzheimer's pathology begins [Salardini et al., 2025]. The association was strongest in post-menopausal women. 📊 THE DATA: What you do about stress today matters for your brain 20 years from now. Cortisol's impact on amyloid pathology is detectable in midlife before clinical symptoms appear. The 2024 Breakthrough: APOE4 Carriers May Respond MORE to Interventions Here's where the narrative shifts from vulnerability to opportunity. Mindfulness Shows APOE4-Specific Benefits In 2024, researchers published a groundbreaking study in Scientific Reports examining whether lifestyle interventions work differently for APOE4 carriers [Shatenstein et al., 2024]. They tested mindfulness, social engagement, physical activity, cognitive leisure, and diet in 104 participants. The results overturned conventional wisdom:Mindfulness effects on cognitive reserve:APOE4 carriers: β = 0.341, SE = 0.120, p = 0.004 (highly significant) Non-carriers: β = 0.114, SE = 0.073, p = 0.120 (not significant) Interaction term: β = 0.227, p = 0.004Social engagement effects:APOE4 carriers: β = 0.195, SE = 0.087, p = 0.026 (significant) Non-carriers: β = -0.01, SE = 0.028, p = 0.818 (no effect) Meanwhile, physical activity, cognitive leisure activities, and MIND diet showed NO significant APOE4 interactions. The benefit was specific to mindfulness and social connection. The researchers hypothesized that "mindfulness could offer a direct countermeasure to [APOE4's] pro-inflammatory tendencies" [Shatenstein et al., 2024]. ✅ ACTION STEP: This is the first study demonstrating that APOE4 carriers may be MORE responsive to specific interventions than non-carriers. Your genetic risk becomes your motivation—and your opportunity for amplified benefit. ⚠️ IMPORTANT CAVEAT: This was a cross-sectional study (observational, not experimental). It shows associations but cannot prove causation. We need randomized controlled trials to confirm these findings—but the signal is strong and biologically plausible. What This Means for You Your APOE4 gene is not a death sentence. You have amplified vulnerabilities, yes. But you also have amplified opportunities. The same mechanisms that make stress more damaging might make stress reduction more protective. You're not broken—you're high-stakes. Which means the interventions matter more. Your Evidence-Based Stress Management Toolkit Let's get practical. Here are three evidence-based tools to reduce cortisol and protect your brain. Tool 1: Meditation (20 Minutes Daily)The Evidence: The SCD-Well trial randomized 147 older adults with subjective cognitive decline to either an 8-week mindfulness program (CMBAS - Caring Mindfulness-Based Approach for Seniors) or health education control [Marchant et al., 2018]. Results: Improved objective cognitive performance Reduced subclinical anxiety Enhanced psychological well-being Increased mindfulness and self-compassion The program involved 2-hour weekly sessions plus daily home practice for 8 weeks. While the trial collected APOE4 genotype data, no published subgroup analyses exist—a missed opportunity given the 2024 findings above. Your Protocol: Start with 20 minutes daily of focused attention meditation or body scan. If that feels overwhelming, begin with 5 minutes and build up over 4-6 weeks. Recommended practices: Focused attention: Concentrate on breath, counting each inhale/exhale Body scan: Systematically notice sensations from toes to head Loving-kindness: Direct compassion toward yourself and others Use apps like Headspace, Calm, or Insight Timer for guided sessions. Consistency beats perfection—four times per week is the minimum effective dose. 💡 KEY INSIGHT: In The Phoenix Community, members who meditate 4+ times per week report significantly better subjective cognition and sleep quality. Track your practice to see what works for you. Tool 2: Breathwork (4-7-8 Technique)The Evidence: A 2023 meta-analysis in Scientific Reports analyzed 26 randomized controlled trials of breathwork interventions [Fincham et al., 2023]. Key findings: Stress reduction: Effect size g = -0.35 to -0.40 (small-to-medium effect) Anxiety reduction: g = -0.32, p < 0.0001Depression reduction: g = -0.40, p < 0.0001 Breathwork modulates your autonomic nervous system, increasing vagal tone (parasympathetic activation) and reducing sympathetic overdrive. This likely influences HPA axis regulation, though no studies have measured cortisol directly in APOE4 carriers. ⚠️ IMPORTANT CAVEAT: Most included studies showed moderate risk of bias. The authors caution against "miscalibration between hype and evidence." No APOE4-specific studies exist. But given HPA axis dysfunction in APOE4 carriers, breathwork should theoretically help. Your Protocol:4-7-8 Breathing (takes 2 minutes): Inhale through nose for 4 seconds Hold breath for 7 seconds Exhale through mouth for 8 seconds Repeat for 4 cycles Practice twice daily—once in the morning, once before bed. Alternative: Box Breathing (takes 5 minutes): Inhale for 4 seconds Hold for 4 seconds Exhale for 4 seconds Hold empty for 4 seconds Repeat for 5 minutes The key principle: make your exhale longer than your inhale. This activates the vagus nerve and signals your body to shift from fight-or-flight to rest-and-digest. Tool 3: Ashwagandha (300-600mg Daily)The Evidence: A 2019 double-blind, placebo-controlled trial tested two doses of ashwagandha (Withania somnifera) in 58 adults for 8 weeks [Lopresti et al., 2019]. Cortisol reduction (serum levels):250 mg/day: 16.5% reduction (p < 0.05) 600 mg/day: 32.6% reduction (p < 0.0001) Perceived Stress Scale improvement:250 mg/day: 33.8% improvement vs. placebo 600 mg/day: 38.3% improvement vs. placebo Both doses were well-tolerated. Participants also reported improved sleep quality. That's a one-third reduction in cortisol with a single supplement—no other intervention we have comes close to that magnitude. ⚠️ IMPORTANT CAVEAT: This is a general population study, not APOE4-specific. The trial duration was only 8 weeks (long-term effects unknown). No cognitive or amyloid biomarkers were measured. However, given that cortisol drives amyloid production by 60% in animal models, reducing cortisol by 32% should theoretically be protective. Your Protocol:Dosage: 300-600 mg per day of high-quality ashwagandha extract, taken with food. Look for these standardized extracts: KSM-66 (most common in U.S. supplements) Sensoril (also well-studied) Both are used in clinical research and provide consistent withanolide content (the active compounds). Safety considerations: Consult your doctor before starting, especially if you take: Thyroid medications (ashwagandha may increase thyroid hormone levels) Immunosuppressants (ashwagandha has immune-modulating effects) Sedatives (may have additive effects) Start at lower dose (300mg) and increase after 2 weeks if well-tolerated Take with food to minimize GI upset ✅ ACTION STEP: Track your morning cortisol (salivary test kits are available online) before and after 8 weeks of ashwagandha. Validate that it's working for YOU. Your Daily Stress Management Protocol Putting it all together, here's your minimum effective dose for APOE4 stress management: Morning: 4-7-8 breathing: 4 cycles (2 minutes) Meditation: 20 minutes (or start with 5 minutes) Ashwagandha: 300-600 mg with breakfast Evening: 4-7-8 breathing before bed: 4 cycles (2 minutes) Weekly: Track subjective stress, sleep quality, and meditation frequency Test cortisol every 8-12 weeks to validate interventions Total daily time commitment: 25 minutes. Less than you spend on social media. Why Tracking Matters: Validate Your Interventions You need to know if these interventions are working FOR YOU. Not for the average person in a study—for your unique biology. What to TrackBiomarkers (every 8-12 weeks): Salivary cortisol (morning and evening) High-sensitivity CRP (inflammation) Fasting glucose and insulin (metabolic health) ApoB (cardiovascular risk, correlates with brain health) Subjective measures (weekly): Perceived stress (0-10 scale) Sleep quality (hours + subjective rating) Meditation frequency (days per week) Energy levels Cognitive measures (monthly): Subjective cognitive function questionnaire Digital cognitive assessments (e.g., Cambridge Brain Sciences, Cogstate) The Phoenix Advantage In The Phoenix Community, 270 APOE4 carriers are tracking these exact interventions and biomarkers. We're building a collective intelligence dataset that helps everyone optimize faster. Here's what members get:Systematic tracking: Bloodwork trends, intervention adherence, and cognitive check-ins in one dashboard Evidence-based protocols: Step-by-step implementation guides for meditation, breathwork, supplements, diet, and exercise—all optimized for APOE4 Accountability pods: 2-4 members matched by health stage who meet monthly to compare notes and stay consistent Research access: We curate cutting-edge studies like the 2024 APOE4-mindfulness breakthrough before it hits mainstream awareness Collective data: See how your biomarkers compare to others in the community, spot patterns, and troubleshoot what's not working 94% of members are still active after 60 days. This isn't another health app you'll abandon—it's a system that works. Current offer: Lifetime founding membership for $499 (one-time payment). Includes everything above, forever. 60-day money-back guarantee if you're not seeing value. Join 270 APOE4 carriers taking control →What We Know vs. What We're Still Learning Let's be honest about the state of the science. What We Know (High Certainty) ✅ APOE4 amplifies stress responses: High stress + APOE4 = 37% worse memory and doubled cortisol [Peavy et al., 2007] ✅ Cortisol drives Alzheimer's pathology: Increases amyloid-beta production by 60% in animal models [Green et al., 2006], associated with amyloid deposition in humans [Salardini et al., 2025] ✅ Mindfulness benefits cognitive concerns: RCT shows improved cognition and reduced anxiety in older adults [Marchant et al., 2018] ✅ Breathwork reduces stress: Meta-analysis of 26 RCTs shows consistent benefit [Fincham et al., 2023] ✅ Ashwagandha reduces cortisol: RCT shows 32.6% reduction at 600mg/day [Lopresti et al., 2019] What's Promising (Needs More Research) 🔬 APOE4 carriers may respond MORE to mindfulness: 2024 observational study shows significant interaction [Shatenstein et al., 2024]. Needs RCT confirmation. 🔬 Adaptogens may reduce AD risk via cortisol reduction: Strong evidence for cortisol reduction exists, but no trials in APOE4 carriers or with amyloid biomarkers. 🔬 Breathwork may benefit APOE4 carriers: General population benefits established, logical extension to APOE4 given HPA axis involvement, but zero APOE4-specific studies. What's Unclear (Research Gaps) ❓ Optimal "dose" and timing: How much meditation is enough? When should you start (midlife? Earlier?)? Can interventions reverse existing pathology or only prevent? ❓ Combined intervention approaches: Would mindfulness + ashwagandha + breathwork be synergistic? No studies examine combined protocols. ❓ Long-term effects: Most supplement trials are 8-12 weeks. What happens after years of consistent practice? The Bottom Line: Your Stress Response Is Different If you're an APOE4 carrier, stress management isn't optional. It's not about feeling calm—it's about reducing the biochemical driver of the disease you're trying to prevent. Your cortisol directly activates genes that produce amyloid-beta. Your HPA axis is more reactive. Your cells are more vulnerable to oxidative stress, mitochondrial dysfunction, and inflammation. But here's the hopeful part: you may respond MORE to the right interventions. Your genetic variant isn't destiny—it's high-stakes. And that means every 20-minute meditation session, every breathwork practice, every day of reduced cortisol matters more. You watched your parent decline. Your story doesn't have to end the same way. Start today: Add 5 minutes of meditation to your morning routine Practice 4-7-8 breathing tonight before bed Research high-quality ashwagandha supplements Track your baseline cortisol this month Join a community that understands You're not alone. 270 APOE4 carriers are doing this work together, comparing notes, and beating the odds. Join The Phoenix Community →Sources Peavy GM, Lange KL, Salmon DP, et al. The effects of prolonged stress and APOE genotype on memory and cortisol in older adults. Biol Psychiatry. 2007;62(5):472-478. https://pmc.ncbi.nlm.nih.gov/articles/PMC2002507/ Gupta V, Khanal A, Wen L, et al. APOE genotype and stress response - a mini review. Lipids Health Dis. 2016;15:121. https://pmc.ncbi.nlm.nih.gov/articles/PMC4960866/ Green KN, Billings LM, Roozendaal B, McGaugh JL, LaFerla FM. Glucocorticoids increase amyloid-β and tau pathology in a mouse model of Alzheimer's disease. J Neurosci. 2006;26(35):9047-9056. https://www.jneurosci.org/content/26/35/9047 Salardini E, Deters KD, Au R, et al. Elevated serum cortisol associated with early-detected increase of brain amyloid deposition in Alzheimer's disease imaging biomarkers among menopausal women: The Framingham Heart Study. Alzheimers Dement. 2025;21(1):e70179. https://pubmed.ncbi.nlm.nih.gov/40271551/ Tene O, Hallevi H, Werbner N, et al. Hypothalamic-pituitary-adrenal (HPA) axis: unveiling the potential mechanisms involved in stress-induced Alzheimer's disease and depression. Cureus. 2024;16(8):e67704. https://pmc.ncbi.nlm.nih.gov/articles/PMC11416836/ Shatenstein B, Ferland G, Belleville S, et al. APOE ε4 carrier status moderates the effect of lifestyle factors on cognitive reserve. Sci Rep. 2024;14:25383. https://pmc.ncbi.nlm.nih.gov/articles/PMC11567825/ Marchant NL, et al. The SCD-Well randomized controlled trial: effects of a mindfulness-based intervention versus health education on mental health in patients with subjective cognitive decline (SCD). Alzheimers Res Ther. 2018;10(1):109. https://alzres.biomedcentral.com/articles/10.1186/s13195-022-01057-w Fincham GW, Strauss C, Montero-Marin J, Cavanagh K. Effect of breathwork on stress and mental health: a meta-analysis of randomised-controlled trials. Sci Rep. 2023;13:432. https://www.nature.com/articles/s41598-022-27247-y Lopresti AL, Smith SJ, Malvi H, Kodgule R. An investigation into the stress-relieving and pharmacological actions of an ashwagandha (Withania somnifera) extract. Medicine (Baltimore). 2019;98(37):e17186. https://pmc.ncbi.nlm.nih.gov/articles/PMC6979308/About The Phoenix Community The Phoenix Community is a tracking and protocol platform for APOE4 carriers committed to preventing Alzheimer's disease. Founded by Kevin (APOE4 4/4), Phoenix helps 270+ members systematically implement evidence-based interventions, track biomarkers, and optimize based on collective data. Learn more at thephoenix.community. Most Newsletters? One-way street.How boring…This is the Phoenix Community after all—so let's make it a two-way street. Got a question? Feedback? Just want to say hi?Hit reply.I read every single one. --- ## Phoenix APOE4 Study: Vagus Nerve Stimulation for Sleep & Stress URL: https://apoe4.co/blog/posts/phoenix-apoe4-study-vagus-nerve-stimulation-for-sleep-stress Published: 2025-11-22T19:32:06+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: community, therapies, sleep Summary: Groundbreaking Phoenix APOE4 study explores vagus nerve stimulation for sleep optimization, revealing innovative stress management strategies for high-risk carriers in a 4-week, risk-free trial. Phoenix APOE4 Study: Vagus Nerve Stimulation for Sleep & Stress4-week study, 41% discount, risk-free trial. Help us prove what works for APOE4 carriers.Dr. Kevin Tran November 22, 2025 Hi friends, Here's the thing about building Phoenix. It's actually stressful as hell. I wake up every night after 4-5 hours. Then my sleep is completely fragmented for the rest of the night. My Oura data looks like a war zone—constant wake-ups, HRV tanking, recovery scores in the gutter. Believe it or not, building Phoenix is one of the most stressful things I've ever done. I value the trust you've all placed in me, and that drives me to deliver as much value as I can, as fast as I can. But this constant stress? It's killing my sleep. And for APOE4 carriers like us, that's dangerous. Why Sleep and Stress Matter More for APOE4 Carriers One night of bad sleep increases amyloid-beta accumulation in your hippocampus—the exact region that gets hammered first in Alzheimer's. The mechanism? Your glymphatic system. During deep sleep, your brain shrinks slightly. Cerebrospinal fluid floods in and washes out metabolic waste—including amyloid-beta and tau proteins. It's like a nightly power-wash for your brain. But here's where APOE4 makes everything worse. Sleep deprivation in APOE4 carriers creates a vicious feed-forward loop. Poor sleep reduces aquaporin-4 (the protein that drives glymphatic clearance), which means more amyloid builds up. More amyloid disrupts sleep even further. Rinse and repeat. The research is brutal. APOE4 carriers under chronic stress show: Higher cortisol levels than APOE3 carriers Worse memory performance Accelerated hippocampal atrophy Increased tau phosphorylation Stress isn't just unpleasant for us. It's neurotoxic. Enter Zenowell: Non-Invasive Vagus Nerve Stimulation I've been researching solutions for months. And I finally found something worth testing. Zenowell uses transcutaneous auricular vagus nerve stimulation (taVNS)—electrical pulses delivered through your ear to activate your parasympathetic nervous system. The "rest and digest" mode. The anti-stress system. Clinical data from real users: 25% improvement in sleep quality within 2-4 weeks 12% better HRV (heart rate variability—a key marker of nervous system health) 45% stress relief28% reduction in inflammation29% improvement in gut motility The device targets the auricular branch of the vagus nerve—the only branch accessible on your body's surface. Unlike neck devices, Zenowell hits 100% of the vagus-innervated region in your ear. Three modes: Sleep, Relax, Meditation. No app required. Works straight out of the box. Phoenix Members Get 41% Off + Risk-Free Trial Here's the deal we negotiated: Regular price: $499 Phoenix study price: $294.48 Savings: $204.52 (41% discount) Money-back guarantee: 30 days, no questions asked Try it for a month. If it doesn't help your sleep, stress, or recovery—send it back for a full refund. We Remain Independent. Always. Phoenix doesn't take affiliate fees or sponsorship money. Period. When partners offer us affiliate commissions, we ask them to pass those savings directly to you as bigger discounts. That's how we got to 41% off. Our only incentive is finding what actually works for APOE4 carriers. What the Study Involves This is a 4-week commitment: Daily 30-second check-ins on the Phoenix app Use Zenowell as directed (20 minutes/day recommended) Track your sleep and HRV with any wearable you already have (optional but encouraged) Complete pre/post questionnaires That's it. Simple, sustainable, and designed to fit into your life. TimelineNovember 25: Live webinar with the Zenowell team—ask anything Enrollment closes: December 4th Study starts: Once you receive your device The Science You Can Review We've compiled the key studies on vagus nerve stimulation, sleep, and Alzheimer's risk in a Google Drive folder here.This Study is Reserved for Phoenix Members If you're not a member yet, you can join while we still have our founding member offer: $499 for lifetime access. We're switching to $499/year soon as we deploy our AI tools (which comes with recurring costs per active member for us). Once we flip the switch, the lifetime offer is gone forever. Why This Matters Right Now Building the future you want—Alzheimer's-free, cognitively sharp at 80, able to recognize your grandchildren—requires managing your biology today. Sleep and stress are two of the biggest modifiable risk factors we have. You can't control your genes. But you can control how you respond to stress and how well you sleep. Zenowell gives us a new tool to do both. I'm testing it myself starting next week. If you want to join the study, reply to this email and I'll send you the enrollment form. Let's beat the odds together. – Kevin PS: Our first medtech study was a home run Last month, 53 members enrolled in our Neuronic study (red light therapy). Early results look strong. This proved something: when we move together, companies pay attention. We're evaluating more partnerships now—photobiomodulation, neurofeedback, vagus nerve stimulation, tDCS. Got a device you want us to test? Email me. If the science is solid and enough members are interested, I'll make it happen. Individually, we're ignored. Collectively, we have leverage. P.P.S.: Have questions before the webinar? Reply to this email. I read every response. Most Newsletters? One-way street.How boring…This is the Phoenix Community after all—so let's make it a two-way street. Got a question? Feedback? Just want to say hi?Hit reply.I read every single one. --- ## Your "normal" lab results aren't normal for APOE4 carriers URL: https://apoe4.co/blog/posts/your-normal-lab-results-aren-t-normal-for-apoe4-carriers Published: 2025-11-18T23:53:35+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: tracking, community, protocols Summary: Decode your bloodwork's hidden risks for APOE4 carriers: Why "normal" lab results can be misleading and how to unlock personalized health insights tailored to your genetic profile. Your "normal" lab results aren't normal for APOE4 carriersUpload your bloodwork. Get APOE4-specific insights.Dr. Kevin Tran November 18, 2025 Hi Phoenix friends,We just launched something you've been asking for… Your blood test is lying to you (here's why) Your doctor says your blood work is "normal."It's not.Let me show you the problem. The 95% problem Most lab ranges come from the middle 95 percent of people the lab considers "healthy." Sounds scientific. Until you realize: The average American is overweight, inflamed, and insulin resistant. So as the population gets sicker, the "normal" range shifts with it. This is why "normal" does not mean optimal.It only means average. And average is sick. Then there's our APOE4 problem Even if lab ranges were based on healthy people... we're not like everyone else. APOE4 carriers have different lipid metabolism. Different inflammatory responses. Different oxidative stress patterns. What's "optimal" for the general population doesn't work for us.Example: ApoB "Normal" lab range: 40-125 mg/dL General optimal: Under 80 mg/dL APOE4 3/4 optimal: Under 70 mg/dLAPOE4 4/4 optimal: Under 60 mg/dL Standard labs won't tell you this.Your doctor doesn't know this.The research exists. But nobody's translated it for you. Until now. The Phoenix Blood Test Analyzer We just launched a module that fixes this. You use your own provider. Your regular doctor. Quest. LabCorp. Private labs like Marek Health or Life Extension. Whoever you trust.Then you upload the results to Phoenix for deep analysis. Why we do it this way: You already have a relationship with your doctor or preferred lab. We're not trying to replace that. We're adding the APOE4-specific interpretation layer that's missing everywhere else. Plus, most members already have 3-5 old blood tests sitting in a drawer. Upload them all. Get insights immediately. 1. Instant biomarker extraction Upload a PDF from Quest, LabCorp, or any lab. AI reads it. Extracts every marker. 30 seconds. 2. APOE4-specific interpretation Here's where it gets real. Not just a number. Context.Why This Matters for APOE4 The science. In plain English. Trend Analysis That's how you know if your interventions are working. 3. Your Phoenix Score One number that tells you: how optimized are you?Breaks down by category: Cardiovascular:MetabolicInflammatoryHormonalNutritionalCognitive It tells you where to focus. Not everything at once. What matters most right now.4. AI-powered recommendations Based on your actual biomarkers, you get: Dietary recommendations:Lifestyle recommendationsSupplement recommendations Not generic advice. Your specific numbers → specific actions.5. APOE4-specific insights This is the killer feature. Every concerning biomarker gets an APOE4-specific explanation: Same blood test. APOE4-specific lens.Not a Phoenix Member yet?Lock in lifetime access to the Phoenix Community: $499 one-time (switching to $499/year soon) What's coming: Community intelligence Right now, the module shows you YOUR data with APOE4-specific ranges. Soon, it shows you what worked for people like you.Example (future state): You see your ApoB is 85 mg/dL. Target: under 60. Click "What works for members like me?" The AI shows:"Based on 47 APOE4 3/4 carriers (age 45-60, baseline ApoB 80-100 mg/dL, similar metabolic profile):Most effective interventions: Zone 2 cardio (200+ min/week): 82% response rate, avg 22% reduction High EPA fish oil (4-5g/day): 68% response rate, avg 18% reduction Very low-carb diet (<75g/day): 71% response rate, avg 19% reduction Seed oil elimination: 54% response rate, avg 12% reduction Your predicted stack: Based on your genetics (APOE4 3/4, MTHFR +/+), baseline markers (TG 145, HDL 48), and lifestyle factors (moderate exercise history), you're likely a high responder to omega-3s and cardiovascular exercise.Predicted outcome: ApoB reduction to 58-64 mg/dL within 12 weeks with Zone 2 (250 min/week) + fish oil (5g/day) + low-carb (<100g/day). Success probability: 76% (based on your cluster) Members in your cluster who tried this combination: Sarah M. (3/4, age 52): ApoB 92 → 61 in 10 weeks David K. (3/4, age 48): ApoB 88 → 59 in 14 weeks Jennifer T. (3/4, age 56): ApoB 95 → 68 in 12 weeks Next blood test recommended: 12-16 weeks" That's the vision. Not just: "Your ApoB is high." But: "Here's what worked for 47 people just like you. Here's your predicted outcome. Here's when to retest." Precision medicine. Powered by community data. The 360-degree health view (what's coming) The blood test module isn't standalone. It's the first piece of a larger system. Here's the full vision: You upload blood tests. Track biomarkers over time. You log interventions. Supplements. Diet changes. Exercise protocols. The AI connects them:"Between March and June, your ApoB dropped 27%.""During that period, you started:" Daily fish oil (4g EPA/DHA) Zone 2 cardio (200 min/week) Eliminated seed oils "Based on 47 members with similar profiles:" Fish oil: 68% saw ApoB reduction (avg 18%) Zone 2: 82% saw reduction (avg 22%) Seed oil elimination: 54% saw reduction (avg 12%) "Your response pattern matches Cluster 3 (high responders to cardio + omega-3).""Next optimization: Try increasing Zone 2 to 250 min/week. Predicted additional 8-12% reduction based on similar APOE4 3/4 carriers in your age group." That's the goal. Not just tracking. Prediction. Not just data. Insights. Not generic advice. What works for people like YOU.Real example (how this plays out): Meet David. 48. APOE4 4/4. Total cholesterol 220 mg/dL. His doctor: "You're in the normal range. Keep doing what you're doing." He joins Phoenix. Uploads the same lab report his doctor just reviewed. We show him: Total cholesterol is misleading. His ApoB is 88 mg/dL. LDL particle count is 1,650 nmol/L. Small dense LDL particles: 720 nmol/L. ALT is 38 U/L. Target for APOE4 4/4: ApoB: Under 60 mg/dL (he's at 88 - 76% above target) LDL-P: Under 700 nmol/L (he's at 1,650 - 136% above target) Small dense LDL: Under 300 nmol/L (he's at 720 - 140% above target) ALT: Under 30 U/L (he's at 38) His doctor said "normal." We showed him he's at massive risk. As a 4/4 carrier with 60% lifetime Alzheimer's risk, these numbers aren't just "suboptimal." They're dangerous. Same blood test. Different interpretation. Life-saving difference. He orders advanced lipid testing from his doctor (NMR LipoProfile). Uploads those results too. Then he looks at what worked for similar 4/4 members: High EPA fish oil (5-6g/day): 18-24% ApoB reduction Very low-carb diet (<50g/day): 22-28% reduction Zone 2 cardio (250+ min/week): 25-35% reduction Elimination of all seed oils: 10-15% reduction He goes aggressive. All five interventions. Tracks everything. 16 weeks later: Gets new blood work from his regular lab. Uploads it.Results: ApoB: 46 mg/dL (down from 88 - 48% reduction) LDL-P: 620 nmol/L (down from 1,650 - 62% reduction) Small dense LDL: 210 nmol/L (down from 720 - 71% reduction) ALT: 24 U/L (down from 38 - normalized) TG: 68 mg/dL (down from 125) HDL: 62 mg/dL (up from 54) Started with low-dose rosuvastatin (5mg) prescribed by his doctor. Combined with lifestyle. Now he's in the 4/4 target zone.The app tells him:"Your response pattern is exceptional. ApoB reduction of 48% places you in the top 15% of responders in your cohort (APOE4 4/4, age 45-55, baseline ApoB 80-100).Analysis of your intervention stack:Zone 2 cardio (270 min/week average): Estimated 18-22% reductionVery low-carb diet (<45g avg): Estimated 15-18% reductionHigh EPA fish oil (5.5g/day): Estimated 12-15% reductionSeed oil elimination: Estimated 8-10% reductionYour ApoB is now at 46 mg/dL - within optimal range for APOE4 4/4 carriers. This represents a 73% reduction in cardiovascular risk and significant reduction in neuroinflammatory burden.Next optimization: Consider adding niacin (extended release, 500mg titrating to 1g) to further reduce Lp(a) if elevated. Members with your profile who added niacin showed additional 15-20% Lp(a) reduction. Monitor liver enzymes monthly if implementing.Cognitive assessment recommended: Establish baseline now that metabolic markers are optimized. This allows us to track if these improvements translate to cognitive protection over time." That's the power. Same labs you're already getting. Different analysis. Better outcomes.We are deploying our own AI toolsPDF extraction - Vision API reads any lab format (Quest, LabCorp, private labs) Pattern recognition - Identifies what changed between tests, flags concerning trends Cohort matching - Finds members similar to you (genetics, age, baseline biomarkers, past interventions) Outcome prediction - Estimates what's likely to work based on your genetics, past responses, and similar members' results This eventually will costs us ~$10/month per active member once all the apps are deployed. That's why we can't keep founder pricing forever. Right now our Founding Member offer is $499 one-time. Lifetime access. Soon: $499/year for new members. We're building AI features that have ongoing costs. The economics changed. Current members? You're grandfathered. Forever. Considering joining? This is your window.Lock in lifetime access now by applying to join the Phoenix Community nowWhat's next (roadmap)Structured Experiments Module Pre-built protocols: Ketogenic diet (APOE4-optimized, not generic keto) Zone 2 training (with heart rate tracking integration) Supplement stacks (evidence-based, tested by members) Track adherence. Measure outcomes. Compare to similar members. Cognitive Assessment Suite Science-backed brain games and cognitive training too for: Executive function Processing speed Working memory Verbal fluency Track cognitive performance over time. Correlate with your interventions. Digital Twin Predictions Upload your genetics (23andMe, AncestryDNA, Nebula). Add your blood work. Log your interventions. The AI builds your "twin" - predicting: Which supplements will work (based on genetics + past responses) Optimal exercise dose (based on age, fitness, APOE status, cardiovascular markers) Diet modifications (based on metabolic markers, inflammatory profile) Expected outcome ranges (what similar members achieved) This is the precision health OS we've been building toward. Not generic advice. Not population averages. What works for YOUR biology. Let’s beat the odds, Kevin Most Newsletters? One-way street.How boring…This is the Phoenix Community after all—so let's make it a two-way street. Got a question? Feedback? Just want to say hi?Hit reply.I read every single one. --- ## Fasting & APOE4: Time-Restricted Eating, Sex Differences, and When It Backfires URL: https://apoe4.co/blog/posts/fasting-apoe4-time-restricted-eating-sex-differences-and-when-it-backfires Published: 2025-11-15T23:18:09+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: protocols, nutrition, research, cognition Summary: Uncover science-backed fasting protocols for APOE4 carriers: Optimize metabolic health, navigate sex differences, and avoid common pitfalls with expert-guided strategies. Fasting & APOE4: Time-Restricted Eating, Sex Differences, and When It BackfiresLonger is not necessarily better.Dr. Kevin Tran November 15, 2025 Hey Phoenix Friends I wanted to share a video I just released on fasting protocols for APOE4 carriers after reviewing the main APOE4 carriers specific studies available out there.. I've spent the last 3 years testing fasting on myself and diving deep into the research. Why I Made This Video: I see a lot of APOE4 carriers doing extreme fasting protocols (OMAD, 20:4, multi-day fasts) thinking "more fasting = more autophagy = more protection." I made the same mistake. But the research shows it's not that simple—especially for women, and especially if you're already under chronic stress. What You'll Learn: 🧬 Why APOE4 brains struggle with glucose but excel with ketones (and what that means for fasting) ⏰ The optimal fasting window based on 2024 research (hint: it's probably shorter than you think) 👩 Sex differences. Women experience 2x higher cortisol response to fasting, and that matters MORE if you're APOE4 🚨 5 red flags where fasting can backfire (chronic stress, poor sleep, peri-menopause, diabetes, eating disorder history) 📊 My personal protocol: 15 hours most days, adjusted based on stress and sleep quality The Research: I cite 11 peer-reviewed studies in the video, including: - 2023 Cell Metabolism study showing time-restricted eating reverses Alzheimer's pathology in mice - 2024 American Heart Association analysis showing <8 hour eating windows = 91% higher cardiovascular death risk - Multiple sex-difference studies showing females respond differently to fasting All sources are linked in the description with direct URLs. Watch Here: If you find it helpful, I'd love for you to share it with other APOE4 carriers who might benefit. We're all in this together, and the more we can learn from each other's experiences and the research, the better our outcomes. Remember: Your family history doesn't define your future. We're not powerless. 💪 — Kevin P.S. If you're a woman with APOE4, I'd especially recommend watching the section on sex differences (starts at 10:00). It changed how I think about fasting protocols entirely. Most Newsletters? One-way street.How boring…This is the Phoenix Community after all—so let's make it a two-way street. Got a question? Feedback? Just want to say hi?Hit reply.I read every single one. --- ## Why cognitive variability predicts Alzheimer's decline better than test scores URL: https://apoe4.co/blog/posts/why-cognitive-variability-predicts-alzheimer-s-decline-better-than-test-scores Published: 2025-11-11T02:15:37+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: research, tracking, cognition Summary: Discover how cognitive variability reveals more about Alzheimer's risk than standard test scores—a breakthrough insight for APOE4 carriers tracking brain health proactively. Why cognitive variability predicts Alzheimer's decline better than test scoresThis changes how we should think about monitoring our brain health.Dr. Kevin Tran November 10, 2025 This changes how we should think about monitoring our brain health.First, monitoring your brain health is critical to track the effectiveness of your interventions. What is tracked can be improved. Without tracking you are basically spinning your wheel.I have written a few articles about tracking on our blog https://apoe4.coIf You’re Not Tracking, You’re GuessingMy Framework for Choosing Which Interventions Are Worth ItOk- back to the video:I just finished analyzing another six presentations from AAIC 2025, and the findings are both sobering and empowering.The core insight: Your "good days and bad days" (or in other words the variability in your cognitive performance) might be a more powerful early warning signal than your average test scores.And here's the part that hit home for me: we as APOE4 carriers show MORE cognitive variability than non-carriers even when we're clinically healthy. Even when traditional testing shows we're "fine."What the research revealed: 📊 Dr. Katie Bangen (UC San Diego) tracked 818 people for 3 years. For APOE4 carriers , high variability at baseline predicted faster decline in real-world functioning (e.g. managing money, taking meds, handling complex tasks) before cognitive tests became abnormal. 📱 Dr. Andy Aschenbrenner (Washington University) used a smartphone app to track people 4x/day for a week. APOE4 carriers had more ups and downs across the week. And here's what's wild: on days when the app showed worse cognition, people had MORE adverse driving events THAT SAME DAY. More hard braking, more speeding, more sudden acceleration. (They analyzed 20,000+ car trips to prove this.)But there's a silver lining: people seemed to know when they were having off days. They avoided risky nighttime driving on low-cognition days without even realizing why.🌍 Dr. Laiss Bertola validated this in 9,000+ Brazilians over 8 years. Higher variability at baseline = higher odds of impairment eight years later.⚠️ Dr. Andrew Kiselica revealed the nuance: variability scores are unreliable in asymptomatic people (mostly just noise), but become highly informative once symptoms appear. This means daily smartphone monitoring might be better for us in the asymptomatic stage.Why this matters for us:Unlike expensive biomarkers ($5K for amyloid PET, $1.5K for CSF testing), variability can be tracked through:✓ Standard neuropsych tests✓ Smartphone apps (minutes per day)✓ Remote monitoring✓ No invasive proceduresMy questions for the community:1. Have any of you noticed patterns in your "good days" vs. "bad days"?2. Would you use a smartphone app to track daily cognitive variability if it were available?3. For those who've had neuropsych testing, did your doctor ever mention your score variability, or just your averages?Most Newsletters? One-way street.How boring…This is the Phoenix Community after all—so let's make it a two-way street. Got a question? Feedback? Just want to say hi?Hit reply.I read every single one. --- ## Phoenix: You qualified a while ago, here's what you missed URL: https://apoe4.co/blog/posts/phoenix-you-qualified-a-while-ago-here-s-what-you-missed Published: 2025-11-08T00:21:04+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: community Summary: And why now is your last chance to lock in founding member pricing. Phoenix: You qualified a while ago, here's what you missedAnd why now is your last chance to lock in founding member pricing.Dr. Kevin Tran November 07, 2025 --- ## What you missed in The Phoenix Community in October URL: https://apoe4.co/blog/posts/what-you-missed-in-the-phoenix-community-in-october Published: 2025-11-07T19:40:07+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: community, research, tracking Summary: Dive into The Phoenix Community's groundbreaking October: 240+ APOE4 carriers advancing cutting-edge research, exclusive studies, and brain health innovations beyond mainstream medicine. What you missed in The Phoenix Community in OctoberResearch breakthroughs, New partnerships, Vagus nerve study launching, 120+ topics discussed, and more!Dr. Kevin Tran November 07, 2025 Hi Phoenix Friends, October was a month of acceleration. While you were watching from the sidelines, our members enrolled in cutting-edge studies, dissected breakthrough research that won't hit mainstream medicine until 2027, and discovered which interventions actually move their biomarkers. Here's what happened while you waited: 🤝 PARTNERSHIPS: The Power of 240+ APOE4 Carriers Moving as OneNeuronic Cohort 1: Closed in Record Time Our first photobiomodulation research partnership with Neuronic exceeded every expectation. Cohort 1 is now full and closed. Members are currently running their 12-week protocols, tracking IL-6, cognitive function, and real-world outcomes. The speed of enrollment proved something crucial: when you give motivated APOE4 carriers access to innovative research, they don't hesitate. Coming Soon: Vagus Nerve Stimulation Study We're launching an exclusive research partnership focused on vagus nerve stimulation for brain health optimization in November. Details dropping in the community first. Pharma Partnerships Advancing to H1 2026 Our discussions with pharmaceutical companies for clinical trial recruitment continue to accelerate. We're targeting H1 2026 for first enrollments in breakthrough therapies. This is what collective power looks like: Early access to trials before public recruitment Baseline data that makes you an ideal candidate Community support through the trial process Shared learnings from members in the same studies Individual patients get ignored. A community of 240+ (and adding 2-4 new members every day) engaged APOE4 carriers gets meetings with pharma leadership.📱 PHOENIX APP: Major November Updates Just Dropped Our app evolved rapidly in October based on member feedback. November updates are now live, including: Blood Test Analysis & Phoenix Score Upload PDFs, get AI-powered analysis in seconds Track 100+ biomarkers with APOE4-specific ranges Receive your personalized "Phoenix Score" Visualize trends and improvements over time Enhanced Supplement Tracker Largest APOE4-specific supplement library Efficacy ratings from real members Side effect tracking Brand recommendations from the community Daily adherence with streak tracking Attribution Wizard (In Development) AI-powered analysis connecting your interventions to biomarker changes Finally answer: "Which of my 15 supplements actually worked?" Data-driven personalization based on YOUR results Members are already using these tools to optimize protocols that took them months to figure out on their own. 💡 WHAT HAPPENED INSIDE THE PHOENIX COMMUNITYThe Pace of Discovery Is Accelerating October brought research revelations that fundamentally change how we think about prevention and treatment. While mainstream doctors are still recommending "eat healthy and exercise," our community dissected: Game-changing drug research that reversed AD in mice using nanoparticles Statistical breakthroughs revealing 43% of "failed" trial patients actually improved (we've been measuring wrong) APOE4-specific mechanisms showing how we transport toxins from gut to brain faster than non-carriers Real-world testing access including pre-FDA clearance p-tau217 blood tests Summary of Most Popular October TopicsRevolutionary Research Members Discussed First: 🔬 Breakthrough Therapeutics Nanoparticles reverse Alzheimer's in mice (actual reversal, not just slowing) Experimental approaches clearing amyloid and tau through novel mechanisms Lecanemab approved by Health Canada (members analyzing real-world data) Stage 3 trial results for APOE4-specific interventions 🧠 APOE4-Specific Mechanisms Revealed How APOE4 blocks the brain's ability to switch from glucose to fat burning (this is HUGE) The gut-brain highway: Why APOE4 carriers transport toxins faster via vagus nerve Why 100% of people with specific brain markers get cognitive decline in 6 years (and what to do about it) 83% protection rate from specific activity combinations 💉 Blood Biomarkers & Testing P-tau217 testing access through CareAccess (before most doctors know it exists) Two FDA-approved tau scans disagree 47% of the time (members learning to navigate this) IL-6 and TNF-alpha tracking for inflammation Advanced lipid panels decoded by the community 🧬 Cutting-Edge Genetics Whole genome sequencing options (Myheritage vs others) CRISPR developments (not 4/4 specific but fascinating) Understanding your full genetic risk beyond just APOE Practical Interventions Members Are Testing: 💊 Supplements & Compounds Rapamycin microdosing discussions and tiny trial results Huperzine A experiences and dosing Melatonin supplementation protocols MOTS-C 12-week self-administration tracking (Week 10 results) Lithium dosing insights from expert interviews 🍽️ Nutrition & Diet N=1 exogenous ketone experiments (BHB Salts vs Ketone IQ vs Delta G) Mediterranean Diet adherence and results Eggs and cholesterol debate for APOE4 carriers (the nuance matters) Meal delivery solutions for busy optimizers 🧘 Lifestyle & Brain Training Kirtan Kriya meditation showing tremendous improvement for APOE4s 40Hz light therapy protocols Vagus nerve stimulation techniques Testosterone for women (neuroprotective properties) 🏡 Environmental Factors Gas stoves and air quality (this affects APOE4 carriers differently) Wireless radiation and oxidative stress Aluminum exposure (Fiji Water discussion) Toxin avoidance strategies Expert Access & Learning: 👨‍🔬 Live Q&As with Leading Researchers The researcher who shook up APOE4 science (live session October 24) Apollo (Bredesen) online event UsAgainstAlzheimers.org advocacy group session Interviews with lithium and rapamycin experts Community Support & Real Talk: 💝 Emotional Resilience "Being APOE4 is expensive" (honest discussion about costs) Updates from members feeling better after difficult periods Weekly goals and accountability posts (October 26-Nov 1) Neurology referral experiences shared All 120+ Discussions by Category📢 Announcements & Updates November App Update: New Features Live + What You Need to Know Neuronic Study Cohort 1 Closed October Monthly Check-Ins 🧬 Research & ScienceBreakthrough Studies: Nanoparticles reverse AD in mice Revolutionary Statistical Models: 43% of "Failed" Patients Actually Improved 100% Get Cognitive Decline in 6 Years With These Brain Markers APOE4 blocks the brain's fuel-switching ability The Gut-Brain Highway: APOE4 Accelerates Transport of Toxic Proteins 83% Protection Rate: The Activity Combo That Beats Alzheimer's APOE4-Specific Research: Apolipoprotein E ε4-dependent associations between carotenoids and cognitive decline Stage 3 trial results showing benefits for APOE4 carriers Cholesterol-lowering drug targets for dementia risk reduction Biomarkers & Testing: CareAccess P-Tau testing access Conference Analysis: Two FDA-approved tau scans disagree 47% of the time IL-6 and TNF-alpha inflammation markers P-tau217 test results and interpretation Blood tests discussion thread 💊 Supplements, Nutrition & MedicationSupplement Discussions: Huperzine A experiences Tiny Rapamycin Trial results MOTS-C 12-Week Self-Administration Summary (Week 10) Melatonin supplementation protocols Vitamin K article insights Nutrition & Diet: N=1 Exogenous Ketone Experiment: BHB Salts vs Ketone IQ vs Delta G Mediterranean Diet adherence Eggs and cholesterol: What are APOE4 substitutes? Meal delivery suggestions Ketone urine strips accuracy Medications & Compounds: Imiprimine and Olanzapine update Lecanemab approval by Health Canada 🧘 Lifestyle Interventions Kirtan Kriya Meditation for APOE4 Prevention (tremendous improvement) 40Hz light therapy protocols Testosterone for Women interview (neuroprotective properties) Grounding/Earthing discussions 💻 Tech, Devices & AI Neuronic Experiences (photobiomodulation) AI summaries of research Using AI as health coach Digital twins and virtual experiments 🧬 Genetics & Testing Whole Genome Sequencing options (Myheritage) CRISPR developments (not 4/4 specific but fascinating) Genetic testing discussions 🏡 Environmental & Lifestyle Factors Gas stove and air quality impacts Wireless radiation, oxidative stress and Alzheimer's Fiji Water and Aluminum exposure Toxins, Pathogens, Heavy metals category discussions 🤝 Community & Support October 26-Nov 1 Weekly Goals and Accountability Post Update since "feeling sad" post Being APOE4 is expensive (real talk) Seeking Functional Medicine Pediatrician Neurology referral experiences 🔥 Why NOW Is The Best Time to Join Here's what members who joined 3 months ago now have that you don't: ✅ 12+ weeks of protocol optimization (they're already seeing biomarker changes)✅ Access to the vagus nerve study launching soon✅ Relationships with 240+ APOE4 carriers who get it✅ A head start on research that won't reach your doctor until 2027✅ Real data from members testing the same interventions you're considering Every week you wait is another week of insights you're missing. The members who joined us in July are now 4+ interventions ahead of where they started. They negotiated better testing prices as a group. They're enrolled in exclusive studies. They're part of something bigger than themselves. 🚀 Limited-Time Founding Member Offer Still Available (But Closing Soon) We're still accepting Founding Members—but this window won't stay open much longer. Right now, you can join with a lifetime membership as a Founding Member. This means permanent access to everything we build, including: AI-powered biomarker analysis Digital twin recommendations Attribution wizard All future app features Once we fully launch our AI features, we're moving to yearly subscriptions. When that happens, the Founding Member lifetime offer disappears forever. Here's What You Get as a Founding Member: ✅ Lifetime access to the Phoenix Community (no recurring fees, ever)✅ Phoenix App access with AI features as they launch✅ Priority enrollment in exclusive research studies✅ Early access to clinical trials and breakthrough therapies (H1 2026)✅ Bulk pricing negotiated through collective buying power✅ Direct connection with 240+ APOE4 carriers, researchers, and clinicians✅ Real-time research translation (not 18-36 months later when it's finally published)✅ Pod matching for accountability and support✅ Expert AMAs with leading longevity researchers Join The Phoenix Community as a Founding Member → Let's beat the odds,Kevin P.S. — Still on the fence? Consider this: In October alone, members discussed 120+ topics that won't reach mainstream medicine for years. That's 4+ discussions per day of cutting-edge insights, real-world data, and practical protocols you could be implementing right now. Join us. Stop watching from the sidelines. →All October Discussions by Topic📢 Announcements & App Updates November App Update: New Features Live + What You Need to Know Neuronic Study Cohort 1 Enrollment Closed October Monthly Check-Ins Complete 🧬 Revolutionary Research BreakthroughsBreakthrough Therapeutics: Nanoparticles reverse AD in mice Revolutionary Statistical Models Reveal 43% of "Failed" Alzheimer's Trial Patients Actually Improved Experimental drug clears 50% of amyloid from AD mouse brains in two hours Lecanemab approved by Health Canada Positive Stage 3 Results for APOE4 trials APOE4-Specific Mechanisms: APOE4 blocks the brain's ability to switch fuels (glucose to fat burning) The Gut-Brain Highway: APOE4 Accelerates Transport of Toxic Proteins from Gut to Brain via Vagus Nerve 100% Get Cognitive Decline in 6 Years With These Brain Markers 83% Protection Rate: The Activity Combo That Beats Alzheimer's Apolipoprotein E ε4-dependent associations between carotenoids and cognitive decline (MIND trial) Blood Biomarkers & Testing Advances: CareAccess P-Tau testing (pre-FDA clearance access) Conference Analysis: Two FDA-approved tau scans disagree 47% of the time, one detects 3-5 years earlier I had 3 p-tau217 tests this year. Here's what happened. Plasma p-Tau can be driven by factors other than abnormal amyloid levels IL-6 and TNF-alpha inflammation markers Blood tests discussion 💊 Supplements, Nutrition & MedicationSupplement Protocols: Huperzine A - Anyone Taking? Tiny Rapamycin Trial MOTS-C 12-Week Self-Administration Summary (Current Week: 10) Is anyone supplementing Melatonin? Interesting article on Improved Vitamin K 30% discount offering on supplements Nutrition & Diet: My N=1 Exogenous Ketone Experiment: Comparing BHB Salts, Ketone IQ & Delta G Mediterranean Diet Eggs provide important nutrients for brain health. But should APOE4's eat them due to the high cholesterol? What are your substitutes? Meal Delivery Suggestions Ketone urine strips - have you found any to be accurate? Medications & Compounds: Anyone hear an update on Imiprimine and Olanzapine? Cholesterol-lowering drug targets reduce risk of dementia Lecanemab approved by Health Canada 🧘 Lifestyle Interventions & OptimizationExercise & Movement: 83% Protection Rate: The Activity Combo That Beats Alzheimer's Mind-Body Practices: Kirtan Kriya Meditation for Alzheimer's Prevention: APOE4s had tremendous improvement Grounding/Earthing discussions Hormones & Brain Health: Testosterone for Women: Great interview from Oct. 21, 2025 with Dr. Kelly Casperson on neuroprotective properties 💻 Technology, Devices & AIMedical Devices: Neuronic Experiences 40Hz light therapy protocols AI & Digital Tools: Using AI? I found a sweet deal AI summaries Digital twins and virtual experiments 🧬 Genetics & Advanced Testing Whole Genome Sequencing (Myheritage) CRISPR use not 4/4 specific but fascinating Genetic testing discussions 23andMe vs other platforms 🏡 Environmental Factors & Toxins Gas stove and air quality New study connects wireless radiation, oxidative stress and Alzheimer's Fiji Water and Aluminum Toxins, Pathogens, Heavy metals discussions 🤝 Community Support & Real Talk 🔥 October 26-Nov 1 Weekly Goals and Accountability Post 🔥 Update since "feeling sad" post Being APOE4 is expensive... (honest discussion) Seeking Functional Medicine Pediatrician Neurology referral experiences How to find a MD ally? 🎓 Expert Sessions & Educational Resources The Researcher Who Shook Up APOE4 Science — Live Q&A This Friday, 10/24/25 Apollo (Bredesen) online event Fantastic interview (lithium, Rapa) Dr. Matt Kaeberline / Jon Berner UsAgainstAlzheimers.org advocacy group session 10-16-2025 Center for Food as Medicine & Longevity Newsletter I am able to refer people for this free one month subscription. Nick Norowitz is a brilliant young scientist who is also a 4/4. 🔬 Research Library & Studies Interesting NeuroAge therapeutics studies biomarkers, genetics and creates a drug with AI specifically for you Very interesting article research on Alzheimer's genetics Digital twins and virtual experiments WEB STUDY: Webinar/Biomarkers If you'd like to join these discussions and stop missing out, apply to join The Phoenix Community here. Onward,KevinMost Newsletters? One-way street.How boring…This is the Phoenix Community after all—so let's make it a two-way street. Got a question? Feedback? Just want to say hi?Hit reply.I read every single one. --- ## The Gut-Brain Highway: APOE4 Accelerates Transport of Toxic Proteins from Gut to Brain via Vagus Nerve URL: https://apoe4.co/blog/posts/the-gut-brain-highway-apoe4-accelerates-transport-of-toxic-proteins-from-gut-to-brain-via-vagus-nerv Published: 2025-11-03T18:15:35+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: research, cognition Summary: Discover how the gut-brain highway accelerates toxic protein transport in APOE4 carriers, revealing groundbreaking insights into Alzheimer's neurodegeneration and potential early intervention strategies. The Gut-Brain Highway: APOE4 Accelerates Transport of Toxic Proteins from Gut to Brain via Vagus NerveNew therapeutical pathway to bypass the BBB!Dr. Kevin Tran November 03, 2025 Just finished analyzing Dr. Mook-Jung's presentation from AAIC 2025, and this one has major implications for us.The gut-brain highway is real. And for APOE4 carriers, it runs faster. 🔬 What the research showed:Dr. Mook-Jung created vagal sensory neurons (the nerve fibers connecting gut to brain) from human stem cells with either APOE3 or APOE4.When they tracked fluorescent-labeled amyloid beta and tau moving through these neurons, BOTH proteins traveled FASTER through E4 neurons compared to E3.The study didn't tell us if having two copies (E4/E4 like some of us) makes it even faster—that's a critical question still unanswered. 🦠 It's not just proteins—it's bacteria too:AD patients have more gram-negative bacteria in their guts. These bacteria produce LPS (lipopolysaccharide)—a toxin that activates inflammation.They found LPS INSIDE amyloid plaques in AD patient brains. Where did it come from?The gut. Via the vagus nerve.When they cut the vagus nerve in AD mice, brain LPS levels dropped significantly. ⏰ And here's the kicker—timing:In mice: Tau showed up in the GUT at 11 months, but wasn't in the BRAIN until 13 months.In human PET scans: Early AD shows high tau in the brainstem (where vagus nerve enters) but low tau in hippocampus.This suggests pathology might START in the gut and SPREAD to the brain. 💊 But there's hope—a therapeutic flip:If the vagus nerve transports toxins FROM gut TO brain......could we use it to transport TREATMENTS from gut to brain?Dr. Mook-Jung proposes packaging drugs in extracellular vesicles that vagal neurons will pick up and deliver to the brain—bypassing the blood-brain barrier.Imagine oral Alzheimer's medications that actually reach your brain. That's the potential here.Full deep dive (27 min):Let's discuss. This could change how we think about early intervention. —KevinSource:Dr. In-hee Mook-Jung"The Gut-Brain Axis in Alzheimer's Disease: Unraveling Pathogenesis and Exploring Novel Therapeutic Strategies"AAIC 2025 Tuesday Plenary SessionMost Newsletters? One-way street.How boring…This is the Phoenix Community after all—so let's make it a two-way street. Got a question? Feedback? Just want to say hi?Hit reply.I read every single one. --- ## Your blood test says 'normal.' But is it optimal for APOE4? URL: https://apoe4.co/blog/posts/your-blood-test-says-normal-but-is-it-optimal-for-apoe4 Published: 2025-10-30T21:17:36+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: community, tracking, supplements Summary: Phoenix App's November update brings APOE4-specific blood analysis, smart supplement tracking, and clinical trial access. See why "normal" lab ranges aren't enough for APOE4 carriers. Your blood test says 'normal.' But is it optimal for APOE4?We built AI that shows APOE4-specific optimal ranges. Plus: see which supplement brands actually work for carriers like you.Dr. Kevin Tran October 30, 2025 Our November App update has just been released, and we are bringing 3 new features! Phoenix friends, Here's something your doctor won't tell you.Pre-diabetic in 1995? = Normal today.Not because we got healthier. Because the "normal range" keeps shifting. Those reference ranges on your blood test? They're based on the 95th percentile of the general population. Which means if 95% of people are declining, the range declines with them. You're not the general population. You're APOE4.And "normal" isn't good enough when you're trying to prevent what's written in your genes. But finding APOE4-specific optimal ranges? Nearly impossible. Unless your doctor specializes in APOE4 (most don't). At The Phoenix we just fixed this problem. Three features that change everything about how APOE4 carriers optimize their health. I added a full demo on Youtube, the link is at the end of this post. Feature #1: AI Blood Test Analysis & APOE4 Specific Insights Upload any blood test.Instead of seeing where you fall in the "normal" range, you'll see APOE4-specific optimal ranges.Here's what you get: Your biomarkers mapped against ranges that actually matter for APOE4 carriers. ApoB. LDL-C pTau-217. Aβ42/40 ratio. GFAP. All the markers that predict what's coming. Bloodwork module in the Phoenix App Then the critical part: personalized intervention protocols. Not generic advice. Specific protocols designed to move YOUR biomarkers from where they are to where they should be. Lower your ApoB from 85 to 60? Here's exactly how.Optimize your inflammatory markers? Here's the protocol. Finally, you'll know which interventions to follow based on your actual data. Then track what actually moved the needle.See every intervention between Blood Test A and Blood Test B on one dashboard. New supplement? Started photobiomodulation? Changed your sleep protocol?You'll know exactly which changes drove your biomarkers up or down. Details for each biomarkers and suggested interventions in the Phoenix AppCurrently in beta. Phoenix members are testing it now.Feature #2: Smart Supplement Tracker Stop guessing which supplement work.Stop wondering if your dosage is right.Stop taking supplements because some podcast mentioned them.Stop blindly picking supplements brands. Long list of 121 supplements in our Phoenix app, filtered by indicationSee what's actually working for APOE4 carriers like you:Average efficacy scores for every supplement (from members taking them) Side effect and efficacy ratings by brand (so you know which brands to take or avoid) Average dosages members are taking What similar carriers are taking based on your profile Get insights on what other APOE4 carriers similar to you are taking. You'll see that Brand A of omega-3 has a 4.2/5 efficacy rating while Brand B sits at 2.8. You'll see that members like you take 2,000mg of resveratrol, not 500mg. Get Insights on most popular and highest rated brands. No more guessing. Feature #3: Early Access to Breakthrough TherapiesResearch portal inside the Phoenix AppClinical Trial Early Access Browse partnerships with pharmaceutical companies. Register interest in trials. Get notified when spots open.Next phase: Automated matching. We'll flag clinical trials you're eligible for based on your biomarkers and profile. I am having advanced discussions with 3 pharma for partnerships coming in H1 2026 to get you the latest innovative therapies ASAP. Because we don’t have time to lose. Group Discounts on Innovative New Medtech Cutting-edge devices usually cost thousands. We negotiate group discounts in exchange for anonymized efficacy data sharing. Members get the device at cost price. Companies get real-world evidence from APOE4 carriers. We generate case studies showing what actually works. And more importantly you know if it works for YOU. Our Neuronic study is ending tomorrow. There is still time to join, link here. Coming in November: Vagus Nerve Stimulation Study Similar to our Neuronic helmet study, we're launching another device trial. This one targets your vagus nerve through auricular stimulation. Early research shows it improves sleep quality and reduces stress. But does it work well for APOE4 carriers specifically? That's what we're testing.More importantly: Does it work for you? We'll share full details in a future post. But if you want early access to the study, spots are opening soon and you can register your interest on our App. Exciting times. Why This Matters Right Now We are moving fast and building for APOE4 carriers around the world.Our founding members are testing them. Giving feedback. Helping us build something that actually works for APOE4 carriers. And they'll never pay another dollar for any of it. Because founding memberships lock in lifetime access. It gives you unlimited lifetime access to everything we build in the future. Every AI feature. Every partnership. Every early access to innovative therapies and medical devices. $499 once. Forever. But here's the thing.AI isn't free to run. It costs us real money. Every single month. For every single member. Take our Digital Twin AI module (coming in 2026). It analyzes your biomarkers, genetics, environment, habits, and existing interventions to predict which protocols will actually work for you. Not generic advice. Personalized predictions based on your data. Estimated cost to run this for one member? ~$10 per month.Now do the math over 20 years: You invest in your health: $499 once Our AI costs: $10/month = $2,400 over 20 years We invest in your health: $1,900 MORE than you paid This is how I thank you for joining the cause early on and believing in our mission to solve APOE4. But here's what's changing. Once our AI features go fully live, we can't keep losing money on every member. We'll move to subscriptions.$49/month. Or $499/year. Founding members? You pay $499 once. Then nothing. Ever. What You Get as a Founding Member:Live today:  Member community Accountability pods with APOE4 carriers like you Direct expert access Supplement tracker with real efficacy data APOE4-specific biomarker analysis Group buying power on cutting-edge devices. In development:  Structured experiments module Digital Twin AI that predicts which interventions work for you, clinical trials database Early access programs with pharma partners Real-world evidence partnerships. No recurring fees. Ever. The window is closing. Lock in founding membership here Here’s the full demo to our new features. KevinFounder, Phoenix Community Most Newsletters? One-way street.How boring…This is the Phoenix Community after all—so let's make it a two-way street. Got a question? Feedback? Just want to say hi?Hit reply.I read every single one. --- ## Red light therapy that clears amyloid in APOE4 brains—join our study by Oct 31 URL: https://apoe4.co/blog/posts/red-light-therapy-that-clears-amyloid-in-apoe4-brains-join-our-study-by-oct-31 Published: 2025-10-25T00:54:04+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: community, therapies, cognition Summary: Breakthrough red light therapy study offers APOE4 carriers hope: $695 off Neuronic helmet to clear brain amyloid, with limited enrollment ending October 31st. Red light therapy that clears amyloid in APOE4 brains—join our study by Oct 3172 APOE4 carriers joined the Neuronic study. $695 off ends October 31st.Dr. Kevin Tran October 24, 2025 Dear Phoenix Friend, A month ago, we announced our groundbreaking photobiomodulation study with Neuronic. The response? 72 Phoenix members have already enrolled. They're getting $695 off the retail price. They're contributing to the largest APOE4-specific red light therapy study ever conducted. And they're taking action now instead of waiting for symptoms to appear. The question is: Will you join them? Last Call: October 31st Due to overwhelming demand, we've extended enrollment one final time. 7 days remaining. After October 31st, this opportunity closes. No exceptions. No extensions. Here's what's at stake. What You're Getting (And What You're Saving) The Neuronic LIGHT 1070nm helmet retails for $1,795.Phoenix members pay $1,100.That's $695 in savings. But here's the critical part: This is cost price from the manufacturer. They're doing this specifically for our APOE4 community. They can't go lower without losing money on every unit. You keep the helmet forever. No rental. No subscription. Yours. Plus, you get during the study: 12 weeks of personalized consultation (bi-weekly 45-minute group office hours) Premium CogniFit account for cognitive assessments PROMIS-7 testing to track your progress Full access to all study results and findings After 3 months, if you don't see measurable improvements? Full money-back guarantee. Zero risk. All upside. Why Red Light Therapy Matters for APOE4 Carriers Let me make this simple. If you're an APOE4 carrier, your brain has three major vulnerabilities: Problem #1: Waste Clearance You have 55-65% reduced ability to clear amyloid-beta and other toxic proteins from your brain. This waste accumulates for decades before symptoms appear. Problem #2: Energy Production Your mitochondria—the power plants in your neurons—are less efficient. Less energy means neurons struggle to function and repair themselves. Problem #3: Inflammation Your brain's immune cells (microglia) activate more easily and stay activated longer. This chronic inflammation damages healthy tissue. Here's what the research shows 1070nm photobiomodulation does: ✓ Activates microglia to clear amyloid deposits (exactly what APOE4 brains need) ✓ Supercharges mitochondrial ATP production by 150-200% ✓ Increases cerebral blood flow and waste removal ✓ Reduces neuroinflammation measurably In one study, healthy adults improved working memory after just 12 minutes of treatment. In older adults, memory task accuracy improved with an effect size of 0.75—that's substantial. In Alzheimer's mouse models, 1070nm light reduced amyloid burden and increased blood vessel density. Most importantly: Starting treatment in early disease stages was significantly more effective than waiting. We don't wait for symptoms. We intervene now. This Is About More Than a Helmet Phoenix Community isn't just about this study. We're building the infrastructure APOE4 carriers desperately need but can't find anywhere else. Diagnostic Partnerships: We're partnering with labs to help you track what works and what doesn't. Biomarkers. Blood work. Cognitive testing. Real data, not guesswork. Pharmaceutical Access: Early access to clinical trials and patient access programs. Connections to researchers developing next-generation therapies. You'll be first in line when new treatments emerge. Phoenix App: Which supplements actually work for APOE4 carriers Optimal dosages based on latest research Brand comparisons and quality rankings Community insights: what 500+ APOE4 carriers are actually taking NEW: Bloodwork analysis with APOE4-specific optimal ranges (releasing next week) Personalized interventions to hit your targets Medical Device Partnerships: More studies like Neuronic. More group buying power. More opportunities to access cutting-edge technology at fraction of retail cost. This is just the beginning. The Founding Member Window Is Closing Right now, you can join Phoenix Community for life with a one-time payment of $499. Do the math: If you're with us for 20 years, that's $2 per month. But here's the truth. As we deploy our AI-powered app and scale our partnerships, our costs are rising. Substantially. We're moving to $49/month or $499/year soon. The founding member lifetime offer ends when we launch the full AI features. That's weeks away, not months. Once we flip the switch, it's gone forever. Now’s your last chance to benefit from our lifetime membership. Here's What You Need to DoStep 1: Become a Phoenix Member The Neuronic study is reserved exclusively for Phoenix members. No membership, no enrollment. Join Phoenix Community ($499 Lifetime) →Step 2: Apply for the Neuronic Study Once you're a member, you'll receive immediate access to the study application. We review applications on a rolling basis and prioritize early applicants. Apply for Neuronic Study (Members Only) →Deadline: October 31st, 11:59 PM PST After that, this opportunity closes. Why This Matters Look, I get it. $1,100 for a helmet seems expensive. $499 for a membership might feel like a commitment. But let me ask you something: What's the cost of waiting until symptoms appear? What's the cost of not knowing which interventions actually work for your APOE4 genotype? What's the cost of trying supplements, therapies, and protocols without data—just hoping something sticks? The 72 members who've already enrolled understand something important: The time to act is now. Not when symptoms appear. Not when a diagnosis forces your hand. Now. They're measuring. Tracking. Building habits. Contributing to research that will benefit thousands of APOE4 carriers. They're taking control. The Bottom Line You have two options. Option 1: Wait. Hope. React when symptoms appear decades from now. Option 2: Join Phoenix. Get the helmet at cost. Participate in groundbreaking research. Access tools and partnerships no one else has. Lock in lifetime membership before prices rise permanently. 72 members chose Option 2 in the first two weeks. What will you choose? Time Remaining: 7 Days Questions? Reply to this email. I read every single one. To your brain health,Dr. Kevin Tran P.S. — The money-back guarantee removes all risk. If the helmet doesn't work for you after 3 months, you get a full refund. The only way to lose is to not try. P.P.S. — I (Kevin) and The Phoenix Community have no financial ties with Neuronic. We receive zero commissions, kickbacks, or affiliate fees. My commitment to you has always been 100% independence and unbiased advice. This is why we don’t have any financial ties with our partners. When there are any affiliate fees, we ask that they are directly passed on as additional savings to our members. Most Newsletters? One-way street.How boring…This is the Phoenix Community after all—so let's make it a two-way street. Got a question? Feedback? Just want to say hi?Hit reply.I read every single one. --- ## 83% Protection Rate: The Activity Combo That Beats Alzheimer's URL: https://apoe4.co/blog/posts/83-protection-rate-the-activity-combo-that-beats-alzheimer-s Published: 2025-10-21T19:26:09+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: research, cognition, exercise Summary: Groundbreaking AAIC research reveals APOE4 carriers can achieve 83% Alzheimer's protection through strategic lifestyle interventions and cognitive resilience strategies. 83% Protection Rate: The Activity Combo That Beats Alzheimer'sAPOE4 Doesn't Mean Decline: 6 Scientists Prove Resilience Is RealDr. Kevin Tran October 21, 2025 Phoenix friends, YOUR GENES ≠ YOUR DESTINY I think after last week's video on A+T+ (that admittedly could be a bit doomy-gloomy), this one comes right in time about how to build cognitive reserve and protective factors.In this groundbreaking AAIC conference session, I analyze findings from 6 leading researchers that fundamentally change how APOE4 carriers should approach brain health:✅ Many APOE4 carriers maintain stable memory across decades✅ Education and midlife health create 8-year cognitive advantage✅ Women preserve memory despite higher pathology burden✅ Specific activity combinations achieve 83% protection accuracy✅ Population-level proof that intervention worksACTIONABLE INSIGHTS (more details in the video):1. Midlife health (50-65) is the critical intervention window2. Combine cognitive, social, leisure, and household activities3. Education provides measurable neuroprotection4. Cardiovascular health especially critical for APOE4 carriersMost Newsletters? One-way street.How boring…This is the Phoenix Community after all—so let's make it a two-way street. Got a question? Feedback? Just want to say hi?Hit reply.I read every single one. Credits: Alzheimer's Association International Conference 2025 Session Chair: Prashanthi Vemuri (Department of Radiology, Mayo Clinic, MN, USA)Roger A. Dixon (University of Alberta, AB, Canada) Session Presenter: Roger A. Dixon (University of Alberta, AB, Canada) - Advancing Research on Diversity and Resilience in Aging and Dementia: Methodological Challenges and Roadmap Recommendations Shireen Sindi (Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Division of Clinical Geriatrics, Center for Alzheimer Research, Sweden; The Ageing Epidemiology (AGE) Research Unit, School of Public Health, Imperial College London, London, United Kingdom, United Kingdom) - The role of hormonal and reproductive events on cognitive aging in a cohort of female civil servants: The Whitehall II Study Prashanthi Vemuri (Department of Radiology, Mayo Clinic, MN, USA) - Integrative Discussion: Clinical Importance and Applied Potential of including Diversity in Resilience Research Elizabeth Muñoz (University of Texas at Austin, TX, USA) - Associations Between Early/Current Neighborhood Deprivation and Midlife Cognitive Functioning: Results from the Colorado Adoption/Twin Study of Lifespan behavioral development and cognitive aging (CATSLife)Gillian Einstein (University of Toronto, ON, Canada) - The role of sex, gender, and SSDH in resilience research Daniel Willie-Permor (Alzheimer's Disease Research Center (ADRC), PA, USA; University of Pittsburgh, PA, USA) - Social, Physical, and Cognitive Activity Patterns and Their Association with Tau and Amyloid Resistance and Resilience --- ## 100% Get Cognitive Decline in 6 Years With These Brain Markers URL: https://apoe4.co/blog/posts/100-get-cognitive-decline-in-6-years-with-these-brain-markers Published: 2025-10-17T20:42:07+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: research, cognition, tracking Summary: Shocking AAIC 2025 research reveals 100% cognitive decline risk within 6 years, but with 15-20 year prevention window and 45% lifestyle-based protection strategies for APOE4 carriers. 100% Get Cognitive Decline in 6 Years With These Brain MarkersA long list of protective factors and what you can do to prevent itDr. Kevin Tran October 17, 2025 Phoenix friends, This was the main presentation at the AAIC 2025, the Welcome Award presentation. It comes with some bad news for many of us, but also a lot of hope.The Bad News First:- In her study, 100% of patient testing positive for amyloid AND tau develop cognitive impairment issues within 6 years- By age 70: 50% of E4/E3 carriers and 90% of E4/E4 carriers have brain amyloid- Women face double vulnerability with inflammation markersBut Here's What Changes Everything: ✅ We have a 15-20 YEAR window to act before symptoms ✅ 45% of our risk is CONTROLLABLE through lifestyleThe Surprises:Mindfulness is the TOP protective factor (not just exercise!)Full list of protective factors in the videoBlood pressure meds protect the brain from amyloidEducation delays pathology even with genetic mutationsNew DORA sleep drugs change brain proteins in just 36 hoursAnd quoting Dr. Villeneuve's directly:"An increased effort needs to be devoted toward finding treatment for APOE4 carriers"Finally, researchers are calling for treatments designed specifically for US, not generic approaches.I break down all the conference learnings here: TAKE ACTION: Join the Phoenix Community to beat the odds and outsmart Alzheimer's →  Credits: Alzheimer's Association International Conference 2025 Sylvia Villeneuve (McGill University, Canada) Most Newsletters? One-way street.How boring…This is the Phoenix Community after all—so let's make it a two-way street. Got a question? Feedback? Just want to say hi?Hit reply.I read every single one. --- ## What you missed in The Phoenix Community in Sep-Oct URL: https://apoe4.co/blog/posts/what-you-missed-in-the-phoenix-community-in-sep-oct Published: 2025-10-16T00:21:35+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: community, tracking, supplements Summary: Exclusive Phoenix Community update: Breakthrough partnerships, app launch, and innovative brain health research for APOE4 carriers, revealing game-changing insights and opportunities. What you missed in The Phoenix Community in Sep-OctRelease of our app, New features, Partnerships, 101 topics discussed, and more!Dr. Kevin Tran October 15, 2025 Hi Friends, I can hardly believe we're already mid-October. This has been an extraordinary month—we've experienced explosive growth, secured crucial funding, and accelerated our mission to serve every APOE4 carrier who wants to take control of their brain health destiny. Here's what happened while you were watching from the sidelines: Partnerships Release of our Phoenix App What happened inside the Phoenix Community 🤝 PARTNERSHIPS: Leveraging Our Collective PowerSuccessful Launch of Photobiomodulation Case Study with Neuronic We kicked off an exclusive research partnership with Neuronic, giving our members first access to discover whether red light therapy could benefit their brain health. Cohort #1 enrollment closes October 21st (hard deadline: helmet received and study started by October 31st). This is the kind of cutting-edge opportunity that only becomes possible when we stand together. Exclusive Access to Innovative Therapies We're in advanced discussions with multiple healthcare companies to secure: Early clinical trial enrollment for promising new treatments Expanded patient access to innovative drugs before they hit the mainstream market Bulk pricing discounts on interventions and biomarker testing Some of these upcoming opportunities are particularly exciting because of their exceptional safety profiles and convenient delivery methods (pills, not infusions). This is what happens when a community has real numbers. We negotiate from strength. We open doors that remain closed to individuals. We turn "not available yet" into "available now." 📱 LAUNCH OF OUR NEW PHOENIX APP FOR APOE4 CARRIERS BY APOE4 CARRIERS The future of personalized brain health optimization just got a major upgrade. Our Phoenix App is now live, and it's already transforming how members track their protocols, stay updated on research, and connect with fellow APOE4 carriers who truly understand the journey. Coming soon: AI-powered features that will analyze your biomarkers, suggest personalized interventions, and help you make sense of the overwhelming amount of research hitting the field every single day. Supplements Tracker Access the largest ApoE4-specific supplement library segmented by health benefits and strength of evidence Find new supplements with efficacy and side effect stats Find the best brands for each supplements Manage daily adherence with calendar tracking Get recommendation based on other members supplements stack that are similar to yours Monthly and Daily Check-Ins Comprehensive health assessments with 20+ metrics Track your journey over time with trend analysis Monitor symptoms, energy levels, and cognitive function Build a detailed health timeline Get access to these app today by applying to join the Phoenix Community!IN DEVELOPMENT - Coming SoonBlood Test Analysis & Phoenix Score Upload PDFs, get AI-powered analysis in seconds Track 100+ biomarkers with ApoE4-specific ranges Receive your personalized "Phoenix Score" Get actionable recommendations for optimization Visualize trends and improvements over time Interventions Dashboard ("My Stack") Unified tracking for supplements, meds, and lifestyle Daily adherence monitoring across all interventions Smart reminders and streak tracking Integration with blood test results Attribution Wizard AI-powered analysis to discover which interventions actually worked Connect the dots between your actions and biomarker changes Understand cause-and-effect in your health journey Data-driven personalization WHAT HAPPENED INSIDE THE PHOENIX COMMUNITYKey Insights You Need to KnowThe pace of breakthroughs is accelerating—and you don't want to miss what's coming next. September and October brought game-changing research that could fundamentally alter how we think about Alzheimer's prevention and treatment. While mainstream media is still catching up, our community has already dissected these findings, shared practical applications, and connected the dots between cutting-edge science and daily actions. Summary of discussions of most popular topics inside the Phoenix CommunityRevolutionary research breakthroughs dominated: Stanford's complete memory restoration in AD models, experimental drugs clearing 50% of amyloid in hours, and new statistical models showing 43% of "failed" trial patients actually improved. Blood biomarkers became more accessible: P-tau217 testing discussions, pre-FDA clearance options, and insights into tau scans disagreeing 47% of the time highlighted the complexity and promise of early detection. Vaccine research gained momentum: Combined shingles and RSV vaccines showed over 30% AD risk reduction, with particularly strong effects in women. Gut-brain connection emerged as a key theme: Fibrinogen's role in brain inflammation and how APOE4 carriers' unique gut bacteria impacts brain health sparked intense discussion. Sleep, supplements, and lifestyle refinements continued: From Lysoveta dosing and nattokinase benefits to protein optimization, grounding practices, and fasting mimicking diets. All discussion by topics below. 🚀 Ready to Stop Reading About It and Start Living It? Every day you wait is another day of insights you're missing, connections you're not making, and optimizations you're not implementing. The members who joined us months ago are now 10+ interventions ahead of where they started. They're negotiating better testing prices. They're enrolled in exclusive studies. They're part of something bigger than themselves. 🔥 Limited-Time Founding Member OfferWe're still accepting Founding Members—but this window is closing fast. Right now, you can join The Phoenix Community with a lifetime membership as a Founding Member. This means you'll have permanent access to everything we build, including the AI-powered features we're about to release. Once our AI features are fully implemented, we're transitioning to a yearly subscription model. When that happens, the Founding Member lifetime offer disappears forever. Here's what you get as a Founding Member:  ✅ Lifetime access to the Phoenix Community (no recurring fees, ever)✅ Access to our new Phoenix App with upcoming AI features ✅ Exclusive research study opportunities (like our Neuronic partnership) ✅ Priority access to early clinical trials and innovative therapies ✅ Bulk pricing discounts negotiated through our collective buying power ✅ Direct connection with thousands of APOE4 carriers, researchers, and clinicians ✅ Real-time research translation (not 18-36 months later) This is your moment. The AI features are coming. The pricing model is changing. The Founding Member window is closing. Join The Phoenix Community as a Founding Member → Don't let another month go by while breakthrough research passes you by. Let’s beat the odds,KevinP.S. — Still on the fence? Consider this: Every person who joined our community three months ago now has access to interventions, studies, and insights that won't reach mainstream medicine until 2026 or later. What could six months of optimized protocols be worth to your future self?All discussions by topic📢 Announcements Launch of our new Phoenix App We're a GO on Neuronic Study + Sep Monthly check ins / Oct Pods 🎁 Perks and Partnerships Neuronic study - Cohort 1 Partnering with Alzheon (Valiltramiprosate) Join our research study: 1070nm Photobiomodulation with Neuronic and get your subsidized device Untitled post (Wendy Rowan, Oct 3) 🧬 ResearchBreakthrough Studies & Clinical Trials: Stanford achieves COMPLETE memory restoration in AD models by blocking metabolic switch + 75% patients have hidden sleep apnea (and it's consequences!) Experimental drug clears 50% of amyloid from AD mouse brains in two hours with a single dose Revolutionary Statistical Models Reveal 43% of "Failed" Alzheimer's Trial Patients Actually Improved Simple Blood Test Detects Alzheimer's 15-20 Years Before Symptoms (P-tau217 + Other New Biomarkers) Conference Analysis: Two FDA-approved tau scans disagree 47% of the time, one detects 3-5 years earlier 3 Hidden Mechanisms of Tau-Driven Neurodegeneration revealed by Cambridge scientists APOE4-Specific Research: Rapamycin for APOE4 Some Apoe4 color and research I received from Dr. Greicius at Stanford earlier this year Cognitive reserve protects mood/behavior, not just memory + Insights on how to build your own cognitive reserve no matter your age Your Gut Bacteria Controls Your Brain (and Why APOE4 Carriers Stand Apart) APOE4/4 in the news - what would scientists do? Vaccine & Prevention Research: Vaccine for shingles and rsv shown to reduce Ad risk by over 30% in combination (20% if only taking shingles vaccine) Stronger effect in women Protein & Biomarker Research: 97% of blood-induced brain inflammation comes from ONE protein (fibrinogen) A protein in the brain called KIBRA may be able to rescue later stage disease Plasma p-Tau can be driven by factors other than abnormal amyloid levels Diet & Lifestyle Research: Mediteranian diet reduces AD risk especially in apoe4 carriers, highest effect in homozygots (more than 35%) 100 grams protein a day, but low fat? How? General Research: Interesting summary and graphics from Scientific American on the 138 ALZ drugs currently under clinical trials Interesting talk and AD hypothesis Very interesting article research on Alzheimer's genetics Interesting NeuroAge therapeutics studies biomarkers, genetics and creates a drug with AI specifically for you Dr. Bruce Yankner interviewed regarding lithium research by Katie Couric Peter Attia summary of Lithium research Digital twins and virtual experiments Mind Crowd Study! Pass it along! Huntington's Breakthrough Lessons from living until 117 WEB STUDY: Webinar/Biomarkers USC new funding News out of Stanford:Rethinking Alzheimer's Biometric scan DMSO for Alzheimer's/ Dementia Article Statin benefits for AD for APOE4/4 carriers? Do we need a section for AD Trials & exclusion factors 💊 Supplements, Nutrition, and MedicationOmega-3 & Phospholipids: Lysoveta optimal dosing Supplements: Huperzine A - Anyone Taking? Anyone supplementing with Creatine? Nattokinase: A Natural Ally for Brain Health in APOE4 Carriers Nutrition & Diet: Exogenous Ketones for brain fog and energy crashes Anyone else done Prolon's Fasting Mimicking diet? Let me share a little about me as I cross post here with the biomarkers post Common Cold Medications: Bristol Myers Squibb's Anti-MTBR-Tau-Targeting Antibody, BMS-986446, Granted Fast Track Designation by U.S. FDA for the Treatment of Alzheimer's Disease Statin causing me to overabsorb now? Supplement Sourcing: 30% discount offering on supplements Favorite Krill Oil? 🏃 Sports, Sleep, and Stress Management Calculate heart rate zones? Thoughts on Grounding/Earthing? 🔬 Biomarkers, Tracking, Monitoring Anyone get any Brain Key reports? Let me share a little about me Free cholesterol test Plasma p-Tau can be driven by factors other than abnormal amyloid levels Pre FDA clearance tau-related blood test Quest p-tau217 plasma result Got my Boston Heart results. Who can help decipher this? I found cheaper cholesterol testing! 💻 Tech and Medical Devices Neuronic Experiences Using AI as a health coach - huge success and some tips! 🧬 Genetics Apoe4 Subset: Exploring Distinct Familial Trajectory Anyone who's done sequencing.com that can help me with a question? Any experience with TellmeGen WGS? Dr. Ben Lynch - Dirty Genes 23andMe Total Health vs Bredesen's Apollo 💝 Mental Health & Emotional Resilience Considering lower face and neck lift for 54th bday present to myself. Having apoe 4 4, makes me totally want to keep looking young. Update since "feeling sad" post Feeling sad... 🤝 General and Off Topic ketone urine strips - have you found any to be accurate? Fragilized teeth due to supplements? South Africa and Israel How to find a MD ally? Personality test very on point :) 🔬 Experiments and Open Journal My N=1 Movement Experiment If you'd like to join the discussion, apply to join the Phoenix Community here.Onward,  Kevin --- ## Revolutionary Statistical Models Reveal 43% of "Failed" Alzheimer's Trial Patients Actually Improved URL: https://apoe4.co/blog/posts/revolutionary-statistical-models-reveal-43-of-failed-alzheimer-s-trial-patients-actually-improved Published: 2025-10-13T02:00:43+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: research, cognition Summary: Groundbreaking AI analysis reveals hidden success: 43% of "failed" Alzheimer's trial patients showed dramatic improvement, transforming clinical trial interpretation for APOE4 carriers. Revolutionary Statistical Models Reveal 43% of "Failed" Alzheimer's Trial Patients Actually ImprovedThis changes EVERYTHING about clinical trials... Dr. Kevin Tran October 12, 2025 Hi Phoenix friends,I just analyzed presentations from 6 different research teams at AAIC 2025, and what they discovered will blow your mind:43% of patients in a "FAILED" Alzheimer's trial actually improved dramatically - their treatment effects were DOUBLE what approved drugs achieve. They were just hidden when all patients got averaged together.Think about what this means for us:- Drugs dismissed as failures might work perfectly for APOE4 carriers- Trials specifically for our genetic profile are becoming feasible (60-70% smaller!)Dr. Lei Liu from Washington University proved this using machine learning on old trial data. The FDA is actively supporting these approaches - they just approved new imaging guidelines last month.I break down all 6 breakthroughs in this Youtube videoKey takeaway: We're not waiting for miracles anymore. The math proves that precision medicine for APOE4 carriers is happening NOW. And this is what we are building towards with the Phoenix Community. Credits: Alzheimer's Association International Conference 2025 Session Chair(s): Sue Jane Wang (Division of Biometrics I, US Food and Drug Administration, MD, USA)Heather M. Snyder (Alzheimer's Association, IL, USA) Session Presenter: Lei Liu (Division of Biostatistics, Washington University in St Louis, MO, USA) - Subgroup Identification in Alzheimer’s Disease Trial Viswanath Devanarayan (Eisai Inc., NJ, USA; University of Illinois Chicago, IL, USA) - Baseline predictions of PACC progression trajectories in preclinical AD improve the precision and power of treatment effect assessments Yan Li (Washington University in St. Louis, MO, USA) - Primary Endpoint and Analysis Model for Prevention Trials with Participants with Preclinical AD: Lessons Learned from the DIAN-TU Platform Trial Kun Jin (Anavex Life Sciences Corp., NY, USA) - A Novel Linear B-Spline Mixed Effect Model for Alzheimer’s Disease Clinical Study Data Jinglin Zhong (Alector, CA, USA) - Beyond A Single Study Visit: Lesson Learned from the AD Clinical Trials John Lawrence (Division of Biometrics I, US Food and Drug Administration, MD, USA) - Discussion of Perspectives on Various Innovative Statistical Methodologies for Alzheimer’s Disease Clinical Trials --- ## Conference Analysis: Two FDA-approved tau scans disagree 47% of the time. One is right. URL: https://apoe4.co/blog/posts/conference-analysis-two-fda-approved-tau-scans-disagree-47-of-the-time-one-is-right Published: 2025-10-08T21:26:09+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: research, tracking, cognition Summary: Breakthrough tau PET scan research reveals critical detection differences: One tracer can catch Alzheimer's 3-5 years earlier, transforming early intervention strategies. Conference Analysis: Two FDA-approved tau scans disagree 47% of the time. One is right.Always be sure to check which tracers they are using for you tau PET scansDr. Kevin Tran October 08, 2025 Just analyzed six presentations from the Imaging in Neurodegenerative Diseases conference. The findings completely change how we understand Alzheimer's detection:The Data- "Concordance is only 47% between tracers" - Dr. Andreia Rocha on MK-6240 vs Flortaucipir- "MK is always one step ahead" - detecting tau 20-30 centiloids (3-5 years) earlier- "Cortical thickness may increase in early stages" - Dr. Ting Qiu's 10-year study showing biphasic patternWhy This Matters:1. If you're getting tau PET, the tracer choice determines whether problems are caught2. Brain enlargement before shrinkage = missed intervention window3. Pharmaceutical companies have already chosen MK-6240 for trialsThe Brain Drainage Discovery:Dr. James LeFevre (Vanderbilt) presented DOORS tool - 96% accurate at detecting enlarged perivascular spaces (failed brain waste clearance) years before symptoms.Action Items:- Ask which tau tracer if getting PET scan- P-tau217 blood test available ($300-400)- Standard MRI can show drainage problemsThe video covers:- All six presentations analyzed- Why scans disagree (different tau conformations)- Three distinct Alzheimer's patterns- What this means for early detectionThoughts on the biphasic brain volume pattern? Anyone else surprised by the scan disagreement rate?Edit: Industry consultant at conference confirmed pharma companies are using MK-6240 exclusively for trials now. --- ## The Phoenix App for APOE4 carriers is here URL: https://apoe4.co/blog/posts/the-phoenix-app-for-apoe4-carriers-is-here Published: 2025-10-04T20:12:00+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: community, tracking, supplements Summary: Launch the Phoenix App: Exclusive Community Supplement Tracker for APOE4 Carriers, with real-time insights and personalized intervention strategies from members sharing their breakthrough health experiences. The Phoenix App for APOE4 carriers is here Founding Member pricing ends when the apps go live. This is your last call.Dr. Kevin Tran October 04, 2025 Dear Phoenix Friends,I have some news. After months of late nights, debugging sessions, and probably too much coffee (ruining my sleep score)…the Phoenix App is finally live. Not all of it. But the first piece just went out to our members, and I wanted you to see what we're building. Here's what just launched: The Community Supplement Tracker.A living database where Phoenix members share exactly which supplements they take, at what dosages, which brands, and whether they're actually finding them useful or not. No more guessing. No more "I think I read somewhere that..." Just real data from real people with APOE4, testing interventions and sharing what works. This is Phase 1. And honestly, it's still rough around the edges. There are bugs. Things will break. But our members are already in there, testing, reporting issues, and helping us make it better. Because that's what we do: we build this together. But this is just the beginning. Here's what's coming next, and why I'm so excited I can barely sleep: Blood test analyzer that detects optimal ranges specifically for APOE4 carriers (not the generic reference ranges your doctor uses) and suggests interventions to correct anything out of range.Health dashboard that captures everything in one place—biomarkers, wearables, medical records—all automatically synced. A true 360° view of your health and progression.Structured experiment builder so you can run your own protocols with scientific rigor and actually know whether an intervention works for YOU (not just "people in general").Digital twins that predict which interventions are most likely to work for your specific profile based on your genetics, environment, habits, and baseline data. This is the future we've been talking about. Personalized, precise, evidence-based prevention. Not someday, but now. Here's the thing. Building this costs real money. AI costs. Server costs. Development costs. And honestly, our simulations show that at $499 for our current lifetime Founding Membership, we'll actually lose money long-term once these apps are fully deployed. Which means this is the last call.We're in the final days of the Founding Member offer. Once these apps go live to the full community, we're moving to a subscription model: $49/month or $499/year. This is for the Phoenix to become fully sustainable. If you've been on the fence, this is your moment. Join us now at $499 lifetime, and you'll have access to everything we build—forever. The supplement tracker. The blood test analyzer. The experiment builder. The digital twins. All of it. This wouldn't be possible without our community. Special thanks to our members, who are giving feedback, comments, actually helping code and debugging. We're building the future of APOE4 prevention. Not in a lab. Not in some pharma company. Right here, with you. If you want to be part of this—if you want access to tools that don't exist anywhere else, built by and for people who refuse to accept "inevitable" decline—this is your moment. Apply to join The Phoenix Community - Founding Member Rate ($499 Lifetime) Once this offer closes, it's gone. See you inside,Kevin P.S. Still not sure? Hit reply and tell me what's holding you back. I read every email. --- ## 3 Hidden Mechanisms of Tau-Driven Neurodegeneration revealed by Cambridge scientists URL: https://apoe4.co/blog/posts/3-hidden-mechanisms-of-tau-driven-neurodegeneration-revealed-by-cambridge-scientists Published: 2025-10-02T19:31:25+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: research, cognition Summary: Breakthrough Cambridge research reveals 3 shocking tau mechanisms driving neurodegeneration, with critical insights for APOE4 carriers and potential early Alzheimer's intervention strategies. 3 Hidden Mechanisms of Tau-Driven Neurodegeneration revealed by Cambridge scientistsDr. Kevin Tran October 02, 2025 Dr. Spillantini worked alongside Nobel laureates (Adam Klug, Max Perutz, Cesar Milstein) to first identify tau as the core component of neurofibrillary tangles. This was the discovery that defined Alzheimer's pathology. What her decades of research reveals is shocking: tau doesn't just kill neurons directly. It hijacks our brain's support system in three devastating ways. KEY MECHANISM #1 - Hyperphosphorylation: → Normal tau: 2-3 phosphorylation sites stabilizing microtubules → Alzheimer's tau: up to 45 phosphorylation sites → Hyperphosphorylated tau detaches, accumulates, aggregates into paired helical filaments → Process starts earlier and accelerates faster in APOE4 carriers KEY MECHANISM #2 - Non-Cell-Autonomous Toxicity: → Astrocytes become dysfunctional WITHOUT direct tau infection → Stop producing thrombospondin critical for synapse formation → Release abnormal cytoplasmic proteins they shouldn't secrete → Transplanted healthy astrocytes rescue neuronal death This reveals tau doesn't just kill neurons directly: it sabotages the support system. KEY MECHANISM #3 - Phagoptosis (The Most Disturbing): → Tau-stressed neurons expose phosphatidylserine while still ALIVE → Microglia misinterpret this as "eat me" signal → Consume living neurons that might have been salvageable → Digesting tau-filled neurons spreads tau fragments to new cells → Microglia then become senescent and dysfunctional Think about this cascade: neurons eaten alive → tau spreads → microglia fail → immune system exhausted. VALIDATION - MAPT Mutations: → Mutations in tau gene (MAPT) cause frontotemporal dementia → No amyloid pathology needed → Proves tau alone drives neurodegeneration → Different isoform ratios cause different diseases (AD, Pick, PSP, CBD) BREAKTHROUGH - Brain Organoid Models: → Human iPSC-derived cortical organoids → Infected with tau seeds from actual Alzheimer's brains → Develop abundant tau aggregates by day 129 → Prove prion-like templated seeding - tau recruits normal tau → Platform for testing interventions in human tissue WHAT THIS MEANS FOR APOE4 CARRIERS: Tau spreads faster in APOE4 backgrounds Microglial dysfunction more pronounced Multiple intervention points identified Not just "stop tau" but "rescue support systems" THE PARADIGM SHIFT: We're moving from "tau tangles kill neurons" to understanding: Astrocyte failure prevents synaptic support Phagoptosis eliminates salvageable neurons Prion-like spread propagates pathology Immune burnout removes defensive capabilities Each mechanism is a potential therapeutic target. TAKE ACTION: Join the Phoenix Community to beat the odds and outsmart Alzheimer's → Get the free ebook: Essential Guide to Thriving with APOE4 → Full conference analysis with speaker clips: Credits: Alzheimer's Association International Conference 2025 Researchers: Basic Science and Pathogenesis Maria Grazia Spillantini (University of Cambridge, United Kingdom) The Multiple Facets of Tau Pathology --- ## Neuronic x Phoenix Study - We are Live! URL: https://apoe4.co/blog/posts/neuronic-x-phoenix-study-we-are-live Published: 2025-09-25T21:48:54+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: community, therapies, tracking Summary: Next steps and how to get your device Neuronic x Phoenix Study - We are Live!Next steps and how to get your deviceDr. Kevin Tran September 25, 2025 --- ## Phoenix: Last Call for Red Light Therapy Study and Lifetime membership + Our New App URL: https://apoe4.co/blog/posts/phoenix-last-call-for-red-light-therapy-study-and-lifetime-membership-our-new-app Published: 2025-09-25T21:02:49+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: community, therapies, supplements, tracking Summary: Breakthrough photobiomodulation study offers APOE4 carriers a limited chance to enhance brain health with red light therapy technology at unprecedented subsidized rates. Phoenix: Last Call for Red Light Therapy Study and Lifetime membership + Our New AppOur new app for Supplements Insights releases next week Dr. Kevin Tran September 25, 2025 Dear Phoenix friends, Our Photobiomodulation Study is Oversubscribed but Still Open For a Few Days 64 ApoE4 carriers just joined our Neuronic photobiomodulation study (read more about it here). We were aiming for 5-15 members and got such an overwhelmingly positive response!! This is great for all future partnerships (read more about upcoming partnerships below)You can still participate and claim up $645 subsidy off the device (from $1,795 to $1,150, this is Neuronic’s break even price), keep a 3-month money-back guarantee, and get a paid CogniFit account to track baseline and week-12 cognition. Who it is for: ApoE4 carriers that qualify (see form below)Time: about 10 minutes per day for 12 weeksWhat you get: $645 device subsidy (device is yours to keep afterwards), 3-month guarantee from Neuronic, CogniFit testing Join the study (for Phoenix Members only) New Phoenix App Feature - Supplements Module We are releasing next week our first member tool: the Supplements Module. Get insights on: What percentage of the community uses each supplement How they rate effectiveness How they rate side effects How many continued versus stopped taking it Which brands are recommended Link to discuss the supplement with the community Next, you will see “members like you” insights. For example: “43 members with a similar profile take creatine at 15 g per day and rate it 4.5/5 in efficacy, and 1/5 for low side effects” A first view demo on the new app (dummy data)Modules Coming Next: Bloodwork Module. Upload labs, see ApoE4-specific targets, and get ranked interventions to move out-of-range markers into range. Experiment Module. Run step-by-step protocols with baseline, intervention, and a 2 to 3 month re-test, so you only keep what measurably helps. On partnerships, we are advancing our discussions to collaborate with a Pharma developing a pill for ApoE4 carriers. We expect to support clinical trial recruitment and generate real-world evidence with members. this is very exciting as it is one of the molecules that we have covered extensively. We are under NDA, but if you want early updates, join the community and you will be first to hear. Now is the best time to join the Phoenix before we close the Founding Member offer for ever We are retiring the $499 Founding Member Lifetime Membership early October and moving to $499 per year after we roll out the first module to everyone. Apply to Join The Phoenix (Founding Member - Lifetime for $499) Questions? Just reply. I read every message. Let’s beat the odds,Kevin --- ## Your Gut Bacteria Controls Your Brain URL: https://apoe4.co/blog/posts/your-gut-bacteria-controls-your-brain Published: 2025-09-17T23:04:06+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: research, nutrition, cognition Summary: Discover how gut bacteria control brain health for APOE4 carriers: Breakthrough research reveals targeted diet strategies to boost protective microbes and slow cognitive decline. Your Gut Bacteria Controls Your Brain and Why APOE4 Carriers Stand ApartDr. Kevin Tran September 17, 2025 Phoenix friends,Five researchers just presented game-changing findings about our gut bacteria... I've been analyzing this multi-speaker conference session on diet and brain health, and what they discovered specifically about us is both sobering and hopeful. Dr. Fernando from Australia studied our gut bacteria at the PRECLINICAL stage (before symptoms) and found: "APOE4 carriers have different bacteria and different representation of organisms." We have FEWER beneficial bacteria like Lactobacillus and Bifidobacteria. The study didn't differentiate between those with one or two copies, but the pattern is clear. BUT HERE'S THE HOPE: Hui Chen's 10-year study proved the MIND diet slows brain shrinkage by 20%. That's 2-3 years of preserved cognition. And Dr. Ngouongo showed that Life's Essential 8 (especially diet, blood sugar, avoiding nicotine) directly increases protective bacteria. The key insight from Dr. Fernando: Middle-aged adults (45-65) have the HIGHEST levels of protective Oscillibacter bacteria. This is our optimal window. Dr. Denier-Fields connected it all: Diet-driven metabolites explain 20-29% of Alzheimer's biomarker variance. What we eat literally changes our brain pathology markers. KEY FINDINGS APOE4 carriers have fewer beneficial bacteria (study didn't differentiate hetero/homo) MIND diet adherence = 20% slower gray matter decline over 10 years Middle-aged adults (45-65) have highest levels of protective Oscillibacter Diet metabolites explain 20% of p-tau217 variance TAKE ACTIONJoin the Phoenix Community to beat the odds and outsmart Alzheimer's → Get the free ebook: Essential Guide to Thriving with APOE4 → Full analysis:Credits All credits to the AAIC 2025 (Alzheimer's Association International Conference) and its researchers. Session Chairs: Jennifer J. Manly (Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Vagelos College of Physicians and Surgeons, Columbia University, NY, USA) Hui Chen (Zhejiang University School of Medicine, Zhejiang, China)**Session Presenters:  Yannick Joel Wadop Ngouongo (Glenn Biggs Institute for Neurodegenerative Diseases, University of Texas Health Science Center at San Antonio, TX, USA) - Gut Microbiome Diversity as a Mediator Between Life's Essential 8 Adherence and Cognitive Function Hui Chen (Zhejiang University School of Medicine, Zhejiang, China) - Adherence to the MIND diet and longitudinal brain structural changes over a decade: evidence from the Framingham Offspring cohort Ameya Patwardhan (Lawson Research Institute; Parkwood Institute, ON, Canada) - bioMIND-A Novel Approach to Integrating Biomarkers in the Diagnostic Workup for Alzheimer’s Disease Warnakulasuriya M.A.D.B. Fernando (Edith Cowan University, Western Australia, Australia; Australian Alzheimer's Research Foundation, Western Australia, Australia) - The Gut-Brain Connection: How Age, Sex, and APOE ε4 Influence Probiotic Balance in Early Alzheimer’s Disease Diandra N. Denier-Fields (University of Wisconsin-Madison, WI, USA) - Diet-Driven Metabolite Patterns Link the MIND Diet to Dementia Biomarkers Deepika Dinesh (Department of Public Health, University of Massachusetts Lowell, MA, USA) - Variations in the Gut Bacteriome and Virome Associated with Cognitive Function in Puerto Rican Adults --- ## Join our research study: 1070nm Photobiomodulation with Neuronic and get your subsidized device URL: https://apoe4.co/blog/posts/join-our-research-study-1070nm-photobiomodulation-with-neuronic-and-get-your-subsidized-device-17c7 Published: 2025-09-15T19:29:22+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: research, therapies, cognition Summary: Breakthrough photobiomodulation study offers APOE4 carriers a chance to enhance brain health with cutting-edge red light therapy technology at unprecedented discounts. Join our research study: 1070nm Photobiomodulation with Neuronic and get your subsidized deviceSave up to $645 on your Red Light Therapy device by participating in the studyDr. Kevin Tran September 15, 2025 Dear Phoenix Community, What if shining specific light wavelengths on your brain for just 10 minutes a day could measurably improve your cognitive function, reduce inflammation, and enhance cellular energy production? This isn't science fiction. It's photobiomodulation, and we've secured an extraordinary opportunity for Phoenix members to access this technology at unprecedented prices while contributing to groundbreaking APOE4 research. What Is Photobiomodulation? The Science Made Simple Photobiomodulation (PBM) uses specific wavelengths of near-infrared light to stimulate cellular processes in your brain. Think of it as "feeding" your neurons with light energy. When 1070nm light penetrates your skull (yes, it goes right through), it: Supercharges mitochondria → More ATP (cellular energy) production Triggers nitric oxide release → Better blood flow and waste clearance Reduces neuroinflammation → Shifts harmful microglial activation patterns Enhances brain connectivity → Improved neural communication What the Research Shows (Why This Matters for Us)Your Brain Works Better University of Texas researchers found that healthy adults who used 1070nm light for just 12 minutes improved their working memory capacity - the ability to hold and manipulate information in your mind (Zhao et al., Science Advances, 2022). In older adults specifically, accuracy on challenging memory tasks improved significantly with an impressive effect size of 0.75 (Yang et al., NeuroImage, 2025). It Actually Clears Amyloid In Alzheimer's mouse models, 1070nm light activated the brain's cleanup cells (microglia) to remove amyloid-beta deposits AND increased blood vessel density - both crucial for brain health. The study noted: "1070-nm light pulsed at 10 Hz can reduce the Aβ burden via eliciting microglia activation" (Tao et al., Light: Science & Applications, 2021). For APOE4 carriers who have 55-65% reduced waste clearance, this is exactly what we need. Early Use = Better Results The same study found that starting treatment in early disease stages was significantly more effective than waiting. Given that APOE4 carriers can have brain changes decades before symptoms, this supports our prevention-first approach. Translation: This isn't just "wellness tech" - it's showing measurable improvements in memory, brain cleaning, and blood flow in peer-reviewed research. Exactly what APOE4 brains need. Sources: https://neuronic.teamaligned.com/room/689502c3609f41f87c242267/overview?avk=9bf41311 📺 Watch our detailed Q&A with Chris from Neuronic explaining the science: https://www.youtube.com/watch?v=JJPIy204OC8🔬 Learn more about the technology: https://www.neuronic.online/The Phoenix-Neuronic Research Partnership We're launching a 12-week pilot study specifically for APOE4 carriers in our community. This is citizen science at its finest—real people generating real data that could change how we approach brain health. Phoenix Group Buying Power in Action The more participants we recruit in this study, the more savings for everyone. Pricing Tiers (Complete Package):5 participants: $1,500 each (save $295) 10 participants: $1,250 each (save $545) 15 participants or more: $1,150 each (save $645) Regular retail price: $1,795EDIT: We actually have surpassed the 15 participants threshold in 3 hours! Which means we are all unlocking the $645 discount. Working with neuronic to see if we can setup some stretch goals.What's Included in Your Research Package: ✅ Neuronic LIGHT 1070nm helmet (yours to keep forever)  ✅ 12 weeks of personalized consultation support  ✅ Premium CogniFit account for cognitive assessments  ✅ Bi-weekly check-ins with the Neuronic team (45 min once every 2 weeks, grouped office hours format) ✅ Customized protocols based on your individual response  ✅ Full access to all study results and findings  ✅ Contribution to research benefiting all APOE4 carriers Zero Risk Guarantee Neuronic offers a 90-day full satisfaction guarantee for customers in North America and the EU. If the device doesn't work for you, simply send it back within 90 days for a complete refund. No questions asked. What You'll Need to DoRequired: Use the device 5x per week (15-30 minutes per session) Complete weekly symptom surveys (10 minutes) Take cognitive assessments via CogniFit (baseline, week 6, week 12) Track your usage and any observations in a simple log  Provide testimonials about your experience Recommended: Blood tests for inflammatory markers (TNF-alpha and IL-6) at baseline and week 12 Share wearable device data (sleep, HRV, activity) Timeline Commitment: Week 0: Baseline assessments and device training Weeks 1-12: Daily use with weekly check-ins Week 12: Final assessments and feedback session Full Transparency: I (Kevin) and The Phoenix Community have no financial ties with Neuronic. We receive zero commissions, kickbacks, or affiliate fees. My commitment to you has always been 100% independence and unbiased advice. This is why we don’t have any financial ties with our partners. When there are any affiliate fees, we ask that they are directly passed on as additional savings to our members.  Who Should Apply?You're an ideal candidate if you: Are a confirmed APOE4 carrier (e3/e4 or e4/e4) Are between 25-75 years old Can commit to 12 weeks of participation Want to contribute to meaningful research Are ready to take proactive steps for brain health You should NOT apply if you have: History of seizures Metal implants in the head Active brain tumor Recent brain bleed (within 3 months) Pregnancy or planning pregnancy 🔓 Not a Phoenix Member Yet? This pricing and study is exclusive to Phoenix members. The math is simple: Phoenix Founding Member is current at $499 Lifetime (PS: are phasing this out in a month and will transition to a yearly subscription model, so now’s the best time to join us and benefit from this lifetime deal) Your savings just on this study: $295-$645 (and there are more partnerships to come!) Your membership pays for itself Join Phoenix Now → Then apply for the study. ❓ Frequently Asked QuestionsQ: When do I pay? After enrollment closes and we confirm final group pricing. You'll know the exact amount before payment. Q: Can I travel during the study? Yes! The device is portable. Maintain your protocol wherever you go. Q: Is there any consent form?You will need to sign this consent form before starting the study ⏰ Applications Start today and Close in 7 Days Don't wait. The sooner we hit our numbers, the better the price for everyone. APPLY NOW FOR THE STUDYShare this with other APOE4s you know! (remember: more participants = lower cost for everyone!) --- ## Stanford achieves COMPLETE memory restoration in AD models by blocking metabolic switch + 75% patients have hidden sleep apnea (and it's consequences!) URL: https://apoe4.co/blog/posts/stanford-achieves-complete-memory-restoration-in-ad-models-by-blocking-metabolic-switch-75-patients Published: 2025-09-12T17:20:42+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: research, sleep, cognition Summary: Breakthrough Stanford research reveals key to memory restoration: Blocking metabolic switch and addressing hidden sleep apnea could revolutionize Alzheimer's prevention strategies. Important for APOE4 carriers to optimize sleep. Stanford achieves COMPLETE memory restoration in AD models by blocking metabolic switch + 75% patients have hidden sleep apnea (and it's consequences!)Wednesday plenary from the AAIC, fresh from July 2025.Dr. Kevin Tran September 12, 2025 As always these conference are the opportunity for researchers to present their latest findings, often not yet published. So if you are curious about the cutting edge science, tune in!Two separate research teams just revealed findings that could give us great insights about how we prevent Alzheimer's.Dr. Andreasson from Stanford discovered neurons aren't dying in AD - they're STARVING. An enzyme called IDO1 hijacks the brain's energy supply. When her team blocked it? Complete memory restoration. Not improvement. RESTORATION.Professor Naismith from Sydney revealed that 75% of memory clinic patients have sleep apnea they don't know about. Every night, their brains are being damaged by oxygen deprivation. One bad night = 2 days of impaired toxic protein clearance.The kicker? We already have treatments:- IDO1 inhibitors passed safety trials- CPAP protects against cognitive decline  - DORAs improve sleep AND reduce tauNeither study looked at APOE4 carriers specifically (we need to advocate for this!), but these are fundamental brain mechanisms that likely affect all of us.I break down everything in detail here: Questions for discussion:- Have you had a sleep study? (75% chance you need one!)- Are you tracking your sleep quality?- What's holding you back from getting evaluated?Sharon L. Naismith (Charles Perkins Centre — University of Sydney, Australia) - Waking Up to the Importance of Sleep in MCI and AD Katrin Andreasson (Stanford University, CA, USA) - Restoring Hippocampal Glucose Metabolism Rescues Cognition Across Alzheimer’s Disease Pathologies --- ## Simple Blood Test Detects Alzheimer's 15-20 Years Before Symptoms URL: https://apoe4.co/blog/posts/simple-blood-test-detects-alzheimer-s-15-20-years-before-symptoms Published: 2025-09-08T20:46:12+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: research, tracking, cognition Summary: Breakthrough biomarker research reveals P-tau217 blood test can detect Alzheimer's 15-20 years early, with 97% accuracy and game-changing early detection strategies. +8 other biomarker advancements for APOE4s and cognitive health innovations from the AAIC 2025 Simple Blood Test Detects Alzheimer's 15-20 Years Before SymptomsP-tau217 + Other New BiomarkersDr. Kevin Tran September 08, 2025 Hi Phoenix Friends,The FDA approved a few months ago (May 2025) the p-tau217 test. If you ever wanted to learn more about the test, and other innovative biomarkers, I cover the AAIC 2025 session about biomarkers advancements.In this video, I analyzed 9 breakthrough presentations from the world's leading biomarker researchers:- P-tau217 blood test: 97% accurate (two-cutoff method)- 6-min MRI (QGRE): Detects 5-10% neuron loss vs 20-30% for standard MRI- Mobile Toolbox: NIH app detects changes 7 years early via "loss of practice effect"- AI Prediction: 85% accurate timeline prediction within 2-3 years- MTBR Tracking: Measures tau's most dangerous form at 10 picograms/mL-And more!Full conference analysis: Session Presenter(s): Daeun Shin (Samsung Medical Center, Seoul, Korea, Republic of (South)) - Biomarker-integrated Prognostic Stagings for Alzheimer's Disease Satya V.V.N. Kothapalli (Washington University School of Medicine in St. Louis, MO, USA) - Pre-atrophic Neurodegeneration: A Novel MRI-Based Biomarker for Early Neuronal Injury Coincident with Early Amyloid Accumulation Noëlle Warmenhoven (Lund University, Sweden) - Comparison of plasma biomarkers measured on a fully automated instrument versus CSF biomarkers for detecting Alzheimer’s disease pathology Xiaqing Jiang (University of California, San Francisco, CA, USA) - AT(N) Biomarkers Across Modalities in the Pathways Between Multimorbidity and Cognition Katie L. Vandeloo (Hurvitz Brain Sciences Program, Sunnybrook Research Institute, ON, Canada) - Sex-Specific Associations Between Systemic Inflammation and Brain Health in Aging: Evidence from a Multi-Ethnic Canadian Cohort María Fernanda Zambrano-Astorga (CICESE, BJ, Mexico) - Identification of an Alzheimer’s Disease Biomarker Signature Using Reproducible Proteomics Data Mining Christopher S. Parker (UCL Hawkes Institute and Department of Computer Science, University College London, United Kingdom; Dementia Research Centre, Queen Square Institute of Neurology, Greater London, United Kingdom) - Longitudinal trajectories of advanced cortical diffusion-weighted imaging measures of tissue microstructure in pre-symptomatic autosomal dominant Alzheimer’s disease Roos J. Jutten (Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Netherlands) - The remote Mobile Toolbox for capturing cognitive change in preclinical Alzheimer’s disease Fernando Gonzalez-Ortiz (University of Gothenburg, Department of Psychiatry And Neurochemistry, Institute of Neuroscience And Physiology, The Sahlgrenska Academy At The University Of Gothenburg, Sweden) - Novel MTBR-specific immunoassays MTBR-1 and MTBR-pTau262 for assessment of tau pathology in Alzheimer's disease --- ## We're securing early pharma access for ApoE4 carriers, and more! (join before pricing changes) URL: https://apoe4.co/blog/posts/we-re-securing-early-pharma-access-for-apoe4-carriers-and-more-join-before-pricing-changes Published: 2025-09-05T16:02:00+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: community, therapies, tracking Summary: Unlock exclusive early access to groundbreaking ApoE4 therapies and discounted medtech devices through Phoenix's innovative patient programs—transforming brain health before market launch. We're securing early pharma access for ApoE4 carriers, and more! (join before pricing changes)The Phoenix in August: Patient Early Access Programs, subsidized Medtech devices, 80+ topics discussedDr. Kevin Tran September 05, 2025 Hi Phoenix Friends, In August, we crossed a critical threshold for our ApoE4 members. We're now in active discussions with multiple pharma companies to secure early access to innovative therapies specifically for ApoE4 carriers—through clinical trials, early patient access programs, and other initiatives. When these programs launch, Phoenix members get cutting-edge therapies before they hit the market. Time is of the essence. The earlier we act, the better the results. That's why leveraging our collective power is one of our core focus. We're building two pathways to earlier interventions:Early pharma access programs - First access to therapies with strong ApoE4 signals Subsidized med-tech partnerships - We've secured heavily discounted pricing on medical devices in exchange for anonymized usage data and outcomes (cognition tests, blood markers, etc.). The medtech companies get real-world evidence. You get interventions at a fraction of the cost. More partnerships details coming in the next newsletter once we finalize the details. The Win-Win Structure We've Built: Healthcare companies get real-world outcomes data, proof their solutions work, and patient advocacy. You get interventions that could change your trajectory—earlier and cheaper than waiting years (or decades!) for general availability. While we build these game-changing partnerships, our community is already delivering value every day. In August alone, Phoenix members engaged in 80+ discussions on interventions, protocols, and strategies specific to ApoE4 carriers. Carriers like you, sharing real results in real-time. We are not a waiting room for future therapies: we are an active laboratory where members are testing, tracking, and sharing what works right now. See the full list of topics at the end of this email. This is your last call for Founding Member status. Once we launch the Phoenix Experiment module (leveraging AI, big data, and digital twin technology to match you with interventions that work for people with your exact health profile), our pricing changes permanently.The recurring costs of running these AI models force us to switch to a subscription model. There's no way around it. Join now as a Founding Member: $499 one-time for LIFETIME access Join after launch: $499 every year. The door closes when the Phoenix Experiment module goes live. Secure Your Lifetime Access for $499 → Make your move.If you have any questions, just reply to this email. I reply personally to each one of them. P.S. The partner discounts we're negotiating could reimburse your lifetime membership with just one subsidized intervention. We're building a portfolio of these partnerships: blood tests, diagnostics, med-tech, pharma, and more. The math is simple. The decision should be too. What you missed in The Phoenix Community in August Quick summary of the most popular topics discussed this past month: ALZ-801, vaccines, and lifestyle trials keep adding signal. This shapes real options you can act on. Lipids stay center stage. Threads on ApoB, ezetimibe, DHA forms, rapamycin, and statins help you choose and track. Fitness and sleep posts show clear wins. VO2 up, deep rest tools in play, and a new suvorexant discussion. Biomarkers got practical. Ptau217 access and costs, direct-access menus by state, and real member data. Genetics nuance grew. Protective variants and ancestry modifiers point to more precise plans. All discussions by Space: 🧬 Research Latest on ALZ-801 trial Large POINTER study finds cognitive improvements with intensive structured lifestyle changes We have to put this controversy to rest once and for allAD clinical studies What I learned from Rhonda Patrick’s analysis APOE4: Scientists reversed memory loss + found social factors override genetics APOE ε4 carriers share immune-related proteomic changes New ApoE4 Science About Estrogen and Brain Health! Reevaluating the role of education on cognitive decline Vaccines and dementia Huge study showing benefits of two common vaccines, Shingles and RSV Varicose veins and dementia ApoE4 & Alzheimer’s: 11 New Discoveries That Changed My Game Plan ApoE4? New Brain Protection Breakthroughs Every Carrier Must See(Small) study says intense lifestyle changes can not only stop but even reverse Alzheimer’s Handgrip study 💊 Supplements, Nutrition, and Medication How to lower APOB Interesting article from Peter Attia on inducing ketosis Small human pilot study shows 20 g creatine supplementation improved brain energetics Ezetimibe for prevention What oil do you use for cooking? Could Statins Be Our Secret Weapon Against Dementia? Update on Lipids after 90 days on statin and ezetimibe Online Source for peptides These Omega-3s, they smell fishy… Next Intervention – Rapamycin Phospholipid-form DHA – what do you use? Methylene Blue? Choline (Alpha GPC), big “no regret” supplement I Have Stopped Taking Ezetimibe My view about keto: not adapted when doing 12h+ of sport per week Has anyone used Saffron? Microdosing Semiglutide Nut Pods Y or N Protein Bars LPC-DHA (Lysoveta) Dairy fat, Cheese, Cream.. Are they all equally bad for LDL-C? Cholesterol medication? Ursolic acid Quality control on Supplement brands Psyllium husk – For fiber and tactical use to blunt absorption Is Alcohol good or bad for you? In moderation or not at all? Anyone with experience with Kisunla (donanemad-azbt)? Modified Citrus Pectin (MCP) and stress reduction What do you do to keep lipids under control? 🏃 Sports, Sleep, and Stress Management Suvorexant Finally focusing on VO2 Max / Zone 4/5 Training Sleep Optimization Sleep Trackers Research & More, Matthew Walker Interview What sports / activities do you do? Neuroplasticity Thread Sleep optimization with mouth taping Outsized effect interventions for brain clarity / avoiding brain fog Factors affecting sleep – mystified NSDR – Non Sleep Deep Rest 🔬 Biomarkers, Tracking, Monitoring Lipoprotein(a) (Lp(a)) Cost of beta amyloid 40/42 and p-tau217 tests Klotho may really help.. Obicetrapib – Delayed Progression p-Tau217 Any experience with Care Access screenings? Direct-Access Testing by U.S. State Cholesterol Balance Test Hyper absorb or Hyper produce Anyone tried Dr Goodenowe’s ProdromeScan? Increase in T-p-tau181 PET scan results indicate BAPL3, indicating substantial plaque build up 🧠 Mental Health & Emotional Resilience You’re not alone — this space is for the emotional side of the journey URGH! I’m overwhelmed and burnt out. When I found out I had APOE4/4, my brain played tricks on me 💻 Tech and Medical Devices Brain Health Dosing with Red Light Therapy Red Light Therapy Wearables 🧬 Genetics My Genetics 3X4 Genetics – Memory and Brain Health Snps Your Ancestry Changes How ApoE4 Works: 3 Breakthroughs Deep dive into 3 protective APOE variants that block Alzheimer’s 📢 Announcements Your Phoenix Monthly Check-In Just Got Smarter (And Way More Personal) Shape the Ultimate Personalized APOE4 Protocol: Decide Which Features Matter to You! 🎁 Perks and Partnerships Whole Genome Sequencing: Nucleus Whole Genome Sequencing: Sequencing.com Photo biomodulation: Neuronic 🤝 General and Off Topic Opening address for Thurs July 31, 2025 at AAIC AAIC presentation: The Importance of Early Detection Alzheimer’s Association International Conference, Toronto, Canada Blacked out 1 week of memory after taking meds for muscle / nerve injury Labcorp vs Quest Made a Decision on Kisunla Today Long Term Care insurance – especially USA Advanced Directive (More than Medical!) Cure for Alzheimer’s? If you’d like to join the discussion, apply to join the Phoenix Community here. Onward,Kevin --- ## Cognitive reserve protects mood/behavior, not just memory URL: https://apoe4.co/blog/posts/cognitive-reserve-protects-mood-behavior-not-just-memory Published: 2025-09-01T20:16:17+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: research, cognition, protocols Summary: Unlock brain resilience: New research reveals how cognitive reserve protects mood, memory, and behavior—scientifically proven strategies to boost mental health at any age. Cognitive reserve protects mood/behavior, not just memory + Insights on how to build your own cognitive reserve no matter your age.Dr. Kevin Tran September 01, 2025 Just analyzed 6 presentations from the Alzheimer's Association International Conference July 2025 on cognitive reserve and resilience. The findings expand way beyond what we previously understood. The Data: 450 participants: Cognitive reserve directly reduces neuropsychiatric symptoms, moderates hippocampal shrinkage effects (Sidhu, U of Calgary) Super agers: 80+ year-olds with memory "at least as good as middle aged adults" - all are socially engaged and "incredibly busy" (Alexander, Ann Arbor VA) 3,000 participants: Financial, cultural, and social capital all independently protect cognition across lifespan (Chen, UC Davis) 1,400 participants: Education builds tau resistance even with high amyloid burden (Birkenbihl, Harvard/MGH) Why This Matters: Cognitive reserve is "modifiable and clinically relevant" at any age Protection extends to mood, behavior, not just thinking Multiple pathways exist - what works varies by population There's a tipping point where reserve gets overwhelmed Video covers: Complete analysis of all 6 presentations Super ager characteristics and habits Three pillars of lifetime protection How to build tau resistance Understanding reserve's limits Anyone else following the cognitive reserve research? Edit: Adding that one researcher noted education effects vary by ethnicity - higher education associated with larger hippocampal volume in Black participants but smaller in Latinx participants, though memory protection occurred across all groups. --- ## APOE4 Carriers: The Great Debate Between Scientific Rigor and Patient Urgency URL: https://apoe4.co/blog/posts/apoe4-carriers-the-great-debate-between-scientific-rigor-and-patient-urgency Published: 2025-08-29T16:16:00+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: research, cognition Summary: We face an impossible choice: Wait decades for perfect science or act on promising but unproven interventions? APOE4 Carriers: The Great Debate Between Scientific Rigor and Patient UrgencyWe face an impossible choice: Wait decades for perfect science or act on promising but unproven interventions?Dr. Kevin Tran August 29, 2025 --- ## Why Most APOE4 Interventions Lack Robust Scientific Evidence: A Candid Interview with Dr. Hussein Yassine on Clinical Trials, Supplements, and Self-Experimentation URL: https://apoe4.co/blog/posts/why-most-apoe4-interventions-lack-evidence-a-candid-interview-with-dr-hussein-yassine-on-clinical-tr Published: 2025-08-29T13:22:28+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: research, community, supplements Summary: Uncover the scientific truth behind APOE4 interventions: Dr. Hussein Yassine reveals why popular brain health strategies fail and what research really shows for high-risk carriers. Why Most APOE4 Interventions Lack Robust Scientific Evidence: A Candid Interview with Dr. Hussein Yassine on Clinical Trials, Supplements, and Self-ExperimentationDr. Kevin Tran August 29, 2025 Introduction Dr. Hussein Yassine is the Volke Endowed Professor of Neurology at the University of Southern California's Keck School of Medicine and Director of the USC Center for Personalized Brain Health—a groundbreaking center launched in 2023 focused on early detection and intervention for APOE4 carriers. With over 150 peer-reviewed publications and decades of research on omega-3 fatty acid metabolism in the brain, Dr. Yassine has emerged as one of the leading voices in understanding how genetic factors, particularly the APOE4 allele, influence brain health and Alzheimer's risk. In this candid interview with the Phoenix Community members, Dr. Yassine pulls no punches. He addresses the reproducibility crisis in science, explains why mouse models rarely translate to human therapies, and offers sobering perspectives on popular interventions from lithium to ketones. A Note from Kevin: Throughout this conversation, I'll be adding my own commentary in [brackets like this] to provide additional context and perspective. While I have tremendous respect for Dr. Yassine's commitment to scientific rigor and his decades of research, I don't always agree with his conclusions (and that's perfectly fine). The Phoenix Community operates well beyond what's considered "scientifically rigorous" in the strictest sense because we're not willing to wait decades for double-blinded randomized controlled human trials that may never come, or that might be conducted on populations vastly different from us in terms of genetics, environment, and real-world circumstances. I believe transparency is crucial, which means sharing perspectives that challenge our approaches. In fact, I think it's dangerous to fall into dogmas or become so convinced of our own correctness that we stop questioning our positions. The Phoenix Community isn't immune to this trap either. So let me be clear: sharing this interview isn't me changing my stance on self-experimentation with interventions we have discussed recently like tramiprosate, lithium, or ketogenic approaches. I still deeply believe in running these calculated self-experiments. Rather, I'm sharing this to ensure you understand that what we're doing isn't considered scientifically robust in the traditional sense. We're operating in the biohacking frontier, which is exciting but comes with inherent risks and consequences. I believe it is my responsibility to inform you of this reality before you decide to join/continue with us on this journey. The InterviewKevin Tran: [Discussing how to evaluate clinical trial results] For a lot of people, we don't necessarily have the knowledge or the time to go look into the protocol to determine if it's robust or not. We usually only read the study itself and sometimes just the abstract. If we look at other rules of thumb, quick things that we can use as proxies to know if it's robust or not, if we should look more into it or not, what would you say? Dr. Hussein Yassine: Well, I would say that look at editorials in respected journals on how they review the work that's being done, and look at usually a letter to the editor or commentary on the work that explains what the strengths and weaknesses are. Avoid going on social media and looking at the company CEO's post. Because often there's a conflict. The company itself most of the time would want to make sure that they have this responsibility toward their investors and stockholders. So you wouldn't typically get—I mean, again, there's exceptions. There are companies who have very high standards and that's not the case, but overall, you want a third party, a scientific third party writing a balanced commentary in a highly respected journal as opposed to a social media platform where people are voicing opinions based on how they feel or what they think is correct. Kevin: Do you have a short list of the most reputable journals according to you? Dr. Yassine: I don't think it's a good idea to actually name one or two or three journals. There's a lot of them. I think, you know, in general, you want to know that the person writing the review is an expert in the field, has no conflict of interest, doesn't have stocks in the company that he or she is criticizing or appraising. The review appears balanced, discusses the primary, the pre-specified protocol analysis, discusses the implications and the gaps. There are many elegant, good journals. It's not like it has to be in this journal or that journal to actually make sense. There are several that are well-respected. But there are certain rules. Now, if you're asking me for a reference for your audience to read, I would guide them to John Ioannidis' famous study in PLOS Medicine many years ago. The title of that article is "Why Most Published Research Findings Are False." And he explains—he has a table within this paper that says if the authors are conflicted, if they don't have the proper methodology, they list all the reasons why sometimes findings are hardly replicated and identifies how to fix this problem. Kevin: Would you say that title is correct? That “most journal publications are false”? Dr. Yassine: I would say, I don't know if "most" is the right term, but I would say many publications cannot be reproduced or replicated because of bias. [Phoenix Member]: Hi, I'm a professor at the University of Michigan in neuroscience, and we've gone through these papers at length, have discussed that with faculty and students. And I would agree—in many fields, more than half of the papers are not reproducible, and "false" can be interpreted in different ways. It may be in a narrow sense. What they say was correct under the circumstances that they were doing it, but the generalization was false. That could be included. But there is a lot of irreproducible stuff, especially in my field in genetics, although things have improved compared to 20 years ago when those papers were written. Dr. Yassine: I think we are in agreement. And when we talk about false, often people think fraudulence. And that may not be the case. It's often bias. And we all have our biases. Sometimes a biased presentation can lead to false conclusions. And that's why we have this reproducibility crisis. Having better methodologies, better reporting, and more transparent systems of clinical research that include blinding and controls and so forth will help us move beyond this reproducibility crisis. Kevin: I think it's interesting because when you think about taking bets on interventions and deciding to test them, how would you navigate these types of things? How would you identify the ones that have potentially high potential and then deciding to test it if you were an APOE4 or if you were to advise a patient? Dr. Yassine: I do understand the background. I understand why sometimes you feel that the time is ticking and disease might be severe and debilitating and you need to do something about it. I fully acknowledge and appreciate that this is very stressful and people want something that works. But I also want to say that this is an opportunity to take advantage of people, to sell snake oils, to promote false information, and that's unfortunate. So I think my response to you is that if the intervention is reasonable, is not toxic, makes sense to you, you feel good about it, and it's not that expensive, somebody might benefit from it. So I would go back and say, use your own clinical judgment. If you're trying a new diet or a new exercise, a new sauna, whatever that is, which may have limited side effects, you might think it works, it's worth trying. But if you're going to try a medication that has not been proven, or a complex dietary intervention that's kind of on the extreme side that has not been proven, I don't know if it's worth taking the risks. So there's always a benefit to risk ratio. And it depends on what the risks are going to be. Kevin: My approach usually is to look for those "no regrets" moves. At worst, they don't do anything but they won't hurt you. At best, they might work, so why not try them? That usually deprioritizes a lot of medication, and it's more about high impact lifestyle interventions, that in the worst cases, they will still benefit your health and longevity anyways. [Kevin's Note: This is exactly the philosophy behind the Phoenix Community—we focus on interventions that have high upside and minimal downside. Even if the specific Alzheimer's prevention benefit isn't proven, things like optimizing exercise, sleep, diet etc. are going to improve your healthspan / lifespan regardless.]On Self-Experimentation and N=1 TrialsKevin: So let's say you find a potentially interesting intervention to do. The next step would be rationally to test it, to make sure that it's actually moving the needle and that you're not doing that daily for the rest of your life for no benefits at all. So how would you design a self-experiment plan? Dr. Yassine: I understand the premise, Kevin, but I think you might be overreaching. I don't think people can practically design an intervention to figure out if an intervention is working. Because we're prone to bias. What is it that I'm going to test to objectively tell if my disease is getting better or if my cognition is improving? I think it is possible to be enrolled in a clinical trial. It is possible to do some annualized cognitive testing at a licensed neuropsychologist. It is possible to see a specialist and get some of the new Alzheimer's disease biomarkers, but I think it is not maybe practical or smart for somebody to do something, take a supplement, or even do an exercise and say, oh, because this changed, that means it's working. I think this is a little bit overreaching because it doesn't work that way. We often need trials with hundreds, if not thousands, of people to figure out if something is working. If one case came to someone and they took a bunch of supplements and then the next time their cognition drastically improved, that doesn't prove much. That could be they learned the test, and sometimes when you learn the cognitive test, your second time you do it, it becomes a lot better, especially those easy screening tests like MMSE and MoCA. It's very easy for a patient to learn it if they don't have dementia. And the next time they do it, their scores go from 25 to 30. That doesn't mean that the supplement they took or the exercise they took or this combination of magic elixir is really curing Alzheimer's. I think we have to be more skeptical. To really get objective measures of this disease process, you either go and participate in a trial that has well-defined outcomes where you might be blinded to your treatment arm, or you see a licensed provider who would be ordering certain interventions or drugs or medications and maybe blood work to figure out if it's truly working or not. As an individual, I want to help and I'm not trying to make it harder for the audience, but it's not easy simply to do blood work and figure out if this is working or not working. [Kevin's Note: Dr. Yassine raises valid concerns about bias in self-experimentation, especially when done alone. This is why in the Phoenix Community, we emphasize structured protocols, tracking multiple biomarkers over time, and comparing notes with hundreds of other carriers doing similar experiments. While we can't eliminate bias entirely, we can reduce it through systematic approaches and peer review within our community.]On Vitamin D and the VITAL TrialKevin: I mean, I guess it also depends on the intervention, right? Let's say you have vitamin D deficiency... Dr. Yassine: So the VITAL trial did exactly that. Brought in people with borderline low vitamin D deficiency states. Thousands of people led by Joanne Manson from Harvard. And they increased their vitamin D levels from 30 to 44, found nothing, nothing whatsoever—no improved bone health, no improved osteoporosis. In fact, more kidney stones. And there are side effects with high doses of vitamin D. You can get calcium in your blood vessels, which is not a good sign. I'm not saying we shouldn't be taking vitamin D. All what I'm saying is be careful when you make an analogy that seems on the surface makes sense, but science doesn't operate that way. And that's why you need to be either part of a trial or talk to a licensed provider because not everything is as intuitive as it seems. For some people, a vitamin D of 10 is really low, and you need to move it to 30 or 40 to avoid fractures. For others, moving to 40 might just give side effects. And that's why we have to be careful. Kevin: I see what you're saying, but if you put yourself in the shoes of a patient, a lot of patients are taking supplements, me included. We can't wait or participate in a clinical trial for everything that we take. On the other hand, we also need to do something, right? So how would you advise us in navigating that? And we're not talking about medication, right? Let's say even diet or very basic supplementation. Dr. Yassine: Well, my advice is very simple. If you have a really good diet that contains nutritious elements—and I would rank them with fibers and good fats as the ranking diets—and if you are exposed to the sun and you have a lot of good ingredients in the diet, you probably may not need a lot of supplements. In fact, these supplements might be actually giving you more side effects than you think. Now, certain people, for example, have dietary restrictions. They don't eat fish or they can't eat certain meats or they can't eat certain diets and they may have deficiencies. And in those individuals, supplements make a lot of sense because they're replacing something that's deficient in the diet. So my approach to supplements and vitamins and minerals and so forth is that they have a role, but not as "more is better." And if I really boost my vitamin D, really boost my omega-3s, I'm going to get more benefit. In fact, this is possibly not true. We know that at really high levels of omega-3s, there might be heart rhythm problems. At really high levels of vitamin D, there might be kidney stones, atherosclerosis. At high levels of vitamin Bs, other neurological things. So I know I'm not answering your question the way you may want to hear the answer, but it's a Goldilocks phenomenon. It can be too little, it can be too high. It has to be just right. And you can get it just right from a healthy lifestyle without breaking the bank. On General Interventions for APOE4 CarriersKevin: So let's say vitamins, supplements, and so on might not necessarily be needed or need more proof that it works. What interventions right now would you advise an APOE4 carrier to do? Dr. Yassine: Well, again, these recommendations are generic and do not apply to all E4 carriers. And we have to be careful that some carriers may have different—these recommendations that I'm sharing with you are just general. And if you really want to know how Kevin may differ from [Phoenix Member 1] or [Phoenix Member 2] or someone else, you need to see a licensed provider who can go over these individual risk factors and make customized recommendations. But in general, we know that whole foods, we know that a diet that is rich in whole foods, plant-based, some animal food within it that is very rich in fibers and limited with ultra-processed foods with less sugar and so forth—we know that this is a diet that actually is good for the brain. It has been tested in several large cohorts and trials, and Mediterranean diet is one example, but not the only example. You don't need just one diet to say this is the right diet. There could be multiple versions of a good diet. We know that common sense exercise makes sense, being active and so forth. We know that sleep makes sense and there are certain ideas about how to optimize sleep. We know that there are activities that people can get engaged in which can help cognition. We also know that there's other factors such as depression, anxiety, loneliness, traumatic brain injuries, chronic risk factors such as diabetes, hypertension, high cholesterol, and many other things. So in general, there are things that somebody who is at risk for dementia can actually try to deal with these risk factors. And finally, the younger you start, the better, because this is a lifelong process. And starting decades before dementia gives the brain the opportunity to heal and recover. [Kevin's Note: I completely agree that everyone is different, and general advice can only go so far. That’s why it’s essential to run self-experiments—not just to identify the right interventions, but also the right dosages. The key is to follow robust protocols: isolate interventions, establish a clear Day 0 baseline, and measure both quantitative and qualitative outcomes.This is exactly what The Phoenix Community is built to provide: clear, step-by-step guides for each intervention, so we can move beyond generic advice and discover what truly works for each of us.]On Healthcare Provider Knowledge of APOE4Kevin: I think I just want to jump back to what you mentioned at the beginning and it reflects what a lot of us in the community experience. We are all unique, right? We are all different, we all have different genetic background, different habits, different environment and so on. So there is no really one-size-fits-all answer except very generic answers. And the solution that you mentioned, which is going to see a licensed healthcare provider. But the problem is for a lot of us when we see them, they actually don't even know what APOE4 is. It's very, very difficult to find someone who is aware of it and on top of the research and everything because in their entire life they have maybe seen one or two maximum and might not even have helped them. So, that's why there is a need to do something from the individual perspective because the healthcare community hasn't been that helpful and that accessible. Dr. Yassine: I want to do a little bit of a pushback, Kevin. I think the way that you're framing it is that we are dealing with a very niche, unique condition that healthcare providers are not trained to do, are ignorant or dismissive. And there's possibly some providers who are ignorant, dismissive, and they do not fully appreciate the gravity of the problem. That's definitely true. But I would say many providers are working overtime to try to help as much as they can. And I think if you want to frame it in brain health, you don't need a subspecialist with an APOE4 background to talk about common ideas to enhance brain health. That doesn't require a very subspecialized provider. The pushback may come if you've got really unique or specific questions on a certain supplement or a certain intervention and that provider may not be trained on. So this is where there might be a little bit of a pushback because the provider may not know if this supplement or this keto diet or this intervention is going to be recommended for an E4 carrier because, to be honest with you, nobody does. Even those who claim they know, they probably don't. And they're making this claim because they have a good heart and they want to help. But we still don't have enough research on these supplements, diets, or modes or protocols to be able to tell you they actually work better than general advice. Kevin: Just to share a little bit my own experience—and maybe because I'm not in the U.S. and not in San Francisco and it might be different around the world—but literally, when I discovered my own status and I went to see either normal physicians or neurologists, because the physician referred me to neurologists, I was literally almost laughed out of the door, saying, "Hey, you're super young. Come back in 30 years when you have symptoms. There's no need to do anything. Just eat clean, exercise, and do that." So that's kind of my experience. I don't know if it's the experience of other people as well out there, but I've seen that mentioned quite a bit. That's why there is this entire movement of trying to take our health into our own hands, because going to see the doctors really didn't yield a lot of results there. Dr. Yassine: All that I can say is that there's a new generation of providers who are better trained and they're more informed. E4 is a big deal, at least to me it is. I mean, we have built a center just focused on E4 carriers and trying to address this gap and need. And we're training doctors, we're training neurologists and primary care about E4. So I think this is something that we also need to understand—that we need a lot more research to be able to be confidently telling you, Kevin, this is what you're supposed to do because you have two copies of E4. Believe it or not, it's really hard to get funding to do research, and when I go to NIH, for example, last year I went to my funder, which is the National Institute of Health, and I said I want to do a trial in those who carry two copies of E4. Unfortunately, I was pushing against a lot of competition because funding rates is like 5%. So to help out with this, we need to advocate for research. We need to advocate for E4. And we need quality research to be able to tell whether this intervention, this protocol, the supplement is really working. Otherwise, we would be selling snake oils. [Kevin's Note: This exchange highlights the exact gap the Phoenix Community was created to fill. When the medical establishment tells you to "come back in 30 years," and research funding is scarce, we as patients need to create our own support systems. We're not replacing medical advice—we're supplementing it with peer support, shared experiences, and structured approaches to testing interventions safely.And I totally agree with Dr Yassine that we need to have more APOE4 advocates. This is one of the core mission of the Phoenix Community.]Audience Question: On Mouse Models[Phoenix Member]: I appreciate you sharing your time with us. I do read a lot of actual studies. But on Facebook, on our 4/4 groups, people will see that the mouse model said this, and it was only one study, and how do you take a mouse this big, and so we need to do this much. So, do you want to comment at all on if we wanted to try something that was effective in a mouse model, how would we even figure out how to do that? Dr. Yassine: Yeah, excellent question. Thank you for asking. Let's talk a little bit about mouse models. The reason why people use mice is because they have a lifespan of approximately two years. Now, most genetic engineering since the 90s have been really optimized for mice models. So, if you want to change the genetic composition of a mouse, the protocols are really straightforward. Mice have very high efficient breeding, which means you have colonies that actually grow quickly. And they have a brain that somehow resembles the human brain. It's a mammalian brain—not like an ape brain or a more sophisticated brain, but they do have brain features that are shared with human physiology. Now, having said that, mice have faster metabolism than humans, right? So their metabolism is estimated to be like three times faster. If you look at their brains at the time of death—a typical mouse can live up to three years—there is no evidence of plaques or tangles. They do not develop amyloid plaques. They do not develop tau tangles. So that makes them really not great models for a disease like Alzheimer's. So what happened about 20 years ago, several investigators started inserting Alzheimer genes into mice models. And they struggled, because when they put the amyloid genes, they developed amyloid plaque, but no tau. And when they put the tau genes, they developed some tau pathology, but no plaques. And then both models did not address the elephant in the room, which is E4. E4 is the strongest genetic risk factor for late-onset AD. If you just put E4 in a mouse model, you wouldn't get tangles, you wouldn't get plaques, maybe you would get inflammation on a high-fat diet. So, just to tell you this background, when it comes to mice and Alzheimer's, you have to take most of the studies with a grain of salt. My lab has many models of mice, including the E4 mice models, the amyloid mice models, the tau mice models. But we don't claim that we're treating Alzheimer's. We're trying to understand mechanisms. So we're trying to understand how does APOE4 increase inflammation. How does APOE4 interact with the amyloid mutations to lead to a plaque that has an inflammatory component? How does it lead to the spread of tau? And other things. So we never make a claim that if we treated this mouse model and cured it, then this is a drug that can be used in humans. So you have to be very careful that treatments of mice does not translate to treatment of humans. If it had, we should have had a cure for human Alzheimer's more than a decade ago. We've cured Alzheimer's in mice a gazillion times. Kevin: So would you say that all mouse models should be disregarded and that we shouldn't act on it? Or are there some exceptions? Dr. Yassine: Absolutely not, Kevin. So what I said is we use mouse models to understand mechanisms of disease. How does APOE4 increase inflammation? How does APOE4 spread tau or amyloid? So we're studying them for understanding the basic mechanisms. How does a drug might work? But we don't use them to actually give a drug and then cure Alzheimer's from the mouse in terms of cognition and behavior. So mice are really valuable. We don't disregard them. But we don't use them as a go/no-go to make a decision whether a drug works to cure Alzheimer's in humans. We use them to understand the mechanism of how a drug might be working on a simplified model. On the Recent Lithium StudyKevin: Yeah, it makes sense. What I mean by "disregard" is more from a patient perspective. I think the example [Phoenix Member] was mentioning is on lithium, right? Which is something that came very recently in Nature, which is a very reputable publication, and they made some claims and it's giving a lot of hope for everyone. Then we're deciding, okay, should we take lithium ourselves or not? So there is this gap, right? And we can't really wait for 10 years. So that is, for example, one of those specific situations. And what would you do in these situations as a patient? Dr. Yassine: Okay, so let's talk about exactly what we just talked about again, but from the perspective of the recent Nature paper by the Tsai Lab on lithium orotate supplements. I think the way that I read this paper—and this is a really nice paper, it's an elegant paper in the sense that they actually looked at many species of lithium and identified a species that is deficient in certain mouse models. And when there's a deficiency, because they took it out from the diet, there was an association with more plaques and more severe disease pathology. And then when they added this lithium salt to the diet, they observed that the plaques were shrinking and there was less pathology and less inflammation. And then they went on to figure out the pathway by looking at how this might be working and landed on an enzyme called GSK3-beta. And then when they manipulated that enzyme, they were able to replicate how lithium might be inhibiting the pathway and changing the readout of amyloid and tau in this mouse model. What this tells me is that lithium in a specific form or orotate at lower doses actually might have a role in how amyloid and tau are affecting disease progression in certain conditions that are set by the experiment published. This doesn't tell me that lithium works in humans. This doesn't tell me what the dose of lithium is that needs to work. This doesn't tell me that if I give lithium to a group of people, I'm going to change their amyloid plaque accumulation, I'm going to alter their amyloid biomarkers, or I'm going to improve cognition. It doesn't tell me any of that, unless we do a human trial where we give people randomly assigned to placebo versus lithium, do some biomarkers with amyloid and tau and ultimately find a signal that makes sense. And then once that is achieved, do another trial that looks at the effect of lithium in a few thousand people on dementia conversion, memory loss, and so forth. I cannot speak with confidence that lithium actually does what it's supposed to do in mice. You're going to ask me the same question: I cannot wait 10 years while you're doing all these studies. I need an answer now. I can tell you, well, Kevin, you like to play cards or you like to flip dice. Flip your dice, take lithium. If you feel that as a lithium supplement, you're not overdosing, you're not getting kidney toxicity, and you're covering your bases, that's fine. But I wouldn't lose sleep if I didn't take lithium, because we may discover in 10 years that the amount of lithium deficiency required to find an effect is really hard. So you have to be living somewhere in Denmark where there's absolutely no lithium at all in the water to actually find an effect. And once you reach a minimal threshold, there's no longer an effect of additional lithium. I don't know. I don't have a crystal ball. But again, the argument that you keep using Kevin is "I have to do something now. Otherwise, I'm doomed." And all that I'm saying is take a breath. There's a lot of good evidence that we have right now with a good diet, with exercise, and we do not need to exaggerate to get benefit. [Kevin's Note: This is where the philosophical divide becomes clear. As someone with two copies of APOE4, I understand Dr. Yassine's caution. But I also understand that waiting 10+ years for definitive trials isn't an option for many of us. This is why the Phoenix Experiment framework focuses on interventions like lithium orotate (as an example) that have minimal downside risk—we're not talking about high-dose pharmaceutical lithium, but trace amounts that some populations naturally get in their water. It's about calculated risks, not reckless experimentation.]Audience Question: On Omega-3s and Fish Oil[Phoenix Member]: I've heard you speak before, Dr. Yassine, around fish oil. I know that just regular fish oil doesn't seem to help 4/4s as much and it's really eating fish that's better, and I wonder if you could talk about that just a little bit. Dr. Yassine: Excellent. Well, thank you so much for asking. Mechanisms of how omega-3s are metabolized by the brain has been our focus for at least a decade. We've published over 50 papers on this topic. I'm not trying to belittle others. I'm not by any means trying to be an elitist. But I'm just telling you that we have been closely looking at this question for a long time. We started looking at this question because over the past 20 years, there has been consistent epidemiology studies suggesting that higher levels of omega-3s in the blood is associated with less dementia. And this has been replicated across Europe, the U.S., China, and many other countries. So there is a signal. So we're not making this up. This is published. So we asked, if that's the case, we should be giving people omega-3 supplements to raise the amount of omega-3s in the blood. So many studies have actually been done on that premise of giving supplements like omega-3 supplements and seeing the effect on cognition. We've summarized those studies last year in a paper that we wrote and found really overwhelmingly negative effects of taking supplements on cognition in most of the trials that we reviewed, the vast majority. We actually excluded small trials because we thought they are unreliable, so we only looked at the trials with an N of 100 and above. So a trial with a sample size of 20, sometimes they were positive, but it's really hard to make a good conclusion because that sample size is highly prone to error. So then we asked, why is it that these trials have not panned out? Some of them are in patients with dementia. Some of them are in patients who are cognitively normal. Some are in MCI. And even my own trial, which is my own baby, spent eight years doing it, called PREVENT E4. It's going to get published hopefully in the next six months. It ended last year. We found no effect for taking the omega-3s at high doses on AD biomarkers and cognitive outcomes. So some people have said, well, maybe you've used the wrong type of omega-3. You haven't used the one that gets into the brain. In fact, our primary outcome is the amount of omega-3s that gets into the brain, and we succeeded. So we actually found that taking high doses of omega-3s indeed had approximately 20% increase in brain omega-3 and that's pretty significant. Other people might say, well, you didn't raise the omega-3 in blood enough. The answer is, no, we did. We went from a 4.8 RBC omega-3 index, which is considered low, to 11%. That's really high. So why didn't we see an effect? And the answer is epidemiology is very complex and observational cohorts often have confoundings. So people who are taking more omega-3s in their natural diet are likely taking cholines, phospholipids. They're likely taking vitamin D, lutein, vitamin E. It's all packed in salmon, for example. They're likely exercising. They're likely seeing their doctor. They're likely getting exposed to the sun. All of that work in concert to make the omega-3s more efficient and behave in a good way that the brain likes. If we decide to make it reductionist and just isolate the omega-3 component and ignore everything else, we're finding little effect. And the example I tell my patients: if some patients go to McDonald's and they love fast food and they have really very low omega-3s in their blood, and they come to our trials and we give them the omega-3 and raise their omega-3 index, do we truly think we're decreasing the risk of their dementia? And the opposite: if somebody does not eat omega-3s at all, but they're constantly in the gym, they have a really healthy diet, they're metabolically very good, and we increased their omega-3 index, do we really believe that that's going to make a big difference? So the answer is we need more personalized approaches to find out who is that person who's going to benefit from such an intervention. [Phoenix Member]: Thank you. That answers my question. And since seeing that, we have a fisherman around here that catches fresh salmon and we try to eat it twice a week. So I hope that's covering my basis. Dr. Yassine: Well, it will cover your basis if you walk to the fisherman, spend some effort getting the fish, walk back upstairs home, bake it with some good fiber and vegetables. Remember, this is a small single piece of a diet. It's not going to make a huge difference. Look at it as a complex pattern. That's what tracks with dementia, not these small individual components. [Kevin's Note: This is a perfect example of why context matters. In the Phoenix Community, we don't just recommend "take omega-3s." We look at the whole picture—your diet, exercise, sleep, stress levels. Dr. Yassine's point about the "complex pattern" is exactly why our Phoenix Experiment protocols track multiple interventions and biomarkers simultaneously.]Audience Question: On p-Tau217 Testing[Phoenix Member]: I saw somebody in the comments section ask about the p-Tau217 test and whether they thought that was a good idea, and I thought that was a great question to ask the doctor. Dr. Yassine: Yeah, so there's been a lot of interest in the new AD biomarkers. I wrote an article on this a few months ago. But long story short, these biomarkers are useful, but only in patients who have mild symptoms or symptoms of cognitive impairment. That's because in those populations, an abnormal biomarker may be predictive of dementia. Or if you have mild cognitive impairment or some kind of impairment and you took the biomarker and it's positive, the chance that you might be getting dementia is a little bit higher than somebody who has a negative biomarker. So this is what the evidence is showing us across many different papers. Now, here's what we don't really know. If you are cognitively normal and you have no cognitive impairment and you have a positive biomarker, what does it mean? And I don't think anybody knows. Could you have an increased risk of dementia? Possible, but the increase might be really small. So I would not recommend measuring them in cognitively normal people because it's gonna generate anxiety. And add to that, E4 homozygotes above the age of 50 will be guaranteed to have a positive biomarker on these blood tests, because we know part of the E4 homozygosity is that amyloid is accumulating in the brain. Now what we don't know is that some of those individuals with amyloid accumulation are going to go into the tau and dementia process and others will not. So this is why having a positive amyloid or tau biomarker in the blood, if you are a carrier of two copies of APOE4, is going to be anxiety-provoking. It's not going to tell you whether you're going to have dementia or not. It's just going to tell you, you've got amyloid in the brain. And I have E4 carriers who are 70s and 80-year-olds with amyloid in their brain with no dementia. On Cognitive Testing and Disease TrackingKevin: I have one more question in terms of tracking disease progression. Is there a test that could be done without a practice effect? Something that we could use as a benchmark to measure disease progression, whether we are symptomatic or not, and to see if whatever we're doing is working or not? Dr. Yassine: That's a really great question and I think, you know, if I did I would probably make a lot of money, but I don't. We've seen, for example, even devices that are able to analyze speech, that supposedly are able to detect it very early. We've seen people repurposing EEGs. We've seen so many actual tests that have so many different randomized questions that normally there's no practice effect, so you can measure that. Kevin: Any of those tests that you feel is more promising than others? Dr. Yassine: I don't know. All that I say is we need to do more research. I urge all of your members and you included to support more research in the field so we can have better answers. I think some of this might pan out in 10 years from now. We will have new devices, new tools, AI generated that can capture early disease and predict it very accurately, but we still need to do the research to figure this out. Audience Question: On Brain Insulin and Glucose Metabolism[Phoenix Member]: Thank you for joining us. I wanted to ask, can you tell us what is known about the role of brain insulin and glucose metabolism specifically in the brain? And as APOE4 carriers, do we essentially practice the same measures we would to have healthy blood glucose? You know, is the brain glucose metabolism system different than the blood glucose, and what is known about the role of development of Alzheimer's and that brain insulin metabolism? Dr. Yassine: This is a really good question. I think a lot of scientists are itching their brains to figure this out because it's not easy to answer or it's not very clear. What I can say is that E4 carriers, when they have dementia or mild cognitive impairment, they clearly show glucose hypometabolism in the brain using PET scans, which means when you inject an 18F labeled glucose, there's less uptake in the brain, meaning that the brain is unable to successfully use glucose as an E4 carrier or somebody with MCI or dementia. Now, if you dial this back and look at people without dementia or without MCI, the effect is low, meaning that it's not very clear if an APOE4 carrier is not capable of utilizing glucose. The concept is, you know, we're born with E4, right? So this is an age-related disease, and for maybe the longest time, the brain can utilize glucose. And, you know, something that's happening between the ages of 45 and 65, where the metabolism is changing, and it's becoming more taxing to utilize glucose, and maybe during that time the brain might prefer more fats. But again, this is all conceptual. Now you mentioned insulin. We don't know much about insulin signaling in the brain and it's overhyped. I think insulin is not required for glucose uptake into the brain. The brain can actually get glucose across the blood-brain barrier through pathways like GLUT3, which is independent of insulin. And that is really important because normal physiology means that we cannot rely on insulin to get glucose inside the brain. Otherwise, it's a catastrophe because you need glucose to maintain your cognition. Long story short, insulin signaling in the brain may be glucose independent. It might be related to something else besides glucose. It's been tied and associated with tau. In terms of lifestyle to enhance glucose sensitivity, I think it holds true for E4 carriers and non-carriers. In terms of what do you make of this information? You could see that in my advice to people, I suggest a high fiber diet, a high fat diet that's rich in good fats. And the fundamental reason for that is because we think a good microbiome with a high fiber and high fat is something that the E4 brain likes, but that does not mean ketogenic diets. Audience Question: On HSV and Alzheimer's[Phoenix Member]: I'd also ask for those of us who are HSV positive but never had any outbreaks, [what is the connection to Alzheimer's risk]? Dr. Yassine: I honestly don't know, but again, this is an area that requires more research. I know there's a lot of questions on social media about this particular topic. Many people show strong evidence either way. I just would ask for caution and not to have any strong opinions on any particular topic simply because we really don't know. There are so many people with HSV infections who may or may not get dementia. Making a big claim when there's not good quality studies is premature. So I don't, I really don't know. Audience Question: On Exogenous Ketones[Phoenix Member]: I was wondering what your opinion was on beta-hydroxybutyrate or exogenous ketones. Is that something that you feel is a good idea for E4 carriers? Dr. Yassine: We don't know. We wrote a review a few years ago on the fact that if the argument that E4 carriers need to take a ketone supplement because glucose is not working—and I'm happy to share it with Kevin, with all of you—it seems it's also not working for ketones. So if the brain is in this state, like MCI or dementia, where it's not able to utilize glucose, it may not also be able to utilize ketones. So I don't know where this concept is being circulated that yes, you need to switch to supplements because of the alternative energy fuel. I don't know if that concept is true. All what I'm saying is we need research. It might be true, but we still need more research. Closing Thoughts: The Tension Between Scientific Rigor and Patient Urgency As our interview with Dr. Yassine drew to a close, his message was clear: while the urgency felt by APOE4 carriers is understandable, the path forward requires both patience and scientific rigor. His parting advice emphasized the importance of supporting more research specifically focused on APOE4 carriers, as this remains the only way to definitively answer the many questions that persist about effective interventions. [Kevin's Final Reflection: This conversation beautifully illustrates the fundamental tension we face as APOE4 carriers. Dr. Yassine represents the voice of scientific caution—necessary, important, and grounded in decades of research. But for those of us carrying this genetic risk, especially homozygotes like myself with a 10-33x increased risk, waiting isn't always an option.The difference between a scientist and a patient-biohacker isn't about intelligence or understanding of science—it's about risk tolerance and time horizons. Dr. Yassine can afford to wait 10 years for definitive trials because that's his job: to find truth through rigorous methodology. But we can't wait 10 years. By then, the pathological cascade may have progressed too far.This doesn't mean we should abandon scientific thinking or embrace every unproven intervention. It means we need to be smart about calculated risks. The Phoenix Community exists precisely in this gap—between the glacial pace of clinical research and the urgent need for action. Every intervention we discuss, every experiment we run, every protocol we test—we do so with full acknowledgment that we're operating in the realm of the experimental. We track, we measure, we compare notes, we adjust. We're not claiming certainty; we're claiming agency.Whether you choose to wait for more robust evidence or embrace the hope and potential of emerging interventions today, that choice is ultimately yours. What matters is that you make it with eyes wide open, understanding both the risks and the potential benefits.]If you want to go further: join the Phoenix CommunityReady to take control of your cognitive future? The Phoenix Community brings together APOE4 carriers and others concerned about brain health to share experiences, run structured experiments, and support each other through this journey. Whether you lean toward Dr. Yassine's cautious approach or feel compelled to explore emerging interventions, you'll find a home in our community. We host regular Q&As with leading researchers, provide frameworks for safe self-experimentation through our Phoenix Experiment protocols, and offer the peer support that's often missing from the traditional medical system. What you'll get: Access to expert interviews and AMAs like this one with Dr. Yassine Structured protocols for testing interventions safely (our XP-Packs) A supportive community of people who truly understand what you're facing Science-based resources without the hype or snake oil Monthly pod matching for accountability and support Don't face APOE4 alone. Join hundreds of members who are turning anxiety into action, fear into focus, and isolation into community. Apply to join the Phoenix community todayThe Phoenix Community and Dr. Kevin Tran extends their gratitude to Dr. Hussein Yassine for his time, candor, and commitment to advancing our understanding of APOE4 and Alzheimer's prevention. While we may sometimes differ in our approaches, we share the same goal: helping APOE4 carriers beat the odds. --- ## Is Valiltramiprosate a Magic Pill for APOE4 carriers? URL: https://apoe4.co/blog/posts/is-valiltramiprosate-a-magic-pill-for-apoe4-carriers-f81b Published: 2025-08-26T16:27:47+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: research, cognition, community Summary: Valiltramiprosate shows remarkable promise for APOE4 carriers: 52% slower decline, brain volume preservation, and a simple daily pill that could revolutionize Alzheimer's prevention strategies. Is Valiltramiprosate a Magic Pill for APOE4 carriers?Great results for APOE4s, and a potential short term solutionDr. Kevin Tran August 26, 2025 Even though the clinical trial did not meet it's primary end point, the results are very encouraging for APOE4 carriers: Main results: 52% benefit on ADAS-cog, maintaining above baseline for 52 weeks (p=0.04) 102% benefit on CDR-SB, remaining at baseline for 78 weeks Zero ARIA-E or ARIA-H across all patients Hippocampal volume protection (p=0.04) correlating with clinical benefit (r=0.89) Brain preservation Preservation of brain volume, a decrease in atrophy Protection across all brain regions Strong correlation between brain preservation and cognitive benefit Some patients showed brain volume increase (neurogenesis?) And here's the kicker: it's just a pill. 265mg twice a day. No monthly infusions. No MRI monitoring every 3 months. No crazy side effects like ARIA No $56,000 annual cost. The drug works by preventing oligomers (those invisible toxic proteins that are 10x worse than the plaques we see on scans) from ever forming. What was also very interesting for me:Patients with the Arctic mutation have full Alzheimer's with completely CLEAN brain scans.Their brains are being destroyed by these oligomers we can't even see.This drug stops that process. Here's a blog post about Homotaurine a potential short term solution while we wait for Valiltramiprosate https://blog.thephoenix.community/p/alz-801-trial-results If you are interested to run an experiment with Homotaurine, I have created a post in our Experiment space in the Phoenix Community. If you are not in, here’s the best time to join us before we move away from the Founding Member period (= lifetime access instead of monthly subscription). Apply to join the Phoenix Community here. Cheers, Kevin --- ## 4-year Alzheimer's trial data just dropped - 69% of early-stage patients showed zero decline URL: https://apoe4.co/blog/posts/4-year-alzheimer-s-trial-data-just-dropped-69-of-early-stage-patients-showed-zero-decline-and-there Published: 2025-08-20T19:38:37+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: research, cognition Summary: Breakthrough Alzheimer's trial reveals hope: 69% of early-stage patients showed zero decline, with promising therapies offering new strategies for APOE4 carriers. 4-year Alzheimer's trial data just dropped - 69% of early-stage patients showed zero decline and there's finally good news for APOE4 carriersDr. Kevin Tran August 20, 2025 In this video, I analyze recent clinical trial findings that highlight what’s on the horizon for innovative therapies targeting APOE4 carriers and Alzheimer’s disease. The game-changing findings:Lecanemab (4-year data from Yale): 56% reduction in progression to dementia 69% of low-tau patients had ZERO decline after 4 years Safety update: 92% of ARIA happens in first 6 months, then drops to placebo levels Donanemab (3-year data from Eli Lilly): Benefits DOUBLED over time (0.6 to 1.2 CDR-SB points) Starting 18 months earlier = 27% better outcomes This suggests actual disease modification, not just temporary slowing Obicetrapib (surprise finding from Amsterdam): It's an oral cholesterol drug (CETP inhibitor) APOE4/4 carriers showed 20% reduction in P-tau217 First oral medication showing specific benefit for E4 carriers Reality check:These drugs slow decline, they don't reverse existing damage. But the fact that benefits keep growing over 4 years (instead of plateauing) is huge. It suggests we're actually changing the disease trajectory. The critical message:If you're at risk, get tested early. The difference between starting treatment immediately vs waiting 18 months is massive. If you are an APOE4 carriers, join us in The Phoenix Community and take action TODAY The insights are summarized from the July 2025 Alzheimer’s Association International Conference session, Developing Topics on Innovative Therapeutic Approaches. I do not have any affiliation with any of the companies mentioned in this video. I am an APOE4/4 carriers looking for solutions myself and sharing what I learn along the way in the Phoenix Community and occasionally with other groups.Sources:The insights are summarized from the July 2025 Alzheimer’s Association International Conference session, Developing Topics on Innovative Therapeutic Approaches. Researchers in this session: John R. Sims (Eli Lilly and Company, IN, USA) - Donanemab in Early Symptomatic Alzheimer's Disease: Efficacy and Safety from the TRAILBLAZER‐ALZ 2 Long-Term Extension Christopher H van Dyck (Yale School of Medicine, CT, USA; Alzheimer's Disease Research Unit, Yale School of Medicine, CT, USA) - The Lecanemab Clarity AD Open-Label Extension in Early Alzheimer’s Disease: Initial Findings From the 48-Month Analysis Hui-dong Tang (Department of Geriatrics, Medical Center on Aging of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, China) - Microglial Activation Correlates with Amyloid Clearance and Cognitive Benefit in Lecanemab-Treated Early AD Patients Philip Scheltens (Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Netherlands) - Effects of Obicetrapib, a Potent Oral CETP Inhibitor, on Alzheimer's Disease Biomarkers in 1727 Patients with cardiovascular disease --- ## MIT's "Disco Light" Brain Therapy: What Every APOE4 Carrier Needs to Know about Red Light Therapy URL: https://apoe4.co/blog/posts/mit-s-disco-light-brain-therapy-what-every-apoe4-carrier-needs-to-know-about-red-light-therapy-bc33 Published: 2025-08-14T19:15:45+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: therapies, cognition, research Summary: Unlock MIT's breakthrough red light therapy (Photobiomodulation) for APOE4 carriers: Discover how 10-minute daily sessions can boost brain health, memory, and combat Alzheimer's risk. MIT's "Disco Light" Brain Therapy: What Every APOE4 Carrier Needs to Know about Red Light TherapyAll your questions about Photobiomodulation answeredDr. Kevin Tran August 14, 2025 If you're carrying APOE4, you've heard it all: "Just eat well and exercise." "We'll know more in 10 years." "There's nothing definitive." A few days ago, we hosted Chris Garvin from Neuronic, revealing data that challenges everything we thought we knew about E4 and brain intervention. Can a helmet improve brain health?1070nm near-infrared light, applied for just 10 minutes daily, produces measurable brain changes in 3-4 weeks. Not years. Not months. Weeks. Here's what the evidence shows: The Science University of Texas Arlington Study (Science Advances, 2022): 90 healthy adults tested Significant working memory improvements Right prefrontal cortex targeting = maximum effect MIT's Parallel Discovery (Dr. Li-Huei Tsai): 40Hz light clears amyloid via glymphatic system Same mechanism, different approach Currently in Phase 3 trials via Cognito Therapeutics Why APOE4 Carriers Respond Better Your E4 brain has three specific vulnerabilities that photobiomodulation directly addresses: Compromised Waste Clearance (55-65% reduced) → Light triggers nitric oxide → vasodilation → enhanced clearance Mitochondrial Dysfunction → Direct ATP production stimulation → energy crisis resolved Chronic Neuroinflammation → Microglial phenotype shift → inflammation reduction The Practical ProtocolDevice: Neuronic 1070nm helmet Duration: 10 minutes daily Timing: Morning optimal Results Timeline: 3-4 weeks for subjective changes Investment: $1,795 (get 10% off with THEPHOENIX)Risk Mitigation: 3-month money-back guarantee Who's Already Using This? Cleveland Clinic ($15M research investment) NFL players (concussion prevention) Long COVID brain fog sufferers Early-stage Alzheimer's patients Preventive biohackers The Critical Questions Before you invest in ANY intervention, you need a framework for evaluation. That's exactly what we're covering tomorrow. Join Us Live: Dr. Hussein Yassine, USC.APOE4 - Smart Science for Actionable PreventionFriday, August 15th - Exclusive Phoenix Community Q&ASession Dr. Yassine, Director of USC's Center for Personalized Brain Health, will teach you: How to evaluate studies (RCTs vs. observational vs. mechanistic) When to act on early evidence vs. wait for robust data (the E4 carrier's dilemma) How to design safe self-experiments (tracking, biomarkers, safety) Which interventions deserve your attention NOW His lab has discovered: Small HDL particles in CSF are protective (developing peptide agents) cPLA₂ enzyme drives E4 inflammation (new blockers 100x more potent) ABCA1 pathway restoration as drug target This is your chance to ask the tough questions directly to a leading APOE4 researcher.Why Phoenix? We're not waiting for pharmaceutical salvation. We're running structured experiments, sharing data, and discovering what actually works. Inside the Phoenix, you get: Direct access to experts like Chris Garvin and Dr. Hussein Yassine Community-verified protocols and results Group buying power to buy devices like Neuronic’s at a discounted price Structured experiment frameworks Real-time support from hundreds E4 carriers taking action And more :) Ready to stop hoping and start doing?Join the phoenix community here Sources:Chris Garvin, from Neuronic --- ## The ultimate proof that Lifestyle Interventions work against Alzheimer's risk URL: https://apoe4.co/blog/posts/the-ultimate-proof-that-lifestyle-interventions-work-against-alzheimer-s-risk Published: 2025-08-12T15:35:00+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: research, protocols, nutrition, exercise Summary: Breakthrough research reveals ApoE4 carriers can slash Alzheimer's risk by 50% through targeted lifestyle interventions—proven strategies to transform brain health and defy genetic odds. The ultimate proof that Lifestyle Interventions work against Alzheimer's riskDiscover how scientists slashed Alzheimer's disease risk by halfDr. Kevin Tran August 12, 2025 The most important Alzheimer's research of 2025 just dropped, and it completely reframes what it means to carry APOE4. I just published a deep-dive video on findings from the AD/PD International Conference that every APOE4 carrier needs to see: The Headline: APOE4 carriers respond BETTER to structured lifestyle interventions than non-carriers. The Evidence: 150% greater improvement in processing speed (vs 60% in non-carriers) 83% better executive function outcomes 60% reduction in multi-morbidity Sustained benefits 11 years after intervention The Mechanism: The same pathways that make APOE4 carriers vulnerable (lipid metabolism, glucose regulation, inflammation) are the exact ones that respond most dramatically to intervention. The Urgency: Biomarker data (p-tau217) shows early intervention is critical. Wait too long, and the window narrows significantly. The Protocol: The FINGER trial's five-domain approach isn't revolutionary in its components - it's revolutionary in its systematic application and proven outcomes. What This Means: If you carry APOE4, you're not less treatable - you're potentially MORE responsive to the right interventions. But timing matters. Those who start with lower p-tau217 levels see dramatically better results.The FINGER protocol isn't complex - it's systematic: Mediterranean-style nutrition Zone 2 cardio + strength training Cognitive engagement Social connection Vascular risk management Watch the full breakdown here: We're implementing these protocols in The Phoenix Community with personalized protocols, tracking, and peer support. This is the best way to beat the odds!But whether you join us or not, please watch this video. The data could change everything about how you approach your APOE4 status. Cheers,Kevin Sources: Expert in the video: Dr. Miia Kivipelto - Professor of Clinical Geriatrics at Karolinska Institutet, Center for Alzheimer Research, and senior geriatrician and Director for Research & Development of Medical Unit Aging at Karolinska University Hospital in Stockholm, Sweden. ADPD Conference topic: PIVOTAL POINTS IN PREVENTION TRIALS AND THE NEW ERA OF PRECISION MEDICINE FOR ALZHEIMER’S DISEASE AND RELATED DISORDERS --- ## APOE4 carriers: Your brain's immune system may already be compromised URL: https://apoe4.co/blog/posts/apoe4-carriers-your-brain-s-immune-system-may-already-be-compromised-8454 Published: 2025-08-06T14:53:41+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: research, cognition, tracking Summary: Uncover how APOE4 rewires brain immunity from birth and explore cutting-edge strategies to activate your brain's natural defense mechanisms against neurodegeneration. APOE4 carriers: Your brain's immune system may already be compromisedResearchers just revealed why APOE4 rewires brain immunity from birth—and potential ways to reverse it...Dr. Kevin Tran August 06, 2025 Picture this: You're in your 30s or 40s, feeling sharp, crushing it at work, maybe even beating your kids at memory games. But if you carry APOE4, your brain's cleanup crew (the microglia) might already be failing at their job. Not failing in the future. Not when you're 70. Right now. I just spent the weekend analyzing 15 groundbreaking insights from the Alzheimer's Association International Conference (the one from March 2025, I am now moving to the one that happened last week in Toronto), and what I found changes how we think about APOE4 prevention. Here's the headline: APOE4 doesn't just increase your Alzheimer's risk, it fundamentally rewires your brain's immune system from birth. The key discoveries: 🧠 Your microglia are stuck in overdrive while failing at cleanup In the chimera experiments, human APOE4 microglia transplanted into mice showed the worst dysfunction: moving chaotically, responding poorly to injury, and leaving debris behind. It's like having security guards who panic at everything but miss actual threats. ⚡ Mitochondrial shutdown starts early The gene CHCHD2 (critical for cellular energy) completely disappears in APOE4 microglia. Your brain's immune cells are literally running on fumes, even if you feel fine. 🧬 Fibronectin creates "molecular velcro" for amyloid APOE4 transforms your blood vessel support cells into scar-tissue factories. They pump out fibronectin,(a sticky protein that acts like velcro for amyloid). This explains why some Alzheimer's drugs cause bleeding in APOE4 carriers. ☀️ The vitamin D connection no one talks about APOE2 carriers (the protected ones) have enhanced vitamin D receptor signaling and IL-10 anti-inflammatory pathways. APOE4? We're missing these built-in brakes. If you have darker skin or live far from the equator, this double-hit could be accelerating your risk. But here's the hope: Researchers found that blocking TGF-beta actually reversed the blood vessel damage. Pericytes returned to their posts. Fibronectin decreased. The blood-brain barrier began healing. This is more than just slowing decline: it's cellular reprogramming. Some APOE4 homozygotes stay sharp into their 90s because of natural fibronectin mutations. They've got the genetic equivalent of teflon while the rest of us have velcro. I break all of this down in a new video where I translate the conference findings into plain English and explain what you can actually DO with this information. The old playbook said "eat blueberries and do crosswords." The new science says: Target microglia. Optimize vitamin D. Protect your blood-brain barrier. Track inflammation markers. Start now. Because waiting for symptoms means waiting 20 years too long. Stay sharp, Kevin P.S. After watching, I'd love to hear what surprised you most. The mitochondrial collapse data? The vitamin D angle? Or that damage might be reversible? Hit reply and let me know: I read every email. P.P.S. If you're ready to turn this science into action with hundreds other APOE4 carriers running structured experiments and sharing what works, check out the Phoenix Community. Dr. Kevin Tran is the founder of the Phoenix Community for APOE4 carriers and a Doctor of Pharmacy with two copies of the APOE4 gene. This newsletter shares cutting-edge research translated for practical prevention.Sources:Alzheimer's Association International Conference on APOE and Lipid Biology (AAIC March 2025) Scientific References (name of Researcher and Session presented): Sarah Marzi, King’s College London, United Kingdom Oligodendrocytes and Mural Cells Joel Blanchard, Mount Sinai, United States Oligodendrocytes --- ## 186 posts, 50+ experiments, 1 mission: What Phoenix members are testing this month URL: https://apoe4.co/blog/posts/186-posts-50-experiments-1-mission-what-phoenix-members-are-testing-this-month-582d Published: 2025-08-05T15:35:00+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: community, supplements, tracking, exercise Summary: Dive into Phoenix's cutting-edge ApoE4 research: 186 posts, 50+ experiments, and real-world insights revealing breakthrough strategies for brain health and genetic potential. 186 posts, 50+ experiments, 1 mission: What Phoenix members are testing this monthShould you try phospholipid DHA? Is Alpha GPC worth it? What about those fishy omega-3s? Phoenix members are testing everything and sharing real results.Dr. Kevin Tran August 05, 2025 Looking at the Phoenix Community discussions from the past month, I'm struck by the sheer depth and variety of what our members are exploring together. Let me give you a glimpse inside our community. The conversations that matter mostCutting-edge research discussions are lighting up our forums. Members are diving deep into the latest APOE4 breakthroughs: from protective variants that block Alzheimer's through different mechanisms to memory reversal studies that challenge everything we thought we knew. The ALZ-801 trial updates have sparked particularly intense debate about prodrug approaches for 4/4 carriers. But here's what makes Phoenix different: we don't just read the studies. We dissect them. Question them. Apply them. Real-world supplement experimentation dominates our threads. Should you use phospholipid-form DHA? What about Alpha GPC as a "no regret" supplement? Members are sharing actual results from their rapamycin trials, methylene blue experiments, and statin protocols. One member's 90-day lipid transformation on statins and ezetimibe triggered a cascade of insights about personalized approaches to cholesterol management. The cooking oil debate alone generated dozens of evidence-based perspectives (spoiler: it's more nuanced than you think). Exercise optimization gets precision-focused. VO2max improvements from 37 to 50 in 7 months? Check. Zone 2 vs Zone 4/5 training protocols? Hotly debated. Members aren't just exercising: they're optimizing based on their genetics, tracking results, and sharing what actually moves the needle. The emotional journey gets equal attention. "You're not alone—this space is for the emotional side of the journey" perfectly captures our ethos. From advance directive planning to dealing with PET scan results showing substantial plaque buildup, members support each other through the tough moments with both empathy and actionable advice. Accountability drives action. Weekly goal threads keep members on track. But these aren't your typical "drink more water" goals. Members are tracking p-tau217 levels, running structured supplement experiments, and measuring cognitive improvements from intensive lifestyle changes. Why this matters Every single day, Phoenix members are: Testing interventions most doctors haven't heard of yet Sharing biomarker results that inform everyone's protocols Supporting each other through diagnosis, testing, and optimization Translating complex research into real-world action We are NOT a passive support group. It's an active laboratory of people determined to beat the odds. The conversations you're missing could change your trajectory. While you're reading this, someone in Phoenix is sharing their successful protocol for improving hippocampal blood flow. Another is decoding the latest research on glymphatic system enhancement. A third is getting encouragement to finally start that exercise program they've been putting off. Ready to join these conversations? Apply to join the Phoenix here → We're selective about who joins: because the quality of our community depends on it. But if you're serious about taking control of your brain health future, you belong here. See you inside, Kevin P.S. Next week, members are diving into the new estrogen and brain health research, comparing direct-access testing options by state, and experimenting on sleep optimization techniques. Don't miss out. All discussions from the past month:🧬 Research Latest on ALZ-801 trial Large POINTER study finds cognitive improvements with intensive structured lifestyle changes We have to put this controversy to rest once and for all Deep dive into 3 protective APOE variants that block Alzheimer's How to lower APOB Huge study showing benefits of two common vaccines, Shingles and RSV Interesting article from Peter Attia on inducing ketosis Suvorexant AD clinical studies The Overlooked Role of Protein in APOE4 and Alzheimer's Prevention Your Ancestry Changes How ApoE4 Works: 3 Breakthroughs Reevaluating the role of education on cognitive decline What I learned from Rhonda Patrick's analysis APOE4: Scientists reversed memory loss + found social factors override genetics APOE ε4 carriers share immune-related proteomic changes Anyone tried Dr Goodenowe's ProdromeScan? 3X4 Genetics- Memory and Brain Health Snps New ApoE4 Science About Estrogen and Brain Health! Small human pilot study shows 20g creatine supplementation improved brain energetics ApoE4 & Alzheimer's: 11 New Discoveries That Changed My Game Plan Vaccines and dementia (Small) study says intense lifestyle changes can not only stop but even reverse Alzheimer's ApoE4? New Brain Protection Breakthroughs Every Carrier Must See Varicose veins and dementia Ezetimibe for prevention 💊 Supplements, Nutrition, and Medication What oil do you use for cooking? Could Statins Be Our Secret Weapon Against Dementia? Update on Lipids after 90 days on statin and ezetimibe Online Source for peptides These Omega-3s, they smell fishy... Next Intervention - Rapamycin Phospholipid-form DHA - what do you use? Methylene Blue? Choline (Alpha GPC), big "no regret" supplement I Have Stopped Taking Ezetimibe My view about keto: not adapted when doing 12h+ of sport per week Has anyone used Saffron? Microdosing Semiglutide Nut Pods Y or N Protein Bars LPC-DHA (Lysoveta) Dairy fat, Cheese, Cream.. Are they all equally bad for LDL-C? Cholesterol medication? Ursolic acid Quality control on Supplement brands Psyllium husk - For fiber and tactical use to blunt absorption Cure for Alzheimer's? Is Alcohol good or bad for you? In moderation or not at all? Anyone with experience with Kisunla (donanemad-azbt)? Modified Citrus Pectin (MCP) and stress reduction What do you do to keep lipids under control? 🏃 Sports, Sleep, and Stress Management Finally focusing on VO2 Max / Zone 4/5 Training Sleep Optimization Sleep Trackers Research & More, Matthew Walker Interview What sports / activities do you do? Neuroplasticity Thread Sleep optimization with mouth taping Outsized effect interventions for brain clarity / avoiding brain fog Factors affecting sleep - mystified When I found out I had APOE4/4, my brain played tricks on me NSDR - Non Sleep Deep Rest VO2max from 37 to 50 in 7 months 🔬 Biomarkers, Tracking, Monitoring Lipoprotein(a) (Lp(a)) Cost of beta amyloid 40/42 and p-tau217 tests Klotho may really help.. Obicetrapib - Delayed Progression p-Tau217 Any experience with Care Access screenings? Direct-Access Testing by U.S. State Cholesterol Balance Test Hyper absorb or Hyper produce 🧠 Mental Health & Emotional Resilience You're not alone — this space is for the emotional side of the journey URGH! I'm overwhelmed and burnt out. PET scan results indicate BAPL3, indicating substantial plaque build up 💻 Tech and Medical Devices Brain Health Dosing with Red Light Therapy Red Light Therapy Wearables 🧬 Genetics My Genetics 🎯 Goals and Accountability July 28-August 11 Weekly Goals and Accountability Thread July 21-28 Weekly Goals Support and Accountability Thread July 14-21 Weekly Goals and Accountability Thread July 7 -14 Goals and Accountability Weekly Thread June 30 Goals and Accountability Weekly Thread June 23rd Weekly Goals and Accountability Thread 📢 Announcements Your Phoenix Monthly Check-In Just Got Smarter (And Way More Personal) Shape the Ultimate Personalized APOE4 Protocol: Decide Which Features Matter to You! June update: Vote for our new look! [Action Needed] June Monthly Check-In Time!! Remember to fill yours! 🎁 Perks and Partnerships Whole Genome Sequencing: Nucleus Whole Genome Sequencing: Sequencing.com 📔 Open Journal New Experiment with Methylene Blue! 🤝 General and Off Topic Opening address for Thurs July 31, 2025 at AAIC AAIC presentation: The Importance of Early Detection Handgrip study Blacked out 1 week of memory after taking meds for muscle / nerve injury Labcorp vs Quest Alzheimer's Association International Conference, Toronto, Canada Made a Decision on Kisnula Today Long Term Care insurance - especially USA Increase in T-p-tau181 Advanced Directive (More than Medical!) --- ## Hope for APOE4 Carriers (ALZ-801 Trial Results + Options Available Today) URL: https://apoe4.co/blog/posts/alz-801-trial-results Published: 2025-08-04T15:25:23+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: research, cognition Summary: Breakthrough APOE4 trial results reveal hope: Discover how ALZ-801 may transform brain health for high-risk carriers and the proactive strategies you can explore today. Hope for APOE4 Carriers (ALZ-801 Trial Results + Options Available Today)Why some Phoenix members aren't waiting, and the experimental protocol we're developingDr. Kevin Tran August 04, 2025 Note: This post covers both the promising ALZ-801 clinical data and practical considerations for those exploring available options today - see the final section for details.I'm not affiliated with Alzheon and have no financial ties with Alzheon or Homotaurine of any kind. This post is based on the July 2025 AAIC session titled “Inhibition of Beta Amyloid Oligomer Neurotoxicity with Oral Valiltramiprosate.”A Major Development That Created Hope in Our Community The recent ALZ-801 clinical trial results have generated significant interest and hope among Phoenix members, particularly those who carry the APOE4 gene variant. For good reason: this represents a fundamental shift in how we might approach Alzheimer's treatment for high-risk individuals. At the recent Toronto AAIC 2025, leading researchers presented data showing APOE4 carriers responding better to treatment than non-carriers (probably because we make more toxic oligomers) Understanding Why This Matters: The Oligomer Problem Dr. Sam Gandy from Mount Sinai explained the core issue: we've been targeting the wrong enemy. Current drugs clear visible amyloid plaques, but the real damage comes from invisible oligomers - small toxic protein clusters that directly damage brain synapses. For APOE4 carriers, this is especially relevant because we may produce ~3x more of these toxic oligomers. Current antibody treatments often cause dangerous brain swelling (ARIA) in 40% of APOE4 carriers, making them essentially unusable for many. The ALZ-801 Clinical Results Dr. John Hey presented compelling data from the APOLLOE4 trial focusing on patients with mild cognitive impairment (MCI): Cognitive Outcomes52% benefit on ADAS-Cog (cognitive assessment) 52% less decline than placebo 102% benefit on CDR-SB (functional abilities) No decline on the functional endpoint Some patients showed no decline over 78 weeks Translation: Patients maintained their ability to perform daily activities while placebo patients lost function. Brain Preservation Preservation of brain volume, a decrease in atrophy Protection across all brain regions Strong correlation between brain preservation and cognitive benefit Some patients showed brain volume increase (neurogenesis?) This is remarkable: actual brain growth in some patients considered “super responders”. Compare this to current treatments where even slowing atrophy is considered a win. The strong correlation with cognitive benefits suggests we're seeing real neuroprotection, not just symptom management. Revolutionary Safety ProfileZero ARIA-E (brain swelling) Zero ARIA-H (microbleeds) Most common side effect: mild nausea This safety profile is game-changing, especially for APOE4 carriers. Consider that Leqembi causes ARIA-E in 20% of all patients and 40% of APOE4 carriers. Aduhelm is even worse. Some ARIA cases have been fatal. Patients need frequent MRI monitoring, and many APOE4 carriers simply can't take these drugs due to safety concerns. Zero ARIA means APOE4 carriers can finally access treatment without fear of brain swelling or bleeding. This transforms a genetic disadvantage into a therapeutic advantage. The Mechanism: Prevention vs. Cleanup Dr. Kenjiro Ono's research showed ALZ-801 works differently than any current treatment: Prevents oligomer formation rather than clearing them Changes protein shape to prevent toxic clustering Achieves 40% brain penetration as an oral medication Uses 265 mg twice daily dosing The oral delivery is revolutionary for patient quality of life. While Leqembi and Donanemab require: Monthly IV infusions at specialized centers 1-2 hours per infusion plus travel time IV access challenges in elderly patients Significant caregiver burden $26,500+ annual costs ALZ-801 offers: Simple twice-daily pills at home No infusion centers or travel No IV complications Minimal caregiver burden Projected to cost 70% less For APOE4 carriers who often face decades of treatment, the difference between monthly hospital visits versus taking pills with breakfast and dinner is transformative. This isn't just about convenience - it's about sustainable, long-term treatment that people can actually maintain. For Phoenix Members: The Current Reality This trial has understandably created significant hope in our community. ALZ-801 is currently in Phase 3 trials with a confirmatory study planned. But what about those who don't want to (or can’t) wait? The Homotaurine Question ALZ-801 (valiltramiprosate) is a prodrug of homotaurine (tramiprosate), a naturally occurring compound first discovered in red algae in the 1950s. Homotaurine has been studied for decades.It's structurally similar to the neurotransmitter GABA and was originally investigated for epilepsy before researchers discovered its anti-amyloid properties in the 1990s. The compound gained attention when Neurochem (now Bellus Health) developed it as Alzhemed and ran large Phase 3 trials in the mid-2000s. Those trials failed, but the story didn't end there: researchers realized the issue wasn't the mechanism but the delivery. What you need to know:Availability : Homotaurine is sold OTC in several countries (Canada, Europe..) The FDA has effectively blocked its sale in the US (likely related to ALZ-801 patent protection) Critical Dosing Differences: ALZ-801: 265 mg twice daily (as valiltramiprosate) Failed homotaurine trial: 100-150 mg twice daily The higher ALZ-801 dose may partially explain its success Why the Original Trial Failed: The Alphase study (2011) showed homotaurine failed due to: Poor and inconsistent bioavailability High gastrointestinal side effects (nausea, vomiting, weight loss) Inadequate brain concentrations The 100-150 mg doses were likely too low Tested on the general population (instead of focusing on APOE4 carriers who may benefit more from ALZ-801 because we produce ~3x more toxic oligomers) The Prodrug Advantage: ALZ-801's valyl ester modification: Dramatically improves absorption Maintains stable blood levels Reduces GI side effects Achieves therapeutic brain concentrations This is one of the cases where pharmacodynamics are similar but pharmacokinetics make a lot of difference. Making an Informed DecisionFor those considering homotaurine:Understand the limitations: The failed trial used 100-150 mg BID (twice daily). Even if you match ALZ-801's equivalent dose, you won't achieve the same bioavailability Consider the math: To potentially match ALZ-801's brain levels, you might need significantly higher homotaurine doses, increasing side effects Monitor carefully if exploring any intervention: Track biomarkers regularly Work with knowledgeable practitioners Be prepared for GI side effects Realistic expectations: Homotaurine ≠ ALZ-801 in effectiveness BUT, it might be better than nothing. This could be one of those situations where even a lower dose might produce some results, as long as the side effects are well tolerated. The Phoenix Experiment I'm creating a special Phoenix Experiment protocol for those interested in exploring this option. This will be directly accessible within the Phoenix Community. The protocol will include: Proper dosage titration strategies Essential tests to perform before and after Methods to measure if it's moving the needle You have to procure Homotaurine yourself (I’ll analyze and recommend brand options) If you live in the US, and can’t get access to it, please read the post in our private Phoenix Community If you are not a member yet, you can apply here. Exciting times.Let’s beat the odds!-Kevin Important Disclaimer: This information is for educational purposes only. Do not make any treatment decisions without consulting qualified healthcare providers.Though I hold a Doctorate of Pharmacy, and providing medical guidance is typically central to that role, this is NOT medical advice. My license is limited to France and select EU countries, and more importantly, this approach remains too experimental for formal recommendation. I simply believe, as a 4/4 carrier myself, there may be potential benefits worth exploring, and that informed individuals should have access to complete information to make their own decisions.Please carefully weigh the pros and cons, consult with your healthcare providers, and make decisions based on your individual situation and risk tolerance. Source: Alzheimer's Association International Conference (AAIC July 2025)Alzheon p --- ## You know you're APOE4. That's half the story (Phoenix Expert Q&A) URL: https://apoe4.co/blog/posts/you-know-you-re-apoe4-that-s-half-the-story-phoenix-expert-q-a-5090 Published: 2025-08-01T15:46:32+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: community, tracking, cognition Summary: Uncover the hidden genetic secrets beyond your ApoE4 status: Decode your complete genetic profile and learn personalized strategies to proactively protect your brain health. You know you're APOE4. That's half the story (Phoenix Expert Q&A)23andMe told you you're an APOE4 carrier, but that's like knowing you're in a storm without having a weather map.Dr. Kevin Tran August 01, 2025 23andMe told you you're an APOE4 carrier, but that's like knowing you're in a storm without having a weather map. Here's what they didn't tell you: Your APOE4 status interacts with hundreds of other genetic variants. Some amplify your risk. Others might actually protect you. And most carriers have no idea which camp they're in. That's why this month's Phoenix Expert Q&A hits different. I sat down with Kian Sadeghi, Founder of Nucleus, to decode what whole genome sequencing reveals that consumer genetic tests miss—and more importantly, how to turn that data into protocols that actually move the needle. What we covered: The hidden genetic variants that modify APOE4 risk (minute 12:34) Why some APOE4/4 carriers never develop Alzheimer's (minute 18:45) How to build precision protocols based on your complete genetic profile (minute 25:12) The specific genes that determine whether keto helps or hurts (minute 31:08) Watch the full Q&A here:  About our partnership philosophy: We always maintain 100% independence. We never have any financial incentives to share about partners. We always ask our partners to pass on any affiliate fees straight back to you as member discounts. Because being unbiased matters when we are dealing with ApoE4. Exclusive Phoenix discount: Use code PHOENIX10 for 10% off whole genome sequencing with Nucleus Not a member yet? This is exactly why we built the Phoenix Community: to turn overwhelming genetic information into clear, actionable protocols. Apply to join here Stay sharp,Kevin P.S. We are still in the “Founding Member” stage where we waive all recurring fees to join the Phoenix. We will switch soon to a monthly / yearly subscription fee for all new members as soon as we release our Phoenix Experiment module. Our cutting edge tech leverages AI and digital twins technology to help you find the interventions (and dosage) that works for you. It is based on guided structured n=1 experiments and community data on what works for people similar to you. You can learn more about our Alpha here. --- ## The woman who defied the Alzheimer's Disease odds (and what it means for APOE4 carriers) URL: https://apoe4.co/blog/posts/the-woman-who-defied-the-alzheimer-s-disease-odds-and-what-it-means-for-apoe4-carriers-1f50 Published: 2025-07-29T15:45:00+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: research, cognition, supplements, sleep Summary: Uncover how one woman defied Alzheimer's genetic odds with rare gene variants, offering hope and actionable insights for ApoE4 carriers to proactively protect brain health. And more insights on APOE2, Christchurch and Jacksonville variants. The woman who defied the Alzheimer's Disease odds (and what it means for APOE4 carriers)3 Alzheimer's-Blocking Genes Reveal What APOE4 Carriers Should Do DifferentlyDr. Kevin Tran July 29, 2025 Phoenix friends, Quick story that's been in my head: Woman in Colombia. Has the mutation for early-onset Alzheimer's (PSEN1). Should have developed symptoms at 44. Instead? Symptoms at 73. Her secret: Two copies of the Christchurch variant. But here's what's wild: her brain was FULL of plaques. The variant didn't prevent them. It prevented what came after. It blocked the tau cascade that actually destroys neurons. This completely changes how we think about the amyloid-tau relationship.Then I dug deeper in that conference and they covered the mechanism of action of two other protective variants: APOE2: Prevents amyloid from ever accumulating (like having a super-efficient garbage truck) Jacksonville (V236E): Improves lipid transport and prevents APOE aggregation (fixes the brain's delivery system) You are probably thinking: “Yeah Kevin, but I don’t have those protective genes. I carry ApoE4 and good for them, but what does it mean for me?” Researchers aren’t just studying these protective genes out of curiosity. They want to understand how they work so they can mimic their effects and eventually develop new therapies. Why this matters: Each variant works on a different part of the protein and targets a different disease mechanism. They're scattered across different protein domains—some affect receptor binding (N-terminal), others affect lipid binding (C-terminal). It's like having different tools that each fix a different part of the problem. So what am I actually doing with this?Still figuring it out, to be honest. But here's where my head is: For amyloid: Really doubling down on sleep quality and anything that enhances glymphatic clearance. If APOE2 keeps the brain "clean," maybe we can mimic that with better waste removal. For tau: This has me rethinking inflammation. The Christchurch variant seems to change how cells respond to stress. Cold exposure? Specific polyphenols? Still researching. For lipid transport: DHA supplementation makes even more sense. So does everything around metabolic health. The real question: Should we be targeting all three pathways instead of focusing over just one? I made a video breaking down all three mechanisms -Kevin P.S. Should mention this isn't medical advice. I’m just sharing research I'm personally tracking for obvious reasons. --- ## Your health data deserves better than dropdown menus URL: https://apoe4.co/blog/posts/your-health-data-deserves-better-than-dropdown-menus-16e3 Published: 2025-07-28T16:11:39+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: community, tracking Summary: Revolutionize your health tracking with personalized insights that go beyond dropdown menus, capturing your unique health journey with nuance and depth. Your health data deserves better than dropdown menusYou know that feeling when health forms ask for a 1-10 rating but you want to tell the whole story? We finally fixed that.Dr. Kevin Tran July 28, 2025 You know that feeling when you're filling out a health form and the dropdown menu options are... close to your experience, but not quite right? Like when the sleep quality scale goes from 1-10, but what you really want to say is: I slept 7 hours, woke up twice because my neighbor's dog has opinions about 3am delivery trucks, felt groggy until my second cup of coffee, but then had great focus all afternoon—oh, and I think the magnesium is helping but I'm not sure if it's that or the blackout curtains I installed last week. That messy, nuanced reality? That's exactly what we're now capturing inside the Phoenix Community. The Old Way vs. The Phoenix Way This month, our Phoenix Community members are experiencing something completely different with their monthly check-ins. Gone are the rigid dropdowns and restrictive checkboxes. Instead, they're finding open text fields that actually want their full story. Why the change? Because we're building something revolutionary. Every detail our members share: from how that new supplement made them feel on Tuesday morning to why they think their Zone 2 training is (or isn't) clicking becomes part of their digital twin. Beyond some abstract AI concept, I am building a continuously learning model that gets smarter about each member specifically with every data point they provide. Individual Intelligence Meets Community Wisdom Here's what's happening behind the scenes with all that rich information: Individual Intelligence: Each member's digital twin learns their unique patterns. Did that 16:8 fasting window work better when combined with cardio? Does their HRV improve more with morning walks or evening hot baths? We go beyond random correlation: we aim to get insights tailored to their biology, their schedule, their life. Community Intelligence: We're also analyzing patterns across members with similar health profiles. If you're a 58-year-old female APOE4 4/4 carrier dealing with brain fog, we're identifying what's working for others who share your genetic makeup, age, and symptoms. No more guessing whether that intervention you read about will actually work for someone like you. Precision Recommendations: Instead of generic advice, digital twins suggest specific interventions with specific dosages: "Based on your sleep patterns and stress markers, try 400mg magnesium glycinate 2 hours before bed for 4 weeks." Then we help design the perfect experiment to validate whether it's working. The Philosophy: Capture Everything, Analyze Later I know it might feel like we're asking for a lot of detail. But here's why: The most powerful insights often come from data points that seem insignificant in isolation. That random Tuesday when you felt unusually sharp? Maybe it was the extra 20 minutes of morning sunlight, or the fact that you had dinner 30 minutes earlier than usual, or that your stress level was lower because you finished a project. Digital twins eventually connect these dots in ways that would take years to figure out on your own. The Phoenix Experiment Platform is Coming (And What It Means for You) I've been absolutely buried in development work these past few weeks, but I'm beyond excited to share what I've been building. The full Phoenix Experiment platform is nearly ready, and I'll be conducting member interviews in the coming weeks to fine-tune the experience. You can learn more in this video Finally, a systematic approach to N=1 experimentation to know what works for APOE4 carriers like us. This platform transforms how our members approach personalized health optimization. The rich dataset they're building through monthly check-ins becomes the foundation for: Smarter experiment selection: Instead of wondering what to try next, members get evidence-based recommendations Better outcome tracking: We help identify the metrics that actually matter for their goals Community insights: Members see how their results compare to others with similar profiles Protocol refinement: Continuously optimize based on what's actually working With the upcoming release of the Phoenix Experiment module, we will be ending our Founding Member period soon.This is your last chance to secure a Founding Member spot with lifetime access. After this, all new members will be on a monthly/yearly subscription plan. This is the future of personalized health for APOE4 carriers, and it's happening inside the Phoenix Community right now. I can't wait to show you what we're creating. Kevin P.S. If you're curious about joining our community of APOE4 carriers who are taking control of their cognitive future through structured experimentation, hit reply. I'd love to hear from you. --- ## Your Ancestry Changes How ApoE4 Works: 3 Breakthroughs That Could Save Your Brain URL: https://apoe4.co/blog/posts/your-ancestry-changes-how-apoe4-works-3-breakthroughs-that-could-save-your-brain-9749 Published: 2025-07-22T14:58:00+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: research, cognition Summary: Uncover how your ancestral DNA uniquely shapes ApoE4's impact on brain health, revealing personalized strategies to potentially prevent Alzheimer's risk. Your Ancestry Changes How ApoE4 Works: 3 Breakthroughs That Could Save Your BrainScientists just discovered why some ApoE4 carriers never develop Alzheimer's—and it has everything to do with where your ancestors came fromDr. Kevin Tran July 22, 2025 Hi Phoenix Friends, What if I told you that two people could carry the exact same "Alzheimer's gene"—but face completely different futures? Not because of lifestyle. Not because of supplements. But because of something encoded in their DNA centuries ago. I just finished analyzing groundbreaking research from Dr. Aura Ramirez that's rewriting everything we know about ApoE4 and genetic risk. Here's the discovery that stopped me cold: When researchers examined brain cells from people of different ancestries, they found that ApoE4 behaves like a completely different gene depending on your genetic background. In African-ancestry brain cells: A hidden DNA segment acts like a volume knob, turning DOWN ApoE4 expression When scientists removed this "brake," ApoE4 expression shot up This natural suppressor doesn't exist in European DNA In European-ancestry brain cells: ApoE4 creates a dangerous imbalance Cholesterol production goes into overdrive But myelin (your brain's insulation) production crashes It's like revving your engine while your transmission falls apart In Amerindian-ancestry brain cells: The pattern completely flips Cholesterol pathways decrease Myelin production increases Same gene, opposite effect It’s not just some random abstract science. This is why some families devastated by Alzheimer's have ApoE4 carriers who live to 95 with sharp minds. It's why blanket statements about genetic risk are becoming obsolete. Watch my full breakdown of this research here:  In the video, I explain: How to think about your own ancestry and risk Why this discovery could lead to new treatments that mimic natural protection What you can do TODAY to work with your genetic profile, not against it The bottom line: Your genes are not your destiny. They're more like a recipe—and how that recipe turns out depends on the kitchen you're cooking in. Some of us inherited kitchens with built-in safety features we're just now discovering. And even if you didn't? We're learning how to renovate. To beating the odds together, Dr. Kevin Tran P.S. Know someone who needs to hear this? Forward this email. The more we spread hope over fear, the faster we'll solve this together. --- ## Two Exciting Phoenix Q&As Coming Up! Genetics and Photobiomodulation URL: https://apoe4.co/blog/posts/two-exciting-phoenix-q-as-coming-up-genetics-and-photobiomodulation-29e8 Published: 2025-07-21T15:33:00+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: community, therapies, cognition Summary: Unlock the power of your genome with two transformative Q&As: dive deep into whole genome sequencing and cutting-edge brain health strategies with Phoenix's expert-led sessions. Two Exciting Phoenix Q&As Coming Up! Genetics and PhotobiomodulationDr. Kevin Tran July 21, 2025 Hi Phoenix friends, I’m thrilled to remind you of two upcoming live Q&A sessions you won’t want to miss.Both designed to help you take the next step in understanding your genetics and boosting your brain health. If you are not a Phoenix Member, I have also decided to open these 2 Q&As to the larger audience of newsletter readers, including our friends at apoe4.info (to celebrate our newly announced partnership!) 1. DNA & Genetics with Kian Sadeghi (Founder of MyNucleus) We’re kicking off with a deep dive into whole genome sequencing (WGS) alongside Kian Sadeghi, CEO and founder of MyNucleus. They’re reimagining what’s possible with WGS using a tech-driven approach, and they’re even exploring new applications like dating and family planning! Don’t worry if you already did your sequencing with another provider (like Sequencing.com): your raw data can be uploaded and interpreted on most platforms, including MyNucleus. Session details:📅 Thursday, July 24🕔 5PM PDT / 8PM EDT (your event time will auto-adjust on Circle)🔗 Event Link & Details for Phoenix MembersHosted on Google Meet (will be recorded for replays)If you are not a Phoenix Member, you can join on the day itself (mark your calendar!) using this link https://meet.google.com/vva-rwro-bro Bring your questions about: DNA testing & interpretation Personalized reports for brain, longevity, or fitness How to use your genetic data for lifestyle decisions Anything else about MyNucleus 2. Medtech Brain Health Q&A with Chris Garvin (Neuronic) Interest in medtech is growing in the community, and I’m personally excited for this one. Chris Garvin from Neuronic will join us to talk about their next-gen transcranial photobiomodulation helmets—wearable devices that deliver near-infrared light (1070 nm) to support memory, focus, sleep, and more. Chris leads business development and works directly with both patients and clinicians. He’ll explain how their tech works, what evidence supports it, and what’s coming next. Session details:📅 Thursday, August 7🕙 10AM EDT / 7AM PDT (again, time auto-adjusts on Circle)🔗 Event Link & Details for Phoenix MembersGoogle Meet, recorded for replayIf you are not a Phoenix Member, you can join on the day itself (mark your calendar!) using this link https://meet.google.com/gti-ittd-yzu Topics you can ask about: How 1070 nm light works & why it’s special Evidence for memory, sleep, cognition, neuroprotection Clinical trials (MCI, Alzheimer’s, long-COVID brain fog) Custom vs preset programs Home use vs clinic use P.S. The Phoenix Experiment is coming, and we need YOU. We’re building the world’s first APOE4 Experiment Platform, in partnership with APOE4.info. No more guessing. Real interventions, real results, tested by us, for us. But to get this right, I need your input.I just launched a 5-minute survey to shape the features you actually want (not what we think you want). At the end, you can book a 30-minute call with me or Dr. Emily Cole (APOE4.info board member and action research expert).This isn’t some boring corporate focus group: it's APOE4 carriers building what we wish existed. Take 5 minutes to help shape the future by filling the survey here. Looking forward to seeing you all at the Q&As and connecting more this month! Stay curious,Kevin --- ## APOE4 Update: Memory Restored + 3 More Findings You Need To Know URL: https://apoe4.co/blog/posts/apoe4-update-memory-restored-3-more-findings-you-need-to-know-9cf0 Published: 2025-07-19T15:26:34+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: research, cognition Summary: Uncover groundbreaking APOE4 research: Memory restoration, social resilience, vascular insights, and microglial dynamics that redefine genetic brain health strategies. APOE4 Update: Memory Restored + 3 More Findings You Need To KnowMemory reversed in mice, social factors override genetics, vascular damage starts at 40, and immune cells won't calm downDr. Kevin Tran July 19, 2025 New data from the Alzheimer's Association APOE Conference (March 2025): Finding 1: Deleting APOE4 from vascular mural cells (pericytes) restored spatial memory in mice. Zero changes to neurons needed. Finding 2: Among 1,000+ Brazilian brains studied, APOE4 carriers with high education + social support maintained cognition despite equal plaque burden. Finding 3: VEGF-R2 drops 45% by age 12-14 months in APOE4 mice. Vascular density follows. This equals your 40s-50s. Finding 4: APOE4 microglia show 3x higher CD68 expression. Even after complete depletion/repopulation, hyperreactivity persists. I break down what each finding means for your daily protocol in this video. → Watch the full analysis: --- ## Shape the Ultimate Personalized APOE4 Protocol: Decide Which Features Matter to You! URL: https://apoe4.co/blog/posts/shape-the-ultimate-personalized-apoe4-protocol-decide-which-features-matter-to-you-eb29 Published: 2025-07-16T13:22:54+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: community, protocols Summary: Empower your APOE4 health journey: Join the groundbreaking Phoenix Experiment and help shape personalized, data-driven strategies that transform genetic risk into proactive wellness. Shape the Ultimate Personalized APOE4 Protocol: Decide Which Features Matter to You!We're not building this for you: we're building it with you. Take the 3-minute survey to shape the future of APOE4 optimization.Dr. Kevin Tran July 16, 2025 The Phoenix Experiment is coming. And we need YOU to shape it to your needs. Picture this: A world where APOE4 carriers don't guess anymore. Where we know what works, specifically for each one of us. Not because some study told us, but because hundreds of us tested it. Systematically. Together. That's the Phoenix Experiment. Here's the deal: The Phoenix Community has been partnering with APOE4.info (the legendary non-profit you probably already know) to build something unprecedented. A platform where APOE4 carriers run structured n=1 health experiments. Think "clinical trials" but for interventions that actually matters to us. Zone 2 training protocols. Supplement stacks. Sleep optimization. Real interventions, real data, real results. APOE4.info is helping design the experiments (and they have another surprise we will reveal later when we have fine tuned the details!) But here's the thing... We're building this FOR you. So we need to hear FROM you. I just launched a 3-minute survey that'll help us nail the features you actually need. Not what we think you need. What you NEED need. At the end? You can book a 30-minute call to go deeper with us. Who's conducting these interviews? Me, and Dr. Emily Cole—APOE4.info board member with a keen interest in action research. This isn't some corporate focus group. It's two APOE4 advocates who genuinely want to build something that changes lives. Our lives. The survey takes 3 minutes. But it might shape the next frontier of APOE4 health optimization. 👉Take the survey here Ready to help us build the future? --- ## ApoE4? New Brain Protection Breakthroughs Every Carrier Must See URL: https://apoe4.co/blog/posts/apoe4-new-brain-protection-breakthroughs-every-carrier-must-see-e3df Published: 2025-07-11T16:17:52+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: research, protocols, cognition Summary: Uncover groundbreaking Alzheimer's prevention insights for ApoE4 carriers: Learn how lifestyle interventions are reversing brain decline and offering real hope. ApoE4? New Brain Protection Breakthroughs Every Carrier Must See After 70+ hours analyzing AAIC and AD/PD conferences, THIS is the video that changes everything.Dr. Kevin Tran July 11, 2025 After 70+ hours spent watching Alzheimer’s conferences recordings, I found it. The presentation sessions that made me literally rewrite our entire Phoenix protocol. You've seen me break down studies before. The good, the bad, the "meh." But there are 2 amazing sessions in AD/PD 2025 that are just GOLD. I cover the first session called “PREVENTION AND THERAPEUTIC INTERVENTIONS IN AD” in this video. (The second session cover will be released next week) This gave me so much hope. Like discovering people in the FINGER trial are still getting BETTER after 4 years. Not slowing down. Not maintaining. Actually improving brain function. Or finding out that having mild brain atrophy might mean you'll respond BETTER to lifestyle changes. (Wait, what?) Or that a specific nutrient blend (that you can make yourself!!) didn't just slow decline—it bought people back 21 months. Real months. Measured in real tests. But here's the kicker: These aren't theoretical models or mouse studies. This is human data, with actionable protocols, showing results that actually move the needle. I turned all 8 breakthroughs into a deep-dive video. No fluff. No "maybes." Just what works, why it works, and what we do about it. Trust me. This one's different. The video on the second session “PIVOTAL POINTS IN PREVENTION TRIALS AND THE NEW ERA OF PRECISION MEDICINE FOR ALZHEIMER’S DISEASE AND RELATED DISORDERS” will be released next week. Subscribe on Youtube and hit the notification bell to not miss it —Kevin P.S. Speaking of doing something about it... The Phoenix Experiment launches very soon. It's how we turn all this science into personalized N=1 experiments. If you're ready to stop reading studies and start running your own, stay tuned. Details coming next week. --- ## 818 Strong: July Updates + Expert Q&A + The Phoenix Experiment Preview URL: https://apoe4.co/blog/posts/818-strong-july-updates-expert-q-a-the-phoenix-experiment-preview-e8e4 Published: 2025-07-08T14:35:48+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: community, tracking, protocols Summary: Discover how 818 strong ApoE4 carriers are rewriting their genetic destiny through The Phoenix Experiment's innovative, science-backed approach to personalized brain health. 818 Strong: July Updates + Expert Q&A + The Phoenix Experiment PreviewOur latest expert Q&As, the new site, and be first to test The Phoenix ExperimentDr. Kevin Tran July 08, 2025 Hi Phoenix friends, It’s been a wild past few weeks.Some days I wake up and can’t believe how fast this is moving. Four months ago, The Phoenix was just an idea. A handful of notes, and a hunch that we could do better for ApoE4 carriers everywhere.I remember sitting in my office thinking about the best way to figure out how to “solve” ApoE4 for myself. I remember sitting in my office thinking: ❝ What would it actually take to solve ApoE4?What’s the fastest way to find the best interventions for my protocol and to stop wasting time on things that don’t move the needle? 4 months ago, The Phoenix was just an idea. Today, on 7/7, we’re 818 strong. (Actually by the time I finished writing this, we are at 826, but 826 strong on 7/7 doesn’t sound as nice 🙂)818 people who refuse to accept the “inevitable.”818 people determined to write their own future.That’s not just a community. That’s a movement. If you’re reading this, you’re part of it. So, thank you. Here’s what’s new (and what’s next): 1. Three expert Q&As:June 26 - Dr. Brandon Colby (CEO, Sequencing.com)We dove into the power of whole genome sequencing, real-world use cases, and how to turn raw DNA into actionable steps for prevention.Watch the replay here:  And coming up: July 25th - Kian Sadeghi (CEO, MyNucleus): Want to finally make sense of your DNA results? Kian’s built a platform that turns raw data into real-world answers. He’ll break down how you can use your genetic code to outsmart risk (no PhD required). August 7th - Chris Garvin (Neuronic): What if boosting your brain didn’t require more pills, but… light? Chris will walk us through the science and practicalities of light therapy helmets: what works, what’s hype, and how to know if it’s for you. Bring your questions. Get honest, cutting-edge answers. 2. Brand New Website (Now Live) We’ve just launched the new Phoenix Community website. It’s a solid foundation for everything we’re building next. This new platform will power all our upcoming features and help us deliver a smarter, more personalized experience for every member.Check it out here3. Something big is coming: The Phoenix Experiment Imagine a tool that doesn’t just track your habits or spit out generic advice.The Phoenix Experiment is about flipping the script on what’s possible for ApoE4 carriers.We leverage your real data, side-by-side with digital twin technology and a living database of what’s working (and what isn’t) for people sharing similar health profile as you. Ever wondered if a new supplement, diet, or protocol will actually move the needle for you. Not just in theory, but in your real life? Tired of sifting through “one-size-fits-all” health advice that doesn’t account for your genetics, your lifestyle, your goals? Want to learn not just from your own n=1 experiments, but from a whole community running structured, tracked interventions, with results you can trust? Here’s what you’ll get: Run your own N=1 experiments (step-by-step, guided by AI) Track your metrics and get a clear answer if you should keep each interventions Get insights from others in the Phoenix to accelerate your experiments (“What works for people like you has a higher chance to work for you”) Spot patterns. Predict your odds. Get science-backed instructions for what to test nextNo more guessing. Just smart, personalized progress. I’m testing the first alpha version now. A handful of early adopters will get access soon.If you want to be a pioneer (or have an idea, question, or wild experiment to propose), hit reply and let me know. I’m all ears. I am also having discussions with a few members to make sure we build what you actually need, if you are interested, let’s chat! Let’s beat the odds,Kevin PS: The Phoenix Experiment is too ambitious for me to build alone and I have a few VERY exciting partnerships (spoiler: it’s with a non-profit, research labs and researchers) to announce very soon. --- ## Shocking New ApoE4 Science About Estrogen and Brain Health! URL: https://apoe4.co/blog/posts/shocking-new-apoe4-science-about-estrogen-and-brain-health-a525 Published: 2025-07-05T16:06:45+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: research, cognition, tracking Summary: Uncover groundbreaking insights on ApoE4, estrogen, and brain health: Learn how female carriers can detect early risks and take proactive steps to protect cognitive function. Shocking New ApoE4 Science About Estrogen and Brain Health!Normal cholesterol levels don’t mean your brain is safe—especially if you’re a woman with ApoE4.Dr. Kevin Tran July 05, 2025 Normal cholesterol levels don’t mean your brain is safe—especially if you’re a woman with ApoE4. In this episode, I break down groundbreaking research from the Alzheimer’s Association International Conference on APOE & Lipid Biology (March 2025). I reveal how female ApoE4 carriers develop cholesterol buildup in brain cells long before cognitive symptoms appear. You'll learn: Why standard blood tests can miss early brain dysfunction How cholesterol gets trapped in endosomes and mitochondria in female APOE4 brains What this tells us about sex-specific Alzheimer’s risk (and how to intervene early) This video is for ApoE4 carriers (especially women in midlife) who want to understand their unique risks and take evidence-based steps to reduce them. --- ## ApoE4 & Alzheimer’s: 11 New Discoveries That Changed My Game Plan URL: https://apoe4.co/blog/posts/apoe4-alzheimer-s-11-new-discoveries-that-changed-my-game-plan-72ea Published: 2025-06-27T23:17:27+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: research, cognition, protocols Summary: Decode the ApoE4 gene's hidden potential with 11 groundbreaking insights that challenge Alzheimer's fate and offer a proactive, science-backed strategy for brain health. ApoE4 & Alzheimer’s: 11 New Discoveries That Changed My Game PlanDr. Kevin Tran June 27, 2025 I carry ApoE4, and I refuse to accept my “destiny.” In this video, I recap 11 eye-opening breakthroughs that are reshaping the fight against Alzheimer’s risk. Let’s be real. Most doctors still see Alzheimer’s as a death sentence for ApoE4 carriers (or they simply ask you to come back when you have symptoms). But the latest research says otherwise —if you know where to look and what to do. Here’s what I cover: Why I now obsess over microglia (your brain’s “immune HQ”). And how these cells might tip you toward decline… or protect you How your ApoE type quietly rewires your brain’s future, sometimes decades before you forget a single thing The wild case studies, knockout experiments, and rare genetic variants that are rewriting our entire approach to prevention I connect all the dots—from inflammation and lipid metabolism to the hidden power of lifestyle and structured intervention. As an ApoE4 carrier, this is more than just “science”: it’s a roadmap for stacking the odds back in your favor. And, yeah, I’m not just recapping research, I’m living this. Every protocol, every hack I mention is something we test inside The Phoenix Community. All insights are from the latest AAIC conference research. No hype. No fluff. Just actionable science and lived experience. And if you never want to miss a new video, hit subscribe and ring the bell. Your future self might just thank you. --- ## Turning Off the ApoE4 Gene To Prevent Alzheimer’s ?! URL: https://apoe4.co/blog/posts/turning-off-the-apoe4-gene-to-prevent-alzheimer-s-fe92 Published: 2025-06-20T15:18:19+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: research, cognition Summary: Insights on myelin, CRISPR gene silencing, lipid metabolism, and prevention. Turning Off the ApoE4 Gene To Prevent Alzheimer’s ?!Insights on myelin, CRISPR gene silencing, lipid metabolism, and prevention.Dr. Kevin Tran June 20, 2025 Hi friends, In this episode, I break down two groundbreaking Alzheimer’s prevention discoveries—directly from the Alzheimer’s Association International Conference on APOE and Lipid Biology (March 2025). These insights reveal how APOE4 disrupts brain metabolism decades before symptoms begin—and what researchers are doing to stop it. You’ll discover: How lipid droplet buildup in oligodendrocytes could be one of the earliest signs of brain dysfunction in ApoE4 carriers A groundbreaking CRISPR interference technique that silences APOE4 in neurons—without editing your DNA Why targeting GSK3-beta and Wnt signaling could help restore healthy fat metabolism and protect myelin Why these findings matter now—for prevention, resilience, and smarter protocols --- ## My Framework for Choosing Which Interventions Are Worth It URL: https://apoe4.co/blog/posts/my-framework-for-choosing-which-interventions-are-worth-it-dc72 Published: 2025-06-17T12:19:11+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: protocols, tracking, cognition Summary: Discover a proven framework for ApoE4 carriers to build a personalized, effective health protocol that protects your brain without sacrificing life's joys. My Framework for Choosing Which Interventions Are Worth ItWhat to Keep, What to Ditch: Building Your ApoE4 Protocol Like a ProDr. Kevin Tran June 17, 2025 Hi friends, Most people waste time on the wrong interventions. They chase the latest supplement, run themselves into burnout, or cut foods they love—only to see barely any change. And as an ApoE4 carrier, that’s not just frustrating—it’s risky. What you need isn’t more advice. You need a system: a clear way to figure out what actually works for you. When you do, everything gets easier: ✅ You’ll stop second-guessing your choices ✅ You’ll focus your energy where it matters ✅ You’ll build a protocol that fits your life, and helps protect your brain This post will show you the exact framework I use to do that. No guesswork. No hype. Just what works, for you. Before we dive in, there are two key truths we need to keep in mind: 1) You still want to enjoy your life Our goal is not to obsess over Alzheimer’s risk or let ApoE4 define your life.We all want to live fully, stay sharp—and enjoy the ride. BUT, you’ll probably end up doing a few interventions daily for the rest of your life (like taking a couple supplements or begrudgingly skipping the cheese platter).So it makes sense to invest a little time upfront to find the protocol that works for you—instead of leaving it to chance. 2) You are unique, so you protocol is too Let’s take a simple example:Say you want to reduce LDL-C / ApoB (one of the key levers for ApoE4 carriers). You might consider: ❌ Cutting steak and cheese from your diet 🏃‍♂️ Running 30km per week 💊 Taking ezetimibe Each one sounds reasonable on paper, but the actual impact? That’s completely personal and depends on your genes, habits, environment etc. If you’re a hyper-absorber of cholesterol, cutting steak and cheese and taking Ezetimibe might drop your LDL-C significantly. But if you are not, the impact might not be that big. And then there’s the part most people ignore:Ease of implementation (i.e. what’s the effort needed for you to implement it) Running 30km a week might feel like therapy for some, and absolute torture for others. That’s why there’s no one-size-fits-all answer.You need a way to map out your interventions in a 2×2 matrix like this (yes I used to work in consulting, why do you ask?) Each dot in this chart represents a hypothetical intervention.We’ve mapped out the three examples above (the positions are purely illustrative) Vertical axis = Impact (measured with biomarkers, cognitive testing, wearables, and other quantitative or qualitative assessments). The higher, the better. Horizontal axis = Ease of implementation (this is all about you—your lifestyle, motivation, and constraints). Right = easy. Left = hard. The vertical axis is the hardest part to get right—measuring impact. That’s where The Phoenix Community comes in: we help you run structured self-experiments, track real-world results, and use predictive tools (like AI, big data, and digital twin models) to identify which interventions actually make a difference.You can apply to join us here. And if that sounds too complex—don’t worry:We’re building an AI-powered app that will simplify this entire process. You’ll simply follow a guided protocol, and the AI will help you prioritize interventions based on your own results—and what’s worked for other members with similar health profiles. I actually have a VERY exciting announcement about this soon, make sure you are subscribed to our newsletter to not miss it! All right let’s go back to our 2×2 matrix Once you’ve plotted your interventions, you can start to prioritize. The chart breaks down into 4 clear quadrants: 🟢 Top right = KeepersHigh impact, easy to do.These are your no-brainers. They stay in your routine—forever if needed. 🔴 Bottom left = Drop themLow impact, hard to do.These are energy drains. They go straight to the bin. 🟡 Diagonal zone = MaybesHere’s where things get flexible.You might go for a quick win from the bottom right quadrant: something easy but low-impact.Or, if you’re feeling especially committed (new year, new you mode), you might add a hard but high-impact intervention to the mix from the top left quadrant. So here’s the bottom line: Not everything is worth doing.And not everything that works for someone else will work for you. If you're serious about protecting your brain, you need more than willpower.You need clarity.A system.A way to track what works, ignore what doesn’t, and build a protocol that fits you. That’s what we do inside The Phoenix. We don’t guess.We test.We learn.And we do it together. Because when you’re facing ApoE4, doing “what everyone else does” just isn’t enough. You need precision. You need support. You need a plan.And with the right system in place,You won’t just survive ApoE4.You’ll thrive with it. --- ## Doctors And Researchers Are Rallying Behind The Phoenix URL: https://apoe4.co/blog/posts/doctors-and-researchers-are-rallying-behind-the-phoenix-b5b8 Published: 2025-06-12T13:30:00+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: community, research Summary: Discover how the Phoenix is transforming brain health, winning over doctors and researchers with a proactive, empowering approach to preventing Alzheimer's before symptoms emerge. Doctors And Researchers Are Rallying Behind The PhoenixWhat started as a grassroots movement is now spreading inside hospitals, clinics, and research labs.Dr. Kevin Tran June 12, 2025 Hi friends, I want to share something that’s made me genuinely hopeful. When I first started building The Phoenix, part of me worried that traditional healthcare professionals—neurologists, researchers, legacy institutions—might reject us. After all, The Phoenix is shaking things up. We challenge old norms. We help people take control before the system usually does.We don’t wait for symptoms.We don’t wait for diagnoses.We act now—because that’s how you beat the odds and win against Alzheimer’s. So part of me expected resistance. Gatekeeping. Maybe even hostility. But that’s not what happened. Instead… They welcomed us. In fact, many healthcare professionals asked how they could help. For example, here’s part of my exchange with Dr. Andrew Ferree, a neurologist at Milford Regional Neurology. Dr Andrew sees patients every day. He sees the gap. And he sees how The Phoenix is filling it. We've had multiple healthcare professionals request a flyer they could print and share with their patients in clinical settings. So—I made one. Flyer for Healthcare Professionals.pdf1.34 MB • PDF File Download If you know a doctor, neurologist, or anyone in healthcare working with ApoE4 patients—please share it. It helps amplify our movement. Beyond clinicians, we’ve also had support from world-class researchers working directly on ApoE4 like Dr. Yadong Huang at UCSF / Gladstone Institute Dr. Hussein Yassine at USC / Center for Personalized Brain Health They’ve offered time, advice, and guidance.They are helping us ground The Phoenix in real science while keeping it actionable for everyday life. The Phoenix isn’t just a fringe community anymore.We are a movement. One that clinicians, researchers, and innovators alike are beginning to believe in. And we’re just getting started. Let’s keep building. Together. —Kevin --- ## ApoE4 Carriers: Can These New Therapies Delay or Prevent Alzheimer’s? URL: https://apoe4.co/blog/posts/apoe4-carriers-can-these-new-therapies-delay-or-prevent-alzheimer-s-ab3e Published: 2025-06-05T10:29:15+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: research, cognition Summary: Uncover groundbreaking research on ApoE4 and Alzheimer's prevention from the AD/PD 2025 conference - innovative therapies, genetic insights, and hope for carriers. ApoE4 Carriers: Can These New Therapies Delay or Prevent Alzheimer’s?Fresh from the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Diseases (April 2025)Dr. Kevin Tran June 05, 2025 Hi friends, In this video, I break down some of the most important findings from the April 2025 international Conference on Alzheimer's and Parkinson's diseases, with direct takeaways for anyone carrying the ApoE4 gene:The ApoE4 Ancestral Puzzle - Genetics, Lipids, and Global Alzheimer’s RiskBeyond the Brain - The Liver’s Surprising Role in ApoE4’s ImpactGood vs. Bad ApoE - Protective VariantsApoE4’s Cellular Effect - How It Disrupts Our Brain CellsInnovative Therapies on the HorizonThis is part a video series where I dissect all the latest research updates that happened at1) The Alzheimer’s Association International Conference on APOE and Lipid Biology (March 2025)2) AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Diseases (April 2025)If you like it, please remember to hit subscribe and hit the notification bell on Youtube so you don’t miss any of my future videos.Feel free to reply to this email if you have any questions or comments, I read all the emails myself :) --- ## MCT Oil, GLP-1, lowering LDL, HSV-1, Keto, Fibers and more! URL: https://apoe4.co/blog/posts/mct-oil-glp-1-lowering-ldl-hsv-1-keto-fibers-and-more Published: 2025-06-02T12:26:20+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: community, tracking, nutrition Summary: The Phoenix Community May Update MCT Oil, GLP-1, lowering LDL, HSV-1, Keto, Fibers and more!The Phoenix Community May UpdateDr. Kevin Tran June 02, 2025 Hi friends, May was so rich in discussions!! We had a fascinating Live Q&A with our Phoenix Founding Member Pr. Margit Burmeister on the topic of DNA and Genetics. Pr. Burmeister has spent decades uncovering the genetic roots of neurological and psychiatric disorders. She brings deep expertise in brain health, gene-environment interactions, and neurodegeneration—and she also happens to be an ApoE2/4 carrier herself, giving her a uniquely personal perspective. Our members were matched in their monthly pods (grouping ApoE4 carriers that share similar health profile — genetics, environment, habits, goals) because there is no one-size fits-all answers when it comes to your health.What works for people similar to you has a much higher chance to work for you too! May Pods Highlights: Lipid Lowering League – Cholesterol Resilience Circle – Stress Deep Sleep Guild – Sleep Quant Crew – Biohack Agility Alliance – Sports As our community continues to double in size each month, we're now exploring more and more fascinating topics.Below, you’ll find a preview of some of the threads started by our members. May Topics Highlights:Supplements, Nutrition, and Medication Would One Meal a Day be cognitive protective? Why? Coconut Oil Optimal macro mix for ApoE4s: Protein %, Carb %, Fat % Help needed determining and tracking macros for ketosis. Acetyl L carnitine and high TMAO Ninja Creami and making ice creams Chobani vs Fage Modified Citrus Pectin (MCP) and stress reduction Soluble fiber – anti-inflammatory, modulates the gut microbiome and more? Microdosing Semaglutide Testosterone Therapy for Males Lithium Microdose Sports, Sleep, and Stress management Swimming seems to have some additional benefits compared to other sports Outsized effect interventions for brain clarity / avoiding brain fog Join the discussion by applying to join The Phoenix. I read all applications myself, so mention you're a newsletter reader to get some extra love :)Biomarkers, Tracking, Monitoring Proof that diet and Strategy do Work for Apoe4! I lowered my LDL 76 points! Updated cholesterol and a1C Cholesterol Balance Test Hyper absorb or Hyper produce Toxins, Pathogens, Heavy metals HSV1 and AD / Dementia risk Tech and Medical devices Cognitive training apps Ketone Monitoring Red Light Therapy Genetics Sequencing.com Kit is processing Detailed sequencing reports, premium plan How many rs protective variants are there? Research The use of GLP-1 s for dementia prevention. IntellxxDNA report and worksheet Stopping inflammation Ezetimibe for prevention Small human pilot study shows 20g creatine supplementation and improved brain energetics Untitled post Evidence Linking SGLT2 Inhibitors to Alzheimer’s/Dementia Prevention 7 APOE4 Breakthroughs That Could Delay Alzheimer’s, from the Alzheimer’s Association International Conference on APOE and Lipid Biology (March 2025) Melatonin: I am receiving a newsletter called Genetic Life Hacks. This article on Melatonin is very interesting. The body’s ability to produce Melatonin is influenced by circadian rhythm. Worth implementing. Alzheimer’s and circadian rhythm. Study showing ApoE4s got better cognition after … HIGH GI and saturated fat meal As always, thank you for being part of this mission to help all ApoE4s beat the odds and defeat Alzheimer’s. 🧡 Kevin --- ## Oops, forgot the link - 7 APOE4 Breakthroughs That Could Delay Alzheimer’s URL: https://apoe4.co/blog/posts/oops-forgot-the-link-7-apoe4-breakthroughs-that-could-delay-alzheimer-s-d287 Published: 2025-05-20T12:58:58+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: research, cognition Summary: Got too excited to share it :) Oops, forgot the link - 7 APOE4 Breakthroughs That Could Delay Alzheimer’sGot too excited to share it :)Dr. Kevin Tran May 20, 2025 --- ## 7 APOE4 Breakthroughs That Could Delay Alzheimer’s URL: https://apoe4.co/blog/posts/7-apoe4-breakthroughs-that-could-delay-alzheimer-s-eed2 Published: 2025-05-20T12:54:00+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: research, cognition Summary: Uncover 7 groundbreaking APOE4 insights from the 2025 Alzheimer's Conference that could transform brain health prevention and rewrite cognitive disease strategies. 7 APOE4 Breakthroughs That Could Delay Alzheimer’sFresh from the Alzheimer’s Association International Conference on APOE and Lipid Biology (March 2025)Dr. Kevin Tran May 20, 2025 Have you ever wondered whether ApoE4’s harmful effects come from a loss of function--or a toxic gain of function?It’s a crucial question, especially for researchers deciding whether to suppress ApoE4… or boost it. This video breaks down the latest findings from the Alzheimer’s Association International Conference on APOE and Lipid Biology (March 2025) You’ll learn about: - Human case studies where partial or total APOE loss delayed or prevented Alzheimer’s- Why microglial APOE4 may be the real trigger—and how targeting it could shift the disease- How ASOs, gene knockdowns, and precision therapies may soon rewire brain inflammation and amyloid buildup This isn’t theoretical—these are real, actionable findings that could inform your prevention protocol right now. If you like it, please remember to hit subscribe and hit the notification bell on Youtube so you don’t miss any of my future videos.I am going to post a video series that dissect all the latest Research updates that happened at 1) The Alzheimer’s Association International Conference on APOE and Lipid Biology (March 2025)2) AD/PD™ 2025 International Conference on Alzheimer’s and Parkinson’s Diseases (April 2025) --- ## May update: Pods, Phoenix experiment, Monthly themes URL: https://apoe4.co/blog/posts/may-update-pods-phoenix-experiment-monthly-themes Published: 2025-05-08T09:11:00+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: community, research Summary: Discover Phoenix's innovative pod matching system powered by AI, where personalized support meets cutting-edge community connection for your health journey. May update: Pods, Phoenix experiment, Monthly themesPhoenix Community update and roadmapDr. Kevin Tran May 08, 2025 Hi everyone! April has been a whirlwind, and I’ve got some exciting updates about where we are and what's ahead for the Phoenix Community. 1. Monthly Pods and Introducing Fenix By now, members of The Phoenix Community should have been matched into your monthly pods. If you intended to join a pod but haven't yet been matched, please send me a note. Pod matching is one of our community’s core features: each month, members are grouped into small peer-support teams (called pods) based on shared goals, lifestyle, and genetic context. These pods are where real support, accountability, and shared experimentation happen—so you’re never going at this alone. Matching took a bit longer this month because we've welcomed someone new: Fenix, our AI support agent. Fenix will enhance our pod matching by analyzing inputs from your application forms, onboarding information, and monthly check-ins. Soon, she’ll also consider community conversations to better understand your needs. Additionally, Fenix will play a key role in the upcoming Phoenix Experiment Module. 2. Monthly Themes: DNA & Genetics (May) We're excited to introduce a new community rhythm: Monthly Themes. Each month we'll explore one important area in depth to support ApoE4 prevention and healthy longevity. Our inaugural theme for May is DNA & Genetics. We'll examine what your genetic code reveals, how to interpret risk reports effectively, and identify additional genetic markers beyond APOE that influence inflammation, detoxification, metabolism, and more. Expect curated posts, expert-led live sessions, vibrant discussions, and opportunities to test personalized interventions aligned with your genetic makeup. 3. Cutting-Edge Research from AAIC & ADPD I’ve been slightly procrastinating on these updates—filming and editing videos aren't my strengths—but I’m embracing the challenge as a valuable skill and brain-sharpening exercise. Starting this month, look forward to new YouTube videos summarizing key insights from the AAIC (Alzheimer’s Association International Conference) and ADPD (International Conference on Alzheimer’s and Parkinson’s Diseases). These sessions are genuinely fascinating, and some of the key topics you'll learn about include: How APOE4 reshapes microglia and disrupts blood vessels in the brain. Innovative interventions targeting cholesterol metabolism and inflammation. New insights into ancestry-specific genetic risks. Emerging therapies such as antisense oligonucleotides to lower APOE4. The growing role of precision medicine in personalized prevention strategies. Each video explains complex science clearly, always concluding with actionable takeaways specifically tailored for ApoE4 carriers. 4. The Phoenix Experiment Module I’ve been collaborating with leading global researchers to design this vital new module. The Phoenix Experiment Module represents the first-ever continuous, community-driven, N-of-Many trial network dedicated exclusively to APOE4 carriers determined to overcome Alzheimer's disease. This innovative system helps you discover, personalize, and optimize your unique protocol for maximizing cognitive health and longevity. It analyzes real-world data from biomarkers, wearables, cognitive assessments, and lifestyle factors, dynamically adapting to create your personalized longevity blueprint. Why is this crucial? Traditional clinical trials often take years and may never happen for non-patentable interventions such as nutrition or stress reduction. Standard medical advice tends to rely on generic, one-size-fits-all recommendations, which aren’t optimal for ApoE4 carriers, given the highly individual nature of genetic risk. The Phoenix Experiment flips the conventional model. Instead of passively waiting for answers, we actively generate them—together. Members run structured experiments, track outcomes, and collectively refine the system, enabling rapid, precise identification of effective interventions. Stay tuned for more details soon—this initiative is my primary focus, and with input from world-class researchers that are joining our scientific board like Pr. Yadong Huang from UCSF / Gladstone Institute, we aim to make it robust and impactful. 5. Community Growth I'm thrilled to announce that we've been doubling our size every month! Why does this matter? A larger community means: Improved pod matching accuracy. Greater access to top researchers and academic experts for live Q&A sessions. Enhanced negotiation power for perks and partnerships. Richer, more meaningful data for the Phoenix Experiment Module. The more we grow, the stronger and more effective we become in our shared mission. If you're reading this newsletter and haven’t yet joined the Phoenix Community, you can apply here. I personally review all applications—mention that you're a newsletter subscriber, and I’ll be sure to give your application a bit of extra love! If you have ideas to help accelerate our community growth or know someone who would benefit from joining us, please reach out—I’d love your help spreading the word. That’s it for our May update! Thank you for being part of The Phoenix Community’s journey—I hope you’re as excited about what's next as I am. --- ## Our Scientific Board, Phoenix Experiment, Partnerships and more! URL: https://apoe4.co/blog/posts/our-scientific-board-phoenix-experiment-partnerships-and-more Published: 2025-05-02T12:18:48+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: community, tracking Summary: April has been 🔥🔥🔥 Our Scientific Board, Phoenix Experiment, Partnerships and more!April has been 🔥🔥🔥Dr. Kevin Tran May 02, 2025 Hi Friends, April was a big one for us — both in science and in community momentum. We’re now doubling our subscribers every month, and I just wanted to take a moment to thank you all for being here. Whether you’re quietly reading or actively engaging, your presence fuels everything we’re building. The Phoenix Community newsletter active subscribers doubling every month!🧠 Dr. Yadong Huang joins our Scientific Board We’re thrilled to welcome Dr. Yadong Huang to our Scientific Advisory Board. He’s a globally recognized leader in ApoE and Alzheimer’s research, known for pioneering work on ApoE4-targeted therapies at the Gladstone Institutes and UCSF. His presence adds major firepower to our mission. He’ll be directly advising us on the Phoenix Experiment—our most ambitious project to date. Speaking of which.. 🔬 Progress on The Phoenix Experiment This is the world’s first continuous, community-driven, N-of-Many trial network for ApoE4 carriers—designed to discover, personalize, and optimize your best possible protocol to beat the odds and defeat Alzheimer’s. Instead of waiting years for traditional clinical trials, we’re creating a system that learns in real-time what’s best for each individual. Your wearables, biomarkers, scans and lifestyle data get matched with others like you (same genes, environment, habits, preferences), so we can detect what really works—faster, smarter, and without the noise. Structured. Personalized. Peer-powered. And built with you, not just for you. 🧬 New Partner: Whole Genome Sequencing at Sequencing.com – 20% Off for Members and Newsletter readersSequencing.com is a platform that offers advanced genetic testing, including whole genome sequencing, and tools to help you interpret your DNA for health, longevity, and disease prevention. We’ve secured 20% off which is the best deal they offer. How? Instead of an affiliate commission, we asked them to pass the savings entirely to you so we can always stay 100% unbiased and give you the best deals. Use code: THEPHOENIX during checkout for 20% Off Dr. Brandon Colby, the founder of Sequencing.com and author of Outsmart your Genes will also be joining us soon for a live Q&A! More partnerships coming soon! 🌱 What We Explored in The Phoenix Community this Month: Join the discussion by applying to The Phoenix—mention you're a newsletter reader to access more insights and exclusive member perks. Supplements, Nutrition, and medication Coconut oil Saturated Fat Psyllium husk - For fiber and tactical use to blunt absorption of glucose / saturated fat Is Alcohol good or bad for you? In moderation or not at all? How do you track your Nutrition? Macros, saturated fat, fiber etc? Dairy fat, Cheese, Cream.. Are they all equally bad for LDL-C? Rapamycin Experience with fasting (intermittent and multi-day) Cholesterol medication? Recipe share Cure for Alzheimer's? "Tactical indulgence": foods with a good "satisfaction-to-damage" ratio Choline (Alpha GPC), big "no regret" supplement Question on MCT oil Coenzyme Q10 (Ubiquinol) LPC-DHA (Lysoveta) Sports, Sleep, and Stress management What sports / activities do you do ? Ways to reduce stress When I found out I had APOE4/4, my brain played tricks on me Biomarkers, Tracking, Monitoring Homocysteine I'm seeing a lot of DETAILED information.... Toxins, Pathogens, Heavy metals Plasma exchange / blood donation Tech and Medical devices Red Light Therapy Genetics BDNF Gene Question Research Studies with sampling bias AD/PD™ 2025 International Conference on Alzheimer’s and Parkinson’s Diseases Interesting study on suvorexant for sleep possibly helping with prevention Not all clinical studies are equal Alzheimer's Association International Conference - Advancements: APOE & Lipid Biology - March 2025 Open journal CGM and getting control of glucose Mediterranean Keto + Fasting (intermittent / multi days) As always, thank you for being part of this mission to explore the science—and build real solutions—for ApoE4. We’re just getting started. 🧡 —Kevin --- ## What Your Raw DNA Actually Tells You (And What to Do About It) URL: https://apoe4.co/blog/posts/what-your-raw-dna-actually-tells-you-and-what-to-do-about-it Published: 2025-04-21T14:16:04+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: protocols, research, cognition Summary: Decode your genome's secrets: Learn how specific gene variants impact brain health, longevity, and personalized wellness with this free, actionable genetic playbook. What Your Raw DNA Actually Tells You (And What to Do About It)ApoE4 is just the beginning. Here’s how to decode the rest of your genome.Dr. Kevin Tran April 21, 2025 By now we all know what to do with ApoE4. But what about the rest of your genome? 💡 What does your raw DNA data actually mean for your brain health and longevity?And more importantly—what should you do with it? Over the past few weeks, I went deep down the PubMed rabbit hole to answer one question: Can I build a playbook from my genome—one that actually changes how I eat, train, and supplement? Turns out: most genes don’t change much. A few change everything.So I distilled the best of what I found into a new resource for you: 🧬 Genetic Playbook for Longevity & Brain HealthWhat to do with your raw DNA data—SNP by SNP. → The most actionable gene variants for cognitive & metabolic health→ What to ignore (seriously—some genes are just trivia)→ Clear next steps: training, labs, supplements Download it for free here: Genetic Playbook for Longevity and Brain Health - Dr. Kevin Tran - The Phoenix Community.pdf1.15 MB • File Download As always, I’d love to hear what you find in your own DNA.Reply to this email if you want to chat! – KevinFounder, The Phoenix --- ## If You’re Not Tracking, You’re Guessing URL: https://apoe4.co/blog/posts/if-you-re-not-tracking-you-re-guessing Published: 2025-04-17T10:17:00+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: tracking, cognition Summary: Track your cognitive health with precision: Learn how systematic biomarker monitoring and personalized tracking empower ApoE4 carriers to make informed, confident wellness decisions. If You’re Not Tracking, You’re GuessingThis is how you validate if what you’re doing is actually workingDr. Kevin Tran April 17, 2025 Why You Need to Track When it comes to cognitive health, especially for ApoE4 carriers, knowing precisely what's working—and what's not—is critical. Without regular tracking, you're essentially navigating without a map. By establishing consistent tracking methods, you transform guesswork into informed decisions, gaining clarity and confidence about your interventions. Tracking allows you to: Identify early trends, ensuring timely adjustments Personalize interventions based on your specific responses Stay motivated by clearly seeing your progress Tracking isn't about worrying or predicting decline—it's about empowerment, optimization, and tangible progress. Quantitative TrackingBloodwork Blood biomarkers offer a straightforward, objective measurement of your internal health. Easily accessible, regular tests can highlight clear physiological changes. Why: Provides objective, actionable data on metabolic and inflammatory markers (e.g., glucose, cholesterol, inflammation). Drawbacks: Variability due to lab standards, equipment accuracy, or even daily fluctuations in lifestyle factors. EEG (Electroencephalogram) An EEG provides insights into brainwave patterns and overall neural function. Why: Detects subtle changes in brain activity, helping track cognitive interventions. AI enhances the analysis and can be used decades before any symptoms. Drawbacks: Requires specialized equipment and interpretation, typically accessible via specialized centers. Wearable Data (Oura, Smartwatch) Wearables seamlessly integrate tracking into your daily routine, capturing sleep, activity, and physiological stress. Why: Continuous, passive tracking of metrics like sleep quality, heart rate variability, and physical activity. Drawbacks: Accuracy can vary between devices, and interpreting data may require additional context. Voice Analysis Advanced analytics can detect subtle cognitive shifts through speech patterns. Why: Non-invasive, simple way to capture cognitive and emotional changes over time. Drawbacks: Emerging technology still under refinement for accuracy and consistency. Cognitive Assessments Standardized cognitive tests provide direct insights into your cognitive performance. Why: Objective measures of memory, processing speed, executive function, and attention. Drawbacks: Potential improvement through familiarity, known scientifically as the "practice effect," where repeated testing artificially boosts performance. Qualitative TrackingQuestionnaires Self-assessments provide personal insights into mood, perceived cognitive clarity, and overall well-being. Why: Captures subjective experiences not easily quantified, like stress, mood, motivation. Drawbacks: Influenced by personal biases and current emotional state. Daily Journaling Consistent reflections can uncover valuable patterns about lifestyle, cognition, and emotional health. Why: Identifies subtle yet meaningful shifts in behavior and emotional resilience. Lots of benefits in overall welleness. Drawbacks: Requires discipline and can be subjective in interpretation. The Need to Have Both Types of Tracking Combining quantitative and qualitative methods provides a comprehensive, holistic picture of your cognitive health. While quantitative data offers clarity and objectivity, qualitative insights add essential context, capturing nuances only you can perceive. How The Phoenix is Making it Easier The Phoenix is uniquely designed to simplify cognitive health tracking for ApoE4 carriers by offering: ✅ Structured Frameworks: Clear protocols for what to do and how to track. All your data (blood test uploads, wearable syncing, monthly check-ins, and questionnaire inputs, etc.) lives in one place. This hub connects the dots between what interventions you tried and the results you saw. ✅ Expert Interpretation: Personalized feedback to interpret your results accurately, accounting for variations and avoiding misinterpretations like the practice effect. ✅ Community Accountability: Ongoing encouragement through accountability pods and group check-ins, helping you stay consistent and engaged. By leveraging The Phoenix, you gain clarity, motivation, and confidence—ensuring every step you take genuinely counts toward your cognitive health.If you are interested to join, apply here. --- ## The Ugly Truth About Which Clinical Trials Get Funded—and Why the Best Interventions Never Will URL: https://apoe4.co/blog/posts/the-ugly-truth-about-which-clinical-trials-get-funded-and-why-the-best-interventions-never-will Published: 2025-04-13T10:06:35+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: community, research, nutrition, exercise Summary: No patent? No funding. We’re here to change that. The Ugly Truth About Which Clinical Trials Get Funded—and Why the Best Interventions Never WillNo patent? No funding. We’re here to change that.Dr. Kevin Tran April 13, 2025 Running a clinical trial costs millions. So most are funded by big pharma or medtech companies—because they hold the patents and profit from the results. That’s not a bad thing. Profit drives innovation. And drug trials are essential. But here's the problem: Some of the most effective interventions will never be properly studied. Not because they don’t work But because no one can make money from them. After all, you can’t patent a good night’s sleep, more fiber, regular cardio, or less stress. So even if they’re powerful... they’re ignored. We’re left in the dark. No Randomized Clinical Trials = no “evidence” = no clear guidance. That’s a huge problem (especially for us, ApoE4 carriers). Because lifestyle changes like exercise, sleep, nutrition, and stress management may be our strongest tools. Yet they’re underfunded. Under-studied. And overlooked. This is where The Phoenix Community steps in: filling the research gaps no one else will. We’re building a massive, decentralized clinical study for lifestyle interventions that will never get funded otherwise. Here’s how: ✅ Structured experimentation: Members follow targeted interventions guided by genetics, lifestyle, and health data ✅ Real-world Monthly check-ins: We capture both objective markers (blood tests, wearables, cognition) and subjective feedback (mood, sleep, energy) ✅ Community scale: More members = more patterns, less noise, stronger insights Is it as controlled as a randomized clinical trial? No. But what we trade in robustness, we gain in scale, diversity, and real-world relevanceOur mission is to bring scientific clarity to interventions ignored because they can’t be monetized. This is a massive blind spot in the research world. And it’s time we fixed it. That’s why this mission is central to The Phoenix. If that mission resonates with you: Apply to join The Phoenix Community --- ## You’re Reading Clinical Studies Wrong (And It's Dangerous) URL: https://apoe4.co/blog/posts/you-re-reading-clinical-studies-wrong-and-it-s-dangerous Published: 2025-04-12T09:47:00+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: research, protocols, community Summary: Learn how to critically evaluate health research and distinguish reliable clinical studies from misleading ones, empowering ApoE4 carriers to make informed wellness decisions. You’re Reading Clinical Studies Wrong (And It's Dangerous)Not every study is reliable. Here's how to spot the difference fast.Dr. Kevin Tran April 12, 2025 Navigating health research, especially for ApoE4 carriers, can feel overwhelming. But not every study carries equal significance and understanding the difference is critical to making informed decisions. Research hierarchy Studies vary widely in quality and relevance, I ranked them here from least robust to most reliable: Animal Studies (e.g., Mouse Models): Useful initial insights, but not directly applicable to humans. Case Studies & Anecdotes: Provide ideas but lack scientific rigor. Observational Studies: Identify correlations but can't confirm causation. Randomized Controlled Trials (RCTs): The gold standard—carefully controlled and reliable. Meta-Analyses: Comprehensive reviews of multiple RCTs, offering the strongest evidence. Real-life example: Fasting in mice vs. humans You just read a study where two days of fasting significantly improved mouse cognitive health. Sounds promising, right? However, mice typically can't survive beyond three days without food. Two days fasting for a mouse equates roughly to two weeks of starvation for a human—clearly impractical and unsafe. Without proper scientific interpretation, such studies can mislead. How the Phoenix Community helps you navigate the science The Phoenix Community’s Science Hub simplifies research interpretation: ✅ Personalized Filtering: Highlights research tailored to ApoE4 carriers and specifically relevant to you based on your personal health data and check-ins ➡️saving you valuable time ✅ Robustness & Impact Scores: Each study is rated from 1–10 on scientific rigor and practical impact ➡️helping you identify the most promising research ✅ Clear Summaries: AI-generated study summaries ➡️Helping you quickly grab what’s most important ✅ Expert Insights: Our network of experts provides clear, actionable interpretations➡️Ensuring you never navigate the complex ApoE4 science alone As always, our goal is to eliminate confusion and guesswork. Join The Phoenix Community and make science-driven choices for your cognitive health. --- ## The Top 3 Mistakes Most ApoE4 Carriers Make (and How to Avoid Them) URL: https://apoe4.co/blog/posts/the-top-3-mistakes-most-apoe4-carriers-make-and-how-to-avoid-them Published: 2025-04-10T10:00:00+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: protocols, cognition, sleep, nutrition Summary: Discover the top 3 critical mistakes ApoE4 carriers unknowingly make that could impact cognitive health, and learn powerful strategies to protect your brain's long-term wellness. The Top 3 Mistakes Most ApoE4 Carriers Make (and How to Avoid Them)These silent mistakes could be quietly undermining your cognitive health.Dr. Kevin Tran April 10, 2025 When you're an ApoE4 carrier, every decision counts. Yet, many unknowingly make critical mistakes that impact their long-term cognitive health. Here are the top 3 mistakes—and how to avoid them: Mistake 1: Over-Relying on Supplements Supplements attract attention because they're convenient—buy a few bottles, pop some pills, and you're done, right? However, lifestyle interventions such as proper nutrition, exercise, quality sleep, and eliminating harmful habits have a far greater impact on your health and Alzheimer’s prevention. Good nutrition alone will get you 80% there; supplements help close the remaining 20%. This doesn’t mean supplements aren’t important. You want to maximize your health, and that final 20% matters deeply. But first, firmly establish foundational habits before turning to supplements as a complementary tool. Mistake 2: Ignoring Sleep and Stress Management Sleep and stress are often overlooked but crucial factors for cognitive health. Sleep: Quality sleep significantly impacts your discipline—when you're rested, you maintain the strength to consistently apply other healthy habits. Additionally, sleep is essential for clearing toxins from your brain and regenerating neural pathways, vital for cognitive function. Stress: Often underappreciated, chronic stress impacts your body profoundly. Elevated stress hormones can contribute to inflammation, disrupt sleep patterns, impair memory, and increase cardiovascular risks—especially problematic for ApoE4 carriers. Prioritizing restful sleep and effective stress management can yield substantial cognitive improvements. Mistake 3: Not Tracking Results Without tracking your interventions, you're merely guessing. Many carriers miss opportunities for improvement because they don't clearly understand what's truly working. It's also about finding the minimum effective dose for each intervention—taking more than you need wastes time, effort, and money. Use quantitative measures (blood tests, cognitive assessments) and qualitative observations (mood, energy, clarity) to objectively evaluate your progress. By avoiding these mistakes, you build a strong foundation for sustained cognitive health. 👉 If you’re ready to stop guessing and start acting on what actually works for ApoE4, apply now to join The Phoenix Community Because the biggest mistake? Trying to do it alone. --- ## 95% of people succeed when they do this (backed by data) URL: https://apoe4.co/blog/posts/95-of-people-succeed-when-they-do-this-backed-by-data Published: 2025-04-09T09:58:00+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: community, protocols Summary: Discover how accountability groups can boost your success rate to 95% and support your health journey, especially for those with ApoE4 gene variations. 95% of people succeed when they do this (backed by data)With ApoE4, consistency isn’t optional. Here’s how to make it last.Dr. Kevin Tran April 09, 2025 Let's be honest: most people don’t fail because they lack information—they fail because they lack structure and support. The data speaks for itself: Accountability groups with regular check-ins have a 95% success rate in maintaining healthy habits (American Society of Training and Development). That's not 95% better—it's a remarkable 95% success rate. When you carry the ApoE4 gene, consistency isn’t optional—it’s essential. Every choice matters, every habit counts, and having a structured support system makes all the difference. It's about having people around you who truly understand your journey. How often have you faced situations where family members or friends just can't fully grasp what you're going through? Having a community of peers who genuinely understand your experiences and challenges—who can cheer you on because they're on the same path—is invaluable. Why The Phoenix Exists The Phoenix isn’t just another community; it’s a focused, high-touch space specifically built for ApoE4 carriers. It's about targeted interventions, expert guidance, and consistent accountability to ensure you don't just know what to do—you actually do it. Here, accountability means: Clearly defined goals Regular check-ins that keep you aligned Expert guidance to navigate complex choices Consistent, structured feedback It's not about pressure; it's about clarity, consistency, and achieving lasting results. If you’re ready to move beyond theory and take meaningful action toward lifelong cognitive health, The Phoenix is built precisely for you. --- ## Stop guessing. Follow this 4-step protocol for ApoE4 URL: https://apoe4.co/blog/posts/stop-guessing-follow-this-4-step-protocol-for-apoe4 Published: 2025-04-08T09:47:33+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: protocols, tracking, community Summary: Learn the robust, scientific approach to knowing what do to when you have ApoE4: from picking interventions, validating them, and crowdsourcing experiments Stop guessing. Follow this 4-step protocol for ApoE4The science-backed approach to test what worksDr. Kevin Tran April 08, 2025 When it comes to ApoE4, there’s no one-size-fits-all solution. Your genetics, environment, and daily habits all shape your health—and what works for someone else may not work for you. That’s why following random advice online (even if well-intentioned) can be more harmful than helpful. So how do you find the right interventions—the ones you’re confident in, and ready to follow for life? Step 1: Start with the “No-Regret Moves” Begin with the high-impact, low-risk habits that benefit almost everyone—especially ApoE4 carriers. These are the foundational habits shared in the ebook I sent earlier. If you missed it, you can grab it here: Download the Free Guide: The Essential Guide to Thriving with ApoE4Step 2: Get clues from your genetic data Our DNA holds powerful clues about what your body needs: BDNF G/G variant? Your brain may benefit more from frequent cardio and HIIT. Low vitamin D receptor activity? You might require higher doses of vitamin D to reach optimal levels. MTHFR mutations? You may struggle to process folate, making methylated B vitamins essential. And many more that we cover in one of our pdf guide. Understanding these patterns helps you prioritize what to test first—so you don't waste time or energy on low-relevance changes. Step 3: Change one variable at a time It’s tempting to overhaul your life all at once. But if you change everything together, you’ll never know what actually made the difference. If your sleep improves, and your energy increases but your inflammation rises, what caused what? The diet? The supplements? The new sports routine? You need clarity—and that only comes from isolating changes. One step at a time. Learn from what your body is telling you. Step 4: Measure progress both quantitatively and qualitatively Quantitative data is your most objective guide: bloodwork, EEG scans, even voice-based cognitive scoring tools can now track your progress in real time. We’ll cover more of these tools in an upcoming email. But numbers aren't the whole story. How you feel—your clarity, focus, sleep quality, mood—often shifts before the data does. Ignoring that would be missing half the picture. That’s why The Phoenix Community builds in monthly check-ins to help you reflect on both the numbers and the human experience behind them. Bonus Insight: You Don’t Have to Do It Alone Trying to figure it all out yourself? That could take years. The smarter shortcut is to learn from others—but not just anyone. You want to learn from people who share your genetic makeup, environment, goals, and lifestyle. That’s exactly what the Phoenix Pod Matching is built for. Every month, we match you with members like you—so you can experiment together, share results, and fast-track your progress. What works for someone like you is far more likely to work for you too. More on pods soon—and if you're ready to stop guessing and start building a lifelong protocol that actually works, The Phoenix Community is here to support you every step of the way. --- ## The Essential Guide To Thriving with ApoE4 URL: https://apoe4.co/blog/posts/the-essential-guide-to-thriving-with-apoe4 Published: 2025-03-31T09:45:00+00:00 Updated: 2026-04-21T17:05:56.057764+00:00 Topics: protocols, nutrition, exercise, sleep Summary: A free, science-backed ebook designed to give ApoE4s a powerful head start. The Essential Guide To Thriving with ApoE4A free, science-backed ebook designed to give you a powerful head start.Dr. Kevin Tran March 31, 2025 A few months ago, I realized something. All the research, testing, and note-taking I was doing for myself as an ApoE4/4 carrier could actually help a lot more people than just me. So I decided to turn it into something useful for everyone in our community. Today, I’m excited to share that with you:👉 The Essential Guide to Thriving with ApoE4A free, science-backed resource that gives you the strongest foundation possible. Overview of the Essential Guide to Thriving with ApoE4Inside, you’ll find:✅ How ApoE4 works and why it matters✅ The exact types of food, exercise, and sleep patterns shown to protect your brain✅ Supplements that might help—and how to test what actually works for you✅ Toxins, habits, and hidden risks to avoid✅ All backed by peer-reviewed research (with links to every paper) Download your free copy here. It’s not about hacks. It’s about getting the foundations right. If you apply even half of what’s inside this guide, you’ll already be in a far stronger position than most. And if you want to go even further, we’ve got something amazing brewing inside The Phoenix Community. But this guide is where it starts. Thanks again for being part of this. Let’s thrive—together.